

Diabetes Excluded Studies List – Main Database

Level 2: Population

[Medical treatment of type 2 diabetes. Recommendations for good practice]. *Diabetes & Metabolism*. 2007;33(1 Pt 2):1S26-105.

Aaboe, K., Krarup, T., Madsbad, S., and Holst, J. J. GLP-1: physiological effects and potential therapeutic applications. *Diabetes, Obesity & Metabolism*. 2008;10(11):994-1003.

Aakre, K. M., Thue, G., Subramaniam-Haavik, S., Bukve, T., Morris, H., Muller, M., Lovrencic, M. V., Plum, I., Kallion, K., Aab, A., Kutt, M., Gillery, P., Schneider, N., Horvath, A. R., Onody, R., Oosterhuis, W., Ricos, C., Perich, C., Nordin, G., and Sandberg, S. Postanalytical external quality assessment of urine albumin in primary health care: an international survey. *Clinical Chemistry*. 2008;54(10):1630-1636.

Aalbers, J. ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients. *Cardiovascular Journal of Africa*. 2010;21(2):118-119.

Abe, H., Minatoguchi, S., Ohashi, H., Murata, I., Minagawa, T., Okuma, T., Yokoyama, H., Takatsu, H., Takaya, T., Nagano, T., Osumi, Y., Kakami, M., Tsukamoto, T., Tanaka, T., Hiei, K., and Fujiwara, H. Renoprotective effect of the addition of losartan to ongoing treatment with an angiotensin converting enzyme inhibitor in type-2 diabetic patients with nephropathy. *Hypertension Research - Clinical & Experimental*. 2007;30(10):929-935.

Abe, M., Kikuchi, F., Kaizu, K., and Matsumoto, K. Combination therapy of pioglitazone with voglibose improves glycemic control safely and rapidly in Japanese type 2-diabetic patients on hemodialysis. *Clinical Nephrology*. 2007;68(5):287-294.

Abe, M., Okada, K., Kikuchi, F., and Matsumoto, K. Clinical investigation of the effects of pioglitazone on the improvement of insulin resistance and blood pressure in type 2-diabetic patients undergoing hemodialysis. *Clinical Nephrology*. 2008;70(3):220-228.

Abidov, M., Ramazanov, A., Jimenez Del Rio, M., and Chkhikvishvili, I. Effect of Blueberin on fasting glucose, C-reactive protein and plasma aminotransferases, in female volunteers with diabetes type 2: double-blind, placebo controlled clinical study. *Georgian Medical News*. 2006;(141):66-72.

Abrishami, M., Heravian, J., Derakhshan, A., Mousavi, M., Banaee, T., Daneshvar, R., and Moghaddam, H. O. Abnormal Cambridge low-contrast grating sensitivity results associated with diabetic retinopathy as a potential screening tool. *Eastern Mediterranean Health Journal*. 2007;13(4):810-818.

Action to Control Cardiovascular Risk in Diabetes Study, Group, Gerstein, H. C., Miller, M. E., Byington, R. P., Goff, D. C., Jr., Bigger, J. T., Buse, J. B., Cushman, W. C., Genuth, S., Ismail-Beigi, F., Grimm, R. H., Jr., Probstfield, J. L., Simons-Morton, D. G., and Friedewald, W. T. Effects of intensive glucose lowering in type 2 diabetes. *New England Journal of Medicine*. 2008;358(24):2545-2559.

Adamia, N., Virsaladze, D., Charkviani, N., Skhirtladze, M., and Khutsishvili, M. Effect of metformin therapy on plasma adiponectin and leptin levels in obese and insulin resistant postmenopausal females with type 2 diabetes. *Georgian Medical News*. 2007;(145):52-55.

Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Grant, R. W., Meigs, J. B., Soumerai, S. B., and Ross-Degnan, D. Medication adherence and racial differences in A1C control. *Diabetes Care*. 2008;31(5):916-921.

Adams, S. Y., Crawford, A. G., Rimal, R. N., Lee, J. S., Janneck, L. M., and Sciamanna, C. N. The effects of a computer-tailored message on secondary prevention in type 2 diabetes: a randomized trial. *Population Health Management*. 2009;12(4):197-204.

Adolfsson, E. T., Starrin, B., Smide, B., and Wikblad, K. Type 2 diabetic patients' experiences of two different educational approaches--a qualitative study. *International Journal of Nursing Studies*. 2008;45(7):986-994.

Adolfsson, E. T., Walker-Engstrom, M. L., Smide, B., and Wikblad, K. Patient education in type 2 diabetes: a randomized controlled 1-year follow-up study. *Diabetes Research & Clinical Practice*. 2007;76(3):341-350.

Adsule, S. M., Baig, M. S., Gade, P. R., and Khandelwal, P. N. A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia. *International Journal Of Diabetes In Developing Countries*. 2009;29(2):74-79.

ADVANCE trial of great importance in preventing cardiovascular deaths in type 2 diabetes. *Cardiovascular Journal of Africa*. 2007;18(5):343-344.

Afilalo, J., Majdan, A. A., and Eisenberg, M. J. Intensive statin therapy in acute coronary syndromes and stable coronary heart disease: a comparative meta-analysis of randomised controlled trials. *Heart*. 2007;93(8):914-921.

Afsar, B., Elsurur, R., Sezer, S., and Ozdemir, F. N. Insulin resistance is associated with increased renal resistive index independent of other factors in newly diagnosed type 2 diabetes mellitus and hypertensive patients. *Metabolism: Clinical & Experimental*. 2010;59(2):279-284.

Afsar, B., Sezer, S., Elsurur, R., and Ozdemir, F. N. Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus?. *Blood Pressure Monitoring*. 2007;12(3):133-139.

Agaba, E. I., Puepet, F. H., Ugoya, S. O., Agaba, P. A., Adabe, R., Duguru, M., and Rowland, A. I. Chronic kidney disease screening and renoprotection in type 2 diabetes. *Annals of African Medicine*. 2009;8(1):52-54.

Agarwal, A. K., Gupta, P. K., Singla, S., Garg, U., Prasad, A., and Yadav, R. Carotid intimomedial thickness in type 2 diabetic patients and its correlation with coronary risk factors. *Journal of the Association of Physicians of India*. 2008;56:581-586.

Agarwal, A. K., Singla, S., Singla, R., Lal, A., Wardhan, H., and Yadav, R. Prevalence of coronary risk factors in type 2 diabetics without manifestations of overt coronary heart disease. *Journal of the Association of Physicians of India*. 2009;57:135-142.

Agarwal, M. M., Dhatt, G. S., Zayed, R., and Bali, N. Gestational diabetes: relevance of diagnostic criteria and preventive strategies for Type 2 diabetes mellitus. *Archives of Gynecology & Obstetrics*. 2007;276(3):237-243.

Agha, A., Bashir, K., and Anwar, E. Use of losartan in reducing microalbuminuria in normotensive patients with type-2 diabetes mellitus. *Nepal Medical College Journal: NMCJ*. 2007;9(2):79-83.

Agha, A. Reduction of microalbuminuria by using losartan in normotensive patients with type 2 diabetes mellitus: A randomized controlled trial. *Saudi journal of kidney diseases and transplantation : an official publication of the Saudi Center for Organ Transplantation, Saudi Arabia*. 2009;20(3):429-435.

Agrawal, A. Effectiveness of the early addition of rosiglitazone to control hyperglycemia after unsuccessful submaximal sulphonylurea monotherapy: the Rosiglitazone Early Versus SULphonylurea Titration (RESULT) Study. *Physician & Sportsmedicine*. 2009;37(1):146-148.

Agrawal, N. K., Maiti, R., Dash, D., and Pandey, B. L. Cilostazol reduces inflammatory burden and oxidative stress in hypertensive type 2 diabetes mellitus patients. *Pharmacological Research*. 2007;56(2):118-123.

Ahmad Khan, H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. *Acta Diabetologica*. 2007;44(4):193-200.

Ahren, B., Foley, J. E., Ferrannini, E., Matthews, D. R., Zinman, B., Dejager, S., and Fonseca, V. A. Changes in prandial glucagon levels after a 2-year treatment with vildagliptin or glimepiride in patients with type 2 diabetes inadequately controlled with metformin monotherapy. *Diabetes Care*. 2010;33(4):730-732.

Ahren, B., Pacini, G., Tura, A., Foley, J. E., and Schweizer, A. Improved meal-related insulin processing contributes to the enhancement of B-cell function by the DPP-4 inhibitor vildagliptin in patients with type 2 diabetes. *Hormone & Metabolic Research*. 2007;39(11):826-829.

Ahren, B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2009;23(4):487-498.

Ahren, B. Vildagliptin enhances islet responsiveness to both hyper- and hypoglycemia in patients with type 2 diabetes. *The Journal of clinical endocrinology and metabolism*. 2009;94(4):1236-1243.

Al Mazroui, N. R., Kamal, M. M., Ghabash, N. M., Yacout, T. A., Kole, P. L., and McElnay, J. C. Influence of pharmaceutical care on health outcomes in patients with Type 2 diabetes mellitus. *British Journal of Clinical Pharmacology*. 2009;67(5):547-557.

Alam, T., Weintraub, N., and Weinreb, J. What is the proper use of hemoglobin A1c monitoring in the elderly?. *Journal of the American Medical Directors Association*. 2005;6(3):200-204.

Alba, M., Sheng, D., Guan, Y., Williams-Herman, D., Larson, P., Sachs, J. R., Thornberry, N., Herman, G., Kaufman, K. D., and Goldstein, B. J. Sitagliptin 100 mg daily effect on DPP-4 inhibition and compound-specific glycemic improvement. *Current Medical Research & Opinion*. 2009;25(10):2507-2514.

Albarracin, C. A., Fuqua, B. C., Evans, J. L., and Goldfine, I. D. Chromium picolinate and biotin combination improves glucose metabolism in treated, uncontrolled overweight to obese patients with type 2 diabetes. *Diabetes/Metabolism Research Reviews*. 2008;24(1):41-51.

Albarracin, C., Fuqua, B., Geohas, J., Juturu, V., Finch, M. R., and Komorowski, J. R. Combination of chromium and biotin improves coronary risk factors in hypercholesterolemic type 2 diabetes mellitus: a placebo-controlled, double-blind randomized clinical trial. *Journal of the CardioMetabolic Syndrome*. 2007;2(2):91-97.

Albert, S. G., Oiknine, R. F., Parseghian, S., Mooradian, A. D., Haas, M. J., and McPherson, T. The effect of glucosamine on Serum HDL cholesterol and apolipoprotein AI levels in people with diabetes. *Diabetes Care*. 2007;30(11):2800-2803.

Albertini, J. P., McMorn, S. O., Chen, H., Mather, R. A., and Valensi, P. Effect of rosiglitazone on factors related to endothelial dysfunction in patients with type 2 diabetes mellitus. *Atherosclerosis*. 2007;195(1):e159-e166.

Albu, J. B., Heilbronn, L. K., Kelley, D. E., Smith, S. R., Azuma, K., Berk, E. S., Pi-Sunyer, F. X., Ravussin, E., and Look, Ahead Adipose Research Group. Metabolic changes following a 1-year diet and exercise intervention in patients with type 2 diabetes. *Diabetes*. 2010;59(3):627-633.

Al-Hussein, F. A. Diabetes control in a primary care setting: a retrospective study of 651 patients. *Annals of Saudi Medicine*. 2008;28(4):267-271.

Ali, N. S. and Khuwaja, A. K. Cost effectiveness of screening of all newly recruited employees for diabetes at a tertiary care hospital. *Journal of Ayub Medical College, Abbottabad: JAMC*. 2007;19(2):23-25.

Ali, Y. S., Linton, M. F., and Fazio, S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2008;15(2):142-146.

Allen, N. A., Fain, J. A., Braun, B., and Chipkin, S. R. Continuous glucose monitoring counseling improves physical activity behaviors of individuals with type 2 diabetes: A randomized clinical trial. *Diabetes Research & Clinical Practice*. 2008;80(3):371-379.

Almustafa, M., Yeo, J. P., and Khutsoane, D. Glycaemic control and hypoglycaemia in the PRESENT study. *Diabetes Research & Clinical Practice*. 2008;81 Suppl 1:S10-S15.

Al-Ozairi, E., Sibal, L., and Home, P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?. *Diabetes Care*. 2007;30(6):1677-1680.

Alvarez Guisasaola, F., Mavros, P., Nocea, G., Alemao, E., Alexander, C. M., and Yin, D. Glycaemic control among patients with type 2 diabetes mellitus in seven European countries: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) study. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 1:8-15.

Alvarsson, M., Sundkvist, G., Lager, I., Berntorp, K., Fernqvist-Forbes, E., Steen, L., Orn, T., Holberg, M. A., Kirksaether, N., and Grill, V. Effects of insulin vs. glibenclamide in recently diagnosed patients with type 2 diabetes: a 4-year follow-up. *Diabetes, Obesity & Metabolism*. 2008;10(5):421-429.

Ambady, R. and Chamukuttan, S. Early diagnosis and prevention of diabetes in developing countries. *Reviews in Endocrine & Metabolic Disorders*. 2008;9(3):193-201.

American Association of Clinical Endocrinologists Board of, Directors and American College of Endocrinologists Board of, Trustees. American Association of Clinical Endocrinologists/American College of Endocrinology statement on the use of hemoglobin A1c for the diagnosis of diabetes. *Endocrine Practice*. 2010;16(2):155-156.

Amori, R. E., Lau, J., and Pittas, A. G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. *Jama*. 2007;298(2):194-206.

Ang, E., Lawrence, M. K., Heilmann, C. R., Ferguson, J. A., Tobian, J. A., Webb, D. M., and Berclaz, P. Y. Safety and efficacy of AIR inhaled insulin compared with subcutaneous insulin in patients having diabetes and asthma: A 12-month, randomized, noninferiority trial. *Diabetes Technology & Therapeutics*. 2009;11 Suppl 2:S35-S44.

Angiolillo, D. J., Capranzano, P., Goto, S., Aslam, M., Desai, B., Charlton, R. K., Suzuki, Y., Box, L. C., Shoemaker, S. B., Zenni, M. M., Guzman, L. A., and Bass, T. A. A randomized study assessing the impact of cilostazol on platelet function profiles in patients with diabetes mellitus and coronary artery disease on dual antiplatelet therapy: results of the OPTIMUS-2 study. *European Heart Journal*. 2008;29(18):2202-2211.

Annemans, L., Demarteau, N., Hu, S., Lee, T. J., Morad, Z., Supaporn, T., Yang, W. C., and Palmer, A. J. An Asian regional analysis of cost-effectiveness of early irbesartan treatment versus conventional antihypertensive, late amlodipine, and late irbesartan treatments in patients with type 2 diabetes, hypertension, and nephropathy. *Value in Health*. 2008;11(3):354-364.

Annemans, L., Marbaix, S., Webb, K., Van Gaal, L., and Scheen, A. Cost effectiveness of atorvastatin in patients with type 2 diabetes mellitus: a pharmacoeconomic analysis of the collaborative atorvastatin diabetes study in the belgian population. *Clinical Drug Investigation*. 2010;30(2):133-142.

Anselmino, M. Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents. *Journal of Diabetes & its Complications*. 2009;23(6):427-433.

Apovian, C. M., Bergenstal, R. M., Cuddihy, R. M., Qu, Y., Lenox, S., Lewis, M. S., and Glass, L. C. Effects of exenatide combined with lifestyle modification in patients with type 2 diabetes. *American Journal of Medicine*. 2010;123(5):468.

Arai, K., Hirao, K., Yamauchi, M., Takagi, H., Kobayashi, M., and Japan Diabetes Clinical Data Management Study, Group. Influence of BMI, Age and duration of diabetes mellitus on glycaemic control with twice-daily injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart (JDDM 18): retrospective reanalysis of a 6-month, randomized, open-label, multicentre trial in Japan. *Clinical Drug Investigation*. 2010;30(1):35-40.

Arca, M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. *Drugs*. 2007;67 Suppl 1:43-54.

Argyropoulou, G. and Doupis, J. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. *Advances in Therapy*. 2009;26(3):272-280.

Arora, E., Shenoy, S., and Sandhu, J. S. Effects of resistance training on metabolic profile of adults with type 2 diabetes. *Indian Journal of Medical Research*. 2009;129(5):515-519.

Asghar, O., Al-Sunni, A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A., Heagerty, A. M., and Malik, R. A. Diabetic cardiomyopathy. *Clinical Science*. 2009;116(10):741-760.

Ashraf, A. Evaluation of effectiveness of local insulin injection in none insulin dependent diabetic patient with carpal tunnel syndrome. *Electromyography and clinical neurophysiology*. 2009;49(4):161-166.

Augstein, P., Vogt, L., Kohnert, K. D., Freyse, E. J., Heinke, P., and Salzsieder, E. Outpatient assessment of Karlsburg Diabetes Management System-based decision support. *Diabetes Care*. 2007;30(7):1704-1708.

Aversa, A., Vitale, C., Volterrani, M., Fabbri, A., Spera, G., Fini, M., and Rosano, G. M. Chronic administration of Sildenafil improves markers of endothelial function in men with Type 2 diabetes. *Diabetic Medicine*. 2008;25(1):37-44.

Azuma, K., Radikova, Z., Mancino, J., Toledo, F. G., Thomas, E., Kangani, C., Dalla Man, C., Cobelli, C., Holst, J. J., Deacon, C. F., He, Y., Ligueros-Saylan, M., Serra, D., Foley, J. E., and Kelley, D. E. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(2):459-464.

Baguet Jp, Asmar R. V. Effects of candesartan cilexetil on carotid remodeling in hypertensive diabetic patients: the MITEC study. *Vascular health and risk management*. 2009;5(1):175-183.

Bailey, C. J., Gross, J. L., Pieters, A., Bastien, A., and List, J. F. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. *Lancet*. 2010;375(9733):2223-2233.

Bain, S. C. Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. *Endocrine Practice*. 2009;15(7):750-762.

Baker, S., Jerums, G., and Proietto, J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. *Diabetes Research & Clinical Practice*. 2009;85(3):235-242.

Bakris, G. L., Toto, R. D., McCullough, P. A., Rocha, R., Purkayastha, D., Davis, P., and Investigators, Guard Study. Effects of different ACE inhibitor combinations on albuminuria: results of the GUARD study. *Kidney International*. 2008;73(11):1303-1309.

Bakris, G., Burgess, E., Weir, M., Davidai, G., Koval, S., and Investigators, Amadeo Study. Telmisartan is more effective than losartan in reducing proteinuria in patients with diabetic nephropathy. *Kidney International*. 2008;74(3):364-369.

Balas, B., Baig, M. R., Watson, C., Dunning, B. E., Ligueros-Saylan, M., Wang, Y., He, Y. L., Darland, C., Holst, J. J., Deacon, C. F., Cusi, K., Mari, A., Foley, J. E., and DeFronzo, R. A. The dipeptidyl

peptidase IV inhibitor vildagliptin suppresses endogenous glucose production and enhances islet function after single-dose administration in type 2 diabetic patients. *Journal of Clinical Endocrinology & Metabolism*. 2007;92(4):1249-1255.

Balasubramanian, R., Varadharajan, S., Kathale, A., Nagraj, L. M., Periyandavar, I., Nayak, U. P., Sharma, A., Bolmall, C., and Baliga, V. P. Assessment of the efficacy and tolerability of a fixed dose combination of atorvastatin 10 mg + metformin SR 500 mg in diabetic dyslipidaemia in adult Indian patients. *Journal of the Indian Medical Association*. 2008;106(7):464-467.

Balde, N. M., Diallo, I., Balde, M. D., Barry, I. S., Kaba, L., Diallo, M. M., Kake, A., Camara, A., Bah, D., Barry, M. M., Sangare-Bah, M., and Maugendre, D. Diabetes and impaired fasting glucose in rural and urban populations in Futa Jallon (Guinea): prevalence and associated risk factors. *Diabetes & Metabolism*. 2007;33(2):114-120.

Barnard, N. D., Cohen, J., Jenkins, D. J., Turner-McGrievy, G., Gloede, L., Green, A., and Ferdowsian, H. A low-fat vegan diet and a conventional diabetes diet in the treatment of type 2 diabetes: a randomized, controlled, 74-wk clinical trial. *American Journal of Clinical Nutrition*. 2009;89(5):1588S-1596S.

Barnard, N. D., Gloede, L., Cohen, J., Jenkins, D. J., Turner-McGrievy, G., Green, A. A., and Ferdowsian, H. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. *Journal of the American Dietetic Association*. 2009;109(2):263-272.

Barnett, A. H., Burger, J., Johns, D., Brodows, R., Kendall, D. M., Roberts, A., and Trautmann, M. E. Tolerability and efficacy of exenatide and titrated insulin glargine in adult patients with type 2 diabetes previously uncontrolled with metformin or a sulfonylurea: a multinational, randomized, open-label, two-period, crossover noninferiority trial. *Clinical Therapeutics*. 2007;29(11):2333-2348.

Barratt, R., Frost, G., Millward, D. J., and Truby, H. A randomised controlled trial investigating the effect of an intensive lifestyle intervention v. standard care in adults with type 2 diabetes immediately after initiating insulin therapy. *British Journal of Nutrition*. 2008;99(5):1025-1031.

Barrios, V., Escobar, C., Tomas, J. P., Calderon, A., and Echarri, R. Comparison of the effects of doxazosin and atenolol on target organ damage in adults with type 2 diabetes mellitus and hypertension in the CARDHIAC study: a 9-month, prospective, randomized, open-label, blinded-evaluation trial. *Clinical Therapeutics*. 2008;30(1):98-107.

Basi, S., Fesler, P., Mimran, A., and Lewis, J. B. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?. *Diabetes Care*. 2008;31 Suppl 2:S194-S201.

Basu, A., Jensen, M. D., McCann, F., Nandy, D., Mukhopadhyay, D., McConnell, J. P., and Rizza, R. A. Lack of an effect of pioglitazone or glipizide on lipoprotein-associated phospholipase A2 in type 2 diabetes. *Endocrine Practice*. 2007;13(2):147-152.

Basu, R., Shah, P., Basu, A., Norby, B., Dicke, B., Chandramouli, V., Cohen, O., Landau, B. R., and Rizza, R. A. Comparison of the effects of pioglitazone and metformin on hepatic and extra-hepatic insulin action in people with type 2 diabetes. *Diabetes*. 2008;57(1):24-31.

Batik, O., Phelan, E. A., Walwick, J. A., Wang, G., and LoGerfo, J. P. Translating a community-based motivational support program to increase physical activity among older adults with diabetes at community clinics: a pilot study of Physical Activity for a Lifetime of Success (PALS). *Preventing Chronic Disease*. 2008;5(1):A18.

Bays, H. E., Bazata, D. D., Clark, N. G., Gavin, J. R., III, Green, A. J., Lewis, S. J., Reed, M. L., Stewart, W., Chapman, R. H., Fox, K. M., and Grandy, S. Prevalence of self-reported diagnosis of diabetes mellitus and associated risk factors in a national survey in the US population: SHIELD (Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes). *BMC Public Health*. 2007;7:277.

Bays, H. E., Goldberg, R. B., Truitt, K. E., and Jones, M. R. Colesevelam hydrochloride therapy in patients with type 2 diabetes mellitus treated with metformin: glucose and lipid effects. *Archives of Internal Medicine*. 2008;168(18):1975-1983.

Bays, H., McElhattan, J., Bryzinski, B. S., and Group, Gallant Study. A double-blind, randomised trial of tesaglitazar versus pioglitazone in patients with type 2 diabetes mellitus. *Diabetes & Vascular Disease Research*. 2007;4(3):181-193.

Bazzano, L. A., Lee, L. J., Shi, L., Reynolds, K., Jackson, J. A., and Fonseca, V. Safety and efficacy of glargine compared with NPH insulin for the treatment of Type 2 diabetes: a meta-analysis of randomized controlled trials. *Diabetic Medicine*. 2008;25(8):924-932.

Bebakar, W. M., Chow, C. C., Kadir, K. A., Suwanwalaikorn, S., Vaz, J. A., Bech, O. M., and group, B. IAsp. Adding biphasic insulin aspart 30 once or twice daily is more efficacious than optimizing oral antidiabetic treatment in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(5):724-732.

Bebb, C., Kendrick, D., Coupland, C., Madeley, R., Stewart, J., Brown, K., Burden, R., and Sturrock, N. A cluster randomised controlled trial of the effect of a treatment algorithm for hypertension in patients with type 2 diabetes. *British Journal of General Practice*. 2007;57(535):136-143.

Bedigian, M. P. Improving the prognosis of diabetic patients: evaluating the role of intensive versus moderate blood pressure control with selective angiotensin II receptor blocker (ARB) therapy. *Journal of the Renin-Angiotensin-Aldosterone System*. 2000;1(2 Suppl):S25-S28.

Belch, J., MacCuish, A., Campbell, I., Cobbe, S., Taylor, R., Prescott, R., Lee, R., Bancroft, J., MacEwan, S., Shepherd, J., Macfarlane, P., Morris, A., Jung, R., Kelly, C., Connacher, A., Peden, N., Jamieson, A., Matthews, D., Leese, G., McKnight, J., O'Brien, I., Semple, C., Petrie, J., Gordon, D., Pringle, S., MacWalter, R., Prevention of Progression of Arterial, Disease, Diabetes Study, Group, Diabetes Registry, Group, and Royal College of Physicians, Edinburgh. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. *Bmj*. 2008;337:a1840.

Bellary, S., O'Hare, J. P., Raymond, N. T., Gumber, A., Mughal, S., Szczepura, A., Kumar, S., Barnett, A. H., and Group, Ukads Study. Enhanced diabetes care to patients of south Asian ethnic origin (the United Kingdom Asian Diabetes Study): a cluster randomised controlled trial. *Lancet*. 2008;371(9626):1769-1776.

Belsey, J. and Krishnarajah, G. Glycaemic control and adverse events in patients with type 2 diabetes treated with metformin + sulphonylurea: a meta-analysis. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 1:1-7.

Bergental, R. M., Freemantle, N., Leyk, M., Cutler, G. B., Jr., Hayes, R. P., and Muchmore, D. B. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. *Diabetes Technology & Therapeutics*. 2009;11 Suppl 2:S45-S52.

Bergental, R. Efficacy and safety of biphasic insulin aspart 70/30 versus exenatide in subjects with type 2 diabetes failing to achieve glycemic control with metformin and a sulfonylurea. *Current medical research and opinion*. 2009;25(1):65-75.

Berger, J. E., Ahmann, A. J., Balfour, D. C., Owens, G. S., Beltran, R., Bush, M. A., Culpepper, L., Ringel, M., and Welty, F. K. Treating to target: implementing an effective diabetes care paradigm for managed care. *American Journal of Managed Care*. 2010;16 Suppl Treating:S4-35.

Berhanu, P., Perez, A., and Yu, S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. *Diabetes, Obesity & Metabolism*. 2007;9(4):512-520.

- Bermudez, V., Cano, R., Cano, C., Bermudez, F., Leal, E., Acosta, K., Mengual, E., Arraiz, N., Briceno, C., Gomez, J., Bustamante, M., Aparicio, D., Cabrera, M., Valdelamar, L., Rodriguez, M., Manuel, V., and Hernandez, R. Homeostasis model assessment (HOMA) as surrogate insulinization criteria in patients with type 2 diabetes. *American Journal of Therapeutics*. 2008;15(4):409-416.
- Bermudez-Pirela, V. J., Cano, C., Medina, M. T., Souki, A., Lemus, M. A., Leal, E. M., Seyfi, H. A., Cano, R., Cisek, A., Bermudez-Arias, F., Contreras, F., Israili, Z. H., Hernandez-Hernandez, R., and Valasco, M. Metformin plus low-dose glimeperide significantly improves Homeostasis Model Assessment for insulin resistance (HOMA(IR)) and beta-cell function (HOMA(beta-cell)) without hyperinsulinemia in patients with type 2 diabetes mellitus. *American Journal of Therapeutics*. 2007;14(2):194-202.
- Berneis, K., Rizzo, M., Stettler, C., Chappuis, B., Braun, M., Diem, P., and Christ, E. R. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. *Expert Opinion on Pharmacotherapy*. 2008;9(3):343-349.
- Berriche, O., Amrouche, C., Jamoussi, H., and Blouza, S. Efficacy and safety of statins in the treatment of diabetic dyslipidemia. *Tunisie Medicale*. 2010;88(2):80-84.
- Berthe, E., Lireux, B., Coffin, C., Goulet-Salmon, B., Houlbert, D., Boutreux, S., Fradin, S., and Reznik, Y. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. *Hormone & Metabolic Research*. 2007;39(3):224-229.
- Bertoni, A. G., Clark, J. M., Feeney, P., Yanovski, S. Z., Bantle, J., Montgomery, B., Safford, M. M., Herman, W. H., Haffner, S., and Look, Ahead Research Group. Suboptimal control of glycemia, blood pressure, and LDL cholesterol in overweight adults with diabetes: the Look AHEAD Study. *Journal of Diabetes & its Complications*. 2008;22(1):1-9.
- Betteridge, D. J. and Gibson, J. M. Effects of rosuvastatin on lipids, lipoproteins and apolipoproteins in the dyslipidaemia of diabetes. *Diabetic Medicine*. 2007;24(5):541-549.
- Betteridge, D. J., Gibson, J. M., and Sager, P. T. Comparison of effectiveness of rosuvastatin versus atorvastatin on the achievement of combined C-reactive protein (
- Beulens, J. W., Patel, A., Vingerling, J. R., Cruickshank, J. K., Hughes, A. D., Stanton, A., Lu, J., Mc, G. Thom, Grobbee, D. E., Stolk, R. P., AdRem project, team, and committee, Advance management. Effects of blood pressure lowering and intensive glucose control on the incidence and progression of retinopathy in patients with type 2 diabetes mellitus: a randomised controlled trial. *Diabetologia*. 2009;52(10):2027-2036.
- Beysen, C., Murphy, E. J., Nagaraja, H., Decaris, M., Riiff, T., Fong, A., Hellerstein, M. K., and Boyle, P. J. A pilot study of the effects of pioglitazone and rosiglitazone on de novo lipogenesis in type 2 diabetes. *Journal of Lipid Research*. 2008;49(12):2657-2663.
- Bianchi, C., Penno, G., Malloggi, L., Barontini, R., Corfini, M., Giovannitti, M. G., Di Cianni, G., Del Prato, S., and Miccoli, R. Non-traditional markers of atherosclerosis potentiate the risk of coronary heart disease in patients with type 2 diabetes and metabolic syndrome. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(1):31-38.
- Bibra, H. Optimized postprandial glucose control is associated with improved cardiac/vascular function - comparison of three insulin regimens in well-controlled type 2 diabetes. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme*. 2009;41(2):109-115.
- Biesenbach, G., Bodlaj, G., Sedlak, M., Pieringer, H., and Kiesling, G. Exercise program for older patients with insulin-treated type 2 diabetes: long-term effects on metabolic control and BMI. *Zeitschrift fur Gerontologie und Geriatrie*. 2009;42(6):465-469.

Bilous, R., Chaturvedi, N., Sjolie, A. K., Fuller, J., Klein, R., Orchard, T., Porta, M., and Parving, H. H. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. *Annals of Internal Medicine*. 151(1):11-20.

Bjorgaas, M. R., Vik, J. T., Stolen, T., Lydersen, S., and Grill, V. Regular use of pedometer does not enhance beneficial outcomes in a physical activity intervention study in type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(5):605-611.

Black, C., Cummins, E., Royle, P., Philip, S., and Waugh, N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. *Health Technology Assessment (Winchester, England)*. 2007;11(33):1-126.

Black, C., Donnelly, P., McIntyre, L., Royle, P. L., Shepherd, J. P., and Thomas, S. Meglitinide analogues for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2007;(2):CD004654.

Blevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J. H., and Aronoff, S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):118-128.

Blickle, J. F., Hancu, N., Piletic, M., Profozic, V., Shestakova, M., Dain, M. P., Jacqueminet, S., and Grimaldi, A. Insulin glargine provides greater improvements in glycaemic control vs. intensifying lifestyle management for people with type 2 diabetes treated with OADs and 7-8% A1c levels. The TULIP study. *Diabetes, Obesity & Metabolism*. 2009;11(4):379-386.

Bloomgarden, Z. T. Exploring treatment strategies for type 2 diabetes. *Diabetes Care*. 2007;30(10):2737-2745.

Bobb, A., Gale, D., Manmohan, S., Mohammed, A., Seetahal, F., Small, P., and Mungrue, K. The impact of the chronic disease assistance plan (CDAP) on the control of type 2 diabetes in Trinidad. *Diabetes Research & Clinical Practice*. 2008;80(3):360-364.

Boehm, C. M. and Smith, S. Altering the course. Screening for prediabetes. *Advance for Nurse Practitioners*. 2007;15(11):43-46.

Bogdanski, P., Pupek-Musialik, D., Dytfeld, J., Jagodzinski, P. P., Jablecka, A., Kujawa, A., and Musialik, K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(10):563-567.

Bohdjalian, A., Prager, G., Rosak, C., Weiner, R., Jung, R., Schramm, M., Aviv, R., Schindler, K., Haddad, W., Rosenthal, N., and Ludvik, B. Improvement in glycemic control in morbidly obese type 2 diabetic subjects by gastric stimulation. *Obesity Surgery*. 2009;19(9):1221-1227.

Bolen, S., Feldman, L., Vassy, J., Wilson, L., Yeh, H. C., Marinopoulos, S., Wiley, C., Selvin, E., Wilson, R., Bass, E. B., and Brancati, F. L. Systematic review: comparative effectiveness and safety of oral medications for type 2 diabetes mellitus. *Annals of Internal Medicine*. 2007;147(6):386-399.

Bolin, K., Gip, C., Mork, A. C., and Lindgren, B. Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005--a register-based approach. *Diabetic Medicine*. 2009;26(9):928-934.

Bonds, D. E., Kurashige, E. M., Bergenstal, R., Brillon, D., Domanski, M., Felicetta, J. V., Fonseca, V. A., Hall, K., Hramiak, I., Miller, M. E., Osei, K., Simons-Morton, D. G., and Group, Accord Study. Severe hypoglycemia monitoring and risk management procedures in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *American Journal of Cardiology*. 2007;99(12A):80i-89i.

Bordenave, S., Brandou, F., Manetta, J., Fedou, C., Mercier, J., and Brun, J. F. Effects of acute exercise on insulin sensitivity, glucose effectiveness and disposition index in type 2 diabetic patients. *Diabetes & Metabolism*. 2008;34(3):250-257.

- Boschmann, M. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients. *The Journal of clinical endocrinology and metabolism*. 2009;94(3):846-852.
- Bosi, E., Camisasca, R. P., Collober, C., Rochotte, E., and Garber, A. J. Effects of vildagliptin on glucose control over 24 weeks in patients with type 2 diabetes inadequately controlled with metformin. *Diabetes Care*. 2007;30(4):890-895.
- Bosi, E., Dotta, F., Jia, Y., and Goodman, M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naïve patients with type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2009;11(5):506-515.
- Bosi, E., Lucotti, P., Setola, E., Monti, L., and Piatti, P. M. Incretin-based therapies in type 2 diabetes: a review of clinical results. *Diabetes Research & Clinical Practice*. 2008;82 Suppl 2:S102-S107.
- Brackenridge, A. L., Jackson, N., Jefferson, W., Stolinski, M., Shojaee-Moradie, F., Hovorka, R., Umpleby, A. M., and Russell-Jones, D. Effects of rosiglitazone and pioglitazone on lipoprotein metabolism in patients with Type 2 diabetes and normal lipids. *Diabetic Medicine*. 2009;26(5):532-539.
- Bradshaw, B. G., Richardson, G. E., Kumpfer, K., Carlson, J., Stanchfield, J., Overall, J., Brooks, A. M., and Kulkarni, K. Determining the efficacy of a resiliency training approach in adults with type 2 diabetes. *Diabetes Educator*. 2007;33(4):650-659.
- Brandle, M., Azoulay, M., and Greiner, R. A. Cost-effectiveness and cost-utility of insulin glargine compared with NPH insulin based on a 10-year simulation of long-term complications with the Diabetes Mellitus Model in patients with type 2 diabetes in Switzerland. *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(4):203-220.
- Brandle, M., Erny-Albrecht, K. M., Goodall, G., Spinaz, G. A., Streit, P., and Valentine, W. J. Exenatide versus insulin glargine: a cost-effectiveness evaluation in patients with Type 2 diabetes in Switzerland. *International Journal of Clinical Pharmacology & Therapeutics*. 2009;47(8):501-515.
- Braun, A., Samann, A., Kubiak, T., Zieschang, T., Kloos, C., Muller, U. A., Oster, P., Wolf, G., and Schiel, R. Effects of metabolic control, patient education and initiation of insulin therapy on the quality of life of patients with type 2 diabetes mellitus. *Patient Education & Counseling*. 2008;73(1):50-59.
- Brazg, R., Xu, L., Dalla Man, C., Cobelli, C., Thomas, K., and Stein, P. P. Effect of adding sitagliptin, a dipeptidyl peptidase-4 inhibitor, to metformin on 24-h glycaemic control and beta-cell function in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(2):186-193.
- Brehm, B. J., Lattin, B. L., Summer, S. S., Boback, J. A., Gilchrist, G. M., Jandacek, R. J., and D'Alessio, D. A. One-year comparison of a high-monounsaturated fat diet with a high-carbohydrate diet in type 2 diabetes. *Diabetes Care*. 2009;32(2):215-220.
- Bretzel, R. G., Dippel, F. W., Linn, T., and Neilson, A. R. Comparison of treatment costs in inadequately controlled type 2 diabetes in Germany based on the APOLLO trial with insulin glargine.[Erratum appears in *J Med Econ*. 2009 Jun;12(2):97]. *Journal of Medical Economics*. 2009;12(2):87-97.
- Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., and Linn, T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.[Erratum appears in *Lancet*. 2008 Aug 30;372(9640):718]. *Lancet*. 2008;371(9618):1073-1084.
- Brodows, R. G., Qu, Y., Johns, D., Kim, D., and Holcombe, J. H. Quantifying the effect of exenatide and insulin glargine on postprandial glucose excursions in patients with type 2 diabetes. *Current Medical Research & Opinion*. 2008;24(5):1395-1397.

Brooks, A. M. and Thacker, S. M. Dapagliflozin for the treatment of type 2 diabetes. *Annals of Pharmacotherapy*. 2009;43(7):1286-1293.

Brooks, N. Strength training improves muscle quality and insulin sensitivity in Hispanic older adults with type 2 diabetes. *International Journal of Medical Sciences*. 2007;4(1):19-27.

Brouwer, B. G., Visseren, F. L., Algra, A., van Bockel, J. H., Bollen, E. L., Doevendans, P. A., Greving, J. P., Kappelle, L. J., Moll, F. L., Pijl, H., Romijn, J. A., van der Wall, E. E., and van der Graaf, Y. Effectiveness of a hospital-based vascular screening programme (SMART) for risk factor management in patients with established vascular disease or type 2 diabetes: a parallel-group comparative study. *Journal of Internal Medicine*. 2010;268(1):83-93.

Brown, S. A., Blozis, S. A., Kouzekanani, K., Garcia, A. A., Winchell, M., and Hanis, C. L. Health beliefs of Mexican Americans with type 2 diabetes: The Starr County border health initiative. *Diabetes Educator*. 2007;33(2):300-308.

Brun, J. F., Bordenave, S., Mercier, J., Jaussent, A., Picot, M. C., and Prefaut, C. Cost-sparing effect of twice-weekly targeted endurance training in type 2 diabetics: a one-year controlled randomized trial. *Diabetes & Metabolism*. 2008;34(3):258-265.

Brunton, S. A. The changing shape of type 2 diabetes. *Medscape journal of medicine*. 2008;10(6):143.

Bunck, M. C., Diamant, M., Corner, A., Eliasson, B., Malloy, J. L., Shaginian, R. M., Deng, W., Kendall, D. M., Taskinen, M. R., Smith, U., Yki-Jarvinen, H., and Heine, R. J. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. *Diabetes Care*. 2009;32(5):762-768.

Buse, J. B., Klonoff, D. C., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Maggs, D. G., and Wintle, M. E. Metabolic effects of two years of exenatide treatment on diabetes, obesity, and hepatic biomarkers in patients with type 2 diabetes: an interim analysis of data from the open-label, uncontrolled extension of three double-blind, placebo-controlled trials. *Clinical Therapeutics*. 2007;29(1):139-153.

Buse, J. B., Wolffenbittel, B. H., Herman, W. H., Shemonsky, N. K., Jiang, H. H., Fahrbach, J. L., Scism-Bacon, J. L., and Martin, S. A. DURAbility of basal versus lispro mix 75/25 insulin efficacy (DURABLE) trial 24-week results: safety and efficacy of insulin lispro mix 75/25 versus insulin glargine added to oral antihyperglycemic drugs in patients with type 2 diabetes. *Diabetes Care*. 2009;32(6):1007-1013.

Bushe, C. J. and Leonard, B. E. Blood glucose and schizophrenia: a systematic review of prospective randomized clinical trials. *Journal of Clinical Psychiatry*. 2007;68(11):1682-1690.

Cabrera de Leon, A., Coello, S. D., Rodriguez Perez Mdel, C., Medina, M. B., Almeida Gonzalez, D., Diaz, B. B., de Fuentes, M. M., and Aguirre-Jaime, A. A simple clinical score for type 2 diabetes mellitus screening in the Canary Islands. *Diabetes Research & Clinical Practice*. 2008;80(1):128-133.

Cade, J. E., Kirk, S. F., Nelson, P., Hollins, L., Deakin, T., Greenwood, D. C., and Harvey, E. L. Can peer educators influence healthy eating in people with diabetes? Results of a randomized controlled trial. *Diabetic Medicine*. 2009;26(10):1048-1054.

Califf, R. M., Boolell, M., Haffner, S. M., Bethel, M. A., McMurray, J., Duggal, A., Holman, R. R., and Group, Navigator Study. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *American Heart Journal*. 2008;156(4):623-632.

Camargo, E. G., Weinert, L. S., Lavinsky, J., Gross, J. L., and Silveiro, S. P. The effect of aspirin on the antiproteinuric properties of enalapril in microalbuminuric type 2 diabetic patients: a randomized, double-blind, placebo-controlled study. *Diabetes Care*. 2007;30(7):e66.

- Campbell, R. K. and White, J. R., Jr. More choices than ever before: emerging therapies for type 2 diabetes. *Diabetes Educator*. 2008;34(3):518-534.
- Campbell, R. K. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. *Journal of the American Pharmacists Association: JAPhA*. 2009;49 Suppl 1:S3-S9.
- Carrington, M. and Stewart, S. Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study. *International Journal of Cardiology*. 2008;127(1):51-56.
- Cefalu, W. T., Mathieu, C., Davidson, J., Freemantle, N., Gough, S., Canovatchel, W., and Coalition, Optimize. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. *Diabetes Technology & Therapeutics*. 2008;10(1):25-38.
- Ceriello, A., Colagiuri, S., Gerich, J., Tuomilehto, J., and Guideline Development, Group. Guideline for management of postmeal glucose. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(4):S17-S33.
- Ceriello, A. Administration of a new diabetes-specific enteral formula results in an improved 24h glucose profile in type 2 diabetic patients. *Diabetes research and clinical practice*. 2009;84(3):259-266.
- Ceriello, A. Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors. *Journal of diabetes and its complications*. 2007;21(1):20-27.
- Cetinkalp, S. S., Karadeniz, M. M., Erdogan, M. A., Ozgen, G. A., and Yilmaz, C. O. Short-term effects of irbesartan treatment on microalbuminuria in patients with normotensive type 2 diabetes. *Saudi Medical Journal*. 2008;29(10):1414-1418.
- Chaiyasit, K. Pharmacokinetic and the effect of capsaicin in *Capsicum frutescens* on decreasing plasma glucose level. *Journal of the Medical Association of Thailand = Chotmaihet thangphaet*. 2009;92(1):108-113.
- Chalmers, J., Joshi, R., and Patel, A. Advances in reducing the burden of vascular disease in type 2 diabetes. *Clinical & Experimental Pharmacology & Physiology*. 2008;35(4):434-437.
- Chalmers, J., Joshi, R., Kengne, A. P., and MacMahon, S. Blood pressure lowering with fixed combination perindopril-indapamide: key findings from ADVANCE. *Journal of Hypertension - Supplement*. 2008;26(2):S11-S15.
- Chalmers, J., Joshi, R., Kengne, A. P., Ninomiya, T., Bi, Y., Bompont, S., Billot, L., Patel, A., and Group, Advance Collaborative. Efficacy and safety of fixed combination of perindopril and indapamide in type 2 diabetes: results from ADVANCE in context of available evidence. *Journal of Hypertension - Supplement*. 2008;26(3):S21-S27.
- Chalmers, J., Kengne, A. P., Joshi, R., Perkovic, V., and Patel, A. New insights from ADVANCE. *Journal of Hypertension*. 2007;25 Suppl 1:S23-S30.
- Chan Jy, Leyk M. F. Relationship between HbA1c and hypoglycaemia in patients with type 2 diabetes treated with different insulin regimens in combination with metformin. *Diabetes/metabolism research and reviews*. 2009;25(3):224-231.
- Chan, B. S., Tsang, M. W., Lee, V. W., and Lee, K. K. Cost of Type 2 Diabetes mellitus in Hong Kong Chinese. *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(8):455-468.
- Chan, J. C., Scott, R., Arjona Ferreira, J. C., Sheng, D., Gonzalez, E., Davies, M. J., Stein, P. P., Kaufman, K. D., Amatruda, J. M., and Williams-Herman, D. Safety and efficacy of sitagliptin in patients with type 2 diabetes and chronic renal insufficiency. *Diabetes, Obesity & Metabolism*. 2008;10(7):545-555.

Chan, J. C., So, W. Y., Yeung, C. Y., Ko, G. T., Lau, I. T., Tsang, M. W., Lau, K. P., Siu, S. C., Li, J. K., Yeung, V. T., Leung, W. Y., Tong, P. C., and Group, Sure Study. Effects of structured versus usual care on renal endpoint in type 2 diabetes: the SURE study: a randomized multicenter translational study. *Diabetes Care*. 2009;32(6):977-982.

Chang, H. C., Chang, Y. C., Lee, S. M., Chen, M. F., Huang, M. C., Peng, C. L., and Yan, C. Y. The effectiveness of hospital-based diabetes case management: an example from a northern Taiwan regional hospital. *Journal of Nursing Research*. 2007;15(4):296-309.

Chappuis, B., Braun, M., Stettler, C., Allemann, S., Diem, P., Lumb, P. J., Wierzbicki, A. S., James, R., and Christ, E. R. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. *Diabetes/Metabolism Research Reviews*. 2007;23(5):392-399.

Charbonneau-Roberts, G., Young, T. K., and Egeland, G. M. Inuit anthropometry and insulin resistance. *International Journal of Circumpolar Health*. 2007;66(2):129-134.

Charbonnel, B., DeFronzo, R., Davidson, J., Schmitz, O., Birkeland, K., Pirags, V., Scheen, A., and investigators, P. ROActive. Pioglitazone use in combination with insulin in the prospective pioglitazone clinical trial in macrovascular events study (PROActive19). *Journal of Clinical Endocrinology & Metabolism*. 2010;95(5):2163-2171.

Charlton-Menys, V. Apolipoproteins, cardiovascular risk and statin response in type 2 diabetes: the Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetologia*. 2009;52(2):218-225.

Charlton-Menys, V. Targets of statin therapy: LDL cholesterol, non-HDL cholesterol, and apolipoprotein B in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS). *Clinical Chemistry*. 2009;55(3):473-480.

Chaves-Fonseca Rm, Matos O. S. L. Implementation of a systematic approach to diabetes in primary care in Bahia, Brazil improves metabolic outcomes: PRODIBA-Programa de Interiorizacao da Assistencia ao Diabetes na Bahia (Project for Dissemination of Diabetes Care in the State of Bahia). *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(3):286-292.

Chen, L., Magliano, D. J., Balkau, B., Colagiuri, S., Zimmet, P. Z., Tonkin, A. M., Mitchell, P., Phillips, P. J., and Shaw, J. E. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures. *Medical Journal of Australia*. 2010;192(4):197-202.

Chen, Y., Rennie, D. C., and Dosman, J. A. Synergy of BMI and family history on diabetes: the Humboldt Study. *Public Health Nutrition*. 2010;13(4):461-465.

Cheskin, L. J., Mitchell, A. M., Jhaveri, A. D., Mitola, A. H., Davis, L. M., Lewis, R. A., Yep, M. A., and Lycan, T. W. Efficacy of meal replacements versus a standard food-based diet for weight loss in type 2 diabetes: a controlled clinical trial. *Diabetes Educator*. 2008;34(1):118-127.

Cheyette, C. Weight no more: a randomised controlled trial for people with type 2 diabetes on insulin therapy. *Practical Diabetes International*. 2007;24(9):450-456.

Chia, C. W. and Egan, J. M. Incretin-based therapies in type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(10):3703-3716.

Chien, H. H., Chang, C. T., Chu, N. F., Hsieh, S. H., Huang, Y. Y., Lee, I. T., Lee, W. J., Tang, Y. J., and Sheu, W. H. Effect of glyburide-metformin combination tablet in patients with type 2 diabetes. *Journal of the Chinese Medical Association: JCMA*. 2007;70(11):473-480.

Chisalita Si, Lindstrom T. E. Differential lipid profile and hormonal response in type 2 diabetes by exogenous insulin aspart versus the insulin secretagogue repaglinide, at the same glycemic control. *Acta Diabetologica*. 2009;46(1):35-42.

- Chogtu, B. Impact of glitazones on metabolic and haemodynamic parameters in patients with type 2 diabetes mellitus. *Singapore Medical Journal*. 2009;50(4):395-399.
- Choi, S. H., Hur, K. Y., Kim, D. J., Ahn, C. W., Kang, E. S., Cha, B. S., Lim, S. K., Huh, K. B., and Lee, H. C. Staged diabetes management according to individual patient insulin resistance and beta-cell function ameliorates glycaemic control in type 2 diabetes mellitus. *Clinical Endocrinology*. 2008;69(4):549-555.
- Cholesterol Treatment Trialists, Collaborators, Kearney, P. M., Blackwell, L., Collins, R., Keech, A., Simes, J., Peto, R., Armitage, J., and Baigent, C. Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis. *Lancet*. 2008;371(9607):117-125.
- Chou, A. F., Brown, A. F., Jensen, R. E., Shih, S., Pawlson, G., and Scholle, S. H. Gender and racial disparities in the management of diabetes mellitus among Medicare patients. *Womens Health Issues*. 2007;17(3):150-161.
- Chou, H. S., Palmer, J. P., Jones, A. R., Waterhouse, B., Ferreira-Cornwell, C., Krebs, J., and Goldstein, B. J. Initial treatment with fixed-dose combination rosiglitazone/glimepiride in patients with previously untreated type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(8):626-637.
- Chou, K. M., Huang, B. Y., Fanchiang, J. K., and Chen, C. H. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients. *Chang Gung Medical Journal*. 2007;30(6):538-546.
- Choy, C. K., Rodgers, J. E., Nappi, J. M., and Haines, S. T. Type 2 diabetes mellitus and heart failure. *Pharmacotherapy*. 2008;28(2):170-192.
- Christian, J. G., Bessesen, D. H., Byers, T. E., Christian, K. K., Goldstein, M. G., and Bock, B. C. Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. *Archives of Internal Medicine*. 2008;168(2):141-146.
- Chu, C. H., Lee, J. K., Lam, H. C., Lu, C. C., Sun, C. C., Wang, M. C., Chuang, M. J., and Wei, M. C. Atorvastatin does not affect insulin sensitivity and the adiponectin or leptin levels in hyperlipidemic Type 2 diabetes. *Journal of Endocrinological Investigation*. 2008;31(1):42-47.
- Civera, M., Merchante, A., Salvador, M., Sanz, J., and Martinez, I. Safety and efficacy of repaglinide in combination with metformin and bedtime NPH insulin as an insulin treatment regimen in type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(1):42-47.
- Clar, C., Royle, P., and Waugh, N. Adding pioglitazone to insulin containing regimens in type 2 diabetes: systematic review and meta-analysis. *PLoS ONE [Electronic Resource]*. 2009;4(7):e6112.
- Clemmons, D. R., Sleevi, M., Allan, G., and Sommer, A. Effects of combined recombinant insulin-like growth factor (IGF)-I and IGF binding protein-3 in type 2 diabetic patients on glycemic control and distribution of IGF-I and IGF-II among serum binding protein complexes. *Journal of Clinical Endocrinology & Metabolism*. 2007;92(7):2652-2658.
- Cleveringa, F. G., Gorter, K. J., van den Donk, M., Pijman, P. L., and Rutten, G. E. Task delegation and computerized decision support reduce coronary heart disease risk factors in type 2 diabetes patients in primary care. *Diabetes Technology & Therapeutics*. 2007;9(5):473-481.
- Cleveringa, F. G., Welsing, P. M., van den Donk, M., Gorter, K. J., Niessen, L. W., Rutten, G. E., and Redekop, W. K. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. *Diabetes Care*. 2010;33(2):258-263.
- Cohen, A. and Horton, E. S. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. *Current Medical Research & Opinion*. 2007;23(4):905-917.

- Cohen, N. D., Dunstan, D. W., Robinson, C., Vulikh, E., Zimmet, P. Z., and Shaw, J. E. Improved endothelial function following a 14-month resistance exercise training program in adults with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(3):405-411.
- Cohen, O., Norymberg, C., Neumann, E., and Dekel, H. Weight gain in type 2 diabetes mellitus--not all uphill. *Diabetes Research & Clinical Practice*. 2008;79(1):128-132.
- Cole, A., Nathan, D. M., Savaria-Porter, E., Copeland, P., Turchin, A., Brunt, M., Zusman, R., Barrett, J. A., Wexler, D., Case, E., McMahon, G. T., and Mort, E. An algorithm for the care of type 2 diabetes. *Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine*. 2009;8(4):156-165.
- Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A., Livingstone, S. J., Charlton-Menys, V., DeMicco, D. A., Fuller, J. H., and Investigators, Cards. Effects of atorvastatin on kidney outcomes and cardiovascular disease in patients with diabetes: an analysis from the Collaborative Atorvastatin Diabetes Study (CARDS). *American Journal of Kidney Diseases*. 2009;54(5):810-819.
- Colson, A., Walker, D., Besser, G. M., Grossman, A. B., Chew, S. L., Jenkins, P. J., Drake, W. M., and Monson, J. P. Role of fasting plasma glucose, glycated haemoglobin and homeostatic model assessment in the detection of glucose intolerance in adult hypopituitary patients during growth hormone replacement therapy. *Hormone Research*. 2008;69(2):83-88.
- Comaschi, M., Corsi, A., Di Pietro, C., Bellatreccia, A., Mariz, S., and Investigators, C. O. M. S. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(5):373-379.
- Comaschi, M., Demicheli, A., Di Pietro, C., Bellatreccia, A., Mariz, S., and Investigators, C. O. M. S. Effects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2007;9(4):387-398.
- Constance, C., Westphal, S., Chung, N., Lund, M., McCrary Sisk, C., Johnson-Levonas, A. O., Massaad, R., and Allen, C. Efficacy of ezetimibe/simvastatin 10/20 and 10/40 mg compared with atorvastatin 20 mg in patients with type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2007;9(4):575-584.
- Contreras, F., Foulhoux, C., Pacheco, B., Maroun, C., Bolivar, H., Lares, M., Leal, E., Cano, R., Bermudez, V., and Velasco, M. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. *American Journal of Therapeutics*. 2008;15(4):397-402.
- Cook, C. B., Hentz, J. G., Tsui, C., Ziemer, D. C., Naylor, D. B., and Miller, W. J. Potentially modifiable metabolic factors and the risk of cardiovascular disease hospitalizations in urban African Americans with diabetes. *Ethnicity & Disease*. 2006;16(4):852-858.
- Cooper, G. J., Young, A. A., Gamble, G. D., Occleshaw, C. J., Dissanayake, A. M., Cowan, B. R., Brunton, D. H., Baker, J. R., Phillips, A. R., Frampton, C. M., Poppitt, S. D., and Doughty, R. N. A copper(II)-selective chelator ameliorates left-ventricular hypertrophy in type 2 diabetic patients: a randomised placebo-controlled study. *Diabetologia*. 2009;52(4):715-722.
- Cooper, M. B., Al Majali, K., Bailey, C. J., and Betteridge, D. J. Reduced postprandial proinsulinaemia and 32-33 split proinsulinaemia after a mixed meal in type 2 diabetic patients following sensitization to insulin with pioglitazone. *Clinical Endocrinology*. 2008;68(5):738-746.
- Coppell, K. J., Kataoka, M., Williams, S. M., Chisholm, A. W., Vorgers, S. M., and Mann, J. I. Nutritional intervention in patients with type 2 diabetes who are hyperglycaemic despite optimised drug

treatment--Lifestyle Over and Above Drugs in Diabetes (LOADD) study: randomised controlled trial. *Bmj*. 2010;341:c3337.

Corser, W., Holmes-Rovner, M., Lein, C., and Gossain, V. A shared decision-making primary care intervention for type 2 diabetes. *Diabetes Educator*. 2007;33(4):700-708.

Cortes-Sanabria, L., Cabrera-Pivaral, C. E., Cueto-Manzano, A. M., Rojas-Campos, E., Barragan, G., Hernandez-Anaya, M., and Martinez-Ramirez, H. R. Improving care of patients with diabetes and CKD: a pilot study for a cluster-randomized trial. *American Journal of Kidney Diseases*. 2008;51(5):777-788.

Cosson, E., Hamo-Tchatchouang, E., Dufaitre-Patouraux, L., Attali, J. R., Paries, J., and Schaepelynck-Belicar, P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. *Diabetes & Metabolism*. 2009;35(4):312-318.

Cosson, E., Nguyen, M. T., Pham, I., Pontet, M., Nitenberg, A., and Valensi, P. N-terminal pro-B-type natriuretic peptide: an independent marker for coronary artery disease in asymptomatic diabetic patients. *Diabetic Medicine*. 2009;26(9):872-879.

Costa, B. M., Fitzgerald, K. J., Jones, K. M., and Dunning Am, T. Effectiveness of IT-based diabetes management interventions: a review of the literature. *BMC Family Practice*. 2009;10:72.

Coutaz, M., Nicod, M., Chassot, M., and Morisod, J. [Monitoring hypoglycemia in elderly diabetic patients: a prospective study]. *Revue Medicale Suisse*. 2007;3(108):1071-1076.

Coutinho, W. F. The obese older female patient: CV risk and the SCOUT study. *International Journal of Obesity*. 2005;31(2).

Coutinho, W. The first decade of sibutramine and orlistat: a reappraisal of their expanding roles in the treatment of obesity and associated conditions. *Arquivos Brasileiros de Endocrinologia e Metabologia*. 2009;53(2):262-270.

Covington, P., Christopher, R., Davenport, M., Fleck, P., Mekki, Q. A., Wann, E. R., and Karim, A. Pharmacokinetic, pharmacodynamic, and tolerability profiles of the dipeptidyl peptidase-4 inhibitor alogliptin: a randomized, double-blind, placebo-controlled, multiple-dose study in adult patients with type 2 diabetes. *Clinical Therapeutics*. 2008;30(3):499-512.

Coyle, D., Rodby, R., Soroka, S., Levin, A., Muirhead, N., de Cotret, P. R., Chen, R., and Palmer, A. Cost-effectiveness of irbesartan 300 mg given early versus late in patients with hypertension and a history of type 2 diabetes and renal disease: a Canadian perspective. *Clinical Therapeutics*. 2007;29(7):1508-1523.

Craig, D., Donoghue, J., Seller, M., and Mitten-Lewis, S. Improving nursing management of patients with diabetes using an action research approach. *Contemporary Nurse*. 2004;17(1-2):71-79.

Cramer, J. S., Sibley, R. F., Bartlett, D. P., Kahn, L. S., and Loffredo, L. An adaptation of the diabetes prevention program for use with high-risk, minority patients with type 2 diabetes. *Diabetes Educator*. 2007;33(3):503-508.

Crepaldi, G., Carruba, M., Comaschi, M., Del Prato, S., Frajese, G., and Paolisso, G. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. *Journal of Endocrinological Investigation*. 2007;30(7):610-614.

Croom, K. F. and McCormack, P. L. Liraglutide: a review of its use in type 2 diabetes mellitus. *Drugs*. 2009;69(14):1985-2004.

Croom, K. F. and Plosker, G. L. Irbesartan: a review of its use in hypertension and diabetic nephropathy. *Drugs*. 2008;68(11):1543-1569.

- Crouse, J. R., III. An evaluation of rosuvastatin: pharmacokinetics, clinical efficacy and tolerability. *Expert Opinion On Drug Metabolism & Toxicology*. 2008;4(3):287-304.
- Cruz, M., Maldonado-Bernal, C., Mondragon-Gonzalez, R., Sanchez-Barrera, R., Wachter, N. H., Carvajal-Sandoval, G., and Kumate, J. Glycine treatment decreases proinflammatory cytokines and increases interferon-gamma in patients with type 2 diabetes. *Journal of Endocrinological Investigation*. 2008;31(8):694-699.
- Cubbon, R., Kahn, M., and Kearney, M. T. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. *International Journal of Clinical Practice*. 2008;62(2):287-299.
- Cucinotta, D., Smirnova, O., Christiansen, J. S., Kanc, K., le Devehat, C., Wojciechowska, M., Lopez de la Torre, M., and Liebl, A. Three different premixed combinations of biphasic insulin aspart - comparison of the efficacy and safety in a randomized controlled clinical trial in subjects with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2009;11(7):700-708.
- Cuellar, N. G. and Ratcliffe, S. J. Restless legs syndrome in type 2 diabetes: implications to diabetes educators. *Diabetes Educator*. 2008;34(2):218-234.
- Culling Ks, Neil H. A. G. Effects of short-term low- and high-carbohydrate diets on postprandial metabolism in non-diabetic and diabetic subjects. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2009;19(5):345-351.
- Cummins, E., Royle, P., Snaith, A., Greene, A., Robertson, L., McIntyre, L., and Waugh, N. Clinical effectiveness and cost-effectiveness of continuous subcutaneous insulin infusion for diabetes: systematic review and economic evaluation. *Health Technology Assessment (Winchester, England)*. 14(11):iii-iv.
- Czupryniak, L., Pawlowski, M., Saryusz-Wolska, M., and Loba, J. Circadian blood pressure variation and antihypertensive medication adjustment in normoalbuminuric type 2 diabetes patients. *Kidney & Blood Pressure Research*. 2007;30(3):182-186.
- Dahabreh, I. J. and Economopoulos, K. Meta-analysis of rare events: an update and sensitivity analysis of cardiovascular events in randomized trials of rosiglitazone.[Erratum appears in Clin Trials. 2008;5(5):559 Note: Economopoulos, K [added]]. *Clinical Trials*. 2008;5(2):116-120.
- Dai, J. Beneficial effects of designed dietary fatty acid compositions on lipids in triacylglycerol-rich lipoproteins among Chinese patients with type 2 diabetes mellitus. *Metabolism: clinical and experimental*. 2009;58(4):510-518.
- Dailey, G. E. Using prandial insulin to achieve glycemic control in type 2 diabetes. *Journal of Family Practice*. 2007;56(9):735-742.
- D'Alessio, D. A., Denney, A. M., Hermiller, L. M., Prigeon, R. L., Martin, J. M., Tharp, W. G., Saylan, M. L., He, Y., Dunning, B. E., Foley, J. E., and Pratley, R. E. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(1):81-88.
- Dallinga-Thie, G. M., van Tol, A., Dullaart, R. P., and Diabetes Atorvastatin lipid intervention study, group. Plasma pre beta-HDL formation is decreased by atorvastatin treatment in type 2 diabetes mellitus: Role of phospholipid transfer protein. *Biochimica et Biophysica Acta*. 2009;1791(8):714-718.
- Dalsgaard, E. M., Lauritzen, T., Christiansen, T., Mai, K. S., Borch-Johnsen, K., and Sandbaek, A. Socioeconomic factors related to attendance at a Type 2 diabetes screening programme. *Diabetic Medicine*. 2009;26(5):518-525.
- Dankner, R., Abdul-Ghani, M. A., Gerber, Y., Chetrit, A., Wainstein, J., and Raz, I. Predicting the 20-

year diabetes incidence rate. *Diabetes/Metabolism Research Reviews*. 2007;23(7):551-558.

Dashora, U. K., Sibal, L., Ashwell, S. G., and Home, P. D. Insulin glargine in combination with nateglinide in people with Type 2 diabetes: a randomized placebo-controlled trial. *Diabetic Medicine*. 2007;24(4):344-349.

Davidson, M. B., Wong, A., Hamrahian, A. H., Stevens, M., and Siraj, E. S. Effect of spironolactone therapy on albuminuria in patients with type 2 diabetes treated with angiotensin-converting enzyme inhibitors. *Endocrine Practice*. 2008;14(8):985-992.

Davies, M. J., Thaware, P. K., Tringham, J. R., Howe, J., Jarvis, J., Johnston, V., Kitchener, D. L., Skinner, T. C., McNally, P. G., and Lawrence, I. G. A randomized controlled trial examining combinations of repaglinide, metformin and NPH insulin. *Diabetic Medicine*. 2007;24(7):714-719.

Davies, M., Evans, R., Storms, F., Gomis, R., and Khunti, K. Initiation of insulin glargine in suboptimally controlled patients with type 2 diabetes: sub-analysis of the AT.LANTUS trial comparing treatment outcomes in subjects from primary and secondary care in the UK. *Diabetes, Obesity & Metabolism*. 2007;9(5):706-713.

Davies, M., Lavalley-Gonzalez, F., Storms, F., Gomis, R., and Group, At Lantus Study. Initiation of insulin glargine therapy in type 2 diabetes subjects suboptimally controlled on oral antidiabetic agents: results from the AT.LANTUS trial. *Diabetes, Obesity & Metabolism*. 2008;10(5):387-399.

Davies, M., Sinnassamy, P., Storms, F., Gomis, R., and Group, At Lantus Study. Insulin glargine-based therapy improves glycemic control in patients with type 2 diabetes sub-optimally controlled on premixed insulin therapies. *Diabetes Research & Clinical Practice*. 2008;79(2):368-375.

Davis Md, Beck R. W. H. Early retinopathy progression in four randomized trials comparing insulin glargine and NPH [corrected] insulin. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*. 2007;115(4):240-243.

Davis, N. J., Tomuta, N., Schechter, C., Isasi, C. R., Segal-Isaacson, C. J., Stein, D., Zonszein, J., and Wylie-Rosett, J. Comparative study of the effects of a 1-year dietary intervention of a low-carbohydrate diet versus a low-fat diet on weight and glycemic control in type 2 diabetes. *Diabetes Care*. 2009;32(7):1147-1152.

De Berardis, G., Sacco, M., Strippoli, G. F., Pellegrini, F., Graziano, G., Tognoni, G., and Nicolucci, A. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. *Bmj*. 2009;339:b4531.

De Block, C., Paquot, N., Daoudi, N., Ballaux, D., Van Gaal, L. F., and Scheen, A. J. [Improved glucose control and weight loss with exenatide in patients with type 2 diabetes: results of a retrospective observational multicentre Belgian study]. *Revue Medicale de Liege*. 2009;64(10):488-495.

de Galan, B. E., Perkovic, V., Ninomiya, T., Pillai, A., Patel, A., Cass, A., Neal, B., Poulter, N., Harrap, S., Mogensen, C. E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancia, G., Woodward, M., Glasziou, P., Grobbee, D. E., MacMahon, S., Chalmers, J., and Group, Advance Collaborative. Lowering blood pressure reduces renal events in type 2 diabetes. *Journal of the American Society of Nephrology*. 2009;20(4):883-892.

de Kroon, M. L., Renders, C. M., Kuipers, E. C., van Wouwe, J. P., van Buuren, S., de Jonge, G. A., and Hirasings, R. A. Identifying metabolic syndrome without blood tests in young adults--the Terneuzen Birth Cohort. *European Journal of Public Health*. 2008;18(6):656-660.

de Mello, V. D., Zelmanovitz, T., Azevedo, M. J., de Paula, T. P., and Gross, J. L. Long-term effect of a chicken-based diet versus enalapril on albuminuria in type 2 diabetic patients with microalbuminuria. *Journal of Renal Nutrition*. 2008;18(5):440-447.

de Rivas, B., Luque, M., Martell, N., Fernandez, C., and Fernandez-Cruz, A. Pioglitazone decreases ambulatory blood pressure in type 2 diabetics with difficult-to-control hypertension. *Journal of Clinical Hypertension*. 2007;9(7):530-537.

De, Mattia G. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. *Acta Diabetologica*. 2009;46(1):67-73.

De, Natale C. Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. *Diabetes Care*. 2009;32(12):2168-2173.

Deeks, E. D. and Keam, S. J. Rosiglitazone : a review of its use in type 2 diabetes mellitus. *Drugs*. 2007;67(18):2747-2779.

DeFronzo, R. A., Fleck, P. R., Wilson, C. A., Mekki, Q., and Alogliptin Study, Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, placebo-controlled study. *Diabetes Care*. 2008;31(12):2315-2317.

DeFronzo, R. A., Hissa, M. N., Garber, A. J., Luiz Gross, J., Yuyan Duan, R., Ravichandran, S., Chen, R. S., and Study, Group. The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. *Diabetes Care*. 2009;32(9):1649-1655.

DeFronzo, R. A., Okerson, T., Viswanathan, P., Guan, X., Holcombe, J. H., and MacConell, L. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. *Current Medical Research & Opinion*. 2008;24(10):2943-2952.

DeFronzo, R. A., Triplitt, C., Qu, Y., Lewis, M. S., Maggs, D., and Glass, L. C. Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin. *Diabetes Care*. 2010;33(5):951-957.

Dejager, S., Razac, S., Foley, J. E., and Schweizer, A. Vildagliptin in drug-naïve patients with type 2 diabetes: a 24-week, double-blind, randomized, placebo-controlled, multiple-dose study. *Hormone & Metabolic Research*. 2007;39(3):218-223.

Dejgaard, A., Lynggaard, H., Rastam, J., and Krogsgaard Thomsen, M. No evidence of increased risk of malignancies in patients with diabetes treated with insulin detemir: a meta-analysis. *Diabetologia*. 2009;52(12):2507-2512.

Del Prato, S., Blonde, L., Martinez, L., Goke, B., Woo, V., Millward, A., Gomis, R., Canovatchel, B., Strack, T., Lawrence, D., Freemantle, N., and Team, Experience Trial. The effect of the availability of inhaled insulin on glycaemic control in patients with Type 2 diabetes failing on oral therapy: the evaluation of Exubera as a therapeutic option on insulin initiation and improvement in glycaemic control in clinical practice (EXPERIENCE) trial. *Diabetic Medicine*. 2008;25(6):662-670.

Delahanty, L. M. and Nathan, D. M. Implications of the diabetes prevention program and Look AHEAD clinical trials for lifestyle interventions. *Journal of the American Dietetic Association*. 2008;108(4 Suppl 1):S66-S72.

Delea Te, Sofrygin O. P. Cost-effectiveness of aliskiren in type 2 diabetes, hypertension, and albuminuria. *Journal of the American Society of Nephrology*. 2009;20(10):2205-2213.

Demir, M., Gokturk, H. S., Ozturk, N. A., Serin, E., and Yilmaz, U. Efficacy of two different *Helicobacter pylori* eradication regimens in patients with type 2 diabetes and the effect of *Helicobacter*

pylori eradication on dyspeptic symptoms in patients with diabetes: a randomized controlled study. *American Journal of the Medical Sciences*. 2009;338(6):459-464.

Derosa, G., Cicero, A. F., D'Angelo, A., Fogari, E., Salvadeo, S., Gravina, A., Ferrari, I., Fassi, R., and Fogari, R. Metabolic and antihypertensive effects of moxonidine and moxonidine plus irbesartan in patients with type 2 diabetes mellitus and mild hypertension: a sequential, randomized, double-blind clinical trial. *Clinical Therapeutics*. 2007;29(4):602-610.

Derosa, G., D'Angelo, A., Fogari, E., Salvadeo, S., Gravina, A., Ferrari, I., and Cicero, A. F. Effects of nateglinide and glibenclamide on prothrombotic factors in naive type 2 diabetic patients treated with metformin: a 1-year, double-blind, randomized clinical trial. *Internal Medicine*. 2007;46(22):1837-1846.

Derosa, G., D'Angelo, A., Salvadeo, S. A., Ferrari, I., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., and Cicero, A. F. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. *Microvascular Research*. 2010;79(2):144-149.

Derosa, G., Fogari, E., Cicero, A. F., D'Angelo, A., Ciccarelli, L., Piccinni, M. N., Pricolo, F., Salvadeo, S. A., Gravina, A., Ferrari, I., and Fogari, R. Blood pressure control and inflammatory markers in type 2 diabetic patients treated with pioglitazone or rosiglitazone and metformin. *Hypertension Research - Clinical & Experimental*. 2007;30(5):387-394.

Derosa, G., Maffioli, P., Salvadeo, S. A., Ferrari, I., Gravina, A., Mereu, R., Palumbo, I., D'Angelo, A., and Cicero, A. F. Direct comparison among oral hypoglycemic agents and their association with insulin resistance evaluated by euglycemic hyperinsulinemic clamp: the 60's study. *Metabolism: Clinical & Experimental*. 2009;58(8):1059-1066.

Derosa, G., Maffioli, P., Salvadeo, S. A., Ferrari, I., Gravina, A., Mereu, R., Palumbo, I., D'Angelo, A., and Cicero, A. F. Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients. *Current Medical Research & Opinion*. 2009;25(8):1973-1983.

Derosa, G., Maffioli, P., Salvadeo, S. A., Ferrari, I., Ragonesi, P. D., Querci, F., Franzetti, I. G., Gadaleta, G., Ciccarelli, L., Piccinni, M. N., D'Angelo, A., and Cicero, A. F. Effects of sitagliptin or metformin added to pioglitazone monotherapy in poorly controlled type 2 diabetes mellitus patients. *Metabolism: Clinical & Experimental*. 2010;59(6):887-895.

Derosa, G. Metabolic effects of pioglitazone and rosiglitazone in patients with diabetes and metabolic syndrome treated with metformin. *Internal Medicine Journal*. 2007;37(2):79-86.

Derosa, G. Nateglinide and glibenclamide metabolic effects in naive type 2 diabetic patients treated with metformin. *Journal of clinical pharmacy and therapeutics*. 2009;34(1):13-23.

Derosa, G. Pioglitazone metabolic effect in metformin-intolerant obese patients treated with sibutramine. *Internal medicine (Tokyo, Japan)*. 2009;48(5):265-271.

Desilets, A. R., Dhakal-Karki, S., and Dunican, K. C. Role of metformin for weight management in patients without type 2 diabetes. *Annals of Pharmacotherapy*. 2008;42(6):817-826.

Dhillon, S. and Weber, J. Saxagliptin. *Drugs*. 2009;69(15):2103-2114.

Dhillon, S. Sitagliptin: a review of its use in the management of type 2 diabetes mellitus. *Drugs*. 2010;70(4):489-512.

Diabetes prevention: still no effective drugs. *Prescrire International*. 2007;16(92):258.

Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., and Trautmann, M. Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *Lancet*. 2010;375(9733):2234-2243.

Dietary measures for type 2 diabetes. Weight loss and a Mediterranean-type diet, with no foods off-limits. *Prescrire International*. 2009;18(103):224.

Dijkstra, R., Braspenning, J., and Grol, R. Implementing diabetes passports to focus practice reorganization on improving diabetes care. *International Journal for Quality in Health Care*. 2008;20(1):72-77.

Dimic, D., Velojic Golubovic, M., Antic, S., and Radenkovic, S. Evaluation of the repaglinide efficiency in comparison to the glimepiride in the type 2 diabetes patients poorly regulated by the metmorfine administration. *Bratislavske Lekarske Listy*. 2009;110(6):335-339.

Dixon, J. B., O'Brien, P. E., Playfair, J., Chapman, L., Schachter, L. M., Skinner, S., Proietto, J., Bailey, M., and Anderson, M. Adjustable gastric banding and conventional therapy for type 2 diabetes: a randomized controlled trial. *Jama*. 2008;299(3):316-323.

Dluhy, R. G. and McMahon, G. T. Intensive glycemic control in the ACCORD and ADVANCE trials. *New England Journal of Medicine*. 2008;358(24):2630-2633.

Dobs, A. Efficacy of simvastatin therapy in attainment of LDL-C and TG goal levels in patients with type 2 diabetic dyslipidemia. *Journal of Clinical Lipidology*. 2008;2(1):12-18.

Doggrell, S. A. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?. *Expert Opinion on Pharmacotherapy*. 2008;9(3):405-420.

Doi, Y., Kubo, M., Yonemoto, K., Ninomiya, T., Iwase, M., Arima, H., Hata, J., Tanizaki, Y., Iida, M., and Kiyohara, Y. Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(9):3425-3429.

Dorkhan, M., Dencker, M., Stagmo, M., and Groop, L. Effect of pioglitazone versus insulin glargine on cardiac size, function, and measures of fluid retention in patients with type 2 diabetes. *Cardiovascular Diabetology*. 2009;8:15.

Drew Bg, Duffy S. J. F. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. *Circulation*. 2009;119(15):2103-2111.

Duckworth, W. and Davis, S. N. Comparison of insulin glargine and NPH insulin in the treatment of type 2 diabetes: a review of clinical studies. *Journal of Diabetes & its Complications*. 2007;21(3):196-204.

Duckworth, W. Glucose control and vascular complications in veterans with type 2 diabetes. *The New England journal of medicine*. 2009;360(2):129-139.

Dullaart Rp, de Vries. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. *European Journal of Clinical Investigation*. 2009;39(3):200-203.

Dunkelgrun, M., Schreiner, F., Schockman, D. B., Hoeks, S. E., Feringa, H. H., Goei, D., Schouten, O., Welten, G. M., Vidakovic, R., Noordzij, P. G., Boersma, E., and Poldermans, D. Usefulness of preoperative oral glucose tolerance testing for perioperative risk stratification in patients scheduled for elective vascular surgery. *American Journal of Cardiology*. 2008;101(4):526-529.

Duran, C. The investigation of the efficacy of insulin glargine on glycemic control when combined with either repaglinide or acarbose in obese Type 2 diabetic patients. *Journal of Endocrinological Investigation*. 2009;32(1):69-73.

Dushay, J. and Abrahamson, M. J. Insulin therapy for type 2 diabetes: making it work. *Journal of Family Practice*. 2010;59(4):E1-E8.

Dyson, P. A., Beatty, S., and Matthews, D. R. A low-carbohydrate diet is more effective in reducing

- body weight than healthy eating in both diabetic and non-diabetic subjects. *Diabetic Medicine*. 2007;24(12):1430-1435.
- Dyson, P. A. A review of low and reduced carbohydrate diets and weight loss in type 2 diabetes. *Journal of Human Nutrition & Dietetics*. 2008;21(6):530-538.
- Ebato, C., Shimizu, T., Arakawa, M., Mita, T., Fujitani, Y., Watada, H., Kawamori, R., and Hirose, T. Effect of sulfonylureas on switching to insulin therapy (twice-daily biphasic insulin aspart 30): comparison of twice-daily biphasic insulin aspart 30 with or without glimepiride in type 2 diabetic patients poorly controlled with sub-maximal glimepiride. *Diabetes Research & Clinical Practice*. 2009;86(1):31-36.
- Eccles, M. P., Hawthorne, G., Johnston, M., Hunter, M., Steen, N., Francis, J., Hrisos, S., Elovainio, M., and Grimshaw, J. M. Improving the delivery of care for patients with diabetes through understanding optimised team work and organisation in primary care. *Implementation Science*. 2009;4:22.
- Elinav, H., Wolf, Z., Szalat, A., Bdolah-Abram, T., Glaser, B., Raz, I., and Leibowitz, G. In-hospital treatment of hyperglycemia: effects of intensified subcutaneous insulin treatment. *Current Medical Research & Opinion*. 2007;23(4):757-765.
- Elrishi, M. A., Jarvis, J., Khunti, K., and Davies, M. J. Insulin glargine and its role in glycaemic management of Type 2 diabetes. *Expert Opinion On Drug Metabolism & Toxicology*. 2008;4(8):1099-1110.
- Erhardt, L. R. Rationale for multiple risk intervention: the need to move from theory to practice. *Vascular Health & Risk Management*. 2007;3(6):985-997.
- Eriksen, L., Dahl-Petersen, I., Haugaard, S. B., and Dela, F. Comparison of the effect of multiple short-duration with single long-duration exercise sessions on glucose homeostasis in type 2 diabetes mellitus.[Reprint in *Ugeskr Laeger*. 2009 Mar 9;171(11):878-80; PMID: 19291864]. *Diabetologia*. 2007;50(11):2245-2253.
- Eriksen, L. Comparison of the effect of multiple short-duration with single long-duration exercise sessions on glucose homeostasis in type 2 diabetes mellitus. *Diabetologia*. 2007;50(11):2245-2253.
- Eriksson, A., Attvall, S., Bonnier, M., Eriksson, J. W., Rosander, B., and Karlsson, F. A. Short-term effects of metformin in type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(4):483-489.
- Ertugrul, D. T., Tural, E., Yildiz, M., Akin, O., Yalcin, A. A., Ure, O. S., Yilmaz, H., Yavuz, B., Deveci, O. S., Ata, N., and Kucukazman, M. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2897-2901.
- Esposito, K., Ciotola, M., Maiorino, M. I., Gualdiero, R., Schisano, B., Ceriello, A., Beneduce, F., Feola, G., and Giugliano, D. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial.[Summary for patients in *Ann Intern Med*. 2008 Oct 21;149(8):I-46; PMID: 18936498]. [Summary for patients in *Ann Intern Med*. 2008 Oct 21;149(8):I-52; PMID: 18936499]. *Annals of Internal Medicine*. 2008;149(8):531-539.
- Esposito, K. Addition of neutral protamine lispro insulin or insulin glargine to oral type 2 diabetes regimens for patients with suboptimal glycemic control: a randomized trial. *Annals of Internal Medicine*. 2008;149(8):531-539.
- Evangelista, V., De Berardis, G., Totani, L., Avanzini, F., Giorda, C. B., Brero, L., Levantesi, G., Marelli, G., Pupillo, M., Iacuiti, G., Pozzoli, G., di Summa, P., Nada, E., de Simone, G., Dell'Elba, G., Amore, C., Manarini, S., Pecce, R., Maione, A., Tognoni, G., and Nicolucci, A. Persistent platelet

activation in patients with type 2 diabetes treated with low doses of aspirin. *Journal of Thrombosis & Haemostasis*. 2007;5(11):2197-2203.

Exenatide: new drug. Type 2 diabetes for some overweight patients. *Prescrire International*. 2007;16(92):228-231.

Faeh, D., William, J., Yerly, P., Paccaud, F., and Bovet, P. Diabetes and pre-diabetes are associated with cardiovascular risk factors and carotid/femoral intima-media thickness independently of markers of insulin resistance and adiposity. *Cardiovascular Diabetology*. 2007;6:32.

Faerch, K., Vaag, A., Holst, J. J., Hansen, T., Jorgensen, T., and Borch-Johnsen, K. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. *Diabetes Care*. 2009;32(3):439-444.

Faerch, K. Predictors of future fasting and 2-h post-OGTT plasma glucose levels in middle-aged men and women-the Inter99 study. *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(4):377-383.

Fahrback, J., Jacober, S., Jiang, H., and Martin, S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(5):831-838.

Fajardo, Montanana C. Less weight gain and hypoglycaemia with once-daily insulin detemir than NPH insulin in intensification of insulin therapy in overweight Type 2 diabetes patients: the PREDICTIVE BMI clinical trial. *Diabetic medicine : a journal of the British Diabetic Association*. 2008;25(8):916-923.

Fakhoury, W., Lockhart, I., Kotchie, R. W., Aagren, M., and LeReun, C. Indirect comparison of once daily insulin detemir and glargine in reducing weight gain and hypoglycaemic episodes when administered in addition to conventional oral anti-diabetic therapy in patients with type-2 diabetes. *Pharmacology*. 2008;82(2):156-163.

Falconer, D. G., Buckley, A., and Colagiuri, R. Counting the cost of type 2 diabetes in Vanuatu. *Diabetes Research & Clinical Practice*. 2010;87(1):92-97.

Fasano, C. J., O'Malley, G., Dominici, P., Aguilera, E., and Latta, D. R. Comparison of octreotide and standard therapy versus standard therapy alone for the treatment of sulfonylurea-induced hypoglycemia. *Annals of Emergency Medicine*. 2008;51(4):400-406.

Fasy, E. A. and Buse, J. B. Treatment of postprandial hyperglycemia in type 2 diabetes. *Postgraduate Medicine*. 2001;110(6 Suppl):14-19.

Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid. *Cardiovascular Journal of Africa*. 2008;19(3):171-172.

Ferland, A., Brassard, P., Lemieux, S., Bergeron, J., Bogaty, P., Bertrand, F., Simard, S., and Poirier, P. Impact of high-fat /low-carbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in Type 2 diabetes. *Diabetic Medicine*. 2009;26(6):589-595.

Fernandez, M., Triplitt, C., Wajcberg, E., Sriwijilkamol, A. A., Musi, N., Cusi, K., DeFronzo, R., and Cersosimo, E. Addition of pioglitazone and ramipril to intensive insulin therapy in type 2 diabetic patients improves vascular dysfunction by different mechanisms. *Diabetes Care*. 2008;31(1):121-127.

Fernandez-Campo, L. Effect of different antihypertensive treatments on Ras, MAPK and Akt activation in hypertension and diabetes. *Clinical science (London, England : 2009;1979)* 116(2):165-173.

Ferrannini, E., Fonseca, V., Zinman, B., Matthews, D., Ahren, B., Byiers, S., Shao, Q., and Dejager, S. Fifty-two-week efficacy and safety of vildagliptin vs. glimepiride in patients with type 2 diabetes

mellitus inadequately controlled on metformin monotherapy.[Erratum appears in Diabetes Obes Metab. 2009 Apr;11(4):405]. Diabetes, Obesity & Metabolism. 2009;11(2):157-166.

FIELD study supports the value of fenofibrate in type 2 diabetes management. Good glycaemic control achieved with no weight gain. Cardiovascular Journal of Africa. 2007;18(3):205-206.

Finn Av, Oh J. S. H. Predictive factors for in-stent late loss and coronary lesion progression in patients with type 2 diabetes mellitus randomized to rosiglitazone or placebo. American Heart Journal. 2009;157(2):383.

Florentin, M., Liberopoulos, E. N., Mikhailidis, D. P., and Elisaf, M. S. Sitagliptin in clinical practice: a new approach in the treatment of type 2 diabetes. Expert Opinion on Pharmacotherapy. 2008;9(10):1705-1720.

Foley, J. E. and Sreenan, S. Efficacy and safety comparison between the DPP-4 inhibitor vildagliptin and the sulfonylurea gliclazide after two years of monotherapy in drug-naïve patients with type 2 diabetes.[Erratum appears in Horm Metab Res. 2009 Dec;41(12):909]. Hormone & Metabolic Research. 2009;41(12):905-909.

Fonseca, V. A., Rosenstock, J., Wang, A. C., Truitt, K. E., and Jones, M. R. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31(8):1479-1484.

Fonseca, V., Bakris, G. L., Bell, D. S., McGill, J. B., Raskin, P., Messerli, F. H., Phillips, R. A., Katholi, R. E., Wright, J. T., Jr., Waterhouse, B., Lukas, M. A., Anderson, K. M., and for the, Gemini Investigators. Differential effect of beta-blocker therapy on insulin resistance as a function of insulin sensitizer use: results from GEMINI. Diabetic Medicine. 2007;24(7):759-763.

Fonseca, V., Baron, M., Shao, Q., and Dejager, S. Sustained efficacy and reduced hypoglycemia during one year of treatment with vildagliptin added to insulin in patients with type 2 diabetes mellitus. Hormone & Metabolic Research. 2008;40(6):427-430.

Fonseca, V., Schweizer, A., Albrecht, D., Baron, M. A., Chang, I., and Dejager, S. Addition of vildagliptin to insulin improves glycaemic control in type 2 diabetes. Diabetologia. 2007;50(6):1148-1155.

Forsblom, C., Hiukka, A., Leinonen, E. S., Sundvall, J., Groop, P. H., and Taskinen, M. R. Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy. Diabetes Care. 2010;33(2):215-220.

Foster, G. D., Borradaile, K. E., Vander Veur, S. S., Leh Shantz, K., Dilks, R. J., Goldbacher, E. M., Oliver, T. L., Lagrotte, C. A., Homko, C., and Satz, W. The effects of a commercially available weight loss program among obese patients with type 2 diabetes: a randomized study. Postgraduate Medicine. 2009;121(5):113-118.

Frampton Mw, Stewart J. C. C. Platelet and vascular effects in type 2 diabetes inhaling ultrafine carbon particles [Abstract]. American Thoracic Society International Conference, May. 2007.

Fraser, A., Abel, R., Lawlor, D. A., Fraser, D., and Elhayany, A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. Diabetologia. 2008;51(9):1616-1622.

Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., and Mahaffey, K. W. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. Postgraduate Medicine. 2010;122(3):16-27.

Fujita, M., Asanuma, H., Kim, J., Liao, Y., Hirata, A., Tsukamoto, O., Minamino, T., Hori, M., Goto, M., Node, K., and Kitakaze, M. Impaired glucose tolerance: a possible contributor to left ventricular hypertrophy and diastolic dysfunction. International Journal of Cardiology. 2007;118(1):76-80.

Gaede, P., Lund-Andersen, H., Parving, H. H., and Pedersen, O. Effect of a multifactorial intervention

on mortality in type 2 diabetes. *New England Journal of Medicine*. 2008;358(6):580-591.

Gaede, P., Valentine, W. J., Palmer, A. J., Tucker, D. M., Lammert, M., Parving, H. H., and Pedersen, O. Cost-effectiveness of intensified versus conventional multifactorial intervention in type 2 diabetes: results and projections from the Steno-2 study. *Diabetes Care*. 2008;31(8):1510-1515.

Gaede, P. Multifactorial intervention in patients with type 2 diabetes: long-term effects on mortality and vascular complications [abstract no: SA-FC042]. *Journal of the American Society of Nephrology*. 2007;18(Abstracts):43A.

Gagliardino, J. J., Santoro, S., Arellano, S., and Di Girolamo, G. New treatments for type 2 diabetes mellitus: combined therapy with sitagliptin. *Expert Opinion on Pharmacotherapy*. 2008;9(9):1495-1507.

Gale, C. R., Kivimaki, M., Lawlor, D. A., Carroll, D., Phillips, A. C., and Batty, G. D. Fasting glucose, diagnosis of type 2 diabetes, and depression: the Vietnam experience study. *Biological Psychiatry*. 2010;67(2):189-192.

Gale, E. A., Beattie, S. D., Hu, J., Koivisto, V., and Tan, M. H. Recruitment to a clinical trial improves glycemic control in patients with diabetes. *Diabetes Care*. 2007;30(12):2989-2992.

Gallagher, A., Butler, T. J., and Home, P. D. The effect of the optimal use of rapid-acting insulin analogues on insulin secretion in Type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;76(3):327-334.

Galle, J., Schwedhelm, E., Pinnetti, S., Boger, R. H., Wanner, C., and investigators, Vivaldi. Antiproteinuric effects of angiotensin receptor blockers: telmisartan versus valsartan in hypertensive patients with type 2 diabetes mellitus and overt nephropathy. *Nephrology Dialysis Transplantation*. 2008;23(10):3174-3183.

Galvano, F., Li Volti, G., Malaguarnera, M., Avitabile, T., Antic, T., and Vacante, M. Effects of simvastatin and carnitine versus simvastatin on lipoprotein(a) and apoprotein(a) in type 2 diabetes mellitus. *Expert Opinion on Pharmacotherapy*. 2009;10(12):1875-1882.

Gandhi, G. Y., Murad, M. H., Fujiyoshi, A., Mullan, R. J., Flynn, D. N., Elamin, M. B., Swiglo, B. A., Isley, W. L., Guyatt, G. H., and Montori, V. M. Patient-important outcomes in registered diabetes trials. *Jama*. 2008;299(21):2543-2549.

Gangji, A. S., Cukierman, T., Gerstein, H. C., Goldsmith, C. H., and Clase, C. M. A systematic review and meta-analysis of hypoglycemia and cardiovascular events: a comparison of glyburide with other secretagogues and with insulin. *Diabetes Care*. 2007;30(2):389-394.

Gao, H., Xiao, W., Wang, C., Zhang, J., Yang, Y., Yang, J., Yang, W., and Hong, T. The metabolic effects of once daily extended-release metformin in patients with type 2 diabetes: a multicentre study. *International Journal of Clinical Practice*. 2008;62(5):695-700.

Gao, Y., Li, G., Li, Y., Guo, X., Yuan, G., Gong, Q., Yan, L., Zheng, Y., and Zhang, J. Postprandial blood glucose response to a standard test meal in insulin-requiring patients with diabetes treated with insulin lispro mix 50 or human insulin mix 50. *International Journal of Clinical Practice*. 2008;62(9):1344-1351.

Gao, Y. Efficacy and safety of exenatide in patients of Asian descent with type 2 diabetes inadequately controlled with metformin or metformin and a sulphonylurea. *Diabetes research and clinical practice*. 2009;83(1):69-76.

Garber, A. J. and Sharma, M. D. Update: vildagliptin for the treatment of Type 2 diabetes. *Expert Opinion on Investigational Drugs*. 2008;17(1):105-113.

Garber, A. J. and Spann, S. J. An overview of incretin clinical trials. *Journal of Family Practice*.

2008;57(9 Suppl):S10-S18.

Garber, A. J., Clauson, P., Pedersen, C. B., and Kolendorf, K. Lower risk of hypoglycemia with insulin detemir than with neutral protamine hagedorn insulin in older persons with type 2 diabetes: a pooled analysis of phase III trials. *Journal of the American Geriatrics Society*. 2007;55(11):1735-1740.

Garber, A. J., Foley, J. E., Banerji, M. A., Ebeling, P., Gudbjornsdottir, S., Camisasca, R. P., Couturier, A., and Baron, M. A. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. *Diabetes, Obesity & Metabolism*. 2008;10(11):1047-1056.

Garber, A. J., Schweizer, A., Baron, M. A., Rochotte, E., and Dejager, S. Vildagliptin in combination with pioglitazone improves glycaemic control in patients with type 2 diabetes failing thiazolidinedione monotherapy: a randomized, placebo-controlled study. *Diabetes, Obesity & Metabolism*. 2007;9(2):166-174.

Garber, A. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. *Lancet*. 2009;373(9662):473-481.

Garcia-Soria, G., Gonzalez-Galvez, G., Argoud, G. M., Gerstman, M., Littlejohn, T. W., III, Schwartz, S. L., O'Farrell, A. M., Li, X., Cherrington, J. M., Bennett, C., and Guler, H. P. The dipeptidyl peptidase-4 inhibitor PHX1149 improves blood glucose control in patients with type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2008;10(4):293-300.

Garg, R. Rosiglitazone: safety and efficacy in combination with insulin in poorly controlled type 2 diabetes mellitus patients treated with insulin alone. *Journal of diabetes and its complications*. 2007;21(1):1-6.

Garnett, S. P., Srinivasan, S., Birt, S. G., Ambler, G. R., Lawrie, E. A., Cowell, C. T., and Craig, M. E. Evaluation of glycaemic status in young people with clinical insulin resistance; fasting glucose, fasting insulin or an oral glucose tolerance test?. *Clinical Endocrinology*. 2010;72(4):475-480.

Gastaldelli, A. Decreased whole body lipolysis as a mechanism of the lipid-lowering effect of pioglitazone in type 2 diabetic patients. *American journal of physiology*. 2009;Endocrinology and metabolism. 297(1):E225-E230.

Gastaldelli, A. Effect of pioglitazone on the metabolic and hormonal response to a mixed meal in type II diabetes. *Clinical pharmacology and therapeutics*. 2007;81(2):205-212.

Gastaldelli, A. Thiazolidinediones improve beta-cell function in type 2 diabetic patients. *American journal of physiology*. 2007;Endocrinology and metabolism. 292(3):E871-E883.

Gautier, A., Balkau, B., Lange, C., Tichet, J., Bonnet, F., and Group, Desir Study. Risk factors for incident type 2 diabetes in individuals with a BMI of

Geloneze, B., Geloneze, S. R., Fiori, C., Stabe, C., Tambascia, M. A., Chaim, E. A., Astiarraga, B. D., and Pareja, J. C. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. *Obesity Surgery*. 2009;19(8):1077-1083.

Gerstein, H. C. M. Effects of intensive glucose lowering in type 2 diabetes. Action to Control Cardiovascular Risk in Diabetes Study Group. *New England Journal of Medicine*. 2008;358(24):2545-2559.

Gerstein, H. C., Riddle, M. C., Kendall, D. M., Cohen, R. M., Goland, R., Feinglos, M. N., Kirk, J. K., Hamilton, B. P., Ismail-Beigi, F., Feeney, P., and Group, Accord Study. Glycemia treatment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *American Journal of Cardiology*. 2007;99(12A):34i-43i.

Gerstein, H. C., Yale, J. F., Harris, S. B., Issa, M., Stewart, J. A., and Dempsey, E. A randomized trial of adding insulin glargine vs. avoidance of insulin in people with Type 2 diabetes on either no oral

glucose-lowering agents or submaximal doses of metformin and/or sulphonylureas. The Canadian INSIGHT (Implementing New Strategies with Insulin Glargine for Hyperglycaemia Treatment) Study. *Diabetic Medicine*. 2006;23(7):736-742.

Gerth, W. C., Remuzzi, G., Viberti, G., Hannedouche, T., Martinez-Castelao, A., Shahinfar, S., Carides, G. W., and Brenner, B. Losartan reduces the burden and cost of ESRD: public health implications from the RENAAL study for the European Union. *Kidney International - Supplement*. 2002;(82):S68-S72.

Getaneh, A., Michelen, W., and Findley, S. The prevalence of cardiovascular risk conditions and awareness among a Latino subgroup: Dominicans in northern Manhattan.[Summary for patients in *Ethn Dis*. 2008 Summer;18(3):389-90; PMID: 18788118]. *Ethnicity & Disease*. 2008;18(3):342-347.

Gibson, A. A., Schaffer, J. E., Peterson, L. R., Bilhorn, K. R., Robert, K. M., Haider, T. A., Farmer, M. S., Holland, M. R., and Miller, J. G. Quantitative analysis of the magnitude and time delay of cyclic variation of myocardial backscatter from asymptomatic type 2 diabetes mellitus subjects. *Ultrasound in Medicine & Biology*. 2009;35(9):1458-1467.

Gill, A., Hoogwerf, B. J., Burger, J., Bruce, S., MacConell, L., Yan, P., Braun, D., Giaconia, J., and Malone, J. Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study. *Cardiovascular Diabetology*. 2010;9:6.

Ginde, A. A., Cagliero, E., Nathan, D. M., and Camargo, C. A., Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. *Academic Emergency Medicine*. 2008;15(12):1241-1247.

Giordanino, C., Bugianesi, E., Smedile, A., Ciancio, A., Abate, M. L., Olivero, A., Pellicano, R., Cassader, M., Gambino, R., Bo, S., Ciccone, G., Rizzetto, M., and Saracco, G. Incidence of type 2 diabetes mellitus and glucose abnormalities in patients with chronic hepatitis C infection by response to treatment: results of a cohort study. *American Journal of Gastroenterology*. 2008;103(10):2481-2487.

Glitazones in type 2 diabetes: an update. *Drug & Therapeutics Bulletin*. 2008;46(4):25-29.

Gobert, C. P., Pipe, E. A., Capes, S. E., Darlington, G. A., Lampe, J. W., and Duncan, A. M. Soya protein does not affect glycaemic control in adults with type 2 diabetes. *British Journal of Nutrition*. 2010;103(3):412-421.

Goderis, G., Borgermans, L., Grol, R., Van Den Broeke, C., Boland, B., Verbeke, G., Carbonez, A., Mathieu, C., and Heyrman, J. Start improving the quality of care for people with type 2 diabetes through a general practice support program: a cluster randomized trial. *Diabetes Research & Clinical Practice*. 2010;88(1):56-64.

Goke, B., Gause-Nilsson, I., Persson, A., and Group, Gallant Study. The effects of tesaglitazar as add-on treatment to metformin in patients with poorly controlled type 2 diabetes. *Diabetes & Vascular Disease Research*. 2007;4(3):204-213.

Goke, B., Hershon, K., Kerr, D., Calle Pascual, A., Schweizer, A., Foley, J., Shao, Q., and Dejager, S. Efficacy and safety of vildagliptin monotherapy during 2-year treatment of drug-naïve patients with type 2 diabetes: comparison with metformin. *Hormone & Metabolic Research*. 2008;40(12):892-895.

Goldberg, R. B., Fonseca, V. A., Truitt, K. E., and Jones, M. R. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. *Archives of Internal Medicine*. 2008;168(14):1531-1540.

Goldberg, R. B. Thiazolidinediones and vascular damage. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2007;14(2):108-115.

Goldfine, A. B., Fonseca, V. A., Jones, M. R., Wang, A. C., Ford, D. M., and Truitt, K. E. Long-term Safety and Tolerability of Colesevelam HCl in Subjects with Type 2 Diabetes. *Hormone & Metabolic*

Research. 2010;42(1):23-30.

Goldfine, A. B., Fonseca, V., Jablonski, K. A., Pyle, L., Staten, M. A., Shoelson, S. E., and Team, Tinsal. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial.[Summary for patients in Ann Intern Med. 2010 Mar 16;152(6):I-40; PMID: 20231550]. Annals of Internal Medicine. 2010;152(6):346-357.

Goldfine, A. B. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. Current Opinion in Cardiology. 2008;23(5):502-511.

Goldfine, A. B. The rough road for rosiglitazone. Current Opinion in Endocrinology, Diabetes & Obesity. 2008;15(2):113-117.

Goldstein Bj, Feinglos M. N. L. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes. Diabetes Care. 2007;30(8):1979-1987.

Goldstein, B. J., Feinglos, M. N., Lunceford, J. K., Johnson, J., Williams-Herman, D. E., and Study, Group. Effect of initial combination therapy with sitagliptin, a dipeptidyl peptidase-4 inhibitor, and metformin on glycemic control in patients with type 2 diabetes.[Erratum appears in Diabetes Care. 2008 Aug;31(8):1713]. Diabetes Care. 2007;30(8):1979-1987.

Golubnitschaja, O. Diabetes care: risk factors, prediction, prevention, and individualized treatment. Infectious Disorders - Drug Targets. 2008;8(2):68-69.

Gonzalez-Ortiz, M., Guerrero-Romero, J. F., Violante-Ortiz, R., Wachter-Rodarte, N., Martinez-Abundis, E., Aguilar-Salinas, C., Islas-Andrade, S., Arechavaleta-Granell, R., Gonzalez-Canudas, J., Rodriguez-Moran, M., Zavala-Suarez, E., Ramos-Zavala, M. G., Metha, R., Revilla-Monsalve, C., and Beltran-Jaramillo, T. J. Efficacy of glimepiride/metformin combination versus glibenclamide/metformin in patients with uncontrolled type 2 diabetes mellitus. Journal of Diabetes & its Complications. 2009;23(6):376-379.

Gonzalez-Ortiz, M., Hernandez-Gonzalez, S. O., Hernandez-Salazar, E., and Martinez-Abundis, E. Effect of oral L-carnitine administration on insulin sensitivity and lipid profile in type 2 diabetes mellitus patients. Annals of Nutrition & Metabolism. 2008;52(4):335-338.

Goodall, G., Jendle, J. H., Valentine, W. J., Munro, V., Brandt, A. B., Ray, J. A., Roze, S., Foos, V., and Palmer, A. J. Biphasic insulin aspart 70/30 vs. insulin glargine in insulin naive type 2 diabetes patients: modelling the long-term health economic implications in a Swedish setting. International Journal of Clinical Practice. 2008;62(6):869-876.

Goodman, M. Efficacy and tolerability of vildagliptin in patients with type 2 diabetes inadequately controlled with metformin monotherapy. Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme. 2009;41(5):368-373.

Gordon, L. A., Morrison, E. Y., McGrowder, D. A., Young, R., Fraser, Y. T., Zamora, E. M., Alexander-Lindo, R. L., and Irving, R. R. Effect of exercise therapy on lipid profile and oxidative stress indicators in patients with type 2 diabetes. BMC Complementary & Alternative Medicine. 2008;8:21.

Gordon, L. Effect of yoga and traditional physical exercise on hormones and percentage insulin binding receptor in patients with type 2 diabetes. American Journal of Biochemistry and Biotechnology. 2008;4(1):35-42.

Gorin, A. A., Niemeier, H. M., Hogan, P., Coday, M., Davis, C., Dillillo, V. G., Gluck, M. E., Wadden, T. A., West, D. S., Williamson, D., Yanovski, S. Z., and Look, Ahead Research Group. Binge eating and weight loss outcomes in overweight and obese individuals with type 2 diabetes: results from the Look AHEAD trial. Archives of General Psychiatry. 2008;65(12):1447-1455.

Govind, S. C., Brodin, L. A., Nowak, J., Arvind, S. R., Ramesh, S. S., Netyo, A., Prasad, K. Y., and Saha, S. Microalbuminuria and left ventricular function in type 2 diabetes: a quantitative assessment by stress echocardiography in the Myocardial Doppler in Diabetes (MYDID) Study III. *Scandinavian Cardiovascular Journal*. 2007;41(6):363-369.

Grant, R. W., Wald, J. S., Schnipper, J. L., Gandhi, T. K., Poon, E. G., Orav, E. J., Williams, D. H., Volk, L. A., and Middleton, B. Practice-linked online personal health records for type 2 diabetes mellitus: a randomized controlled trial. *Archives of Internal Medicine*. 2008;168(16):1776-1782.

Gredal, C., Rosenfalck, A. M., Dejgaard, A., and Hilsted, J. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2007;67(3):327-336.

Gredal, C., Rosenfalck, A. M., Dejgaard, A., and Hilsted, J. Targeting postprandial hyperglycaemia in patients with recently diagnosed type 2 diabetes with a fixed, weight-based dose of insulin Aspart. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2008;68(8):739-744.

Gredal, C., Rosenfalck, A., Dejgaard, A., and Hilsted, J. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;80(2):293-298.

Gross, J. L., Nakano, M., Colon-Vega, G., Ortiz-Carasquillo, R., Ferguson, J. A., Althouse, S., Tobian, J. A., Berclaz, P. Y., and Milicevic, Z. Initiation of prandial insulin therapy with AIR inhaled insulin or insulin lispro in patients with type 2 diabetes: A randomized noninferiority trial. *Diabetes Technology & Therapeutics*. 2009;11 Suppl 2:S27-S34.

Grossman Ld, Parlan G. B. Tolerability outcomes of a multicenter, observational, open-label, drug-surveillance study in patients with type 2 diabetes mellitus treated with pioglitazone for 2 years. *Clinical Therapeutics*. 2009;31(1):74-88.

Group, Accord Study, Cushman, W. C., Evans, G. W., Byington, R. P., Goff, D. C., Jr., Grimm, R. H., Jr., Cutler, J. A., Simons-Morton, D. G., Basile, J. N., Corson, M. A., Probstfield, J. L., Katz, L., Peterson, K. A., Friedewald, W. T., Buse, J. B., Bigger, J. T., Gerstein, H. C., and Ismail-Beigi, F. Effects of intensive blood-pressure control in type 2 diabetes mellitus. *New England Journal of Medicine*. 2010;362(17):1575-1585.

Group, Accord Study, Ginsberg, H. N., Elam, M. B., Lovato, L. C., Crouse, J. R., III, Leiter, L. A., Linz, P., Friedewald, W. T., Buse, J. B., Gerstein, H. C., Probstfield, J., Grimm, R. H., Ismail-Beigi, F., Bigger, J. T., Goff, D. C., Jr., Cushman, W. C., Simons-Morton, D. G., and Byington, R. P. Effects of combination lipid therapy in type 2 diabetes mellitus. *New England Journal of Medicine*. 2010;362(17):1563-1574.

Group, Accord Study, Group, Accord Eye Study, Chew, E. Y., Ambrosius, W. T., Davis, M. D., Danis, R. P., Gangaputra, S., Greven, C. M., Hubbard, L., Esser, B. A., Lovato, J. F., Perdue, L. H., Goff, D. C., Jr., Cushman, W. C., Ginsberg, H. N., Elam, M. B., Genuth, S., Gerstein, H. C., Schubart, U., and Fine, L. J. Effects of medical therapies on retinopathy progression in type 2 diabetes. *New England Journal of Medicine*. 2010;363(3):233-244.

Group, Advance Collaborative, Patel, A., MacMahon, S., Chalmers, J., Neal, B., Billot, L., Woodward, M., Marre, M., Cooper, M., Glasziou, P., Grobbee, D., Hamet, P., Harrap, S., Heller, S., Liu, L., Mancia, G., Mogensen, C. E., Pan, C., Poulter, N., Rodgers, A., Williams, B., Bompoint, S., de Galan, B. E., Joshi, R., and Travert, F. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. *New England Journal of Medicine*. 2008;358(24):2560-2572.

Group, D. Study. A randomized trial of therapies for type 2 diabetes and coronary artery disease. *The New England journal of medicine*. 2009;360(24):2503-2515.

Grover-Paez, F., Villegas Rivera, G., and Guillen Ortiz, R. Sildenafil citrate diminishes microalbuminuria and the percentage of A1c in male patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;78(1):136-140.

Grunberger, G. The benefits of early intervention in obese diabetic patients with FBCx: a new dietary fibre. *Diabetes/metabolism research and reviews*. 2007;23(1):56-62.

Guo LL, Pan Y. J. Adiponectin is positively associated with insulin resistance in subjects with type 2 diabetic nephropathy and effects of angiotensin II type 1 receptor blocker losartan. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2009;24(6):1876-1883.

Gupta, A. K., Smith, S. R., Greenway, F. L., and Bray, G. A. Pioglitazone treatment in type 2 diabetes mellitus when combined with portion control diet modifies the metabolic syndrome. *Diabetes, Obesity & Metabolism*. 2009;11(4):330-337.

Gupta, M., Braga, M. B., and Verma, S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. *Canadian Journal of Cardiology*. 2008;24(10):e65-e69.

Gutschall, M. D., Miller, C. K., Mitchell, D. C., and Lawrence, F. R. A randomized behavioural trial targeting glycaemic index improves dietary, weight and metabolic outcomes in patients with type 2 diabetes. *Public Health Nutrition*. 2009;12(10):1846-1854.

Hadaegh, F., Bozorgmanesh, M. R., Ghasemi, A., Harati, H., Saadat, N., and Azizi, F. High prevalence of undiagnosed diabetes and abnormal glucose tolerance in the Iranian urban population: Tehran Lipid and Glucose Study. *BMC Public Health*. 2008;8:176.

Hadaegh, F., Khalili, D., Fahimfar, N., Tohidi, M., Eskandari, F., and Azizi, F. Glucose intolerance and risk of cardiovascular disease in Iranian men and women: results of the 7.6-year follow-up of the Tehran Lipid and Glucose Study (TLGS). *Journal of Endocrinological Investigation*. 2009;32(9):724-730.

Hadjadj, S., Gourdy, P., Zaoui, P., Guerci, B., Roudaut, N., Gautier, J. F., Chabin, M., Mauco, G., Ragot, S., and Group, Radian Study. Effect of raloxifene -- a selective oestrogen receptor modulator -- on kidney function in post-menopausal women with Type 2 diabetes: results from a randomized, placebo-controlled pilot trial. *Diabetic Medicine*. 2007;24(8):906-910.

Hadjibabaie, M. Comparative efficacy of daily versus alternate-day dosing of atorvastatin in type 2 diabetic patients. *Therapy*. 2007;4(5):541-545.

Hage, C., Norhammar, A., Grip, L., Malmberg, K., Sarkar, N., Svane, B., and Ryden, L. Glycaemic control and restenosis after percutaneous coronary interventions in patients with diabetes mellitus: a report from the Insulin Diabetes Angioplasty study. *Diabetes & Vascular Disease Research*. 2009;6(2):71-79.

Haimoto, H., Iwata, M., Wakai, K., and Umegaki, H. Long-term effects of a diet loosely restricting carbohydrates on HbA1c levels, BMI and tapering of sulfonylureas in type 2 diabetes: a 2-year follow-up study. *Diabetes Research & Clinical Practice*. 2008;79(2):350-356.

Haluzik Mm, Anderlova K. D. Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment. *Physiological research / Academia Scientiarum Bohemoslovaca*. 2009;58(1):93-99.

Hamann, A., Garcia-Puig, J., Paul, G., Donaldson, J., and Stewart, M. Comparison of fixed-dose rosiglitazone/metformin combination therapy with sulphonylurea plus metformin in overweight individuals with Type 2 diabetes inadequately controlled on metformin alone. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116(1):6-13.

Han, J. R., Deng, B., Sun, J., Chen, C. G., Corkey, B. E., Kirkland, J. L., Ma, J., and Guo, W. Effects of dietary medium-chain triglyceride on weight loss and insulin sensitivity in a group of moderately overweight free-living type 2 diabetic Chinese subjects. *Metabolism: Clinical & Experimental*. 2007;56(7):985-991.

Hanai, Y., Adachi, S., Yasuda, I., Takai, S., Matsushima-Nishiwaki, R., Kato, H., Enomoto, Y., Akamatsu, S., Sakakibara, S., Ogura, S., Iwama, T., Kozawa, O., and Tokuda, H. Collagen-induced p38 MAP kinase activation is a biomarker of platelet hyper-aggregation in patients with diabetes mellitus. *Life Sciences*. 2009;85(9-10):386-394.

Hanefeld, M. and Schaper, F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. *Expert Review of Cardiovascular Therapy*. 2008;6(2):153-163.

Hanefeld, M., Herman, G. A., Wu, M., Mickel, C., Sanchez, M., Stein, P. P., and Sitagliptin Study, Investigators. Once-daily sitagliptin, a dipeptidyl peptidase-4 inhibitor, for the treatment of patients with type 2 diabetes. *Current Medical Research & Opinion*. 2007;23(6):1329-1339.

Hanefeld, M. A one-year study comparing the efficacy and safety of rosiglitazone and glibenclamide in the treatment of type 2 diabetes. *Nutrition, metabolism, and cardiovascular diseases : NMCD*. 2007;17(1):13-23.

Hanefeld, M. Anti-inflammatory effects of pioglitazone and/or simvastatin in high cardiovascular risk patients with elevated high sensitivity C-reactive protein: the PIOSTAT Study. *Journal of the American College of Cardiology*. 2007;49(3):290-297.

Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. *Cardiovascular Diabetology*. 2007;6:20.

Hanif, M. W., Valsamakis, G., Dixon, A., Boutsiadis, A., Jones, A. F., Barnett, A. H., and Kumar, S. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. *Diabetes, Obesity & Metabolism*. 2008;10(9):755-762.

Harris, S., Yale, J. F., Dempsey, E., and Gerstein, H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. *Canadian Family Physician*. 2008;54(4):550-558.

Harsch Ia, Koebnick C. T. Ghrelin and obestatin levels in type 2 diabetic patients with and without delayed gastric emptying. *Digestive Diseases & Sciences*. 2009;54(10):2161-2166.

Hartweg, J., Farmer, A. J., Holman, R. R., and Neil, H. A. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on haematological and thrombogenic factors in type 2 diabetes. *Diabetologia*. 2007;50(2):250-258.

Hartweg, J., Farmer, A. J., Perera, R., Holman, R. R., and Neil, H. A. Meta-analysis of the effects of n-3 polyunsaturated fatty acids on lipoproteins and other emerging lipid cardiovascular risk markers in patients with type 2 diabetes. *Diabetologia*. 2007;50(8):1593-1602.

Hartweg, Janine, Perera, Rafael, Montori, Victor M., Dinneen, Sean F., Neil, Andrew Hawn, and Farmer, Andrew J. Omega-3 polyunsaturated fatty acids (PUFA) for type 2 diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Hattori, Y., Hashizume, K., Nakajima, K., Nishimura, Y., Naka, M., and Miyanaga, K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. *Current Medical Research & Opinion*. 2007;23(8):1913-1917.

Hausmann, M., Dellweg, S., Osborn, C., Heinemann, L., Buchwald, A., Roszkamp, R., Genova, P., and Heise, T. Inhaled insulin as adjunctive therapy in subjects with type 2 diabetes failing oral agents: a

controlled proof-of-concept study. *Diabetes, Obesity & Metabolism*. 2006;8(5):574-580.

Havale, S. H. and Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. *Bioorganic & Medicinal Chemistry*. 2009;17(5):1783-1802.

Hawthorne, K., Robles, Y., Cannings-John, R., and Edwards, A. G. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. *Cochrane Database of Systematic Reviews*. 2008;(3):CD006424.

Hayashi, T., Kawashima, S., Itoh, H., Yamada, N., Sone, H., Watanabe, H., Hattori, Y., Ohru, T., Yoshizumi, M., Yokote, K., Kubota, K., Nomura, H., Umegaki, H., Iguchi, A., and Japan, C. D. M. Importance of lipid levels in elderly diabetic individuals: baseline characteristics and 1-year survey of cardiovascular events. *Circulation Journal*. 2008;72(2):218-225.

Hayashi, T., Takai, S., and Yamashita, C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. *Current Vascular Pharmacology*. 2010;8(2):189-197.

Hayashino, Y., Shimbo, T., Tsujii, S., Ishii, H., Kondo, H., Nakamura, T., Nagata-Kobayashi, S., and Fukui, T. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. *International Journal of Cardiology*. 2007;118(1):88-96.

Hayden, M. R., Kolb, L., Chowdbury, N., Karuparthi, P. R., Khanna, R., and Sowers, J. R. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus. *Missouri Medicine*. 2006;103(5):533-538.

He Yl, Horowitz A. W. Vildagliptin does not affect C-peptide clearance in patients with type 2 diabetes. *Journal of Clinical Pharmacology*. 2007;47(1):127-131.

He Yl, Sabo R. P. Study of the pharmacokinetic interaction of vildagliptin and metformin in patients with type 2 diabetes. *Current medical research and opinion*. 2009;25(5):1265-1272.

He, Y. L., Serra, D., Wang, Y., Campestrini, J., Riviere, G. J., Deacon, C. F., Holst, J. J., Schwartz, S., Nielsen, J. C., and Ligueros-Saylan, M. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus. *Clinical Pharmacokinetics*. 2007;46(7):577-588.

He, Y. L., Wang, Y., Bullock, J. M., Deacon, C. F., Holst, J. J., Dunning, B. E., Ligueros-Saylan, M., and Foley, J. E. Pharmacodynamics of vildagliptin in patients with type 2 diabetes during OGTT. *Journal of Clinical Pharmacology*. 2007;47(5):633-641.

He, Y., Zhai, F., Ma, G., Feskens, E. J., Zhang, J., Fu, P., Van't Veer, P., and Yang, X. Abdominal obesity and the prevalence of diabetes and intermediate hyperglycaemia in Chinese adults. *Public Health Nutrition*. 2009;12(8):1078-1084.

Healy, G. N., Dunstan, D. W., Salmon, J., Cerin, E., Shaw, J. E., Zimmet, P. Z., and Owen, N. Objectively measured light-intensity physical activity is independently associated with 2-h plasma glucose. *Diabetes Care*. 2007;30(6):1384-1389.

Hedblad, B. Rosiglitazone and carotid IMT progression rate in a mixed cohort of patients with type 2 diabetes and the insulin resistance syndrome: main results from the Rosiglitazone Atherosclerosis Study. *Journal of Internal Medicine*. 2007;261(3):293-305.

Heinisch, B. B., Francesconi, M., Mittermayer, F., Schaller, G., Gouya, G., Wolzt, M., and Pleiner, J. Alpha-lipoic acid improves vascular endothelial function in patients with type 2 diabetes: a placebo-controlled randomized trial. *European Journal of Clinical Investigation*. 2010;40(2):148-154.

Heise, T., Eckers, U., Kanc, K., Nielsen, J. N., and Nosek, L. The pharmacokinetic and pharmacodynamic properties of different formulations of biphasic insulin aspart: a randomized, glucose

clamp, crossover study. *Diabetes Technology & Therapeutics*. 2008;10(6):479-485.

Heise, T., Mathieu, C., Hey-Hadavi, J., Strack, T., and Lawrence, D. Glycemic control with preprandial versus basal insulin in patients with type 2 diabetes mellitus poorly controlled by oral antidiabetes agents. *Diabetes Technology & Therapeutics*. 2010;12(2):135-141.

Heliovaara, M. K., Herz, M., Teppo, A. M., Leinonen, E., and Ebeling, P. Pioglitazone has anti-inflammatory effects in patients with Type 2 diabetes. *Journal of Endocrinological Investigation*. 2007;30(4):292-297.

Heljic, B. The statins in prevention of coronary heart diseases in type 2 diabetics. *Bosnian journal of basic medical sciences / Udruzenje basicnih medicinskih znanosti = Association of Basic Medical Sciences*. 2009;9(1):71-76.

Heller, S. R. and Group, Advance Collaborative. A summary of the ADVANCE Trial. *Diabetes Care*. 2009;32 Suppl 2:S357-S361.

Henry, R. R. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. *Current Medical Research & Opinion*. 2008;24(8):2189-2202.

Herman, G. A., Stein, P. P., Thornberry, N. A., and Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. *Clinical Pharmacology & Therapeutics*. 2007;81(5):761-767.

Hermansen, K. and Mortensen, L. S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. *Drug Safety*. 2007;30(12):1127-1142.

Hermansen, K., Kipnes, M., Luo, E., Fanurik, D., Khatami, H., Stein, P., and Sitagliptin Study, Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, in patients with type 2 diabetes mellitus inadequately controlled on glimepiride alone or on glimepiride and metformin. *Diabetes, Obesity & Metabolism*. 2007;9(5):733-745.

Hermansen, M. L., Eriksen, N. M., Mortensen, L. S., Holm, L., and Hermansen, K. Can the Glycemic Index (GI) be used as a tool in the prevention and management of Type 2 diabetes?. *The Review of Diabetic Studies*. 2006;3(2):61-71.

Hettihewa Lm, Jayasinghe S. S. I. Correlation between changes of blood pressure with insulin resistance in type 2 diabetes mellitus with 4 weeks of pioglitazone therapy. *International Journal Of Diabetes In Developing Countries*. 2008;28(1):26-30.

Heufelder, A. E., Saad, F., Bunck, M. C., and Gooren, L. Fifty-two-week treatment with diet and exercise plus transdermal testosterone reverses the metabolic syndrome and improves glycemic control in men with newly diagnosed type 2 diabetes and subnormal plasma testosterone. *Journal of Andrology*. 2009;30(6):726-733.

Higher type 2 diabetes-related mortality when HbA1c levels are too low. *Prescrire International*. 2008;17(97):213.

Hill, N. R. and Matthews, D. R. Pioglitazone and metformin. *Drugs of Today*. 2007;43(7):443-454.

Himelhoch, S., Leith, J., Goldberg, R., Kreyenbuhl, J., Medoff, D., and Dixon, L. Care and management of cardiovascular risk factors among individuals with schizophrenia and type 2 diabetes who smoke. *General Hospital Psychiatry*. 2009;31(1):30-32.

Hirani, V., Zaninotto, P., and Primatesta, P. Generalised and abdominal obesity and risk of diabetes, hypertension and hypertension-diabetes co-morbidity in England. *Public Health Nutrition*. 2008;11(5):521-527.

Hirao, K., Arai, K., Yamauchi, M., Takagi, H., Kobayashi, M., and Japan Diabetes Clinical Data Management Study, Group. Six-month multicentric, open-label, randomized trial of twice-daily

injections of biphasic insulin aspart 30 versus multiple daily injections of insulin aspart in Japanese type 2 diabetic patients (JDDM 11). *Diabetes Research & Clinical Practice*. 2008;79(1):171-176.

Hirao, K., Maeda, H., Urata, S., Takisawa, Y., Hirao, S., Sasako, T., and Sasaki, T. Comparison of the pharmacokinetic and pharmacodynamic profiles of biphasic insulin aspart 50 and 30 in patients with type 2 diabetes mellitus: a single-center, randomized, double-blind, two-period, crossover trial in Japan. *Clinical Therapeutics*. 2007;29(5):927-934.

Hiss, R. G., Armbruster, B. A., Gillard, M. L., and McClure, L. A. Nurse care manager collaboration with community-based physicians providing diabetes care: a randomized controlled trial. *Diabetes Educator*. 2007;33(3):493-502.

Hiukka, A., Leinonen, E., Jauhiainen, M., Sundvall, J., Ehnholm, C., Keech, A. C., and Taskinen, M. R. Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.[Erratum appears in *Diabetologia*. 2007 Dec;50(12):2611-3]. *Diabetologia*. 2007;50(10):2067-2075.

Hiukka, A., Westerbacka, J., Leinonen, E. S., Watanabe, H., Wiklund, O., Hulten, L. M., Salonen, J. T., Tuomainen, T. P., Yki-Jarvinen, H., Keech, A. C., and Taskinen, M. R. Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus. *Journal of the American College of Cardiology*. 2008;52(25):2190-2197.

Hlatky, M. A., Boothroyd, D. B., Melsop, K. A., Kennedy, L., Rihal, C., Rogers, W. J., Venkitachalam, L., Brooks, M. M., and Bypass, Angioplasty Revascularization, I. Economic outcomes of treatment strategies for type 2 diabetes mellitus and coronary artery disease in the Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. *Circulation*. 2009;120(25):2550-2558.

Hogue, J. C., Lamarche, B., Tremblay, A. J., Bergeron, J., Gagne, C., and Couture, P. Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(3):380-386.

Holbrook, A., Thabane, L., Keshavjee, K., Dolovich, L., Bernstein, B., Chan, D., Troyan, S., Foster, G., Gerstein, H., and Investigators, Compete II. Individualized electronic decision support and reminders to improve diabetes care in the community: COMPETE II randomized trial. *CMAJ Canadian Medical Association Journal*. 2009;181(1-2):37-44.

Hollander, P. A., Amod, A., Litwak, L. E., Chaudhari, U., and Group, Arpeggio Study. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. *Diabetes Care*. 2010;33(3):605-607.

Hollander, P. A., Cefalu, W. T., Mitnick, M., Lawrence, D., and Rosenstock, J. Titration of inhaled human insulin (Exubera) in a treat-to-target regimen for patients with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2010;12(3):185-191.

Hollander, P., Cooper, J., Bregnhøj, J., and Pedersen, C. B. A 52-week, multinational, open-label, parallel-group, noninferiority, treat-to-target trial comparing insulin detemir with insulin glargine in a basal-bolus regimen with mealtime insulin aspart in patients with type 2 diabetes. *Clinical Therapeutics*. 2008;30(11):1976-1987.

Hollander, P., Li, J., Allen, E., Chen, R., and Investigators, C. V. Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(12):4810-4819.

Hollander, P., Yu, D., and Chou, H. S. Low-dose rosiglitazone in patients with insulin-requiring type 2 diabetes. *Archives of Internal Medicine*. 2007;167(12):1284-1290.

Hollander, P. Endocannabinoid blockade for improving glycemic control and lipids in patients with

type 2 diabetes mellitus. *The American journal of medicine*. 2007;120(2 Suppl 1):S18-S28.

Hollenberg, N. K., Parving, H. H., Viberti, G., Remuzzi, G., Ritter, S., Zelenkofske, S., Kandra, A., Daley, W. L., and Rocha, R. Albuminuria response to very high-dose valsartan in type 2 diabetes mellitus. *Journal of Hypertension*. 2007;25(9):1921-1926.

Holman, R. R., Farmer, A. J., Davies, M. J., Levy, J. C., Darbyshire, J. L., Keenan, J. F., Paul, S. K., and Group, T. Study. Three-year efficacy of complex insulin regimens in type 2 diabetes. *New England Journal of Medicine*. 2009;361(18):1736-1747.

Holman, R. R., Paul, S., Farmer, A., Tucker, L., Stratton, I. M., Neil, H. A., and Atorvastatin in Factorial with Omega. Atorvastatin in Factorial with Omega-3 EE90 Risk Reduction in Diabetes (AFORRD): a randomised controlled trial. *Diabetologia*. 2009;52(1):50-59.

Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., Levy, J. C., and Group, T. Study. Addition of biphasic, prandial, or basal insulin to oral therapy in type 2 diabetes. *New England Journal of Medicine*. 2007;357(17):1716-1730.

Home, P. D. and Lagarenne, P. Combined randomised controlled trial experience of malignancies in studies using insulin glargine. *Diabetologia*. 2009;52(12):2499-2506.

Home, P. D., Bailey, C. J., Donaldson, J., Chen, H., and Stewart, M. W. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes. *Diabetic Medicine*. 2007;24(6):618-625.

Home, P. D., Bailey, C. J., Donaldson, J., Chen, H., and Stewart, M. W. A double-blind randomized study comparing the effects of continuing or not continuing rosiglitazone + metformin therapy when starting insulin therapy in people with Type 2 diabetes.[Erratum appears in *Diabet Med*. 2010 May;27(5):611]. *Diabetic Medicine*. 2007;24(6):618-625.

Home, P. D., Jones, N. P., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Komajda, M., Curtis, P., and Group, Record Study. Rosiglitazone RECORD study: glucose control outcomes at 18 months. *Diabetic Medicine*. 2007;24(6):626-634.

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., McMurray, J. J., and Team, Record Study. Rosiglitazone evaluated for cardiovascular outcomes in oral agent combination therapy for type 2 diabetes (RECORD): a multicentre, randomised, open-label trial. *Lancet*. 2009;373(9681):2125-2135.

Home, P. D., Pocock, S. J., Beck-Nielsen, H., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., McMurray, J. J., and Group, Record Study. Rosiglitazone evaluated for cardiovascular outcomes--an interim analysis. *New England Journal of Medicine*. 2007;357(1):28-38.

Hompesch, M., Ocheltree, S. M., Wondmagegnehu, E. T., Morrow, L. A., Kollmeier, A. P., Campaigne, B. N., and Jacober, S. J. Pharmacokinetics and pharmacodynamics of insulin lispro protamine suspension compared with insulin glargine and insulin detemir in type 2 diabetes. *Current Medical Research & Opinion*. 2009;25(11):2679-2687.

Hompesch, M., Troupin, B., Heise, T., Elbroend, B., Endahl, L., Haahr, H., and Heinemann, L. Time-action profile of insulin detemir and NPH insulin in patients with type 2 diabetes from different ethnic groups. *Diabetes, Obesity & Metabolism*. 2006;8(5):568-573.

Hompesch, M. Glycemic exposure is affected favorably by inhaled human insulin (Exubera) as compared with subcutaneous insulin glargine (Lantus) in patients with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2009;11(5):307-313.

Hoogwerf, B. J., Action to Control Cardiovascular Risk, in, and Diabetes Study, Group. Does intensive therapy of type 2 diabetes help or harm? Seeking accord on ACCORD. *Cleveland Clinic Journal of*

Medicine. 2008;75(10):729-737.

Hoque, R., Rahman, M. S., and Iqbal, M. Effect of enalapril and losartan on proteinuria in type 2 diabetic nephropathy patients. *Bangladesh Medical Research Council Bulletin*. 2009;35(2):44-48.

Hordern, M. D., Coombes, J. S., Cooney, L. M., Jeffriess, L., Prins, J. B., and Marwick, T. H. Effects of exercise intervention on myocardial function in type 2 diabetes. *Heart*. 2009;95(16):1343-1349.

Hordern, M. D., Cooney, L. M., Beller, E. M., Prins, J. B., Marwick, T. H., and Coombes, J. S. Determinants of changes in blood glucose response to short-term exercise training in patients with Type 2 diabetes. *Clinical Science*. 2008;115(9):273-281.

Horton, E. S. Can newer therapies delay the progression of type 2 diabetes mellitus?. *Endocrine Practice*. 2008;14(5):625-638.

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzner, T. W., Plank, J., Kaiser, T., Pieber, T. R., and Siebenhofer, A. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2007;(2):CD005613.

Horvath, Karl, Jeitler, Klaus, Berghold, Andrea, Ebrahim, Susanne H., Gratzner, Thomas W., Plank, Johannes, Kaiser, Thomas, Pieber, Thomas R., and Siebenhofer, Andrea. Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Houlden, R., Ross, S., Harris, S., Yale, J. F., Sauriol, L., and Gerstein, H. C. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. *Diabetes Research & Clinical Practice*. 2007;78(2):254-258.

Houweling, S. T., Kleefstra, N., van Hateren, K. J., Kooy, A., Groenier, K. H., Ten Vergert, E., Meyboom-de Jong, B., Bilo, H. J., and Langerhans Medical Research, Group. Diabetes specialist nurse as main care provider for patients with type 2 diabetes. *Netherlands Journal of Medicine*. 2009;67(7):279-284.

Hovens, M. M., Snoep, J. D., Groeneveld, Y., Frolich, M., Tamsma, J. T., and Huisman, M. V. Effects of aspirin on serum C-reactive protein and interleukin-6 levels in patients with type 2 diabetes without cardiovascular disease: a randomized placebo-controlled crossover trial. *Diabetes, Obesity & Metabolism*. 2008;10(8):668-674.

Hrisos, S., Eccles, M. P., Francis, J. J., Bosch, M., Dijkstra, R., Johnston, M., Grol, R., Kaner, E. F., and Steen, I. N. Using psychological theory to understand the clinical management of type 2 diabetes in Primary Care: a comparison across two European countries. *BMC Health Services Research*. 2009;9:140.

Hsieh, C. H., He, C. T., Lee, C. H., Wu, L. Y., and Hung, Y. J. Both slow-release and regular-form metformin improve glycemic control without altering plasma visfatin level in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2007;56(8):1087-1092.

Hu, D., Fu, P., Xie, J., Chen, C. S., Yu, D., Whelton, P. K., He, J., Gu, D., and Group, M. S. Increasing prevalence and low awareness, treatment and control of diabetes mellitus among Chinese adults: the InterASIA study. *Diabetes Research & Clinical Practice*. 2008;81(2):250-257.

Huang, M. C., Hsu, C. C., Wang, H. S., and Shin, S. J. Prospective randomized controlled trial to evaluate effectiveness of registered dietitian-led diabetes management on glycemic and diet control in a primary care setting in Taiwan. *Diabetes Care*. 2010;33(2):233-239.

Huisman, S. D., De Gucht, V., Dusseldorp, E., and Maes, S. The effect of weight reduction interventions for persons with type 2 diabetes: a meta-analysis from a self-regulation perspective.

Diabetes Educator. 2009;35(5):818-835.

Huizinga, M. M., Gebretsadik, T., Garcia Ulen, C., Shintani, A. K., Michon, S. R., Shackelford, L. O., Wolff, K. L., Brown, A. W., Rothman, R. L., and Elasy, T. A. Preventing glycaemic relapse in recently controlled type 2 diabetes patients: a randomised controlled trial. *Diabetologia*. 2010;53(5):832-839.

Hussain, S. A., Khadim, H. M., Khalaf, B. H., Ismail, S. H., Hussein, K. I., and Sahib, A. S. Effects of melatonin and zinc on glycemic control in type 2 diabetic patients poorly controlled with metformin. *Saudi Medical Journal*. 2006;27(10):1483-1488.

Hussain, S. A. Silymarin as an adjunct to glibenclamide therapy improves long-term and postprandial glycemic control and body mass index in type 2 diabetes. *Journal of Medicinal Food*. 2007;10(3):543-547.

Hwang, Y. C., Lee, E. Y., Lee, W. J., Cha, B. S., Yoon, K. H., Park, K. S., and Lee, M. K. Effects of rosiglitazone on body fat distribution and insulin sensitivity in Korean type 2 diabetes mellitus patients. *Metabolism: Clinical & Experimental*. 2008;57(4):479-487.

Hydrie Mzi, Qasim R. A. Effect of simvastatin on insulin sensitivity in type 2 diabetic subjects. *Pakistan Journal of Medical Sciences*. 2007;23(5):755-759.

Icks, A., Rathmann, W., Haastert, B., Gandjour, A., Holle, R., John, J., Giani, G., and Group, Kora Study. Clinical and cost-effectiveness of primary prevention of Type 2 diabetes in a 'real world' routine healthcare setting: model based on the KORA Survey 2000. *Diabetic Medicine*. 2007;24(5):473-480.

Idris, I. and Donnelly, R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. *Diabetes, Obesity & Metabolism*. 2007;9(2):153-165.

Ikeda, H. Comparison of effects of amlodipine and angiotensin receptor blockers on the intima-media thickness of carotid arterial wall (AAA study: amlodipine vs. ARB in atherosclerosis study). *Diabetes research and clinical practice*. 2009;83(1):50-53.

Ilag, L. L., Kerr, L., Malone, J. K., and Tan, M. H. Prandial premixed insulin analogue regimens versus basal insulin analogue regimens in the management of type 2 diabetes: an evidence-based comparison. *Clinical Therapeutics*. 2007;29 Spec No:1254-1270.

Iliadis, F., Kadoglou, N. P., Hatzitolios, A., Karamouzis, M., Alevizos, M., and Karamitsos, D. Metabolic effects of rosiglitazone and metformin in Greek patients with recently diagnosed type 2 diabetes. *In Vivo*. 2007;21(6):1107-1114.

Imai S, Kozai. Intervention with delivery of diabetic meals improves glycemic control in patients with type 2 diabetes mellitus. *Journal of Clinical Biochemistry and Nutrition*. 2008;42(1):59-63.

Inami, N., Nomura, S., Shouzu, A., Omoto, S., Kimura, Y., Takahashi, N., Tanaka, A., Nanba, M., Shouda, Y., and Iwasaka, T. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. *Pathophysiology of Haemostasis & Thrombosis*. 2007;36(1):1-8.

Inoue, K., Matsumoto, M., and Akimoto, K. The threshold for definition of impaired fasting glucose in a Japanese population. *Diabetic Medicine*. 2009;26(11):1175-1178.

Irvine, C. and Taylor, N. F. Progressive resistance exercise improves glycaemic control in people with type 2 diabetes mellitus: a systematic review. *Australian Journal of Physiotherapy*. 2009;55(4):237-246.

Israel, M. K., Istvan, E., and Baron, M. A. Safety and efficacy of nateglinide/metformin combination therapy in the treatment of type 2 diabetes. *Vascular Health & Risk Management*. 2008;4(6):1167-1178.

Iwamoto, K., Nasu, R., Yamamura, A., Kothare, P. A., Mace, K., Wolka, A. M., and Linnebjerg, H. Safety, tolerability, pharmacokinetics, and pharmacodynamics of exenatide once weekly in Japanese patients with type 2 diabetes. *Endocrine Journal*. 2009;56(8):951-962.

Jackson, R. Assessment of the transtheoretical model as used by dietitians in promoting physical

activity in people with type 2 diabetes. *Journal of human nutrition and dietetics : the official journal of the British Dietetic Association*. 2007;20(1):27-36.

Jacob, A. N., Salinas, K., Adams-Huet, B., and Raskin, P. Weight gain in type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2007;9(3):386-393.

Jacob, S., Rabbia, M., Meier, M. K., and Hauptman, J. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss. *Diabetes, Obesity & Metabolism*. 2009;11(4):361-371.

Jadzinsky, M., Pfutzner, A., Paz-Pacheco, E., Xu, Z., Allen, E., Chen, R., and Investigators, C. V. Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. *Diabetes, Obesity & Metabolism*. 2009;11(6):611-622.

Jakicic, J. M., Jaramillo, S. A., Balasubramanyam, A., Bancroft, B., Curtis, J. M., Mathews, A., Pereira, M., Regensteiner, J. G., Ribisl, P. M., and Look, Ahead Study Group. Effect of a lifestyle intervention on change in cardiorespiratory fitness in adults with type 2 diabetes: results from the Look AHEAD Study. *International Journal of Obesity*. 2009;33(3):305-316.

Janka Hu, Plewe G. B. Combination of oral antidiabetic agents with basal insulin versus premixed insulin alone in randomized elderly patients with type 2 diabetes mellitus. *Journal of the American Geriatrics Society*. 2007;55(2):182-188.

Janka, H. U. and Hogen, B. Economic evaluation of the treatment of type 2 diabetes with insulin glargine based on the LAPTOP trial. *European Journal of Health Economics*. 2008;9(2):165-170.

Janka, H. U., Hessel, F., Walzer, S., and Ma Ller, E. Insulin glargine added to therapy with oral antidiabetic agents improves glycemic control and reduces long-term complications in patients with type 2 diabetes - a simulation with the Diabetes Mellitus Model (DMM). *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(12):623-630.

Jarmuzewska, E. A., Rocchi, R., Guidoni, A., and Mangoni, A. A. ACE inhibitor-based treatment and antihypertensive effects in patients with type 2 diabetes. *Panminerva Medica*. 2008;50(3):207-216.

Jarnert, C. A randomized trial of the impact of strict glycaemic control on myocardial diastolic function and perfusion reserve: a report from the DADD (Diabetes mellitus And Diastolic Dysfunction) study. *European journal of heart failure : journal of the Working Group on Heart Failure of the European Society of Cardiology*. 2009;11(1):39-47.

Javaid, A. A comparative study of the effects of hypoglycemic agents on serum electrolytes in the diabetic patients. *Pakistan Journal of Pharmaceutical Sciences*. 2007;20(1):67-71.

Jeerakathil, T., Johnson, J. A., Simpson, S. H., and Majumdar, S. R. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. *Stroke*. 2007;38(6):1739-1743.

Jeitler, K., Horvath, K., Berghold, A., Gratzner, T. W., Neeser, K., Pieber, T. R., and Siebenhofer, A. Continuous subcutaneous insulin infusion versus multiple daily insulin injections in patients with diabetes mellitus: systematic review and meta-analysis. *Diabetologia*. 2008;51(6):941-951.

Jenkins, D. J., Kendall, C. W., McKeown-Eyssen, G., Josse, R. G., Silverberg, J., Booth, G. L., Vidgen, E., Josse, A. R., Nguyen, T. H., Corrigan, S., Banach, M. S., Ares, S., Mitchell, S., Emam, A., Augustin, L. S., Parker, T. L., and Leiter, L. A. Effect of a low-glycemic index or a high-cereal fiber diet on type 2 diabetes: a randomized trial. *Jama*. 2008;300(23):2742-2753.

Jennings, A. E., Alberga, A., Sigal, R. J., Jay, O., Boule, N. G., and Kenny, G. P. The effect of exercise training on resting metabolic rate in type 2 diabetes mellitus. *Medicine & Science in Sports & Exercise*.

2009;41(8):1558-1565.

Jialal, I. Concomitant reduction in low-density lipoprotein cholesterol and glycated hemoglobin with colesevelam hydrochloride in patients with type 2 diabetes: a pooled analysis. *Metabolic syndrome and related disorders*. 2009;7(3):255-258.

Jin, H. M. and Pan, Y. Angiotensin type-1 receptor blockade with losartan increases insulin sensitivity and improves glucose homeostasis in subjects with type 2 diabetes and nephropathy. *Nephrology Dialysis Transplantation*. 2007;22(7):1943-1949.

Jin, H. M. and Pan, Y. Renoprotection provided by losartan in combination with pioglitazone is superior to renoprotection provided by losartan alone in patients with type 2 diabetic nephropathy. *Kidney & Blood Pressure Research*. 2007;30(4):203-211.

Joffe, H. V., Kwong, R. Y., Gerhard-Herman, M. D., Rice, C., Feldman, K., and Adler, G. K. Beneficial effects of eplerenone versus hydrochlorothiazide on coronary circulatory function in patients with diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2007;92(7):2552-2558.

Joffe, H. V., Parks, M. H., and Temple, R. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. *Reviews in Endocrine & Metabolic Disorders*. 2010;11(1):21-30.

Johansen, O. E. and Birkeland, K. I. Defining the role of repaglinide in the management of type 2 diabetes mellitus: a review. *American Journal of Cardiovascular Drugs*. 2007;7(5):319-335.

Johansen, O. E., Gullestad, L., Blaasaas, K. G., Orvik, E., and Birkeland, K. I. Effects of structured hospital-based care compared with standard care for Type 2 diabetes-The Asker and Baerum Cardiovascular Diabetes Study, a randomized trial. *Diabetic Medicine*. 2007;24(9):1019-1027.

Jones Ja, Miller D. R. W. Does periodontal care improve glycemic control? The Department of Veterans Affairs Dental Diabetes Study. *Journal of Clinical Periodontology*. 2007;34(1):46-52.

Jones, L. H. and Ficca, M. Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes?. *Journal of School Nursing*. 2007;23(5):247-251.

Jones, L. The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy. *ClinicalTrials.Gov*, National Institutes of Health [<http://www.clinicaltrials.gov>]. 2007.

Jones, M. C. Therapies for diabetes: pramlintide and exenatide. *American Family Physician*. 2007;75(12):1831-1835.

Jones, P. H., Cusi, K., Davidson, M. H., Kelly, M. T., Setze, C. M., Thakker, K., Sleep, D. J., and Stolzenbach, J. C. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. *American Journal of Cardiovascular Drugs*. 2010;10(2):73-84.

Jonker, J. T., Lamb, H. J., van der Meer, R. W., Rijzewijk, L. J., Menting, L. J., Diamant, M., Bax, J. J., de Roos, A., Romijn, J. A., and Smit, J. W. Pioglitazone compared with metformin increases pericardial fat volume in patients with type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(1):456-460.

Jonsson, T., Granfeldt, Y., Ahren, B., Branell, U. C., Palsson, G., Hansson, A., Soderstrom, M., and Lindeberg, S. Beneficial effects of a Paleolithic diet on cardiovascular risk factors in type 2 diabetes: a randomized cross-over pilot study. *Cardiovascular Diabetology*. 2009;8:35.

Juurinen, L. Nateglinide combination therapy with basal insulin and metformin in patients with Type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(4):409-415.

Kabakov, E., Norymberg, C., Osher, E., Koffler, M., Tordjman, K., Greenman, Y., and Stern, N. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. *Journal of the CardioMetabolic Syndrome*. 2006;1(2):95-101.

Kadoglou, N. P., Iliadis, F., Angelopoulou, N., Perrea, D., Ampatzidis, G., Liapis, C. D., and Alevizos, M. The anti-inflammatory effects of exercise training in patients with type 2 diabetes mellitus. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2007;14(6):837-843.

Kadoglou, N. P., Iliadis, F., Angelopoulou, N., Perrea, D., Liapis, C. D., and Alevizos, M. Beneficial effects of rosiglitazone on novel cardiovascular risk factors in patients with Type 2 diabetes mellitus. *Diabetic Medicine*. 2008;25(3):333-340.

Kadoglou, N. P., Iliadis, F., Liapis, C. D., Perrea, D., Angelopoulou, N., and Alevizos, M. Beneficial effects of combined treatment with rosiglitazone and exercise on cardiovascular risk factors in patients with type 2 diabetes. *Diabetes Care*. 2007;30(9):2242-2244.

Kadoglou, N. P., Iliadis, F., Sailer, N., Athanasiadou, Z., Vitta, I., Kapelouzou, A., Karayannacos, P. E., Liapis, C. D., Alevizos, M., Angelopoulou, N., and Vrabas, I. S. Exercise training ameliorates the effects of rosiglitazone on traditional and novel cardiovascular risk factors in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(4):599-607.

Kadoglou, N. P., Tsanikidis, H., Kapelouzou, A., Vrabas, I., Vitta, I., Karayannacos, P. E., Liapis, C. D., and Sailer, N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(3):373-379.

Kadoglou, N. P., Vrabas, I. S., Sailer, N., Kapelouzou, A., Fotiadis, G., Noussios, G., Karayannacos, P. E., and Angelopoulou, N. Exercise ameliorates serum MMP-9 and TIMP-2 levels in patients with type 2 diabetes. *Diabetes & Metabolism*. 2010;36(2):144-151.

Kadowaki, T., Namba, M., Yamamura, A., Sowa, H., Wolka, A. M., and Brodows, R. G. Exenatide exhibits dose-dependent effects on glycemic control over 12 weeks in Japanese patients with suboptimally controlled type 2 diabetes. *Endocrine Journal*. 2009;56(3):415-424.

Kahn, S. E. and Zinman, B. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. *Diabetes Care*. 2007;30(6):1672-1676.

Kahn, S. E., Haffner, S. M., Viberti, G., Herman, W. H., Lachin, J. M., Kravitz, B. G., Yu, D., Paul, G., Holman, R. R., Zinman, B., and Diabetes Outcome Progression Trial Study, Group. Rosiglitazone decreases C-reactive protein to a greater extent relative to glyburide and metformin over 4 years despite greater weight gain: observations from a Diabetes Outcome Progression Trial (ADOPT). *Diabetes Care*. 2010;33(1):177-183.

Kakinuma, H., Oi, T., Hashimoto-Tsuchiya, Y., Arai, M., Kawakita, Y., Fukasawa, Y., Iida, I., Hagima, N., Takeuchi, H., Chino, Y., Asami, J., Okumura-Kitajima, L., Io, F., Yamamoto, D., Miyata, N., Takahashi, T., Uchida, S., and Yamamoto, K. (1S)-1,5-anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a potent, selective sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for type 2 diabetes treatment. *Journal of Medicinal Chemistry*. 2010;53(8):3247-3261.

Kaku, K., Daida, H., Kashiwagi, A., Yamashina, A., Yamazaki, T., Momomura, S., Iwase, T., Yamasaki, Y., Nagatsuka, K., Kitagawa, K., and Kawamori, R. Long-term effects of pioglitazone in Japanese patients with type 2 diabetes without a recent history of macrovascular morbidity. *Current Medical Research & Opinion*. 2009;25(12):2925-2932.

Kaku, K., Tanaka, S., Origasa, H., Kikuchi, M., and Akanuma, Y. Addition of mitiglinide to pioglitazone monotherapy improves overall glycemic control in Japanese patients with type 2 diabetes: a randomized double blind trial. *Endocrine Journal*. 2009;56(5):657-664.

Kaku, K., Tanaka, S., Origasa, H., Kikuchi, M., and Akanuma, Y. Effect of mitiglinide on glycemic control over 52 weeks in Japanese type 2 diabetic patients insufficiently controlled with pioglitazone monotherapy. *Endocrine Journal*. 2009;56(6):739-746.

Kaku, K. Efficacy and safety of therapy with metformin plus pioglitazone in the treatment of patients with type 2 diabetes: a double-blind, placebo-controlled, clinical trial. *Current medical research and opinion*. 2009;25(5):1111-1119.

Kalaitzidis, R. and Bakris, G. Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. *Journal of Clinical Hypertension*. 2009;11(11):636-643.

Kanat, M., Serin, E., Tunckale, A., Yildiz, O., Sahin, S., Bolayirli, M., Arinc, H., Dirican, A., Karagoz, Y., Altuntas, Y., Celebi, H., and Oguz, A. A multi-center, open label, crossover designed prospective study evaluating the effects of lipid lowering treatment on steroid synthesis in patients with Type 2 diabetes (MODEST Study). *Journal of Endocrinological Investigation*. 2009;32(10):852-856.

Kapitza, C., Heise, T., Birman, P., Jallet, K., Ramis, J., and Balena, R. Pharmacokinetic and pharmacodynamic properties of taspoglutide, a once-weekly, human GLP-1 analogue, after single-dose administration in patients with Type 2 diabetes. *Diabetic Medicine*. 2009;26(11):1156-1164.

Kappelle, P. J., Dallinga-Thie, G. M., Dullaart, R. P., and Diabetes Atorvastatin lipid intervention study, group. Atorvastatin treatment lowers fasting remnant-like particle cholesterol and LDL subfraction cholesterol without affecting LDL size in type 2 diabetes mellitus: Relevance for non-HDL cholesterol and apolipoprotein B guideline targets. *Biochimica et Biophysica Acta*. 2010;1801(1):89-94.

Kar, P. and Holt, R. I. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. *Cardiovascular Drugs & Therapy*. 2008;22(3):207-213.

Karagiannis, E., Pfitzner, A., Forst, T., Lubben, G., Roth, W., Grabelius, M., Flannery, M., and Schondorf, T. The IRIS V study: pioglitazone improves systemic chronic inflammation in patients with type 2 diabetes under daily routine conditions. *Diabetes Technology & Therapeutics*. 2008;10(3):206-212.

Karalliedde, J., Smith, A., DeAngelis, L., Mirenda, V., Kandra, A., Botha, J., Ferber, P., and Viberti, G. Valsartan improves arterial stiffness in type 2 diabetes independently of blood pressure lowering. *Hypertension*. 2008;51(6):1617-1623.

Karalliedde, J. Choice of monotherapy in newly diagnosed type 2 diabetic patients: Clinical perspective of ADOPT. *Therapy*. 2007;4(5):535-540.

Karasik, A., Aschner, P., Katzeff, H., Davies, M. J., and Stein, P. P. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. *Current Medical Research & Opinion*. 2008;24(2):489-496.

Karastergiou, K. and Kaski, J. C. Medical management of the diabetic patient with coronary artery disease. *Current Pharmaceutical Design*. 2008;14(25):2527-2536.

Karjalainen, J., Peltonen, M., Vanhala, M., Korpi-Hyovalti, E., Puolijoki, H., Saltevo, J., Oksa, H., Saaristo, T., Tuomilehto, J., and Kujala, U. M. Leisure time physical activity in individuals with screen-detected type 2 diabetes compared to those with known type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;81(1):110-116.

Karl, D., Philis-Tsimikas, A., Darsow, T., Lorenzi, G., Kellmeyer, T., Lutz, K., Wang, Y., and Frias, J. P. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. *Diabetes Technology & Therapeutics*. 2007;9(2):191-199.

Karter, A. J., Moffet, H. H., Liu, J., Parker, M. M., Ahmed, A. T., Go, A. S., and Selby, J. V. Glycemic response to newly initiated diabetes therapies. *American Journal of Managed Care*. 2007;13(11):598-606.

Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., and Martin, B. C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. *Medical Care*. 2008;46(11):1125-1133.

Katakami, N., Kim, Y. S., Kawamori, R., and Yamasaki, Y. The phosphodiesterase inhibitor cilostazol induces regression of carotid atherosclerosis in subjects with type 2 diabetes mellitus: principal results of the Diabetic Atherosclerosis Prevention by Cilostazol (DAPC) study: a randomized trial. *Circulation*. 2010;121(23):2584-2591.

Katakura, M., Naka, M., Kondo, T., Komatsu, M., Yamauchi, K., Hashizume, K., Aizawa, T., and Nagano Elderly Diabetes Study, Group. Normal mortality in the elderly with diabetes under strict glycemic and blood pressure control: outcome of 6-year prospective study. *Diabetes Research & Clinical Practice*. 2007;78(1):108-114.

Katakura, M., Naka, M., Kondo, T., Komatsu, M., Yamauchi, K., Hashizume, K., and Aizawa, T. Development, worsening, and improvement of diabetic microangiopathy in older people: six-year prospective study of patients under intensive diabetes control. *Journal of the American Geriatrics Society*. 2007;55(4):541-547.

Katayama, S., Kawamori, R., Iwamoto, Y., Saito, I., Kuramoto, K., and Group, Attest Study. In half of hypertensive diabetics, co-administration of a calcium channel blocker and an angiotensin-converting enzyme inhibitor achieved a target blood pressure of

Katerndahl, D. and Parchman, M. L. Dynamical difference in patients encounters involving uncontrolled diabetes: an orbital decomposition analysis. *Journal of Evaluation in Clinical Practice*. 2010;16(1):211-219.

Katon, W. J. The comorbidity of diabetes mellitus and depression. *American Journal of Medicine*. 2008;121(11 Suppl 2):S8-15.

Katz, D. L. and Nordwall, B. Novel interactive cell-phone technology for health enhancement. *Journal of Diabetes Science & Technology*. 2008;2(1):147-153.

Kaul, S. and Diamond, G. A. Rosiglitazone and cardiovascular risk. *Current Atherosclerosis Reports*. 2008;10(5):398-404.

Kautzky-Willer, A., Tura, A., Winzer, C., Wagner, O. F., Ludvik, B., Hanusch-Enserer, U., Prager, R., and Pacini, G. Insulin sensitivity during oral glucose tolerance test and its relations to parameters of glucose metabolism and endothelial function in type 2 diabetic subjects under metformin and thiazolidinedione. *Diabetes, Obesity & Metabolism*. 2006;8(5):561-567.

Kavookjian, J., Elswick, B. M., and Whetsel, T. Interventions for being active among individuals with diabetes: a systematic review of the literature. *Diabetes Educator*. 2007;33(6):962-988.

Kavouras, S. A., Panagiotakos, D. B., Pitsavos, C., Chrysoshoou, C., Anastasiou, C. A., Lentzas, Y., and Stefanadis, C. Physical activity, obesity status, and glycemic control: The ATTICA study.[Erratum appears in *Med Sci Sports Exerc*. 2007 Nov;39(11):2093]. *Medicine & Science in Sports & Exercise*. 2007;39(4):606-611.

Kawai, T., Funae, O., Shimada, A., Tabata, M., Hirata, T., Atsumi, Y., and Itoh, H. Effects of pretreatment with low-dose metformin on metabolic parameters and weight gain by pioglitazone in Japanese patients with type 2 diabetes. *Internal Medicine*. 2008;47(13):1181-1188.

Kawamori, R., Eliaschewitz, F. G., Takayama, H., and Hayashida, C. Y. Efficacy of insulin glargine and glimepiride in controlling blood glucose of ethnic Japanese patients with type 2 diabetes mellitus. *Diabetes Research & Clinical Practice*. 2008;79(1):97-102.

Kawamoto, R., Kohara, K., Tabara, Y., Miki, T., Ohtsuka, N., Kusunoki, T., and Abe, M. Alcohol

consumption is associated with decreased insulin resistance independent of body mass index in Japanese community-dwelling men. *Tohoku Journal of Experimental Medicine*. 2009;218(4):331-337.

Kawasaki, D., Kosugi, K., Waki, H., Yamamoto, K., Tsujino, T., and Masuyama, T. Role of activated renin-angiotensin system in myocardial fibrosis and left ventricular diastolic dysfunction in diabetic patients--reversal by chronic angiotensin II type 1A receptor blockade. *Circulation Journal*. 2007;71(4):524-529.

Kearney-Schwartz, A., Virion, J. M., Stoltz, J. F., Drouin, P., and Zannad, F. Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy. *Fundamental & Clinical Pharmacology*. 2007;21(4):387-396.

Keating, C. L., Dixon, J. B., Moodie, M. L., Peeters, A., Bulfone, L., Maglianno, D. J., and O'Brien, P. E. Cost-effectiveness of surgically induced weight loss for the management of type 2 diabetes: modeled lifetime analysis. *Diabetes Care*. 2009;32(4):567-574.

Keating, C. L., Dixon, J. B., Moodie, M. L., Peeters, A., Playfair, J., and O'Brien, P. E. Cost-efficacy of surgically induced weight loss for the management of type 2 diabetes: a randomized controlled trial. *Diabetes Care*. 2009;32(4):580-584.

Kebapci, N., Yenilmez, A., Efe, B., Entok, E., and Demirustu, C. Bladder dysfunction in type 2 diabetic patients. *Neurourology & Urodynamics*. 2007;26(6):814-819.

Keech, A. C., Mitchell, P., Summanen, P. A., O'Day, J., Davis, T. M., Moffitt, M. S., Taskinen, M. R., Simes, R. J., Tse, D., Williamson, E., Merrifield, A., Laatikainen, L. T., d'Emden, M. C., Crimet, D. C., O'Connell, R. L., Colman, P. G., and investigators, Field study. Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial. *Lancet*. 2007;370(9600):1687-1697.

Kellar, I., Sutton, S., Griffin, S., Prevost, A. T., Kinmonth, A. L., and Marteau, T. M. Evaluation of an informed choice invitation for type 2 diabetes screening. *Patient Education & Counseling*. 2008;72(2):232-238.

Kelley, G. A. and Kelley, K. S. Effects of aerobic exercise on lipids and lipoproteins in adults with type 2 diabetes: a meta-analysis of randomized-controlled trials. *Public Health*. 2007;121(9):643-655.

Kelly, A. S., Thelen, A. M., Kaiser, D. R., Gonzalez-Campoy, J. M., and Bank, A. J. Rosiglitazone improves endothelial function and inflammation but not asymmetric dimethylarginine or oxidative stress in patients with type 2 diabetes mellitus. *Vascular Medicine*. 2007;12(4):311-318.

Kelly, T. N., Bazzano, L. A., Fonseca, V. A., Thethi, T. K., Reynolds, K., and He, J. Systematic review: glucose control and cardiovascular disease in type 2 diabetes. *Annals of Internal Medicine*. 2009;151(6):394-403.

Ker, J., Rheeder, P., and Van Tonder, R. Frequency of the metabolic syndrome in screened South African corporate executives. *Cardiovascular Journal of Southern Africa*. 2007;18(1):30-33.

Kernohan, A. F., Sattar, N., Hilditch, T., Cleland, S. J., Small, M., Lumsden, M. A., Connell, J. M., and Petrie, J. R. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. *Clinical Endocrinology*. 2007;66(1):27-34.

Khanderia, U., Pop-Busui, R., and Eagle, K. A. Thiazolidinediones in type 2 diabetes: a cardiology perspective. *Annals of Pharmacotherapy*. 2008;42(10):1466-1474.

Khanolkar, M. P., Morris, R. H., Thomas, A. W., Bolusani, H., Roberts, A. W., Geen, J., Jackson, S. K., and Evans, L. M. Rosiglitazone produces a greater reduction in circulating platelet activity compared with glimepiride in patients with type 2 diabetes mellitus--an effect probably mediated by direct platelet

PPARgamma activation. *Atherosclerosis*. 2008;197(2):718-724.

Khaodhiar, L. Effect of valsartan on left ventricular anatomy and systolic function and aortic elasticity. *Metabolism: clinical and experimental*. 2009;58(5):682-688.

Kikuchi, M. Vildagliptin dose-dependently improves glycemic control in Japanese patients with type 2 diabetes mellitus. *Diabetes research and clinical practice*. 2009;83(2):233-240.

Kilpatrick, E. S., Bloomgarden, Z. T., and Zimmet, P. Z. Is haemoglobin A1c a step forward for diagnosing diabetes?. *Bmj*. 2009;339:b4432.

Kim Jh, Jung W. S. C. Health-promoting effects of bovine colostrum in Type 2 diabetic patients can reduce blood glucose, cholesterol, triglyceride and ketones. *The Journal of nutritional biochemistry*. 2009;20(4):298-303.

Kim, D., MacConell, L., Zhuang, D., Kothare, P. A., Trautmann, M., Fineman, M., and Taylor, K. Effects of once-weekly dosing of a long-acting release formulation of exenatide on glucose control and body weight in subjects with type 2 diabetes. *Diabetes Care*. 2007;30(6):1487-1493.

Kim, H. J., Kang, E. S., Kim, D. J., Kim, S. H., Ahn, C. W., Cha, B. S., Nam, M., Chung, C. H., Lee, K. W., Nam, C. M., and Lee, H. C. Effects of rosiglitazone and metformin on inflammatory markers and adipokines: decrease in interleukin-18 is an independent factor for the improvement of homeostasis model assessment-beta in type 2 diabetes mellitus. *Clinical Endocrinology*. 2007;66(2):282-289.

Kim, H. S. and Song, M. S. Technological intervention for obese patients with type 2 diabetes. *Applied Nursing Research*. 2008;21(2):84-89.

King Ab, Wolfe G. S. Evaluation of a diabetes specialist-guided primary care diabetes treatment program. *Journal of the American Academy of Nurse Practitioners*. 2009;21(1):24-30.

King, A. B. No higher dose requirements with insulin detemir than glargine in type 2 diabetes: a crossover, double-blind, and randomized study using continuous glucose monitoring. *Journal of Diabetes Science & Technology*. 2010;4(1):151-154.

King, A. B. Once-daily insulin detemir is comparable to once-daily insulin glargine in providing glycaemic control over 24 h in patients with type 2 diabetes: a double-blind, randomized, crossover study. *Diabetes, Obesity & Metabolism*. 2009;11(1):69-71.

Kingry, C., Bastien, A., Booth, G., Geraci, T. S., Kirpach, B. R., Lovato, L. C., Margolis, K. L., Rosenberg, Y., Sperl-Hillen, J. M., Vargo, L., Williamson, J. D., Probstfield, J. L., and Group, Accord Study. Recruitment strategies in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial. *American Journal of Cardiology*. 2007;99(12A):68i-79i.

Kirk, A. A randomized trial investigating the 12-month changes in physical activity and health outcomes following a physical activity consultation delivered by a person or in written form in Type 2 diabetes: Time2Act. *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(3):293-301.

Kirk, J. K., Graves, D. E., Craven, T. E., Lipkin, E. W., Austin, M., and Margolis, K. L. Restricted-carbohydrate diets in patients with type 2 diabetes: a meta-analysis. *Journal of the American Dietetic Association*. 2008;108(1):91-100.

Kirwan, J. P., Solomon, T. P., Wojta, D. M., Staten, M. A., and Holloszy, J. O. Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. *American Journal of Physiology - Endocrinology & Metabolism*. 2009;297(1):E151-E156.

Kiyici, S., Ersoy, C., Kaderli, A., Fazlioglu, M., Budak, F., Duran, C., Gul, O. O., Sigirli, D., Baran, I., Tuncel, E., Erturk, E., and Imamoglu, S. Effect of rosiglitazone, metformin and medical nutrition treatment on arterial stiffness, serum MMP-9 and MCP-1 levels in drug naive type 2 diabetic patients.

Diabetes Research & Clinical Practice. 2009;86(1):44-50.

Kjeldsen, S. E., Naditch-Brule, L., Perlini, S., Zidek, W., and Farsang, C. Increased prevalence of metabolic syndrome in uncontrolled hypertension across Europe: the Global Cardiometabolic Risk Profile in Patients with hypertension disease survey. *Journal of Hypertension*. 2008;26(10):2064-2070.

Kjeldsen, S. E., Schmieder, R. E., Unger, T., and Mancia, G. Telmisartan and hydrochlorothiazide combination therapy for the treatment of hypertension. *Current Medical Research & Opinion*. 2010;26(4):879-887.

Kleefstra, N., Landman, G. W., Houweling, S. T., Ubink-Veltmaat, L. J., Logtenberg, S. J., Meyboom-de Jong, B., Coyne, J. C., Groenier, K. H., and Bilo, H. J. Prediction of mortality in type 2 diabetes from health-related quality of life (ZODIAC-4). *Diabetes Care*. 2008;31(5):932-933.

Klein, O., Lynge, J., Endahl, L., Damholt, B., Nosek, L., and Heise, T. Albumin-bound basal insulin analogues (insulin detemir and NN344): comparable time-action profiles but less variability than insulin glargine in type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(3):290-299.

Kleppinger, E. L. and Helms, K. The role of vildagliptin in the management of type 2 diabetes mellitus. *Annals of Pharmacotherapy*. 2007;41(5):824-832.

Kloner, R. A., Neutel, J., Roth, E. M., Weiss, R., Weinberger, M. H., Thakker, K. M., Schwartz, B., Shi, H., Gregg, A. M., and Investigators, Adht. Blood pressure control with amlodipine add-on therapy in patients with hypertension and diabetes: results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial. *Annals of Pharmacotherapy*. 2008;42(11):1552-1562.

Klonoff, D. C., Buse, J. B., Nielsen, L. L., Guan, X., Bowlus, C. L., Holcombe, J. H., Wintle, M. E., and Maggs, D. G. Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. *Current Medical Research & Opinion*. 2008;24(1):275-286.

Kloos, C., Samann, A., Lehmann, T., Braun, A., Heckmann, B., and Muller, U. A. Flexible intensive versus conventional insulin therapy in insulin-naïve adults with type 2 diabetes: an open-label, randomized, controlled, crossover clinical trial of metabolic control and patient preference. *Diabetes Care*. 2007;30(12):3031-3032.

Knudsen, S. T., Andersen, N. H., Poulsen, S. H., Eiskjaer, H., Hansen, K. W., Helleberg, K., Poulsen, P. L., and Mogensen, C. E. Pulse pressure lowering effect of dual blockade with candesartan and lisinopril vs. high-dose ACE inhibition in hypertensive type 2 diabetic subjects: a CALM II study post-hoc analysis. *American Journal of Hypertension*. 2008;21(2):172-176.

Kobalava, Z. D., Kotovskaya, Y. V., Villevalde, S. V., Moiseev, V. S., and Study, Argus. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. *Current Medical Research & Opinion*. 2009;25(9):2229-2237.

Kocic, R., Spirovski, D., Ciric, V., and Velija-Asimi, Z. Impact of diet, physical activity, lipid status and glycoregulation in estimation of score (systematic coronary risk evaluation) for ten years in postmenopausal women. *Bosnian Journal of Basic Medical Sciences*. 2007;7(3):197-204.

Kodama, S., Saito, K., Tanaka, S., Maki, M., Yachi, Y., Sato, M., Sugawara, A., Totsuka, K., Shimano, H., Ohashi, Y., Yamada, N., and Sone, H. Influence of fat and carbohydrate proportions on the metabolic profile in patients with type 2 diabetes: a meta-analysis. *Diabetes Care*. 2009;32(5):959-965.

Koh, K. K., Quon, M. J., Han, S. H., Ahn, J. Y., Lee, Y., and Shin, E. K. Combined therapy with ramipril and simvastatin has beneficial additive effects on tissue factor activity and prothrombin fragment 1+2 in patients with type 2 diabetes. *Atherosclerosis*. 2007;194(1):230-237.

Kohlmann, O., Jr., Roca-Cusachs, A., Laurent, S., Schmieder, R. E., Wenzel, R. R., and Fogari, R.

Fixed-dose manidipine/delapril versus losartan/hydrochlorothiazide in hypertensive patients with type 2 diabetes and microalbuminuria. *Advances in Therapy*. 2009;26(3):313-324.

Kohnert, K. D., Augstein, P., Heinke, P., Zander, E., Peterson, K., Freyse, E. J., and Salzsieder, E. Chronic hyperglycemia but not glucose variability determines HbA1c levels in well-controlled patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;77(3):420-426.

Kojima, S., Sakamoto, T., Ogawa, H., Kitagawa, A., Matsui, K., Shimomura, H., Kimura, K., Ogata, Y., Sakaino, N., and Multicenter Study for Aggressive Lipid-lowering Strategy by. Standard-dose statin therapy provides incremental clinical benefits in normocholesterolemic diabetic patients. *Circulation Journal*. 2010;74(4):779-785.

Kokanovic, R. and Manderson, L. Exploring doctor-patient communication in immigrant Australians with type 2 diabetes: a qualitative study. *Journal of General Internal Medicine*. 2007;22(4):459-463.

Kokoszka, A., Pouwer, F., Jodko, A., Radzio, R., Mucko, P., Bienkowska, J., Kuligowska, E., Smoczynska, O., and Sklodowska, Z. Serious diabetes-specific emotional problems in patients with type 2 diabetes who have different levels of comorbid depression: a Polish study from the European Depression in Diabetes (EDID) Research Consortium. *European Psychiatry: the Journal of the Association of European Psychiatrists*. 2009;24(7):425-430.

Koleva-Georgieva, D. and Sivkova, N. Assessment of serous macular detachment in eyes with diabetic macular edema by use of spectral-domain optical coherence tomography. *Graefes Archive for Clinical & Experimental Ophthalmology*. 2009;247(11):1461-1469.

Koleva-Georgieva, D. N. and Sivkova, N. P. Optical coherence tomography for the detection of early macular edema in diabetic patients with retinopathy. *Folia Medica (Plovdiv)*. 2010;52(1):40-48.

Koleva-Georgieva, D. N. and Sivkova, N. P. Types of diabetic macular edema assessed by optical coherence tomography. *Folia Medica (Plovdiv)*. 2008;50(3):30-38.

Komaba, H., Igaki, N., Goto, S., Yokota, K., Takemoto, T., Hirose, Y., and Goto, T. Adiponectin is associated with brain natriuretic peptide and left ventricular hypertrophy in hemodialysis patients with type 2 diabetes mellitus. *Nephron*. 2007;107(3):c103-c108.

Komajda, M., Curtis, P., Hanefeld, M., Beck-Nielsen, H., Pocock, S. J., Zambanini, A., Jones, N. P., Gomis, R., Home, P. D., and Group, Record Study. Effect of the addition of rosiglitazone to metformin or sulfonylureas versus metformin/sulfonylurea combination therapy on ambulatory blood pressure in people with type 2 diabetes: a randomized controlled trial (the RECORD study). *Cardiovascular Diabetology*. 2008;7:10.

Komoroski, B. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. *Clinical pharmacology and therapeutics*. 2009;85(5):513-519.

Kong, A. P., Yang, X., Ko, G. T., So, W. Y., Chan, W. B., Ma, R. C., Ng, V. W., Chow, C. C., Cockram, C. S., Tong, P. C., Wong, V., and Chan, J. C. Effects of treatment targets on subsequent cardiovascular events in Chinese patients with type 2 diabetes. *Diabetes Care*. 2007;30(4):953-959.

Konishi, K., Nakano, S., Tsuda, S., Nakagawa, A., Kigoshi, T., and Koya, D. AST-120 (Kremezin) initiated in early stage chronic kidney disease stunts the progression of renal dysfunction in type 2 diabetic subjects. *Diabetes Research & Clinical Practice*. 2008;81(3):310-315.

Konya, H., Miuchi, M., Konishi, K., Nagai, E., Ueyama, T., Kusunoki, Y., Kimura, Y., Nakamura, Y., Ishikawa, T., Inokuchi, C., Katsuno, T., Hamaguchi, T., Miyagawa, J., and Namba, M. Pleiotropic effects of mitiglinide in type 2 diabetes mellitus. *Journal of International Medical Research*. 2009;37(6):1904-1912.

Koopman, R. J., Mainous, A. G., III, Everett, C. J., and Carter, R. E. Tool to assess likelihood of fasting

glucose impairment (TAG-IT). *Annals of Family Medicine*. 2008;6(6):555-561.

Kooy, A., de Jager, J., Leher, P., Bets, D., Wulffele, M. G., Donker, A. J., and Stehouwer, C. D. Long-term effects of metformin on metabolism and microvascular and macrovascular disease in patients with type 2 diabetes mellitus. *Archives of Internal Medicine*. 2009;169(6):616-625.

Kopelman, P., Groot Gde, H., Rissanen, A., Rossner, S., Toubro, S., Palmer, R., Hallam, R., Bryson, A., and Hickling, R. I. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical). *Obesity*. 2010;18(1):108-115.

Korkiakangas, E. E., Alahuhta, M. A., and Laitinen, J. H. Barriers to regular exercise among adults at high risk or diagnosed with type 2 diabetes: a systematic review. *Health Promotion International*. 2009;24(4):416-427.

Koro, C. E., Fu, Q., and Stender, M. An assessment of the effect of thiazolidinedione exposure on the risk of myocardial infarction in type 2 diabetic patients. *Pharmacoepidemiology & Drug Safety*. 2008;17(10):989-996.

Koro, C. E., Lee, B. H., and Bowlin, S. J. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. *Clinical Therapeutics*. 2009;31(11):2608-2617.

Koro, C. E., Sowell, M. O., Stender, M., and Qizilbash, N. The risk of myopathy associated with thiazolidinediones and statins in patients with type 2 diabetes: a nested case-control analysis. *Clinical Therapeutics*. 2008;30(3):535-542.

Koshiyama, H., Taniguchi, A., Tanaka, K., Kagimoto, S., Fujioka, Y., Hirata, K., Nakamura, Y., Iwakura, A., Hara, K., Yamamoto, T., Kuroe, A., Ohya, M., Fujimoto, S., Hamamoto, Y., Honjo, S., Ikeda, H., Nabe, K., Tsuda, K., Inagaki, N., Seino, Y., Kume, N., Kansai Investigation of Statin for Hyperlipidemic Intervention in, Metabolism, and Endocrinology, Investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. *Journal of Atherosclerosis & Thrombosis*. 2008;15(6):345-350.

Kothare Pa, Linnebjerg H. S. Exenatide effects on statin pharmacokinetics and lipid response. *International journal of clinical pharmacology and therapeutics*. 2007;45(2):114-120.

Kothare, P. A., Linnebjerg, H., Isaka, Y., Uenaka, K., Yamamura, A., Yeo, K. P., de la Pena, A., Teng, C. H., Mace, K., Fineman, M., Shigeta, H., Sakata, Y., and Irie, S. Pharmacokinetics, pharmacodynamics, tolerability, and safety of exenatide in Japanese patients with type 2 diabetes mellitus. *Journal of Clinical Pharmacology*. 2008;48(12):1389-1399.

Kouremenou, C. American Diabetes Association--69th Scientific sessions. Hyperinsulinism, insulin resistance and the treatment of diabetes: Part 2. *Idrugs*. 2009;12(8):465-466.

Kouremenou, C. American Diabetes Association--69th Scientific sessions. Obesity management and treatment of type 2 diabetes: Part 1. *Idrugs*. 2009;12(8):463-464.

Koya, D., Haneda, M., Inomata, S., Suzuki, Y., Suzuki, D., Makino, H., Shikata, K., Murakami, Y., Tomino, Y., Yamada, K., Araki, S. I., Kashiwagi, A., Kikkawa, R., and Low-Protein Diet Study, Group. Long-term effect of modification of dietary protein intake on the progression of diabetic nephropathy: a randomised controlled trial. *Diabetologia*. 2009;52(10):2037-2045.

Kraemer de Aguiar, L. G., Laflor, C. M., Bahia, L., Villela, N. R., Wiernsperger, N., Bottino, D. A., and Bouskela, E. Metformin improves skin capillary reactivity in normoglycaemic subjects with the metabolic syndrome. *Diabetic Medicine*. 2007;24(3):272-279.

Krag, M. B., Nielsen, S., Guo, Z., Pedersen, S. B., Schmitz, O., Christiansen, J. S., and Jorgensen, J. O. Peroxisome proliferator-activated receptor gamma agonism modifies the effects of growth hormone on lipolysis and insulin sensitivity. *Clinical Endocrinology*. 2008;69(3):452-461.

Krag, M. B., Rasmussen, L. M., Hansen, T. K., Frystyk, J., Flyvbjerg, A., Moller, N., and Jorgensen, J. O. Peroxisome proliferator-activated receptor gamma (PPAR) agonism reduces the insulin-stimulated increase in circulating interleukin-6 in GH replaced GH-deficient adults. *Clinical Endocrinology*. 2009;71(3):363-368.

Kraja, A. T., Borecki, I. B., North, K., Tang, W., Myers, R. H., Hopkins, P. N., Arnett, D., Corbett, J., Adelman, A., and Province, M. A. Longitudinal and age trends of metabolic syndrome and its risk factors: the Family Heart Study. *Nutrition & Metabolism*. 2006;3:41.

Kramer, C. K., Araneta, M. R., and Barrett-Connor, E. A1C and diabetes diagnosis: The Rancho Bernardo Study. *Diabetes Care*. 2010;33(1):101-103.

Kramer, H., Reboussin, D., Bertoni, A. G., Marcovina, S., Lipkin, E., Greenway, F. L., III, Brancati, F. L., and Look Ahead Research, Group. Obesity and albuminuria among adults with type 2 diabetes: the Look AHEAD (Action for Health in Diabetes) Study. *Diabetes Care*. 2009;32(5):851-853.

Krass, I., Armour, C. L., Mitchell, B., Brilliant, M., Dienaar, R., Hughes, J., Lau, P., Peterson, G., Stewart, K., Taylor, S., and Wilkinson, J. The Pharmacy Diabetes Care Program: assessment of a community pharmacy diabetes service model in Australia. *Diabetic Medicine*. 2007;24(6):677-683.

Kraus, W. E. and Slentz, C. A. Exercise training, lipid regulation, and insulin action: a tangled web of cause and effect. *Obesity*. 2009;17 Suppl 3:S21-S26.

Krcma, M. Effect of mild increase of physical activity on microvascular reactivity in obese subjects with diabetes mellitus type 2. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*. 2009;117(3):150-152.

Kreyenbuhl, J., Dixon, L. B., McCarthy, J. F., Soliman, S., Ignacio, R. V., and Valenstein, M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?. *Schizophrenia Bulletin*. 2010;36(2):428-435.

Krones, R. The rapid-acting properties of insulin aspart are preserved in elderly people with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2009;11(1):41-44.

Krousel-Wood, M. A., Berger, L., Jiang, X., Blonde, L., Myers, L., and Webber, L. Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial. *Diabetes Research & Clinical Practice*. 2008;79(2):230-236.

Kruger, D. F. Exploring the pharmacotherapeutic options for treating type 2 diabetes. *Diabetes Educator*. 2008;34 Suppl 3:60S-65S.

Kruk, J. Physical activity in the prevention of the most frequent chronic diseases: an analysis of the recent evidence. *Asian Pacific Journal of Cancer Prevention: Apjcp*. 2007;8(3):325-338.

Kulasa, K. M. and Henry, R. R. Pharmacotherapy of hyperglycemia. *Expert Opinion on Pharmacotherapy*. 2009;10(15):2415-2432.

Kumar, A., Nagpal, J., and Bhartia, A. Direct cost of ambulatory care of type 2 diabetes in the middle and high income group populace of Delhi: the DEDICOM survey. *Journal of the Association of Physicians of India*. 2008;56:667-674.

Kumar, P. R., Bhansali, A., Ravikiran, M., Bhansali, S., Dutta, P., Thakur, J. S., Sachdeva, N., Bhadada, S. K., and Walia, R. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2832-2835.

Kumashiro, N., Yoshihara, T., Kanazawa, Y., Shimizu, T., Watada, H., Tanaka, Y., Fujitani, Y., Kawamori, R., and Hirose, T. Long-term effect of combination therapy with mitiglinide and once daily insulin glargine in patients who were successfully switched from intensive insulin therapy in short-term study. *Endocrine Journal*. 2007;54(1):163-166.

Kung, C. M., Tseng, Z. L., and Wang, H. L. Erythrocyte fragility increases with level of glycosylated hemoglobin in type 2 diabetic patients. *Clinical Hemorheology & Microcirculation*. 2009;43(4):345-351.

Kusaka, I., Nagasaka, S., Horie, H., and Ishibashi, S. Metformin, but not pioglitazone, decreases postchallenge plasma ghrelin levels in type 2 diabetic patients: a possible role in weight stability?. *Diabetes, Obesity & Metabolism*. 2008;10(11):1039-1046.

Kushner Rf, Sujak M. Prevention of weight gain in adult patients with type 2 diabetes treated with pioglitazone. *Obesity (Silver Spring, Md.)*. 2009;17(5):1017-1022.

Labrousse-Lhermine, F., Cazals, L., Ruidavets, J. B., Group, Gedec Study, and Hanaire, H. Long-term treatment combining continuous subcutaneous insulin infusion with oral hypoglycaemic agents is effective in type 2 diabetes. *Diabetes & Metabolism*. 2007;33(4):253-260.

Lafontan, M., Piazza, P. V., and Girard, J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. *Diabetes & Metabolism*. 2007;33(2):85-95.

Lafuma, A., Colin, X., and Solesse, A. Cost-effectiveness of atorvastatin in the prevention of cardiovascular events in diabetic patients: a French adaptation of CARDS. *Archives of cardiovascular diseases*. 2008;101(5):327-332.

Lage, M. J., Fabunmi, R., Boye, K. S., and Misurski, D. A. Comparison of costs among patients with type 2 diabetes treated with exenatide or sitagliptin therapy. *Advances in Therapy*. 2009;26(2):217-229.

Lalic, N. M., Micic, D., Antic, S., Bajovic, L., Pantelinac, P., Jotic, A., Kendereski, A., Dimic, D., Djukic, A., Mitrovic, M., and Vujasin, M. Effect of biphasic insulin aspart on glucose and lipid control in patients with Type 2 diabetes mellitus. *Expert Opinion on Pharmacotherapy*. 2007;8(17):2895-2901.

Lam, P., Dennis, S. M., Diamond, T. H., and Zwar, N. Improving glycaemic and BP control in type 2 diabetes. The effectiveness of tai chi. *Australian Family Physician*. 2008;37(10):884-887.

LaMarr, B., Valdez, C., Driscoll, K., and Ryan, M. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. *American Journal of Health-System Pharmacy*. 2010;67(4):290-294.

Lambers Heerspink, H. J., Agarwal, R., Coyne, D. W., Parving, H. H., Ritz, E., Remuzzi, G., Audhya, P., Amdahl, M. J., Andress, D. L., and de Zeeuw, D. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. *American Journal of Nephrology*. 2009;30(3):280-286.

Lambers, S., Van Laethem, C., Van Acker, K., and Calders, P. Influence of combined exercise training on indices of obesity, diabetes and cardiovascular risk in type 2 diabetes patients. *Clinical Rehabilitation*. 2008;22(6):483-492.

Lammert, A., Kratzsch, J., Selhorst, J., Humpert, P. M., Bierhaus, A., Birck, R., Kusterer, K., and Hammes, H. P. Clinical benefit of a short term dietary oatmeal intervention in patients with type 2 diabetes and severe insulin resistance: a pilot study. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116(2):132-134.

Landman, G. W., van Hateren, K. J., Kleefstra, N., Groenier, K. H., Gans, R. O., and Bilo, H. J. The relationship between glycaemic control and mortality in patients with type 2 diabetes in general practice (ZODIAC-11). *British Journal of General Practice*. 2010;60(572):172-175.

Lang, C. D., Arora, R. R., Saha, S. A., and Molnar, J. Bayesian meta-analysis of tissue angiotensin-converting enzyme inhibitors for reduction of adverse cardiovascular events in patients with diabetes mellitus and preserved left ventricular function. *Journal of the CardioMetabolic Syndrome*. 2008;3(1):45-52.

Lankisch, M. R., Ferlinz, K. C., Leahy, J. L., Scherbaum, W. A., Orals Plus, Apidra, and group, Lantus study. Introducing a simplified approach to insulin therapy in type 2 diabetes: a comparison of two single-dose regimens of insulin glulisine plus insulin glargine and oral antidiabetic drugs.[Erratum appears in *Diabetes Obes Metab*. 2010 May;12(5):461]. *Diabetes, Obesity & Metabolism*. 2008;10(12):1178-1185.

Larsen Cm, Faulenbach M. V. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. *The New England journal of medicine*. 2007;356(15):1517-1526.

Larsen, C. M., Faulenbach, M., Vaag, A., Ehse, J. A., Donath, M. Y., and Mandrup-Poulsen, T. Sustained effects of interleukin-1 receptor antagonist treatment in type 2 diabetes. *Diabetes Care*. 2009;32(9):1663-1668.

LaSalle, J. R. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. *Postgraduate Medicine*. 2010;122(1):144-152.

Lasserson, D. S., Glasziou, P., Perera, R., Holman, R. R., and Farmer, A. J. Optimal insulin regimens in type 2 diabetes mellitus: systematic review and meta-analyses. *Diabetologia*. 2009;52(10):1990-2000.

Lastra-Gonzalez, G., Manrique, C. M., Govindarajan, G., Whaley-Connell, A., and Sowers, J. R. Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. *Expert Opinion on Pharmacotherapy*. 2005;6(13):2209-2221.

Lawlor, D. A., Patel, R., Fraser, A., Smith, G. D., and Ebrahim, S. The association of life course socio-economic position with diagnosis, treatment, control and survival of women with diabetes: findings from the British Women's Heart and Health Study. *Diabetic Medicine*. 2007;24(8):892-900.

Lawton, J., Ahmad, N., Hanna, L., Douglas, M., Bains, H., and Hallowell, N. 'We should change ourselves, but we can't': accounts of food and eating practices amongst British Pakistanis and Indians with type 2 diabetes. *Ethnicity & Health*. 2008;13(4):305-319.

Lawton, J., Peel, E., Parry, O., and Douglas, M. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. *Diabetic Medicine*. 2008;25(4):491-495.

Leal, J., Gray, A. M., and Clarke, P. M. Development of life-expectancy tables for people with type 2 diabetes. *European Heart Journal*. 2009;30(7):834-839.

Lebovitz, H. E. Glycaemic control and vascular complications in type 2 diabetes: new observations and clinical significance. *Journal of the Indian Medical Association*. 2008;106(11):724-726.

Lee Tm, Lin M. S. T. Effects of sulfonylureas on left ventricular mass in type 2 diabetic patients. *American journal of physiology*. 2007;Heart and circulatory physiology. 292(1):H608-H613.

Lee, C. M., Huxley, R. R., Wildman, R. P., and Woodward, M. Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. *Journal of Clinical Epidemiology*. 2008;61(7):646-653.

Lee, H., Jang, H. C., Park, H. K., Metzger, B. E., and Cho, N. H. Prevalence of type 2 diabetes among women with a previous history of gestational diabetes mellitus. *Diabetes Research & Clinical Practice*. 2008;81(1):124-129.

Lee, J. E., Huh, W., Son, H. J., Kim, Y. G., Kim, D. J., Lee, M. K., and Oh, H. Y. Association of metabolic syndrome with microalbuminuria in non-hypertensive type 2 diabetic patients. *Nephron*.

2007;106(3):c98-103.

Lee, J. M., Kim, J. H., Son, H. S., Hong, E. G., Yu, J. M., Han, K. A., Min, K. W., and Chang, S. A. Valsartan increases circulating adiponectin levels without changing HOMA-IR in patients with type 2 diabetes mellitus and hypertension. *Journal of International Medical Research*. 2010;38(1):234-241.

Lee, M. S., Chen, K. W., Choi, T. Y., and Ernst, E. Qigong for type 2 diabetes care: a systematic review. *Complementary Therapies in Medicine*. 2009;17(4):236-242.

Lee, M. S., Pittler, M. H., Guo, R., and Ernst, E. Qigong for hypertension: a systematic review of randomized clinical trials. *Journal of Hypertension*. 2007;25(8):1525-1532.

Lee, T. I., Yeh, Y. T., Liu, C. T., and Chen, P. L. Development and evaluation of a patient-oriented education system for diabetes management. *International Journal of Medical Informatics*. 2007;76(9):655-663.

Lee, V. W., Ho, I. C., Chan, W. S., Tam, K. Y., and Lee, K. K. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong. *American Journal of Cardiovascular Drugs*. 2008;8(3):199-205.

Lee, W. J., Ser, K. H., Chong, K., Lee, Y. C., Chen, S. C., Tsou, J. J., Chen, J. C., and Chen, C. M. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. *Surgery*. 2010;147(5):664-669.

Leehey, D. J., Moinuddin, I., Bast, J. P., Qureshi, S., Jelinek, C. S., Cooper, C., Edwards, L. C., Smith, B. M., and Collins, E. G. Aerobic exercise in obese diabetic patients with chronic kidney disease: a randomized and controlled pilot study. *Cardiovascular Diabetology*. 2009;8:62.

Legrix, D. [Monitoring of patients using atypical psychotics and screening for metabolic syndrome]. *Soins - Psychiatrie*. 2010;(266):25-29.

Leibbrandt, A. J., Kiefte-de Jong, J. C., Hogenelst, M. H., Snoek, F. J., and Weijs, P. J. Effects of the PRO-active Interdisciplinary Self-MANagement (PRISMA, Dutch DESMOND) program on dietary intake in type 2 diabetes outpatients: a pilot study. *Clinical Nutrition*. 2010;29(2):199-205.

Leitao, C. B., Krahe, A. L., Nabinger, G. B., Picon, P. X., Pecis, M., Zaslavsky, L. M., Gross, J. L., and Canani, L. H. Aspirin therapy is still underutilized among patients with type 2 diabetes. *Arquivos Brasileiros de Endocrinologia e Metabologia*. 2006;50(6):1014-1019.

Leiter, L. A., Martineau, P., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Langer, A., Actfast, and investigators. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. *Journal of Family Practice*. 2008;57(10):661-668.

Leiter, L. A. Should you put all diabetic patients on statins?. *Journal of Family Practice*. 2007;56(4):294-300.

Lencioni, C., Lupi, R., and Del Prato, S. Beta-cell failure in type 2 diabetes mellitus. *Current Diabetes Reports*. 2008;8(3):179-184.

Lenfant, C. Can prevention of hypertension work?. *American Journal of Therapeutics*. 2008;15(4):334-339.

LeRoith, D. Dyslipidemia and glucose dysregulation in overweight and obese patients. *Clinical Cornerstone*. 2007;8(3):38-52.

LeRoith, D. Treatment of diabetes: a clinical update on insulin trials. *Clinical Cornerstone*. 2007;8(2):21-29.

Leslie, R. D., Kolb, H., Schloot, N. C., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Sarti, C., Thivolet, C., Hadden, D., Hunter, S., Scherthaner, G., Scherbaum, W., Williams, R., and Pozzilli,

- P. Diabetes classification: grey zones, sound and smoke: Action LADA 1. *Diabetes/Metabolism Research Reviews*. 2008;24(7):511-519.
- Leung, P. S. and de Gasparo, M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. *Journal of the CardioMetabolic Syndrome*. 2006;1(3):197-203.
- Leung, P. S. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. *Diabetic Medicine*. 2007;24(2):110-116.
- Leverve, X. M. [Metformin and type 2 diabetes: the UKPDS experience]. *Journées Annuelles de Diabetologie de l'Hotel-Dieu*. 2007;5-11.
- Levetan, C. Oral antidiabetic agents in type 2 diabetes. *Current Medical Research & Opinion*. 2007;23(4):945-952.
- Levy, P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. *Medgenmed [Computer File]: Medscape General Medicine*. 2007;9(2):12.
- Lewin, A. J. and Weir, M. R. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. *Clinical Therapeutics*. 2008;30(12):2354-2365.
- Lewin, A., Lipetz, R., Wu, J., and Schwartz, S. Comparison of extended-release metformin in combination with a sulfonylurea (glyburide) to sulfonylurea monotherapy in adult patients with type 2 diabetes: a multicenter, double-blind, randomized, controlled, phase III study. *Clinical Therapeutics*. 2007;29(5):844-855.
- Lewis, S. J., Fox, K. M., Grandy, S., and Group, Shield Study. Self-reported diagnosis of heart disease: results from the SHIELD study. *International Journal of Clinical Practice*. 2009;63(5):726-734.
- Li, C., Xia, J., Zhang, G., Wang, S., and Wang, L. Nateglinide versus repaglinide for type 2 diabetes mellitus in China. *Acta Diabetologica*. 2009;46(4):325-333.
- Li, H., Li, W., Gu, Y., Han, Y., Wang, J., Xu, B., Li, F., Yu, Y., and Wu, G. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration.[Erratum appears in *Diabetes Res Clin Pract*. 2009 Sep;85(3):342]. *Diabetes Research & Clinical Practice*. 2009;84(2):158-162.
- Li, H. Comparison of continual insulin or secretagogue treatment in type 2 diabetic patients with alternate insulin-secretagogue administration. *Diabetes research and clinical practice*. 2009;84(2):158-162.
- Li, J., Luo, Y., Xu, Y., Yang, J., Zheng, L., Hasimu, B., Yu, J., and Hu, D. Risk factors of peripheral arterial disease and relationship between low ankle - brachial index and mortality from all-cause and cardiovascular disease in Chinese patients with type 2 diabetes. *Circulation Journal*. 2007;71(3):377-381.
- Li, J., Tian, H., Li, Q., Wang, N., Wu, T., Liu, Y., Ni, Z., Yu, H., Liang, J., Luo, R., Li, Y., and Huang, L. Improvement of insulin sensitivity and beta-cell function by nateglinide and repaglinide in type 2 diabetic patients - a randomized controlled double-blind and double-dummy multicentre clinical trial. *Diabetes, Obesity & Metabolism*. 2007;9(4):558-565.
- Li, J., Wu, Hong M., Zhang, L., Zhu, B., and Dong, B. R. Heparin and related substances for preventing diabetic kidney disease (Systematic Review). Li Jun, Wu Hong Mei., Zhang.Ling, Zhu.Bin., Dong.Bi Rong.Heparin.and related substances.for preventing diabetic kidney disease.Cochrane Database of Systematic Reviews: Reviews 2010.Issue 9 John.Wiley & Sons., Ltd.Chichester, UK DOI.: 10.1002/14651858.CD. 2010;(9).
- Li, Y. X., Zeng, J. B., Yu, K., Sun, Q., Liu, Q. Y., Qin, W., Zhang, Q., Yu, J. C., and Wang, H.

Beneficial effects of a diabetes specific formula on insulin sensitivity and free fatty acid in patients with type 2 diabetes mellitus. *Chinese Medical Journal*. 2008;121(8):691-695.

Li, Y., Li, Q., Li, C. J., Wang, C. J., Zheng, Y. M., Issa, M., and Zhang, J. Comparison of HbA1c in Chinese patients with type 1 or type 2 diabetes randomized to twice daily insulin lispro low mix 25 or twice daily human insulin mix 30/70. *Chinese Medical Journal*. 2009;122(21):2540-2546.

Li, Z. Z., Lu, X. Z., Liu, J. B., and Chen, L. Serum retinol-binding protein 4 levels in patients with diabetic retinopathy. *Journal of International Medical Research*. 2010;38(1):95-99.

Li, Z., Hu, X., and Tang, N. Significance of neuroelectrophysiological tests in the early diagnosis of sub-clinical neuropathy with diabetes mellitus. *Journal of Huazhong University of Science and Technology*. 2006;Medical Sciences. 26(4):429-431.

Liao, Z. H., Chen, Y. L., Li, F. P., Yan, X., Lu, H., Yan, L., Zhou, Z. G., Zhu, D. L., Ji, L. N., Weng, J. P., and Study, Group. Multicenter clinical study on the efficacy and safety of inhalable insulin aerosol in the treatment of type 2 diabetes. *Chinese Medical Journal*. 2008;121(13):1159-1164.

Liebl, A. Comparison of insulin analogue regimens in people with type 2 diabetes mellitus in the PREFER Study: a randomized controlled trial. *Diabetes, Obesity & Metabolism*. 2009;11(1):45-52.

Liebl, A. Insulin intensification--the rationale and the target. *International Journal of Clinical Practice*. 2009;Supplement.(164):1-5.

Lim, H. S. and Lip, G. Y. From diabetes to metabolic syndrome: a viewpoint on an evolving concept. *Current Pharmaceutical Design*. 2007;13(25):2580-2583.

Lim, M. C., Lee, S. Y., Cheng, B. C., Wong, D. W., Ong, S. G., Ang, C. L., and Yeo, I. Y. Diabetic retinopathy in diabetics referred to a tertiary centre from a nationwide screening programme. *Annals of the Academy of Medicine, Singapore*. 2008;37(9):753-759.

Lim, S. C., Koh, A. F., Goh, S. K., Chua, C. L., Heng, B. L., Subramaniam, T., and Sum, C. F. Angiotensin receptor antagonist vs. angiotensin-converting enzyme inhibitor in Asian subjects with type 2 diabetes and albuminuria - a randomized crossover study. *Diabetes, Obesity & Metabolism*. 2007;9(4):477-482.

Lima, L. C., Assis, G. V., Hiyane, W., Almeida, W. S., Arsa, G., Baldissera, V., Campbell, C. S., and Simoes, H. G. Hypotensive effects of exercise performed around anaerobic threshold in type 2 diabetic patients. *Diabetes Research & Clinical Practice*. 2008;81(2):216-222.

Lin, C. Y., Chen, M. F., Lin, L. Y., Liao, C. S., Lee, Y. T., and Su, T. C. Insulin resistance is the major determinant for microalbuminuria in severe hypertriglyceridemia: implication for high-risk stratification. *Internal Medicine*. 2008;47(12):1091-1097.

Lin, J. D., Hsia, T. L., Wu, C. Z., Su, C. C., Ma, W. Y., Hsieh, A. T., Hsieh, C. H., Wang, K., Chu, Y. M., and Pei, D. The first and second phase of insulin secretion in naive Chinese type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(6):780-786.

Lin, K. D., Chang, Y. H., Wang, C. L., Yang, Y. H., Hsiao, P. J., Li, T. H., and Shin, S. J. Thiazolidinedione addition reduces the serum retinol-binding protein 4 in type 2 diabetic patients treated with metformin and sulfonylurea. *Translational Research: The Journal Of Laboratory & Clinical Medicine*. 2008;151(6):309-314.

Lincoff, A. M., Wolski, K., Nicholls, S. J., and Nissen, S. E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. *Jama*. 2007;298(10):1180-1188.

Lindeberg, S., Jonsson, T., Granfeldt, Y., Borgstrand, E., Soffman, J., Sjostrom, K., and Ahren, B. A Palaeolithic diet improves glucose tolerance more than a Mediterranean-like diet in individuals with

ischaemic heart disease. *Diabetologia*. 2007;50(9):1795-1807.

Linn, T., Fischer, B., Soydan, N., Eckhard, M., Ehl, J., Kunz, C., and Bretzel, R. G. Nocturnal glucose metabolism after bedtime injection of insulin glargine or neutral protamine hagedorn insulin in patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(10):3839-3846.

Linnebjerg, H., Park, S., Kothare, P. A., Trautmann, M. E., Mace, K., Fineman, M., Wilding, I., Nauck, M., and Horowitz, M. Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes. *Regulatory Peptides*. 2008;151(1-3):123-129.

Lipsett, M., Hanley, S., Castellarin, M., Austin, E., Suarez-Pinzon, W. L., Rabinovitch, A., and Rosenberg, L. The role of islet neogenesis-associated protein (INGAP) in islet neogenesis. *Cell Biochemistry & Biophysics*. 2007;48(2-3):127-137.

Liraglutide (Victoza) for type 2 diabetes. *Medical Letter on Drugs & Therapeutics*. 2010;52(1335):25-27.

List, J. F., Woo, V., Morales, E., Tang, W., and Fiedorek, F. T. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. *Diabetes Care*. 2009;32(4):650-657.

Liu, M. C., Riese, R. J., Van Gundy, K., Norwood, P., Sullivan, B. E., Schwartz, P. F., and Teeter, J. G. Effects of inhaled human insulin on airway lining fluid composition in adults with diabetes. *European Respiratory Journal*. 2008;32(1):180-188.

Livesey, G., Taylor, R., Hulshof, T., and Howlett, J. Glycemic response and health--a systematic review and meta-analysis: relations between dietary glycemic properties and health outcomes. *American Journal of Clinical Nutrition*. 2008;87(1):258S-268S.

Lloret-Linares, C., Greenfield, J. R., and Czernichow, S. Effect of weight-reducing agents on glycaemic parameters and progression to Type 2 diabetes: a review. *Diabetic Medicine*. 2008;25(10):1142-1150.

Locatelli, F., Del Vecchio, L., and Cavalli, A. Inhibition of the renin-angiotensin system in chronic kidney disease: a critical look to single and dual blockade. *Nephron*. 2009;113(4):c286-c293.

Logtenberg Sj, Kleefstra N. H. Effect of device-guided breathing exercises on blood pressure in hypertensive patients with type 2 diabetes mellitus: a randomized controlled trial. *Journal of Hypertension*. 2007;25(1):241-246.

Logtenberg, S. J., Kleefstra, N., Ubink-Veltmaat, L. J., Houweling, S. T., and Bilo, H. J. Intensification of therapy and no increase in body mass index with longer disease duration in type 2 diabetes mellitus (ZODIAC-5). *Family Practice*. 2007;24(6):529-531.

Loimaala, A., Groundstroem, K., Rinne, M., Nenonen, A., Huhtala, H., and Vuori, I. Exercise training does not improve myocardial diastolic tissue velocities in Type 2 diabetes. *Cardiovascular Ultrasound*. 2007;5:32.

Loimaala, A. Effect of long-term endurance and strength training on metabolic control and arterial elasticity in patients with type 2 diabetes mellitus. *The American journal of cardiology*. 2009;103(7):972-977.

Lonardo, A., Carulli, N., and Loria, P. HCV and diabetes. A two-question-based reappraisal. *Digestive & Liver Disease*. 2007;39(8):753-761.

Look Ahead Research Group, Pi-Sunyer, X., Blackburn, G., Brancati, F. L., Bray, G. A., Bright, R., Clark, J. M., Curtis, J. M., Espeland, M. A., Foreyt, J. P., Graves, K., Haffner, S. M., Harrison, B., Hill, J. O., Horton, E. S., Jakicic, J., Jeffery, R. W., Johnson, K. C., Kahn, S., Kelley, D. E., Kitabchi, A. E., Knowler, W. C., Lewis, C. E., Maschak-Carey, B. J., Montgomery, B., Nathan, D. M., Patricio, J., Peters, A., Redmon, J. B., Reeves, R. S., Ryan, D. H., Safford, M., Van Dorsten, B., Wadden, T. A., Wagenknecht, L., Wesche-Thobaben, J., Wing, R. R., and Yanovski, S. Z. Reduction in weight and

cardiovascular disease risk factors in individuals with type 2 diabetes: one-year results of the look AHEAD trial. *Diabetes Care*. 2007;30(6):1374-1383.

Lopez Stewart, G., Tambascia, M., Rosas Guzman, J., Etchegoyen, F., Ortega Carrion, J., and Artemenko, S. Control of type 2 diabetes mellitus among general practitioners in private practice in nine countries of Latin America. *Pan American Journal of Public Health*. 2007;22(1):12-20.

Lorig, K., Ritter, P. L., Villa, F. J., and Armas, J. Community-based peer-led diabetes self-management: a randomized trial. *Diabetes Educator*. 2009;35(4):641-651.

Lorusso, R., De Cicco, G., Beghi, C., Gherli, T., Poli, E., Corradi, D., Maestri, R., Bonadonna, S., Mancini, T., and Giustina, A. Functional effects of nitric oxide-releasing aspirin on vein conduits of diabetic patients undergoing CABG. *International Journal of Cardiology*. 2007;118(2):164-169.

Lottenberg, S. A., Glezer, A., and Turatti, L. A. Metabolic syndrome: identifying the risk factors. *Jornal de Pediatria*. 2007;83(5 Suppl):S204-S208.

Lotz, T. F., Chase, J. G., McAuley, K. A., Shaw, G. M., Wong, X. W., Lin, J., Lecompte, A., Hann, C. E., and Mann, J. I. Monte Carlo analysis of a new model-based method for insulin sensitivity testing. *Computer Methods & Programs in Biomedicine*. 2008;89(3):215-225.

Lovas, K., Rost, T. H., Skorve, J., Ulvik, R. J., Gudbrandsen, O. A., Bohov, P., Wensaas, A. J., Rustan, A. C., Berge, R. K., and Husebye, E. S. Tetradecylthioacetic acid attenuates dyslipidaemia in male patients with type 2 diabetes mellitus, possibly by dual PPAR-alpha/delta activation and increased mitochondrial fatty acid oxidation. *Diabetes, Obesity & Metabolism*. 2009;11(4):304-314.

Love, T. E., Cebul, R. D., Einstadter, D., Jain, A. K., Miller, H., Harris, C. M., Greco, P. J., Husak, S. S., Dawson, N. V., and Investigators, Dig It. Electronic medical record-assisted design of a cluster-randomized trial to improve diabetes care and outcomes. *Journal of General Internal Medicine*. 2008;23(4):383-391.

Lovegrove, J. A. CVD risk in South Asians: the importance of defining adiposity and influence of dietary polyunsaturated fat. *Proceedings of the Nutrition Society*. 2007;66(2):286-298.

Loveman, E., Frampton, G. K., and Clegg, A. J. The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review. *Health Technology Assessment (Winchester, England)*. 12(9):1-116.

Lovestam-Adrian, M., Hansson-Lundblad, C., and Torffvit, O. Sight-threatening retinopathy is associated with lower mortality in type 2 diabetic subjects: a 10-year observation study. *Diabetes Research & Clinical Practice*. 2007;77(1):141-147.

Lu, B., Song, X., Dong, X., Yang, Y., Zhang, Z., Wen, J., Li, Y., Zhou, L., Zhao, N., Zhu, X., and Hu, R. High prevalence of chronic kidney disease in population-based patients diagnosed with type 2 diabetes in downtown Shanghai. *Journal of Diabetes & its Complications*. 2008;22(2):96-103.

Lu, F. R., Shen, L., Qin, Y., Gao, L., Li, H., and Dai, Y. Clinical observation on trigonella foenum-graecum L. total saponins in combination with sulfonylureas in the treatment of type 2 diabetes mellitus. *Chinese Journal of Integrative Medicine*. 2008;14(1):56-60.

Lu, Y., Levin, G. V., and Donner, T. W. Tagatose, a new antidiabetic and obesity control drug. *Diabetes, Obesity & Metabolism*. 2008;10(2):109-134.

Lu, Z. X., Walker, K. Z., O'Dea, K., Sikaris, K. A., and Shaw, J. E. A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. *Diabetes Care*. 2010;33(4):817-819.

Luckie, R., Leese, G., McAlpine, R., MacEwen, C. J., Baines, P. S., Morris, A. D., Ellis, J. D., and collaboration, Darts Memo. Fear of visual loss in patients with diabetes: results of the prevalence of

diabetic eye disease in Tayside, Scotland (P-DETS) study. *Diabetic Medicine*. 2007;24(10):1086-1092.

Lujan, J., Ostwald, S. K., and Ortiz, M. Promotora diabetes intervention for Mexican Americans. *Diabetes Educator*. 2007;33(4):660-670.

Lukas, M. A. Beta blockade in diabetic heart failure. *Heart Failure Clinics*. 2006;2(1):89-99.

Lund Ss, Tarnow L. F. Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial. *Bmj*. 4324;339:.

Lund, S. S., Tarnow, L., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., and Vaag, A. A. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes. *European Journal of Endocrinology*. 2008;158(1):35-46.

Lund, S. S., Tarnow, L., Stehouwer, C. D., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., and Vaag, A. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes, Obesity & Metabolism*. 2007;9(3):394-407.

Lund, S. S., Tarnow, L., Stehouwer, C. D., Schalkwijk, C. G., Teerlink, T., Gram, J., Winther, K., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., and Vaag, A. A. Impact of metformin versus repaglinide on non-glycaemic cardiovascular risk markers related to inflammation and endothelial dysfunction in non-obese patients with type 2 diabetes. *European Journal of Endocrinology*. 2008;158(5):631-641.

Lundgren, J. D., Battegay, M., Behrens, G., De Wit, S., Guaraldi, G., Katlama, C., Martinez, E., Nair, D., Powderly, W. G., Reiss, P., Sutinen, J., Vigano, A., and Committee, Eacs Executive. European AIDS Clinical Society (EACS) guidelines on the prevention and management of metabolic diseases in HIV. *HIV Medicine*. 2008;9(2):72-81.

Lundgren, V. M., Isomaa, B., Lyssenko, V., Laurila, E., Korhonen, P., Groop, L. C., Tuomi, T., and Botnia Study, Group. GAD antibody positivity predicts type 2 diabetes in an adult population. *Diabetes*. 2010;59(2):416-422.

Luscombe, F. A. Health-related quality of life measurement in type 2 diabetes. *Value in Health*. 2000;3 Suppl 1:15-28.

Lutsey, P. L., Jacobs, D. R., Jr., Kori, S., Mayer-Davis, E., Shea, S., Steffen, L. M., Szklo, M., and Tracy, R. Whole grain intake and its cross-sectional association with obesity, insulin resistance, inflammation, diabetes and subclinical CVD: The MESA Study. *British Journal of Nutrition*. 2007;98(2):397-405.

Luzio, S., Peter, R., Dunseath, G. J., Mustafa, L., and Owens, D. R. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. *Diabetes Research & Clinical Practice*. 2008;79(2):269-275.

Luzio, S., Piehlmeier, W., Tovar, C., Eberl, S., Latzsch, G., Fallbohmer, E., Rumpel, E., Owens, D. R., and Landgraf, R. Results of the pilot study of DIADEM: a comprehensive disease management programme for type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;76(3):410-417.

Lyseng-Williamson, K. A. Sitagliptin. *Drugs*. 2007;67(4):587-597.

Lysy, Z., Da Costa, D., and Dasgupta, K. The association of physical activity and depression in Type 2 diabetes. *Diabetic Medicine*. 2008;25(10):1133-1141.

Ma, J., Stevens, J. E., Cukier, K., Maddox, A. F., Wishart, J. M., Jones, K. L., Clifton, P. M., Horowitz, M., and Rayner, C. K. Effects of a protein preload on gastric emptying, glycemia, and gut hormones

after a carbohydrate meal in diet-controlled type 2 diabetes. *Diabetes Care*. 2009;32(9):1600-1602.

Ma, J., Yang, W., Fang, N., Zhu, W., and Wei, M. The association between intensive glycemic control and vascular complications in type 2 diabetes mellitus: a meta-analysis. *Nutrition Metabolism & Cardiovascular Diseases*. 2009;19(9):596-603.

Ma, Y., Olendzki, B. C., Merriam, P. A., Chiriboga, D. E., Culver, A. L., Li, W., Hebert, J. R., Ockene, I. S., Griffith, J. A., and Pagoto, S. L. A randomized clinical trial comparing low-glycemic index versus ADA dietary education among individuals with type 2 diabetes. *Nutrition*. 2008;24(1):45-56.

Macfarlane, D. P., Paterson, K. R., and Fisher, M. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(7):533-544.

Machado-Alba, J. E., Moncada-Escobar, J. C., and Gaviria, H. Quality and effectiveness of diabetes care for a group of patients in Colombia. *Pan American Journal of Public Health*. 2009;26(6):529-535.

Macic-Dzankovic, A., Dzankovic, F., Pojskic, B., and Velija-Asimi, Z. Evaluation of risk markers fluctuation during an initial therapy with rosiglitazone in patients suffering from metabolic syndrome. *Bosnian Journal of Basic Medical Sciences*. 2009;9(4):320-328.

Macisaac, R. J., Jerums, G., Weekes, A. J., and Thomas, M. C. Patterns of glycaemic control in Australian primary care (NEFRON 8). *Internal Medicine Journal*. 2009;39(8):512-518.

Mackin, P., Bishop, D., Watkinson, H. M., and Ferrier, I. N. A prospective study of glycaemic status in anti-psychotic-treated patients. *Journal of Psychopharmacology*. 2008;22(5):563-566.

MacMahon, Tone J. An intensive nurse-led, multi-interventional clinic is more successful in achieving vascular risk reduction targets than standard diabetes care. *Irish Journal of Medical Science*. 2009;178(2):179-186.

Macasai, E., Cseh, A., Budai, G., Meszaros, G., Vasarhelyi, B., Fischer, K., Szabo, A., and Treszl, A. Effect of 3 months of doxazosin therapy on T-cell subsets in type 2 diabetic patients. *Journal of International Medical Research*. 2009;37(6):1982-1987.

Madden, K. M., Lockhart, C., Cuff, D., Potter, T. F., and Meneilly, G. S. Short-term aerobic exercise reduces arterial stiffness in older adults with type 2 diabetes, hypertension, and hypercholesterolemia. *Diabetes Care*. 2009;32(8):1531-1535.

Madsbad, S., Krarup, T., Deacon, C. F., and Holst, J. J. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2008;11(4):491-499.

Madsbad, S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2009;23(4):463-477.

Maegawa, H., Nishio, Y., Nakao, K., Ugi, S., Maeda, K., Uzu, T., and Kashiwagi, A. Short-term low-dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. *Endocrine Journal*. 2007;54(4):613-618.

Mafong, D. D. and Henry, R. R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. *Current Atherosclerosis Reports*. 2008;10(1):55-60.

Maggioni, A. P., Caterson, I., Coutinho, W., Finer, N., Gaal, L. V., Sharma, A. M., Torp-Pedersen, C., Bacher, P., Shepherd, G., Sun, R., James, P., and investigators, Scout. Tolerability of sibutramine during a 6-week treatment period in high-risk patients with cardiovascular disease and/or diabetes: a preliminary analysis of the Sibutramine Cardiovascular Outcomes (SCOUT) Trial. *Journal of Cardiovascular Pharmacology*. 2008;52(5):393-402.

Magliano, D. J., Barr, E. L., Zimmet, P. Z., Cameron, A. J., Dunstan, D. W., Colagiuri, S., Jolley, D., Owen, N., Phillips, P., Tapp, R. J., Welborn, T. A., and Shaw, J. E. Glucose indices, health behaviors, and incidence of diabetes in Australia: the Australian Diabetes, Obesity and Lifestyle Study. *Diabetes Care*. 2008;31(2):267-272.

Maiti, R., Agrawal, N. K., Dash, D., and Pandey, B. L. Effect of Pentoxifylline on inflammatory burden, oxidative stress and platelet aggregability in hypertensive type 2 diabetes mellitus patients. *Vascular Pharmacology*. 2007;47(2-3):118-124.

Majid, A. Prevention and management of coronary artery disease in patients with diabetes mellitus. *Acta Medica Indonesiana*. 2009;41(1):41-44.

Maki, K. C., Beiseigel, J. M., Jonnalagadda, S. S., Gugger, C. K., Reeves, M. S., Farmer, M. V., Kaden, V. N., and Rains, T. M. Whole-grain ready-to-eat oat cereal, as part of a dietary program for weight loss, reduces low-density lipoprotein cholesterol in adults with overweight and obesity more than a dietary program including low-fiber control foods. *Journal of the American Dietetic Association*. 2010;110(2):205-214.

Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., and Group, Innovation Study. Microalbuminuria reduction with telmisartan in normotensive and hypertensive Japanese patients with type 2 diabetes: a post-hoc analysis of The Incipient to Overt: Angiotensin II Blocker, Telmisartan, Investigation on Type 2 Diabetic Nephropathy (INNOVATION) study. *Hypertension Research - Clinical & Experimental*. 2008;31(4):657-664.

Makino, H., Haneda, M., Babazono, T., Moriya, T., Ito, S., Iwamoto, Y., Kawamori, R., Takeuchi, M., Katayama, S., and Group, Innovation Study. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. *Diabetes Care*. 2007;30(6):1577-1578.

Makrilakis, K. and Katsilambros, N. Prediction and prevention of type 2 diabetes. *Hormones*. 2003;2(1):22-34.

Malaguarnera, M., Vacante, M., Motta, M., Li Volti, G., and Galvano, F. Effect of L-carnitine on the size of low-density lipoprotein particles in type 2 diabetes mellitus patients treated with simvastatin. *Metabolism: Clinical & Experimental*. 2009;58(11):1618-1623.

Malaisse, W. J. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. *Expert Opinion on Pharmacotherapy*. 2008;9(15):2691-2698.

Malin, S.K.; Stephens, B. R; Sharoff, C. G; Hagobian, T. A; Chipkin, S. R; and Braun, B. Metformin's effect on exercise and postexercise substrate oxidation. *International Journal of Sport Nutrition & Exercise Metabolism*. 2010;20(1):63-71.

Mancini, T; Mazziotti, G; Doga, M; Carpinteri, R., Simetovic, N., Vescovi, P. P., and Giustina, A. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. *Bone*. 2009;45(4):784-788.

Manders, R. J., Van Dijk, J. W., and van Loon, L. J. Low-intensity exercise reduces the prevalence of hyperglycemia in type 2 diabetes. *Medicine & Science in Sports & Exercise*. 2010;42(2):219-225.

Mann, D. M., Bertoni, A. G., Shimbo, D., Carnethon, M. R., Chen, H., Jenny, N. S., and Muntner, P. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. *American Journal of Epidemiology*. 2010;171(9):980-988.

Mann, J. F., Green, D., Jamerson, K., Ruilope, L. M., Kuranoff, S. J., Littke, T., Viberti, G., and Group, Ascend Study. Avosentan for overt diabetic nephropathy. *Journal of the American Society of Nephrology*. 2010;21(3):527-535.

Mannucci, E. and Monami, M. Is the evidence from clinical trials for cardiovascular risk or harm for glitazones convincing?. *Current Diabetes Reports*. 2009;9(5):342-347.

- Mannucci, E. and Rotella, C. M. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(9):639-645.
- Mannucci, E., Bartali, B., Molino Lova, R., Papucci, M., Lauretani, F., Luisi, M. L., Pietrobelli, A., and Macchi, C. Eating habits in elderly diabetic subjects: assessment in the InCHIANTI Study. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(4):278-282.
- Mannucci, E., Monami, M., and Rotella, C. M. How many components for the metabolic syndrome? Results of exploratory factor analysis in the FIBAR study. *Nutrition Metabolism & Cardiovascular Diseases*. 2007;17(10):719-726.
- Mannucci, E., Monami, M., Lamanna, C., Gori, F., and Marchionni, N. Prevention of cardiovascular disease through glycemic control in type 2 diabetes: a meta-analysis of randomized clinical trials. *Nutrition Metabolism & Cardiovascular Diseases*. 2009;19(9):604-612.
- Mansour, A. A., Al-Hassan, A. A., and Al-Jazairi, M. I. Cut-off values for waist circumference in rural Iraqi adults for the diagnosis of metabolic syndrome. *Rural & Remote Health*. 2007;7(4):765.
- Maple-Brown, L., Cunningham, J., Dunne, K., Whitbread, C., Howard, D., Weeramanthri, T., Tatipata, S., Dunbar, T., Harper, C. A., Taylor, H. R., Zimmet, P., O'Dea, K., and Shaw, J. E. Complications of diabetes in urban Indigenous Australians: the DRUID study. *Diabetes Research & Clinical Practice*. 2008;80(3):455-462.
- Marazzi, G., Wajngarten, M., Vitale, C., Patrizi, R., Pelliccia, F., Gebara, O., Pierri, H., Ramires, J. A., Volterrani, M., Fini, M., and Rosano, G. M. Effect of free fatty acid inhibition on silent and symptomatic myocardial ischemia in diabetic patients with coronary artery disease. *International Journal of Cardiology*. 2007;120(1):79-84.
- Marcinkowska, M., Lewandowski, K. C., Lewinski, A., Bienkiewicz, M., Basinska-Lewandowska, M., Salata, I., and Randeve, H. S. Visfatin levels do not change after the oral glucose tolerance test and after a dexamethasone-induced increase in insulin resistance in humans. *Endokrynologia Polska*. 2007;58(3):188-194.
- Marcus, R. L., Smith, S., Morrell, G., Addison, O., Dibble, L. E., Wahoff-Stice, D., and LaStayo, P. C. Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus.[Erratum appears in *Phys Ther*. 2009 Jan;89(1):103]. *Physical Therapy*. 2008;88(11):1345-1354.
- Margolis, K. L., Lihong, Qi, Brzyski, R., Bonds, D. E., Howard, B. V., Kempainen, S., Simin, Liu, Robinson, J. G., Safford, M. M., Tinker, L. T., Phillips, L. S., and Women Health Initiative, Investigators. Validity of diabetes self-reports in the Women's Health Initiative: comparison with medication inventories and fasting glucose measurements. *Clinical Trials*. 2008;5(3):240-247.
- Mari, A., Degn, K., Brock, B., Rungby, J., Ferrannini, E., and Schmitz, O. Effects of the long-acting human glucagon-like peptide-1 analog liraglutide on beta-cell function in normal living conditions. *Diabetes Care*. 2007;30(8):2032-2033.
- Mari, A., Scherbaum, W. A., Nilsson, P. M., Lalanne, G., Schweizer, A., Dunning, B. E., Jauffret, S., and Foley, J. E. Characterization of the influence of vildagliptin on model-assessed -cell function in patients with type 2 diabetes and mild hyperglycemia. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(1):103-109.
- Marino, M. T. DPP-4 inhibitors. A new class of drugs for type 2 diabetes. *Diabetes Self-Management*. 25(4):60.
- Marketou, M. E., Zacharis, E. A., Koukouraki, S., Stathaki, M. I., Arfanakis, D. A., Kochiadakis, G. E., Chlouverakis, G., Karkavitsas, N. S., and Vardas, P. E. Effect of angiotensin-converting enzyme

inhibitors on systemic inflammation and myocardial sympathetic innervation in normotensive patients with type 2 diabetes mellitus. *Journal of Human Hypertension*. 2008;22(3):191-196.

Marley, J. V., Davis, S., Coleman, K., Hayhow, B. D., Brennan, G., Mein, J. K., Nelson, C., Atkinson, D., and Maguire, G. P. Point-of-care testing of capillary glucose in the exclusion and diagnosis of diabetes in remote Australia. *Medical Journal of Australia*. 2007;186(10):500-503.

Marre, M., Shaw, J., Brandle, M., Bebakar, W. M., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., Colagiuri, S., and group, Lead Su study. Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*. 2009;26(3):268-278.

Marrero, D. G. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. *Clinical Cornerstone*. 2007;8(2):33-40.

Mars, G. M., Kempen, G. I., Mesters, I., Proot, I. M., and van Eijk, J. T. Characteristics of social participation as defined by older adults with a chronic physical illness. *Disability & Rehabilitation*. 2008;30(17):1298-1308.

Marshall, V., Wilton, L., and Shakir, S. Safety profile of repaglinide as used in general practice in England: results of a prescription-event monitoring study. *Acta Diabetologica*. 2006;43(1):6-13.

Marso, S. P., Kennedy, K. F., House, J. A., and McGuire, D. K. The effect of intensive glucose control on all-cause and cardiovascular mortality, myocardial infarction and stroke in persons with type 2 diabetes mellitus: a systematic review and meta-analysis. *Diabetes & Vascular Disease Research*. 2010;7(2):119-130.

Martin, C. L. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. *Diabetes Educator*. 2008;34 Suppl 3:66S-72S.

Martin, S. C. and Viljoen, A. The value of a specialist lipid clinic. *International Journal of Clinical Practice*. 2008;62(6):961-966.

Martina, V., Masha, A., Gigliardi, V. R., Brocato, L., Manzato, E., Berchio, A., Massarenti, P., Settanni, F., Della Casa, L., Bergamini, S., and Iannone, A. Long-term N-acetylcysteine and L-arginine administration reduces endothelial activation and systolic blood pressure in hypertensive patients with type 2 diabetes. *Diabetes Care*. 2008;31(5):940-944.

Martinez, L., Consoli, S. M., Monnier, L., Simon, D., Wong, O., Yomtov, B., Gueron, B., Benmedjahed, K., Guillemin, I., and Arnould, B. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. *Health & Quality of Life Outcomes*. 2007;5:53.

Martinez, Y. V., Prado-Aguilar, C. A., Rascon-Pacheco, R. A., and Valdivia-Martinez, J. J. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. *BMC Health Services Research*. 2008;8:164.

Martinez-Martin, F. J. and Saiz-Satjes, M. Add-on manidipine versus amlodipine in diabetic patients with hypertension and microalbuminuria: the AMANDHA study. *Expert Review of Cardiovascular Therapy*. 2008;6(10):1347-1355.

Martinez-Ramirez, H. R., Cortes-Sanabria, L., Rojas-Campos, E., Barragan, G., Alfaro, G., Hernandez, M., Canales-Munoz, J. L., and Cueto-Manzano, A. M. How frequently the clinical practice recommendations for nephropathy are achieved in patients with type 2 diabetes mellitus in a primary health-care setting?. *Revista de Investigacion Clinica*. 2008;60(3):217-226.

Marx, N. and Walcher, D. Vascular effects of PPARgamma activators - from bench to bedside.

Progress in Lipid Research. 2007;46(6):283-296.

Massin, P., Chabouis, A., Erginay, A., Viens-Bitker, C., Lecleire-Collet, A., Meas, T., Guillausseau, P. J., Choupot, G., Andre, B., and Denormandie, P. OPHDIAT: a telemedical network screening system for diabetic retinopathy in the Ile-de-France. *Diabetes & Metabolism*. 2008;34(3):227-234.

Masuda, H., Sakamoto, M., Irie, J., Kitaoka, A., Shiono, K., Inoue, G., Atsuda, K., and Yamada, S. Comparison of twice-daily injections of biphasic insulin lispro and basal-bolus therapy: glycaemic control and quality-of-life of insulin-naive type 2 diabetic patients. *Diabetes, Obesity & Metabolism*. 2008;10(12):1261-1265.

Masuda, S., Tamura, K., Wakui, H., Kanaoka, T., Ohsawa, M., Maeda, A., Dejima, T., Yanagi, M., Azuma, K., and Umemura, S. Effects of angiotensin II type 1 receptor blocker on ambulatory blood pressure variability in hypertensive patients with overt diabetic nephropathy. *Hypertension Research - Clinical & Experimental*. 2009;32(11):950-955.

Mathiassen, O. N., Buus, N. H., Sihm, I., Thybo, N. K., Morn, B., Schroeder, A. P., Thygesen, K., Aalkjaer, C., Lederballe, O., Mulvany, M. J., and Christensen, K. L. Small artery structure is an independent predictor of cardiovascular events in essential hypertension. *Journal of Hypertension*. 2007;25(5):1021-1026.

Mathieu, C. and Degrande, E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. *Vascular Health & Risk Management*. 2008;4(6):1349-1360.

Mathieu, C. and Robbrecht, S. Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 2:14-23.

Mathieu, C., Cuddihy, R., Arakaki, R. F., Belin, R. M., Planquois, J. M., Lyons, J. N., and Heilmann, C. R. A comparison between simplified and intensive dose-titration algorithms using AIR inhaled insulin for insulin-naive patients with type 2 diabetes in a randomized noninferiority trial. *Diabetes Technology & Therapeutics*. 2009;11 Suppl 2:S53-S61.

Matikainen, N., Kahri, J., and Taskinen, M. R. Reviewing statin therapy in diabetes--towards the best practise. *Primary care diabetes*. 2010;4(1):9-15.

Matikainen, N., Manttari, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., and Taskinen, M. R. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes. *Diabetologia*. 2006;49(9):2049-2057.

Matin, A., Gavande, N., Kim, M. S., Yang, N. X., Salam, N. K., Hanrahan, J. R., Roubin, R. H., and Hibbs, D. E. 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists. *Journal of Medicinal Chemistry*. 2009;52(21):6835-6850.

Matsuki, M., Matsuda, M., Kohara, K., Shimoda, M., Kanda, Y., Tawaramoto, K., Shigetoh, M., Kawasaki, F., Kotani, K., and Kaku, K. Pharmacokinetics and pharmacodynamics of glimepiride in type 2 diabetic patients: compared effects of once- versus twice-daily dosing. *Endocrine Journal*. 2007;54(4):571-576.

Matteucci, E. and Giampietro, O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. *Current Medicinal Chemistry*. 2009;16(23):2943-2951.

Matthews, J. E., Stewart, M. W., De Boever, E. H., Dobbins, R. L., Hodge, R. J., Walker, S. E., Holland, M. C., Bush, M. A., and Albiglutide Study, Group. Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(12):4810-4817.

Matthews, V. B. and Febbraio, M. A. CNTF: a target therapeutic for obesity-related metabolic disease?.

Journal of Molecular Medicine. 2008;86(4):353-361.

Matza, L. S., Yurgin, N., Boye, K. S., Malley, K., and Shorr, J. M. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. *Current Medical Research & Opinion*. 2007;23(9):2051-2062.

May, H. T., Anderson, J. L., Pearson, R. R., Jensen, J. R., Horne, B. D., Lavasani, F., Yannicelli, H. D., and Muhlestein, J. B. Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study). *American Journal of Cardiology*. 2008;101(4):486-489.

Mayerson, A. B. Levemir Early Clinical Experience Case Series. *Endocrinology & Metabolism Clinics of North America*. 2007;36 Suppl 1:45-52.

Maynard, J. D., Rohrscheib, M., Way, J. F., Nguyen, C. M., and Ediger, M. N. Noninvasive type 2 diabetes screening: superior sensitivity to fasting plasma glucose and A1C. *Diabetes Care*. 2007;30(5):1120-1124.

Mayor, S. International Diabetes Federation consensus on prevention of type 2 diabetes. *International Journal of Clinical Practice*. 2007;61(10):1773-1775.

Mazarska, M. and Mysliwiec, M. Telmisartan lowers albuminuria in type 2 diabetic patients treated with angiotensin enzyme inhibitors. *Advances in Medical Sciences*. 2009;54(1):37-40.

Mazze, R. S., Powers, M. A., Wetzler, H. P., and Ofstead, C. L. Partners in advancing care and education solutions study: impact on processes and outcomes of diabetes care. *Population Health Management*. 2008;11(6):297-305.

Mazze, R., Strock, E., Morgan, B., Wesley, D., Bergenstal, R., and Cuddihy, R. Diurnal glucose patterns of exenatide once weekly: a 1-year study using continuous glucose monitoring with ambulatory glucose profile analysis. *Endocrine Practice*. 2009;15(4):326-334.

Mazzone, T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. *American Journal of Medicine*. 2007;120(9 Suppl 2):S26-S32.

Mc Hugh, S., O'Keeffe, J., Fitzpatrick, A., de Siun, A., O'Mullane, M., Perry, I., Bradley, C., and National Diabetes Register, Project. Diabetes care in Ireland: a survey of general practitioners. *Primary care diabetes*. 2009;3(4):225-231.

McBane, R. D., Hardison, R. M., Sobel, B. E., and Group, Bari D. S. Comparison of plasminogen activator inhibitor-1, tissue type plasminogen activator antigen, fibrinogen, and D-dimer levels in various age decades in patients with type 2 diabetes mellitus and stable coronary artery disease (from the BARI 2D trial). *American Journal of Cardiology*. 2010;105(1):17-24.

McCall, A. L. Does a weight loss medicine make sense for obese type 2 diabetes? New information on endocannabinoid blockers. *Current Diabetes Reports*. 2007;7(5):329-332.

McCormick, B. B., Sydor, A., Akbari, A., Fergusson, D., Doucette, S., and Knoll, G. The effect of pentoxifylline on proteinuria in diabetic kidney disease: a meta-analysis. *American Journal of Kidney Diseases*. 2008;52(3):454-463.

McCullough, P. A. and Lepor, N. E. The rosiglitazone meta-analysis. *Reviews in Cardiovascular Medicine*. 2007;8(2):123-126.

McDonald, K. J. and Jardine, A. G. The use of fluvastatin in cardiovascular risk management. *Expert Opinion on Pharmacotherapy*. 2008;9(8):1407-1414.

McDowell, J. R., McPhail, K., Halyburton, G., Brown, M., and Lindsay, G. Perceptions of a service

redesign by adults living with type 2 diabetes. *Journal of Advanced Nursing*. 2009;65(7):1432-1441.

McFarlane, P. A. Lessons for dialysis investigators from the Steno-2 Study. *Journal of Nephrology*. 2008;21(1):6-13.

McFarlane, S. I. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials. *Expert Review of Cardiovascular Therapy*. 2009;7(11):1363-1371.

McGill, J. B., Bakris, G. L., Fonseca, V., Raskin, P., Messerli, F. H., Phillips, R. A., Katholi, R. E., Wright, J. T., Jr., Iyengar, M., Anderson, K. M., Lukas, M. A., Dalal, M. R., and Bell, D. S. beta-blocker use and diabetes symptom score: results from the GEMINI study. *Diabetes, Obesity & Metabolism*. 2007;9(3):408-417.

McGuire, D. K., Winterfield, J. R., Rytlewski, J. A., and Ferrannini, E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. *Diabetes & Vascular Disease Research*. 2008;5(1):59-66.

McIntosh, C. H. Dipeptidyl peptidase IV inhibitors and diabetes therapy. *Frontiers in Bioscience*. 2008;13:1753-1773.

McKillop, A. M., Duffy, N. A., Lindsay, J. R., Green, B. D., Patterson, S., O'Harte, F. P., Bell, P. M., and Flatt, P. R. Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. *European Journal of Endocrinology*. 2009;161(6):877-885.

McKimmie, R. L., Daniel, K. R., Carr, J. J., Bowden, D. W., Freedman, B. I., Register, T. C., Hsu, F. C., Lohman, K. K., Weinberg, R. B., and Wagenknecht, L. E. Hepatic steatosis and subclinical cardiovascular disease in a cohort enriched for type 2 diabetes: the Diabetes Heart Study. *American Journal of Gastroenterology*. 2008;103(12):3029-3035.

McLaughlin, D. M., Atkinson, A. B., Ennis, C. N., Browne, J., Hunter, S. J., Sheridan, B., and Bell, P. M. Comparison of effects of combined ACE inhibitor and low-dose thiazide diuretic with ACE inhibitor alone on insulin action in patients with hypertension and Type 2 diabetes: a double-blind crossover study. *Diabetic Medicine*. 2008;25(5):631-634.

McLaughlin, T., Carter, S., Lamendola, C., Abbasi, F., Schaaf, P., Basina, M., and Reaven, G. Clinical efficacy of two hypocaloric diets that vary in overweight patients with type 2 diabetes: comparison of moderate fat versus carbohydrate reductions. *Diabetes Care*. 2007;30(7):1877-1879.

McNally, P. G., Dean, J. D., Morris, A. D., Wilkinson, P. D., Compion, G., and Heller, S. R. Using continuous glucose monitoring to measure the frequency of low glucose values when using biphasic insulin aspart 30 compared with biphasic human insulin 30: a double-blind crossover study in individuals with type 2 diabetes. *Diabetes Care*. 2007;30(5):1044-1048.

McPherson, M. L., Smith, S. W., Powers, A., and Zuckerman, I. H. Association between diabetes patients' knowledge about medications and their blood glucose control. *Research In Social & Administrative Pharmacy*. 2008;4(1):37-45.

Meex, R. C., Schrauwen-Hinderling, V. B., Moonen-Kornips, E., Schaart, G., Mensink, M., Phielix, E., van de Weijer, T., Sels, J. P., Schrauwen, P., and Hesselink, M. K. Restoration of muscle mitochondrial function and metabolic flexibility in type 2 diabetes by exercise training is paralleled by increased myocellular fat storage and improved insulin sensitivity. *Diabetes*. 2010;59(3):572-579.

Mehta Nn, Sheetz M. P. Selective PKC beta inhibition with ruboxistaurin and endothelial function in type-2 diabetes mellitus. *Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy*. 2009;23(1):17-24.

Mehta, A. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. *Postgraduate Medicine*. 2010;122(3):61-70.

Meier, C., Bodmer, M., Meier, C. R., and Kraenzlin, M. E. [Thiazolidinediones and skeletal health]. *Revue Medicale Suisse*. 1312;5(207):1309-1310.

Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., and Meier, C. R. Use of thiazolidinediones and fracture risk. *Archives of Internal Medicine*. 2008;168(8):820-825.

Meier, M. and Hummel, M. Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies. *Vascular Health & Risk Management*. 2009;5:859-871.

Meisinger, C., Heier, M., Landgraf, R., Happich, M., Wichmann, H. E., and Piehlmeier, W. Albuminuria, cardiovascular risk factors and disease management in subjects with type 2 diabetes: a cross sectional study. *BMC Health Services Research*. 2008;8:226.

Melander, A., Folino-Gallo, P., Walley, T., Schwabe, U., Groop, P. H., Klaukka, T., Vallano, A., Laporte, J. R., Gallego, M. R., Schiappa, M., Roder, M., Kampmann, J. P., de Swaef, A., Aberg, M., Mansson, N. O., and Lindblad, U. Utilisation of antihyperglycaemic drugs in ten European countries: different developments and different levels. *Diabetologia*. 2006;49(9):2024-2029.

Menard, J. Quality of life in type 2 diabetes patients under intensive multitherapy. *Diabetes & Metabolism*. 2007;33(1):54-60.

Meneghini, L. F., Rosenberg, K. H., Koenen, C., Merilainen, M. J., and Luddeke, H. J. Insulin detemir improves glycaemic control with less hypoglycaemia and no weight gain in patients with type 2 diabetes who were insulin naive or treated with NPH or insulin glargine: clinical practice experience from a German subgroup of the PREDICTIVE study. *Diabetes, Obesity & Metabolism*. 2007;9(3):418-427.

Meneghini, L., Artola, S., Caputo, S., Damci, T., Dzida, G., Kaiser, M., Khunti, K., Liebl, A., Ligthelm, R., Maran, A., Orozco-Beltran, D., Ross, S., and Yale, J. F. Practical guidance to insulin management. Primary care diabetes. 2010;4 Suppl 1:S43-S56.

Meneghini, L., Koenen, C., Weng, W., and Selam, J. L. The usage of a simplified self-titration dosing guideline (303 Algorithm) for insulin detemir in patients with type 2 diabetes--results of the randomized, controlled PREDICTIVE 303 study. *Diabetes, Obesity & Metabolism*. 2007;9(6):902-913.

Mengual, L., Roura, P., Serra, M., Montasell, M., Prieto, G., and Bonet, S. Multifactorial control and treatment intensity of type-2 diabetes in primary care settings in Catalonia. *Cardiovascular Diabetology*. 2010;9:14.

Menzin, J., Korn, J. R., Cohen, J., Lobo, F., Zhang, B., Friedman, M., and Neumann, P. J. Relationship between glycemic control and diabetes-related hospital costs in patients with type 1 or type 2 diabetes mellitus. *Journal of Managed Care Pharmacy*. 2010;16(4):264-275.

Meredith, P. A. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. *Current Medical Research & Opinion*. 2007;23(7):1693-1705.

Messerli, F. H., Bell, D. S., Fonseca, V., Katholi, R. E., McGill, J. B., Phillips, R. A., Raskin, P., Wright, J. T., Jr., Bangalore, S., Holdbrook, F. K., Lukas, M. A., Anderson, K. M., Bakris, G. L., and Investigators, Gemini. Body weight changes with beta-blocker use: results from GEMINI. *American Journal of Medicine*. 2007;120(7):610-615.

Mestek, M. L., Plaisance, E. P., Ratcliff, L. A., Taylor, J. K., Wee, S. O., and Grandjean, P. W. Aerobic exercise and postprandial lipemia in men with the metabolic syndrome. *Medicine & Science in Sports & Exercise*. 2008;40(12):2105-2111.

Metzger, B. E. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. *Clinical Obstetrics & Gynecology*. 2007;50(4):972-979.

Meulepas, M. A., Braspenning, J. C., de Grauw, W. J., Lucas, A. E., Harms, L., Akkermans, R. P., and Grol, R. P. Logistic support service improves processes and outcomes of diabetes care in general practice. *Family Practice*. 2007;24(1):20-25.

Meulepas, M. A., Braspenning, J. C., de Grauw, W. J., Lucas, A. E., Wijkel, D., and Grol, R. P. Patient-oriented intervention in addition to centrally organised checkups improves diabetic patient outcome in primary care. *Quality & Safety in Health Care*. 2008;17(5):324-328.

Miche, E., Herrmann, G., Nowak, M., Wirtz, U., Tietz, M., Hurst, M., Zoller, B., and Radzewitz, A. Effect of an exercise training program on endothelial dysfunction in diabetic and non-diabetic patients with severe chronic heart failure. *Clinical Research in Cardiology*. 2006;95 Suppl 1:1117-1124.

Michishita, R., Shono, N., Kasahara, T., and Tsuruta, T. Effects of low intensity exercise therapy on early phase insulin secretion in overweight subjects with impaired glucose tolerance and type 2 diabetes mellitus. *Diabetes Research & Clinical Practice*. 2008;82(3):291-297.

Migdalís, I. N. Effects of treatment of hypertension on cardiovascular outcome in type 2 diabetes. *Research Communications in Molecular Pathology & Pharmacology*. 2006;119(1-6):105-114.

Mikhail, N. Combination therapy with DPP-4 inhibitors and pioglitazone in type 2 diabetes: theoretical consideration and therapeutic potential. *Vascular Health & Risk Management*. 2008;4(6):1221-1227.

Mikhail, N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. *Expert Opinion on Investigational Drugs*. 2008;17(6):845-853.

Miksch, A., Laux, G., Ose, D., Joos, S., Campbell, S., Riens, B., and Szecsenyi, J. Is there a survival benefit within a German primary care-based disease management program?. *American Journal of Managed Care*. 2010;16(1):49-54.

Milicevic, Z. Effect of two starting insulin regimens in patients with type II diabetes not controlled on a combination of oral antihyperglycemic medications. *Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association*. 2009;117(5):223-229.

Miljkovic-Gacic, I., Wang, X., Kammerer, C. M., Gordon, C. L., Bunker, C. H., Kuller, L. H., Patrick, A. L., Wheeler, V. W., Evans, R. W., and Zmuda, J. M. Fat infiltration in muscle: new evidence for familial clustering and associations with diabetes. *Obesity*. 2008;16(8):1854-1860.

Miller Ck, Gutschall M. A randomized trial about glycemic index and glycemic load improves outcomes among adults with type 2 diabetes. *Health education & behavior : the official publication of the Society for Public Health Education*. 2009;36(3):615-626.

Miller, C. K., Gutshcall, M. D., and Mitchell, D. C. Change in food choices following a glycemic load intervention in adults with type 2 diabetes. *Journal of the American Dietetic Association*. 2009;109(2):319-324.

Miller, M. E., Bonds, D. E., Gerstein, H. C., Seaquist, E. R., Bergenstal, R. M., Calles-Escandon, J., Childress, R. D., Craven, T. E., Cuddihy, R. M., Dailey, G., Feinglos, M. N., Ismail-Beigi, F., Largay, J. F., O'Connor, P. J., Paul, T., Savage, P. J., Schubart, U. K., Sood, A., Genuth, S., and Investigators, Accord. The effects of baseline characteristics, glycaemia treatment approach, and glycated haemoglobin concentration on the risk of severe hypoglycaemia: post hoc epidemiological analysis of the ACCORD study. *Bmj*. 2010;340:b5444.

Milton, E. C., Herman, W. H., Aiello, A. E., Danielson, K. R., Mendoza-Avelarez, M. O., and Piette, J. D. Validation of a type 2 diabetes screening tool in rural Honduras. *Diabetes Care*. 2010;33(2):275-277.

Minshall, M. E., Oglesby, A. K., Wintle, M. E., Valentine, W. J., Roze, S., and Palmer, A. J. Estimating the long-term cost-effectiveness of exenatide in the United States: an adjunctive treatment for type 2 diabetes mellitus. *Value in Health*. 2008;11(1):22-33.

Miranda, V. P., Rodrigues, M. J., Goncalves, F. R., and Nunes, J. P. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88]. *Revista Portuguesa de Cardiologia*. 2009;28(10):1099-1119.

Mirshahi, A., Roohipour, R., Lashay, A., Mohammadi, S. F., Abdoallahi, A., and Faghihi, H. Bevacizumab-augmented retinal laser photocoagulation in proliferative diabetic retinopathy: a randomized double-masked clinical trial. *European Journal of Ophthalmology*. 2008;18(2):263-269.

Misra, A., Bachmann, M. O., Greenwood, R. H., Jenkins, C., Shaw, A., Barakat, O., Flatman, M., and Jones, C. D. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. *Diabetic Medicine*. 2009;26(10):1040-1047.

Misurski, D., Lage, M. J., Fabunmi, R., and Boye, K. S. A comparison of costs among patients with type 2 diabetes mellitus who initiated therapy with exenatide or insulin glargine. *Applied Health Economics & Health Policy*. 2009;7(4):245-254.

Mita, T., Watada, H., Nakayama, S., Abe, M., Ogihara, T., Shimizu, T., Uchino, H., Hirose, T., and Kawamori, R. Preferable effect of pravastatin compared to atorvastatin on beta cell function in Japanese early-state type 2 diabetes with hypercholesterolemia. *Endocrine Journal*. 2007;54(3):441-447.

Mita, T., Watada, H., Shimizu, T., Tamura, Y., Sato, F., Watanabe, T., Choi, J. B., Hirose, T., Tanaka, Y., and Kawamori, R. Nateglinide reduces carotid intima-media thickening in type 2 diabetic patients under good glycemic control. *Arteriosclerosis, Thrombosis & Vascular Biology*. 2007;27(11):2456-2462.

Mita, T. Eicosapentaenoic acid reduces the progression of carotid intima-media thickness in patients with type 2 diabetes. *Atherosclerosis*. 2007;191(1):162-167.

Mitri, J. and Hamdy, O. Diabetes medications and body weight. *Expert Opinion on Drug Safety*. 2009;8(5):573-584.

Miyashita, Y., Endo, K., Saiki, A., Ban, N., Yamaguchi, T., Kawana, H., Nagayama, D., Ohira, M., Oyama, T., and Shirai, K. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. *Journal of Atherosclerosis & Thrombosis*. 2009;16(5):539-545.

Miyashita, Y., Nishimura, R., Nemoto, M., Matsudaira, T., Kurata, H., Yokota, T., Yokota, K., Tojo, K., Utsunomiya, K., and Tajima, N. Prospective randomized study for optimal insulin therapy in type 2 diabetic patients with secondary failure. *Cardiovascular Diabetology*. 2008;7:16.

Miyashita, Y., Saiki, A., Endo, K., Ban, N., Yamaguchi, T., Kawana, H., Nagayama, D., Ohira, M., Oyama, T., and Shirai, K. Effects of olmesartan, an angiotensin II receptor blocker, and amlodipine, a calcium channel blocker, on Cardio-Ankle Vascular Index (CAVI) in type 2 diabetic patients with hypertension. *Journal of Atherosclerosis & Thrombosis*. 2009;16(5):621-626.

Miyazaki, Y., Cersosimo, E., Triplitt, C., and DeFronzo, R. A. Rosiglitazone decreases albuminuria in type 2 diabetic patients. *Kidney International*. 2007;72(11):1367-1373.

Mizuno, C. S., Chittiboyina, A. G., Kurtz, T. W., Pershadsingh, H. A., and Avery, M. A. Type 2 diabetes and oral antihyperglycemic drugs. *Current Medicinal Chemistry*. 2008;15(1):61-74.

Moczulski, D. Pedometer improves doctor's advice to enhance physical activity in type 2 diabetes. *Diabetologia Doswiadczalna i Kliniczna*. 2008;8(1):33-37.

Moebus, S., Hanisch, J. U., Aidsburger, P., Bramlage, P., Wasem, J., and Jockel, K. H. Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk Project (GEMCAS). *Cardiovascular Diabetology*. 2007;6:22.

Moebus, S., Stang, A., Mohlenkamp, S., Dragano, N., Schmermund, A., Slomiany, U., Hoffmann, B., Bauer, M., Broecker-Preuss, M., Mann, K., Siegrist, J., Erbel, R., Jockel, K. H., and Heinz Nixdorf Recall Study, Group. Association of impaired fasting glucose and coronary artery calcification as a marker of subclinical atherosclerosis in a population-based cohort--results of the Heinz Nixdorf Recall Study. *Diabetologia*. 2009;52(1):81-89.

Mogos, T. and Dondoi, C. Evaluation of glycemic control of type II diabetes mellitus treated only with diet. *Romanian Journal of Internal Medicine*. 2007;45(2):205-208.

Mohamed, M. and Diabcare-Asia Study, Group. An audit on diabetes management in Asian patients treated by specialists: the Diabcare-Asia 1998 and 2003 studies. *Current Medical Research & Opinion*. 2008;24(2):507-514.

Mohan, V., Gokulakrishnan, K., Ganesan, A., and Kumar, S. B. Association of Indian Diabetes Risk Score with arterial stiffness in Asian Indian nondiabetic subjects: the Chennai Urban Rural Epidemiology Study (CURES-84). *Journal of Diabetes Science & Technology*. 2010;4(2):337-343.

Mohan, V., Radhika, G., Sathya, R. M., Tamil, S. R., Ganesan, A., and Sudha, V. Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59). *British Journal of Nutrition*. 2009;102(10):1498-1506.

Mohan, V., Radhika, G., Sathya, R. M., Tamil, S. R., Ganesan, A., and Sudha, V. Dietary carbohydrates, glycaemic load, food groups and newly detected type 2 diabetes among urban Asian Indian population in Chennai, India (Chennai Urban Rural Epidemiology Study 59).[Erratum appears in *Br J Nutr*. 2010 Jun;103(12):1851-2]. *British Journal of Nutrition*. 2009;102(10):1498-1506.

Mohan, V., Shanthirani, C. S., Deepa, M., Datta, M., Williams, O. D., and Deepa, R. Community empowerment--a successful model for prevention of non-communicable diseases in India--the Chennai Urban Population Study (CUPS-17). *Journal of the Association of Physicians of India*. 2006;54:858-862.

Mohan, V., Vijayachandrika, V., Gokulakrishnan, K., Anjana, R. M., Ganesan, A., Weber, M. B., and Narayan, K. M. A1C cut points to define various glucose intolerance groups in Asian Indians.[Erratum appears in *Diabetes Care*. 2010 May;33(5):1151]. *Diabetes Care*. 2010;33(3):515-519.

Mohan, V. Efficacy and safety of sitagliptin in the treatment of patients with type 2 diabetes in China, India, and Korea. *Diabetes research and clinical practice*. 2009;83(1):106-116.

Mohanram, A., Zhang, Z., Shahinfar, S., Lyle, P. A., and Toto, R. D. The effect of losartan on hemoglobin concentration and renal outcome in diabetic nephropathy of type 2 diabetes. *Kidney International*. 2008;73(5):630-636.

Moharram, M. M. and Farahat, F. M. Quality improvement of diabetes care using flow sheets in family health practice. *Saudi Medical Journal*. 2008;29(1):98-101.

Mohlig, M., Floter, A., Spranger, J., Weickert, M. O., Schill, T., Schlosser, H. W., Brabant, G., Pfeiffer, A. F., Selbig, J., and Schofl, C. Predicting impaired glucose metabolism in women with polycystic ovary syndrome by decision tree modelling. *Diabetologia*. 2006;49(11):2572-2579.

Mohlig, M., Weickert, M. O., Ghadamgahi, E., Arafat, A. M., Spranger, J., Pfeiffer, A. F., and Schofl, C. Retinol-binding protein 4 is associated with insulin resistance, but appears unsuited for metabolic screening in women with polycystic ovary syndrome. *European Journal of Endocrinology*. 2008;158(4):517-523.

Mokhtari, D. and Welsh, N. Potential utility of small tyrosine kinase inhibitors in the treatment of diabetes. *Clinical Science*. 2010;118(4):241-247.

Molife, C., Lee, L. J., Shi, L., Sawhney, M., and Lenox, S. M. Assessment of patient-reported outcomes

of insulin pen devices versus conventional vial and syringe. *Diabetes Technology & Therapeutics*. 2009;11(8):529-538.

Mollaoglu, M. and Beyazit, E. Influence of diabetic education on patient metabolic control. *Applied Nursing Research*. 2009;22(3):183-190.

Momose, M., Babazono, T., Kondo, C., Kobayashi, H., Nakajima, T., and Kusakabe, K. Prognostic significance of stress myocardial ECG-gated perfusion imaging in asymptomatic patients with diabetic chronic kidney disease on initiation of haemodialysis. *European Journal of Nuclear Medicine & Molecular Imaging*. 2009;36(8):1315-1321.

Monahan, P. O., Lane, K. A., Hayes, R. P., McHorney, C. A., and Marrero, D. G. Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D. *Quality of Life Research*. 2009;18(7):941-952.

Monami, M., Cresci, B., Colombini, A., Pala, L., Balzi, D., Gori, F., Chiasserini, V., Marchionni, N., Rotella, C. M., and Mannucci, E. Bone fractures and hypoglycemic treatment in type 2 diabetic patients: a case-control study. *Diabetes Care*. 2008;31(2):199-203.

Monami, M., Iacomelli, I., Marchionni, N., and Mannucci, E. Dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. *Nutrition Metabolism & Cardiovascular Diseases*. 2010;20(4):224-235.

Monami, M., Lamanna, C., Balzi, D., Bartalucci, F., Melani, C., Masotti, G., Marchionni, N., and Mannucci, E. Metabolic syndrome and cardiovascular mortality in older type 2 diabetic patients: a longitudinal study. *Journals of Gerontology Series A-Biological Sciences & Medical Sciences*. 2008;63(6):646-649.

Monami, M., Lamanna, C., Marchionni, N., and Mannucci, E. Comparison of different drugs as add-on treatments to metformin in type 2 diabetes: a meta-analysis. *Diabetes Research & Clinical Practice*. 2008;79(2):196-203.

Monami, M., Marchionni, N., and Mannucci, E. Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. *Diabetes Research & Clinical Practice*. 2008;81(2):184-189.

Monami, M., Marchionni, N., and Mannucci, E. Winners and losers at the rosiglitazone gamble A meta-analytical approach at the definition of the cardiovascular risk profile of rosiglitazone. *Diabetes Research & Clinical Practice*. 2008;82(1):48-57.

Monami, M., Marchionni, N., Masotti, G., and Mannucci, E. Effect of combined secretagogue/biguanide treatment on mortality in type 2 diabetic patients with and without ischemic heart disease. *International Journal of Cardiology*. 2008;126(2):247-251.

Monami, M., Marchionni, N., Masotti, G., and Mannucci, E. IDF and ATP-III definitions of metabolic syndrome in the prediction of all-cause mortality in type 2 diabetic patients. *Diabetes, Obesity & Metabolism*. 2007;9(3):350-353.

Monami, M., Marchionni, N., Masotti, G., and Mannucci, E. Prognostic value of International Diabetes Federation and Adult Treatment Panel III definitions of metabolic syndrome in Type 2 diabetic patients: what makes the difference?. *Journal of Endocrinological Investigation*. 2007;30(8):626-630.

Monda, K. L., Ballantyne, C. M., and North, K. E. Longitudinal impact of physical activity on lipid profiles in middle-aged adults: the Atherosclerosis Risk in Communities Study. *Journal of Lipid Research*. 2009;50(8):1685-1691.

Monnier, L. and Colette, C. Fasting glucose and postprandial glycemia: which is the best target for improving outcomes? The Apollo and 4-T Trials. *Expert Opinion on Pharmacotherapy*. 2008;9(16):2857-2865.

Montanya, E. and Sesti, G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. *Clinical Therapeutics*. 2009;31(11):2472-2488.

Monte, S. V., Schentag, J. J., Adelman, M. H., and Paladino, J. A. Characterization of cardiovascular outcomes in a type 2 diabetes glucose supply and insulin demand model. *Journal of Diabetes Science & Technology*. 2010;4(2):382-390.

Montori, V. M., Breslin, M., Maleska, M., and Weymiller, A. J. Creating a conversation: insights from the development of a decision aid. *PLoS Medicine / Public Library of Science*. 2007;4(8):e233.

Moore, K. B. and Saudek, C. D. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. *American Journal of Therapeutics*. 2008;15(5):484-491.

Moore, K. B., McKenna, K., Osman, M., Tormey, W. P., McDonald, D., and Thompson, C. J. Atrial natriuretic peptide increases urinary albumin excretion in people with normoalbuminuric type-2 diabetes. *Irish Journal of Medical Science*. 2007;176(2):67-73.

Morales, J. Defining the role of insulin detemir in Basal insulin therapy. *Drugs*. 2007;67(17):2557-2584.

Moreno, L., Dale, S. B., Chen, A. Y., and Magee, C. A. Costs to Medicare of the Informatics for Diabetes Education and Telemedicine (IDEATel) home telemedicine demonstration: findings from an independent evaluation. *Diabetes Care*. 2009;32(7):1202-1204.

Moretto Tj, Milton D. R. R. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. *Clinical Therapeutics*. 2008;30(8):1448-1460.

Moretto, T. J., Milton, D. R., Ridge, T. D., Macconell, L. A., Okerson, T., Wolka, A. M., and Brodows, R. G. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naïve patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.[Erratum appears in *Clin Ther*. 2008 Oct;30(10):1937]. *Clinical Therapeutics*. 2008;30(8):1448-1460.

Mori, K., Emoto, M., Araki, T., Yokoyama, H., Lee, E., Teramura, M., Koyama, H., Shoji, T., Inaba, M., and Nishizawa, Y. Effects of pioglitazone on serum fetuin-A levels in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(9):1248-1252.

Mori, Y., Itoh, Y., and Tajima, N. Telmisartan improves lipid metabolism and adiponectin production but does not affect glycemic control in hypertensive patients with type 2 diabetes. *Advances in Therapy*. 2007;24(1):146-153.

Moriyama, M., Nakano, M., Kuroe, Y., Nin, K., Niitani, M., and Nakaya, T. Efficacy of a self-management education program for people with type 2 diabetes: results of a 12 month trial. *Japan Journal of Nursing Science: JJNS*. 2009;6(1):51-63.

Morrison, S., Colberg, S. R., Mariano, M., Parson, H. K., and Vinik, A. I. Balance training reduces falls risk in older individuals with type 2 diabetes. *Diabetes Care*. 2010;33(4):748-750.

Mosdol, A., Witte, D. R., Frost, G., Marmot, M. G., and Brunner, E. J. Dietary glycemic index and glycemic load are associated with high-density-lipoprotein cholesterol at baseline but not with increased risk of diabetes in the Whitehall II study. *American Journal of Clinical Nutrition*. 2007;86(4):988-994.

Moses, A. C., Raskin, P., and Khutoryansky, N. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. *Diabetic Medicine*. 2008;25(2):200-205.

Mostad, I. L., Bjerve, K. S., Basu, S., Sutton, P., Frayn, K. N., and Grill, V. Addition of n-3 fatty acids to a 4-hour lipid infusion does not affect insulin sensitivity, insulin secretion, or markers of oxidative stress in subjects with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2009;58(12):1753-1761.

Motomura, T., Okamoto, M., Kitamura, T., Yamamoto, H., Otsuki, M., Asanuma, N., Takagi, M., Kurebayashi, S., Hashimoto, K., Sumitani, S., Saito, H., Kouhara, H., Nshii, K., Nakao, M., Koga, M., Sato, B., Morimoto, Y., and Kasayama, S. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. *Journal of Atherosclerosis & Thrombosis*. 2009;16(5):546-552.

Mou, S., Wang, Q., Liu, J., Che, X., Zhang, M., Cao, L., Zhou, W., and Ni, Z. Prevalence of non-diabetic renal disease in patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2010;87(3):354-359.

Mount, D. L., Feeney, P., Fabricatore, A. N., Coday, M., Bahnson, J., Byington, R., Phelan, S., Wilmoth, S., Knowler, W. C., Hramiak, I., Osei, K., Sweeney, M. E., Espeland, M. A., Look, Ahead, and Groups, Accord Research. Constructing common cohorts from trials with overlapping eligibility criteria: implications for comparing effect sizes between trials. *Clinical Trials*. 2009;6(5):416-429.

Moustafa Ta, Kamel H. S. E. High dietary fibre intake (Talbina) as adjunct in the management of diabetic macular edema. *Journal of Medical Sciences*. 2007;7(1):81-87.

Movahed, M. R., Hashemzadeh, M., and Jamal, M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. *Heart & Vessels*. 2007;22(4):251-253.

Mozdzan, M., Ruxer, J., Loba, J., Siejka, A., and Markuszewski, L. Safety of various methods of intensive insulin therapy in hospital condition assessed by hypoglycaemic episodes detected with the use of continuous glucose monitoring system. *Advances in Medical Sciences*. 2006;51:133-136.

Mudaliar, S. Inhaled insulin using AERx insulin Diabetes Management System (AERx iDMS). *Expert Opinion on Investigational Drugs*. 2007;16(10):1673-1681.

Mukai, J., Tada, H., Watanabe, Y., Miura, M., Katsuyama, S., Shoji, T., Mouri, K., Eto, M., and Suzuki, T. Lipids behavior and adverse effects for oral antidiabetic agents in patients with Type 2 diabetes treated with sulfonylureas alone based on systematic review. *Yakugaku Zasshi - Journal of the Pharmaceutical Society of Japan*. 2007;127(10):1747-1756.

Mukherjee, A. K., Reddy, V. S., Shah, S., Jhingan, A. K., Ramakrishnan, P., Prusty, V., and Singh, N. S. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. *Journal of the Indian Medical Association*. 2009;107(7):464-470.

Mukherjee, J. J., Khoo, C. M., Thai, A. C., Chionh, S. B., Pin, L., and Lee, K. O. Type 2 diabetic patients with resistant hypertension should be screened for primary aldosteronism. *Diabetes & Vascular Disease Research*. 2010;7(1):6-13.

Mukherjee, S., Mukhopadhyay, P., Pandit, K., and Chowdhury, S. Atorvastatin improves arterial stiffness in normotensive normolipidaemic persons with type 2 diabetes. *Journal of the Indian Medical Association*. 2008;106(11):716-719.

Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebe, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., and Smith, S. A. The diabetes mellitus medication choice decision aid: a randomized trial. *Archives of Internal Medicine*. 2009;169(17):1560-1568.

Mullins, P., Sharplin, P., Yki-Jarvinen, H., Riddle, M. C., and Haring, H. U. Negative binomial meta-regression analysis of combined glycosylated hemoglobin and hypoglycemia outcomes across eleven

Phase III and IV studies of insulin glargine compared with neutral protamine Hagedorn insulin in type 1 and type 2 diabetes mellitus. *Clinical Therapeutics*. 2007;29(8):1607-1619.

Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah-Muthu, S. S., Colhoun, H. M., Lawrenson, R. A., and De Vries, C. S. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. *Diabetologia*. 2008;51(9):1639-1645.

Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah-Muthu, S. S., Colhoun, H. M., Lawrenson, R. A., and De Vries, C. S. Risk of stroke in people with type 2 diabetes in the UK: a study using the General Practice Research Database. *Diabetologia*. 2006;49(12):2859-2865.

Murakami, H., Nigawara, T., Sakihara, S., Kageyama, K., Yamashita, M., Matsuki, K., Tanabe, J., Matsui, J., Tamasawa, N., and Suda, T. The frequency of type 2 diabetic patients who meet the endocrinological screening criteria of subclinical Cushing's disease. *Endocrine Journal*. 2010;57(3):267-272.

Murakami, Y., Kusaka, S., Oshima, Y., Tano, Y., Avery, R. L., Pieramici, D. J., and Arevalo, J. F. Diagnostic and therapeutic challenges. *Retina*. 2008;28(9):1357-1360.

Murphy, C. E. and Rodgers, P. T. Effects of thiazolidinediones on bone loss and fracture. *Annals of Pharmacotherapy*. 2007;41(12):2014-2018.

Murrock, C. J., Higgins, P. A., and Killion, C. Dance and peer support to improve diabetes outcomes in African American women. *Diabetes Educator*. 2009;35(6):995-1003.

Myhill, P., Davis, W. A., Bruce, D. G., Mackay, I. R., Zimmet, P., and Davis, T. M. Chronic complications and mortality in community-based patients with latent autoimmune diabetes in adults: the Fremantle Diabetes Study. *Diabetic Medicine*. 2008;25(10):1245-1250.

Mynatt, R. L. Carnitine and type 2 diabetes. *Diabetes/Metabolism Research Reviews*. 2009;25 Suppl 1:S45-S49.

Nabipour, I., Vahdat, K., Jafari, S. M., Beigi, S., Assadi, M., Azizi, F., and Sanjdideh, Z. Elevated high sensitivity C-reactive protein is associated with type 2 diabetes mellitus: the Persian Gulf Healthy Heart Study. *Endocrine Journal*. 2008;55(4):717-722.

Nadeau, D. A. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):7-15.

Nagajothi, N., Adigopula, S., Balamuthusamy, S., Velazquez-Cecena, J. L., Raghunathan, K., Khraisat, A., Singh, S., Molnar, J., Khosla, S., and Benatar, D. Pioglitazone and the risk of myocardial infarction and other major adverse cardiac events: a meta-analysis of randomized, controlled trials. *American Journal of Therapeutics*. 2008;15(6):506-511.

Nagamani, M., Szymajda, A., Sepilian, V., Urban, R. J., and Gilkison, C. Effects of raloxifene on insulin sensitivity, beta-cell function, and hepatic insulin extraction in normal postmenopausal women. *Fertility & Sterility*. 2008;89(3):614-619.

Nair, S. and Wilding, J. P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(1):34-42.

Nair, S., Phillips, A. O., Norton, N., Spurlock, G., Williams, H. J., Craig, K. J., Williams, J. D., Williams, N. M., and Bowen, T. Further evidence for the association of MMP9 with nephropathy in type 2 diabetes and application of DNA pooling technology to candidate gene screening. *Journal of Nephrology*. 2008;21(3):400-405.

Nakagami, H., Kaneda, Y., Ogihara, T., and Morishita, R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. *Current Diabetes Reviews*. 2005;1(1):59-63.

Nakagami, T., Tominaga, M., Nishimura, R., Daimon, M., Oizumi, T., Yoshiike, N., and Tajima, N.

Combined use of fasting plasma glucose and glycated hemoglobin A1c in a stepwise fashion to detect undiagnosed diabetes mellitus. *Tohoku Journal of Experimental Medicine*. 2007;213(1):25-32.

Nakayama S, Watada. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-state type-2 diabetics with hypertension. *Hypertension Research*. 2008;31(1):7-13.

Nakayama, T., Komiyama, N., Yokoyama, M., Namikawa, S., Kuroda, N., Kobayashi, Y., and Komuro, I. Pioglitazone induces regression of coronary atherosclerotic plaques in patients with type 2 diabetes mellitus or impaired glucose tolerance: a randomized prospective study using intravascular ultrasound. *International Journal of Cardiology*. 2010;138(2):157-165.

Narva, A. S. Reducing the burden of chronic kidney disease among American Indians. *Advances in Chronic Kidney Disease*. 2008;15(2):168-173.

Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., Zinman, B., American Diabetes Association, and European Association for the Study of Diabetes. Medical management of hyperglycaemia in type 2 diabetes mellitus: a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetologia*. 2009;52(1):17-30.

Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., and Group, A. Translating the A1C assay into estimated average glucose values.[Erratum appears in *Diabetes Care*. 2009 Jan;32(1):207]. *Diabetes Care*. 2008;31(8):1473-1478.

Nauck Ma, Ellis G. C. F. Efficacy and safety of adding the dipeptidyl peptidase-4 inhibitor alogliptin to metformin therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a multicentre, randomised, double-blind, placebo-controlled study. *International Journal of Clinical Practice*. 2009;63(1):46-55.

Nauck, M. A., Duran, S., Kim, D., Johns, D., Northrup, J., Festa, A., Brodows, R., and Trautmann, M. A comparison of twice-daily exenatide and biphasic insulin aspart in patients with type 2 diabetes who were suboptimally controlled with sulfonylurea and metformin: a non-inferiority study. *Diabetologia*. 2007;50(2):259-267.

Nauck, M. A., Meininger, G., Sheng, D., Terranella, L., Stein, P. P., and Sitagliptin Study, Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor, sitagliptin, compared with the sulfonylurea, glipizide, in patients with type 2 diabetes inadequately controlled on metformin alone: a randomized, double-blind, non-inferiority trial. *Diabetes, Obesity & Metabolism*. 2007;9(2):194-205.

Nauck, M. A., Ratner, R. E., Kapitzka, C., Berria, R., Boldrin, M., and Balena, R. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study. *Diabetes Care*. 2009;32(7):1237-1243.

Nauck, M. and Smith, U. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2009;23(4):513-523.

Nauck, M. Adding liraglutide to oral antidiabetic drug monotherapy: efficacy and weight benefits. *Postgraduate Medicine*. 2009;121(3):5-15.

Neeser, K. and Weber, C. Cost impact of self-measurement of blood glucose on complications of type 2 diabetes: the Spanish perspective. *Diabetes Technology & Therapeutics*. 2009;11(8):509-516.

Negrean, M., Stirban, A., Stratmann, B., Gawlowski, T., Horstmann, T., Gotting, C., Kleesiek, K., Mueller-Roesel, M., Koschinsky, T., Uribarri, J., Vlassara, H., and Tschoepe, D. Effects of low- and

high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus.[Erratum appears in Am J Clin Nutr. 2007 Oct;86(4):1256]. American Journal of Clinical Nutrition. 2007;85(5):1236-1243.

Negrean, M. Effects of low- and high-advanced glycation endproduct meals on macro- and microvascular endothelial function and oxidative stress in patients with type 2 diabetes mellitus. The American journal of clinical nutrition. 2007;85(5):1236-1243.

Nellemann, B., Gormsen, L. C., Dollerup, J., Schmitz, O., Mogensen, C. E., Rasmussen, L. M., and Nielsen, S. Simvastatin reduces plasma osteoprotegerin in type 2 diabetic patients with microalbuminuria. Diabetes Care. 2007;30(12):3122-3124.

Nelson, P., Poon, T., Guan, X., Schnabel, C., Wintle, M., and Fineman, M. The incretin mimetic exenatide as a monotherapy in patients with type 2 diabetes. Diabetes Technology & Therapeutics. 2007;9(4):317-326.

Nemesure, B., Wu, S. Y., Hennis, A., Leske, M. C., and Barbados Eye Study, Group. Hypertension, type 2 diabetes, and blood groups in a population of African ancestry. Ethnicity & Disease. 2006;16(4):822-829.

Neumiller, J. J. and Campbell, R. K. Liraglutide: a once-daily incretin mimetic for the treatment of type 2 diabetes mellitus. Annals of Pharmacotherapy. 2009;43(9):1433-1444.

Neumiller, J. J. and Setter, S. M. Pharmacologic management of the older patient with type 2 diabetes mellitus. American Journal of Geriatric Pharmacotherapy. 2009;7(6):324-342.

Neumiller, J. J., White, J. R., Jr., and Campbell, R. K. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. Drugs. 2010;70(4):377-385.

Neumiller, J. J., Wood, L., and Campbell, R. K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. Pharmacotherapy. 2010;30(5):463-484.

Neumiller, J. J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. Journal of the American Pharmacists Association: JAPhA. 2009;49 Suppl 1:S16-S29.

Neutel, J. M., Kereiakes, D. J., Waverczak, W. F., Stoakes, K. A., Xu, J., and Shojaee, A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. Current Medical Research & Opinion. 2010;26(3):721-728.

Newcomer, J. W. Metabolic syndrome and mental illness. American Journal of Managed Care. 2007;13(7 Suppl):S170-S177.

Newman, C. B., Szarek, M., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A., DeMicco, D. A., Auster, S., Fuller, J. H., and Cards, Investigators. The safety and tolerability of atorvastatin 10 mg in the Collaborative Atorvastatin Diabetes Study (CARDS). Diabetes & Vascular Disease Research. 2008;5(3):177-183.

Neyestani, T. R., Shariatzadeh, N., Gharavi, A., Kalayi, A., and Khalaji, N. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. Journal of Endocrinological Investigation. 2007;30(10):833-838.

Nichols, G. A., Gandra, S. R., Chiou, C. F., Anthony, M. S., Alexander-Bridges, M., and Brown, J. B. Successes and challenges of insulin therapy for type 2 diabetes in a managed-care setting. Current Medical Research & Opinion. 2010;26(1):9-15.

Nicolson, G. L. Metabolic syndrome and mitochondrial function: molecular replacement and antioxidant supplements to prevent membrane peroxidation and restore mitochondrial function. Journal

of Cellular Biochemistry. 2007;100(6):1352-1369.

Nicolucci, A. and Rossi, M. C. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. *Acta Bio-Medica de l Ateneo Parmense*. 2008;79(3):184-191.

Nield, L., Moore, H. J., Hooper, L., Cruickshank, J. K., Vyas, A., Whittaker, V., and Summerbell, C. D. Dietary advice for treatment of type 2 diabetes mellitus in adults. *Cochrane Database of Systematic Reviews*. 2007;(3):CD004097.

Nield, L., Summerbell, C. D., Hooper, L., Whittaker, V., and Moore, H. Dietary advice for the prevention of type 2 diabetes mellitus in adults. *Cochrane Database of Systematic Reviews*. 2008;(3):CD005102.

Nielsen, J. V. and Joensson, E. Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up. *Nutrition & Metabolism*. 2006;3:22.

Nielsen, J., Mogensen, M., Vind, B. F., Sahlin, K., Hojlund, K., Schroder, H. D., and Ortenblad, N. Increased subsarcolemmal lipids in type 2 diabetes: effect of training on localization of lipids, mitochondria, and glycogen in sedentary human skeletal muscle. *American Journal of Physiology - Endocrinology & Metabolism*. 2010;298(3):E706-E713.

Nielsen, L. L., Okerson, T., Holcombe, J., and Hoogwerf, B. Effects of exenatide on diabetes, obesity, cardiovascular risk factors, and hepatic biomarkers in patients with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(2):255-260.

Nielson, C. and Fleming, R. M. Blood glucose and cerebrovascular disease in nondiabetic patients. *Angiology*. 2007;58(5):625-629.

Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Mogensen, C. E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancina, G., Woodward, M., MacMahon, S., Chalmers, J., and Group, Advance Collaborative. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *Journal of the American Society of Nephrology*. 2009;20(8):1813-1821.

Nissen, S. E. and Wolski, K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes.[Erratum appears in *N Engl J Med*. 2007 Jul 5;357(1):100.]. *New England Journal of Medicine*. 2007;356(24):2457-2471.

Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochelliere, R., Staniloae, C. S., Mavromatis, K., Saw, J., Hu, B., Lincoff, A. M., Tuzcu, E. M., and Investigators, Periscope. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. *Jama*. 2008;299(13):1561-1573.

Nitiyanant, W., Chetthakul, T., Sang, A. kad, Therakiatkumjorn, C., Kunsuikmengrai, K., and Yeo, J. P. A survey study on diabetes management and complication status in primary care setting in Thailand. *Journal of the Medical Association of Thailand*. 2007;90(1):65-71.

Noh, J. H., Cho, Y. J., Nam, H. W., Kim, J. H., Kim, D. J., Yoo, H. S., Kwon, Y. W., Woo, M. H., Cho, J. W., Hong, M. H., Yoo, J. H., Gu, M. J., Kim, S. A., An, K. E., Jang, S. M., Kim, E. K., and Yoo, H. J. Web-based comprehensive information system for self-management of diabetes mellitus. *Diabetes Technology & Therapeutics*. 2010;12(5):333-337.

Noh, J. H., Kim, S. K., Cho, Y. J., Nam, H. U., Kim, I. J., Jeong, I. K., Choi, M. G., Yoo, H. J., Ahn, Y. H., Bae, H. Y., and Jang, H. C. Current status of diabetes management in elderly Koreans with diabetes. *Diabetes Research & Clinical Practice*. 2007;77 Suppl 1:S71-S75.

Noh, Y. H., Lee, S. M., Kim, E. J., Kim, D. Y., Lee, H., Lee, J. H., Park, S. Y., Koo, J. H., Wang, J. H., Lim, I. J., and Choi, S. B. Improvement of cardiovascular risk factors in patients with type 2 diabetes

after long-term continuous subcutaneous insulin infusion. *Diabetes/Metabolism Research Reviews*. 2008;24(5):384-391.

Nolan, R. P., Barry-Bianchi, S. M., Mechettiuc, A. E., and Chen, M. H. Sex-based differences in the association between duration of type 2 diabetes and heart rate variability. *Diabetes & Vascular Disease Research*. 2009;6(4):276-282.

Nomura S, Inami. The effects of pitavastatin, eicosapentaenoic acid and combined therapy on platelet-derived microparticles and adiponectin in hyperlipidemic, diabetic patients. *Platelets*. 2009;20(1):16-22.

Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Fukuhara, S., and Iwasaka, T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. *Thrombosis Research*. 2006;117(4):385-392.

Nonaka, K., Kakikawa, T., Sato, A., Okuyama, K., Fujimoto, G., Kato, N., Suzuki, H., Hirayama, Y., Ahmed, T., Davies, M. J., and Stein, P. P. Efficacy and safety of sitagliptin monotherapy in Japanese patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(2):291-298.

Nonaka, K. Effects of once-daily sitagliptin on 24-h glucose control following 4 weeks of treatment in Japanese patients with type 2 diabetes mellitus. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et métabolisme*. 2009;41(3):232-237.

Norberg, M., Stenlund, H., Lindahl, B., Andersson, C., Eriksson, J. W., and Weinehall, L. Work stress and low emotional support is associated with increased risk of future type 2 diabetes in women. *Diabetes Research & Clinical Practice*. 2007;76(3):368-377.

Norberg, M., Stenlund, H., Lindahl, B., Andersson, C., Weinehall, L., Hallmans, G., and Eriksson, J. W. Components of metabolic syndrome predicting diabetes: no role of inflammation or dyslipidemia. *Obesity*. 2007;15(7):1875-1885.

Norris, S. L., Lee, N., Thakurta, S., and Chan, B. K. Exenatide efficacy and safety: a systematic review. *Diabetic Medicine*. 2009;26(9):837-846.

Nunes, S., Pires, I., Rosa, A., Duarte, L., Bernardes, R., and Cunha-Vaz, J. Microaneurysm turnover is a biomarker for diabetic retinopathy progression to clinically significant macular edema: findings for type 2 diabetics with nonproliferative retinopathy. *Ophthalmologica*. 2009;223(5):292-297.

Nuttall, F. Q., Schweim, K., Hoover, H., and Gannon, M. C. Effect of the LoBAG30 diet on blood glucose control in people with type 2 diabetes. *British Journal of Nutrition*. 2008;99(3):511-519.

Nwose, E. U., Jelinek, H. F., Richards, R. S., and Kerr, P. G. Erythrocyte oxidative stress in clinical management of diabetes and its cardiovascular complications. *British Journal of Biomedical Science*. 2007;64(1):35-43.

Ober, S. K., Watts, S., and Lawrence, R. H. Insulin use in elderly diabetic patients. *Clinical Interventions In Aging*. 2006;1(2):107-113.

Oberlinner, C., Neumann, S. M., Ott, M. G., and Zober, A. Screening for pre-diabetes and diabetes in the workplace. *Occupational Medicine (Oxford)*. 2008;58(1):41-45.

Oberlinner, C., Zober, A., Nawroth, P. P., Humpert, P. M., and Morcos, M. Alanine-aminotransferase levels predict impaired glucose tolerance in a worksite population. *Acta Diabetologica*. 2010;47(2):161-165.

Ochiai, H., Ooka, H., Shida, C., Ishikawa, T., Inoue, D., and Okazaki, R. Acarbose treatment increases serum total adiponectin levels in patients with type 2 diabetes. *Endocrine Journal*. 2008;55(3):549-556.

Odegaard, A. O., Koh, W. P., Arakawa, K., Yu, M. C., and Pereira, M. A. Soft drink and juice consumption and risk of physician-diagnosed incident type 2 diabetes: the Singapore Chinese Health Study. *American Journal of Epidemiology*. 2010;171(6):701-708.

Odegard, P. S. and Capoccia, K. Medication taking and diabetes: a systematic review of the literature. *Diabetes Educator*. 2007;33(6):1014-1029.

Odegard, P. S. and Gray, S. L. Barriers to medication adherence in poorly controlled diabetes mellitus. *Diabetes Educator*. 2008;34(4):692-697.

Ofili, E. O., Cable, G., Neutel, J. M., and Saunders, E. Efficacy and safety of fixed combinations of irbesartan/hydrochlorothiazide in hypertensive women: the inclusive trial. *Journal of Women's Health*. 2008;17(6):931-938.

Ogasawara, D. Pioglitazone reduces the necrotic-core component in coronary plaque in association with enhanced plasma adiponectin in patients with type 2 diabetes mellitus. *Circulation journal : official journal of the Japanese Circulation Society*. 2009;73(2):343-351.

Ogawa, H. Low-dose aspirin for primary prevention of atherosclerotic events in patients with type 2 diabetes: a randomized controlled trial. *JAMA : the journal of the American Medical Association*. 2008;300(18):2134-2141.

Ogawa, S., Mori, T., Nako, K., and Ito, S. Combination therapy with renin-angiotensin system inhibitors and the calcium channel blocker amlodipine decreases plasma inflammatory markers and urinary oxidative stress markers in patients with diabetic nephropathy. *Hypertension Research - Clinical & Experimental*. 2008;31(6):1147-1155.

Ogawa, S., Mori, T., Nako, K., Ishizuka, T., and Ito, S. Reduced albuminuria with sarpogrelate is accompanied by a decrease in monocyte chemoattractant protein-1 levels in type 2 diabetes. *Clinical Journal of The American Society of Nephrology: CJASN*. 2008;3(2):362-368.

Ogawa, S., Takeuchi, K., Mori, T., Nako, K., and Ito, S. Spironolactone further reduces urinary albumin excretion and plasma B-type natriuretic peptide levels in hypertensive type II diabetes treated with angiotensin-converting enzyme inhibitor. *Clinical & Experimental Pharmacology & Physiology*. 2006;33(5-6):477-479.

Ogawa, S., Takeuchi, K., Mori, T., Nako, K., Tsubono, Y., and Ito, S. Effects of monotherapy of temocapril or candesartan with dose increments or combination therapy with both drugs on the suppression of diabetic nephropathy. *Hypertension Research - Clinical & Experimental*. 2007;30(4):325-334.

Ogihara, T., Saruta, T., Rakugi, H., Fujimoto, A., Ueshima, K., Yasuno, S., Oba, K., Takeda, K., Higaki, J., Nakao, K., and Group, Case. Relationship between the achieved blood pressure and the incidence of cardiovascular events in Japanese hypertensive patients with complications: a sub-analysis of the CASE-J trial. *Hypertension Research - Clinical & Experimental*. 2009;32(4):248-254.

Oguz, A., Uzunlulu, M., Yorulmaz, E., Yalcin, Y., Hekim, N., and Fici, F. Effect of nebivolol and metoprolol treatments on serum asymmetric dimethylarginine levels in hypertensive patients with type 2 diabetes mellitus. *Anadolu Kardiyoloji Dergisi*. 2007;7(4):383-387.

Oh, J. Y., Lim, S., Kim, D. J., Kim, N. H., Moon, S. D., Jang, H. C., Cho, Y. M., Song, K. H., Ahn, C. W., Sung, Y. A., Park, J. Y., Shin, C., Lee, H. K., Park, K. S., Committee of the Korean Diabetes Association on the, Diagnosis, and Classification of Diabetes, Mellitus. A report on the diagnosis of intermediate hyperglycemia in Korea: A pooled analysis of four community-based cohort studies. *Diabetes Research & Clinical Practice*. 2008;80(3):463-468.

Ohira, M., Miyashita, Y., Ebisuno, M., Saiki, A., Endo, K., Koide, N., Oyama, T., Murano, T., Watanabe, H., and Shirai, K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. *Diabetes Research & Clinical Practice*. 2007;78(1):34-41.

Ohmura, C., Watada, H., Shimizu, T., Sakai, K., Uchino, H., Fujitani, Y., Kanazawa, A., Hirose, T.,

and Kawamori, R. Calcium channel blocker, azelnidipine, reduces lipid hydroperoxides in patients with type 2 diabetes independent of blood pressure. *Endocrine Journal*. 2007;54(5):805-811.

Ohno, Y. Anti-albuminuric effect of losartan versus amlodipine in hypertensive Japanese patients with type 2 diabetes mellitus: A prospective, open-label, randomized, comparative study. *Current Therapeutic Research - Clinical and Experimental*. 2007;68(2):94-106.

Oikawa, S., Kita, T., Mabuchi, H., Matsuzaki, M., Matsuzawa, Y., Nakaya, N., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., and Group, J. Lit Study. Risk of coronary events in Japanese patients with both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). *Atherosclerosis*. 2007;191(2):440-446.

Okamoto, T., Okamoto, L., Lisanti, M. P., and Akishita, M. Switch to oral hypoglycemic agent therapy from insulin injection in patients with type 2 diabetes. *Geriatrics & gerontology international*. 2008;8(4):218-226.

Okerson, T., Yan, P., Stonehouse, A., and Brodows, R. Effects of exenatide on systolic blood pressure in subjects with type 2 diabetes. *American Journal of Hypertension*. 2010;23(3):334-339.

Okumura, Y., Ito, H., Kobayashi, M., Mayahara, K., Matsumoto, Y., and Hirakawa, J. Prevalence of diabetes and antipsychotic prescription patterns in patients with schizophrenia: a nationwide retrospective cohort study. *Schizophrenia Research*. 2010;119(1-3):145-152.

Olafsdottir, E. and Stefansson, E. Biennial eye screening in patients with diabetes without retinopathy: 10-year experience. *British Journal of Ophthalmology*. 2007;91(12):1599-1601.

Olenak, J. L. and Calpin, M. Establishing a cardiovascular health and wellness program in a community pharmacy: screening for metabolic syndrome. *Journal of the American Pharmacists Association: JAPhA*. 2010;50(1):32-36.

Oli, J. M., Adeyemo, A. A., Okafor, G. O., Ofoegbu, E. N., Onyenekwe, B., Chukwuka, C. J., Onwasigwe, C. N., Ufelle, S., Chen, G., and Rotimi, C. N. Basal insulin resistance and secretion in Nigerians with type 2 diabetes mellitus. *Metabolic Syndrome & Related Disorders*. 2009;7(6):595-599.

Oliveira, A. F., Valente, J. G., Leite Ida, C., Schramm, J. M., Azevedo, A. S., and Gadelha, A. M. Global burden of disease attributable to diabetes mellitus in Brazil. *Cadernos de Saude Publica*. 2009;25(6):1234-1244.

Oliver, A. and Pritchard, C. Economic evaluations relating to diabetes: a descriptive review and their compliance with guidance. *Value in Health*. 2000;3 Suppl 1:7-14.

Oliveros, R. A., Zion, A. S., Rosenberg, Y., Selvaraj, C. L., and Chilton, R. Impaired fasting glucose as a treatment target in diabetes management. *Current Cardiology Reports*. 2009;11(6):460-467.

Olufadi, R. and Byrne, C. D. Clinical and laboratory diagnosis of the metabolic syndrome. *Journal of Clinical Pathology*. 2008;61(6):697-706.

Omolase, C. O., Adekanle, O., Owoeye, J. F., and Omolase, B. O. Diabetic retinopathy in a Nigerian community. *Singapore Medical Journal*. 2010;51(1):56-59.

On, Y. K., Park, H. K., Hyon, M. S., and Jeon, E. S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. *Circulation Journal*. 2007;71(6):868-873.

Onat, A., Hergenc, G., Sari, I., Karabulut, A., and Can, G. Elevated LDL-cholesterol level predicts diabetes in centrally obese women but not men: relative roles of insulin resistance and central obesity. *Circulation Journal*. 2007;71(9):1463-1467.

Onyemelukwe Gc, Wokoma S. S. O. The efficacy and safety of rosiglitazone with concurrent sulphonylurea therapy in subjects with type 2 diabetes mellitus in Nigeria. *International Journal of*

Diabetes and Metabolism. 2007;15(2):62-67.

Origin Trial, Investigators, Gerstein, H., Yusuf, S., Riddle, M. C., Ryden, L., and Bosch, J. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). *American Heart Journal*. 155(1):26-32.

Orozco-Beltran, D., Gil-Guillen, V. F., Quirce, F., Navarro-Perez, J., Pineda, M., Gomez-de-la-Camara, A., Pita, S., Diez-Espino, J., Mateos, J., Merino, J., Serrano-Rios, M., and Collaborative Diabetes Study, Investigators. Control of diabetes and cardiovascular risk factors in patients with type 2 diabetes in primary care. The gap between guidelines and reality in Spain. *International Journal of Clinical Practice*. 2007;61(6):909-915.

Ortolani, P., Balducelli, M., Marzaroli, P., Piovacari, G., Menozzi, A., Guiducci, V., Sangiorgio, P., Tarantino, F., Geraci, G., Castriota, F., Tondi, S., Saia, F., Cooke, R. M., Guastaroba, P., Grilli, R., Marzocchi, A., and Maresta, A. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry. *Circulation*. 2008;117(7):923-930.

Ose, D., Wensing, M., Szecsenyi, J., Joos, S., Hermann, K., and Miksch, A. Impact of primary care-based disease management on the health-related quality of life in patients with type 2 diabetes and comorbidity. *Diabetes Care*. 2009;32(9):1594-1596.

Osher, E. and Stern, N. Diastolic pressure in type 2 diabetes: can target systolic pressure be reached without "diastolic hypotension"? *Diabetes Care*. 2008;31 Suppl 2:S249-S254.

Osterbrand, M., Fahlen, M., Oden, A., and Eliasson, B. A method to predict the metabolic effects of changes in insulin treatment in subgroups of a large population based patient cohort. *European Journal of Epidemiology*. 2007;22(3):151-157.

Otto, C., Otto, B., Frost, R. J., Vogeser, M., Pfeiffer, A. F., Spranger, J., and Parhofer, K. G. Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia. *Acta Diabetologica*. 2007;44(2):65-68.

Owen, K. R., Skupien, J., Malecki, M. T., and Consortium, Ceed. The clinical application of non-genetic biomarkers for differential diagnosis of monogenic diabetes. *Diabetes Research & Clinical Practice*. 2009;86 Suppl 1:S15-S21.

Owens, D. R. and Bolli, G. B. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. *Diabetes Technology & Therapeutics*. 2008;10(5):333-349.

Oyama, T., Saiki, A., Endoh, K., Ban, N., Nagayama, D., Ohhira, M., Koide, N., Miyashita, Y., and Shirai, K. Effect of acarbose, an alpha-glucosidase inhibitor, on serum lipoprotein lipase mass levels and common carotid artery intima-media thickness in type 2 diabetes mellitus treated by sulfonylurea. *Journal of Atherosclerosis & Thrombosis*. 2008;15(3):154-159.

Oyer, D. S., Shepherd, M. D., Coulter, F. C., Bhargava, A., Brett, J., Chu, P. L., Trippe, B. S., and Group, I. NITIAEplus Study. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIAEplus trial). *American Journal of Medicine*. 2009;122(11):1043-1049.

Paddison, C. A., Alpass, F. M., and Stephens, C. V. Psychological factors account for variation in metabolic control and perceived quality of life among people with type 2 diabetes in New Zealand. *International Journal of Behavioral Medicine*. 2008;15(3):180-186.

Paddison, C. A. Exploring physical and psychological wellbeing among adults with Type 2 diabetes in New Zealand: identifying a need to improve the experiences of Pacific peoples. *New Zealand Medical*

Journal. 2010;123(1310):30-42.

Padoin, A. V., Galvao Neto, M., Moretto, M., Barancelli, F., Schroer, C. E., and Mottin, C. C. Obese patients with type 2 diabetes submitted to banded gastric bypass: greater incidence of dumping syndrome. *Obesity Surgery*. 2009;19(11):1481-1484.

Padwal, R. J., Hemmelgarn, B. R., Khan, N. A., Grover, S., McAlister, F. A., McKay, D. W., Wilson, T., Penner, B., Burgess, E., Bolli, P., Hill, M. D., Mahon, J., Myers, M. G., Abbott, C., Schiffrin, E. L., Honos, G., Mann, K., Tremblay, G., Milot, A., Cloutier, L., Chockalingam, A., Rabkin, S. W., Dawes, M. D., Touyz, R. M., Bell, C., Burns, K. D., Ruzicka, M., Campbell, N. R., Lebel, M., Tobe, S. W., and Canadian Hypertension Education, Program. The 2008 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1 - blood pressure measurement, diagnosis and assessment of risk. *Canadian Journal of Cardiology*. 2008;24(6):455-463.

Padwal, R. S., Hemmelgarn, B. R., Khan, N. A., Grover, S., McKay, D. W., Wilson, T., Penner, B., Burgess, E., McAlister, F. A., Bolli, P., Hill, M. D., Mahon, J., Myers, M. G., Abbott, C., Schiffrin, E. L., Honos, G., Mann, K., Tremblay, G., Milot, A., Cloutier, L., Chockalingam, A., Rabkin, S. W., Dawes, M., Touyz, R. M., Bell, C., Burns, K. D., Ruzicka, M., Campbell, N. R., Vallee, M., Prasad, R., Lebel, M., Tobe, S. W., and Canadian Hypertension Education, Program. The 2009 Canadian Hypertension Education Program recommendations for the management of hypertension: Part 1--blood pressure measurement, diagnosis and assessment of risk. *Canadian Journal of Cardiology*. 2009;25(5):279-286.

Pagel-Langenickel, I., Schwartz, D. R., Arena, R. A., Minerbi, D. C., Johnson, D. T., Wacławski, M. A., Cannon, R. O., III, Balaban, R. S., Tripodi, D. J., and Sack, M. N. A discordance in rosiglitazone mediated insulin sensitization and skeletal muscle mitochondrial content/activity in Type 2 diabetes mellitus. *American Journal of Physiology - Heart & Circulatory Physiology*. 2007;293(5):H2659-H2666.

Paile-Hyvarinen, M., Wahlbeck, K., and Eriksson, J. G. Quality of life and metabolic status in mildly depressed patients with type 2 diabetes treated with paroxetine: a double-blind randomised placebo controlled 6-month trial. *BMC Family Practice*. 2007;8:34.

Pala, L., Mannucci, E., Dicembrini, I., and Rotella, C. M. A comparison of mealtime insulin aspart and human insulin in combination with metformin in type 2 diabetes patients. *Diabetes Research & Clinical Practice*. 2007;78(1):132-135.

Palmas, W., Pickering, T. G., Teresi, J., Schwartz, J. E., Field, L., Weinstock, R. S., and Shea, S. Telemedicine home blood pressure measurements and progression of albuminuria in elderly people with diabetes. *Hypertension*. 2008;51(5):1282-1288.

Palmer, A. J., Valentine, W. J., and Ray, J. A. Irbesartan treatment of patients with type 2 diabetes, hypertension and renal disease: a UK health economics analysis. *International Journal of Clinical Practice*. 2007;61(10):1626-1633.

Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., and Rodby, R. A. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. *Nephrology Dialysis Transplantation*. 2008;23(4):1216-1223.

Palmer, J. L., Gibbs, M., Scheijbeler, H. W., Kotchie, R. W., Nielsen, S., White, J., and Valentine, W. J. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. *Advances in Therapy*. 2008;25(8):752-774.

Pan Cy, Sinnassamy P. C. Insulin glargine versus NPH insulin therapy in Asian Type 2 diabetes patients. *Diabetes research and clinical practice*. 2007;76(1):111-118.

Pan, C. Y., Ho, L. T., Soegondo, S., Prodjosudjadi, W., Suwanwalaikorn, S., Lim, S. C., Chan, T. M., Chow, K. W., Thoenes, M., Choi, D. S., and Investigators, Demand Study. Prevalence of albuminuria

and cardiovascular risk profile in a referred cohort of patients with type 2 diabetes: an Asian perspective. *Diabetes Technology & Therapeutics*. 2008;10(5):397-403.

Pan, C., Yang, W., Barona, J. P., Wang, Y., Niggli, M., Mohideen, P., and Foley, J. E. Comparison of vildagliptin and acarbose monotherapy in patients with Type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetic Medicine*. 2008;25(4):435-441.

Pan, Y., Guo, L. L., and Jin, H. M. Low-protein diet for diabetic nephropathy: a meta-analysis of randomized controlled trials. *American Journal of Clinical Nutrition*. 2008;88(3):660-666.

Panikar, V., Joshi, S. R., Bukkavar, A., Nasikkar, N., and Santwana, C. Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination. *Journal of the Association of Physicians of India*. 2007;55:333-337.

Panina, G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. *Diabetes, Obesity & Metabolism*. 2007;9 Suppl 1:32-39.

Pankow, J. S., Kwan, D. K., Duncan, B. B., Schmidt, M. I., Couper, D. J., Golden, S., and Ballantyne, C. M. Cardiometabolic risk in impaired fasting glucose and impaired glucose tolerance: the Atherosclerosis Risk in Communities Study. *Diabetes Care*. 2007;30(2):325-331.

Panzetta, G., Basile, C., Santoro, A., Ancarani, E., Costantini, S., Guarnieri, F., and Verzetti, G. Diabetics on dialysis in Italy: a nationwide epidemiological study. *Nephrology Dialysis Transplantation*. 2008;23(12):3988-3995.

Paolisso, G. Pathophysiology of diabetes in elderly people. *Acta Bio-Medica de l Ateneo Parmense*. 2010;81 Suppl 1:47-53.

Papa, G., Fedele, V., Chiavetta, A., Lorenti, I., Leotta, C., Luca, S., Rabuazzo, A. M., Piro, S., Alagona, C., Spadaro, L., Purrello, F., and Pezzino, V. Therapeutic options for elderly diabetic subjects: open label, randomized clinical trial of insulin glargine added to oral antidiabetic drugs versus increased dosage of oral antidiabetic drugs. *Acta Diabetologica*. 2008;45(1):53-59.

Papadogeorgos, N. O., Bengtsson, M., and Kalani, M. Selective endothelin A-receptor blockade attenuates coronary microvascular dysfunction after coronary stenting in patients with type 2 diabetes. *Vascular Health & Risk Management*. 2009;5:893-899.

Papadopoulos, A. A., Kontodimopoulos, N., Frydas, A., Ikonomakis, E., and Niakas, D. Predictors of health-related quality of life in type II diabetic patients in Greece. *BMC Public Health*. 2007;7:186.

Papanas, N., Kakagia, D., Papatheodorou, K., Papazoglou, D., Alexandridou, M., Pagkalos, A., Karadimas, E. J., and Maltezos, E. Lanarkshire Oximetry Index as a diagnostic tool for peripheral arterial disease in type 2 diabetes: a pilot study. *Angiology*. 2010;61(4):388-391.

Papanas, N., Symeonidis, G., Mavridis, G., Georgiadis, G. S., Papas, T. T., Lazarides, M. K., and Maltezos, E. Ankle-brachial index: a surrogate marker of microvascular complications in type 2 diabetes mellitus?. *International Angiology*. 2007;26(3):253-257.

Papathanassiou, K. Pioglitazone vs glimepiride: Differential effects on vascular endothelial function in patients with type 2 diabetes. *Atherosclerosis*. 2009;205(1):221-226.

Park, J. S., Cho, M. H., Nam, J. S., Ahn, C. W., Cha, B. S., Lee, E. J., Lim, S. K., Kim, K. R., and Lee, H. C. Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients. *Acta Diabetologica*. 2010;47(2):113-118.

Park, L. and Wexler, D. Update in diabetes and cardiovascular disease: synthesizing the evidence from recent trials of glycemic control to prevent cardiovascular disease. *Current Opinion in Lipidology*. 2010;21(1):8-14.

Park, S. E., Kang, E. S., Kim, D. H., Kim, S. K., Lee, J. H., Ahn, C. W., Lee, H. C., and Cha, B. S. Effect of ABCA1 variant on atherogenic dyslipidaemia in patients with Type 2 diabetes treated with rosiglitazone. *Diabetic Medicine*. 2009;26(6):577-581.

Parkash, O., Almas, A., Hameed, A., and Islam, M. Comparison of non cardiac chest pain (NCCP) and acute coronary syndrome (ACS) patients presenting to a tertiary care center. *JPMA - Journal of the Pakistan Medical Association*. 2009;59(10):667-671.

Parkner, T., Laursen, T., Chen, J. W., Moller, M. K., Thomsen, H. F., Jorgensen, C., Smedegaard, J. S., Lauritzen, T., and Christiansen, J. S. Overnight versus 24 hours of continuous subcutaneous insulin infusion as supplement to oral antidiabetic drugs in type 2 diabetes. *Journal of Diabetes Science & Technology*. 2007;1(5):704-710.

Parkner, T., Laursen, T., Vestergaard, E. T., Hartvig, H., Smedegaard, J. S., Lauritzen, T., and Christiansen, J. S. Insulin and glucose profiles during continuous subcutaneous insulin infusion compared with injection of a long-acting insulin in Type 2 diabetes. *Diabetic Medicine*. 2008;25(5):585-591.

Parkner, T., Moller, M. K., Chen, J. W., Laursen, T., Jorgensen, C., Smedegaard, J. S., Lauritzen, T., and Christiansen, J. S. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(7):556-563.

Paroni, R., Ceriotti, F., Galanello, R., Battista Leoni, G., Panico, A., Scurati, E., Paleari, R., Chemello, L., Quaino, V., Scaldaferrì, L., Lapolla, A., and Mosca, A. Performance characteristics and clinical utility of an enzymatic method for the measurement of glycated albumin in plasma. *Clinical Biochemistry*. 2007;40(18):1398-1405.

Parving Hh, Brenner B. M. M. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2009;24(5):1663-1671.

Parving, H. H., de Zeeuw, D., Cooper, M. E., Remuzzi, G., Liu, N., Luncford, J., Shahinfar, S., Wong, P. H., Lyle, P. A., Rossing, P., and Brenner, B. M. ACE gene polymorphism and losartan treatment in type 2 diabetic patients with nephropathy. *Journal of the American Society of Nephrology*. 2008;19(4):771-779.

Parving, H. H., Persson, F., Lewis, J. B., Lewis, E. J., Hollenberg, N. K., and Investigators, Avoid Study. Aliskiren combined with losartan in type 2 diabetes and nephropathy.[Reprint in *Ugeskr Laeger*. 2009 Mar 9;171(11):881-4; PMID: 19291865]. *New England Journal of Medicine*. 2008;358(23):2433-2446.

Patel S, Drew. Reconstituted high-density lipoprotein increases plasma high-density lipoprotein anti-inflammatory properties and cholesterol efflux capacity in patients with type 2 diabetes. *Journal of the American College of Cardiology*. 2009;53(11):962-971.

Patel, A., Group, Advance Collaborative, MacMahon, S., Chalmers, J., Neal, B., Woodward, M., Billot, L., Harrap, S., Poulter, N., Marre, M., Cooper, M., Glasziou, P., Grobbee, D. E., Hamet, P., Heller, S., Liu, L. S., Mancia, G., Mogensen, C. E., Pan, C. Y., Rodgers, A., and Williams, B. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet*. 2007;370(9590):829-840.

Patel, J. V., Gunarathne, A., Lane, D., Lim, H. S., Tracey, I., Panja, N. C., Lip, G. Y., and Hughes, E. A. Widening access to cardiovascular healthcare: community screening among ethnic minorities in inner-city Britain - the Healthy Hearts Project. *BMC Health Services Research*. 2007;7:192.

Patel, P. and Macerollo, A. Diabetes mellitus: diagnosis and screening. *American Family Physician*. 2010;81(7):863-870.

Paudyal, G., Shrestha, M. K., Meyer, J. J., Thapa, R., Gurung, R., and Ruit, S. Prevalence of diabetic retinopathy following a community screening for diabetes. *Nepal Medical College Journal: NMCJ*. 2008;10(3):160-163.

Paul, G. M., Smith, S. M., Whitford, D. L., O'Shea, E., O'Kelly, F., and O'Dowd, T. Peer support in type 2 diabetes: a randomised controlled trial in primary care with parallel economic and qualitative analyses: pilot study and protocol. *BMC Family Practice*. 2007;8:45.

Pavlatou, M. G., Mastorakos, G., Lekakis, I., Liatis, S., Vamvakou, G., Zoumakis, E., Papassotiriou, I., Rabavilas, A. D., Katsilambros, N., and Chrousos, G. P. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. *Stress*. 2008;11(1):62-72.

Pearce, K. A., Love, M. M., Shelton, B. J., Schoenberg, N. E., Williamson, M. A., Barron, M. A., Houlihan, J. M., and Kentucky Ambulatory, Network. Cardiovascular risk education and social support (CaRESS): report of a randomized controlled trial from the Kentucky Ambulatory Network (KAN). *Journal of the American Board of Family Medicine: JABFM*. 2008;21(4):269-281.

Pearce, K. L., Noakes, M., Keogh, J., and Clifton, P. M. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. *American Journal of Clinical Nutrition*. 2008;87(3):638-644.

Pearson, E. R., Donnelly, L. A., Kimber, C., Whitley, A., Doney, A. S., McCarthy, M. I., Hattersley, A. T., Morris, A. D., and Palmer, C. N. Variation in TCF7L2 influences therapeutic response to sulfonylureas: a GoDARTs study. *Diabetes*. 2007;56(8):2178-2182.

Pedersen, S. D., Kang, J., and Kline, G. A. Portion control plate for weight loss in obese patients with type 2 diabetes mellitus: a controlled clinical trial. *Archives of Internal Medicine*. 2007;167(12):1277-1283.

Pei, Z., Li, X., von Geldern, T. W., Longenecker, K., Pireh, D., Stewart, K. D., Backes, B. J., Lai, C., Lubben, T. H., Ballaron, S. J., Beno, D. W., Kempf-Grote, A. J., Sham, H. L., and Trevillyan, J. M. Discovery and structure-activity relationships of piperidinone- and piperidine-constrained phenethylamines as novel, potent, and selective dipeptidyl peptidase IV inhibitors. *Journal of Medicinal Chemistry*. 2007;50(8):1983-1987.

Pelletier, E. M., Shim, B., Ben-Joseph, R., and Caro, J. J. Economic outcomes associated with microvascular complications of type 2 diabetes mellitus: results from a US claims data analysis. *Pharmacoeconomics*. 2009;27(6):479-490.

Pelletier, E. M., Smith, P. J., Boye, K. S., Misurski, D. A., Tunis, S. L., and Minshall, M. E. Direct medical costs for type 2 diabetes mellitus complications in the US commercial payer setting: a resource for economic research. *Applied Health Economics & Health Policy*. 2008;6(2-3):103-112.

Penfornis, A., Borot, S., and Raccach, D. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. *Diabetes & Metabolism*. 2008;34 Suppl 2:S78-S90.

Penning-van Beest, F. J., Wolffenbuttel, B. H., and Herings, R. M. Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study. *Clinical Drug Investigation*. 2008;28(8):487-493.

Peres, D. S., Franco, L. J., and dos Santos, M. A. Feelings of women after the diagnosis of type 2 diabetes. *Revista Latino-Americana de Enfermagem*. 2008;16(1):101-108.

Perez Perez, A., Ybarra Munoz, J., Blay Cortes, V., and de Pablos Velasco, P. Obesity and cardiovascular disease. *Public Health Nutrition*. 2007;10(10A):1156-1163.

Perez, A., Zhao, Z., Jacks, R., and Spanheimer, R. Efficacy and safety of pioglitazone/metformin fixed-

dose combination therapy compared with pioglitazone and metformin monotherapy in treating patients with T2DM. *Current Medical Research & Opinion*. 2009;25(12):2915-2923.

Perico, N., Ruggenenti, P., and Remuzzi, G. Losartan in diabetic nephropathy. *Expert Review of Cardiovascular Therapy*. 2004;2(4):473-483.

PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes. *Cardiovascular Journal of Africa*. 2008;19(3):159-162.

Perkovic, V., Joshi, R., Patel, A., Bompont, S., Chalmers, J., and Group, Advance Collaborative. ADVANCE: lessons from the run-in phase of a large study in type 2 diabetes. *Blood Pressure*. 2006;15(6):340-346.

Perria, C., Mandolini, D., Guerrera, C., Jefferson, T., Billi, P., Calzini, V., Fiorillo, A., Grasso, G., Leotta, S., Marrocco, W., Suraci, C., and Pasquarella, A. Implementing a guideline for the treatment of type 2 diabetics: results of a cluster-randomized controlled trial (C-RCT). *BMC Health Services Research*. 2007;7:79.

Perriello, G., Pampanelli, S., Brunetti, P., Di Pietro, C., Mariz, S., and Italian Pioglitazone Study, Group. Long-term effects of pioglitazone versus gliclazide on hepatic and humoral coagulation factors in patients with type 2 diabetes. *Diabetes & Vascular Disease Research*. 2007;4(3):226-230.

Persson, F., Rossing, P., Hovind, P., Stehouwer, C. D., Schalkwijk, C. G., Tarnow, L., and Parving, H. H. Endothelial dysfunction and inflammation predict development of diabetic nephropathy in the Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria (IRMA 2) study. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2008;68(8):731-738.

Persson, F., Rossing, P., Reinhard, H., Juhl, T., Stehouwer, C. D., Schalkwijk, C., Danser, A. H., Boomsma, F., Frandsen, E., and Parving, H. H. Renal effects of aliskiren compared with and in combination with irbesartan in patients with type 2 diabetes, hypertension, and albuminuria. *Diabetes Care*. 2009;32(10):1873-1879.

Persson, F., Rossing, P., Schjoedt, K. J., Juhl, T., Tarnow, L., Stehouwer, C. D., Schalkwijk, C., Boomsma, F., Frandsen, E., and Parving, H. H. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. *Kidney International*. 2008;73(12):1419-1425.

Peters, A. Incretin-based therapies: review of current clinical trial data. *American Journal of Medicine*. 2010;123(3 Suppl):S28-S37.

Peterson, K. A., Radosevich, D. M., O'Connor, P. J., Nyman, J. A., Prineas, R. J., Smith, S. A., Arneson, T. J., Corbett, V. A., Weinhandl, J. C., Lange, C. J., and Hannan, P. J. Improving Diabetes Care in Practice: findings from the TRANSLATE trial. *Diabetes Care*. 2008;31(12):2238-2243.

Petrak, F., Stridde, E., Leverkus, F., Crispin, A. A., Forst, T., and Pfitzner, A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. *Diabetes Care*. 2007;30(9):2199-2204.

Petrazzi, L., Grassi, D., Polidoro, L., D'Aurelio, A., Croce, G., Properzi, G., Tiberti, S., Desideri, G., and Ferri, C. Cardiovascular risk and cardiometabolic protection: role of glitazones. *Journal of Nephrology*. 2008;21(6):826-835.

Petrica, L., Petrica, M., Vlad, A., Dragos Jianu, C., Gluhovschi, G., Ianculescu, C., Dumitrascu, V., Giju, S., Gluhovschi, C., Bob, F., Ursoniu, S., Gadalean, F., Velciov, S., Bozdog, G., and Marian, R. Nephro- and neuroprotective effects of rosiglitazone versus glimepiride in normoalbuminuric patients with type 2 diabetes mellitus: a randomized controlled trial. *Wiener Klinische Wochenschrift*. 2009;121(23-24):765-775.

Petrofsky, J., Lee, S., Cuneo-Libarona, M., and Apodaca, P. The effect of rosiglitazone on orthostatic

tolerance during heat exposure in individuals with type II diabetes. *Diabetes Technology & Therapeutics*. 2007;9(4):377-386.

Peyrot, M. and Rubin, R. R. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. *Diabetes Technology & Therapeutics*. 2010;12(1):49-55.

Peyrot, M., Rubin, R. R., and Polonsky, W. H. Diabetes distress and its association with clinical outcomes in patients with type 2 diabetes treated with pramlintide as an adjunct to insulin therapy. *Diabetes Technology & Therapeutics*. 2008;10(6):461-466.

Peyrot, M., Rubin, R. R., Polonsky, W. H., and Best, J. H. Patient reported outcomes in adults with type 2 diabetes on basal insulin randomized to addition of mealtime pramlintide or rapid-acting insulin analogs. *Current Medical Research & Opinion*. 2010;26(5):1047-1054.

Peyrot, M., Skovlund, S. E., and Landgraf, R. Epidemiology and correlates of weight worry in the multinational Diabetes Attitudes, Wishes and Needs study. *Current Medical Research & Opinion*. 2009;25(8):1985-1993.

Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., Feyzi, J. M., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J. B., McMurray, J. J., Parfrey, P., Parving, H. H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., and Investigators, Treat. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. *New England Journal of Medicine*. 2009;361(21):2019-2032.

Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J., McMurray, J. J., Parfrey, P., Parving, H. H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., Uno, H., and Investigators, Treat. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *American Journal of Kidney Diseases*. 2009;54(1):59-69.

Pfutzner, A., Marx, N., Walcher, D., Lobig, M., Seidel, D., and Forst, T. Impact of rosiglitazone on visfatin and adiponectin plasma concentrations in patients with type 2 diabetes and coronary artery disease. *Clinical Laboratory*. 2008;54(7-8):237-241.

Pfutzner, A., Weber, M. M., and Forst, T. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. *Expert Opinion on Pharmacotherapy*. 2007;8(12):1985-1998.

Pfutzner, A., Wilhelm, B., and Forst, T. Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. *Vascular Health & Risk Management*. 2007;3(2):211-220.

Pham, D. Q., Nogid, A., and Plakogiannis, R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. *American Journal of Health-System Pharmacy*. 2008;65(6):521-531.

Pham, T. T., Sim, J. J., Kujubu, D. A., Liu, I. L., and Kumar, V. A. Prevalence of nondiabetic renal disease in diabetic patients. *American Journal of Nephrology*. 2007;27(3):322-328.

Phelan, S., Grodstein, F., and Brown, J. S. Clinical research in diabetes and urinary incontinence: what we know and need to know. *Journal of Urology*. 2009;182(6 Suppl):S14-S17.

Philippe, J. and Raccach, D. Treating type 2 diabetes: how safe are current therapeutic agents?. *International Journal of Clinical Practice*. 2009;63(2):321-332.

Philis-Tsimikas, A. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). *Expert Opinion on Pharmacotherapy*. 2008;9(12):2181-2195.

Phillips, L. S., Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Chatterjee, R., Narayan, K. M., and Koch, D. D. Glucose challenge test screening for prediabetes and undiagnosed diabetes. *Diabetologia*. 2009;52(9):1798-1807.

Phillips, R. A., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Bell, D. S., Raskin, P., Wright, J. T., Jr., Iyengar, M., Anderson, K. M., Lukas, M. A., Bakris, G. L., and Investigators, Gemini. Demographic analyses of the effects of carvedilol vs metoprolol on glycemic control and insulin sensitivity in patients with type 2 diabetes and hypertension in the Glycemic Effects in Diabetes Mellitus: Carvedilol-Metoprolol Comparison in Hypertensives (GEMINI) study. *Journal of the CardioMetabolic Syndrome*. 2008;3(4):211-217.

Phillips, S. A., Kung, J., Ciaraldi, T. P., Choe, C., Christiansen, L., Mudaliar, S., and Henry, R. R. Selective regulation of cellular and secreted multimeric adiponectin by antidiabetic therapies in humans. *American Journal of Physiology - Endocrinology & Metabolism*. 2009;297(3):E767-E773.

Phung, O. J., Scholle, J. M., Talwar, M., and Coleman, C. I. Effect of noninsulin antidiabetic drugs added to metformin therapy on glycemic control, weight gain, and hypoglycemia in type 2 diabetes. *Jama*. 2010;303(14):1410-1418.

Pieters, M., Covic, N., Loots du, T., van der Westhuizen, F. H., van Zyl, D. G., Rheeder, P., Jerling, J. C., and Weisel, J. W. The effect of glycaemic control on fibrin network structure of type 2 diabetic subjects. *Thrombosis & Haemostasis*. 2006;96(5):623-629.

Pikilidou Mi, Lasaridis A. N. S. Insulin sensitivity increase after calcium supplementation and change in intraplatelet calcium and sodium-hydrogen exchange in hypertensive patients with Type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(3):211-219.

Pikilidou, M. I., Befani, C. D., Sarafidis, P. A., Nilsson, P. M., Koliakos, G. G., Tziolas, I. M., Kazakos, K. A., Yovos, J. G., and Lasaridis, A. N. Oral calcium supplementation ambulatory blood pressure and relation to changes in intracellular ions and sodium-hydrogen exchange. *American Journal of Hypertension*. 2009;22(12):1263-1269.

Pinelli, N. R., Cha, R., Brown, M. B., and Jaber, L. A. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. *Annals of Pharmacotherapy*. 2008;42(11):1541-1551.

Pinto, S. L., Lively, B. T., Siganga, W., Holiday-Goodman, M., and Kamm, G. Using the Health Belief Model to test factors affecting patient retention in diabetes-related pharmaceutical care services. *Research In Social & Administrative Pharmacy*. 2006;2(1):38-58.

Pi-Sunyer Fx, Schweizer A. M. Efficacy and tolerability of vildagliptin monotherapy in drug-naive patients with type 2 diabetes. *Diabetes research and clinical practice*. 2007;76(1):132-138.

Pi-Sunyer, F. X. The effects of pharmacologic agents for type 2 diabetes mellitus on body weight. *Postgraduate Medicine*. 2008;120(2):5-17.

Pi-Sunyer, X. The metabolic syndrome: how to approach differing definitions. *Medical Clinics of North America*. 91(6):1025-1040.

Pitocco, D. Pioglitazone reduces monocyte activation in type 2 diabetes. *Acta Diabetologica*. 2009;46(1):75-77.

Plastino, M., Fava, A., Pirritano, D., Cotronei, P., Sacco, N., Sperli, T., Spano, A., Gallo, D., Mungari, P., Consoli, D., and Bosco, D. Effects of insulinic therapy on cognitive impairment in patients with Alzheimer disease and diabetes mellitus type-2. *Journal of the Neurological Sciences*. 2010;288(1-2):112-116.

Plockinger, U., Topuz, M., Langer, M., and Reuter, T. Problems of diabetes management in the immigrant population in Germany. *Diabetes Research & Clinical Practice*. 2010;87(1):77-86.

Plotnikoff, R. C., Courneya, K. S., Sigal, R. J., Johnson, J. A., Birkett, N., Lau, D., Raine, K., Johnson, S. T., and Karunamuni, N. Alberta Diabetes and Physical Activity Trial (ADAPT): a randomized theory-based efficacy trial for adults with type 2 diabetes--rationale, design, recruitment, evaluation,

and dissemination. *Trials* [Electronic Resource]. 2010;11:4.

Poh, Z. X. and Goh, K. P. A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2009;9(4):392-398.

Poirier, P., Despres, J. P., and Bertrand, O. F. Identifying which patients with diabetes should be tested for the presence of coronary artery disease--the importance of baseline electrocardiogram and exercise testing. *Canadian Journal of Cardiology*. 2006;22 Suppl A:9A-15A.

Poizot-Martin, I. A randomized, double-blind, placebo-controlled study of benfluorex in HIV-infected patients with insulin resistance or impaired glucose tolerance. *HIV clinical trials*. 2009;10(1):33-40.

Pola, P., Kumar, R., Reddy, A. P., Rajagopal, G., Harinarayan, C. V., Suresh, V., Suchitra, M. M., and Sachan, A. Efficacy of low dose atorvastatin in diabetic dyslipidaemia. *Journal of the Indian Medical Association*. 2009;107(11):807-809.

Policker, S., Haddad, W., and Yaniv, I. Treatment of type 2 diabetes using meal-triggered gastric electrical stimulation. *Israel Medical Association Journal: Imaj*. 2009;11(4):206-208.

Pollack, M. F., Purayidathil, F. W., Bolge, S. C., and Williams, S. A. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. *Diabetes Research & Clinical Practice*. 2010;87(2):204-210.

Polonsky, T., Mazzone, T., and Davidson, M. The clinical implications of the CHICAGO study for the management of cardiovascular risk in patients with type 2 diabetes mellitus. *Trends in Cardiovascular Medicine*. 2009;19(3):94-99.

Pongwecharak, J., Tengmeesri, N., Malanusorn, N., Panthong, M., and Pawangkapin, N. Prescribing metformin in type 2 diabetes with a contraindication: prevalence and outcome. *Pharmacy World & Science*. 2009;31(4):481-486.

Pop-Busui, R. Impact of rosiglitazone and glyburide on nitrosative stress and myocardial blood flow regulation in type 2 diabetes mellitus. *Metabolism: clinical and experimental*. 2009;58(7):989-994.

Postma, M. J., Boersma, C., and Gansevoort, R. T. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. *Nephrology Dialysis Transplantation*. 2008;23(4):1103-1106.

Poulsen, M. K., Henriksen, J. E., Dahl, J., Johansen, A., Gerke, O., Vach, W., Haghfelt, T., Hoilund-Carlsen, P. F., Beck-Nielsen, H., and Moller, J. E. Left ventricular diastolic function in type 2 diabetes mellitus: prevalence and association with myocardial and vascular disease. *Circulation*. 2010;Cardiovascular imaging. 3(1):24-31.

Poulsen, M. K., Henriksen, J. E., Dahl, J., Johansen, A., Moller, J. E., Gerke, O., Vach, W., Haghfelt, T., Beck-Nielsen, H., and Hoilund-Carlsen, P. F. Myocardial ischemia, carotid, and peripheral arterial disease and their interrelationship in type 2 diabetes patients. *Journal of Nuclear Cardiology*. 2009;16(6):878-887.

Poulsen, M. K., Henriksen, J. E., Vach, W., Dahl, J., Moller, J. E., Johansen, A., Gerke, O., Haghfelt, T., Hoilund-Carlsen, P. F., and Beck-Nielsen, H. Identification of asymptomatic type 2 diabetes mellitus patients with a low, intermediate and high risk of ischaemic heart disease: is there an algorithm?. *Diabetologia*. 2010;53(4):659-667.

Poulter, N. R. Blood pressure and glucose control in subjects with diabetes: new analyses from ADVANCE. *Journal of Hypertension - Supplement*. 2009;27(1):S3-S8.

Pouwer, F. and Hermanns, N. Insulin therapy and quality of life. A review. *Diabetes/Metabolism Research Reviews*. 2009;25 Suppl 1:S4-S10.

Pouwer, F. Should we screen for emotional distress in type 2 diabetes mellitus?. *Nature Reviews Endocrinology*. 2009;5(12):665-671.

Povey, R. C. and Clark-Carter, D. Diabetes and healthy eating: a systematic review of the literature. *Diabetes Educator*. 2007;33(6):931-959.

Practical implications for clinical monitoring. *Postgraduate Medicine*. 2003;114(6 Suppl Managing Metabolic):87-89.

Practical implications for clinical monitoring. *Postgraduate Medicine*. 2003;114(6 Suppl Managing Metabolic):87-89.

Pradeepa, R., Anitha, B., Mohan, V., Ganesan, A., and Rema, M. Risk factors for diabetic retinopathy in a South Indian Type 2 diabetic population--the Chennai Urban Rural Epidemiology Study (CURES) Eye Study 4. *Diabetic Medicine*. 2008;25(5):536-542.

Pradhan, A. D., Everett, B. M., Cook, N. R., Rifai, N., and Ridker, P. M. Effects of initiating insulin and metformin on glycemic control and inflammatory biomarkers among patients with type 2 diabetes: the LANCET randomized trial. *Jama*. 2009;302(11):1186-1194.

Pradhan, A. D., Rifai, N., Buring, J. E., and Ridker, P. M. Hemoglobin A1c predicts diabetes but not cardiovascular disease in nondiabetic women. *American Journal of Medicine*. 2007;120(8):720-727.

Praet, S. F., Jonkers, R. A., Schep, G., Stehouwer, C. D., Kuipers, H., Keizer, H. A., and van Loon, L. J. Long-standing, insulin-treated type 2 diabetes patients with complications respond well to short-term resistance and interval exercise training. *European Journal of Endocrinology*. 2008;158(2):163-172.

Praet, S. F., van Rooij, E. S., Wijtvliet, A., Boonman-de Winter, L. J., Enneking, T., Kuipers, H., Stehouwer, C. D., and van Loon, L. J. Brisk walking compared with an individualised medical fitness programme for patients with type 2 diabetes: a randomised controlled trial. *Diabetologia*. 2008;51(5):736-746.

Prakash, J., Hota, J. K., Singh, S., and Sharma, O. P. Clinical spectrum of chronic renal failure in the elderly: a hospital based study from eastern India. *International Urology & Nephrology*. 2006;38(3-4):821-827.

Prakash, J., Lodha, M., Singh, S. K., Vohra, R., Raja, R., and Usha. Diabetic retinopathy is a poor predictor of type of nephropathy in proteinuric type 2 diabetic patients. *Journal of the Association of Physicians of India*. 2007;55:412-416.

Pratley Re, Kipnes M. S. F. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. *Diabetes, Obesity & Metabolism*. 2009;11(2):167-176.

Pratley, R. E. and Salsali, A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. *Current Medical Research & Opinion*. 2007;23(4):919-931.

Pratley, R. E., McCall, T., Fleck, P. R., Wilson, C. A., and Mekki, Q. Alogliptin use in elderly people: a pooled analysis from phase 2 and 3 studies. *Journal of the American Geriatrics Society*. 2009;57(11):2011-2019.

Pratley, R. E., Nauck, M., Bailey, T., Montanya, E., Cuddihy, R., Filetti, S., Thomsen, A. B., Sondergaard, R. E., Davies, M., and Group, Lira Dpp. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. *Lancet*. 2010;375(9724):1447-1456.

Pratley, R. E., Reusch, J. E., Fleck, P. R., Wilson, C. A., Mekki, Q., and Alogliptin Study, Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients

with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *Current Medical Research & Opinion*. 2009;25(10):2361-2371.

Pratley, R. E., Rosenstock, J., Pi-Sunyer, F. X., Banerji, M. A., Schweizer, A., Couturier, A., and Dejager, S. Management of type 2 diabetes in treatment-naïve elderly patients: benefits and risks of vildagliptin monotherapy. *Diabetes Care*. 2007;30(12):3017-3022.

Pratley, R. E., Schweizer, A., Rosenstock, J., Foley, J. E., Banerji, M. A., Pi-Sunyer, F. X., Mills, D., and Dejager, S. Robust improvements in fasting and prandial measures of beta-cell function with vildagliptin in drug-naïve patients: analysis of pooled vildagliptin monotherapy database. *Diabetes, Obesity & Metabolism*. 2008;10(10):931-938.

Pratley, R. E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. *Medscape journal of medicine*. 2008;10(7):171.

Pratt, N., Roughead, E. E., Ryan, P., and Gilbert, A. L. Differential impact of NSAIDs on rate of adverse events that require hospitalization in high-risk and general veteran populations: a retrospective cohort study. *Drugs & Aging*. 2010;27(1):63-71.

Probst, Y. C., Faraji, S., Batterham, M., Steel, D. G., and Tapsell, L. C. Computerized dietary assessments compare well with interviewer administered diet histories for patients with type 2 diabetes mellitus in the primary healthcare setting. *Patient Education & Counseling*. 2008;72(1):49-55.

Pruski, M., Krysiak, R., and Okopien, B. Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. *Diabetes Care*. 2009;32(8):1421-1424.

Pscherer, S., Dietrich, E. S., Dippel, F. W., and Neilson, A. R. Comparison of one-year costs of type 2 diabetes treatment with insulin glargine or insulin detemir in a basal supported oral therapy (BOT) in Germany. *International Journal of Clinical Pharmacology & Therapeutics*. 2010;48(2):129-137.

Pu, L. J., Lu, L., Shen, W. F., Zhang, Q., Zhang, R. Y., Zhang, J. S., Hu, J., Yang, Z. K., Ding, F. H., Chen, Q. J., Shen, J., Fang, D. H., and Lou, S. Increased serum glycated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. *Circulation Journal*. 2007;71(7):1067-1073.

Puepet, F. H. and Ohwovoriole, A. E. Prevalence of risk factors for diabetes mellitus in a non-diabetic population in Jos, Nigeria. *Nigerian Journal of Medicine: Journal of the National Association of Resident Doctors of Nigeria*. 2008;17(1):71-74.

Puig Jg, Marre M. K. Efficacy of indapamide SR compared with enalapril in elderly hypertensive patients with type 2 diabetes. *American Journal of Hypertension*. 2007;20(1):90-97.

Punjabi, N. M. and Workshop, Participants. Do sleep disorders and associated treatments impact glucose metabolism?. *Drugs*. 2009;69 Suppl 2:13-27.

Qayyum, R., Bolen, S., Maruthur, N., Feldman, L., Wilson, L. M., Marinopoulos, S. S., Ranasinghe, P., Amer, M., and Bass, E. B. Systematic review: comparative effectiveness and safety of premixed insulin analogues in type 2 diabetes. *Annals of Internal Medicine*. 2008;149(8):549-559.

Qiao, Q. and Nyamdorj, R. The optimal cutoff values and their performance of waist circumference and waist-to-hip ratio for diagnosing type II diabetes. *European Journal of Clinical Nutrition*. 2010;64(1):23-29.

Quattrin, T. Inhaled insulin: a novel and non-invasive way for insulin administration?. *Current Drug Safety*. 2006;1(2):151-158.

Quinn, C. C., Clough, S. S., Minor, J. M., Lender, D., Okafor, M. C., and Gruber-Baldini, A. WellDoc mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes

and patient and physician satisfaction. *Diabetes Technology & Therapeutics*. 2008;10(3):160-168.

Qureshi, N. and Kai, J. Informing patients of familial diabetes mellitus risk: How do they respond? A cross-sectional survey. *BMC Health Services Research*. 2008;8:37.

Rabbani, N. High-dose thiamine therapy for patients with type 2 diabetes and microalbuminuria: a randomised, double-blind placebo-controlled pilot study. *Diabetologia*. 2009;52(2):208-212.

Raccach, D. Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. *Diabetes & Metabolism*. 2006;32 Spec No2:2S48-2S51.

Raccach, D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 2:76-82.

Radermecker, R. P., Philips, J. C., Jandrain, B., Paquot, N., and Scheen, A. J. [Blood glucose control and cardiovascular disease in patients with type 2 diabetes. Results of ACCORD, ADVANCE and VA-Diabetes trials]. *Revue Medicale de Liege*. 2008;63(7-8):511-518.

Radtke, M., Kollind, M., Qvigstad, E., and Grill, V. Twelve weeks' treatment with diazoxide without insulin supplementation in Type 2 diabetes is feasible but does not improve insulin secretion. *Diabetic Medicine*. 2007;24(2):172-177.

Raff, M., Tholstrup, T., Basu, S., Nonboe, P., Sorensen, M. T., and Straarup, E. M. A diet rich in conjugated linoleic acid and butter increases lipid peroxidation but does not affect atherosclerotic, inflammatory, or diabetic risk markers in healthy young men. *Journal of Nutrition*. 2008;138(3):509-514.

Raguenaud, M. E., Isaakidis, P., Reid, T., Chy, S., Keuky, L., Arellano, G., and Van Damme, W. Treating 4,000 diabetic patients in Cambodia, a high-prevalence but resource-limited setting: a 5-year study. *BMC Medicine*. 2009;7:33.

Rahman, A., Yahya, K., Ahmed, T., and Sharif-Ul-Hasan, K. Diagnostic value of tear films tests in type 2 diabetes. *JPM - Journal of the Pakistan Medical Association*. 2007;57(12):577-581.

Rahman, M., Simmons, R. K., Harding, A. H., Wareham, N. J., and Griffin, S. J. A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. *Family Practice*. 2008;25(3):191-196.

Raikkonen, K., Matthews, K. A., and Kuller, L. H. Depressive symptoms and stressful life events predict metabolic syndrome among middle-aged women: a comparison of World Health Organization, Adult Treatment Panel III, and International Diabetes Foundation definitions.[Erratum appears in *Diabetes Care*. 2007 Oct;30(10):2761]. *Diabetes Care*. 2007;30(4):872-877.

Raikou, M., McGuire, A., Colhoun, H. M., Betteridge, D. J., Durrington, P. N., Hitman, G. A., Neil, H. A., Livingstone, S. J., Charlton-Menys, V., Fuller, J. H., and Investigators, Cards. Cost-effectiveness of primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes: results from the Collaborative Atorvastatin Diabetes Study (CARDS). *Diabetologia*. 2007;50(4):733-740.

Rajamani, K. Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial. *Lancet*. 2009;373(9677):1780-1788.

Rakel, A. Beneficial effects of gliclazide modified release compared with glibenclamide on endothelial activation and low-grade inflammation in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(1):127-129.

Ralston, J. D., Hirsch, I. B., Hoath, J., Mullen, M., Cheadle, A., and Goldberg, H. I. Web-based collaborative care for type 2 diabetes: a pilot randomized trial. *Diabetes Care*. 2009;32(2):234-239.

Ramachandran, A., Mary, S., Sathish, C. K., Selvam, S., Catherin Seeli, A., Muruganandam, M.,

- Yamuna, A., Murugesan, N., and Snehalatha, C. Population based study of quality of diabetes care in southern India. *Journal of the Association of Physicians of India*. 2008;56:513-516.
- Ramachandran, A., Snehalatha, C., Sivasankari, S., Hitman, G. A., and Vijay, V. Parental influence on the spectrum of type 2 diabetes in the offspring among Indians. *Journal of the Association of Physicians of India*. 2007;55:560-562.
- Ramsey, S. D., Clarke, L. D., Roberts, C. S., Sullivan, S. D., Johnson, S. J., and Liu, L. Z. An economic evaluation of atorvastatin for primary prevention of cardiovascular events in type 2 diabetes. *Pharmacoeconomics*. 2008;26(4):329-339.
- Randolph, S., Mustad, V. A., Lee, J., and Sun, J. Economic analysis of a diabetes-specific nutritional meal replacement for patients with type 2 diabetes. *Asia Pacific Journal of Clinical Nutrition*. 2010;19(1):1-7.
- Rani, P. K., Raman, R., Subramani, S., Perumal, G., Kumaramanickavel, G., and Sharma, T. Knowledge of diabetes and diabetic retinopathy among rural populations in India, and the influence of knowledge of diabetic retinopathy on attitude and practice. *Rural & Remote Health*. 2008;8(3):838.
- Rao, A. D., Kuhadiya, N., Reynolds, K., and Fonseca, V. A. Is the combination of sulfonylureas and metformin associated with an increased risk of cardiovascular disease or all-cause mortality?: a meta-analysis of observational studies. *Diabetes Care*. 2008;31(8):1672-1678.
- Raskin Pr, Hollander P. A. L. Basal insulin or premix analogue therapy in type 2 diabetes patients. *European Journal of Internal Medicine*. 2007;18(1):56-62.
- Raskin, P., Gylvin, T., Weng, W., and Chaykin, L. Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes. *Diabetes/Metabolism Research Reviews*. 2009;25(6):542-548.
- Raskin, P. Addition of biphasic insulin aspart 30 to optimized metformin and pioglitazone treatment of type 2 diabetes mellitus: The ACTION Study (Achieving Control Through Insulin plus Oral ageNts). *Diabetes, Obesity & Metabolism*. 2009;11(1):27-32.
- Raskin, P. Efficacy and safety of insulin detemir. *Endocrinology & Metabolism Clinics of North America*. 2007;36 Suppl 1:21-32.
- Raskin, P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(12):1167-1177.
- Raslova, K., Tamer, S. C., Clauson, P., and Karl, D. Insulin detemir results in less weight gain than NPH insulin when used in basal-bolus therapy for type 2 diabetes mellitus, and this advantage increases with baseline body mass index. *Clinical Drug Investigation*. 2007;27(4):279-285.
- Rathmann, W., Haastert, B., Giani, G., Koenig, W., Imhof, A., Herder, C., Holle, R., and Mielck, A. Is inflammation a causal chain between low socioeconomic status and type 2 diabetes? Results from the KORA Survey 2000. *European Journal of Epidemiology*. 2006;21(1):55-60.
- Rathmann, W., Strassburger, K., Heier, M., Holle, R., Thorand, B., Giani, G., and Meisinger, C. Incidence of Type 2 diabetes in the elderly German population and the effect of clinical and lifestyle risk factors: KORA S4/F4 cohort study. *Diabetic Medicine*. 2009;26(12):1212-1219.
- Ratner, R. E., Cannon, C. P., Gerstein, H. C., Nesto, R. W., Serruys, P. W., van Es, G. A., Kolatkar, N. S., Kravitz, B. G., Zalewski, A., Fitzgerald, P. J., and Group, Approach Study. Assessment on the Prevention of Progression by Rosiglitazone on Atherosclerosis in diabetes patients with Cardiovascular History (APPROACH): study design and baseline characteristics. *American Heart Journal*. 2008;156(6):1074-1079.
- Ratner, R. E., Parikh, S., Tou, C., and Group, Gallant Study. Efficacy, safety and tolerability of

tesaglitazar when added to the therapeutic regimen of poorly controlled insulin-treated patients with type 2 diabetes. *Diabetes & Vascular Disease Research*. 2007;4(3):214-221.

Rave, K., Heise, T., Heinemann, L., and Boss, A. H. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(2):205-212.

Rave, K., Heise, T., Pflutzner, A., and Boss, A. H. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. *Diabetes Care*. 2007;30(9):2307-2308.

Ravikumar, B., Gerrard, J., Dalla Man, C., Firbank, M. J., Lane, A., English, P. T., Cobelli, C., and Taylor, R. Pioglitazone decreases fasting and postprandial endogenous glucose production in proportion to decrease in hepatic triglyceride content. *Diabetes*. 2008;57(9):2288-2295.

Ray Ja, Boye K. S. Y. Exenatide versus insulin glargine in patients with type 2 diabetes in the UK: a model of long-term clinical and cost outcomes. *Current medical research and opinion*. 2007;23(3):609-622.

Ray Ja, Valentine W. J. R. Insulin therapy in type 2 diabetes patients failing oral agents: cost-effectiveness of biphasic insulin aspart 70/30 vs. insulin glargine in the US. *Diabetes, Obesity & Metabolism*. 2007;9(1):103-113.

Ray, K. K., Seshasai, S. R., Wijesuriya, S., Sivakumaran, R., Nethercott, S., Preiss, D., Erqou, S., and Sattar, N. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. *Lancet*. 2009;373(9677):1765-1772.

Rayman, G., Profozic, V., and Middle, M. Insulin glulisine imparts effective glycaemic control in patients with Type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;76(2):304-312.

Raymond, N. T., Varadhan, L., Reynold, D. R., Bush, K., Sankaranarayanan, S., Bellary, S., Barnett, A. H., Kumar, S., O'Hare, J. P., and Group, U. K. A. Higher prevalence of retinopathy in diabetic patients of South Asian ethnicity compared with white Europeans in the community: a cross-sectional study. *Diabetes Care*. 2009;32(3):410-415.

Rayner, B. and Becker, P. The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa. *Cardiovascular Journal of Southern Africa*. 2006;17(5):245-249.

Raynor, H. A., Jeffery, R. W., Ruggiero, A. M., Clark, J. M., Delahanty, L. M., and Look, Ahead Research Group. Weight loss strategies associated with BMI in overweight adults with type 2 diabetes at entry into the Look AHEAD (Action for Health in Diabetes) trial. *Diabetes Care*. 2008;31(7):1299-1304.

Raz, I., Chen, Y., Wu, M., Hussain, S., Kaufman, K. D., Amatruda, J. M., Langdon, R. B., Stein, P. P., and Alba, M. Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. *Current Medical Research & Opinion*. 2008;24(2):537-550.

Raz, I., Hanefeld, M., Xu, L., Caria, C., Williams-Herman, D., Khatami, H., and Sitagliptin Study, Group. Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus. *Diabetologia*. 2006;49(11):2564-2571.

Reaven, G. M., Lieberman, J. A., Sethuraman, G., Kraemer, H., Davis, J. M., Blasey, C., Tsuang, M. T., and Schatzberg, A. F. In search of moderators and mediators of hyperglycemia with atypical antipsychotic treatment. *Journal of Psychiatric Research*. 2009;43(11):997-1002.

Reaven, P. D., Moritz, T. E., Schwenke, D. C., Anderson, R. J., Criqui, M., Detrano, R., Emanuele, N., Kayshap, M., Marks, J., Mudaliar, S., Harsha Rao, R., Shah, J. H., Goldman, S., Reda, D. J., McCarren, M., Abaira, C., Duckworth, W., and Veterans Affairs Diabetes, Trial. Intensive glucose-lowering

therapy reduces cardiovascular disease events in veterans affairs diabetes trial participants with lower calcified coronary atherosclerosis. *Diabetes*. 2009;58(11):2642-2648.

Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits. *Cardiovascular Journal of Africa*. 2007;18(6):400.

Regensteiner, J. G., Bauer, T. A., Reusch, J. E., Quaife, R. A., Chen, M. Y., Smith, S. C., Miller, T. M., Groves, B. M., and Wolfel, E. E. Cardiac dysfunction during exercise in uncomplicated type 2 diabetes. *Medicine & Science in Sports & Exercise*. 2009;41(5):977-984.

Reid, R. D., Tulloch, H. E., Sigal, R. J., Kenny, G. P., Fortier, M., McDonnell, L., Wells, G. A., Boule, N. G., Phillips, P., and Coyle, D. Effects of aerobic exercise, resistance exercise or both, on patient-reported health status and well-being in type 2 diabetes mellitus: a randomised trial. *Diabetologia*. 2010;53(4):632-640.

Rema, M. and Pradeepa, R. Diabetic retinopathy: an Indian perspective. *Indian Journal of Medical Research*. 2007;125(3):297-310.

Retnakaran, R. and Shah, B. R. Abnormal screening glucose challenge test in pregnancy and future risk of diabetes in young women. *Diabetic Medicine*. 2009;26(5):474-477.

Retnakaran, R., Qi, Y., Sermer, M., Connelly, P. W., Hanley, A. J., and Zinman, B. Glucose intolerance in pregnancy and future risk of pre-diabetes or diabetes. *Diabetes Care*. 2008;31(10):2026-2031.

Retnakaran, R. Glucose tolerance status in pregnancy: a window to the future risk of diabetes and cardiovascular disease in young women. *Current Diabetes Reviews*. 2009;5(4):239-244.

Reynolds, L. R., Kingsley, F. J., Karounos, D. G., and Tannock, L. R. Differential effects of rosiglitazone and insulin glargine on inflammatory markers, glycemic control, and lipids in type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;77(2):180-187.

Rhodes, K. S., Weintraub, M. S., Biesemeier, C. K., and Rubenfire, M. The lipid management nutrition outcomes project: perspectives from a national experience in protocol implementation and nutrition outcomes tracking. *Journal of the American Dietetic Association*. 2008;108(2):332-339.

Riaz, S., Alam, S. S., and Akhtar, M. W. Proteomic identification of human serum biomarkers in diabetes mellitus type 2. *Journal of Pharmaceutical & Biomedical Analysis*. 2010;51(5):1103-1107.

Ribeiro, L. W., Ribeiro, J. P., Stein, R., Leitao, C., and Polanczyk, C. A. Trimetazidine added to combined hemodynamic antianginal therapy in patients with type 2 diabetes: a randomized crossover trial. *American Heart Journal*. 2007;154(1):78.

Ribeiro, M. L., Seres, A. I., Carneiro, A. M., Stur, M., Zourdani, A., Caillon, P., Cunha-Vaz, J. G., and Group, D. X. R. Effect of calcium dobesilate on progression of early diabetic retinopathy: a randomised double-blind study. *Graefes Archive for Clinical & Experimental Ophthalmology*. 2006;244(12):1591-1600.

Ribisl, P. M., Lang, W., Jaramillo, S. A., Jakicic, J. M., Stewart, K. J., Bahnson, J., Bright, R., Curtis, J. F., Crow, R. S., Soberman, J. E., and Look, Ahead Research Group. Exercise capacity and cardiovascular/metabolic characteristics of overweight and obese individuals with type 2 diabetes: the Look AHEAD clinical trial. *Diabetes Care*. 2007;30(10):2679-2684.

Richardson, C. R., Mehari, K. S., McIntyre, L. G., Janney, A. W., Fortlage, L. A., Sen, A., Strecher, V. J., and Piette, J. D. A randomized trial comparing structured and lifestyle goals in an internet-mediated walking program for people with type 2 diabetes. *International Journal of Behavioral Nutrition & Physical Activity*. 2007;4:59.

Riche, D. M. and McClendon, K. S. Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. *American Journal of Health-System Pharmacy*. 2007;64(15):1603-1610.

Richter, B., Bandeira-Echtler, E., Bergerhoff, K., and Lerch, C. L. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2008;(2):CD006739.

Richter, B., Bandeira-Echtler, E., Bergerhoff, K., and Lerch, C. Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes. *Vascular Health & Risk Management*. 2008;4(4):753-768.

Richter, B., Bandeira-Echtler, E., Bergerhoff, K., Clar, C., and Ebrahim, S. H. Rosiglitazone for type 2 diabetes mellitus. *Cochrane Database of Systematic Reviews*. 2007;(3):CD006063.

Richter, Bernd, Bandeira-Echtler, Elizabeth, Bergerhoff, Karla, and Lerch, Christian. Dipeptidyl peptidase-4 (DPP-4) inhibitors for type 2 diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Richter, Bernd, Bandeira-Echtler, Elizabeth, Bergerhoff, Karla, Clar, Christine, and Ebrahim, Susanne H. Pioglitazone for type 2 diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Riddle, M. C., Ambrosius, W. T., Brillon, D. J., Buse, J. B., Byington, R. P., Cohen, R. M., Goff, D. C., Jr., Malozowski, S., Margolis, K. L., Probstfield, J. L., Schnall, A., Seaquist, E. R., and Action to Control Cardiovascular Risk in Diabetes, Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. *Diabetes Care*. 2010;33(5):983-990.

Riddle, M., Frias, J., Zhang, B., Maier, H., Brown, C., Lutz, K., and Kolterman, O. Pramlintide improved glycemic control and reduced weight in patients with type 2 diabetes using basal insulin. *Diabetes Care*. 2007;30(11):2794-2799.

Riddle, M., Pencek, R., Charenkavanich, S., Lutz, K., Wilhelm, K., and Porter, L. Randomized comparison of pramlintide or mealtime insulin added to basal insulin treatment for patients with type 2 diabetes. *Diabetes Care*. 2009;32(9):1577-1582.

Riegersperger, M. and Sunder-Plassmann, G. How to prevent progression to end stage renal disease. *Journal of Renal Care*. 2007;33(3):105-107.

Rigby, S. P., Handelsman, Y., Lai, Y. L., Abby, S. L., Tao, B., and Jones, M. R. Effects of colesevelam, rosiglitazone, or sitagliptin on glycemic control and lipid profile in patients with type 2 diabetes mellitus inadequately controlled by metformin monotherapy. *Endocrine Practice*. 2010;16(1):53-63.

Rignell-Hydbom, A., Lidfeldt, J., Kiviranta, H., Rantakokko, P., Samsioe, G., Agardh, C. D., and Rylander, L. Exposure to p,p'-DDE: a risk factor for type 2 diabetes. *PLoS ONE [Electronic Resource]*. 2009;4(10):e7503.

Rignell-Hydbom, A., Rylander, L., and Hagmar, L. Exposure to persistent organochlorine pollutants and type 2 diabetes mellitus. *Human & Experimental Toxicology*. 2007;26(5):447-452.

Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics. *Cardiovascular Journal of Africa*. 2008;19(5):282-283.

Ripsin, C. M., Kang, H., and Urban, R. J. Management of blood glucose in type 2 diabetes mellitus. *American Family Physician*. 2009;79(1):29-36.

Riserus, U., Willett, W. C., and Hu, F. B. Dietary fats and prevention of type 2 diabetes. *Progress in Lipid Research*. 2009;48(1):44-51.

Ristic, S., Collober-Maugeais, C., Cressier, F., Tang, P., and Pecher, E. Nateglinide or gliclazide in combination with metformin for treatment of patients with type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone: 1-year trial results. *Diabetes, Obesity & Metabolism*. 2007;9(4):506-511.

Ristic, S., Collober-Maugeais, C., Pecher, E., and Cressier, F. Comparison of nateglinide and gliclazide in combination with metformin, for treatment of patients with Type 2 diabetes mellitus inadequately controlled on maximum doses of metformin alone. *Diabetic Medicine*. 2006;23(7):757-762.

Ritz, E. Total cardiovascular risk management. *American Journal of Cardiology*. 2007;100(3A):53J-60J.

Riveline, J. P., Teynie, J., Belmouaz, S., Franc, S., Dardari, D., Bauwens, M., Caudwell, V., Ragot, S., Bridoux, F., Charpentier, G., Marechaud, R., and Hadjadj, S. Glycaemic control in type 2 diabetic patients on chronic haemodialysis: use of a continuous glucose monitoring system. *Nephrology Dialysis Transplantation*. 2009;24(9):2866-2871.

Rivellese, A. A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R., and Riccardi, G. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. *Clinical Nutrition*. 2008;27(1):133-141.

Rizkalla Sw, Laromiguiere M. C. Effect of baking process on postprandial metabolic consequences: randomized trials in normal and type 2 diabetic subjects. *European Journal of Clinical Nutrition*. 2007;61(2):175-183.

Rizzo, M., Rizvi, A. A., Spinass, G. A., Rini, G. B., and Berneis, K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. *Expert Opinion on Investigational Drugs*. 2009;18(10):1495-1503.

Roach, P. and Malone, J. K. Comparison of insulin lispro mixture 25/75 with insulin glargine during a 24-h standardized test-meal period in patients with Type 2 diabetes. *Diabetic Medicine*. 2006;23(7):743-749.

Robbins, D. C., Beisswenger, P. J., Ceriello, A., Goldberg, R. B., Moses, R. G., Pagkalos, E. M., Milicevic, Z., Jones, C. A., Sarwat, S., and Tan, M. H. Mealtime 50/50 basal + prandial insulin analogue mixture with a basal insulin analogue, both plus metformin, in the achievement of target HbA1c and pre- and postprandial blood glucose levels in patients with type 2 diabetes: a multinational, 24-week, randomized, open-label, parallel-group comparison. *Clinical Therapeutics*. 2007;29(11):2349-2364.

Roberts, A. W., Clark, A. L., and Witte, K. K. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease--do we need to screen our patients?. *Diabetes & Vascular Disease Research*. 2009;6(3):153-163.

Robertson, C., Drexler, A. J., and Vernillo, A. T. Update on diabetes diagnosis and management. *Journal of the American Dental Association*. 2003;134 Spec No:16S-23S.

Robertson, L., Waugh, N., and Robertson, A. Protein restriction for diabetic renal disease. *Cochrane Database of Systematic Reviews*. 2007;(4):CD002181.

Robertson, Lynn M., Waugh, Norman, and Robertson, Aileen. Protein restriction for diabetic renal disease [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Robinson, J. G., Fox, K. M., Grandy, S., and Group, Shield Study. Attitudes about health and health-related behaviors in patients with cardiovascular disease or at elevated risk for cardiovascular disease. *Preventive Cardiology*. 2009;12(3):136-143.

Roca-Cusachs, A., Schmieder, R. E., Triposkiadis, F., Wenzel, R. R., Laurent, S., Kohlmann, O., Jr., Fogari, R., and Group, More Study. Efficacy of manidipine/delapril versus losartan/hydrochlorothiazide fixed combinations in patients with hypertension and diabetes. *Journal of Hypertension*. 2008;26(4):813-818.

Rocha, P. M., Barata, J. T., Teixeira, P. J., Ross, R., and Sardinha, L. B. Independent and opposite associations of hip and waist circumference with metabolic syndrome components and with

inflammatory and atherothrombotic risk factors in overweight and obese women. *Metabolism: Clinical & Experimental*. 2008;57(10):1315-1322.

Roche, E., Reig, J. A., Campos, A., Paredes, B., Isaac, J. R., Lim, S., Calne, R. Y., and Soria, B. Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. *Transplant Immunology*. 2005;15(2):113-129.

Rocic, B., Bajuk, N. B., Rocic, P., Weber, D. S., Boras, J., and Lovrencic, M. V. Comparison of antihyperglycemic effects of creatine and metformin in type II diabetic patients. *Clinical & Investigative Medicine - Medecine Clinique et Experimentale*. 2009;32(6):E322.

Rodbard, H. W., Green, A. J., Fox, K. M., Grandy, S., and Group, Shield Study. Impact of type 2 diabetes mellitus on prescription medication burden and out-of-pocket healthcare expenses. *Diabetes Research & Clinical Practice*. 2010;87(3):360-365.

Roden, M. Free fatty acid kinetics during long-term treatment with pioglitazone added to sulfonylurea or metformin in Type 2 diabetes. *Journal of Internal Medicine*. 2009;265(4):476-487.

Rodriguez, A., Cipres, L., Tofe, S., Polavieja, P., and Reviriego, J. Clinical evaluation of combined therapy for type 2 diabetes. *Current Medical Research & Opinion*. 2010;26(5):1171-1183.

Rodriguez-Idigoras, M. I., Sepulveda-Munoz, J., Sanchez-Garrido-Escudero, R., Martinez-Gonzalez, J. L., Escolar-Castello, J. L., Paniagua-Gomez, I. M., Bernal-Lopez, R., Fuentes-Simon, M. V., and Garofano-Serrano, D. Telemedicine influence on the follow-up of type 2 diabetes patients. *Diabetes Technology & Therapeutics*. 2009;11(7):431-437.

Rogers, S. L., Magliano, D. J., Levison, D. B., Webb, K., Clarke, P. J., Grobler, M. P., and Liew, D. A dose-specific meta-analysis of lipid changes in randomized controlled trials of atorvastatin and simvastatin. *Clinical Therapeutics*. 2007;29(2):242-252.

Roine, E., Roine, R. P., Rasanen, P., Vuori, I., Sintonen, H., and Saarto, T. Cost-effectiveness of interventions based on physical exercise in the treatment of various diseases: a systematic literature review. *International Journal of Technology Assessment in Health Care*. 2009;25(4):427-454.

Roman, G. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme*. 2009;41(2):116-122.

Roosbeh, J., Banihashemi, M. A., Ghezlou, M., Afshariani, R., Salari, S., Moini, M., and Sagheb, M. M. Captopril and combination therapy of captopril and pentoxifylline in reducing proteinuria in diabetic nephropathy. *Renal Failure*. 2010;32(2):172-178.

Rosal, M. C., Benjamin, E. M., Pekow, P. S., Lemon, S. C., and von Goeler, D. Opportunities and challenges for diabetes prevention at two community health centers. *Diabetes Care*. 2008;31(2):247-254.

Rosenson Rs, Abby S. L. J. Colesevelam HCl effects on atherogenic lipoprotein subclasses in subjects with type 2 diabetes. *Atherosclerosis*. 2009;204(2):342-344.

Rosenstock, J. and Fitchet, M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. *International Journal of Clinical Practice*. 2008;Supplement.(159):15-23.

Rosenstock, J. and Zinman, B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2007;14(2):98-107.

Rosenstock, J., Aguilar-Salinas, C., Klein, E., Nepal, S., List, J., Chen, R., and Investigators, C. V. S. Effect of saxagliptin monotherapy in treatment-naïve patients with type 2 diabetes. *Current Medical Research & Opinion*. 2009;25(10):2401-2411.

Rosenstock, J., Ahmann, A. J., Colon, G., Scism-Bacon, J., Jiang, H., and Martin, S. Advancing insulin

therapy in type 2 diabetes previously treated with glargine plus oral agents: prandial premixed (insulin lispro protamine suspension/lispro) versus basal/bolus (glargine/lispro) therapy. *Diabetes Care*. 2008;31(1):20-25.

Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., and Schweizer, A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.[Erratum appears in *Diabetes Care*. 2007 May;30(5):1330]. *Diabetes Care*. 2007;30(2):217-223.

Rosenstock, J., Bergenstal, R., DeFronzo, R. A., Hirsch, I. B., Klonoff, D., Boss, A. H., Kramer, D., Petrucci, R., Yu, W., Levy, B., and Study, Group. Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naïve type 2 diabetes suboptimally controlled with oral agents. *Diabetes Care*. 2008;31(11):2177-2182.

Rosenstock, J., Cefalu, W. T., Hollander, P. A., Belanger, A., Eliaschewitz, F. G., Gross, J. L., Klioze, S. S., St Aubin, L. B., Foyt, H., Ogawa, M., and Duggan, W. T. Two-year pulmonary safety and efficacy of inhaled human insulin (Exubera) in adult patients with type 2 diabetes. *Diabetes Care*. 2008;31(9):1723-1728.

Rosenstock, J., Chou, H. S., Matthaei, S., Seidel, D. K., and Hamann, A. Potential benefits of early addition of rosiglitazone in combination with glimepiride in the treatment of type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(10):862-873.

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., and Schernthaner, G. A randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naïve people with type 2 diabetes. *Diabetologia*. 2008;51(3):408-416.

Rosenstock, J., Eliaschewitz, F. G., Heilmann, C. R., Muchmore, D. B., Hayes, R. P., and Belin, R. M. Comparison of prandial AIR inhaled insulin alone to intensified insulin glargine alone and to AIR insulin plus intensified insulin glargine in patients with type 2 diabetes previously treated with once-daily insulin glargine. *Diabetes Technology & Therapeutics*. 2009;11 Suppl 2:S63-S73.

Rosenstock, J., Hollander, P., Chevalier, S., Iranmanesh, A., and Group, Serenade Study. SERENADE: the Study Evaluating Rimnabant Efficacy in Drug-naïve Diabetic Patients: effects of monotherapy with rimnabant, the first selective CB1 receptor antagonist, on glycemic control, body weight, and lipid profile in drug-naïve type 2 diabetes. *Diabetes Care*. 2008;31(11):2169-2176.

Rosenstock, J., Hollander, P., Gadde, K. M., Sun, X., Strauss, R., Leung, A., and Group, O. B. D. S. A randomized, double-blind, placebo-controlled, multicenter study to assess the efficacy and safety of topiramate controlled release in the treatment of obese type 2 diabetic patients. *Diabetes Care*. 2007;30(6):1480-1486.

Rosenstock, J., Kim, S. W., Baron, M. A., Camisasca, R. P., Cressier, F., Couturier, A., and Dejager, S. Efficacy and tolerability of initial combination therapy with vildagliptin and pioglitazone compared with component monotherapy in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2007;9(2):175-185.

Rosenstock, J., Lorber, D. L., Gnudi, L., Howard, C. P., Bilheimer, D. W., Chang, P. C., Petrucci, R. E., Boss, A. H., and Richardson, P. C. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. *Lancet*. 2010;375(9733):2244-2253.

Rosenstock, J., Niggli, M., and Maldonado-Lutomirsky, M. Long-term 2-year safety and efficacy of vildagliptin compared with rosiglitazone in drug-naïve patients with type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2009;11(6):571-578.

Rosenstock, J., Rood, J., Cobitz, A., Biswas, N., Chou, H., and Garber, A. Initial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either

rosiglitazone or metformin in patients with uncontrolled type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2006;8(6):650-660.

Rosenstock, J., Rood, J., Cobitz, A., Huang, C., and Garber, A. Improvement in glycaemic control with rosiglitazone/metformin fixed-dose combination therapy in patients with type 2 diabetes with very poor glycaemic control. *Diabetes, Obesity & Metabolism*. 2006;8(6):643-649.

Rosenstock, J., Sankoh, S., and List, J. F. Glucose-lowering activity of the dipeptidyl peptidase-4 inhibitor saxagliptin in drug-naïve patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(5):376-386.

Rosenstock, J. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial. *Diabetes Care*. 2007;30(2):217-223.

Rosenzweig, S., Reibel, D. K., Greeson, J. M., Edman, J. S., Jasser, S. A., McMearty, K. D., and Goldstein, B. J. Mindfulness-based stress reduction is associated with improved glycemic control in type 2 diabetes mellitus: a pilot study. *Alternative Therapies in Health & Medicine*. 2007;13(5):36-38.

Rossi, M. C. and Nicolucci, A. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. *Acta Bio-Medica de l Ateneo Parmense*. 2009;80(2):93-101.

Rossi, M. C., Nicolucci, A., Pellegrini, F., Comaschi, M., Ceriello, A., Cucinotta, D., Giorda, C., Pomili, B., Valentini, U., Vespasiani, G., and De Cosmo, S. Obesity and changes in urine albumin/creatinine ratio in patients with type 2 diabetes: the DEMAND study. *Nutrition Metabolism & Cardiovascular Diseases*. 2010;20(2):110-116.

Rossi, M. C., Nicolucci, A., Pellegrini, F., Comaschi, M., Ceriello, A., Cucinotta, D., Giorda, C., Valentini, U., Vespasiani, G., and De Cosmo, S. Identifying patients with type 2 diabetes at high risk of microalbuminuria: results of the DEMAND (Developing Education on Microalbuminuria for Awareness of reNal and cardiovascular risk in Diabetes) Study. *Nephrology Dialysis Transplantation*. 2008;23(4):1278-1284.

Rostambeigi, N., Shaw, J. E., Atkins, R. C., Ghanbarian, A., Cameron, A. J., Forbes, A., Momenan, A., Hadaegh, F., Mirmiran, P., Zimmet, P. Z., Azizi, F., and Tonkin, A. M. Waist circumference has heterogeneous impact on development of diabetes in different populations: longitudinal comparative study between Australia and Iran. *Diabetes Research & Clinical Practice*. 2010;88(1):117-124.

Roux, L., Pratt, M., Tengs, T. O., Yore, M. M., Yanagawa, T. L., Van Den Bos, J., Rutt, C., Brownson, R. C., Powell, K. E., Heath, G., Kohl, H. W., III, Teutsch, S., Cawley, J., Lee, I. M., West, L., and Buchner, D. M. Cost effectiveness of community-based physical activity interventions. *American Journal of Preventive Medicine*. 2008;35(6):578-588.

Rubin, C. J., De Pril, V., and Fiedorek, F. T. Coadministration of muraglitazar plus glyburide: improvement of glycaemic and lipid profiles in patients with type 2 diabetes. *Diabetes & Vascular Disease Research*. 2009;6(2):120-132.

Rubin, C. J., Ledezine, J. M., and Fiedorek, F. T. Improvement of glycaemic and lipid profiles with muraglitazar plus metformin in patients with type 2 diabetes: an active-control trial with glimepiride. *Diabetes & Vascular Disease Research*. 2008;5(3):168-176.

Rubin, C. J., Viraswami-Appanna, K., and Fiedorek, F. T. Efficacy and safety of muraglitazar: a double-blind, 24-week, dose-ranging study in patients with type 2 diabetes. *Diabetes & Vascular Disease Research*. 2009;6(3):205-215.

Ruboxistaurin: LY 333531. *Drugs in R & D*. 2007;8(3):193-199.

Rudnisky, C. J., Tennant, M. T., Weis, E., Ting, A., Hinz, B. J., and Greve, M. D. Web-based grading of compressed stereoscopic digital photography versus standard slide film photography for the

diagnosis of diabetic retinopathy. *Ophthalmology*. 2007;114(9):1748-1754.

Rudofsky, G., Jr., Reismann, P., Grafe, I. A., Konrade, I., Djuric, Z., Tafel, J., Buchbinder, S., Zorn, M., Humpert, P. M., Hamann, A., Morcos, M., Nawroth, P. P., and Bierhaus, A. Improved vascular function upon pioglitazone treatment in type 2 diabetes is not associated with changes in mononuclear NF-kappaB binding activity. *Hormone & Metabolic Research*. 2007;39(9):665-671.

Ruilope, L. M. New ADVANCEs in guidelines. *Journal of Hypertension - Supplement*. 2008;26(2):S16-S18.

Rush, E., Crook, N., and Simmons, D. Point-of-care testing as a tool for screening for diabetes and pre-diabetes. *Diabetic Medicine*. 2008;25(9):1070-1075.

Russell-Jones, D., Vaag, A., Schmitz, O., Sethi, B. K., Lalic, N., Antic, S., Zdravkovic, M., Ravn, G. M., Simo, R., Liraglutide, Effect, and Action, in Diabetes. Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial. *Diabetologia*. 2009;52(10):2046-2055.

Rutter, M. K., Wilson, P. W., Sullivan, L. M., Fox, C. S., D'Agostino, R. B., Sr., and Meigs, J. B. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. *Circulation*. 2008;117(8):1003-1009.

Ryan, G., Briscoe, T. A., and Jobe, L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. *Drug design, development & therapy*. 2009;2:203-214.

Sacks, F. M. After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate. *American Journal of Cardiology*. 2008;102(12A):34L-40L.

Sadikot, S. M. and Mogensen, C. E. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. *Diabetes Research & Clinical Practice*. 2008;82(3):391-395.

Sahay, B. K. Role of yoga in diabetes. *Journal of the Association of Physicians of India*. 2007;55:121-126.

Salinari, S., Bertuzzi, A., Iaconelli, A., Manco, M., and Mingrone, G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. *Diabetologia*. 2008;51(7):1276-1284.

Salpeter, S. R., Walsh, J. M., Ormiston, T. M., Greyber, E., Buckley, N. S., and Salpeter, E. E. Meta-analysis: effect of hormone-replacement therapy on components of the metabolic syndrome in postmenopausal women. *Diabetes, Obesity & Metabolism*. 2006;8(5):538-554.

Sampaio, E. and Delfino, V. D. Assessing albuminuria in spot morning samples from diabetic patients. *Arquivos Brasileiros de Endocrinologia e Metabologia*. 2008;52(9):1482-1488.

Sanyal Aj, Mudaliar S. Henry. A new therapy for nonalcoholic fatty liver disease and diabetes? INT-747-the first FXR hepatic therapeutic study. *Hepatology*. 2009;50(4 (Supl)):389A-390A.

Sato, K. K., Hayashi, T., Harita, N., Yoneda, T., Nakamura, Y., Endo, G., and Kambe, H. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the Kansai Healthcare Study. *Diabetes Care*. 2009;32(4):644-646.

Savoia, C. Angiotensin type 2 receptor in resistance arteries of type 2 diabetic hypertensive patients. *Hypertension*. 2007;49(2):341-346.

Sawaki, H., Terasaki, J., Fujita, A., Nakagawa, S., Kanatsuna, N., Sadahiro, K., Isotani, H., Imagawa, A., and Hanafusa, T. A renoprotective effect of low dose losartan in patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(1):86-90.

Schaller, G., Kretschmer, S., Gouya, G., Haider, D. G., Mittermayer, F., Riedl, M., Wagner, O., Pacini, G.,

Wolzt, M., and Ludvik, B. Alcohol acutely increases vascular reactivity together with insulin sensitivity in type 2 diabetic men. *Experimental & Clinical Endocrinology & Diabetes*. 2010;118(1):57-60.

Scharnagl, H., Stojakovic, T., Winkler, K., Rosinger, S., Marz, W., and Boehm, B. O. The HMG-CoA reductase inhibitor cerivastatin lowers advanced glycation end products in patients with type 2 diabetes. *Experimental & Clinical Endocrinology & Diabetes*. 2007;115(6):372-375.

Scheede-Bergdahl, C., Benee Olsen, D., Reving, D., Boushel, R., and Dela, F. Cardiovascular disease markers in type 2 diabetes: the effects of a moderate home-based exercise training programme. *Diabetes & Vascular Disease Research*. 2009;6(4):291-296.

Scheen, A. J. and Krzesinski, J. M. [Clinical trial of the month. ADVANCE: improved survival and better vascular and renal outcomes with a fixed combination of perindopril and indapamide in patients with type 2 diabetes]. *Revue Medicale de Liege*. 2007;62(10):639-643.

Schein Mh, Gavish B. B. Treating hypertension in type II diabetic patients with device-guided breathing: a randomized controlled trial. *Journal of Human Hypertension*. 2009;23(5):325-331.

Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Jauffret, S., and Foley, J. E. Efficacy and tolerability of vildagliptin in drug-naïve patients with type 2 diabetes and mild hyperglycaemia*. *Diabetes, Obesity & Metabolism*. 2008;10(8):675-682.

Scherbaum, W. A., Schweizer, A., Mari, A., Nilsson, P. M., Lalanne, G., Wang, Y., Dunning, B. E., and Foley, J. E. Evidence that vildagliptin attenuates deterioration of glycaemic control during 2-year treatment of patients with type 2 diabetes and mild hyperglycaemia. *Diabetes, Obesity & Metabolism*. 2008;10(11):1114-1124.

Schmieder Re, Delles C. M. Impact of telmisartan versus ramipril on renal endothelial function in patients with hypertension and type 2 diabetes. *Diabetes Care*. 2007;30(6):1351-1356.

Schmittiel, J. A., Traylor, A., Uratsu, C. S., Mangione, C. M., Ferrara, A., and Subramanian, U. The association of patient-physician gender concordance with cardiovascular disease risk factor control and treatment in diabetes. *Journal of Women's Health*. 2009;18(12):2065-2070.

Schmitz, N., Nitka, D., Gariepy, G., Malla, A., Wang, J., Boyer, R., Messier, L., Strychar, I., and Lesage, A. Association between neighborhood-level deprivation and disability in a community sample of people with diabetes. *Diabetes Care*. 2009;32(11):1998-2004.

Schneeberger, C., Stolk, R. P., Devries, J. H., Schneeberger, P. M., Herings, R. M., and Geerlings, S. E. Differences in the pattern of antibiotic prescription profile and recurrence rate for possible urinary tract infections in women with and without diabetes. *Diabetes Care*. 2008;31(7):1380-1385.

Schneider Sm, Robergs R. A. A. Impaired orthostatic response in patients with type 2 diabetes mellitus after 48 hours of bed rest. *Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists*. 2009;15(2):104-110.

Schoffski, O., Breitschdel, L., Benter, U., Dippel, F. W., Muller, M., Volk, M., and Pfohl, M. Resource utilisation and costs in patients with type 2 diabetes mellitus treated with insulin glargine or conventional basal insulin under real-world conditions in Germany: LIVE-SPP study. *Journal of Medical Economics*. 2008;11(4):695-712.

Schondorf, T., Lubben, G., Hoopmann, M., Borchert, M., Forst, T., Hohberg, C., Lobig, M., Armbruster, F. P., Roth, W., Grabellus, M., and Pfutzner, A. Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. *Gynecological Endocrinology*. 2007;23(6):356-360.

Schrier, R. W., Estacio, R. O., Mehler, P. S., and Hiatt, W. R. Appropriate blood pressure control in hypertensive and normotensive type 2 diabetes mellitus: a summary of the ABCD trial. *Nature Clinical*

Practice Nephrology. 2007;3(8):428-438.

Schubert, C. M., Sun, S. S., Burns, T. L., Morrison, J. A., and Huang, T. T. Predictive ability of childhood metabolic components for adult metabolic syndrome and type 2 diabetes. *Journal of Pediatrics*. 2009;155(3):S6.

Schulze, M. B., Weikert, C., Pischon, T., Bergmann, M. M., Al-Hasani, H., Schleicher, E., Fritsche, A., Haring, H. U., Boeing, H., and Joost, H. G. Use of multiple metabolic and genetic markers to improve the prediction of type 2 diabetes: the EPIC-Potsdam Study. *Diabetes Care*. 2009;32(11):2116-2119.

Schwartz, S. L., Ratner, R. E., Kim, D. D., Qu, Y., Fechner, L. L., Lenox, S. M., and Holcombe, J. H. Effect of exenatide on 24-hour blood glucose profile compared with placebo in patients with type 2 diabetes: a randomized, double-blind, two-arm, parallel-group, placebo-controlled, 2-week study. *Clinical Therapeutics*. 2008;30(5):858-867.

Schwarz, B., Gouveia, M., Chen, J., Nocea, G., Jameson, K., Cook, J., Krishnarajah, G., Alemao, E., Yin, D., and Sintonen, H. Cost-effectiveness of sitagliptin-based treatment regimens in European patients with type 2 diabetes and haemoglobin A1c above target on metformin monotherapy. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 1:43-55.

Schwarz, S. L., Gerich, J. E., Marcellari, A., Jean-Louis, L., Purkayastha, D., and Baron, M. A. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(8):652-660.

Schweizer, A., Couturier, A., Foley, J. E., and Dejager, S. Comparison between vildagliptin and metformin to sustain reductions in HbA(1c) over 1 year in drug-naïve patients with Type 2 diabetes. *Diabetic Medicine*. 2007;24(9):955-961.

Scott, R., Loeys, T., Davies, M. J., Engel, S. S., and Sitagliptin Study, Group. Efficacy and safety of sitagliptin when added to ongoing metformin therapy in patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(10):959-969.

Scott, R. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. *International Journal of Clinical Practice*. 2007;61(1):171-180.

Sejil, S., Janand-Delenne, B., Avierinos, J. F., Habib, G., Labastie, N., Raccah, D., Vague, P., and Lassmann-Vague, V. Six-year follow-up of a cohort of 203 patients with diabetes after screening for silent myocardial ischaemia. *Diabetic Medicine*. 2006;23(11):1186-1191.

Seki, N., Hashimoto, N., Suzuki, Y., Yagui, K., and Saito, Y. Differential effects of RAS inhibitors associated with ACE gene polymorphisms in type 2 diabetic nephropathy. *Diabetes Research & Clinical Practice*. 2006;72(2):135-141.

Selam, J. L. and Meneghini, L. F. Basal-bolus therapy with insulin detemir using the 303 algorithm in the US PREDICTIVE 303 trial. *Advances in Therapy*. 2009;26(2):194-207.

Selam, J. L., Koenen, C., Weng, W., and Meneghini, L. Improving glycemic control with insulin detemir using the 303 Algorithm in insulin naïve patients with type 2 diabetes: a subgroup analysis of the US PREDICTIVE 303 study. *Current Medical Research & Opinion*. 2008;24(1):11-20.

Sesti, G., Andreozzi, F., Bonadonna, R. C., De Mattia, G., Leonetti, F., Luzi, L., Marini, M. A., Natali, A., Vettor, R., Bonora, E., and Group of Italian Scientists of Insulin, Resistance. Impact of lowering the criterion for impaired fasting glucose on identification of individuals with insulin resistance. The GISIR database. *Diabetes/Metabolism Research Reviews*. 2008;24(2):130-136.

Setter, S. M., Levien, T. L., Iltz, J. L., Odegard, P. S., Neumiller, J. J., Baker, D. E., and Campbell, R. K. Inhaled dry powder insulin for the treatment of diabetes mellitus. *Clinical Therapeutics*. 2007;29(5):795-813.

Settergren, M. L-arginine and tetrahydrobiopterin protects against ischemia/reperfusion-induced endothelial dysfunction in patients with type 2 diabetes mellitus and coronary artery disease. *Atherosclerosis*. 2009;204(1):73-78.

Seufert, J. and Urquhart, R. 2-year effects of pioglitazone add-on to sulfonylurea or metformin on oral glucose tolerance in patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(3):453-460.

Shahar Dr, Abel R. E. Does dairy calcium intake enhance weight loss among overweight diabetic patients?. *Diabetes Care*. 2007;30(3):485-489.

Sharma, A. M., Davidson, J., Koval, S., and Lacourciere, Y. Telmisartan/hydrochlorothiazide versus valsartan/hydrochlorothiazide in obese hypertensive patients with type 2 diabetes: the SMOOTH study. *Cardiovascular Diabetology*. 2007;6:28.

Sharma, S. K., Al-Mustafa, M., Oh, S. J., Azar, S. T., Shestakova, M., Guler, S., and Vaz, J. A. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. *Current Medical Research & Opinion*. 2008;24(3):645-652.

Sheehy, A. M., Flood, G. E., Tuan, W. J., Liou, J. I., Coursin, D. B., and Smith, M. A. Analysis of guidelines for screening diabetes mellitus in an ambulatory population. *Mayo Clinic Proceedings*. 2010;85(1):27-35.

Shenoy, S., Guglani, R., and Sandhu, J. S. Effectiveness of an aerobic walking program using heart rate monitor and pedometer on the parameters of diabetes control in Asian Indians with type 2 diabetes. *Primary care diabetes*. 2010;4(1):41-45.

Shibayama, T., Kobayashi, K., Takano, A., Kadowaki, T., and Kazuma, K. Effectiveness of lifestyle counseling by certified expert nurse of Japan for non-insulin-treated diabetic outpatients: a 1-year randomized controlled trial. *Diabetes Research & Clinical Practice*. 2007;76(2):265-268.

Shih, H. C., Chou, P., Chen, S. J., Liu, J. H., Lee, F. L., Liu, C. M., and Tung, T. H. A community-based study of the willingness to pay associated with screening for diabetic retinopathy among type 2 diabetes in Kinmen, Taiwan. *Journal of Epidemiology*. 2007;17(6):186-193.

Shoelson, S. E., Herrero, L., and Naaz, A. Obesity, inflammation, and insulin resistance. *Gastroenterology*. 2007;132(6):2169-2180.

Siegmund, T., Schumm-Draeger, P. M., Antoni, D., and Bibra, H. V. Beneficial effects of ramipril on myocardial diastolic function in patients with type 2 diabetes mellitus, normal LV systolic function and without coronary artery disease: a prospective study using tissue Doppler. *Diabetes & Vascular Disease Research*. 2007;4(4):358-364.

Sievenpiper, J. L., Carleton, A. J., Chatha, S., Jiang, H. Y., de Souza, R. J., Beyene, J., Kendall, C. W., and Jenkins, D. J. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. *Diabetes Care*. 2009;32(10):1930-1937.

Sigal Rj, Kenny G. P. B. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial. *Annals of Internal Medicine*. 2007;147(6):357-369.

Sigal, R. J., Kenny, G. P., Boule, N. G., Wells, G. A., Prud'homme, D., Fortier, M., Reid, R. D., Tulloch, H., Coyle, D., Phillips, P., Jennings, A., and Jaffey, J. Effects of aerobic training, resistance training, or both on glycemic control in type 2 diabetes: a randomized trial.[Summary for patients in *Ann Intern Med*. 2007 Sep 18;147(6):116; PMID: 17876015]. *Annals of Internal Medicine*. 2007;147(6):357-369.

Sigdel, M., Rajbhandari, N., Basnet, S., Nagila, A., Basnet, P., and Tamrakar, B. K. Microalbuminuria among type-2 diabetes mellitus patients in Pokhara, Nepal. *Nepal Medical College Journal: NMCJ*. 2008;10(4):242-245.

Simmons, R. K., Griffin, S. J., Steele, R., Wareham, N. J., Ekelund, U., and ProActive Research, Team. Increasing overall physical activity and aerobic fitness is associated with improvements in metabolic risk: cohort analysis of the ProActive trial. *Diabetologia*. 2008;51(5):787-794.

Simmons, R. K., Harding, A. H., Wareham, N. J., Griffin, S. J., and Team, E. PIC-Norfolk Project. Do simple questions about diet and physical activity help to identify those at risk of Type 2 diabetes?. *Diabetic Medicine*. 2007;24(8):830-835.

Simoens, S., De Coster, S., Dethier, M., Lenie, J., Meuwissen, P., and Laekeman, G. Cardiovascular drug use prior to diagnosis of diabetes: a pilot study in community pharmacy. *International Journal of Pharmacy Practice*. 2009;17(2):127-129.

Simpson, K. A. and Singh, M. A. Effects of exercise on adiponectin: a systematic review. *Obesity*. 2008;16(2):241-256.

Singh, K. P., Periyandavar, I., Rajadhyaksha, G. C., Jayaram, S., Mishra, A. B., Kinagi, S., Sharma, A., and Baliga, V. P. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients with uncomplicated type 2 diabetes mellitus. *Journal of the Indian Medical Association*. 105(6):344.

Singh, S. and Loke, Y. K. The safety of rosiglitazone in the treatment of type 2 diabetes. *Expert Opinion on Drug Safety*. 2008;7(5):579-585.

Singh, S., Loke, Y. K., and Furberg, C. D. Long-term risk of cardiovascular events with rosiglitazone: a meta-analysis. *Jama*. 2007;298(10):1189-1195.

Singh-Franco, D., Robles, G., and Gazze, D. Pramlintide acetate injection for the treatment of type 1 and type 2 diabetes mellitus. *Clinical Therapeutics*. 2007;29(4):535-562.

Sirois, C., Poirier, P., Moisan, J., and Gregoire, J. P. The benefit of aspirin therapy in type 2 diabetes: what is the evidence?. *International Journal of Cardiology*. 2008;129(2):172-179.

Sitagliptin/metformin (Janumet) for type 2 diabetes. *Medical Letter on Drugs & Therapeutics*. 2007;49(1262):45-47.

Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks. *Prescrire International*. 2008;17(93):12-15.

Siu Am, Chan C. C. P. Evaluation of the chronic disease self-management program in a Chinese population. *Patient education and counseling*. 2007;65(1):42-50.

Sixta, C. S. and Ostwald, S. Texas-Mexico border intervention by promotores for patients with type 2 diabetes. *Diabetes Educator*. 2008;34(2):299-309.

Skoro-Kondza, L. Community based yoga classes for type 2 diabetes: an exploratory randomised controlled trial. *BMC Health Services Research*. 2009;9(33):.

Smith, D. M., Pickering, R. M., and Lewith, G. T. A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus. *Qjm*. 2008;101(5):351-358.

Soell, M., Feki, A., Hannig, M., Sano, H., Pinget, M., and Selimovic, D. Chromogranin A detection in saliva of type 2 diabetes patients. *Bosnian Journal of Basic Medical Sciences*. 2010;10(1):2-8.

Somannavar, S., Ganesan, A., Deepa, M., Datta, M., and Mohan, V. Random capillary blood glucose cut points for diabetes and pre-diabetes derived from community-based opportunistic screening in India. *Diabetes Care*. 2009;32(4):641-643.

- Song, M. S. and Kim, H. S. Effect of the diabetes outpatient intensive management programme on glycaemic control for type 2 diabetic patients. *Journal of Clinical Nursing*. 2007;16(7):1367-1373.
- Song, S. H. and Hardisty, C. A. Diagnosing metabolic syndrome in type 2 diabetes: does it matter?. *Qjm*. 2008;101(6):487-491.
- Song, Y., Manson, J. E., Tinker, L., Howard, B. V., Kuller, L. H., Nathan, L., Rifai, N., and Liu, S. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. *Diabetes Care*. 2007;30(7):1747-1752.
- Soto-Pedre, E., Hernaez-Ortega, M. C., and Pinies, J. A. Duration of diabetes and screening coverage for retinopathy among patients with type 2 diabetes. *Ophthalmic Epidemiology*. 2007;14(2):76-79.
- Sowers, J. R., Lastra, G., Rocha, R., Seifu, Y., Crikelair, N., and Levy, D. G. Initial combination therapy compared with monotherapy in diabetic hypertensive patients. *Journal of Clinical Hypertension*. 2008;10(9):668-676.
- Spanheimer, R., Betteridge, D. J., Tan, M. H., Ferrannini, E., Charbonnel, B., and investigators, P. ROactive. Long-term lipid effects of pioglitazone by baseline anti-hyperglycemia medication therapy and statin use from the PROactive experience (PROactive 14). *American Journal of Cardiology*. 2009;104(2):234-239.
- Sridhar, B., Haleagrahara, N., Bhat, R., Kulur, A. B., Avabratha, S., and Adhikary, P. Increase in the heart rate variability with deep breathing in diabetic patients after 12-month exercise training. *Tohoku Journal of Experimental Medicine*. 2010;220(2):107-113.
- St Charles, M., Minshall, M. E., Pandya, B. J., Baran, R. W., and Tunis, S. L. A cost-effectiveness analysis of pioglitazone plus metformin compared with rosiglitazone plus metformin from a third-party payer perspective in the US.[Erratum appears in *Curr Med Res Opin*. 2009 Jun;25(6):1353]. *Current Medical Research & Opinion*. 2009;25(6):1343-1353.
- Stancakova, A., Javorsky, M., Kuulasmaa, T., Haffner, S. M., Kuusisto, J., and Laakso, M. Changes in insulin sensitivity and insulin release in relation to glycemia and glucose tolerance in 6,414 Finnish men. *Diabetes*. 2009;58(5):1212-1221.
- Steiner, G. How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD. *Cardiovascular Drugs & Therapy*. 2009;23(5):403-408.
- Steiner, G. Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. *Current Opinion in Lipidology*. 2008;19(6):585-591.
- Stirban, A., Nandreaan, S., Negrean, M., Koschinsky, T., and Tschoepe, D. Skin autofluorescence increases postprandially in human subjects. *Diabetes Technology & Therapeutics*. 2008;10(3):200-205.
- Stirban, A. Acute effects of sildenafil on flow mediated dilatation and cardiovascular autonomic nerve function in type 2 diabetic patients. *Diabetes/metabolism research and reviews*. 2009;25(2):136-143.
- Stocker Dj, Taylor A. J. L. A randomized trial of the effects of rosiglitazone and metformin on inflammation and subclinical atherosclerosis in patients with type 2 diabetes. *American Heart Journal*. 2007;153(3):445.
- Stolinski, M., Alam, S., Jackson, N. C., Shojaee-Moradie, F., Pentecost, C., Jefferson, W., Christ, E. R., Jones, R. H., and Umpleby, A. M. Effect of 6-month supervised exercise on low-density lipoprotein apolipoprotein B kinetics in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(11):1608-1614.
- Stone, M. A., Burden, A. C., Burden, M., Baker, R., and Khunti, K. Near patient testing for glycated

haemoglobin in people with Type 2 diabetes mellitus managed in primary care: acceptability and satisfaction. *Diabetic Medicine*. 2007;24(7):792-795.

Strippoli, F. M. G., Bonifati, Carmen, Craig, Maria E., Navaneethan, Sankar D., and Craig, Jonathan C. Angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists for preventing the progression of diabetic kidney disease [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2010;4:4.

Strippoli-Giovanni, F. M., Craig, Maria E., Craig, Jonathan C., Lv, Jicheng, and Perkovic, Vlado. Antihypertensive agents for preventing diabetic kidney disease (Systematic Review). *Cochrane Database of Systematic Reviews: Reviews 2005 Issue 4* John.Wiley & Sons., Ltd.Chichester, UK DOI.: 2005;(4).

Strojek, K., Bebakar, W. M., Khutsoane, D. T., Pesic, M., Smahelova, A., Thomsen, H. F., and Kalra, S. Once-daily initiation with biphasic insulin aspart 30 versus insulin glargine in patients with type 2 diabetes inadequately controlled with oral drugs: an open-label, multinational RCT. *Current Medical Research & Opinion*. 2009;25(12):2887-2894.

Stuckey, H. L., Dellasega, C., Graber, N. J., Mauger, D. T., Lendel, I., and Gabbay, R. A. Diabetes nurse case management and motivational interviewing for change (DYNAMIC): study design and baseline characteristics in the Chronic Care Model for type 2 diabetes. *Contemporary Clinical Trials*. 2009;30(4):366-374.

Stumvoll, M., Haring, H. U., and Matthaei, S. Metformin. *Endocrine Research*. 2007;32(1-2):39-57.

Sturt, J. A., Whitlock, S., Fox, C., Hearnshaw, H., Farmer, A. J., Wakelin, M., Eldridge, S., Griffiths, F., and Dale, J. Effects of the Diabetes Manual 1:1 structured education in primary care. *Diabetic Medicine*. 2008;25(6):722-731.

Su, Y., Xu, Y., Sun, Y. M., Li, J., Liu, X. M., Li, Y. B., Liu, G. D., and Bi, S. Comparison of the effects of simvastatin versus atorvastatin on oxidative stress in patients with type 2 diabetes mellitus. *Journal of Cardiovascular Pharmacology*. 2010;55(1):21-25.

Subramanian, U., Ackermann, R. T., Brizendine, E. J., Saha, C., Rosenman, M. B., Willis, D. R., and Marrero, D. G. Effect of advanced access scheduling on processes and intermediate outcomes of diabetes care and utilization. *Journal of General Internal Medicine*. 2009;24(3):327-333.

Subramanian, U., Hofer, T. P., Klamerus, M. L., Zikmund-Fisher, B. J., Heisler, M., and Kerr, E. A. Knowledge of blood pressure targets among patients with diabetes. *Primary care diabetes*. 2007;1(4):195-198.

Sulistio, M. S., Zion, A., Thukral, N., and Chilton, R. PPARgamma agonists and coronary atherosclerosis. *Current Atherosclerosis Reports*. 2008;10(2):134-141.

Sullivan, M. D., Anderson, R. T., Aron, D., Atkinson, H. H., Bastien, A., Chen, G. J., Feeney, P., Gafni, A., Hwang, W., Katz, L. A., Narayan, K. M., Nwachuku, C., O'Connor, P. J., Zhang, P., and Group, Accord Study. Health-related quality of life and cost-effectiveness components of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: rationale and design. *American Journal of Cardiology*. 2007;99(12A):90i-102i.

Sullivan, S. D., Alfonso-Cristancho, R., Conner, C., Hammer, M., and Blonde, L. A simulation of the comparative long-term effectiveness of liraglutide and glimepiride monotherapies in patients with type 2 diabetes mellitus. *Pharmacotherapy*. 2009;29(11):1280-1288.

Sullivan, S. D., Alfonso-Cristancho, R., Conner, C., Hammer, M., and Blonde, L. Long-term outcomes in patients with type 2 diabetes receiving glimepiride combined with liraglutide or rosiglitazone. *Cardiovascular Diabetology*. 2009;8:12.

Sun, F., Tao, Q., and Zhan, S. An accurate risk score for estimation 5-year risk of type 2 diabetes based on a health screening population in Taiwan. *Diabetes Research & Clinical Practice*. 2009;85(2):228-234.

Sun, J., Wang, Y., Chen, X., Chen, Y., Feng, Y., Zhang, X., Pan, Y., Hu, T., Xu, J., Du, L., Zhou, W., Zhao, H., Riley, R. E., and Mustad, V. A. An integrated intervention program to control diabetes in overweight Chinese women and men with type 2 diabetes. *Asia Pacific Journal of Clinical Nutrition*. 2008;17(3):514-524.

Sun, P., Wang, R., and Jacober, S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. *Current Medical Research & Opinion*. 2007;23(12):3017-3023.

Suraamornkul, S., Kwacharoen, R., Ovartharnporn, M., Rawdaree, P., and Bajaj, M. Insulin clamp-derived measurements of insulin sensitivity and insulin secretion in lean and obese asian type 2 diabetic patients. *Metabolic Syndrome & Related Disorders*. 2010;8(2):113-118.

Suvisaari, J., Perala, J., Saarni, S. I., Harkanen, T., Pirkola, S., Joukamaa, M., Koskinen, S., Lonnqvist, J., and Reunanen, A. Type 2 diabetes among persons with schizophrenia and other psychotic disorders in a general population survey. *European Archives of Psychiatry & Clinical Neuroscience*. 2008;258(3):129-136.

Suwa, A., Yamamoto, T., Sawada, A., Minoura, K., Hosogai, N., Tahara, A., Kurama, T., Shimokawa, T., and Aramori, I. Discovery and functional characterization of a novel small molecule inhibitor of the intracellular phosphatase, SHIP2. *British Journal of Pharmacology*. 2009;158(3):879-887.

Suzuki, K., Yanagawa, T., Shibasaki, T., Kaniwa, N., Hasegawa, R., and Tohkin, M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2006;72(2):148-154.

Swaminathan, K., Davies, J., George, J., Rajendra, N. S., Morris, A. D., and Struthers, A. D. Spironolactone for poorly controlled hypertension in type 2 diabetes: conflicting effects on blood pressure, endothelial function, glycaemic control and hormonal profiles. *Diabetologia*. 2008;51(5):762-768.

Sweet, S. N., Fortier, M. S., Guerin, E., Tulloch, H., Sigal, R. J., Kenny, G. P., and Reid, R. D. Understanding physical activity in adults with type 2 diabetes after completing an exercise intervention trial: A mediation model of self-efficacy and autonomous motivation. *Psychology Health & Medicine*. 2009;14(4):419-429.

Swellam, M., Sayed, Mahmoud, and Abdel-Fatah Ali, A. Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. *Disease Markers*. 2009;27(6):269-278.

Swinnen, S. G. and Devries, J. H. Contact frequency determines outcome of basal insulin initiation trials in type 2 diabetes. *Diabetologia*. 2009;52(11):2324-2327.

Swinnen, S. G., Mullins, P., Miller, M., Hoekstra, J. B., and Holleman, F. Changing the glucose cut-off values that define hypoglycaemia has a major effect on reported frequencies of hypoglycaemia. *Diabetologia*. 2009;52(1):38-41.

Swinnen, S. G., Snoek, F. J., Dain, M. P., Devries, J. H., Hoekstra, J. B., and Holleman, F. Rationale, design, and baseline data of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study: A multinational, randomized noninferiority trial of basal insulin initiation in type 2 diabetes. *Diabetes Technology & Therapeutics*. 2009;11(11):739-743.

Symeonides, P., Koulouris, S., Vratisista, E., Triantafyllou, K., Ioannidis, G., Thalassinou, N., and Katritsis, D. Both ramipril and telmisartan reverse indices of early diabetic cardiomyopathy: a comparative study. *European Journal of Echocardiography*. 2007;8(6):480-486.

Szecsényi, J., Rosemann, T., Joos, S., Peters-Klimm, F., and Miksch, A. German diabetes disease

management programs are appropriate for restructuring care according to the chronic care model: an evaluation with the patient assessment of chronic illness care instrument. *Diabetes Care*. 2008;31(6):1150-1154.

Szendroedi, J., Anderwald, C., Krssak, M., Bayerle-Eder, M., Esterbauer, H., Pfeiler, G., Brehm, A., Nowotny, P., Hofer, A., Waldhausl, W., and Roden, M. Effects of high-dose simvastatin therapy on glucose metabolism and ectopic lipid deposition in nonobese type 2 diabetic patients. *Diabetes Care*. 2009;32(2):209-214.

Szewieczek, J., Dulawa, J., Strzalkowska, D., Batko-Szwaczka, A., and Hornik, B. Normal insulin response to short-term intense exercise is abolished in Type 2 diabetic patients treated with gliclazide. *Journal of Diabetes & its Complications*. 2009;23(6):380-386.

Szewieczek, J., Dulawa, J., Strzalkowska, D., Hornik, B., and Kawecki, G. Impact of the short-term, intense exercise on postprandial glycemia in type 2 diabetic patients treated with gliclazide. *Journal of Diabetes & its Complications*. 2007;21(2):101-107.

Szumita, P. M. The hospital pharmacist: an integral part of the hyperglycaemic management team. *Journal of Clinical Pharmacy & Therapeutics*. 2009;34(6):613-621.

Szymborska-Kajanek, A. Glucose and insulin profiles in type 2 diabetic patients treated with gliclazide MR and glimepiride: An 8-week, randomised, single-centre, open-label, controlled, cross-over study. *Diabetologia Doswiadczalna i Kliniczna*. 2007;7(1):33-38.

Tabak, A. G., Jokela, M., Akbaraly, T. N., Brunner, E. J., Kivimaki, M., and Witte, D. R. Trajectories of glycaemia, insulin sensitivity, and insulin secretion before diagnosis of type 2 diabetes: an analysis from the Whitehall II study. *Lancet*. 2009;373(9682):2215-2221.

Tabatabaei, Malazy O. Comparison of a generic and a brand metformin products in type II diabetes: A double blind randomized clinical trial study. *Daru*. 2007;15(2):113-117.

Tabrizi, J. S., Wilson, A. J., Coyne, E. T., and O'Rourke, P. K. Review of patient-reported type 2 diabetes service quality. *Australian Health Review*. 2008;32(1):23-33.

Tabrizi, J. S., Wilson, A. J., O'Rourke, P. K., and Coyne, E. T. Patient perspectives on consistency of medical care with recommended care in type 2 diabetes. *Diabetes Care*. 2007;30(11):2855-2856.

Tack, C. J., Christov, V., de Galan, B. E., Derwahl, K. M., Klausmann, G., Pelikanova, T., Perusicova, J., Boss, A. H., Amin, N., Kramer, D., Petrucci, R., Yu, W., and Study, Group. Randomized forced titration to different doses of technosphere insulin demonstrates reduction in postprandial glucose excursions and hemoglobin A1c in patients with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(1):47-57.

Tahrani, A. A., Piya, M. K., and Barnett, A. H. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. *Advances in Therapy*. 2009;26(3):249-262.

Tajiri, Y., Takei, R., Mimura, K., and Umeda, F. Indicators for the efficacy of pioglitazone before and during treatment in Japanese patients with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2007;9(5):429-437.

Takagi, T. A prospective, multicenter, randomized trial to assess efficacy of pioglitazone on in-stent neointimal suppression in type 2 diabetes: POPPS (Prevention of In-Stent Neointimal Proliferation by Pioglitazone Study). *Jacc*. 2009;Cardiovascular interventions. 2(6):524-531.

Takarabe, D., Kishimoto, M., Tanaka, T., Takahashi, Y., Kajio, H., Harano, K., and Noda, M. Hemoglobin variant HbE found in two South Asian diabetic patients. *Internal Medicine*. 2009;48(16):1397-1401.

Takebayashi, K., Suetsugu, M., Wakabayashi, S., Aso, Y., and Inukai, T. Retinol binding protein-4

levels and clinical features of type 2 diabetes patients. *Journal of Clinical Endocrinology & Metabolism*. 2007;92(7):2712-2719.

Takebayashi, K. Effects of rosuvastatin and colestimide on metabolic parameters and urinary monocyte chemoattractant protein-1 in type 2 diabetic patients with hyperlipidemia. *Southern Medical Journal*. 2009;102(4):361-368.

Tam, H. L., Shiu, S. W., Wong, Y., Chow, W. S., Betteridge, D. J., and Tan, K. C. Effects of atorvastatin on serum soluble receptors for advanced glycation end-products in type 2 diabetes. *Atherosclerosis*. 2010;209(1):173-177.

Tamaki, M., Shimizu, T., Kanazawa, A., Fujitani, Y., Watada, H., Kawamori, R., and Hirose, T. Effects of changes in basal/total daily insulin ratio in type 2 diabetes patients on intensive insulin therapy including insulin glargine (JUN-LAN Study 6). *Diabetes Research & Clinical Practice*. 2008;81(2):e1-e3.

Tamamoto, H., Ikoma, A., Saitoh, T., Ishikawa, S. E., and Kawakami, M. Comparison of once-daily glargine plus sulfonylurea with twice-daily 70/30 aspart premix in insulin-naïve Japanese patients with diabetes. *Diabetes Technology & Therapeutics*. 2007;9(3):246-253.

Tamita, K., Katayama, M., Takagi, T., Akasaka, T., Yamamuro, A., Kaji, S., Morioka, S., and Kihara, Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. *Circulation Journal*. 2007;71(6):834-841.

Tan, F., Chan, G., Wong, J. S., and Rozario, F. Standard of care for type 2 diabetic patients in a public hospital general medical clinic: report of a self-audit. *Medical Journal of Malaysia*. 2008;63(3):224-228.

Tan, F., Mukherjee, J. J., Lee, K. O., Lim, P., and Liew, C. F. Dual blockade of the renin-angiotensin-aldosterone system is safe and effective in reducing albuminuria in Asian type 2 diabetic patients with nephropathy. *Singapore Medical Journal*. 2010;51(2):151-156.

Tan, K. C., Chow, W. S., Tso, A. W., Xu, A., Tse, H. F., Hoo, R. L., Betteridge, D. J., and Lam, K. S. Thiazolidinedione increases serum soluble receptor for advanced glycation end-products in type 2 diabetes. *Diabetologia*. 2007;50(9):1819-1825.

Tang, T. S., Brown, M. B., Funnell, M. M., and Anderson, R. M. Social support, quality of life, and self-care behaviors among African Americans with type 2 diabetes. *Diabetes Educator*. 2008;34(2):266-276.

Tangelder, G. J., Van der Heijde, R. G., Polak, B. C., and Ringens, P. J. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. *Investigative Ophthalmology & Visual Science*. 2008;49(6):2627-2634.

Tapp, R. J., O'Neil, A., Shaw, J. E., Zimmet, P. Z., Oldenburg, B. F., and AusDiab Study, Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Diabetes Care*. 2010;33(4):757-762.

Tapp, R. J., Tikellis, G., Wong, T. Y., Harper, C. A., Zimmet, P. Z., Shaw, J. E., Australian Diabetes, Obesity, and Lifestyle Study, Group. Longitudinal association of glucose metabolism with retinopathy: results from the Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Diabetes Care*. 2008;31(7):1349-1354.

Targher, G., Bertolini, L., Zenari, L., Lippi, G., Pichiri, I., Zoppini, G., Muggeo, M., and Arcaro, G. Diabetic retinopathy is associated with an increased incidence of cardiovascular events in Type 2 diabetic patients. *Diabetic Medicine*. 2008;25(1):45-50.

Tarini, J. and Wolever, T. M. The fermentable fibre inulin increases postprandial serum short-chain fatty acids and reduces free-fatty acids and ghrelin in healthy subjects. *Applied Physiology, Nutrition, & Metabolism = Physiologie Appliquee, Nutrition et Metabolisme*. 2010;35(1):9-16.

Tarride, J. E., Hopkins, R., Blackhouse, G., Bowen, J. M., Bischof, M., Von Keyserlingk, C., O'Reilly, D., Xie, F., and Goeree, R. A review of methods used in long-term cost-effectiveness models of diabetes mellitus treatment. *Pharmacoeconomics*. 2010;28(4):255-277.

Task Force for, Diagnosis, Treatment of Pulmonary Hypertension of European Society of, Cardiology, European Respiratory, Society, International Society of, Heart, Lung, Transplantation, Galie, N., Hoeper, M. M., Humbert, M., Torbicki, A., Vachiery, J. L., Barbera, J. A., Beghetti, M., Corris, P., Gaine, S., Gibbs, J. S., Gomez-Sanchez, M. A., Jondeau, G., Klepetko, W., Opitz, C., Peacock, A., Rubin, L., Zellweger, M., and Simonneau, G. Guidelines for the diagnosis and treatment of pulmonary hypertension. *European Respiratory Journal*. 2009;34(6):1219-1263.

Taskinen Mr, Sullivan D. R. E. Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate. *Arteriosclerosis, thrombosis, and vascular biology*. 2009;29(6):950-955.

Taton, J., Piatkiewicz, P., and Czech, A. Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus?. *Endokrynologia Polska*. 2010;61(1):75-81.

Tatti, P., Arrigoni, F., Longobardi, A., Costanza, F., Di Blasi, P., and Merante, D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. *Clinical Drug Investigation*. 2008;28(5):327-332.

Taubes, G. Diabetes. Paradoxical effects of tightly controlled blood sugar. *Science*. 2008;322(5900):365-367.

Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A., Pirraglia, P. A., and Wu, W. C. Pharmacist-led group medical appointment model in type 2 diabetes. *Diabetes Educator*. 2010;36(1):109-117.

Taylor, C. and Hobbs, F. D. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. *British Journal of General Practice*. 2009;59(564):520-524.

Taylor, J. D., Fletcher, J. P., and Tiarks, J. Impact of physical therapist-directed exercise counseling combined with fitness center-based exercise training on muscular strength and exercise capacity in people with type 2 diabetes: a randomized clinical trial. *Physical Therapy*. 2009;89(9):884-892.

Taylor, J. D. The impact of a supervised strength and aerobic training program on muscular strength and aerobic capacity in individuals with type 2 diabetes. *Journal of Strength & Conditioning Research*. 2007;21(3):824-830.

Taylor, J. D. The impact of electronic mail versus print delivery of an exercise program on muscular strength and aerobic capacity in people with type 2 diabetes. *Journal of Strength & Conditioning Research*. 2008;22(5):1696-1704.

Taylor, J. R. and Campbell, K. M. Diabetes drug update: how 4 new options stack up. *Journal of Family Practice*. 2007;56(3):207-215.

Teeuw, W. J., Gerdes, V. E., and Loos, B. G. Effect of periodontal treatment on glycemic control of diabetic patients: a systematic review and meta-analysis. *Diabetes Care*. 2010;33(2):421-427.

Tekin, A., Tekin, G., Sezgin, A. T., and Muderrisoglu, H. Short- and long-term effect of simvastatin therapy on the heterogeneity of cardiac repolarization in diabetic patients. *Pharmacological Research*. 2008;57(5):393-397.

Tenenbaum, A., Fisman, E. Z., Motro, M., and Adler, Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. *Advances in Cardiology*. 2008;45:127-153.

Tentolouris, N., Papazafiropoulou, A., Moyssakis, I., Liatis, S., Perrea, D., Kostakis, M., and

Katsilambros, N. Metabolic syndrome is not associated with reduction in aortic distensibility in subjects with type 2 diabetes mellitus. *Cardiovascular Diabetology*. 2008;7:1.

Teramoto, T., Yamada, N., Shirai, K., and Saito, Y. Effects of pioglitazone hydrochloride on Japanese patients with type 2 diabetes mellitus. *Journal of Atherosclerosis & Thrombosis*. 2007;14(2):86-93.

Terra, S. G., Francone, O. L., Contant, C. F., Gao, X., Lewin, A. J., and Nguyen, T. T. Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus. *American Journal of Cardiology*. 2008;102(4):434-439.

Tervaert, T. W., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., Joh, K., Noel, L. H., Radhakrishnan, J., Seshan, S. V., Bajema, I. M., Bruijn, J. A., and Renal Pathology, Society. Pathologic classification of diabetic nephropathy. *Journal of the American Society of Nephrology*. 2010;21(4):556-563.

Tesch, G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. *American Journal of Physiology - Renal Physiology*. 2008;294(4):F697-F701.

Tessari, P., Kiwanuka, E., Cristini, M., Zaramella, M., Enslen, M., Zurlo, C., and Garcia-Rodenas, C. Slow versus fast proteins in the stimulation of beta-cell response and the activation of the entero-insular axis in type 2 diabetes. *Diabetes/Metabolism Research Reviews*. 2007;23(5):378-385.

Thomann, R., Lenherr, C., and Keller, U. Glycaemic control in hospitalised diabetic patients at the University Hospital Basel in 2002 and in 2005. *Swiss Medical Weekly*. 2009;139(37-38):547-552.

Thomas, Diana and Elliott, Elizabeth J. Low glycaemic index, or low glycaemic load, diets for diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2009;1:1.

Thomas, G. N. and Tomlinson, B. Prevention of macrovascular disease in type 2 diabetic patients: blockade of the renin-angiotensin-aldosterone system. *Current Diabetes Reviews*. 2008;4(1):63-78.

Thomas, G., Rojas, M. C., Epstein, S. K., Balk, E. M., Liangos, O., and Jaber, B. L. Insulin therapy and acute kidney injury in critically ill patients a systematic review. *Nephrology Dialysis Transplantation*. 2007;22(10):2849-2855.

Thomaseth, K., Pavan, A., Berria, R., Glass, L., DeFronzo, R., and Gastaldelli, A. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. *Computer Methods & Programs in Biomedicine*. 2008;89(2):132-140.

Thongtang, N. and Sriwijitkamol, A. Incretins: the novel therapy of type 2 diabetes. *Journal of the Medical Association of Thailand*. 2008;91(6):943-954.

Thorand, B., Baumert, J., Kolb, H., Meisinger, C., Chambless, L., Koenig, W., and Herder, C. Sex differences in the prediction of type 2 diabetes by inflammatory markers: results from the MONICA/KORA Augsburg case-cohort study, 1984-2002. *Diabetes Care*. 2007;30(4):854-860.

Thornberry, N. A. and Weber, A. E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Current Topics in Medicinal Chemistry*. 2007;7(6):557-568.

Thornit, D. N., Sander, B., la Cour, M., and Lund-Andersen, H. The effects of peroral glycerol on plasma osmolarity in diabetic patients and healthy individuals. *Basic & Clinical Pharmacology & Toxicology*. 2009;105(5):289-293.

Tibaldi, J. T. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice. *Advances in Therapy*. 2007;24(6):1348-1356.

Tibaldi, J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. *American Journal of Medicine*. 2008;121(6 Suppl):S20-S29.

Tiberti, C., Giordano, C., Locatelli, M., Bosi, E., Bottazzo, G. F., Buzzetti, R., Cucinotta, D., Galluzzo, A., Falorni, A., and Dotta, F. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes*. 2008;57(5):1276-1283.

Tien, K. J., Hung, H. C., Hsiao, J. Y., Hsu, S. C., Hsin, S. C., Shin, S. J., and Hsieh, M. C. Effectiveness of comprehensive diabetes care program in Taiwanese with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;79(2):276-283.

Tiessen, R. G., Castaigne, J. P., Dreyfus, J. F., Nemansky, M., Kruizinga, H. H., and van Vliet, A. A. Pharmacokinetics and tolerability of a novel long-acting glucagon-like peptide-1 analog, CJC-1131, in healthy and diabetic subjects. *International Journal of Clinical Pharmacology & Therapeutics*. 2008;46(9):443-452.

Tikhonova, I. G., Sum, C. S., Neumann, S., Engel, S., Raaka, B. M., Costanzi, S., and Gershengorn, M. C. Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. *Journal of Medicinal Chemistry*. 2008;51(3):625-633.

Tiwari, A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. *Current Opinion in Investigational Drugs*. 2009;10(10):1091-1104.

Tkac, I. Effect of intensive glycemic control on cardiovascular outcomes and all-cause mortality in type 2 diabetes: Overview and metaanalysis of five trials. *Diabetes Research & Clinical Practice*. 2009;86 Suppl 1:S57-S62.

Tobe, S., Vincent, L., Wentworth, J., Hildebrandt, D., Kiss, A., Perkins, N., Hartman, S., Ironstand, L., Hoppe, J., Hunter, K., and Pylypchuk, G. Blood pressure 2 years after a chronic disease management intervention study. *International Journal of Circumpolar Health*. 2010;69(1):50-60.

Tofe Povedano, S. and Garcia De La Villa, B. 24-hour and nighttime blood pressures in type 2 diabetic hypertensive patients following morning or evening administration of olmesartan. *Journal of Clinical Hypertension*. 2009;11(8):426-431.

Toft, A. D. European Association for the Study of Diabetes--43rd Annual Meeting. Therapeutic approaches: Part 2. 18-21 September 2007, Amsterdam, the Netherlands. *Idrugs*. 2007;10(11):769-771.

Toledo, F. G., Menshikova, E. V., Ritov, V. B., Azuma, K., Radikova, Z., DeLany, J., and Kelley, D. E. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. *Diabetes*. 2007;56(8):2142-2147.

Tomlin, A. M., Dovey, S. M., and Tilyard, M. W. Risk factors for hospitalization due to diabetes complications. *Diabetes Research & Clinical Practice*. 2008;80(2):244-252.

Toobert, D. J., Glasgow, R. E., Strycker, L. A., Barrera, M., Jr., Ritzwoller, D. P., and Weidner, G. Long-term effects of the Mediterranean lifestyle program: a randomized clinical trial for postmenopausal women with type 2 diabetes. *International Journal of Behavioral Nutrition & Physical Activity*. 2007;4:1.

Toplak, H. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study. *International journal of obesity (2005)*. 2007;31(1):138-146.

Toprak, O. Conflicting and new risk factors for contrast induced nephropathy. *Journal of Urology*. 2007;178(6):2277-2283.

Torp-Pedersen, C., Caterson, I., Coutinho, W., Finer, N., Van Gaal, L., Maggioni, A., Sharma, A., Brisco, W., Deaton, R., Shepherd, G., James, P., and investigators, Scout. Cardiovascular responses to weight management and sibutramine in high-risk subjects: an analysis from the SCOUT trial. *European Heart Journal*. 2007;28(23):2915-2923.

Toth, P. P. The role of statins in managing diabetic dyslipidemia. *Journal of Family Practice*. 2010;59(5 Suppl):S23-S29.

Tousoulis, D. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmetrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. *Heart (British Cardiac Society)*. 2007;93(2):244-246.

Trial watch: SGLT2 inhibitor shows promise in type 2 diabetes. *Nature Reviews*. 2010;Drug Discovery. 9(3):182.

Triyanti, K., Suhardjono, Soewondo, P., and Shatri, H. Renal function decrement in type 2 diabetes mellitus patients in Cipto Mangunkusumo Hospital. *Acta Medica Indonesiana*. 2008;40(4):192-200.

Tropeano, A. I., Katsahian, S., Molle, D., Grimaldi, A., and Laurent, S. Lowering of brachial pulse pressure in 9379 hypertensives with type 2 diabetes and reduction of cardiovascular events. *Blood Pressure*. 2008;17(1):26-33.

True, M. W. An analysis of dosing equivalence of insulin detemir and insulin glargine: more evidence?. *Journal of Diabetes Science & Technology*. 2010;4(1):155-157.

Trujillo, J. M., Barsky, E. E., Greenwood, B. C., Wahlstrom, S. A., Shaykevich, S., Pendergrass, M. L., and Schnipper, J. L. Improving glycemic control in medical inpatients: a pilot study. *Journal of Hospital Medicine (Online)*. 2008;3(1):55-63.

Tsai, C. Y., Tung, T. H., Woung, L. C., Liu, J. H., Lee, F. L., Shih, H. C., Chen, S. J., and Chou, P. Population-based study of cataract surgery among patients with type 2 diabetes in Kinmen, Taiwan. *Canadian Journal of Ophthalmology*. 2007;42(2):262-267.

Tsang, T., Orr, R., Lam, P., Comino, E. J., and Singh, M. F. Health benefits of Tai Chi for older patients with type 2 diabetes: the "Move It For Diabetes study"--a randomized controlled trial. *Clinical Interventions In Aging*. 2007;2(3):429-439.

Tsang, T., Orr, R., Lam, P., Comino, E., and Singh, M. F. Effects of Tai Chi on glucose homeostasis and insulin sensitivity in older adults with type 2 diabetes: a randomised double-blind sham-exercise-controlled trial. *Age & Ageing*. 2008;37(1):64-71.

Tseng, C. H., Chong, C. K., Tseng, C. P., and Tai, T. Y. The association between urinary albumin excretion and ankle-brachial index in elderly Taiwanese patients with type 2 diabetes mellitus. *Age & Ageing*. 2008;37(1):77-82.

Tseng, C. H., Chong, C. K., Tseng, C. P., Shau, W. Y., and Tai, T. Y. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. *Circulation Journal*. 2008;72(9):1419-1424.

Tsilchorozidou, T., Batterham, R. L., and Conway, G. S. Metformin increases fasting plasma peptide tyrosine tyrosine (PYY) in women with polycystic ovarian syndrome (PCOS). *Clinical Endocrinology*. 2008;69(6):936-942.

Tsuchiya, K., Akaza, I., Yoshimoto, T., and Hirata, Y. Pioglitazone improves endothelial function with increased adiponectin and high-density lipoprotein cholesterol levels in type 2 diabetes. *Endocrine Journal*. 2009;56(5):691-698.

Tudiver, F. Primary care providers' perceptions of home diabetes telemedicine care in the IDEATel project. *The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association*. 2007;23(1):55-61.

Tung, T. H., Shih, H. C., Chen, S. J., Chou, P., Liu, C. M., and Liu, J. H. Economic evaluation of screening for diabetic retinopathy among Chinese type 2 diabetics: a community-based study in

Kinmen, Taiwan. *Journal of Epidemiology*. 2008;18(5):225-233.

Tung, T. H., Shih, H. C., Tsai, S. T., Chou, P., Chen, S. J., Lee, F. L., Chuang, S. Y., and Liu, J. H. A community-based study of the relationship between insulin resistance/beta-cell dysfunction and diabetic retinopathy among type II diabetics in Kinmen, Taiwan. *Ophthalmic Epidemiology*. 2007;14(3):148-154.

Turkmen, Kemal Y. Effects of rosiglitazone on plasma brain natriuretic peptide levels and myocardial performance index in patients with type 2 diabetes mellitus. *Acta Diabetologica*. 2007;44(3):149-156.

Turnacilar, M., Sancar, M., Apikoglu-Rabus, S., Hursitoglu, M., and Izzettin, F. V. Improvement of diabetes indices of care by a short pharmaceutical care program. *Pharmacy World & Science*. 2009;31(6):689-695.

Turnbull, F. M., Abaira, C., Anderson, R. J., Byington, R. P., Chalmers, J. P., Duckworth, W. C., Evans, G. W., Gerstein, H. C., Holman, R. R., Moritz, T. E., Neal, B. C., Ninomiya, T., Patel, A. A., Paul, S. K., Travert, F., and Woodward, M. Intensive glucose control and macrovascular outcomes in type 2 diabetes. *Diabetologia*. 2009;52(11):2288-2298.

Turner-McGrievy, G. M., Barnard, N. D., Cohen, J., Jenkins, D. J., Gloede, L., and Green, A. A. Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-fat vegan diet or a conventional diabetes diet for 22 weeks. *Journal of the American Dietetic Association*. 2008;108(10):1636-1645.

Tuttle, K. R. Protein kinase C-beta inhibition for diabetic kidney disease. *Diabetes Research & Clinical Practice*. 2008;82 Suppl 1:S70-S74.

Type 2 diabetes and HbA1c targets. *Prescrire International*. 2008;17(98):254.

Type 2 diabetes: target HbA1c of about 7%. *Prescrire International*. 2009;18(102):177.

Tzoulaki, I., Molokhia, M., Curcin, V., Little, M. P., Millett, C. J., Ng, A., Hughes, R. I., Khunti, K., Wilkins, M. R., Majeed, A., and Elliott, P. Risk of cardiovascular disease and all cause mortality among patients with type 2 diabetes prescribed oral antidiabetes drugs: retrospective cohort study using UK general practice research database. *Bmj*. 2009;339:b4731.

Uchigata, Y., Otani, T., Takaike, H., Miura, J., Osawa, M., Tukahara, S., Kasahara, T., and Iwamoto, Y. Time-course changes in clinical features of early-onset Japanese type 1 and type 2 diabetes: TWMU hospital-based study. *Diabetes Research & Clinical Practice*. 2008;82(1):80-86.

Uehara, Y., Makino, H., Seiki, K., Urade, Y., and Kidney, L. Pgds Clinical Research. Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study. *Nephrology Dialysis Transplantation*. 2009;24(2):475-482.

Ueta, I., Saito, Y., Hosoe, M., Okamoto, M., Ohkita, H., Shirai, S., Tamura, H., and Jinno, K. Breath acetone analysis with miniaturized sample preparation device: in-needle preconcentration and subsequent determination by gas chromatography-mass spectroscopy. *Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences*. 2009;877(24):2551-2556.

Ugur-Altun, B., Altun, A., Guldiken, S., Tatli, E., Kara, M., and Tugrul, A. Silent myocardial ischemia in middle-aged asymptomatic patients with type 2 diabetes in Turkish population. *Angiology*. 2007;58(5):535-542.

Ukinc, K., Ersoz, H. O., Erem, C., Hacıhasanoglu, A. B., and Karti, S. S. Effects of one year simvastatin and atorvastatin treatments on acute phase reactants in uncontrolled type 2 diabetic patients. *Endocrine*. 2009;35(3):380-388.

Ulrich, H., Snyder, B., and Garg, S. K. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. *Vascular Health & Risk Management*. 2007;3(3):245-254.

Umpierrez, G. E., Hor, T., Smiley, D., Temponi, A., Umpierrez, D., Ceron, M., Munoz, C., Newton, C., Peng, L., and Baldwin, D. Comparison of inpatient insulin regimens with detemir plus aspart versus neutral protamine hagedorn plus regular in medical patients with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(2):564-569.

Umpierrez, G. E., Smiley, D., Robalino, G., Peng, L., Kitabchi, A. E., Khan, B., Le, A., Quyyumi, A., Brown, V., and Phillips, L. S. Intravenous intralipid-induced blood pressure elevation and endothelial dysfunction in obese African-Americans with type 2 diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(2):609-614.

Umpierrez, G. E., Smiley, D., Zisman, A., Prieto, L. M., Palacio, A., Ceron, M., Puig, A., and Mejia, R. Randomized study of basal-bolus insulin therapy in the inpatient management of patients with type 2 diabetes (RABBIT 2 trial). *Diabetes Care*. 2007;30(9):2181-2186.

Unger, J. and Nadeau, D. A. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. *Journal of Family Practice*. 2007;56(12 Suppl New):S4-S10.

Unger, J. and Parkin, C. G. Type 2 diabetes: an expanded view of pathophysiology and therapy. *Postgraduate Medicine*. 2010;122(3):145-157.

Unger, J. Diagnosis and management of type 2 diabetes and prediabetes. *Primary Care; Clinics in Office Practice*. 34(4):731-759.

Urdea, M., Kolberg, J., Wilber, J., Gerwien, R., Moler, E., Rowe, M., Jorgensen, P., Hansen, T., Pedersen, O., Jorgensen, T., and Borch-Johnsen, K. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). *Journal of Diabetes Science & Technology*. 2009;3(4):748-755.

Ushakova, O., Sokolovskaya, V., Morozova, A., Valeeva, F., Zanozina, O., Sazonova, O., Zhadanova, E., Starceva, M., Kazakova, E., Saifullina, M., Shapiro, I., Tarasov, A., Al-Tayar, B., and Starkova, N. Comparison of biphasic insulin aspart 30 given three times daily or twice daily in combination with metformin versus oral antidiabetic drugs alone in patients with poorly controlled type 2 diabetes: a 16-week, randomized, open-label, parallel-group trial conducted in russia. *Clinical Therapeutics*. 2007;29(11):2374-2384.

Ustundag, A., Tugrul, A., Ustundag, S., Sut, N., and Demirkan, B. The effects of spironolactone on nephron function in patients with diabetic nephropathy. *Renal Failure*. 2008;30(10):982-991.

Usui, I., Fujisaka, S., Yamazaki, K., Takano, A., Murakami, S., Yamazaki, Y., Urakaze, M., Hachiya, H., Takata, M., Senda, S., Iwata, M., Satoh, A., Sasaoka, T., Ak, N. D., Temaru, R., and Kobayashi, M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. *Diabetes Research & Clinical Practice*. 2007;77(2):210-214.

Utz, S. W., Williams, I. C., Jones, R., Hinton, I., Alexander, G., Yan, G., Moore, C., Blankenship, J., Steeves, R., and Oliver, M. N. Culturally tailored intervention for rural African Americans with type 2 diabetes. *Diabetes Educator*. 2008;34(5):854-865.

Uzu, T. Effects of high sodium intake and diuretics on the circadian rhythm of blood pressure in type 2 diabetic patients treated with an angiotensin II receptor blocker. *Clinical and experimental nephrology*. 2009;13(4):300-306.

Uzu, T. Reduction of microalbuminuria in patients with type 2 diabetes: the Shiga Microalbuminuria Reduction Trial (SMART). Shiga Microalbuminuria Reduction Trial (SMART) Group. *Diabetes Care*. 2007;30(6):1581-1583.

Uzunlulu, M. and Oguz, A. Is metabolic syndrome a condition independent of prediabetes and type 2 diabetes mellitus? A report from Turkey. *Endocrine Journal*. 2007;54(5):745-750.

Vahatalo, M., Ronnema, T., and Viikari, J. Recognition of fasting or overall hyperglycaemia when starting insulin treatment in patients with type 2 diabetes in general practice. *Scandinavian Journal of Primary Health Care*. 2007;25(3):147-153.

Valdes, S., Botas, P., Delgado, E., Alvarez, F., and Cadorniga, F. D. Does the new American Diabetes Association definition for impaired fasting glucose improve its ability to predict type 2 diabetes mellitus in Spanish persons? The Asturias Study. *Metabolism: Clinical & Experimental*. 2008;57(3):399-403.

Valensi, P. and Cosson, E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. *Diabetes & Metabolism*. 2010;36(2):91-96.

Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Wenying, Y., and Panel, Improve Study Group. The IMPROVE study--a multinational, observational study in type 2 diabetes: baseline characteristics from eight national cohorts.[Erratum appears in *Int J Clin Pract*. 2009 Mar;63(3):532]. *International Journal of Clinical Practice*. 2008;62(11):1809-1819.

Valensi, P. Effect of candesartan cilexetil on carotid intima-media thickness in hypertensive type 2 diabetic patients. MITEC study: Design and baseline characteristics. *British Journal of Diabetes and Vascular Disease*. 2007;7(1):18-24.

Valentine, W. J., Bottomley, J. M., Palmer, A. J., Brandle, M., Foos, V., Williams, R., Dormandy, J. A., Yates, J., Tan, M. H., Massi-Benedetti, M., and Group, P. ROactive Study. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. *Diabetic Medicine*. 2007;24(9):982-1002.

Valentine, W. J., Erny-Albrecht, K. M., Ray, J. A., Roze, S., Cobden, D., and Palmer, A. J. Therapy conversion to insulin detemir among patients with type 2 diabetes treated with oral agents: a modeling study of cost-effectiveness in the United States. *Advances in Therapy*. 2007;24(2):273-290.

Valentine, W. J., Goodall, G., Aagren, M., Nielsen, S., Palmer, A. J., and Erny-Albrecht, K. Evaluating the cost-effectiveness of therapy conversion to insulin detemir in patients with type 2 diabetes in Germany: a modelling study of long-term clinical and cost outcomes. *Advances in Therapy*. 2008;25(6):567-584.

Vallance, J. H., Wilson, P. J., Leese, G. P., McAlpine, R., MacEwen, C. J., and Ellis, J. D. Diabetic retinopathy: more patients, less laser: a longitudinal population-based study in Tayside, Scotland. *Diabetes Care*. 2008;31(6):1126-1131.

van Avendonk, M. J. and Rutten, G. E. Insulin therapy in type 2 diabetes: what is the evidence?. *Diabetes, Obesity & Metabolism*. 2009;11(5):415-432.

van Bruggen, J. A., Gorter, K. J., Stolk, R. P., and Rutten, G. E. Shared and delegated systems are not quick remedies for improving diabetes care: a systematic review. *Primary care diabetes*. 2007;1(2):59-68.

van der Linden, M. W., Plat, A. W., Erkens, J. A., Emneus, M., and Herings, R. M. Large impact of antidiabetic drug treatment and hospitalizations on economic burden of diabetes mellitus in The Netherlands during 2000 to 2004. *Value in Health*. 2009;12(6):909-914.

van der Meer Rw, Rijzewijk. Pioglitazone improves cardiac function and alters myocardial substrate metabolism without affecting cardiac triglyceride accumulation and high-energy phosphate metabolism in patients with well-controlled type 2 diabetes mellitus. *Circulation*. 2009;119(15):2069-2077.

Van Gaal, L. F., Gutkin, S. W., and Nauck, M. A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. *European Journal of Endocrinology*. 2008;158(6):773-784.

van Hateren, K. J., Landman, G. W., Kleefstra, N., Logtenberg, S. J., Groenier, K. H., Kamper, A. M., Houweling, S. T., and Bilo, H. J. The lipid profile and mortality risk in elderly type 2 diabetic patients: a ten-year follow-up study (ZODIAC-13). *PLoS ONE [Electronic Resource]*. 2009;4(12):e8464.

van, Bruggen R. Implementation of locally adapted guidelines on type 2 diabetes. *Family Practice*. 2008;25(6):430-437.

van, Bruggen R. Refill adherence and polypharmacy among patients with type 2 diabetes in general practice. *Pharmacoepidemiology and drug safety*. 2009;18(11):983-991.

van, Doorn M. Evaluation of metabolite profiles as biomarkers for the pharmacological effects of thiazolidinediones in Type 2 diabetes mellitus patients and healthy volunteers. *British Journal of Clinical Pharmacology*. 2007;63(5):562-574.

van, Hoek M. Role of plasma adiponectin on the HDL-cholesterol raising effect of atorvastatin in patients with type 2 diabetes. *Current medical research and opinion*. 2009;25(1):93-101.

Vancea Dm, Vancea J. N. P. Effect of frequency of physical exercise on glycemic control and body composition in type 2 diabetic patients. *Arquivos Brasileiros de Cardiologia*. 2009;92(1):23-30.

VanDeKoppel, S., Choe, H. M., and Sweet, B. V. Managed care perspective on three new agents for type 2 diabetes. *Journal of Managed Care Pharmacy*. 2008;14(4):363-380.

Vanschoonbeek, K., Lansink, M., van Laere, K. M., Senden, J. M., Verdijk, L. B., and van Loon, L. J. Slowly digestible carbohydrate sources can be used to attenuate the postprandial glycemic response to the ingestion of diabetes-specific enteral formulas. *Diabetes Educator*. 2009;35(4):631-640.

Vanzetto, G., Boizel, R., Halimi, S., Ormezzano, O., Belle, L., Fagret, D., and Machecourt, J. Effects of a myocardial ischaemia-guided therapeutic program on survival and incidence of coronary events in asymptomatic patients with diabetes: the ARCADIA study. *Diabetes & Metabolism*. 2007;33(6):459-465.

Vargas, R. B., Mangione, C. M., Asch, S., Keesey, J., Rosen, M., Schonlau, M., and Keeler, E. B. Can a chronic care model collaborative reduce heart disease risk in patients with diabetes?. *Journal of General Internal Medicine*. 2007;22(2):215-222.

Varghese, A., Yee, M. S., Chan, C. F., Crowe, L. A., Keenan, N. G., Johnston, D. G., and Pennell, D. J. Effect of rosiglitazone on progression of atherosclerosis: insights using 3D carotid cardiovascular magnetic resonance. *Journal of Cardiovascular Magnetic Resonance*. 2009;11(1):24.

Varma, R., Macias, G. L., Torres, M., Klein, R., Pena, F. Y., Azen, S. P., and Los Angeles Latino Eye Study, Group. Biologic risk factors associated with diabetic retinopathy: the Los Angeles Latino Eye Study. *Ophthalmology*. 2007;114(7):1332-1340.

Vascular and renal benefits are additive using intensive blood pressure control and incremental glucose control in type 2 diabetic patients. *Cardiovascular Journal of Africa*. 2008;19(5):284-286.

Vasudevan, M. M. and Ballantyne, C. M. Advances in lipid testing and management in patients with diabetes mellitus. *Endocrine Practice*. 2009;15(6):641-652.

Vega-Lopez, S. and Mayol-Kreiser, S. N. Use of the glycemic index for weight loss and glycemic control: a review of recent evidence. *Current Diabetes Reports*. 2009;9(5):379-388.

Velazquez, Lopez L. Effect of protein restriction diet on renal function and metabolic control in patients with type 2 diabetes: a randomized clinical trial. *Nutricion hospitalaria : organo oficial de la Sociedad Espanola de Nutricion Parenteral y Enteral*. 2008;23(2):141-147.

Velojic-Golubovic, M. Biphasic insulin aspart 30: better glycemic control than with premixed human insulin 30 in obese patients with Type 2 diabetes. *Journal of Endocrinological Investigation*.

2009;32(1):23-27.

Venables, M. C. and Jeukendrup, A. E. Physical inactivity and obesity: links with insulin resistance and type 2 diabetes mellitus. *Diabetes/Metabolism Research Reviews*. 2009;25 Suppl 1:S18-S23.

Verges, B., Florentin, E., Baillot-Rudoni, S., Monier, S., Petit, J. M., Rageot, D., Gambert, P., and Duvillard, L. Effects of 20 mg rosuvastatin on VLDL1-, VLDL2-, IDL- and LDL-ApoB kinetics in type 2 diabetes. *Diabetologia*. 2008;51(8):1382-1390.

Verges, B., Florentin, E., Baillot-Rudoni, S., Petit, J. M., Brindisi, M. C., Pais de Barros, J. P., Lagrost, L., Gambert, P., and Duvillard, L. Rosuvastatin 20 mg restores normal HDL-apoA-I kinetics in type 2 diabetes. *Journal of Lipid Research*. 2009;50(6):1209-1215.

Verhoeven, F., van Gemert-Pijnen, L., Dijkstra, K., Nijland, N., Seydel, E., and Stehouder, M. The contribution of teleconsultation and videoconferencing to diabetes care: a systematic literature review. *Journal of Medical Internet Research*. 2007;9(5):e37.

Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., and Yin, D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 1:16-24.

Vgontzas, A. N., Liao, D., Pejovic, S., Calhoun, S., Karataraki, M., and Bixler, E. O. Insomnia with objective short sleep duration is associated with type 2 diabetes: A population-based study. *Diabetes Care*. 2009;32(11):1980-1985.

Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O'Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., and for the, Adopt Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. *Diabetic Medicine*. 2006;23(12):1289-1294.

Vijay Sk, Mishra M. K. Effect of pioglitazone and rosiglitazone on mediators of endothelial dysfunction, markers of angiogenesis and inflammatory cytokines in type-2 diabetes. *Acta Diabetologica*. 2009;46(1):27-33.

Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. *Prescrire International*. 2008;17(97):188.

Villacorta, L., Schopfer, F. J., Zhang, J., Freeman, B. A., and Chen, Y. E. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. *Clinical Science*. 2009;116(3):205-218.

Vilsboll, T., Brock, B., Perrild, H., Levin, K., Lervang, H. H., Kolendorf, K., Krarup, T., Schmitz, O., Zdravkovic, M., Le-Thi, T., and Madsbad, S. Liraglutide, a once-daily human GLP-1 analogue, improves pancreatic B-cell function and arginine-stimulated insulin secretion during hyperglycaemia in patients with Type 2 diabetes mellitus. *Diabetic Medicine*. 2008;25(2):152-156.

Vilsboll, T., Zdravkovic, M., Le-Thi, T., Krarup, T., Schmitz, O., Courreges, J. P., Verhoeven, R., Buganova, I., and Madsbad, S. Liraglutide, a long-acting human glucagon-like peptide-1 analog, given as monotherapy significantly improves glycemic control and lowers body weight without risk of hypoglycemia in patients with type 2 diabetes. *Diabetes Care*. 2007;30(6):1608-1610.

Vincent, D., Pasvogel, A., and Barrera, L. A feasibility study of a culturally tailored diabetes intervention for Mexican Americans. *Biological Research for Nursing*. 2007;9(2):130-141.

Vinik Ai, Zhang Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes. *Diabetes Care*. 2007;30(4):795-800.

Vinik, A. I. and Zhang, Q. Adding insulin glargine versus rosiglitazone: health-related quality-of-life impact in type 2 diabetes.[Erratum appears in *Diabetes Care*. 2007 Jun;30(6):1684]. *Diabetes Care*.

2007;30(4):795-800.

Vinik, A. Advancing therapy in type 2 diabetes mellitus with early, comprehensive progression from oral agents to insulin therapy. *Clinical Therapeutics*. 2007;29 Spec No:1236-1253.

Vistisen, D., Colagiuri, S., Borch-Johnsen, K., and Collaboration, Detect. Bimodal distribution of glucose is not universally useful for diagnosing diabetes. *Diabetes Care*. 2009;32(3):397-403.

Vitolins, M. Z., Anderson, A. M., Delahanty, L., Raynor, H., Miller, G. D., Mobley, C., Reeves, R., Yamamoto, M., Champagne, C., Wing, R. R., Mayer-Davis, E., and Look, Ahead Research Group. Action for Health in Diabetes (Look AHEAD) trial: baseline evaluation of selected nutrients and food group intake. *Journal of the American Dietetic Association*. 2009;109(8):1367-1375.

Vivian, E. M. The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus. *Consultant Pharmacist*. 2007;22(4):320-332.

von, Bibra H. Rosiglitazone, but not glimepiride, improves myocardial diastolic function in association with reduction in oxidative stress in type 2 diabetic patients without overt heart disease. *Diabetes & vascular disease research : official journal of the International Society of Diabetes and Vascular Disease*. 2008;5(4):310-318.

von, Eynatten M. Changes in adiponectin multimer distribution in response to atorvastatin treatment in patients with type 2 diabetes. *Clinical Endocrinology*. 2009;71(1):27-32.

Voruganti, L. P., Punthakee, Z., Van Lieshout, R. J., MacCrimmon, D., Parker, G., Awad, A. G., and Gerstein, H. C. Dysglycemia in a community sample of people treated for schizophrenia: the Diabetes in Schizophrenia in Central-South Ontario (DiSCO) study. *Schizophrenia Research*. 2007;96(1-3):215-222.

Vossler, S., Fullert, S., Schneider, F., Haak, E., Haak, T., Samigullin, R., Tritschler, H., Tooke, J. E., and Konrad, T. Pharmacodynamic effects of orally administered dexlipotam on endothelial function in type 2-diabetic patients. *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(7):385-393.

Vrablik, M., Dobiasova, M., Stulc, T., Kasalova, Z., Dolezalova, R., Prazny, M., Fait, T., and Ceska, R. Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus. *Neuroendocrinology Letters*. 2008;29(1):146-150.

Vrbikova, J., Dvorakova, K., Grimmichova, T., Hill, M., Stanicka, S., Cibula, D., Bendlova, B., Starka, L., and Vondra, K. Prevalence of insulin resistance and prediction of glucose intolerance and type 2 diabetes mellitus in women with polycystic ovary syndrome. *Clinical Chemistry & Laboratory Medicine*. 2007;45(5):639-644.

Vuksan, V., Rogovik, A. L., Jovanovski, E., and Jenkins, A. L. Fiber facts: benefits and recommendations for individuals with type 2 diabetes. *Current Diabetes Reports*. 2009;9(5):405-411.

Wackers, F. J., Chyun, D. A., Young, L. H., Heller, G. V., Iskandrian, A. E., Davey, J. A., Barrett, E. J., Taillefer, R., Wittlin, S. D., Filipchuk, N., Ratner, R. E., Inzucchi, S. E., and Detection of Ischemia in Asymptomatic Diabetics, Investigators. Resolution of asymptomatic myocardial ischemia in patients with type 2 diabetes in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study. *Diabetes Care*. 2007;30(11):2892-2898.

Wadden Ta, West D. S. N. One-year weight losses in the Look AHEAD study: factors associated with success. *Obesity (Silver Spring, Md.)*. 2009;17(4):713-722.

Waeber, B., de la Sierra, A., and Ruilope, L. M. The ADVANCE trial: clarifying the role of perindopril/indapamide fixed-dose combination in the reduction of cardiovascular and renal events in patients with diabetes mellitus. *American Journal of Cardiovascular Drugs*. 2009;9(5):283-291.

Waheed, P., Naveed, A. K., and Farooq, F. Levels of inflammatory markers and their correlation with dyslipidemia in diabetics. *Jcsp, Journal of the College of Physicians & Surgeons - Pakistan*. 2009;19(4):207-210.

Wajcberg, E., Sriwijitkamol, A., Musi, N., DeFronzo, R. A., and Cersosimo, E. Relationship between vascular reactivity and lipids in Mexican-Americans with type 2 diabetes treated with pioglitazone. *Journal of Clinical Endocrinology & Metabolism*. 2007;92(4):1256-1262.

Wajchenberg, B. L. beta-cell failure in diabetes and preservation by clinical treatment. *Endocrine Reviews*. 2007;28(2):187-218.

Wajchenberg, B. L. Clinical approaches to preserve beta-cell function in diabetes. *Advances in Experimental Medicine & Biology*. 2010;654:515-535.

Waksman, J. C. Cardiovascular risk of rosiglitazone: another perspective. *Journal of Pharmacy & Pharmacology*. 2008;60(12):1573-1582.

Wall, B. M., Hardison, R. M., Molitch, M. E., Marroquin, O. C., McGill, J. B., August, P. A., and Group, Bari D. S. High prevalence and diversity of kidney dysfunction in patients with type 2 diabetes mellitus and coronary artery disease: the BARI 2D baseline data. *American Journal of the Medical Sciences*. 2010;339(5):401-410.

Wan, Q., Harris, M. F., Davies, G. P., Jayasinghe, U. W., Flack, J., Georgiou, A., Burns, J. R., and Penn, D. L. Cardiovascular risk management and its impact in Australian general practice patients with type 2 diabetes in urban and rural areas. *International Journal of Clinical Practice*. 2008;62(1):53-58.

Wand, H., Calmy, A., Carey, D. L., Samaras, K., Carr, A., Law, M. G., Cooper, D. A., Emery, S., and Committee, Initio Trial International Coordinating. Metabolic syndrome, cardiovascular disease and type 2 diabetes mellitus after initiation of antiretroviral therapy in HIV infection. *Aids*. 2007;21(18):2445-2453.

Wandell, P. E., de Faire, U., and Hellenius, M. L. High intake of alcohol is associated with newly diagnosed diabetes in 60 years old men and women. *Nutrition Metabolism & Cardiovascular Diseases*. 2007;17(8):598-608.

Wang Xl, Lu J. M. P. Evaluation of the superiority of insulin glargine as basal insulin replacement by continuous glucose monitoring system. *Diabetes research and clinical practice*. 2007;76(1):30-36.

Wang, C. H., Leung, C. H., Liu, S. C., and Chung, C. H. Safety and effectiveness of rosiglitazone in type 2 diabetes patients with nonalcoholic Fatty liver disease. *Journal of the Formosan Medical Association*. 2006;105(9):743-752.

Wang, F., Wang, W., Zhang, R., Lin, Y., Hong, L., Zhao, Y., Ni, Q., Zhang, L., Isiiyasutomo, Tutiutitakuya, Kosikawafusako, Kisitaiti, Havukiyutaka, and Suzukiakio. Clinical observation on physiological and psychological effects of Eight-Section Brocade on type 2 diabetic patients. *Journal of Traditional Chinese Medicine*. 2008;28(2):101-105.

Wang, Han, Deng, Lin Jue, Yue, Jirong, Li, Jun, and Hou, Bin Yan. Prostaglandin E1 for preventing the progression of diabetic kidney disease [Systematic Review]. *Cochrane Database of Systematic Reviews*. 2010;4:4.

Wang, N., Xu, X., Zou, H., Zhu, J., Wang, W., and Ho, P. C. The status of diabetic retinopathy and diabetic macular edema in patients with type 2 diabetes: a survey from Beixinjing District of Shanghai city in China. *Ophthalmologica*. 2008;222(1):32-36.

Wang, T., Xiao, X. H., Li, W. H., Wang, H., Sun, Q., Yuan, T., and Yang, G. H. Effects of glucagon on islet beta cell function in patients with diabetes mellitus. *Chinese Medical Sciences Journal*. 2008;23(2):117-120.

- Wangberg, S. C. An Internet-based diabetes self-care intervention tailored to self-efficacy. *Health Education Research*. 2008;23(1):170-179.
- Wangi, H. and Asdie, R. H. Correlation between lower-extremity functional status and obesity in type-II diabetic patients with and without peripheral arterial disease at Dr. Sardjito Central General Hospital, Yogyakarta. *Acta Medica Indonesiana*. 2009;41(1):2-5.
- Wani, J. H., John-Kalarickal, J., and Fonseca, V. A. Dipeptidyl peptidase-4 as a new target of action for type 2 diabetes mellitus: a systematic review. *Cardiology Clinics*. 2008;26(4):639-648.
- Wanjihia, V. W., Kiplamai, F. K., Waudu, J. N., and Boit, M. K. Post-prandial glucose levels and consumption of omega 3 fatty acids and saturated fats among two rural populations in Kenya. *East African Medical Journal*. 2009;86(6):259-266.
- Wannamethee, S. G. The metabolic syndrome and cardiovascular risk in the British Regional Heart Study. *International Journal of Obesity*. 2008;32 Suppl 2:S25-S29.
- Warunek, D. and Stankovic, A. K. Evaluation of lancets for pain perception and capillary blood volume for glucose monitoring. *Clinical Laboratory Science*. 2008;21(4):215-218.
- Watson, A. J., Kvedar, J. C., Rahman, B., Pelletier, A. C., Salber, G., and Grant, R. W. Diabetes connected health: a pilot study of a patient- and provider-shared glucose monitoring web application. *Journal of Diabetes Science & Technology*. 2009;3(2):345-352.
- Wattana, C., Srisuphan, W., Pothiban, L., and Upchurch, S. L. Effects of a diabetes self-management program on glycemic control, coronary heart disease risk, and quality of life among Thai patients with type 2 diabetes. *Nursing & Health Sciences*. 2007;9(2):135-141.
- Weikert, C., Weikert, S., Schulze, M. B., Pischon, T., Fritsche, A., Bergmann, M. M., Willich, S. N., and Boeing, H. Presence of gallstones or kidney stones and risk of type 2 diabetes. *American Journal of Epidemiology*. 2010;171(4):447-454.
- Weir, M. R., Hollenberg, N. K., Zappe, D. H., Meng, X., Parving, H. H., Viberti, G., and Remuzzi, G. Antihypertensive effects of double the maximum dose of valsartan in African-American patients with type 2 diabetes mellitus and albuminuria. *Journal of Hypertension*. 2010;28(1):186-193.
- Weir, M. R., Levy, D., Crikelair, N., Rocha, R., Meng, X., and Glazer, R. Time to achieve blood-pressure goal: influence of dose of valsartan monotherapy and valsartan and hydrochlorothiazide combination therapy. *American Journal of Hypertension*. 2007;20(7):807-815.
- Weir, M. R., Neutel, J. M., Bhaumik, A., De Obaldia, M. E., and Lapuerta, P. The efficacy and safety of initial use of irbesartan/hydrochlorothiazide fixed-dose combination in hypertensive patients with and without high cardiovascular risk. *Journal of Clinical Hypertension*. 2007;9(12 Suppl 5):23-30.
- Weir, M. R., Yeh, F., Silverman, A., Devereux, R. B., Galloway, J. M., Henderson, J. A., Howard, W. J., Russell, M., Wilson, C., Ratner, R., Sorkin, J., Umans, J. G., Fleg, J. L., Stylianou, M., Lee, E., and Howard, B. V. Safety and feasibility of achieving lower systolic blood pressure goals in persons with type 2 diabetes: the SANDS trial. *Journal of Clinical Hypertension*. 2009;11(10):540-548.
- Weir, M. R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. *Clinical Therapeutics*. 2007;29(9):1803-1824.
- Weires, M. B., Tausch, B., Haug, P. J., Edwards, C. Q., Wetter, T., and Cannon-Albright, L. A. Familiality of diabetes mellitus. *Experimental & Clinical Endocrinology & Diabetes*. 2007;115(10):634-640.
- Weitzman, S., Greenfield, S., Billimek, J., Hava, T., Schwartzman, P., Yehiel, E., Tandeter, H., Eilat-Tsanani, S., and Kaplan, S. H. Improving combined diabetes outcomes by adding a simple patient

intervention to physician feedback: a cluster randomized trial. *Israel Medical Association Journal: Imaj*. 2009;11(12):719-724.

Welch, G., Garb, J., Zagarins, S., Lendel, I., and Gabbay, R. A. Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. *Diabetes Research & Clinical Practice*. 2010;88(1):1-6.

Wells, B. J., Jain, A., Arrigain, S., Yu, C., Rosenkrans, W. A., Jr., and Kattan, M. W. Predicting 6-year mortality risk in patients with type 2 diabetes. *Diabetes Care*. 2008;31(12):2301-2306.

Wens, J., Vermeire, E., Hearnshaw, H., Lindenmeyer, A., Biot, Y., and van Royen, P. Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes: A sub-analysis of a systematic review of randomised controlled trials. *Diabetes Research & Clinical Practice*. 2008;79(3):377-388.

Wenying, Y., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Ligthelm, R., Valensi, P., and Panel, Improve Study Group. Improved glycaemic control with BIAsp 30 in insulin-naive type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. *Current Medical Research & Opinion*. 2009;25(11):2643-2654.

Werner, C., Kamani, C. H., Gensch, C., Bohm, M., and Laufs, U. The peroxisome proliferator-activated receptor-gamma agonist pioglitazone increases number and function of endothelial progenitor cells in patients with coronary artery disease and normal glucose tolerance. *Diabetes*. 2007;56(10):2609-2615.

West, D. S., Dillillo, V., Bursac, Z., Gore, S. A., and Greene, P. G. Motivational interviewing improves weight loss in women with type 2 diabetes. *Diabetes Care*. 2007;30(5):1081-1087.

Weymiller, A. J., Montori, V. M., Jones, L. A., Gafni, A., Guyatt, G. H., Bryant, S. C., Christianson, T. J., Mullan, R. J., and Smith, S. A. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. *Archives of Internal Medicine*. 2007;167(10):1076-1082.

White, J. R., Jr. Do people with diabetes need statins?. *Diabetes Educator*. 2008;34(4):664-673.

White, J. Efficacy and safety of incretin based therapies: clinical trial data. *Journal of the American Pharmacists Association: JAPhA*. 2009;49 Suppl 1:S30-S40.

White, K. M., Terry, D. J., Troup, C., and Rempel, L. A. Behavioral, normative and control beliefs underlying low-fat dietary and regular physical activity behaviors for adults diagnosed with type 2 diabetes and/or cardiovascular disease. *Psychology Health & Medicine*. 2007;12(4):485-494.

White, R. D. The treat-to-target A1C approach to control type 2 diabetes and prevent complications. *Advances in Therapy*. 2007;24(3):545-559.

White, R. O., DeWalt, D. A., Malone, R. M., Osborn, C. Y., Pignone, M. P., and Rothman, R. L. Leveling the field: addressing health disparities through diabetes disease management. *American Journal of Managed Care*. 2010;16(1):42-48.

Whitson, B. A., Leslie, D. B., Kellogg, T. A., Maddaus, M. A., Buchwald, H., Billington, C. J., and Ikramuddin, S. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. *Journal of Surgical Research*. 2007;141(1):31-39.

Whittemore, R. Culturally competent interventions for Hispanic adults with type 2 diabetes: a systematic review. *Journal of Transcultural Nursing*. 2007;18(2):157-166.

Wiedeman, P. E. DPP4V inhibition: promising therapy for the treatment of type 2 diabetes. *Progress in Medicinal Chemistry*. 2007;45:63-109.

Wijesuriya, M., Williams, R., and Yajnik, C. The Kathmandu Declaration: "Life Circle" approach to

prevention and care of diabetes mellitus. *Diabetes Research & Clinical Practice*. 2010;87(1):20-26.

Wikstrom, K., Peltonen, M., Eriksson, J. G., Aunola, S., Ilanne-Parikka, P., Keinanen-Kiukaanniemi, S., Uusitupa, M., Tuomilehto, J., and Lindstrom, J. Educational attainment and effectiveness of lifestyle intervention in the Finnish Diabetes Prevention Study. *Diabetes Research & Clinical Practice*. 2009;86(1):e1-e5.

Wilcox, R., Kupfer, S., Erdmann, E., and investigators, P. ROactive Study. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10).[Erratum appears in *Am Heart J*. 2008 Aug;156(2):255]. *American Heart Journal*. 2008;155(4):712-717.

Wilcox, R. Effects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04). *Stroke; a journal of cerebral circulation*. 2007;38(3):865-873.

Wilcox, R. Effects of pioglitazone on major adverse cardiovascular events in high-risk patients with type 2 diabetes: results from PROspective pioglitAzone Clinical Trial In macro Vascular Events (PROactive 10). *American Heart Journal*. 2008;155(4):712-717.

Wilding, J. P., Gause-Nilsson, I., Persson, A., and Group, Gallant Study. Tesaglitazar, as add-on therapy to sulphonylurea, dose-dependently improves glucose and lipid abnormalities in patients with type 2 diabetes. *Diabetes & Vascular Disease Research*. 2007;4(3):194-203.

Wilding, J. P., Norwood, P., T'Joel, C., Bastien, A., List, J. F., and Fiedorek, F. T. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. *Diabetes Care*. 2009;32(9):1656-1662.

Wilke, M. S., French, M. A., Goh, Y. K., Ryan, E. A., Jones, P. J., and Clandinin, M. T. Synthesis of specific fatty acids contributes to VLDL-triacylglycerol composition in humans with and without type 2 diabetes. *Diabetologia*. 2009;52(8):1628-1637.

Williams, G. C., Lynch, M., and Glasgow, R. E. Computer-assisted intervention improves patient-centered diabetes care by increasing autonomy support. *Health Psychology*. 2007;26(6):728-734.

Williams, M. E., Bolton, W. K., Khalifah, R. G., Degenhardt, T. P., Schotzinger, R. J., and McGill, J. B. Effects of pyridoxamine in combined phase 2 studies of patients with type 1 and type 2 diabetes and overt nephropathy. *American Journal of Nephrology*. 2007;27(6):605-614.

Williams, N. H., Hendry, M., France, B., Lewis, R., and Wilkinson, C. Effectiveness of exercise-referral schemes to promote physical activity in adults: systematic review. *British Journal of General Practice*. 2007;57(545):979-986.

Williams, P. T., Hoffman, K., and La, I. Weight-related increases in hypertension, hypercholesterolemia, and diabetes risk in normal weight male and female runners. *Arteriosclerosis, Thrombosis & Vascular Biology*. 2007;27(8):1811-1819.

Williams, P. T. Vigorous exercise, fitness and incident hypertension, high cholesterol, and diabetes. *Medicine & Science in Sports & Exercise*. 2008;40(6):998-1006.

Williams-Herman, D., Round, E., Swern, A. S., Musser, B., Davies, M. J., Stein, P. P., Kaufman, K. D., and Amatruda, J. M. Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. *BMC Endocrine Disorders*. 2008;8:14.

Williamson, D. A., Rejeski, J., Lang, W., Van Dorsten, B., Fabricatore, A. N., Toledo, K., and Look, Ahead Research Group. Impact of a weight management program on health-related quality of life in overweight adults with type 2 diabetes. *Archives of Internal Medicine*. 2009;169(2):163-171.

Williamson, J. D., Miller, M. E., Bryan, R. N., Lazar, R. M., Coker, L. H., Johnson, J., Cukierman, T.,

Horowitz, K. R., Murray, A., Launer, L. J., and Group, Accord Study. The Action to Control Cardiovascular Risk in Diabetes Memory in Diabetes Study (ACCORD-MIND): rationale, design, and methods. *American Journal of Cardiology*. 2007;99(12A):112i-122i.

Wing, R. R., Jakicic, J., Neiberg, R., Lang, W., Blair, S. N., Cooper, L., Hill, J. O., Johnson, K. C., Lewis, C. E., and Look Ahead Research, Group. Fitness, fatness, and cardiovascular risk factors in type 2 diabetes: look ahead study. *Medicine & Science in Sports & Exercise*. 2007;39(12):2107-2116.

Winkler, K., Ablethausen, C. B., Gimpelewicz, C., Bortolini, M., and Isaacsohn, J. L. Risk reduction and tolerability of fluvastatin in patients with the metabolic syndrome: a pooled analysis of thirty clinical trials. *Clinical Therapeutics*. 2007;29(9):1987-2000.

Winnick, J. J., Gaillard, T., and Schuster, D. P. Resistance training differentially affects weight loss and glucose metabolism of White and African American patients with type 2 diabetes mellitus. *Ethnicity & Disease*. 2008;18(2):152-156.

Winnick, J. J., Sherman, W. M., Habash, D. L., Stout, M. B., Failla, M. L., Belury, M. A., and Schuster, D. P. Short-term aerobic exercise training in obese humans with type 2 diabetes mellitus improves whole-body insulin sensitivity through gains in peripheral, not hepatic insulin sensitivity. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(3):771-778.

Wint, Y. B., Duff, E. M., McFarlane-Anderson, N., O'Connor, A., Bailey, E. Y., and Wright-Pascoe, R. A. Knowledge, motivation and barriers to diabetes control in adults in Jamaica. *West Indian Medical Journal*. 2006;55(5):330-333.

Winterbone Ms, Sampson M. J. S. Pro-oxidant effect of alpha-tocopherol in patients with type 2 diabetes after an oral glucose tolerance test--a randomised controlled trial. *Cardiovascular Diabetology*. 2007;6(8):.

Wittlin, S. D., Marcus, A. O., Weng, C. S., Howard, C. P., Schorr, A. B., and Group, Control Study. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. *Diabetes Technology & Therapeutics*. 2008;10(1):1-10.

Wittmann, I., Molnar, G. A., Wagner, L., Koszegi, T., Wagner, Z., Laczy, B., Tamasko, M., Marko, L., Mohas, M., and Nagy, J. Single dose of acetylsalicylic acid in patients with Type 2 diabetes mellitus and/or chronic renal failure ameliorates anaemia by decreasing the rate of neocytolysis. *Acta Physiologica Hungarica*. 2007;94(1-2):159-166.

Wiviott, S. D., Braunwald, E., Angiolillo, D. J., Meisel, S., Dalby, A. J., Verheugt, F. W., Goodman, S. G., Corbalan, R., Purdy, D. A., Murphy, S. A., McCabe, C. H., Antman, E. M., and Investigators, Triton Timi. Greater clinical benefit of more intensive oral antiplatelet therapy with prasugrel in patients with diabetes mellitus in the trial to assess improvement in therapeutic outcomes by optimizing platelet inhibition with prasugrel-Thrombolysis in Myocardial Infarction 38. *Circulation*. 2008;118(16):1626-1636.

Wlodarczyk, J., Sullivan, D., and Smith, M. Comparison of benefits and risks of rosuvastatin versus atorvastatin from a meta-analysis of head-to-head randomized controlled trials. *American Journal of Cardiology*. 2008;102(12):1654-1662.

Woehl, A., Evans, M., Tetlow, A. P., and McEwan, P. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom. *Cardiovascular Diabetology*. 2008;7:24.

Woerle, H. J., Neumann, C., Zschau, S., Tenner, S., Irsigler, A., Schirra, J., Gerich, J. E., and Goke, B. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. *Diabetes Research & Clinical Practice*. 2007;77(2):280-285.

- Wofford, M. R., King, D. S., and Harrell, T. K. Drug-induced metabolic syndrome. *Journal of Clinical Hypertension*. 2006;8(2):114-119.
- Wolever, T. M., Gibbs, A. L., Mehling, C., Chiasson, J. L., Connelly, P. W., Josse, R. G., Leiter, L. A., Maheux, P., Rabasa-Lhoret, R., Rodger, N. W., and Ryan, E. A. The Canadian Trial of Carbohydrates in Diabetes (CCD), a 1-y controlled trial of low-glycemic-index dietary carbohydrate in type 2 diabetes: no effect on glycated hemoglobin but reduction in C-reactive protein. *American Journal of Clinical Nutrition*. 2008;87(1):114-125.
- Wolever, T. M., Mehling, C., Chiasson, J. L., Josse, R. G., Leiter, L. A., Maheux, P., Rabasa-Lhoret, R., Rodger, N. W., and Ryan, E. A. Low glycaemic index diet and disposition index in type 2 diabetes (the Canadian trial of carbohydrates in diabetes): a randomised controlled trial. *Diabetologia*. 2008;51(9):1607-1615.
- Wolf, A. M., Siadat, M. S., Crowther, J. Q., Nadler, J. L., Wagner, D. L., Cavalieri, S. L., Elward, K. S., and Bovbjerg, V. E. Impact of lifestyle intervention on lost productivity and disability: improving control with activity and nutrition. *Journal of Occupational & Environmental Medicine*. 2009;51(2):139-145.
- Wolf, A. M., Siadat, M., Yaeger, B., Conaway, M. R., Crowther, J. Q., Nadler, J. L., and Bovbjerg, V. E. Effects of lifestyle intervention on health care costs: Improving Control with Activity and Nutrition (ICAN). *Journal of the American Dietetic Association*. 2007;107(8):1365-1373.
- Wolffenbittel, B. H., Klaff, L. J., Bhushan, R., Fahrbach, J. L., Jiang, H., and Martin, S. Initiating insulin therapy in elderly patients with Type 2 diabetes: efficacy and safety of lispro mix 25 vs. basal insulin combined with oral glucose-lowering agents. *Diabetic Medicine*. 2009;26(11):1147-1155.
- Wong, J., Molyneaux, L., Constantino, M., Twigg, S. M., and Yue, D. K. Timing is everything: age of onset influences long-term retinopathy risk in type 2 diabetes, independent of traditional risk factors. *Diabetes Care*. 2008;31(10):1985-1990.
- Wong, T. Y., Liew, G., Tapp, R. J., Schmidt, M. I., Wang, J. J., Mitchell, P., Klein, R., Klein, B. E., Zimmet, P., and Shaw, J. Relation between fasting glucose and retinopathy for diagnosis of diabetes: three population-based cross-sectional studies.[Erratum appears in *Lancet*. 2008 May 31;371(9627):1838]. *Lancet*. 2008;371(9614):736-743.
- Woo, J., Sea, M. M., Tong, P., Ko, G. T., Lee, Z., Chan, J., and Chow, F. C. Effectiveness of a lifestyle modification programme in weight maintenance in obese subjects after cessation of treatment with Orlistat. *Journal of Evaluation in Clinical Practice*. 2007;13(6):853-859.
- Woo, V. C. Dapagliflozin: where does it fit in the treatment of type 2 diabetes?. *Expert Opinion on Pharmacotherapy*. 2009;10(15):2527-2535.
- Worley, M. M. Testing a pharmacist-patient relationship quality model among older persons with diabetes. *Research In Social & Administrative Pharmacy*. 2006;2(1):1-21.
- Wright, J. T., Jr., Bakris, G. L., Bell, D. S., Fonseca, V., Katholi, R. E., McGill, J. B., Messerli, F. H., Phillips, R. A., Raskin, P., Holdbrook, F. K., Lukas, M. A., and Iyengar, M. Lowering blood pressure with beta-blockers in combination with other renin-angiotensin system blockers in patients with hypertension and type 2 diabetes: results from the GEMINI Trial. *Journal of Clinical Hypertension*. 2007;9(11):842-849.
- Wright, S. W., Ammirati, M. J., Andrews, K. M., Brodeur, A. M., Danley, D. E., Doran, S. D., Lillquist, J. S., Liu, S., McClure, L. D., McPherson, R. K., Olson, T. V., Orena, S. J., Parker, J. C., Rocke, B. N., Soeller, W. C., Soglia, C. B., Treadway, J. L., Vanvolkenburg, M. A., Zhao, Z., and Cox, E. D. (3R,4S)-4-(2,4,5-Trifluorophenyl)-pyrrolidin-3-ylamine inhibitors of dipeptidyl peptidase IV: synthesis, in vitro, in vivo, and X-ray crystallographic characterization. *Bioorganic & Medicinal*

Chemistry Letters. 2007;17(20):5638-5642.

Wu, S. F., Courtney, M., Edwards, H., McDowell, J., Shortridge-Baggett, L. M., and Chang, P. J. Self-efficacy, outcome expectations and self-care behaviour in people with type 2 diabetes in Taiwan. *Journal of Clinical Nursing*. 2007;16(11C):250-257.

Wu, T. J., Ou, H. Y., Chou, C. W., Hsiao, S. H., Lin, C. Y., and Kao, P. C. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. *Annals of Clinical & Laboratory Science*. 2007;37(2):158-166.

Wycherley, T. P., Brinkworth, G. D., Noakes, M., Buckley, J. D., and Clifton, P. M. Effect of caloric restriction with and without exercise training on oxidative stress and endothelial function in obese subjects with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(11):1062-1073.

Wycherley, T. P., Noakes, M., Clifton, P. M., Cleanthous, X., Keogh, J. B., and Brinkworth, G. D. A high-protein diet with resistance exercise training improves weight loss and body composition in overweight and obese patients with type 2 diabetes. *Diabetes Care*. 2010;33(5):969-976.

Wyness, L. Understanding the role of diet in type 2 diabetes prevention. *British Journal of Community Nursing*. 2009;14(9):374-379.

Wysham, C., Lush, C., Zhang, B., Maier, H., and Wilhelm, K. Effect of pramlintide as an adjunct to basal insulin on markers of cardiovascular risk in patients with type 2 diabetes. *Current Medical Research & Opinion*. 2008;24(1):79-85.

Xanthos, T., Ekmektzoglou, K. A., and Papadimitriou, L. Reviewing myocardial silent ischemia: specific patient subgroups. *International Journal of Cardiology*. 2008;124(2):139-148.

Xi, G. L., Cheng, J. W., and Lu, G. C. Meta-analysis of randomized controlled trials comparing telmisartan with losartan in the treatment of patients with hypertension. *American Journal of Hypertension*. 2008;21(5):546-552.

Xin, L., Miller, Y. D., and Brown, W. J. A qualitative review of the role of qigong in the management of diabetes. *Journal of Alternative & Complementary Medicine*. 2007;13(4):427-433.

Xu, L., Jiang, C. Q., Lam, T. H., Cheng, K. K., Yue, X. J., Lin, J. M., Zhang, W. S., and Thomas, G. N. Impact of impaired fasting glucose and impaired glucose tolerance on arterial stiffness in an older Chinese population: the Guangzhou Biobank Cohort Study-CVD. *Metabolism: Clinical & Experimental*. 2010;59(3):367-372.

Xu, L., Man, C. D., Charbonnel, B., Meninger, G., Davies, M. J., Williams-Herman, D., Cobelli, C., and Stein, P. P. Effect of sitagliptin, a dipeptidyl peptidase-4 inhibitor, on beta-cell function in patients with type 2 diabetes: a model-based approach. *Diabetes, Obesity & Metabolism*. 2008;10(12):1212-1220.

Xu, W., Li, Y. B., Deng, W. P., Hao, Y. T., and Weng, J. P. Remission of hyperglycemia following intensive insulin therapy in newly diagnosed type 2 diabetic patients: a long-term follow-up study. *Chinese Medical Journal*. 2009;122(21):2554-2559.

Yajima, K., Shimada, A., Hirose, H., Kasuga, A., and Saruta, T. "Low dose" metformin improves hyperglycemia better than acarbose in type 2 diabetics. *The Review of Diabetic Studies*. 2004;1(2):89-94.

Yalcin, B. M., Karahan, T. F., Ozelik, M., and Igde, F. A. The effects of an emotional intelligence program on the quality of life and well-being of patients with type 2 diabetes mellitus. *Diabetes Educator*. 2008;34(6):1013-1024.

Yamada, S., Ano, N., Toda, K., Kitaoka, A., Shiono, K., Inoue, G., Atsuda, K., and Irie, J. Telmisartan but not candesartan affects adiponectin expression in vivo and in vitro. *Hypertension Research* -

Clinical & Experimental. 2008;31(4):601-606.

Yamada, S., Watanabe, M., Funae, O., Atsumi, Y., Suzuki, R., Yajima, K., Nakamura, Y., Kawai, T., Oikawa, Y., and Shimada, A. Effect of combination therapy of a rapid-acting insulin secretagogue (glinide) with premixed insulin in type 2 diabetes mellitus. *Internal Medicine*. 2007;46(23):1893-1897.

Yamada, S., Watanabe, M., Kitaoka, A., Shiono, K., Atsuda, K., Tsukamoto, Y., Kawana, Y., and Irie, J. Switching from premixed human insulin to premixed insulin lispro: a prospective study comparing the effects on glucose control and quality of life. *Internal Medicine*. 2007;46(18):1513-1517.

Yamada, T., Fukatsu, M., Suzuki, S., Wada, T., Yoshida, T., and Joh, T. Fatty liver predicts impaired fasting glucose and type 2 diabetes mellitus in Japanese undergoing a health checkup. *Journal of Gastroenterology & Hepatology*. 2010;25(2):352-356.

Yamakawa, M. and Makimoto, K. Positive experiences of type 2 diabetes in Japanese patients: an exploratory qualitative study. *International Journal of Nursing Studies*. 2008;45(7):1032-1041.

Yamakawa, T., Takano, T., Utsunomiya, H., Kadosono, K., and Okamura, A. Effect of colestimide therapy for glycemic control in type 2 diabetes mellitus with hypercholesterolemia. *Endocrine Journal*. 2007;54(1):53-58.

Yamakoshi, M. and Kawazu, S. Lucica MI urinary myoinositol kit: a new diagnostic test for diabetes mellitus and glucose intolerance. *Molecular Diagnosis & Therapy*. 2008;12(3):189-191.

Yancy, W. S., Jr., Foy, M., Chalecki, A. M., Vernon, M. C., and Westman, E. C. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. *Nutrition & Metabolism*. 2005;2:34.

Yancy, W. S., Jr., Westman, E. C., McDuffie, J. R., Grambow, S. C., Jeffreys, A. S., Bolton, J., Chalecki, A., and Oddone, E. Z. A randomized trial of a low-carbohydrate diet vs orlistat plus a low-fat diet for weight loss. *Archives of Internal Medicine*. 2010;170(2):136-145.

Yang, J. K., Liu, W., Shi, J., and Li, Y. B. An association between subclinical hypothyroidism and sight-threatening diabetic retinopathy in type 2 diabetic patients. *Diabetes Care*. 2010;33(5):1018-1020.

Yang, L., Zhou, Z. G., Tan, S. Z., Huang, G., Jin, P., Yan, X., Li, X., Peng, H., and Hagopian, W. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. *Annals of the New York Academy of Sciences*. 2008;1150:263-266.

Yang, W. Y., Ji, Q. H., Zhu, D. L., Yang, J. K., Chen, L. L., Liu, Z. M., Yu, D. M., and Yan, L. Thrice-daily biphasic insulin aspart 30 may be another therapeutic option for Chinese patients with type 2 diabetes inadequately controlled with oral antidiabetic agents. *Chinese Medical Journal*. 2009;122(14):1704-1708.

Yang, W., Gao, Y., Liu, G., Chen, L., Fu, Z., Zou, D., Feng, P., and Zhao, Z. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. *Current Medical Research & Opinion*. 2010;26(1):101-107.

Yang, W., Ji, Q., Zhu, D., Yang, J., Chen, L., Liu, Z., Yu, D., and Yan, L. Biphasic insulin aspart 30 three times daily is more effective than a twice-daily regimen, without increasing hypoglycemia, in Chinese subjects with type 2 diabetes inadequately controlled on oral antidiabetes drugs. *Diabetes Care*. 2008;31(5):852-856.

Yang, X., Ko, G. T., So, W. Y., Ma, R. C., Kong, A. P., Lam, C. W., Ho, C. S., Chow, C. C., Tong, P. C., Chan, J. C., and Hong Kong Diabetes Registry. Additive interaction of hyperglycemia and albuminuria on risk of ischemic stroke in type 2 diabetes: Hong Kong Diabetes Registry. *Diabetes Care*. 2008;31(12):2294-2300.

Yang, Y. H., He, X. J., Chen, S. R., Wang, L., Li, E. M., and Xu, L. Y. Changes of serum and urine

neutrophil gelatinase-associated lipocalin in type-2 diabetic patients with nephropathy: one year observational follow-up study. *Endocrine*. 2009;36(1):45-51.

Yang, Y. H., Zhang, S., Cui, J. F., Lu, B., Dong, X. H., Song, X. Y., Liu, Y. K., Zhu, X. X., and Hu, R. M. Diagnostic potential of serum protein pattern in Type 2 diabetic nephropathy. *Diabetic Medicine*. 2007;24(12):1386-1392.

Yang, Y. S., Peng, C. H., Lin, C. K., Wang, C. P., and Huang, C. N. Use of serum cystatin C to detect early decline of glomerular filtration rate in type 2 diabetes. *Internal Medicine*. 2007;46(12):801-806.

Yates, T., Davies, M., Brady, E., Webb, D., Gorely, T., Bull, F., Talbot, D., Sattar, N., and Khunti, K. Walking and inflammatory markers in individuals screened for type 2 diabetes. *Preventive Medicine*. 2008;47(4):417-421.

Yazbeck, R., Howarth, G. S., and Abbott, C. A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. *Trends in Pharmacological Sciences*. 2009;30(11):600-607.

Ye, S. D., Zheng, M., Zhao, L. L., Qian, Y., Yao, X. M., Ren, A., Li, S. M., and Jing, C. Y. Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. *European Journal of Clinical Investigation*. 2009;39(11):980-985.

Yeh, H. C., Duncan, B. B., Schmidt, M. I., Wang, N. Y., and Brancati, F. L. Smoking, smoking cessation, and risk for type 2 diabetes mellitus: a cohort study.[Summary for patients in *Ann Intern Med*. 2010 Jan 5;152(1):I-44; PMID: 20048264]. *Annals of Internal Medicine*. 2010;152(1):10-17.

Yener S, Comlekci. Soluble CD40 ligand, plasminogen activator inhibitor-1 and thrombin-activatable fibrinolysis inhibitor-1-antigen in normotensive type 2 diabetic subjects without diabetic complications. Effects of metformin and rosiglitazone. *Medical principles and practice : international journal of the Kuwait University, Health Science Centre*. 2009;18(4):266-271.

Yener, S., Comlekci, A., Akinci, B., Akan, P., Demir, T., Bayraktar, F., and Yesil, S. Serum transforming growth factor-beta 1 levels in normoalbuminuric and normotensive patients with type 2 diabetes. Effect of metformin and rosiglitazone. *Hormones*. 2008;7(1):70-76.

Yeung, V. T., Lee, K. F., Chan, S. H., Ho, L. F., Leung, S. K., Wong, H. Y., and Investigators, Maps. MicroAlbuminuria Prevalence Study (MAPS) in hypertensive type 2 diabetic patients in Hong Kong. *Hong Kong Medical Journal*. 2006;12(3):185-190.

Yilmaz, H., Gursoy, A., Sahin, M., and Guvener Demirag, N. Comparison of insulin monotherapy and combination therapy with insulin and metformin or insulin and rosiglitazone or insulin and acarbose in type 2 diabetes. *Acta Diabetologica*. 2007;44(4):187-192.

Yilmaz, M. I., Axelsson, J., Sonmez, A., Carrero, J. J., Saglam, M., Eyileten, T., Caglar, K., Kirkpantur, A., Celik, T., Oguz, Y., Vural, A., Yenicesu, M., Lindholm, B., and Stenvinkel, P. Effect of renin angiotensin system blockade on pentraxin 3 levels in type-2 diabetic patients with proteinuria. *Clinical Journal of The American Society of Nephrology: CJASN*. 2009;4(3):535-541.

Yki-Jarvinen, H., Juurinen, L., Alvarsson, M., Bystedt, T., Caldwell, I., Davies, M., Lahdenpera, S., Nijpels, G., and Vahatalo, M. Initiate Insulin by Aggressive Titration and Education (INITIATE): a randomized study to compare initiation of insulin combination therapy in type 2 diabetic patients individually and in groups. *Diabetes Care*. 2007;30(6):1364-1369.

Yokoyama, H., Kannno, S., Ishimura, I., and Node, K. Miglitol increases the adiponectin level and decreases urinary albumin excretion in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2007;56(11):1458-1463.

Yokoyama, H., Kawai, K., Kobayashi, M., and Japan Diabetes Clinical Data Management Study, Group. Microalbuminuria is common in Japanese type 2 diabetic patients: a nationwide survey from the

Japan Diabetes Clinical Data Management Study Group (JDDM 10).[Erratum appears in Diabetes Care. 2007 Aug;30(8):2175-6]. Diabetes Care. 2007;30(4):989-992.

Yokoyama, H., Oishi, M., Kawai, K., Sone, H., and Japan Diabetes Clinical Data Management Study, Group. Reduced GFR and microalbuminuria are independently associated with prevalent cardiovascular disease in Type 2 diabetes: JDDM study 16. Diabetic Medicine. 2008;25(12):1426-1432.

Yokoyama, H. Effect of insulin-unstimulated diabetic therapy with miglitol on serum cystatin C level and its clinical significance. Diabetes research and clinical practice. 2009;83(1):77-82.

Yoneda, T., Takeda, Y., Usukura, M., Oda, N., Takata, H., Yamamoto, Y., Karashima, S., and Yamagishi, M. Aldosterone breakthrough during angiotensin II receptor blockade in hypertensive patients with diabetes mellitus. American Journal of Hypertension. 2007;20(12):1329-1333.

Yoo, H. J., An, H. G., Park, S. Y., Ryu, O. H., Kim, H. Y., Seo, J. A., Hong, E. G., Shin, D. H., Kim, Y. H., Kim, S. G., Choi, K. M., Park, I. B., Yu, J. M., and Baik, S. H. Use of a real time continuous glucose monitoring system as a motivational device for poorly controlled type 2 diabetes. Diabetes Research & Clinical Practice. 2008;82(1):73-79.

Yoo, H. J., Park, M. S., Kim, T. N., Yang, S. J., Cho, G. J., Hwang, T. G., Baik, S. H., Choi, D. S., Park, G. H., and Choi, K. M. A Ubiquitous Chronic Disease Care system using cellular phones and the internet. Diabetic Medicine. 2009;26(6):628-635.

Yoo, W. S., Kim, H. J., Kim, D., Lee, M. Y., and Chung, H. K. Early detection of asymptomatic coronary artery disease in patients with type 2 diabetes mellitus. Korean Journal of Internal Medicine. 2009;24(3):183-189.

Yoon, K. H. and Kim, H. S. A short message service by cellular phone in type 2 diabetic patients for 12 months. Diabetes Research & Clinical Practice. 2008;79(2):256-261.

Yoon, N. M., Cavaghan, M. K., Brunelle, R. L., and Roach, P. Exenatide added to insulin therapy: a retrospective review of clinical practice over two years in an academic endocrinology outpatient setting. Clinical Therapeutics. 2009;31(7):1511-1523.

Yoshikawa, R., Wada, J., Seiki, K., Matsuoka, T., Miyamoto, S., Takahashi, K., Ota, S., Tani, K., Hida, K., Yamakado, M., Shikata, K., Uehara, Y., Urade, Y., and Makino, H. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. Diabetes Research & Clinical Practice. 2007;76(3):358-367.

Young, L. H., Wackers, F. J., Chyun, D. A., Davey, J. A., Barrett, E. J., Taillefer, R., Heller, G. V., Iskandrian, A. E., Wittlin, S. D., Filipchuk, N., Ratner, R. E., Inzucchi, S. E., and Investigators, Diad. Cardiac outcomes after screening for asymptomatic coronary artery disease in patients with type 2 diabetes: the DIAD study: a randomized controlled trial. Jama. 2009;301(15):1547-1555.

Yu, B. S. and Wang, A. R. Glucagon-like peptide 1 based therapy for type 2 diabetes. World Journal of Pediatrics. 2008;4(1):8-13.

Yu, D., Huang, J., Hu, D., Chen, J., Cao, J., and Li, J. Is an appropriate cutoff of hypertriglyceridemic waist designated for type 2 diabetes among Chinese adults?. Clinical Nutrition. 2010;29(2):192-198.

Yu, J., Jin, N., Wang, G., Zhang, F., Mao, J., and Wang, X. Peroxisome proliferator-activated receptor gamma agonist improves arterial stiffness in patients with type 2 diabetes mellitus and coronary artery disease. Metabolism: Clinical & Experimental. 2007;56(10):1396-1401.

Yu, J., Zhang, Z., Li, Z., Feng, X., He, L., Liu, S., Mao, J., Wang, G., and Wang, X. Peroxisome proliferator-activated receptor-gamma(PPARgamma) agonist improves coronary artery endothelial function in diabetic patients with coronary artery disease. Journal of International Medical Research. 2010;38(1):86-94.

Yumlu, S., Barany, R., Eriksson, M., and Rocken, C. Localized insulin-derived amyloidosis in patients with diabetes mellitus: a case report. *Human Pathology*. 2009;40(11):1655-1660.

Yurgin, N., Secnik, K., and Lage, M. J. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. *Clinical Therapeutics*. 2007;29(2):316-325.

Yusof, B. N., Talib, R. A., Kamaruddin, N. A., Karim, N. A., Chinna, K., and Gilbertson, H. A low-GI diet is associated with a short-term improvement of glycaemic control in Asian patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2009;11(4):387-396.

Yusuff, K. B., Obe, O., and Joseph, B. Y. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. *Pharmacy World & Science*. 2008;30(6):876-883.

Zachariadou, T., Stoffers, H. E., Christophi, C. A., Philalithis, A., and Lionis, C. Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study. *BMC Health Services Research*. 2008;8:148.

Zannad, F. Implications of the ADVANCE study for clinical practice. *Journal of Hypertension - Supplement*. 2008;26(3):S29-S32.

Zanuso, S., Jimenez, A., Pugliese, G., Corigliano, G., and Balducci, S. Exercise for the management of type 2 diabetes: a review of the evidence. *Acta Diabetologica*. 2010;47(1):15-22.

Zarowitz, B. J. and Conner, C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. *Pharmacotherapy*. 2009;29(12 Pt 2):55S-67S.

Zbidi, H., Lopez, J. J., Amor, N. B., Bartegi, A., Salido, G. M., and Rosado, J. A. Enhanced expression of STIM1/Orai1 and TRPC3 in platelets from patients with type 2 diabetes mellitus. *Blood Cells Molecules & Diseases*. 2009;43(2):211-213.

Zdravkovic, M., Kruse, M., Rost, K. L., Moss, J., and Kecskes, A. The effects of NN414, a SUR1/Kir6.2 selective potassium channel opener in subjects with type 2 diabetes. *Experimental & Clinical Endocrinology & Diabetes*. 2007;115(6):405-406.

Zeman, M., Jirak, R., Jachymova, M., Vecka, M., Tvrzicka, E., and Zak, A. Leptin, adiponectin, leptin to adiponectin ratio and insulin resistance in depressive women. *Neuroendocrinology Letters*. 2009;30(3):387-395.

Zeqiri, S., Ylli, A., and Zeqiri, N. The effect of physical activity in glycemia in patients with diabetes mellitus. *Medicinski Arhiv*. 2007;61(3):146-149.

Zerilli, T. and Pyon, E. Y. Sitagliptin phosphate: a DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. *Clinical Therapeutics*. 2007;29(12):2614-2634.

Zghal-Mokni, I., Nacef, L., Letaief, I., Mahjoub, S., Bouguila, H., Blouza, S., Jeddi, A., and Ayed, S. [Ocular manifestations of diabetes: 285 cases]. *Tunisie Medicale*. 2008;86(11):1004-1007.

Zhang, C. Y., Sun, A. J., Zhang, S. N., Wu, C. N., Fu, M. Q., Xia, G., Wang, K. Q., Zou, Y. Z., and Ge, J. B. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Annals of Medicine*. 2010;42(4):305-315.

Zhang, C., Sun, A., Zhang, P., Wu, C., Zhang, S., Fu, M., Wang, K., Zou, Y., and Ge, J. Aspirin for primary prevention of cardiovascular events in patients with diabetes: A meta-analysis. *Diabetes Research & Clinical Practice*. 2010;87(2):211-218.

Zhang, L., Qiao, Q., Tuomilehto, J., Hammar, N., Alberti, K. G., Eliasson, M., Heine, R. J., Stehouwer, C. D., Ruotolo, G., and Group, Decode Study. Blood lipid levels in relation to glucose status in European men and women without a prior history of diabetes: the DECODE Study. *Diabetes Research*

& Clinical Practice. 2008;82(3):364-377.

Zhang, L., Qiao, Q., Tuomilehto, J., Hammar, N., Ruotolo, G., Stehouwer, C. D., Heine, R. J., Eliasson, M., Zethelius, B., and Group, Decode Study. The impact of dyslipidaemia on cardiovascular mortality in individuals without a prior history of diabetes in the DECODE Study. *Atherosclerosis*. 2009;206(1):298-302.

Zhang, L., Qiao, Q., Tuomilehto, J., Janus, E. D., Lam, T. H., Ramachandran, A., Mohan, V., Stehouwer, C. D., Dong, Y., Nakagami, T., Onat, A., Soderberg, S., and Group, Decode Decoda Study. Distinct ethnic differences in lipid profiles across glucose categories. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(4):1793-1801.

Zhang, Q., Tang, N., Schepmoes, A. A., Phillips, L. S., Smith, R. D., and Metz, T. O. Proteomic profiling of nonenzymatically glycosylated proteins in human plasma and erythrocyte membranes. *Journal of Proteome Research*. 2008;7(5):2025-2032.

Zhang, W. L., Lopez-Garcia, E., Li, T. Y., Hu, F. B., and Van Dam, R. M. Coffee consumption and risk of cardiovascular events and all-cause mortality among women with type 2 diabetes. *Diabetologia*. 2009;52(5):810-817.

Zhang, X., Norris, S. L., Chowdhury, F. M., Gregg, E. W., and Zhang, P. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. *Medical Care*. 2007;45(9):820-834.

Zhang, Y. and Fu, F. H. Effects of 14-week Tai Ji Quan exercise on metabolic control in women with type 2 diabetes. *American Journal of Chinese Medicine*. 2008;36(4):647-654.

Zhao, G., Ford, E. S., Li, C., and Mokdad, A. H. Compliance with physical activity recommendations in US adults with diabetes. *Diabetic Medicine*. 2008;25(2):221-227.

Zhao, X., Zhong, J., Mo, Y., Chen, X., Chen, Y., and Yang, D. Association of biochemical hyperandrogenism with type 2 diabetes and obesity in Chinese women with polycystic ovary syndrome. *International Journal of Gynaecology & Obstetrics*. 2010;108(2):148-151.

Zheng, L. Effect of antihypertensive therapy on progression of carotid intima-media thickness in patients with type 2 diabetes mellitus. *The American journal of cardiology*. 2007;99(7):956-960.

Zhou, J., Chen, X., Xie, Y., Li, J., Yamanaka, N., and Tong, X. A differential diagnostic model of diabetic nephropathy and non-diabetic renal diseases. *Nephrology Dialysis Transplantation*. 2008;23(6):1940-1945.

Zhou, L., Deng, W., Fang, P., He, D., Zhang, W., Liu, K., and Hu, R. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. *Current Diabetes Reviews*. 2009;5(3):171-184.

Zhou, X. H., Ji, L. N., Luo, Y. Y., Zhang, X. Y., Han, X. Y., and Qiao, Q. Performance of HbA(1c) for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. *Diabetic Medicine*. 2009;26(12):1262-1268.

Zhou, X., Pang, Z., Gao, W., Wang, S., Zhang, L., Ning, F., and Qiao, Q. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. *Diabetes Care*. 2010;33(3):545-550.

Zhu, C. F., Li, G. Z., Peng, H. B., Zhang, F., Chen, Y., and Li, Y. Effect of marine collagen peptides on markers of metabolic nuclear receptors in type 2 diabetic patients with/without hypertension. *Biomedical & Environmental Sciences*. 2010;23(2):113-120.

Zhu, H. and Shi, C. H. Analysis of the diagnostic value of plasma endothelin for diabetic retinopathy

using the receiver operating characteristic curve. *Ophthalmic Research*. 2007;39(5):289-293.

Zhu, J. R., Tomlinson, B., Ro, Y. M., Sim, K. H., Lee, Y. T., and Sriratanasathavorn, C. A randomised study comparing the efficacy and safety of rosuvastatin with atorvastatin for achieving lipid goals in clinical practice in Asian patients at high risk of cardiovascular disease (DISCOVERY-Asia study). *Current Medical Research & Opinion*. 2007;23(12):3055-3068.

Zib, I., Jacob, A. N., Lingvay, I., Salinas, K., McGavock, J. M., Raskin, P., and Szczepaniak, L. S. Effect of pioglitazone therapy on myocardial and hepatic steatosis in insulin-treated patients with type 2 diabetes. *Journal of Investigative Medicine*. 2007;55(5):230-236.

Zibadi, S., Rohdewald, P. J., Park, D., and Watson, R. R. Reduction of cardiovascular risk factors in subjects with type 2 diabetes by Pycnogenol supplementation. *Nutrition Research*. 2008;28(5):315-320.

Zick, R., Petersen, B., Richter, M., Haug, C., and Group, Safir Study. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. *Diabetes Technology & Therapeutics*. 2007;9(6):483-492.

Zidek, W., Schrader, J., Luders, S., Matthaei, S., Hasslacher, C., Hoyer, J., Bramlage, P., Sturm, C. D., and Paar, W. D. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADAPT investigation. *Cardiovascular Diabetology*. 2008;7:22.

Ziemer, D. C., Kolm, P., Foster, J. K., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Varughese, R. M., Tsui, C. W., Koch, D. D., Twombly, J. G., Narayan, K. M., and Phillips, L. S. Random plasma glucose in serendipitous screening for glucose intolerance: screening for impaired glucose tolerance study 2. *Journal of General Internal Medicine*. 2008;23(5):528-535.

Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Caudle, J. M., Irving, J. M., Koch, D. D., Narayan, K. M., and Phillips, L. S. Age, BMI, and race are less important than random plasma glucose in identifying risk of glucose intolerance: the Screening for Impaired Glucose Tolerance Study (SIGT 5). *Diabetes Care*. 2008;31(5):884-886.

Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Twombly, J. G., Narayan, K. M., Koch, D. D., and Phillips, L. S. Glucose-independent, black-white differences in hemoglobin A1c levels: a cross-sectional analysis of 2 studies. *Annals of Internal Medicine*. 2010;152(12):770-777.

Ziemer, D. C., Tsui, C., Caudle, J., Barnes, C. S., Dames, F., and Phillips, L. S. An informatics-supported intervention improves diabetes control in a primary care setting. *Amia .. 2006;Annual Symposium Proceedings/AMIA Symposium*.:1160.

Zieve, F. J., Kalin, M. F., Schwartz, S. L., Jones, M. R., and Bailey, W. L. Results of the glucose-lowering effect of WelChol study (GLOWS): a randomized, double-blind, placebo-controlled pilot study evaluating the effect of colesevelam hydrochloride on glycemic control in subjects with type 2 diabetes. *Clinical Therapeutics*. 2007;29(1):74-83.

Zihl, J., Schaaf, L., and Zillmer, E. A. The relationship between adult neuropsychological profiles and diabetic patients' glycemic control. *Applied Neuropsychology*. 2010;17(1):44-51.

Zimering, M. B., Anderson, R. J., Luo, P., Moritz, T. E., and Investigators for the Veterans Affairs Diabetes, Trial. Plasma basic fibroblast growth factor is correlated with plasminogen activator inhibitor-1 concentration in adults from the Veterans Affairs Diabetes Trial. *Metabolism: Clinical & Experimental*. 2008;57(11):1563-1569.

Zindah, M., Belbeisi, A., Walke, H., and Mokdad, A. H. Obesity and diabetes in Jordan: findings from the behavioral risk factor surveillance system, 2004. *Preventing Chronic Disease*. 2008;5(1):A17.

Zinman, B., Gerich, J., Buse, J. B., Lewin, A., Schwartz, S., Raskin, P., Hale, P. M., Zdravkovic, M.,

Blonde, L., and Investigators, Lead. Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD). *Diabetes Care*. 2009;32(7):1224-1230.

Zinman, B. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial. *Annals of Internal Medicine*. 2007;146(7):477-485.

Zisser, H. C., Bailey, T. S., Schwartz, S., Ratner, R. E., and Wise, J. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. *Journal of Diabetes Science & Technology*. 2009;3(5):1146-1154.

Zivkovic, A. M. and German, J. B. Metabolomics for assessment of nutritional status. *Current Opinion in Clinical Nutrition & Metabolic Care*. 2009;12(5):501-507.

Ziyadeh, N., McAfee, A. T., Koro, C., Landon, J., and Arnold Chan, K. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. *Clinical Therapeutics*. 2009;31(11):2665-2677.

Zloczower, M., Reznick, A. Z., Zouby, R. O., and Nagler, R. M. Relationship of flow rate, uric acid, peroxidase, and superoxide dismutase activity levels with complications in diabetic patients: can saliva be used to diagnose diabetes?. *Antioxidants & Redox Signaling*. 2007;9(6):765-773.

Zois, C. E., Tokmakidis, S. P., Volaklis, K. A., Kotsa, K., Touvra, A. M., Douda, E., and Yovos, I. G. Lipoprotein profile, glycemic control and physical fitness after strength and aerobic training in post-menopausal women with type 2 diabetes.[Erratum appears in *Eur J Appl Physiol*. 2009 Aug;106(6):909 Note: Christos, Zois E [corrected to Zois, Christos E]]. *European Journal of Applied Physiology*. 2009;106(6):901-907.

Zoungas, S., de Galan, B. E., Ninomiya, T., Grobbee, D., Hamet, P., Heller, S., MacMahon, S., Marre, M., Neal, B., Patel, A., Woodward, M., Chalmers, J., Group, Advance Collaborative, Cass, A., Glasziou, P., Harrap, S., Lisheng, L., Mancia, G., Pillai, A., Poulter, N., Perkovic, V., and Travert, F. Combined effects of routine blood pressure lowering and intensive glucose control on macrovascular and microvascular outcomes in patients with type 2 diabetes: New results from the ADVANCE trial. *Diabetes Care*. 2009;32(11):2068-2074.

Level 2: Inappropriate Studies

Antipsychotics and diabetes: case reports and cohort studies. *Postgraduate Medicine*. 2003;114(6 Suppl Managing Metabolic):59-71.

Abraham, N. G., Brunner, E. J., Eriksson, J. W., and Robertson, R. P. Metabolic syndrome: psychosocial, neuroendocrine, and classical risk factors in type 2 diabetes. *Annals of the New York Academy of Sciences*. 2007;1113:256-275.

Abuissa, H. and O'Keefe, J., Jr. The role of renin-angiotensin-aldosterone system-based therapy in diabetes prevention and cardiovascular and renal protection. *Diabetes, Obesity & Metabolism*. 2008;10(12):1157-1166.

Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Grant, R. W., Meigs, J. B., Soumerai, S. B., and Ross-Degnan, D. Medication adherence and racial differences in A1C control. *Diabetes Care*. 2008;31(5):916-921.

Adams, S. Y., Crawford, A. G., Rimal, R. N., Lee, J. S., Janneck, L. M., and Sciamanna, C. N. The effects of a computer-tailored message on secondary prevention in type 2 diabetes: a randomized trial. *Population Health Management*. 2009;12(4):197-204.

Afsar, B., Elsurur, R., Sezer, S., and Ozdemir, F. N. Insulin resistance is associated with increased renal

- resistive index independent of other factors in newly diagnosed type 2 diabetes mellitus and hypertensive patients. *Metabolism: Clinical & Experimental*. 2010;59(2):279-284.
- Afsar, B., Sezer, S., Elsurur, R., and Ozdemir, F. N. Is HOMA index a predictor of nocturnal nondipping in hypertensives with newly diagnosed type 2 diabetes mellitus?. *Blood Pressure Monitoring*. 2007;12(3):133-139.
- Ahmad Khan, H. Clinical significance of HbA1c as a marker of circulating lipids in male and female type 2 diabetic patients. *Acta Diabetologica*. 2007;44(4):193-200.
- Ahmad, J., Ahmmed, F., Siddiqui, M. A., Khan, A. R., Katyal, P., Hameed, B., and Ahmad, I. Inflammatory markers, insulin resistance and carotid intima-media thickness in North-Indian type 2 diabetic subjects. *Journal of the Association of Physicians of India*. 2007;55:693-699.
- Alam, T., Weintraub, N., and Weinreb, J. What is the proper use of hemoglobin A1c monitoring in the elderly?. *Journal of the American Medical Directors Association*. 2005;6(3):200-204.
- Al-Hussein, F. A. Diabetes control in a primary care setting: a retrospective study of 651 patients. *Annals of Saudi Medicine*. 2008;28(4):267-271.
- Anan, F., Masaki, T., Ono, E., Eto, T., Iwao, T., Eshima, N., Saikawa, T., and Yoshimatsu, H. Predictors for prehypertension in patients with impaired glucose tolerance. *Hypertension Research - Clinical & Experimental*. 2008;31(10):1913-1920.
- Ashraf, A. Evaluation of effectiveness of local insulin injection in none insulin dependent diabetic patient with carpal tunnel syndrome. *Electromyography and clinical neurophysiology*. 2009;49(4):161-166.
- Balde, N. M., Diallo, I., Balde, M. D., Barry, I. S., Kaba, L., Diallo, M. M., Kake, A., Camara, A., Bah, D., Barry, M. M., Sangare-Bah, M., and Mougendre, D. Diabetes and impaired fasting glucose in rural and urban populations in Futa Jallon (Guinea): prevalence and associated risk factors. *Diabetes & Metabolism*. 2007;33(2):114-120.
- Balde, N. M., Kaba, M. L., Balde, M. D., Diallo, A. O., Goepogui, A., and Diakite, M. [Frequency of diabetic microangiopathy in newly diagnosed diabetes mellitus in Conakry: late diagnosis and lack of screening]. *Dakar Medical*. 2007;52(3):165-170.
- Barnett, A. H., Mackin, P., Chaudhry, I., Farooqi, A., Gadsby, R., Heald, A., Hill, J., Millar, H., Peveler, R., Rees, A., Singh, V., Taylor, D., Vora, J., and Jones, P. B. Minimising metabolic and cardiovascular risk in schizophrenia: diabetes, obesity and dyslipidaemia. *Journal of Psychopharmacology*. 2007;21(4):357-373.
- Basi, S., Fesler, P., Mimran, A., and Lewis, J. B. Microalbuminuria in type 2 diabetes and hypertension: a marker, treatment target, or innocent bystander?. *Diabetes Care*. 2008;31 Suppl 2:S194-S201.
- Beverly, E. A., Miller, C. K., and Wray, L. A. Spousal support and food-related behavior change in middle-aged and older adults living with type 2 diabetes. *Health Education & Behavior*. 2008;35(5):707-720.
- Bogdanski, P., Pupek-Musialik, D., Dytfeld, J., Jagodzinski, P. P., Jablecka, A., Kujawa, A., and Musialik, K. Influence of insulin therapy on expression of chemokine receptor CCR5 and selected inflammatory markers in patients with type 2 diabetes mellitus. *International Journal of Clinical Pharmacology & Therapeutics*. 2007;45(10):563-567.
- Bradshaw, B. G., Richardson, G. E., Kumpfer, K., Carlson, J., Stanchfield, J., Overall, J., Brooks, A. M., and Kulkarni, K. Determining the efficacy of a resiliency training approach in adults with type 2 diabetes. *Diabetes Educator*. 2007;33(4):650-659.
- Bushe, C. J. and Leonard, B. E. Blood glucose and schizophrenia: a systematic review of prospective

randomized clinical trials. *Journal of Clinical Psychiatry*. 2007;68(11):1682-1690.

Chaves-Fonseca Rm, Matos O. S. L. Implementation of a systematic approach to diabetes in primary care in Bahia, Brazil improves metabolic outcomes: PRODIBA-Programa de Interiorizacao da Assistencia ao Diabetes na Bahia (Project for Dissemination of Diabetes Care in the State of Bahia). *Diabetic medicine : a journal of the British Diabetic Association*. 2009;26(3):286-292.

Christian, J. G., Bessesen, D. H., Byers, T. E., Christian, K. K., Goldstein, M. G., and Bock, B. C. Clinic-based support to help overweight patients with type 2 diabetes increase physical activity and lose weight. *Archives of Internal Medicine*. 2008;168(2):141-146.

Coppell, K., Williams, S., Anderson, K., Lamb, C., and Mann, J. Characteristics and cardiovascular risk of new cases of type 2 diabetes in Otago, New Zealand, 1998-2004. *Diabetes Research & Clinical Practice*. 2008;82(3):396-401.

Corser, W., Holmes-Rovner, M., Lein, C., and Gossain, V. A shared decision-making primary care intervention for type 2 diabetes. *Diabetes Educator*. 2007;33(4):700-708.

Costa, B., Vizcaino, J., Pinol, J. L., Cabre, J. J., Fuentes, C. M., and Recor, D. Research Group. Relevance of casual undetected hyperglycemia among high-risk individuals for developing diabetes. *Diabetes Research & Clinical Practice*. 2007;78(2):289-292.

Cox, M., Boyle, P. J., Davey, P., and Morris, A. Does health-selective migration following diagnosis strengthen the relationship between Type 2 diabetes and deprivation?. *Social Science & Medicine*. 2007;65(1):32-42.

Cramer, J. S., Sibley, R. F., Bartlett, D. P., Kahn, L. S., and Loffredo, L. An adaptation of the diabetes prevention program for use with high-risk, minority patients with type 2 diabetes. *Diabetes Educator*. 2007;33(3):503-508.

Cuellar, N. G. and Ratcliffe, S. J. Restless legs syndrome in type 2 diabetes: implications to diabetes educators. *Diabetes Educator*. 2008;34(2):218-234.

Derosa, G., D'Angelo, A., Salvadeo, S. A., Ferrari, I., Fogari, E., Gravina, A., Mereu, R., Palumbo, I., Maffioli, P., Randazzo, S., and Cicero, A. F. Modification of vascular and inflammation biomarkers after OGTT in overweight healthy and diabetic subjects. *Microvascular Research*. 2010;79(2):144-149.

Doyle, A., Desilva, P., Koduah, D., Birdi, J., Sabah, M., and King, R. An insight into undiagnosed impaired glucose regulation. *Primary care diabetes*. 2007;1(3):155-158.

Duiverman, M. L., Cohen, D., van Oven, W., and Nieboer, P. A patient treated with olanzapine developing diabetes de novo: proposal for hyperglycaemia screening. *Netherlands Journal of Medicine*. 2007;65(9):346-348.

Ertugrul, D. T., Tatal, E., Yildiz, M., Akin, O., Yalcin, A. A., Ure, O. S., Yilmaz, H., Yavuz, B., Deveci, O. S., Ata, N., and Kucukazman, M. Aspirin resistance is associated with glycemic control, the dose of aspirin, and obesity in type 2 diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2897-2901.

Evangelista, V., De Berardis, G., Totani, L., Avanzini, F., Giorda, C. B., Brero, L., Levantesi, G., Marelli, G., Pupillo, M., Iacuiti, G., Pozzoli, G., di Summa, P., Nada, E., de Simone, G., Dell'Elba, G., Amore, C., Manarini, S., Pecce, R., Maione, A., Tognoni, G., and Nicolucci, A. Persistent platelet activation in patients with type 2 diabetes treated with low doses of aspirin. *Journal of Thrombosis & Haemostasis*. 2007;5(11):2197-2203.

Ferland, A., Brassard, P., Lemieux, S., Bergeron, J., Bogaty, P., Bertrand, F., Simard, S., and Poirier, P. Impact of high-fat /low-carbohydrate, high-, low-glycaemic index or low-caloric meals on glucose regulation during aerobic exercise in Type 2 diabetes. *Diabetic Medicine*. 2009;26(6):589-595.

Fernandez-Campo, L. Effect of different antihypertensive treatments on Ras, MAPK and Akt activation in hypertension and diabetes. *Clinical science (London, England :. 2009;1979)* 116(2):165-173.

Fornengo, P., Bosio, A., Epifani, G., Pallisco, O., Mancuso, A., and Pascale, C. Prevalence of silent myocardial ischaemia in new-onset middle-aged Type 2 diabetic patients without other cardiovascular risk factors. *Diabetic Medicine*. 2006;23(7):775-779.

Frampton Mw, Stewart J. C. C. Platelet and vascular effects in type 2 diabetes inhaling ultrafine carbon particles [Abstract]. *American Thoracic Society International Conference*, May. 2007.

French Dp, Eborall H. G. Completing a postal health questionnaire did not affect anxiety or related measures: randomized controlled trial. *Journal of Clinical Epidemiology*. 2009;62(1):74-80.

Fuh, J. L., Wang, S. J., Hwu, C. M., and Lu, S. R. Glucose tolerance status and cognitive impairment in early middle-aged women. *Diabetic Medicine*. 2007;24(7):788-791.

Gale, E. A., Beattie, S. D., Hu, J., Koivisto, V., and Tan, M. H. Recruitment to a clinical trial improves glycemic control in patients with diabetes. *Diabetes Care*. 2007;30(12):2989-2992.

Gibson, A. A., Schaffer, J. E., Peterson, L. R., Bilhorn, K. R., Robert, K. M., Haider, T. A., Farmer, M. S., Holland, M. R., and Miller, J. G. Quantitative analysis of the magnitude and time delay of cyclic variation of myocardial backscatter from asymptomatic type 2 diabetes mellitus subjects. *Ultrasound in Medicine & Biology*. 2009;35(9):1458-1467.

Gomez-Ambrosi, J., Rodriguez, A., Catalan, V., Ramirez, B., Silva, C., Rotellar, F., Gil, M. J., Salvador, J., and Fruhbeck, G. Serum retinol-binding protein 4 is not increased in obesity or obesity-associated type 2 diabetes mellitus, but is reduced after relevant reductions in body fat following gastric bypass. *Clinical Endocrinology*. 2008;69(2):208-215.

Gong, W., Lu, B., Yang, Z., Ye, W., Du, Y., Wang, M., Li, Q., Zhang, W., Pan, Y., Feng, X., Zhou, W., Zhang, Y., Yang, Y., Zhu, X., and Hu, R. Early-stage atherosclerosis in newly diagnosed, untreated type 2 diabetes mellitus and impaired glucose tolerance. *Diabetes & Metabolism*. 2009;35(6):458-462.

Grandy, S. and Fox, K. M. EQ-5D visual analog scale and utility index values in individuals with diabetes and at risk for diabetes: Findings from the Study to Help Improve Early evaluation and management of risk factors Leading to Diabetes (SHIELD). *Health & Quality of Life Outcomes*. 2008;6:18.

Gredal, C., Rosenfalck, A. M., Dejgaard, A., and Hilsted, J. Impaired first-phase insulin response predicts postprandial blood glucose increment in patients with recently diagnosed type 2 diabetes. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2007;67(3):327-336.

Hagelberg, A., Ivert, T., Efendic, S., Ohrvik, J., and Anderson, R. E. Insulin glargine improves glycaemic control after coronary surgery in patients with diabetes or pre-diabetes. *Scandinavian Cardiovascular Journal*. 2008;42(1):71-76.

Hanefeld, M. Effect of acarbose on postmeal mononuclear blood cell response in patients with early type 2 diabetes: the AI(I)DA study. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme*. 2009;41(2):132-136.

Hawthorne, K., Robles, Y., Cannings-John, R., and Edwards, A. G. Culturally appropriate health education for type 2 diabetes mellitus in ethnic minority groups. *Cochrane Database of Systematic Reviews*. 2008;(3):CD006424.

Hayashi, T., Kawashima, S., Itoh, H., Yamada, N., Sone, H., Watanabe, H., Hattori, Y., Ohru, T., Yoshizumi, M., Yokote, K., Kubota, K., Nomura, H., Umegaki, H., Iguchi, A., and Japan, C. D. M. Importance of lipid levels in elderly diabetic individuals: baseline characteristics and 1-year survey of cardiovascular events. *Circulation Journal*. 2008;72(2):218-225.

Hayashi, T., Takai, S., and Yamashita, C. Impact of the renin-angiotensin-aldosterone-system on cardiovascular and renal complications in diabetes mellitus. *Current Vascular Pharmacology*. 2010;8(2):189-197.

Hayashino, Y., Shimbo, T., Tsujii, S., Ishii, H., Kondo, H., Nakamura, T., Nagata-Kobayashi, S., and Fukui, T. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines. *International Journal of Cardiology*. 2007;118(1):88-96.

Hayden, M. R., Kolb, L., Chowdbury, N., Karuparthi, P. R., Khanna, R., and Sowers, J. R. Detecting microalbuminuria and taking action in the cardiometabolic syndrome and type 2 diabetes mellitus. *Missouri Medicine*. 2006;103(5):533-538.

Inoue, K., Matsumoto, M., and Akimoto, K. Fasting plasma glucose and HbA1c as risk factors for Type 2 diabetes. *Diabetic Medicine*. 2008;25(10):1157-1163.

International Expert, Committee. International Expert Committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32(7):1327-1334.

Jeerakathil, T., Johnson, J. A., Simpson, S. H., and Majumdar, S. R. Short-term risk for stroke is doubled in persons with newly treated type 2 diabetes compared with persons without diabetes: a population-based cohort study. *Stroke*. 2007;38(6):1739-1743.

Kabakov, E., Norymberg, C., Osher, E., Koffler, M., Tordjman, K., Greenman, Y., and Stern, N. Prevalence of hypertension in type 2 diabetes mellitus: impact of the tightening definition of high blood pressure and association with confounding risk factors. *Journal of the CardioMetabolic Syndrome*. 2006;1(2):95-101.

Kapoor, N., Sankaran, S., Hyer, S., and Shehata, H. Diabetes in pregnancy: a review of current evidence. *Current Opinion in Obstetrics & Gynecology*. 2007;19(6):586-590.

Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., and Martin, B. C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. *Medical Care*. 2008;46(11):1125-1133.

Katerndahl, D. and Parchman, M. L. Dynamical difference in patients encounters involving uncontrolled diabetes: an orbital decomposition analysis. *Journal of Evaluation in Clinical Practice*. 2010;16(1):211-219.

Katz, D. L. and Nordwall, B. Novel interactive cell-phone technology for health enhancement. *Journal of Diabetes Science & Technology*. 2008;2(1):147-153.

Kawahara, T., Takahashi, K., Inazu, T., Arao, T., Kawahara, C., Tabata, T., Moriyama, H., Okada, Y., Morita, E., and Tanaka, Y. Reduced progression to type 2 diabetes from impaired glucose tolerance after a 2-day in-hospital diabetes educational program: the Joetsu Diabetes Prevention Trial. *Diabetes Care*. 2008;31(10):1949-1954.

Kernohan, A. F., Sattar, N., Hilditch, T., Cleland, S. J., Small, M., Lumsden, M. A., Connell, J. M., and Petrie, J. R. Effects of low-dose continuous combined hormone replacement therapy on glucose homeostasis and markers of cardiovascular risk in women with type 2 diabetes. *Clinical Endocrinology*. 2007;66(1):27-34.

Khunti, K., Skinner, T. C., Heller, S., Carey, M. E., Dallosso, H. M., Davies, M. J., and Collaborative, Desmond. Biomedical, lifestyle and psychosocial characteristics of people newly diagnosed with Type 2 diabetes: baseline data from the DESMOND randomized controlled trial. *Diabetic Medicine*. 2008;25(12):1454-1461.

Kilpatrick, E. S., Bloomgarden, Z. T., and Zimmet, P. Z. Is haemoglobin A1c a step forward for

diagnosing diabetes?. *Bmj*. 2009;339:b4432.

Kim, S. H., Shim, W. S., Kim, E. A., Kim, E. J., Lee, S. H., Hong, S. B., Kim, Y. S., Park, S. G., Leem, J. H., Lee, H. J., and Nam, M. The effect of lowering the threshold for diagnosis of impaired fasting glucose.[Erratum appears in *Yonsei Med J*. 2008 Aug 30;49(4):687 Note: Lim, Jong Whan [corrected to Leem, Jong Han]]. *Yonsei Medical Journal*. 2008;49(2):217-223.

Knol, M. J., Heerdink, E. R., Egberts, A. C., Geerlings, M. I., Gorter, K. J., Numans, M. E., Grobbee, D. E., Klungel, O. H., and Burger, H. Depressive symptoms in subjects with diagnosed and undiagnosed type 2 diabetes. *Psychosomatic Medicine*. 2007;69(4):300-305.

Ko, T. C., Tong, C. Y., So, W. Y., Cockram, S. C., and Chan, C. N. Association between smoking, pancreatic insulin secretion and insulin resistance in Chinese subjects with or without glucose intolerance. *Chinese Medical Journal*. 2007;120(24):2233-2237.

Korkiakangas, E. E., Alahuhta, M. A., and Laitinen, J. H. Barriers to regular exercise among adults at high risk or diagnosed with type 2 diabetes: a systematic review. *Health Promotion International*. 2009;24(4):416-427.

Koro, C. E., Lee, B. H., and Bowlin, S. J. Antidiabetic medication use and prevalence of chronic kidney disease among patients with type 2 diabetes mellitus in the United States. *Clinical Therapeutics*. 2009;31(11):2608-2617.

Kreyenbuhl, J., Dixon, L. B., McCarthy, J. F., Soliman, S., Ignacio, R. V., and Valenstein, M. Does adherence to medications for type 2 diabetes differ between individuals with vs without schizophrenia?. *Schizophrenia Bulletin*. 2010;36(2):428-435.

Laakso, M., Zilinskaite, J., Hansen, T., Boesgaard, T. W., Vanttinen, M., Stancakova, A., Jansson, P. A., Pellme, F., Holst, J. J., Kuulasmaa, T., Hribal, M. L., Sesti, G., Stefan, N., Fritsche, A., Haring, H., Pedersen, O., Smith, U., and Consortium, Eugene. Insulin sensitivity, insulin release and glucagon-like peptide-1 levels in persons with impaired fasting glucose and/or impaired glucose tolerance in the EUGENE2 study. *Diabetologia*. 2008;51(3):502-511.

Laaksonen, D. E., Niskanen, L., Mykkanen, H., Juntunen, K. S., Schwab, U., Kolehmainen, M., Rauramaa, R., Tuomilehto, J., and Uusitupa, M. Long-term repeatability of measures of early insulin secretion derived from an intravenous glucose tolerance test and conversion from impaired glucose tolerance to diabetes. *Annals of Medicine*. 2008;40(4):303-311.

Lara, C., Ponce de Leon, S., Foncerrada, H., and Vega, M. Diabetes or impaired glucose tolerance: does the label matter?. *Diabetes Care*. 2007;30(12):3029-3030.

Latham, C. L. and Calvillo, E. A health protection model for Hispanic adults with Type 2 diabetes. *Journal of Clinical Nursing*. 2007;16(7B):186-196.

Lawton, J., Ahmad, N., Hanna, L., Douglas, M., Bains, H., and Hallowell, N. 'We should change ourselves, but we can't': accounts of food and eating practices amongst British Pakistanis and Indians with type 2 diabetes. *Ethnicity & Health*. 2008;13(4):305-319.

Lawton, J., Peel, E., Parry, O., and Douglas, M. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. *Diabetic Medicine*. 2008;25(4):491-495.

Leal, J., Gray, A. M., and Clarke, P. M. Development of life-expectancy tables for people with type 2 diabetes. *European Heart Journal*. 2009;30(7):834-839.

Lee, J. E., Huh, W., Son, H. J., Kim, Y. G., Kim, D. J., Lee, M. K., and Oh, H. Y. Association of metabolic syndrome with microalbuminuria in non-hypertensive type 2 diabetic patients. *Nephron*. 2007;106(3):c98-103.

Leslie, R. D., Kolb, H., Schloot, N. C., Buzzetti, R., Mauricio, D., De Leiva, A., Yderstraede, K., Sarti,

- C., Thivolet, C., Hadden, D., Hunter, S., Schernthaner, G., Scherbaum, W., Williams, R., and Pozzilli, P. Diabetes classification: grey zones, sound and smoke: Action LADA 1. *Diabetes/Metabolism Research Reviews*. 2008;24(7):511-519.
- Li, Z., Hu, X., and Tang, N. Significance of neuroelectrophysiological tests in the early diagnosis of sub-clinical neuropathy with diabetes mellitus. *Journal of Huazhong University of Science and Technology*. 2006;Medical Sciences. 26(4):429-431.
- Lin, J. D., Hsia, T. L., Wu, C. Z., Su, C. C., Ma, W. Y., Hsieh, A. T., Hsieh, C. H., Wang, K., Chu, Y. M., and Pei, D. The first and second phase of insulin secretion in naive Chinese type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(6):780-786.
- Lonardo, A., Carulli, N., and Loria, P. HCV and diabetes. A two-question-based reappraisal. *Digestive & Liver Disease*. 2007;39(8):753-761.
- Lorig, K., Ritter, P. L., Villa, F. J., and Armas, J. Community-based peer-led diabetes self-management: a randomized trial. *Diabetes Educator*. 2009;35(4):641-651.
- Loveman, E., Frampton, G. K., and Clegg, A. J. The clinical effectiveness of diabetes education models for Type 2 diabetes: a systematic review. *Health Technology Assessment (Winchester, England)*. 12(9):1-116.
- Luscombe, F. A. Health-related quality of life measurement in type 2 diabetes. *Value in Health*. 2000;3 Suppl 1:15-28.
- Luzio, S., Peter, R., Dunseath, G. J., Mustafa, L., and Owens, D. R. A comparison of preprandial insulin glulisine versus insulin lispro in people with Type 2 diabetes over a 12-h period. *Diabetes Research & Clinical Practice*. 2008;79(2):269-275.
- Lyerly, G. W., Sui, X., Lavie, C. J., Church, T. S., Hand, G. A., and Blair, S. N. The association between cardiorespiratory fitness and risk of all-cause mortality among women with impaired fasting glucose or undiagnosed diabetes mellitus. *Mayo Clinic Proceedings*. 2009;84(9):780-786.
- Lysy, Z., Da Costa, D., and Dasgupta, K. The association of physical activity and depression in Type 2 diabetes. *Diabetic Medicine*. 2008;25(10):1133-1141.
- Maa, A. Y. and Sullivan, B. R. Relationship of hemoglobin A1C with the presence and severity of retinopathy upon initial screening of Type II diabetes mellitus. *American Journal of Ophthalmology*. 2007;144(3):456-457.
- Machado-Alba, J. E., Moncada-Escobar, J. C., and Gaviria, H. Quality and effectiveness of diabetes care for a group of patients in Colombia. *Pan American Journal of Public Health*. 2009;26(6):529-535.
- Mancini, T., Mazziotti, G., Doga, M., Carpinteri, R., Simetovic, N., Vescovi, P. P., and Giustina, A. Vertebral fractures in males with type 2 diabetes treated with rosiglitazone. *Bone*. 2009;45(4):784-788.
- Mannucci, E., Bartali, B., Molino Lova, R., Papucci, M., Lauretani, F., Luisi, M. L., Pietrobelli, A., and Macchi, C. Eating habits in elderly diabetic subjects: assessment in the InCHIANTI Study. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(4):278-282.
- Marrero, D. G. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. *Clinical Cornerstone*. 2007;8(2):33-40.
- Mars, G. M., Kempen, G. I., Mesters, I., Proot, I. M., and van Eijk, J. T. Characteristics of social participation as defined by older adults with a chronic physical illness. *Disability & Rehabilitation*. 2008;30(17):1298-1308.
- Marteau, T. M., Mann, E., Prevost, A. T., Vasconcelos, J. C., Kellar, I., Sanderson, S., Parker, M., Griffin, S., Sutton, S., and Kinmonth, A. L. Impact of an informed choice invitation on uptake of

screening for diabetes in primary care (DICISION): randomised trial. *Bmj*. 2010;340:c2138.

Matza, L. S., Yurgin, N., Boye, K. S., Malley, K., and Shorr, J. M. Obese versus non-obese patients with type 2 diabetes: patient-reported outcomes and utility of weight change. *Current Medical Research & Opinion*. 2007;23(9):2051-2062.

McPherson, M. L., Smith, S. W., Powers, A., and Zuckerman, I. H. Association between diabetes patients' knowledge about medications and their blood glucose control. *Research In Social & Administrative Pharmacy*. 2008;4(1):37-45.

Meneghini, L., Artola, S., Caputo, S., Damci, T., Dzida, G., Kaiser, M., Khunti, K., Liebl, A., Ligthelm, R., Maran, A., Orozco-Beltran, D., Ross, S., and Yale, J. F. Practical guidance to insulin management. *Primary care diabetes*. 2010;4 Suppl 1:S43-S56.

Metcalf, P. A., Wells, S., Scragg, R. K., and Jackson, R. Comparison of three different methods of assessing cardiovascular disease risk in New Zealanders with Type 2 diabetes mellitus. *New Zealand Medical Journal*. 2008;121(1281):49-57.

Mohan, V., Sandeep, S., Deepa, M., Gokulakrishnan, K., Datta, M., and Deepa, R. A diabetes risk score helps identify metabolic syndrome and cardiovascular risk in Indians - the Chennai Urban Rural Epidemiology Study (CURES-38). *Diabetes, Obesity & Metabolism*. 2007;9(3):337-343.

Molife, C., Lee, L. J., Shi, L., Sawhney, M., and Lenox, S. M. Assessment of patient-reported outcomes of insulin pen devices versus conventional vial and syringe. *Diabetes Technology & Therapeutics*. 2009;11(8):529-538.

Monahan, P. O., Lane, K. A., Hayes, R. P., McHorney, C. A., and Marrero, D. G. Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D. *Quality of Life Research*. 2009;18(7):941-952.

Moreno, L., Dale, S. B., Chen, A. Y., and Magee, C. A. Costs to Medicare of the Informatics for Diabetes Education and Telemedicine (IDEATel) home telemedicine demonstration: findings from an independent evaluation. *Diabetes Care*. 2009;32(7):1202-1204.

Moses, A. C., Raskin, P., and Khutoryansky, N. Does serum 1,5-anhydroglucitol establish a relationship between improvements in HbA1c and postprandial glucose excursions? Supportive evidence utilizing the differential effects between biphasic insulin aspart 30 and insulin glargine. *Diabetic Medicine*. 2008;25(2):200-205.

Motta, M., Bennati, E., Cardillo, E., Ferlito, L., and Malaguarnera, M. The value of glycosylated hemoglobin (HbA1c) as a predictive risk factor in the diagnosis of diabetes mellitus (DM) in the elderly. *Archives of Gerontology & Geriatrics*. 2010;50(1):60-64.

Motta, M., Bennati, E., Cardillo, E., Ferlito, L., Passamonte, M., Vacante, M., and Malaguarnera, M. A combination of glycosylated hemoglobin, impaired fasting glucose and waist circumference is effective in screening for individuals at risk for future type 2 diabetes. *Archives of Gerontology & Geriatrics*. 2010;50(1):105-109.

Mou, S., Wang, Q., Liu, J., Che, X., Zhang, M., Cao, L., Zhou, W., and Ni, Z. Prevalence of non-diabetic renal disease in patients with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2010;87(3):354-359.

Movahed, M. R., Hashemzadeh, M., and Jamal, M. Increased prevalence of ventricular fibrillation in patients with type 2 diabetes mellitus. *Heart & Vessels*. 2007;22(4):251-253.

Mulnier, H. E., Seaman, H. E., Raleigh, V. S., Soedamah-Muthu, S. S., Colhoun, H. M., Lawrenson, R. A., and De Vries, C. S. Risk of myocardial infarction in men and women with type 2 diabetes in the UK: a cohort study using the General Practice Research Database. *Diabetologia*. 2008;51(9):1639-

1645.

Murakami, Y., Kusaka, S., Oshima, Y., Tano, Y., Avery, R. L., Pieramici, D. J., and Arevalo, J. F. Diagnostic and therapeutic challenges. *Retina*. 2008;28(9):1357-1360.

Nakashima, Y., Inukai, K., Imai, K., Ikegami, Y., Awata, T., and Katayama, S. Involvement of low adiponectin levels in impaired glucose tolerance. *Metabolism: Clinical & Experimental*. 2008;57(10):1350-1354.

Nakhjavani, M., Khalilzadeh, O., Khajeali, L., Esteghamati, A., Morteza, A., Jamali, A., and Dadkhahipour, S. Serum oxidized-LDL is associated with diabetes duration independent of maintaining optimized levels of LDL-cholesterol. *Lipids*. 2010;45(4):321-327.

Narva, A. S. Reducing the burden of chronic kidney disease among American Indians. *Advances in Chronic Kidney Disease*. 2008;15(2):168-173.

Nathan, D. M., Kuenen, J., Borg, R., Zheng, H., Schoenfeld, D., Heine, R. J., and Group, A. Translating the A1C assay into estimated average glucose values.[Erratum appears in *Diabetes Care*. 2009 Jan;32(1):207]. *Diabetes Care*. 2008;31(8):1473-1478.

Neyestani, T. R., Shariatzadeh, N., Gharavi, A., Kalayi, A., and Khalaji, N. Physiological dose of lycopene suppressed oxidative stress and enhanced serum levels of immunoglobulin M in patients with Type 2 diabetes mellitus: a possible role in the prevention of long-term complications. *Journal of Endocrinological Investigation*. 2007;30(10):833-838.

Nichols, G. A., Hillier, T. A., and Brown, J. B. Progression from newly acquired impaired fasting glucose to type 2 diabetes.[Erratum appears in *Diabetes Care*. 2008 Dec;31(12):2414]. *Diabetes Care*. 2007;30(2):228-233.

Nicholson, W. K., Wilson, L. M., Witkop, C. T., Baptiste-Roberts, K., Bennett, W. L., Bolen, S., Barone, B. B., Golden, S. H., Gary, T. L., Neale, D. M., and Bass, E. B. Therapeutic management, delivery, and postpartum risk assessment and screening in gestational diabetes. *Evidence Report/Technology Assessment*. 2008;(162):1-96.

Ockleford, E., Shaw, R. L., Willars, J., and Dixon-Woods, M. Education and self-management for people newly diagnosed with type 2 diabetes: a qualitative study of patients' views. *Chronic Illness*. 2008;4(1):28-37.

Odegard, P. S. and Capoccia, K. Medication taking and diabetes: a systematic review of the literature. *Diabetes Educator*. 2007;33(6):1014-1029.

Olendzki, B. C., Ma, Y., Hebert, J. R., Pagoto, S. L., Merriam, P. A., Rosal, M. C., and Ockene, I. S. Underreporting of energy intake and associated factors in a Latino population at risk of developing type 2 diabetes. *Journal of the American Dietetic Association*. 2008;108(6):1003-1008.

Oli, J. M., Adeyemo, A. A., Okafor, G. O., Ofoegbu, E. N., Onyenekwe, B., Chukwuka, C. J., Onwasigwe, C. N., Ufelle, S., Chen, G., and Rotimi, C. N. Basal insulin resistance and secretion in Nigerians with type 2 diabetes mellitus. *Metabolic Syndrome & Related Disorders*. 2009;7(6):595-599.

Olivarius Nde, F., Siersma, V., Hansen, L. J., Drivsholm, T., and Horder, M. Changes in levels of haemoglobin A1c during the first 6 years after diagnosis of clinical type 2 diabetes. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2009;69(8):851-857.

Oliveira, A. F., Valente, J. G., Leite Ida, C., Schramm, J. M., Azevedo, A. S., and Gadelha, A. M. Global burden of disease attributable to diabetes mellitus in Brazil. *Cadernos de Saude Publica*. 2009;25(6):1234-1244.

Omolase, C. O., Adeganle, O., Owioye, J. F., and Omolase, B. O. Diabetic retinopathy in a Nigerian

community. *Singapore Medical Journal*. 2010;51(1):56-59.

On, Y. K., Park, H. K., Hyon, M. S., and Jeon, E. S. Serum resistin as a biological marker for coronary artery disease and restenosis in type 2 diabetic patients. *Circulation Journal*. 2007;71(6):868-873.

Osher, E. and Stern, N. Diastolic pressure in type 2 diabetes: can target systolic pressure be reached without "diastolic hypotension"? *Diabetes Care*. 2008;31 Suppl 2:S249-S254.

Oyer, D. S., Shepherd, M. D., Coulter, F. C., Bhargava, A., Brett, J., Chu, P. L., Trippe, B. S., and Group, I. NITIAEplus Study. A(1c) control in a primary care setting: self-titrating an insulin analog pre-mix (INITIAEplus trial). *American Journal of Medicine*. 2009;122(11):1043-1049.

Ozbek, M., Erdogan, M., Karadeniz, M., Cetinkalp, S., Ozgen, A. G., Saygili, F., Yilmaz, C., and Tuzun, M. Evaluation of beta cell dysfunction by mixed meal tolerance test and oral L-arginine in patients with newly diagnosed type 2 diabetes mellitus. *Experimental & Clinical Endocrinology & Diabetes*. 2009;117(10):573-576.

Padoin, A. V., Galvao Neto, M., Moretto, M., Barancelli, F., Schroer, C. E., and Mottin, C. C. Obese patients with type 2 diabetes submitted to banded gastric bypass: greater incidence of dumping syndrome. *Obesity Surgery*. 2009;19(11):1481-1484.

Pan, H. Y., Guo, L., and Li, Q. Changes of serum omentin-1 levels in normal subjects and in patients with impaired glucose regulation and with newly diagnosed and untreated type 2 diabetes. *Diabetes Research & Clinical Practice*. 2010;88(1):29-33.

Park, J. S., Cho, M. H., Nam, J. S., Ahn, C. W., Cha, B. S., Lee, E. J., Lim, S. K., Kim, K. R., and Lee, H. C. Visceral adiposity and leptin are independently associated with C-reactive protein in Korean type 2 diabetic patients. *Acta Diabetologica*. 2010;47(2):113-118.

Park, J. S., Cho, M. H., Nam, J. S., Yoo, J. S., Lee, Y. B., Roh, J. M., Ahn, C. W., Jee, S. H., Cha, B. S., Lee, E. J., Lim, S. K., Kim, K. R., and Lee, H. C. Adiponectin is independently associated with apolipoprotein B to A-1 ratio in Koreans. *Metabolism: Clinical & Experimental*. 2010;59(5):677-682.

Park, K., Saudek, C. D., and Hart, G. W. Increased expression of beta-N-acetylglucosaminidase in erythrocytes from individuals with pre-diabetes and diabetes. *Diabetes*. 2010;59(7):1845-1850.

Parving Hh, Brenner B. M. M. Aliskiren Trial in Type 2 Diabetes Using Cardio-Renal Endpoints (ALTITUDE): rationale and study design. *Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association*. 2009;24(5):1663-1671.

Pavlatou, M. G., Papastamataki, M., Apostolakou, F., Papassotiriou, I., and Tentolouris, N. FORT and FORD: two simple and rapid assays in the evaluation of oxidative stress in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2009;58(11):1657-1662.

Pearce, K. A., Love, M. M., Shelton, B. J., Schoenberg, N. E., Williamson, M. A., Barron, M. A., Houlihan, J. M., and Kentucky Ambulatory, Network. Cardiovascular risk education and social support (CaRESS): report of a randomized controlled trial from the Kentucky Ambulatory Network (KAN). *Journal of the American Board of Family Medicine: JABFM*. 2008;21(4):269-281.

Pearce, K. L., Noakes, M., Keogh, J., and Clifton, P. M. Effect of carbohydrate distribution on postprandial glucose peaks with the use of continuous glucose monitoring in type 2 diabetes. *American Journal of Clinical Nutrition*. 2008;87(3):638-644.

Penn, L., Moffatt, S. M., and White, M. Participants' perspective on maintaining behaviour change: a qualitative study within the European Diabetes Prevention Study. *BMC Public Health*. 2008;8:235.

Pham, T. T., Sim, J. J., Kujubu, D. A., Liu, I. L., and Kumar, V. A. Prevalence of nondiabetic renal

disease in diabetic patients. *American Journal of Nephrology*. 2007;27(3):322-328.

Phelan, S., Grodstein, F., and Brown, J. S. Clinical research in diabetes and urinary incontinence: what we know and need to know. *Journal of Urology*. 2009;182(6 Suppl):S14-S17.

Pinto, S. L., Lively, B. T., Siganga, W., Holiday-Goodman, M., and Kamm, G. Using the Health Belief Model to test factors affecting patient retention in diabetes-related pharmaceutical care services. *Research In Social & Administrative Pharmacy*. 2006;2(1):38-58.

Plotnikoff, R. C., Lippke, S., Karunamuni, N., Eves, N., Courneya, K. S., Sigal, R., and Birkett, N. J. Co-morbidity, functionality and time since diagnosis as predictors of physical activity in individuals with type 1 or type 2 diabetes. *Diabetes Research & Clinical Practice*. 2007;78(1):115-122.

Poirier, P., Despres, J. P., and Bertrand, O. F. Identifying which patients with diabetes should be tested for the presence of coronary artery disease--the importance of baseline electrocardiogram and exercise testing. *Canadian Journal of Cardiology*. 2006;22 Suppl A:9A-15A.

Postma, M. J., Boersma, C., and Gansevoort, R. T. Pharmacoeconomics in nephrology: considerations on cost-effectiveness of screening for albuminuria. *Nephrology Dialysis Transplantation*. 2008;23(4):1103-1106.

Pouwer, F. and Hermanns, N. Insulin therapy and quality of life. A review. *Diabetes/Metabolism Research Reviews*. 2009;25 Suppl 1:S4-S10.

Pouwer, F. Should we screen for emotional distress in type 2 diabetes mellitus?. *Nature Reviews Endocrinology*. 2009;5(12):665-671.

Pu, L. J., Lu, L., Shen, W. F., Zhang, Q., Zhang, R. Y., Zhang, J. S., Hu, J., Yang, Z. K., Ding, F. H., Chen, Q. J., Shen, J., Fang, D. H., and Lou, S. Increased serum glycosylated albumin level is associated with the presence and severity of coronary artery disease in type 2 diabetic patients. *Circulation Journal*. 2007;71(7):1067-1073.

Raccach, D. Importance of blood glucose management in the multifactorial approach of absolute cardiovascular risk in type 2 diabetes: the lessons from the Steno 2 study. *Diabetes & Metabolism*. 2006;32 Spec No2:2S48-2S51.

Rahman, S., Ismail, A. A., Ismail, S. B., Naing, N. N., and Rahman, A. R. Early manifestation of macrovasculopathy in newly diagnosed never treated type II diabetic patients with no traditional CVD risk factors. *Diabetes Research & Clinical Practice*. 2008;80(2):253-258.

Rayner, B. and Becker, P. The prevalence of microalbuminuria and ECG left ventricular hypertrophy in hypertensive patients in private practices in South Africa. *Cardiovascular Journal of Southern Africa*. 2006;17(5):245-249.

Rema, M. and Pradeepa, R. Diabetic retinopathy: an Indian perspective. *Indian Journal of Medical Research*. 2007;125(3):297-310.

Retnakaran, R., Cull, C. A., Thorne, K. I., Adler, A. I., Holman, R. R., and Group, Ukpds Study. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. *Diabetes*. 2006;55(6):1832-1839.

Rhee, S. Y., Chon, S., Oh, S., Kim, S. W., Kim, J. W., Kim, Y. S., and Woo, J. T. Insulin secretion and insulin resistance in newly diagnosed, drug naive prediabetes and type 2 diabetes patients with/without metabolic syndrome. *Diabetes Research & Clinical Practice*. 2007;76(3):397-403.

Rizkalla Sw, Laromiguiere M. C. Effect of baking process on postprandial metabolic consequences: randomized trials in normal and type 2 diabetic subjects. *European Journal of Clinical Nutrition*. 2007;61(2):175-183.

Roberts, A. W., Clark, A. L., and Witte, K. K. Review article: Left ventricular dysfunction and heart failure in metabolic syndrome and diabetes without overt coronary artery disease--do we need to screen our patients?. *Diabetes & Vascular Disease Research*. 2009;6(3):153-163.

Robinson, J. G., Fox, K. M., Grandy, S., and Group, Shield Study. Attitudes about health and health-related behaviors in patients with cardiovascular disease or at elevated risk for cardiovascular disease. *Preventive Cardiology*. 2009;12(3):136-143.

Rutter, M. K., Wilson, P. W., Sullivan, L. M., Fox, C. S., D'Agostino, R. B., Sr., and Meigs, J. B. Use of alternative thresholds defining insulin resistance to predict incident type 2 diabetes mellitus and cardiovascular disease. *Circulation*. 2008;117(8):1003-1009.

Sampaio, E. and Delfino, V. D. Assessing albuminuria in spot morning samples from diabetic patients. *Arquivos Brasileiros de Endocrinologia e Metabologia*. 2008;52(9):1482-1488.

Sattar, N., McConnachie, A., Ford, I., Gaw, A., Cleland, S. J., Forouhi, N. G., McFarlane, P., Shepherd, J., Cobbe, S., and Packard, C. Serial metabolic measurements and conversion to type 2 diabetes in the west of Scotland coronary prevention study: specific elevations in alanine aminotransferase and triglycerides suggest hepatic fat accumulation as a potential contributing factor. *Diabetes*. 2007;56(4):984-991.

Schaller, G., Kretschmer, S., Gouya, G., Haider, D. G., Mittermayer, F., Riedl, M., Wagner, O., Pacini, G., Wolzt, M., and Ludvik, B. Alcohol acutely increases vascular reactivity together with insulin sensitivity in type 2 diabetic men. *Experimental & Clinical Endocrinology & Diabetes*. 2010;118(1):57-60.

Schinner, S., Kempf, K., Overmann, H., Willenberg, H. S., Schott, M., Rose, B., Scherbaum, W. A., and Herder, C. Association of impaired glucose metabolism in morbid obesity with hypoadiponectinaemia. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116 Suppl 1:S64-S69.

Schondorf, T., Lubben, G., Hoopmann, M., Borchert, M., Forst, T., Hohberg, C., Lobig, M., Armbruster, F. P., Roth, W., Grabellus, M., and Pfutzner, A. Relaxin expression correlates significantly with serum fibrinogen variation in response to antidiabetic treatment in women with type 2 diabetes mellitus. *Gynecological Endocrinology*. 2007;23(6):356-360.

Serrano, E., Leiferman, J., and Dauber, S. Self-efficacy and health behaviors toward the prevention of diabetes among high risk individuals living in Appalachia. *Journal of Community Health*. 2007;32(2):121-133.

Sievenpiper, J. L., Carleton, A. J., Chatha, S., Jiang, H. Y., de Souza, R. J., Beyene, J., Kendall, C. W., and Jenkins, D. J. Heterogeneous effects of fructose on blood lipids in individuals with type 2 diabetes: systematic review and meta-analysis of experimental trials in humans. *Diabetes Care*. 2009;32(10):1930-1937.

Soell, M., Feki, A., Hannig, M., Sano, H., Pinget, M., and Selimovic, D. Chromogranin A detection in saliva of type 2 diabetes patients. *Bosnian Journal of Basic Medical Sciences*. 2010;10(1):2-8.

Song, Y., Manson, J. E., Tinker, L., Howard, B. V., Kuller, L. H., Nathan, L., Rifai, N., and Liu, S. Insulin sensitivity and insulin secretion determined by homeostasis model assessment and risk of diabetes in a multiethnic cohort of women: the Women's Health Initiative Observational Study. *Diabetes Care*. 2007;30(7):1747-1752.

Stirban, A., Nandreaan, S., Negrean, M., Koschinsky, T., and Tschoepe, D. Skin autofluorescence increases postprandially in human subjects. *Diabetes Technology & Therapeutics*. 2008;10(3):200-205.

Stone, M. A., Burden, A. C., Burden, M., Baker, R., and Khunti, K. Near patient testing for glycated

haemoglobin in people with Type 2 diabetes mellitus managed in primary care: acceptability and satisfaction. *Diabetic Medicine*. 2007;24(7):792-795.

Sturt, J. A., Whitlock, S., Fox, C., Hearnshaw, H., Farmer, A. J., Wakelin, M., Eldridge, S., Griffiths, F., and Dale, J. Effects of the Diabetes Manual 1:1 structured education in primary care. *Diabetic Medicine*. 2008;25(6):722-731.

Suzuki, K., Yanagawa, T., Shibasaki, T., Kaniwa, N., Hasegawa, R., and Tohkin, M. Effect of CYP2C9 genetic polymorphisms on the efficacy and pharmacokinetics of glimepiride in subjects with type 2 diabetes. *Diabetes Research & Clinical Practice*. 2006;72(2):148-154.

Sweet, S. N., Fortier, M. S., Guerin, E., Tulloch, H., Sigal, R. J., Kenny, G. P., and Reid, R. D. Understanding physical activity in adults with type 2 diabetes after completing an exercise intervention trial: A mediation model of self-efficacy and autonomous motivation. *Psychology Health & Medicine*. 2009;14(4):419-429.

Swellam, M., Sayed, Mahmoud, and Abdel-Fatah Ali, A. Clinical implications of adiponectin and inflammatory biomarkers in type 2 diabetes mellitus. *Disease Markers*. 2009;27(6):269-278.

Szecsényi, J., Rosemann, T., Joos, S., Peters-Klimm, F., and Miksch, A. German diabetes disease management programs are appropriate for restructuring care according to the chronic care model: an evaluation with the patient assessment of chronic illness care instrument. *Diabetes Care*. 2008;31(6):1150-1154.

Szepietowska, B., Gorska, M., and Szelachowska, M. Plasma relaxin concentration is related to beta-cell function and insulin sensitivity in women with type 2 diabetes mellitus. *Diabetes Research & Clinical Practice*. 2008;79(3):e1-e3.

Tabrizi, J. S., Wilson, A. J., Coyne, E. T., and O'Rourke, P. K. Review of patient-reported type 2 diabetes service quality. *Australian Health Review*. 2008;32(1):23-33.

Tabrizi, J. S., Wilson, A. J., O'Rourke, P. K., and Coyne, E. T. Patient perspectives on consistency of medical care with recommended care in type 2 diabetes. *Diabetes Care*. 2007;30(11):2855-2856.

Tamita, K., Katayama, M., Takagi, T., Akasaka, T., Yamamuro, A., Kaji, S., Morioka, S., and Kihara, Y. Impact of newly diagnosed abnormal glucose tolerance on long-term prognosis in patients with acute myocardial infarction. *Circulation Journal*. 2007;71(6):834-841.

Tangelder, G. J., Van der Heijde, R. G., Polak, B. C., and Ringens, P. J. Precision and reliability of retinal thickness measurements in foveal and extrafoveal areas of healthy and diabetic eyes. *Investigative Ophthalmology & Visual Science*. 2008;49(6):2627-2634.

Tapp, R. J., O'Neil, A., Shaw, J. E., Zimmet, P. Z., Oldenburg, B. F., and AusDiab Study, Group. Is there a link between components of health-related functioning and incident impaired glucose metabolism and type 2 diabetes? The Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Diabetes Care*. 2010;33(4):757-762.

Tapp, R. J., Tikellis, G., Wong, T. Y., Harper, C. A., Zimmet, P. Z., Shaw, J. E., Australian Diabetes, Obesity, and Lifestyle Study, Group. Longitudinal association of glucose metabolism with retinopathy: results from the Australian Diabetes Obesity and Lifestyle (AusDiab) study. *Diabetes Care*. 2008;31(7):1349-1354.

Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A., Pirraglia, P. A., and Wu, W. C. Pharmacist-led group medical appointment model in type 2 diabetes. *Diabetes Educator*. 2010;36(1):109-117.

Taylor, J. D., Fletcher, J. P., and Tiarks, J. Impact of physical therapist-directed exercise counseling combined with fitness center-based exercise training on muscular strength and exercise capacity in

people with type 2 diabetes: a randomized clinical trial. *Physical Therapy*. 2009;89(9):884-892.

Taylor, J. D. The impact of a supervised strength and aerobic training program on muscular strength and aerobic capacity in individuals with type 2 diabetes. *Journal of Strength & Conditioning Research*. 2007;21(3):824-830.

Taylor, J. D. The impact of electronic mail versus print delivery of an exercise program on muscular strength and aerobic capacity in people with type 2 diabetes. *Journal of Strength & Conditioning Research*. 2008;22(5):1696-1704.

Tervaert, T. W., Mooyaart, A. L., Amann, K., Cohen, A. H., Cook, H. T., Drachenberg, C. B., Ferrario, F., Fogo, A. B., Haas, M., de Heer, E., Joh, K., Noel, L. H., Radhakrishnan, J., Seshan, S. V., Bajema, I. M., Bruijn, J. A., and Renal Pathology, Society. Pathologic classification of diabetic nephropathy. *Journal of the American Society of Nephrology*. 2010;21(4):556-563.

Tesch, G. H. MCP-1/CCL2: a new diagnostic marker and therapeutic target for progressive renal injury in diabetic nephropathy. *American Journal of Physiology - Renal Physiology*. 2008;294(4):F697-F701.

Thomaseth, K., Pavan, A., Berria, R., Glass, L., DeFronzo, R., and Gastaldelli, A. Model-based assessment of insulin sensitivity of glucose disposal and endogenous glucose production from double-tracer oral glucose tolerance test. *Computer Methods & Programs in Biomedicine*. 2008;89(2):132-140.

Thornberry, N. A. and Weber, A. E. Discovery of JANUVIA (Sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. *Current Topics in Medicinal Chemistry*. 2007;7(6):557-568.

Tiberti, C., Giordano, C., Locatelli, M., Bosi, E., Bottazzo, G. F., Buzzetti, R., Cucinotta, D., Galluzzo, A., Falorni, A., and Dotta, F. Identification of tyrosine phosphatase 2(256-760) construct as a new, sensitive marker for the detection of islet autoimmunity in type 2 diabetic patients: the non-insulin requiring autoimmune diabetes (NIRAD) study 2. *Diabetes*. 2008;57(5):1276-1283.

Tikellis, G., Wang, J. J., Tapp, R., Simpson, R., Mitchell, P., Zimmet, P. Z., Shaw, J., and Wong, T. Y. The relationship of retinal vascular calibre to diabetes and retinopathy: the Australian Diabetes, Obesity and Lifestyle (AusDiab) study. *Diabetologia*. 2007;50(11):2263-2271.

Toprak, O. Conflicting and new risk factors for contrast induced nephropathy. *Journal of Urology*. 2007;178(6):2277-2283.

Toshihiro, M., Saito, K., Takikawa, S., Takebe, N., Onoda, T., and Satoh, J. Psychosocial factors are independent risk factors for the development of Type 2 diabetes in Japanese workers with impaired fasting glucose and/or impaired glucose tolerance. *Diabetic Medicine*. 2008;25(10):1211-1217.

Triyanti, K., Suhardjono, Soewondo, P., and Shatri, H. Renal function decrement in type 2 diabetes mellitus patients in Cipto Mangunkusumo Hospital. *Acta Medica Indonesiana*. 2008;40(4):192-200.

Troughton, J., Jarvis, J., Skinner, C., Robertson, N., Khunti, K., and Davies, M. Waiting for diabetes: perceptions of people with pre-diabetes: a qualitative study. *Patient Education & Counseling*. 2008;72(1):88-93.

Tsai, C. Y., Tung, T. H., Woung, L. C., Liu, J. H., Lee, F. L., Shih, H. C., Chen, S. J., and Chou, P. Population-based study of cataract surgery among patients with type 2 diabetes in Kinmen, Taiwan. *Canadian Journal of Ophthalmology*. 2007;42(2):262-267.

Tseng, C. H., Chong, C. K., Tseng, C. P., Shau, W. Y., and Tai, T. Y. Hypertension is the most important component of metabolic syndrome in the association with ischemic heart disease in Taiwanese type 2 diabetic patients. *Circulation Journal*. 2008;72(9):1419-1424.

Turner-McGrievy, G. M., Barnard, N. D., Cohen, J., Jenkins, D. J., Gloede, L., and Green, A. A. Changes in nutrient intake and dietary quality among participants with type 2 diabetes following a low-

- fat vegan diet or a conventional diabetes diet for 22 weeks. *Journal of the American Dietetic Association*. 2008;108(10):1636-1645.
- Uchigata, Y., Otani, T., Takaike, H., Miura, J., Osawa, M., Tukahara, S., Kasahara, T., and Iwamoto, Y. Time-course changes in clinical features of early-onset Japanese type 1 and type 2 diabetes: TWMU hospital-based study. *Diabetes Research & Clinical Practice*. 2008;82(1):80-86.
- Uehara, Y., Makino, H., Seiki, K., Urade, Y., and Kidney, L. Pgds Clinical Research. Urinary excretions of lipocalin-type prostaglandin D synthase predict renal injury in type-2 diabetes: a cross-sectional and prospective multicentre study. *Nephrology Dialysis Transplantation*. 2009;24(2):475-482.
- Ueki, K. Weight loss and blood pressure reduction in obese subjects in response to nutritional guidance using information communication technology. *Clinical and experimental hypertension (New York, N.Y.)*. 2009;(3):231-240.
- Ueta, I., Saito, Y., Hosoe, M., Okamoto, M., Ohkita, H., Shirai, S., Tamura, H., and Jinno, K. Breath acetone analysis with miniaturized sample preparation device: in-needle preconcentration and subsequent determination by gas chromatography-mass spectroscopy. *Journal of Chromatography B: Analytical Technologies in the Biomedical & Life Sciences*. 2009;877(24):2551-2556.
- Umpierrez, G. E., Smiley, D., Robalino, G., Peng, L., Gosmanov, A. R., and Kitabchi, A. E. Lack of lipotoxicity effect on β -cell dysfunction in ketosis-prone type 2 diabetes. *Diabetes Care*. 2010;33(3):626-631.
- Unal, R., Yao-Borengasser, A., Varma, V., Rasouli, N., Labbate, C., Kern, P. A., and Ranganathan, G. Matrix metalloproteinase-9 is increased in obese subjects and decreases in response to pioglitazone. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2993-3001.
- Valensi, P. and Cosson, E. It is not yet the time to stop screening diabetic patients for silent myocardial ischaemia. *Diabetes & Metabolism*. 2010;36(2):91-96.
- Vambergue, A., Dognin, C., Boulogne, A., Rejou, M. C., Biaisque, S., and Fontaine, P. Increasing incidence of abnormal glucose tolerance in women with prior abnormal glucose tolerance during pregnancy: DIAGEST 2 study. *Diabetic Medicine*. 2008;25(1):58-64.
- van Bruggen, J. A., Gorter, K. J., Stolk, R. P., and Rutten, G. E. Shared and delegated systems are not quick remedies for improving diabetes care: a systematic review. *Primary care diabetes*. 2007;1(2):59-68.
- van Winkel, R., De Hert, M., Wampers, M., Van Eyck, D., Hanssens, L., Scheen, A., and Peuskens, J. Major changes in glucose metabolism, including new-onset diabetes, within 3 months after initiation of or switch to atypical antipsychotic medication in patients with schizophrenia and schizoaffective disorder. *Journal of Clinical Psychiatry*. 2008;69(3):472-479.
- Venkatesham, A., Srinivas, M., Krishna, D. R., and Narayana, P. Differential expression of dipeptidyl peptidase-IV (DPP-IV) in Indian type-2 diabetic population. *Journal of the Association of Physicians of India*. 2009;57:627-630.
- Verhoeven, F., van Gemert-Pijnen, L., Dijkstra, K., Nijland, N., Seydel, E., and Stehouder, M. The contribution of teleconsultation and videoconferencing to diabetes care: a systematic literature review. *Journal of Medical Internet Research*. 2007;9(5):e37.
- Vincent, D., Pasvogel, A., and Barrera, L. A feasibility study of a culturally tailored diabetes intervention for Mexican Americans. *Biological Research for Nursing*. 2007;9(2):130-141.
- Wahab, S., Mahmood, N., Shaikh, Z., and Kazmi, W. H. Frequency of retinopathy in newly diagnosed type 2 diabetes patients. *JPMA - Journal of the Pakistan Medical Association*. 2008;58(10):557-561.
- Wang, C. H., Leung, C. H., Liu, S. C., and Chung, C. H. Safety and effectiveness of rosiglitazone in

- type 2 diabetes patients with nonalcoholic Fatty liver disease. *Journal of the Formosan Medical Association*. 2006;105(9):743-752.
- Wang, J. J., Li, H. B., Kinnunen, L., Hu, G., Jarvinen, T. M., Miettinen, M. E., Yuan, S., and Tuomilehto, J. How well does the metabolic syndrome defined by five definitions predict incident diabetes and incident coronary heart disease in a Chinese population?. *Atherosclerosis*. 2007;192(1):161-168.
- Wang, T., Xiao, X. H., Li, W. H., Wang, H., Sun, Q., Yuan, T., and Yang, G. H. Effects of glucagon on islet beta cell function in patients with diabetes mellitus. *Chinese Medical Sciences Journal*. 2008;23(2):117-120.
- Wangberg, S. C. An Internet-based diabetes self-care intervention tailored to self-efficacy. *Health Education Research*. 2008;23(1):170-179.
- Warunek, D. and Stankovic, A. K. Evaluation of lancets for pain perception and capillary blood volume for glucose monitoring. *Clinical Laboratory Science*. 2008;21(4):215-218.
- Weires, M. B., Tausch, B., Haug, P. J., Edwards, C. Q., Wetter, T., and Cannon-Albright, L. A. Familiality of diabetes mellitus. *Experimental & Clinical Endocrinology & Diabetes*. 2007;115(10):634-640.
- Welch, G., Garb, J., Zagarins, S., Lendel, I., and Gabbay, R. A. Nurse diabetes case management interventions and blood glucose control: results of a meta-analysis. *Diabetes Research & Clinical Practice*. 2010;88(1):1-6.
- Wells, B. J., Jain, A., Arrigain, S., Yu, C., Rosenkrans, W. A., Jr., and Kattan, M. W. Predicting 6-year mortality risk in patients with type 2 diabetes. *Diabetes Care*. 2008;31(12):2301-2306.
- Wens, J., Vermeire, E., Hearnshaw, H., Lindenmeyer, A., Biot, Y., and van Royen, P. Educational interventions aiming at improving adherence to treatment recommendations in type 2 diabetes: A sub-analysis of a systematic review of randomised controlled trials. *Diabetes Research & Clinical Practice*. 2008;79(3):377-388.
- Weymiller, A. J., Montori, V. M., Jones, L. A., Gafni, A., Guyatt, G. H., Bryant, S. C., Christianson, T. J., Mullan, R. J., and Smith, S. A. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. *Archives of Internal Medicine*. 2007;167(10):1076-1082.
- White, K. M., Terry, D. J., Troup, C., and Rempel, L. A. Behavioral, normative and control beliefs underlying low-fat dietary and regular physical activity behaviors for adults diagnosed with type 2 diabetes and/or cardiovascular disease. *Psychology Health & Medicine*. 2007;12(4):485-494.
- Whittemore, R. Culturally competent interventions for Hispanic adults with type 2 diabetes: a systematic review. *Journal of Transcultural Nursing*. 2007;18(2):157-166.
- Williams, G. C., Lynch, M., and Glasgow, R. E. Computer-assisted intervention improves patient-centered diabetes care by increasing autonomy support. *Health Psychology*. 2007;26(6):728-734.
- Worley, M. M. Testing a pharmacist-patient relationship quality model among older persons with diabetes. *Research In Social & Administrative Pharmacy*. 2006;2(1):1-21.
- Wu, C. Z., Pei, D., Hsieh, A. T., Wang, K., Lin, J. D., Lee, L. H., Chu, Y. M., Hsiao, F. C., Pei, C., and Hsia, T. L. Comparison of insulin sensitivity, glucose sensitivity, and first phase insulin secretion in patients treated with repaglinide or gliclazide. *Archives of Pharmacal Research*. 2010;33(3):411-416.
- Wu, H. Y., Chen, L. L., Zheng, J., Liao, Y. F., and Zhou, M. Simple anthropometric indices in relation to cardiovascular risk factors in Chinese type 2 diabetic patients. *Chinese Journal of Physiology*. 2007;50(3):135-142.

Xiang, G. D., Sun, H. L., Zhao, L. S., Hou, J., Yue, L., and Xu, L. The antioxidant alpha-lipoic acid improves endothelial dysfunction induced by acute hyperglycaemia during OGTT in impaired glucose tolerance. *Clinical Endocrinology*. 2008;68(5):716-723.

Xu, M., Li, X. Y., Wang, J. G., Wang, X. J., Huang, Y., Cheng, Q., Huang, H. E., Li, R., Xiang, J., Tan, J. R., Dai, M., and Ning, G. Retinol-binding protein 4 is associated with impaired glucose regulation and microalbuminuria in a Chinese population. *Diabetologia*. 2009;52(8):1511-1519.

Yamakawa, M. and Makimoto, K. Positive experiences of type 2 diabetes in Japanese patients: an exploratory qualitative study. *International Journal of Nursing Studies*. 2008;45(7):1032-1041.

Yamakoshi, M. and Kawazu, S. Lucica MI urinary myoinositol kit: a new diagnostic test for diabetes mellitus and glucose intolerance. *Molecular Diagnosis & Therapy*. 2008;12(3):189-191.

Yang, L., Zhou, Z. G., Tan, S. Z., Huang, G., Jin, P., Yan, X., Li, X., Peng, H., and Hagopian, W. Carboxypeptidase-H autoantibodies differentiate a more latent subset of autoimmune diabetes from phenotypic type 2 diabetes among Chinese adults. *Annals of the New York Academy of Sciences*. 2008;1150:263-266.

Yang, Y. H., Zhang, S., Cui, J. F., Lu, B., Dong, X. H., Song, X. Y., Liu, Y. K., Zhu, X. X., and Hu, R. M. Diagnostic potential of serum protein pattern in Type 2 diabetic nephropathy. *Diabetic Medicine*. 2007;24(12):1386-1392.

Yates, T., Davies, M., Brady, E., Webb, D., Gorely, T., Bull, F., Talbot, D., Sattar, N., and Khunti, K. Walking and inflammatory markers in individuals screened for type 2 diabetes. *Preventive Medicine*. 2008;47(4):417-421.

Yates, T., Davies, M., Gorely, T., Bull, F., and Khunti, K. Effectiveness of a pragmatic education program designed to promote walking activity in individuals with impaired glucose tolerance: a randomized controlled trial. *Diabetes Care*. 2009;32(8):1404-1410.

Yoshikawa, R., Wada, J., Seiki, K., Matsuoka, T., Miyamoto, S., Takahashi, K., Ota, S., Taniai, K., Hida, K., Yamakado, M., Shikata, K., Uehara, Y., Urade, Y., and Makino, H. Urinary PGDS levels are associated with vascular injury in type 2 diabetes patients. *Diabetes Research & Clinical Practice*. 2007;76(3):358-367.

Yusuff, K. B., Obe, O., and Joseph, B. Y. Adherence to anti-diabetic drug therapy and self management practices among type-2 diabetics in Nigeria. *Pharmacy World & Science*. 2008;30(6):876-883.

Zachariadou, T., Stoffers, H. E., Christophi, C. A., Philalithis, A., and Lionis, C. Implementing the European guidelines for cardiovascular disease prevention in the primary care setting in Cyprus: lessons learned from a health care services study. *BMC Health Services Research*. 2008;8:148.

Zbidi, H., Lopez, J. J., Amor, N. B., Bartegi, A., Salido, G. M., and Rosado, J. A. Enhanced expression of STIM1/Orai1 and TRPC3 in platelets from patients with type 2 diabetes mellitus. *Blood Cells Molecules & Diseases*. 2009;43(2):211-213.

Zhang, Q., Tang, N., Schepmoes, A. A., Phillips, L. S., Smith, R. D., and Metz, T. O. Proteomic profiling of nonenzymatically glycated proteins in human plasma and erythrocyte membranes. *Journal of Proteome Research*. 2008;7(5):2025-2032.

Zhang, X., Norris, S. L., Chowdhury, F. M., Gregg, E. W., and Zhang, P. The effects of interventions on health-related quality of life among persons with diabetes: a systematic review. *Medical Care*. 2007;45(9):820-834.

Zhao, G., Ford, E. S., Li, C., and Mokdad, A. H. Compliance with physical activity recommendations in US adults with diabetes. *Diabetic Medicine*. 2008;25(2):221-227.

Zhou, L., Deng, W., Fang, P., He, D., Zhang, W., Liu, K., and Hu, R. Prevalence, incidence and risk factors of chronic heart failure in the type 2 diabetic population: systematic review. *Current Diabetes Reviews*. 2009;5(3):171-184.

Zhou, M., Ma, X., Li, H., Pan, X., Tang, J., Gao, Y., Hou, X., Lu, H., Bao, Y., and Jia, W. Serum osteocalcin concentrations in relation to glucose and lipid metabolism in Chinese individuals. *European Journal of Endocrinology*. 2009;161(5):723-729.

Zisser, H. C., Bailey, T. S., Schwartz, S., Ratner, R. E., and Wise, J. Accuracy of the SEVEN continuous glucose monitoring system: comparison with frequently sampled venous glucose measurements. *Journal of Diabetes Science & Technology*. 2009;3(5):1146-1154.

Zloczower, M., Reznick, A. Z., Zouby, R. O., and Nagler, R. M. Relationship of flow rate, uric acid, peroxidase, and superoxide dismutase activity levels with complications in diabetic patients: can saliva be used to diagnose diabetes?. *Antioxidants & Redox Signaling*. 2007;9(6):765-773.

Level 2: Study Design

Dietary measures for type 2 diabetes. Weight loss and a Mediterranean-type diet, with no foods off-limits. *Prescrire International*. 2009;18(103):224.

Exenatide: new drug. Type 2 diabetes for some overweight patients. *Prescrire International*. 2007;16(92):228-231.

FIELD study supports the value of fenofibrate in type 2 diabetes management. Good glycaemic control achieved with no weight gain. *Cardiovascular Journal of Africa*. 2007;18(3):205-206.

Liraglutide (Victoza) for type 2 diabetes. *Medical Letter on Drugs & Therapeutics*. 2010;52(1335):25-27.

PERISCOPE: pioglitazone offers the right cluster of effects to confer benefit in type 2 diabetes. *Cardiovascular Journal of Africa*. 2008;19(3):159-162.

Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits. *Cardiovascular Journal of Africa*. 2007;18(6):400.

Rimonabant improves weight and glycaemic control: first oral antidiabetic therapy in newly diagnosed type 2 diabetics. *Cardiovascular Journal of Africa*. 2008;19(5):282-283.

Sitagliptin: new drug. Type 2 diabetes: limited efficacy, too many unknown risks. *Prescrire International*. 2008;17(93):12-15.

Vildagliptin and vildagliptin/metformin: new drug. Same limited efficacy as sitagliptin in type 2 diabetes. *Prescrire International*. 2008;17(97):188.

Aaboe, K., Krarup, T., Madsbad, S., and Holst, J. J. GLP-1: physiological effects and potential therapeutic applications. *Diabetes, Obesity & Metabolism*. 2008;10(11):994-1003.

Absetz, P., Valve, R., Oldenburg, B., Heinonen, H., Nissinen, A., Fogelholm, M., Ilvesmaki, V., Talja, M., and Uutela, A. Type 2 diabetes prevention in the "real world": one-year results of the GOAL Implementation Trial. *Diabetes Care*. 2007;30(10):2465-2470.

Adriaanse, M. C., Twisk, J. W., Dekker, J. M., Spijkerman, A. M., Nijpels, G., Heine, R. J., and Snoek, F. J. Perceptions of risk in adults with a low or high risk profile of developing type 2 diabetes; a cross-sectional population-based study. *Patient Education & Counseling*. 2008;73(2):307-312.

Ahren, B. Clinical results of treating type 2 diabetic patients with sitagliptin, vildagliptin or saxagliptin-diabetes control and potential adverse events. *Best Practice & Research Clinical Endocrinology &*

Metabolism. 2009;23(4):487-498.

Ali, Y. S., Linton, M. F., and Fazio, S. Targeting cardiovascular risk in patients with diabetes: management of dyslipidemia. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2008;15(2):142-146.

Al-Ozairi, E., Sibal, L., and Home, P. Counterpoint: A Diabetes Outcome Progression Trial (ADOPT): good for sulfonylureas?. *Diabetes Care*. 2007;30(6):1677-1680.

Ambady, R. and Chamukuttan, S. Early diagnosis and prevention of diabetes in developing countries. *Reviews in Endocrine & Metabolic Disorders*. 2008;9(3):193-201.

Anselmino, M. Cardiovascular prevention in type 2 diabetes mellitus patients: the role of oral glucose-lowering agents. *Journal of Diabetes & its Complications*. 2009;23(6):427-433.

Arca, M. Atorvastatin efficacy in the prevention of cardiovascular events in patients with diabetes mellitus and/or metabolic syndrome. *Drugs*. 2007;67 Suppl 1:43-54.

Argyropoulou, G. and Doupis, J. DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. *Advances in Therapy*. 2009;26(3):272-280.

Asghar, O., Al-Sunni, A., Khavandi, K., Khavandi, A., Withers, S., Greenstein, A., Heagerty, A. M., and Malik, R. A. Diabetic cardiomyopathy. *Clinical Science*. 2009;116(10):741-760.

Bain, S. C. Treatment of type 2 diabetes mellitus with orally administered agents: advances in combination therapy. *Endocrine Practice*. 2009;15(7):750-762.

Baker, S., Jerums, G., and Proietto, J. Effects and clinical potential of very-low-calorie diets (VLCDs) in type 2 diabetes. *Diabetes Research & Clinical Practice*. 2009;85(3):235-242.

Baynard, T., Carhart, R. L., Jr., Ploutz-Snyder, L. L., Weinstock, R. S., and Kanaley, J. A. Short-term training effects on diastolic function in obese persons with the metabolic syndrome. *Obesity*. 2008;16(6):1277-1283.

Bloem, C. J. and Chang, A. M. Short-term exercise improves beta-cell function and insulin resistance in older people with impaired glucose tolerance. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(2):387-392.

Bloomgarden, Z. T. Exploring treatment strategies for type 2 diabetes. *Diabetes Care*. 2007;30(10):2737-2745.

Bobb, A., Gale, D., Manmohan, S., Mohammed, A., Seetahal, F., Small, P., and Mungrue, K. The impact of the chronic disease assistance plan (CDAP) on the control of type 2 diabetes in Trinidad. *Diabetes Research & Clinical Practice*. 2008;80(3):360-364.

Boehm, C. M. and Smith, S. Altering the course. Screening for prediabetes. *Advance for Nurse Practitioners*. 2007;15(11):43-46.

Boltri, J. M., Davis-Smith, Y. M., Seale, J. P., Shellenberger, S., Okosun, I. S., and Cornelius, M. E. Diabetes prevention in a faith-based setting: results of translational research. *Journal of Public Health Management & Practice*. 2008;14(1):29-32.

Bosi, E., Lucotti, P., Setola, E., Monti, L., and Piatti, P. M. Incretin-based therapies in type 2 diabetes: a review of clinical results. *Diabetes Research & Clinical Practice*. 2008;82 Suppl 2:S102-S107.

Botomino, A., Bruppacher, R., Krahenbuhl, S., and Hersberger, K. E. Change of body weight and lifestyle of persons at risk for diabetes after screening and counselling in pharmacies. *Pharmacy World & Science*. 2008;30(3):222-226.

Bourdel-Marchasson, I., Helmer, C., Barberger-Gateau, P., Peuchant, E., Fevrier, B., Ritchie, K., and

Dartigues, J. F. Characteristics of undiagnosed diabetes in community-dwelling French elderly: the 3C study. *Diabetes Research & Clinical Practice*. 2007;76(2):257-264.

Brooks, A. M. and Thacker, S. M. Dapagliflozin for the treatment of type 2 diabetes. *Annals of Pharmacotherapy*. 2009;43(7):1286-1293.

Brown, J. B., Conner, C., and Nichols, G. A. Secondary failure of metformin monotherapy in clinical practice. *Diabetes Care*. 2010;33(3):501-506.

Califf, R. M., Boolell, M., Haffner, S. M., Bethel, M. A., McMurray, J., Duggal, A., Holman, R. R., and Group, Navigator Study. Prevention of diabetes and cardiovascular disease in patients with impaired glucose tolerance: rationale and design of the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research (NAVIGATOR) Trial. *American Heart Journal*. 2008;156(4):623-632.

Campbell, R. K. and White, J. R., Jr. More choices than ever before: emerging therapies for type 2 diabetes. *Diabetes Educator*. 2008;34(3):518-534.

Campbell, R. K. Type 2 diabetes: where we are today: an overview of disease burden, current treatments, and treatment strategies. *Journal of the American Pharmacists Association: JAPhA*. 2009;49 Suppl 1:S3-S9.

Ceriello, A., Colagiuri, S., Gerich, J., Tuomilehto, J., and Guideline Development, Group. Guideline for management of postmeal glucose. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(4):S17-S33.

Chandra, S. T., Priya, G., Khurana, M. L., Jyotsna, V. P., Sreenivas, V., Dwivedi, S., and Ammini, A. C. Comparison of gliclazide with insulin as initial treatment modality in newly diagnosed type 2 diabetes. *Diabetes Technology & Therapeutics*. 2008;10(5):363-368.

Charfen, M. A., Ipp, E., Kaji, A. H., Saleh, T., Qazi, M. F., and Lewis, R. J. Detection of undiagnosed diabetes and prediabetic states in high-risk emergency department patients. *Academic Emergency Medicine*. 2009;16(5):394-402.

Choy, C. K., Rodgers, J. E., Nappi, J. M., and Haines, S. T. Type 2 diabetes mellitus and heart failure. *Pharmacotherapy*. 2008;28(2):170-192.

Chung, H. K., Chae, J. S., Hyun, Y. J., Paik, J. K., Kim, J. Y., Jang, Y., Kwon, H. M., Song, Y. D., Lee, H. C., and Lee, J. H. Influence of adiponectin gene polymorphisms on adiponectin level and insulin resistance index in response to dietary intervention in overweight-obese patients with impaired fasting glucose or newly diagnosed type 2 diabetes. *Diabetes Care*. 2009;32(4):552-558.

Cogneau, J., Balkau, B., Weill, A., Liard, F., and Simon, D. Assessment of diabetes screening by general practitioners in France: the EPIDIA Study. *Diabetic Medicine*. 2006;23(7):803-807.

Cohen, A. and Horton, E. S. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control. *Current Medical Research & Opinion*. 2007;23(4):905-917.

Cole, A., Nathan, D. M., Savaria-Porter, E., Copeland, P., Turchin, A., Brunt, M., Zusman, R., Barrett, J. A., Wexler, D., Case, E., McMahon, G. T., and Mort, E. An algorithm for the care of type 2 diabetes. *Critical Pathways in Cardiology: A Journal of Evidence-Based Medicine*. 2009;8(4):156-165.

Contreras, F., Foullioux, C., Pacheco, B., Maroun, C., Bolivar, H., Lares, M., Leal, E., Cano, R., Bermudez, V., and Velasco, M. Effect of drugs interacting with the dopaminergic receptors on glucose levels and insulin release in healthy and type 2 diabetic subjects. *American Journal of Therapeutics*. 2008;15(4):397-402.

Cook, M. N., Girman, C. J., Stein, P. P., and Alexander, C. M. Initial monotherapy with either metformin or sulphonylureas often fails to achieve or maintain current glycaemic goals in patients with

Type 2 diabetes in UK primary care. *Diabetic Medicine*. 2007;24(4):350-358.

Cooper-DeHoff, R. M. and Pepine, C. J. Metabolic syndrome and cardiovascular disease: challenges and opportunities. *Clinical Cardiology*. 2007;30(12):593-597.

Crepaldi, G., Carruba, M., Comaschi, M., Del Prato, S., Frajese, G., and Paolisso, G. Dipeptidyl peptidase 4 (DPP-4) inhibitors and their role in Type 2 diabetes management. *Journal of Endocrinological Investigation*. 2007;30(7):610-614.

Cubbon, R., Kahn, M., and Kearney, M. T. Secondary prevention of cardiovascular disease in type 2 diabetes and prediabetes: a cardiologist's perspective. *International Journal of Clinical Practice*. 2008;62(2):287-299.

Dailey, G. E. Using prandial insulin to achieve glycemic control in type 2 diabetes. *Journal of Family Practice*. 2007;56(9):735-742.

Dhillon, S. and Weber, J. Saxagliptin. *Drugs*. 2009;69(15):2103-2114.

Doggrell, S. A. Clinical trials with thiazolidinediones in subjects with Type 2 diabetes--is pioglitazone any different from rosiglitazone?. *Expert Opinion on Pharmacotherapy*. 2008;9(3):405-420.

Drew Bg, Duffy S. J. F. High-density lipoprotein modulates glucose metabolism in patients with type 2 diabetes mellitus. *Circulation*. 2009;119(15):2103-2111.

Dullaart Rp, de Vries. Serum paraoxonase-I activity is unaffected by short-term administration of simvastatin, bezafibrate, and their combination in type 2 diabetes mellitus. *European Journal of Clinical Investigation*. 2009;39(3):200-203.

Eborall, H., Davies, R., Kinmonth, A. L., Griffin, S., and Lawton, J. Patients' experiences of screening for type 2 diabetes: prospective qualitative study embedded in the ADDITION (Cambridge) randomised controlled trial. *Bmj*. 2007;335(7618):490.

Eldin, W. S., Emara, M., and Shoker, A. Prediabetes: a must to recognise disease state. *International Journal of Clinical Practice*. 2008;62(4):642-648.

Evans, P., Langley, P., and Gray, D. P. Diagnosing type 2 diabetes before patients complain of diabetic symptoms--clinical opportunistic screening in a single general practice. *Family Practice*. 2008;25(5):376-381.

Fadini, G. P., Pucci, L., Vanacore, R., Baesso, I., Penno, G., Balbarini, A., Di Stefano, R., Miccoli, R., de Kreutzenberg, S., Coracina, A., Tiengo, A., Agostini, C., Del Prato, S., and Avogaro, A. Glucose tolerance is negatively associated with circulating progenitor cell levels. *Diabetologia*. 2007;50(10):2156-2163.

Fahrbach, J., Jacober, S., Jiang, H., and Martin, S. The DURABLE trial study design: comparing the safety, efficacy, and durability of insulin glargine to insulin lispro mix 75/25 added to oral antihyperglycemic agents in patients with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(5):831-838.

Farah, R., Shurtz-Swirski, R., and Lapin, O. Intensification of oxidative stress and inflammation in type 2 diabetes despite antihyperglycemic treatment. *Cardiovascular Diabetology*. 2008;7:20.

Fasy, E. A. and Buse, J. B. Treatment of postprandial hyperglycemia in type 2 diabetes. *Postgraduate Medicine*. 2001;110(6 Suppl):14-19.

Fonseca, V. A. Early identification and treatment of insulin resistance: impact on subsequent prediabetes and type 2 diabetes. *Clinical Cornerstone*. 2007;8 Suppl 7:S7-18.

Fonseca, V. A. Identification and treatment of prediabetes to prevent progression to type 2 diabetes.

Clinical Cornerstone. 2008;9(2):51-59.

Fraser, A., Abel, R., Lawlor, D. A., Fraser, D., and Elhayany, A. A modified Mediterranean diet is associated with the greatest reduction in alanine aminotransferase levels in obese type 2 diabetes patients: results of a quasi-randomised controlled trial. *Diabetologia*. 2008;51(9):1616-1622.

Furber, S., Monger, C., Franco, L., Mayne, D., Jones, L. A., Laws, R., and Waters, L. The effectiveness of a brief intervention using a pedometer and step-recording diary in promoting physical activity in people diagnosed with type 2 diabetes or impaired glucose tolerance. *Health Promotion Journal of Australia*. 2008;19(3):189-195.

Garber, A. J. and Sharma, M. D. Update: vildagliptin for the treatment of Type 2 diabetes. *Expert Opinion on Investigational Drugs*. 2008;17(1):105-113.

Garber, A. J. and Spann, S. J. An overview of incretin clinical trials. *Journal of Family Practice*. 2008;57(9 Suppl):S10-S18.

Garber, A. J., Handelsman, Y., Einhorn, D., Bergman, D. A., Bloomgarden, Z. T., Fonseca, V., Garvey, W. T., Gavin, J. R., III, Grunberger, G., Horton, E. S., Jellinger, P. S., Jones, K. L., Lebovitz, H., Levy, P., McGuire, D. K., Moghissi, E. S., and Nesto, R. W. Diagnosis and management of prediabetes in the continuum of hyperglycemia: when do the risks of diabetes begin? A consensus statement from the American College of Endocrinology and the American Association of Clinical Endocrinologists. *Endocrine Practice*. 2008;14(7):933-946.

Giugliano, D., Ceriello, A., and Esposito, K. Are there specific treatments for the metabolic syndrome?. *American Journal of Clinical Nutrition*. 2008;87(1):8-11.

Goldberg, R. B. Thiazolidinediones and vascular damage. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2007;14(2):108-115.

Goldfine, A. B. Modulating LDL cholesterol and glucose in patients with type 2 diabetes mellitus: targeting the bile acid pathway. *Current Opinion in Cardiology*. 2008;23(5):502-511.

Goldfine, A. B. The rough road for rosiglitazone. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2008;15(2):113-117.

Greenfield, J. R., Farooqi, I. S., Keogh, J. M., Henning, E., Habib, A. M., Blackwood, A., Reimann, F., Holst, J. J., and Gribble, F. M. Oral glutamine increases circulating glucagon-like peptide 1, glucagon, and insulin concentrations in lean, obese, and type 2 diabetic subjects. *American Journal of Clinical Nutrition*. 2009;89(1):106-113.

Gupta, M., Braga, M. B., and Verma, S. A randomized, controlled trial of the effects of rosiglitazone on adipokines, and inflammatory and fibrinolytic markers in diabetic patients: study design and protocol. *Canadian Journal of Cardiology*. 2008;24(10):e65-e69.

Hanefeld, M. and Schaper, F. Acarbose: oral anti-diabetes drug with additional cardiovascular benefits. *Expert Review of Cardiovascular Therapy*. 2008;6(2):153-163.

Hanefeld, M. Cardiovascular benefits and safety profile of acarbose therapy in prediabetes and established type 2 diabetes. *Cardiovascular Diabetology*. 2007;6:20.

Hanif, M. W., Valsamakis, G., Dixon, A., Boutsiadis, A., Jones, A. F., Barnett, A. H., and Kumar, S. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. *Diabetes, Obesity & Metabolism*. 2008;10(9):755-762.

Harris, M. Challenges in diabetes management. *Australian Family Physician*. 2008;37(9):716-720.

Havale, S. H. and Pal, M. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase-4 for the treatment of type 2 diabetes. *Bioorganic & Medicinal Chemistry*. 2009;17(5):1783-1802.

Henry, R. R. Evolving concepts of type 2 diabetes management with oral medications: new approaches to an old disease. *Current Medical Research & Opinion*. 2008;24(8):2189-2202.

Herman, G. A., Stein, P. P., Thornberry, N. A., and Wagner, J. A. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes: focus on sitagliptin. *Clinical Pharmacology & Therapeutics*. 2007;81(5):761-767.

Herman, W. H. and Fajans, S. S. Hemoglobin A1c for the diagnosis of diabetes: practical considerations. *Polskie Archiwum Medycyny Wewnętrznej*. 2010;120(1-2):37-40.

Hermansen, K. and Mortensen, L. S. Bodyweight changes associated with antihyperglycaemic agents in type 2 diabetes mellitus. *Drug Safety*. 2007;30(12):1127-1142.

Hermansen, M. L., Eriksen, N. M., Mortensen, L. S., Holm, L., and Hermansen, K. Can the Glycemic Index (GI) be used as a tool in the prevention and management of Type 2 diabetes?. *The Review of Diabetic Studies*. 2006;3(2):61-71.

Hofso, D., Jenssen, T., Hager, H., Roislien, J., and Hjelmessaeth, J. Fasting plasma glucose in the screening for type 2 diabetes in morbidly obese subjects. *Obesity Surgery*. 2010;20(3):302-307.

Horton, E. S. Can newer therapies delay the progression of type 2 diabetes mellitus?. *Endocrine Practice*. 2008;14(5):625-638.

Hunt, K. J. and Conway, D. L. Who returns for postpartum glucose screening following gestational diabetes mellitus?. *American Journal of Obstetrics & Gynecology*. 2008;198(4):404.

Idris, I. and Donnelly, R. Dipeptidyl peptidase-IV inhibitors: a major new class of oral antidiabetic drug. *Diabetes, Obesity & Metabolism*. 2007;9(2):153-165.

Inami, N., Nomura, S., Shouzu, A., Omoto, S., Kimura, Y., Takahashi, N., Tanaka, A., Nanba, M., Shouda, Y., and Iwasaka, T. Effects of pitavastatin on adiponectin in patients with hyperlipidemia. *Pathophysiology of Haemostasis & Thrombosis*. 2007;36(1):1-8.

Janssen, P. G., Gorter, K. J., Stolk, R. P., and Rutten, G. E. Screen detected subjects with type 2 diabetes and impaired glucose tolerance have more adverse cardiovascular risk than subjects with impaired fasting glucose especially when they are obese: the ADDITION Netherlands study. *Primary care diabetes*. 2007;1(2):69-74.

Joffe, H. V., Parks, M. H., and Temple, R. Impact of cardiovascular outcomes on the development and approval of medications for the treatment of diabetes mellitus. *Reviews in Endocrine & Metabolic Disorders*. 2010;11(1):21-30.

Jones, L. H. and Ficca, M. Is Acanthosis Nigricans a reliable indicator for risk of type 2 diabetes?. *Journal of School Nursing*. 2007;23(5):247-251.

Jones, L. The Collaborative Study Group Trial: The Effect of Sulodexide in Overt Type 2 Diabetic Nephropathy. *ClinicalTrials.gov*, National Institutes of Health [<http://www.clinicaltrials.gov>]. 2007.

Jones, M. C. Therapies for diabetes: pramlintide and exenatide. *American Family Physician*. 2007;75(12):1831-1835.

Juul, L., Sandbaek, A., Foldspang, A., Frydenberg, M., Borch-Johnsen, K., and Lauritzen, T. Adherence to guidelines in people with screen-detected type 2 diabetes, ADDITION, Denmark. *Scandinavian Journal of Primary Health Care*. 2009;27(4):223-231.

Kahn, S. E. and Zinman, B. Point: Recent long-term clinical studies support an enhanced role for thiazolidinediones in the management of type 2 diabetes. *Diabetes Care*. 2007;30(6):1672-1676.

Kalaitzidis, R. and Bakris, G. Pathogenesis and treatment of microalbuminuria in patients with diabetes:

the road ahead. *Journal of Clinical Hypertension*. 2009;11(11):636-643.

Kar, P. and Holt, R. I. The effect of sulphonylureas on the microvascular and macrovascular complications of diabetes. *Cardiovascular Drugs & Therapy*. 2008;22(3):207-213.

Karasik, A., Aschner, P., Katzeff, H., Davies, M. J., and Stein, P. P. Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trials. *Current Medical Research & Opinion*. 2008;24(2):489-496.

Karastergiou, K. and Kaski, J. C. Medical management of the diabetic patient with coronary artery disease. *Current Pharmaceutical Design*. 2008;14(25):2527-2536.

Karjalainen, J., Peltonen, M., Vanhala, M., Korpi-Hyovalti, E., Puolijoki, H., Saltevo, J., Oksa, H., Saaristo, T., Tuomilehto, J., and Kujala, U. M. Leisure time physical activity in individuals with screen-detected type 2 diabetes compared to those with known type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;81(1):110-116.

Karter, A. J., Moffet, H. H., Liu, J., Parker, M. M., Ahmed, A. T., Go, A. S., and Selby, J. V. Glycemic response to newly initiated diabetes therapies. *American Journal of Managed Care*. 2007;13(11):598-606.

Kato, M., Noda, M., Suga, H., Matsumoto, M., and Kanazawa, Y. Fasting plasma glucose and incidence of diabetes --- implication for the threshold for impaired fasting glucose: results from the population-based Omiya MA cohort study. *Journal of Atherosclerosis & Thrombosis*. 2009;16(6):857-861.

Katon, W. J. The comorbidity of diabetes mellitus and depression. *American Journal of Medicine*. 2008;121(11 Suppl 2):S8-15.

Katula, J. A., Vitolins, M. Z., Rosenberger, E. L., Blackwell, C., Espeland, M. A., Lawlor, M. S., Rejeski, W. J., and Goff, D. C. Healthy Living Partnerships to Prevent Diabetes (HELP PD): design and methods. *Contemporary Clinical Trials*. 2010;31(1):71-81.

Kaul, S. and Diamond, G. A. Rosiglitazone and cardiovascular risk. *Current Atherosclerosis Reports*. 2008;10(5):398-404.

Kaushik, S. V., Plaisance, E. P., Kim, T., Huang, E. Y., Mahurin, A. J., Grandjean, P. W., and Mathews, S. T. Extended-release niacin decreases serum fetuin-A concentrations in individuals with metabolic syndrome. *Diabetes/Metabolism Research Reviews*. 2009;25(5):427-434.

Kearney-Schwartz, A., Virion, J. M., Stoltz, J. F., Drouin, P., and Zannad, F. Haemorheological disturbances in hypertensive type 2 diabetic patients--influence of antihypertensive therapy. *Fundamental & Clinical Pharmacology*. 2007;21(4):387-396.

Keller, U. From obesity to diabetes. *International Journal for Vitamin & Nutrition Research*. 2006;76(4):172-177.

Kilckinen, A., Heistaro, S., Laatikainen, T., Janus, E., Chapman, A., Absetz, P., and Dunbar, J. Prevention of type 2 diabetes in a primary health care setting. Interim results from the Greater Green Triangle (GGT) Diabetes Prevention Project. *Diabetes Research & Clinical Practice*. 2007;76(3):460-462.

Kilpelainen To, Lakka. Physical activity modifies the effect of SNPs in the SLC2A2 (GLUT2) and ABCC8 (SUR1) genes on the risk of developing type 2 diabetes. *Physiological Genomics*. 2007;31(2):264-272.

Kirwan, J. P., Solomon, T. P., Wojta, D. M., Staten, M. A., and Holloszy, J. O. Effects of 7 days of exercise training on insulin sensitivity and responsiveness in type 2 diabetes mellitus. *American Journal*

of Physiology - Endocrinology & Metabolism. 2009;297(1):E151-E156.

Kivimaki, M., Tabak, A. G., Batty, G. D., Singh-Manoux, A., Jokela, M., Akbaraly, T. N., Witte, D. R., Brunner, E. J., Marmot, M. G., and Lawlor, D. A. Hyperglycemia, type 2 diabetes, and depressive symptoms: the British Whitehall II study. *Diabetes Care*. 2009;32(10):1867-1869.

Klein Woolthuis, E. P., de Grauw, W. J., van Gerwen, W. H., van den Hoogen, H. J., van de Lisdonk, E. H., Metsemakers, J. F., and van Weel, C. Screening for type 2 diabetes in primary care using a stepwise protocol: the Diabscreen study. *Primary care diabetes*. 2007;1(4):199-202.

Klonoff, D. C. The personalized medicine for diabetes meeting summary report. *Journal of Diabetes Science & Technology*. 2009;3(4):677-679.

Kobalava, Z. D., Kotovskaya, Y. V., Villevalde, S. V., Moiseev, V. S., and Study, Argus. Treating hypertension by rational use of diuretics: results of the Russian ARGUS-2 Study. *Current Medical Research & Opinion*. 2009;25(9):2229-2237.

Kocic, R., Spirovski, D., Ciric, V., and Velija-Asimi, Z. Impact of diet, physical activity, lipid status and glycoregulation in estimation of score (systematic coronary risk evaluation) for ten years in postmenopausal women. *Bosnian Journal of Basic Medical Sciences*. 2007;7(3):197-204.

Koh, D., Miller, Y. D., Marshall, A. L., Brown, W. J., and McIntyre, D. Health-enhancing physical activity behaviour and related factors in postpartum women with recent gestational diabetes mellitus. *Journal of Science & Medicine in Sport*. 2010;13(1):42-45.

Korhonen, P., Aarnio, P., Saaresranta, T., Jaatinen, P., and Kantola, I. Glucose homeostasis in hypertensive subjects. *Hypertension*. 2008;51(4):945-949.

Koshiyama, H., Taniguchi, A., Tanaka, K., Kagimoto, S., Fujioka, Y., Hirata, K., Nakamura, Y., Iwakura, A., Hara, K., Yamamoto, T., Kuroe, A., Ohya, M., Fujimoto, S., Hamamoto, Y., Honjo, S., Ikeda, H., Nabe, K., Tsuda, K., Inagaki, N., Seino, Y., Kume, N., Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism, and Endocrinology, Investigators. Effects of pitavastatin on lipid profiles and high-sensitivity CRP in Japanese subjects with hypercholesterolemia: Kansai Investigation of Statin for Hyperlipidemic Intervention in Metabolism and Endocrinology (KISHIMEN) investigators. *Journal of Atherosclerosis & Thrombosis*. 2008;15(6):345-350.

Kruger, D. F. Exploring the pharmacotherapeutic options for treating type 2 diabetes. *Diabetes Educator*. 2008;34 Suppl 3:60S-65S.

Krysiak, R., Stachura-Kulach, A., and Okopien, B. Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances. *Pharmacological Reports: PR*. 2010;62(1):120-130.

Kulasa, K. M. and Henry, R. R. Pharmacotherapy of hyperglycemia. *Expert Opinion on Pharmacotherapy*. 2009;10(15):2415-2432.

Kutoh, E. and Fukushima, T. Insulin-dependent actions of pioglitazone in newly diagnosed, drug naive patients with type 2 diabetes. *Endocrine*. 2009;35(3):333-340.

Laatikainen, T., Dunbar, J. A., Chapman, A., Kilkkinen, A., Vartiainen, E., Heistaro, S., Philpot, B., Absetz, P., Bunker, S., O'Neil, A., Reddy, P., Best, J. D., and Janus, E. D. Prevention of type 2 diabetes by lifestyle intervention in an Australian primary health care setting: Greater Green Triangle (GGT) Diabetes Prevention Project. *BMC Public Health*. 2007;7:249.

Lafontan, M., Piazza, P. V., and Girard, J. Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients. *Diabetes & Metabolism*. 2007;33(2):85-95.

Lakerveld, J., Bot, S. D., Chinapaw, M. J., van Tulder, M. W., van Oppen, P., Dekker, J. M., and Nijpels, G. Primary prevention of diabetes mellitus type 2 and cardiovascular diseases using a cognitive

behavior program aimed at lifestyle changes in people at risk: Design of a randomized controlled trial. *BMC Endocrine Disorders*. 2008;8:6.

Lakka, T. A. and Laaksonen, D. E. Physical activity in prevention and treatment of the metabolic syndrome. *Applied Physiology, Nutrition, & Metabolism = Physiologie Appliquee, Nutrition et Metabolisme*. 2007;32(1):76-88.

LaMarr, B., Valdez, C., Driscoll, K., and Ryan, M. Influence of pharmacist intervention on prescribing of angiotensin-converting-enzyme inhibitors, angiotensin II-receptor blockers, and aspirin for diabetic patients. *American Journal of Health-System Pharmacy*. 2010;67(4):290-294.

Lambers Heerspink, H. J., Agarwal, R., Coyne, D. W., Parving, H. H., Ritz, E., Remuzzi, G., Audhya, P., Amdahl, M. J., Andress, D. L., and de Zeeuw, D. The selective vitamin D receptor activator for albuminuria lowering (VITAL) study: study design and baseline characteristics. *American Journal of Nephrology*. 2009;30(3):280-286.

Lan, C., Su, T. C., Chen, S. Y., and Lai, J. S. Effect of T'ai chi chuan training on cardiovascular risk factors in dyslipidemic patients. *Journal of Alternative & Complementary Medicine*. 2008;14(7):813-819.

LaSalle, J. R. Reaching HbA1c goals with saxagliptin in combination with other oral antidiabetic drugs. *Postgraduate Medicine*. 2010;122(1):144-152.

Lastra-Gonzalez, G., Manrique, C. M., Govindarajan, G., Whaley-Connell, A., and Sowers, J. R. Insights into the emerging cardiometabolic prevention and management of diabetes mellitus. *Expert Opinion on Pharmacotherapy*. 2005;6(13):2209-2221.

Lechleitner, M. Obesity and the metabolic syndrome in the elderly--a mini-review. *Gerontology*. 2008;54(5):253-259.

Lee, V. W., Ho, I. C., Chan, W. S., Tam, K. Y., and Lee, K. K. Statin utilization patterns for the primary prevention of cardiovascular events: a retrospective study in patients with diabetes mellitus in Hong Kong. *American Journal of Cardiovascular Drugs*. 2008;8(3):199-205.

Lee, W. J., Ser, K. H., Chong, K., Lee, Y. C., Chen, S. C., Tsou, J. J., Chen, J. C., and Chen, C. M. Laparoscopic sleeve gastrectomy for diabetes treatment in nonmorbidly obese patients: efficacy and change of insulin secretion. *Surgery*. 2010;147(5):664-669.

Leiter, L. A., Martineau, P., de Teresa, E., Farsang, C., Gaw, A., Gensini, G., Langer, A., Actfast, and investigators. How to reach LDL targets quickly in patients with diabetes or metabolic syndrome. *Journal of Family Practice*. 2008;57(10):661-668.

Leiter, L. A. Should you put all diabetic patients on statins?. *Journal of Family Practice*. 2007;56(4):294-300.

Lencioni, C., Lupi, R., and Del Prato, S. Beta-cell failure in type 2 diabetes mellitus. *Current Diabetes Reports*. 2008;8(3):179-184.

LeRoith, D. Dyslipidemia and glucose dysregulation in overweight and obese patients. *Clinical Cornerstone*. 2007;8(3):38-52.

LeRoith, D. Treatment of diabetes: a clinical update on insulin trials. *Clinical Cornerstone*. 2007;8(2):21-29.

Leung, P. S. and de Gasparo, M. Involvement of the pancreatic renin-angiotensin system in insulin resistance and the metabolic syndrome. *Journal of the CardioMetabolic Syndrome*. 2006;1(3):197-203.

Leung, P. S. Mechanisms of protective effects induced by blockade of the renin-angiotensin system: novel role of the pancreatic islet angiotensin-generating system in Type 2 diabetes. *Diabetic Medicine*.

2007;24(2):110-116.

Levy, P. Insulin analogs or premixed insulin analogs in combination with oral agents for treatment of type 2 diabetes. Medgenmed [Computer File]: Medscape General Medicine. 2007;9(2):12.

Lewin, A. J. and Weir, M. R. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial. Clinical Therapeutics. 2008;30(12):2354-2365.

Li, K., Li, L., Yang, M., Zong, H., Liu, H., and Yang, G. Effects of rosiglitazone on fasting plasma fibroblast growth factor-21 levels in patients with type 2 diabetes mellitus. European Journal of Endocrinology. 2009;161(3):391-395.

Liebl, A. Insulin intensification--the rationale and the target. International Journal of Clinical Practice. 2009;Supplement.(164):1-5.

Liese, A. D., Nichols, M., Sun, X., D'Agostino, R. B., Jr., and Haffner, S. M. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. Diabetes Care. 2009;32(8):1434-1436.

Likhari, T., Aulakh, T. S., Singh, B. M., and Gama, R. Does HbA1C predict isolated impaired fasting glycaemia in the oral glucose tolerance test in subjects with impaired fasting glycaemia?. Annals of Clinical Biochemistry. 2008;45(Pt 4):418-420.

Lin, S. F., Lin, P. K., Chang, F. L., and Tsai, R. K. Transient hyperopia after intensive treatment of hyperglycemia in newly diagnosed diabetes. Ophthalmologica. 2009;223(1):68-71.

Lingvay, I., Kaloyanova, P. F., Adams-Huet, B., Salinas, K., and Raskin, P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. Journal of Investigative Medicine. 2007;55(2):62-68.

Lingvay, I., Raskin, P., and Szczepaniak, L. S. Effect of insulin-metformin combination on hepatic steatosis in patients with type 2 diabetes. Journal of Diabetes & its Complications. 2007;21(3):137-142.

Lu, Y., Levin, G. V., and Donner, T. W. Tagatose, a new antidiabetic and obesity control drug. Diabetes, Obesity & Metabolism. 2008;10(2):109-134.

Lu, Z. X., Walker, K. Z., O'Dea, K., Sikaris, K. A., and Shaw, J. E. A1C for screening and diagnosis of type 2 diabetes in routine clinical practice. Diabetes Care. 2010;33(4):817-819.

Lukas, M. A. Beta blockade in diabetic heart failure. Heart Failure Clinics. 2006;2(1):89-99.

Lyseng-Williamson, K. A. Sitagliptin. Drugs. 2007;67(4):587-597.

Macfarlane, D. P., Paterson, K. R., and Fisher, M. Cardiovascular drugs as antidiabetic agents: evidence for the prevention of type 2 diabetes. Diabetes, Obesity & Metabolism. 2008;10(7):533-544.

Macic-Dzankovic, A., Dzankovic, F., Pojskic, B., and Velija-Asimi, Z. Evaluation of risk markers fluctuation during an initial therapy with rosiglitazone in patients suffering from metabolic syndrome. Bosnian Journal of Basic Medical Sciences. 2009;9(4):320-328.

Madsbad, S., Krarup, T., Deacon, C. F., and Holst, J. J. Glucagon-like peptide receptor agonists and dipeptidyl peptidase-4 inhibitors in the treatment of diabetes: a review of clinical trials. Current Opinion in Clinical Nutrition & Metabolic Care. 2008;11(4):491-499.

Madsbad, S. Exenatide and liraglutide: different approaches to develop GLP-1 receptor agonists (incretin mimetics)--preclinical and clinical results. Best Practice & Research Clinical Endocrinology & Metabolism. 2009;23(4):463-477.

Maegawa, H., Nishio, Y., Nakao, K., Ugi, S., Maeda, K., Uzu, T., and Kashiwagi, A. Short-term low-

- dosage pioglitazone treatment improves vascular dysfunction in patients with type 2 diabetes. *Endocrine Journal*. 2007;54(4):613-618.
- Mafong, D. D. and Henry, R. R. Exenatide as a treatment for diabetes and obesity: implications for cardiovascular risk reduction. *Current Atherosclerosis Reports*. 2008;10(1):55-60.
- Mai, K. S., Sandbaek, A., Borch-Johnsen, K., and Lauritzen, T. Are lifestyle changes achieved after participation in a screening programme for Type 2 diabetes? The ADDITION Study, Denmark. *Diabetic Medicine*. 2007;24(10):1121-1128.
- Majid, A. Prevention and management of coronary artery disease in patients with diabetes mellitus. *Acta Medica Indonesiana*. 2009;41(1):41-44.
- Makrilakis, K. and Katsilambros, N. Prediction and prevention of type 2 diabetes. *Hormones*. 2003;2(1):22-34.
- Malaisse, W. J. Mitiglinide: a rapid- and short-acting non-sulfonylurea insulinotropic agent for the treatment of type 2 diabetic patients. *Expert Opinion on Pharmacotherapy*. 2008;9(15):2691-2698.
- Mannucci, E. and Rotella, C. M. Future perspectives on glucagon-like peptide-1, diabetes and cardiovascular risk. *Nutrition Metabolism & Cardiovascular Diseases*. 2008;18(9):639-645.
- Marcus, R. L., Smith, S., Morrell, G., Addison, O., Dibble, L. E., Wahoff-Stice, D., and LaStayo, P. C. Comparison of combined aerobic and high-force eccentric resistance exercise with aerobic exercise only for people with type 2 diabetes mellitus.[Erratum appears in *Phys Ther*. 2009 Jan;89(1):103]. *Physical Therapy*. 2008;88(11):1345-1354.
- Marino, M. T. DPP-4 inhibitors. A new class of drugs for type 2 diabetes. *Diabetes Self-Management*. 25(4):60.
- Martin, C. L. Beyond glycemic control: the effects of incretin hormones in type 2 diabetes. *Diabetes Educator*. 2008;34 Suppl 3:66S-72S.
- Marx, N. and Walcher, D. Vascular effects of PPARgamma activators - from bench to bedside. *Progress in Lipid Research*. 2007;46(6):283-296.
- Mathieu, C. and Degrande, E. Vildagliptin: a new oral treatment for type 2 diabetes mellitus. *Vascular Health & Risk Management*. 2008;4(6):1349-1360.
- Mathieu, C. and Robbrecht, S. Reaching glycaemic targets while minimizing hypoglycaemia in insulin-treated type 2 diabetes patients. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 2:14-23.
- Mathur, R., Alexander, C. J., Yano, J., Trivax, B., and Azziz, R. Use of metformin in polycystic ovary syndrome. *American Journal of Obstetrics & Gynecology*. 2008;199(6):596-609.
- Matikainen, N., Kahri, J., and Taskinen, M. R. Reviewing statin therapy in diabetes--towards the best practise. *Primary care diabetes*. 2010;4(1):9-15.
- Matteucci, E. and Giampietro, O. Dipeptidyl peptidase-4 (CD26): knowing the function before inhibiting the enzyme. *Current Medicinal Chemistry*. 2009;16(23):2943-2951.
- Mazzone, T. Prevention of macrovascular disease in patients with diabetes mellitus: opportunities for intervention. *American Journal of Medicine*. 2007;120(9 Suppl 2):S26-S32.
- McBride, P. E., Einerson, J. A., Grant, H., Sargent, C., Underbakke, G., Vitcenda, M., Zeller, L., and Stein, J. H. Putting the Diabetes Prevention Program into practice: a program for weight loss and cardiovascular risk reduction for patients with metabolic syndrome or type 2 diabetes mellitus. *Journal of Nutrition, Health & Aging*. 2008;12(10):745S-749S.
- McFarlane, S. I. Role of angiotensin receptor blockers in diabetes: implications of recent clinical trials.

- Expert Review of Cardiovascular Therapy. 2009;7(11):1363-1371.
- McGuire, D. K., Winterfield, J. R., Rytlewski, J. A., and Ferrannini, E. Blocking the renin-angiotensin-aldosterone system to prevent diabetes mellitus. *Diabetes & Vascular Disease Research*. 2008;5(1):59-66.
- McIntosh, C. H. Dipeptidyl peptidase IV inhibitors and diabetes therapy. *Frontiers in Bioscience*. 2008;13:1753-1773.
- Mehta, A. Management of cardiovascular risk associated with insulin resistance, diabetes, and the metabolic syndrome. *Postgraduate Medicine*. 2010;122(3):61-70.
- Melton, C. E., Tucker, P. S., Fisher-Wellman, K. H., Schilling, B. K., and Bloomer, R. J. Acute exercise does not attenuate postprandial oxidative stress in prediabetic women. *Physician & Sportsmedicine*. 2009;37(1):27-36.
- Meredith, P. A. Candesartan cilexetil--a review of effects on cardiovascular complications in hypertension and chronic heart failure. *Current Medical Research & Opinion*. 2007;23(7):1693-1705.
- Metzger, B. E. Long-term outcomes in mothers diagnosed with gestational diabetes mellitus and their offspring. *Clinical Obstetrics & Gynecology*. 2007;50(4):972-979.
- Michishita, R., Shono, N., Kasahara, T., and Tsuruta, T. Effects of low intensity exercise therapy on early phase insulin secretion in overweight subjects with impaired glucose tolerance and type 2 diabetes mellitus. *Diabetes Research & Clinical Practice*. 2008;82(3):291-297.
- Migdalís, I. N. Effects of treatment of hypertension on cardiovascular outcome in type 2 diabetes. *Research Communications in Molecular Pathology & Pharmacology*. 2006;119(1-6):105-114.
- Mikhail, N. Incretin mimetics and dipeptidyl peptidase 4 inhibitors in clinical trials for the treatment of type 2 diabetes. *Expert Opinion on Investigational Drugs*. 2008;17(6):845-853.
- Miranda, V. P., Rodrigues, M. J., Goncalves, F. R., and Nunes, J. P. Effects of hypoglycemic agents on mortality and major cardiovascular outcomes in patients with type 2 diabetes mellitus: a narrative review [88]. *Revista Portuguesa de Cardiologia*. 2009;28(10):1099-1119.
- Mitri, J. and Hamdy, O. Diabetes medications and body weight. *Expert Opinion on Drug Safety*. 2009;8(5):573-584.
- Miyashita, Y., Endo, K., Saiki, A., Ban, N., Yamaguchi, T., Kawana, H., Nagayama, D., Ohira, M., Oyama, T., and Shirai, K. Effects of pitavastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, on cardio-ankle vascular index in type 2 diabetic patients. *Journal of Atherosclerosis & Thrombosis*. 2009;16(5):539-545.
- Mizuno, C. S., Chittiboyina, A. G., Kurtz, T. W., Pershadsingh, H. A., and Avery, M. A. Type 2 diabetes and oral antihyperglycemic drugs. *Current Medicinal Chemistry*. 2008;15(1):61-74.
- Mogos, T. and Dondoi, C. Evaluation of glycemic control of type II diabetes mellitus treated only with diet. *Romanian Journal of Internal Medicine*. 2007;45(2):205-208.
- Moore, K. B. and Saudek, C. D. Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus. *American Journal of Therapeutics*. 2008;15(5):484-491.
- Morales, J. Defining the role of insulin detemir in Basal insulin therapy. *Drugs*. 2007;67(17):2557-2584.
- Morrison, M. K., Collins, C. E., and Lowe, J. M. Postnatal testing for diabetes in Australian women following gestational diabetes mellitus. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2009;49(5):494-498.

Motomura, T., Okamoto, M., Kitamura, T., Yamamoto, H., Otsuki, M., Asanuma, N., Takagi, M., Kurebayashi, S., Hashimoto, K., Sumitani, S., Saito, H., Kouhara, H., Nshii, K., Nakao, M., Koga, M., Sato, B., Morimoto, Y., and Kasayama, S. Effects of pitavastatin on serum lipids and high sensitivity C-reactive protein in type 2 diabetic patients. *Journal of Atherosclerosis & Thrombosis*. 2009;16(5):546-552.

Nadeau, D. A. Partnering with patients to improve therapeutic outcomes: incretin-based therapy for type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):7-15.

Nag, S. S., Daniel, G. W., Bullano, M. F., Kamal-Bahl, S., Sajjan, S. G., Hu, H., and Alexander, C. LDL-C goal attainment among patients newly diagnosed with coronary heart disease or diabetes in a commercial HMO. *Journal of Managed Care Pharmacy*. 2007;13(8):652-663.

Nair, S. and Wilding, J. P. Sodium glucose cotransporter 2 inhibitors as a new treatment for diabetes mellitus. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(1):34-42.

Nakagami, H., Kaneda, Y., Ogihara, T., and Morishita, R. Endothelial dysfunction in hyperglycemia as a trigger of atherosclerosis. *Current Diabetes Reviews*. 2005;1(1):59-63.

Nauck, M. and Smith, U. Incretin-based therapy: how do incretin mimetics and DPP-4 inhibitors fit into treatment algorithms for type 2 diabetic patients?. *Best Practice & Research Clinical Endocrinology & Metabolism*. 2009;23(4):513-523.

Neumiller, J. J., White, J. R., Jr., and Campbell, R. K. Sodium-glucose co-transport inhibitors: progress and therapeutic potential in type 2 diabetes mellitus. *Drugs*. 2010;70(4):377-385.

Neumiller, J. J., Wood, L., and Campbell, R. K. Dipeptidyl peptidase-4 inhibitors for the treatment of type 2 diabetes mellitus. *Pharmacotherapy*. 2010;30(5):463-484.

Neumiller, J. J. Differential chemistry (structure), mechanism of action, and pharmacology of GLP-1 receptor agonists and DPP-4 inhibitors. *Journal of the American Pharmacists Association: JAPhA*. 2009;49 Suppl 1:S16-S29.

Neutel, J. M., Kereiakes, D. J., Waverczak, W. F., Stoakes, K. A., Xu, J., and Shojaee, A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. *Current Medical Research & Opinion*. 2010;26(3):721-728.

Nicolucci, A. and Rossi, M. C. Incretin-based therapies: a new potential treatment approach to overcome clinical inertia in type 2 diabetes. *Acta Bio-Medica de l Ateneo Parmense*. 2008;79(3):184-191.

Nielsen, J. V. and Joensson, E. Low-carbohydrate diet in type 2 diabetes. Stable improvement of bodyweight and glycemic control during 22 months follow-up. *Nutrition & Metabolism*. 2006;3:22.

Nomura, S., Shouzu, A., Omoto, S., Nishikawa, M., Fukuhara, S., and Iwasaka, T. Effect of valsartan on monocyte/endothelial cell activation markers and adiponectin in hypertensive patients with type 2 diabetes mellitus. *Thrombosis Research*. 2006;117(4):385-392.

Ober, S. K., Watts, S., and Lawrence, R. H. Insulin use in elderly diabetic patients. *Clinical Interventions In Aging*. 2006;1(2):107-113.

Ohira, M., Miyashita, Y., Ebisuno, M., Saiki, A., Endo, K., Koide, N., Oyama, T., Murano, T., Watanabe, H., and Shirai, K. Effect of metformin on serum lipoprotein lipase mass levels and LDL particle size in type 2 diabetes mellitus patients. *Diabetes Research & Clinical Practice*. 2007;78(1):34-41.

Oikawa, S., Kita, T., Mabuchi, H., Matsuzaki, M., Matsuzawa, Y., Nakaya, N., Saito, Y., Sasaki, J., Shimamoto, K., Itakura, H., and Group, J. Lit Study. Risk of coronary events in Japanese patients with

both hypercholesterolemia and type 2 diabetes mellitus on low-dose simvastatin therapy: implication from Japan Lipid Intervention Trial (J-LIT). *Atherosclerosis*. 2007;191(2):440-446.

Oliveros, R. A., Zion, A. S., Rosenberg, Y., Selvaraj, C. L., and Chilton, R. Impaired fasting glucose as a treatment target in diabetes management. *Current Cardiology Reports*. 2009;11(6):460-467.

Owens, D. R. and Bolli, G. B. Beyond the era of NPH insulin--long-acting insulin analogs: chemistry, comparative pharmacology, and clinical application. *Diabetes Technology & Therapeutics*. 2008;10(5):333-349.

Pan, C. Y. and Landen, H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. *Clinical Drug Investigation*. 2007;27(6):397-405.

Pan, C. Y. Reducing the risk of type 2 diabetes: early identification of high-risk individuals and treatment with acarbose. *Current Diabetes Reviews*. 2007;3(2):141-148.

Panikar, V., Joshi, S. R., Bukkavar, A., Nasikkar, N., and Santwana, C. Induction of long-term glycemic control in type 2 diabetic patients using pioglitazone and metformin combination. *Journal of the Association of Physicians of India*. 2007;55:333-337.

Panina, G. The DPP-4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond. *Diabetes, Obesity & Metabolism*. 2007;9 Suppl 1:32-39.

Paolisso, G. Pathophysiology of diabetes in elderly people. *Acta Bio-Medica de l Ateneo Parmense*. 2010;81 Suppl 1:47-53.

Patel, P. and Macerollo, A. Diabetes mellitus: diagnosis and screening. *American Family Physician*. 2010;81(7):863-870.

Pavlatou, M. G., Mastorakos, G., Lekakis, I., Liatis, S., Vamvakou, G., Zoumakis, E., Papassotiriou, I., Rabavilas, A. D., Katsilambros, N., and Chrousos, G. P. Chronic administration of an angiotensin II receptor antagonist resets the hypothalamic-pituitary-adrenal (HPA) axis and improves the affect of patients with diabetes mellitus type 2: preliminary results. *Stress*. 2008;11(1):62-72.

Payne, W. R., Walsh, K. J., Harvey, J. T., Livy, M. F., McKenzie, K. J., Donaldson, A., Atkinson, M. G., Keogh, J. B., Moss, R. S., Dunstan, D. W., and Hubbard, W. A. Effect of a low-resource-intensive lifestyle modification program incorporating gymnasium-based and home-based resistance training on type 2 diabetes risk in Australian adults. *Diabetes Care*. 2008;31(12):2244-2250.

Penfornis, A., Borot, S., and Raccach, D. Therapeutic approach of type 2 diabetes mellitus with GLP-1 based therapies. *Diabetes & Metabolism*. 2008;34 Suppl 2:S78-S90.

Penning-van Beest, F. J., Wolffenbuttel, B. H., and Herings, R. M. Haemoglobin A1c goal attainment in relation to dose in patients with diabetes mellitus taking metformin: a nested, case-control study. *Clinical Drug Investigation*. 2008;28(8):487-493.

Perez-Jauregui, J., Gonzalez-Cardel, A. M., Olay-Fuentes, G., Reza-Albarran, A., Mehta, R., and Aguilar-Salinas, C. A. Inclusion of educational messages in laboratory reports aids to complete the diagnostic workup of hyperglycemia. *Diabetes Care*. 2008;31(5):882-883.

Perico, N., Ruggenenti, P., and Remuzzi, G. Losartan in diabetic nephropathy. *Expert Review of Cardiovascular Therapy*. 2004;2(4):473-483.

Persson, F., Rossing, P., Schjoedt, K. J., Juhl, T., Tarnow, L., Stehouwer, C. D., Schalkwijk, C., Boomsma, F., Frandsen, E., and Parving, H. H. Time course of the antiproteinuric and antihypertensive effects of direct renin inhibition in type 2 diabetes. *Kidney International*. 2008;73(12):1419-1425.

Peters, A. Incretin-based therapies: review of current clinical trial data. *American Journal of Medicine*.

2010;123(3 Suppl):S28-S37.

Petrazzi, L., Grassi, D., Polidoro, L., D'Aurelio, A., Croce, G., Properzi, G., Tiberti, S., Desideri, G., and Ferri, C. Cardiovascular risk and cardiometabolic protection: role of glitazones. *Journal of Nephrology*. 2008;21(6):826-835.

Pfutzner, A., Weber, M. M., and Forst, T. Pioglitazone: update on an oral antidiabetic drug with antiatherosclerotic effects. *Expert Opinion on Pharmacotherapy*. 2007;8(12):1985-1998.

Pfutzner, A., Wilhelm, B., and Forst, T. Rosiglitazone and glimeperide: review of clinical results supporting a fixed dose combination. *Vascular Health & Risk Management*. 2007;3(2):211-220.

Pham, D. Q., Nogid, A., and Plakogiannis, R. Sitagliptin: a novel agent for the management of type 2 diabetes mellitus. *American Journal of Health-System Pharmacy*. 2008;65(6):521-531.

Philippe, J. and Raccach, D. Treating type 2 diabetes: how safe are current therapeutic agents?. *International Journal of Clinical Practice*. 2009;63(2):321-332.

Philis-Tsimikas, A. An update on the use of insulin detemir, with a focus on type 2 diabetes (drug evaluation update). *Expert Opinion on Pharmacotherapy*. 2008;9(12):2181-2195.

Poh, Z. X. and Goh, K. P. A current update on the use of alpha lipoic acid in the management of type 2 diabetes mellitus. *Endocrine, Metabolic & Immune Disorders Drug Targets*. 2009;9(4):392-398.

Policker, S., Haddad, W., and Yaniv, I. Treatment of type 2 diabetes using meal-triggered gastric electrical stimulation. *Israel Medical Association Journal: Imaj*. 2009;11(4):206-208.

Pratley, R. E. and Salsali, A. Inhibition of DPP-4: a new therapeutic approach for the treatment of type 2 diabetes. *Current Medical Research & Opinion*. 2007;23(4):919-931.

Pratley, R. E. Overview of glucagon-like peptide-1 analogs and dipeptidyl peptidase-4 inhibitors for type 2 diabetes. *Medscape journal of medicine*. 2008;10(7):171.

Quattrin, T. Inhaled insulin: a novel and non-invasive way for insulin administration?. *Current Drug Safety*. 2006;1(2):151-158.

Raccach, D. Options for the intensification of insulin therapy when basal insulin is not enough in type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2008;10 Suppl 2:76-82.

Raguenaud, M. E., Isaakidis, P., Reid, T., Chy, S., Keuky, L., Arellano, G., and Van Damme, W. Treating 4,000 diabetic patients in Cambodia, a high-prevalence but resource-limited setting: a 5-year study. *BMC Medicine*. 2009;7:33.

Raskin, P. Efficacy and safety of insulin detemir. *Endocrinology & Metabolism Clinics of North America*. 2007;36 Suppl 1:21-32.

Raskin, P. Oral combination therapy: repaglinide plus metformin for treatment of type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(12):1167-1177.

Rasmussen, S. S., Glumer, C., Sandbaek, A., Lauritzen, T., and Borch-Johnsen, K. Determinants of progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screened population: 3 year follow-up in the ADDITION study, Denmark. *Diabetologia*. 2008;51(2):249-257.

Rasmussen, S. S., Glumer, C., Sandbaek, A., Lauritzen, T., and Borch-Johnsen, K. Progression from impaired fasting glucose and impaired glucose tolerance to diabetes in a high-risk screening programme in general practice: the ADDITION Study, Denmark. *Diabetologia*. 2007;50(2):293-297.

Rasmussen, S. S., Glumer, C., Sandbaek, A., Lauritzen, T., Carstensen, B., and Borch-Johnsen, K. Short-term reproducibility of impaired fasting glycaemia, impaired glucose tolerance and diabetes The

ADDITION study, DK. *Diabetes Research & Clinical Practice*. 2008;80(1):146-152.

Ratner, R. E. Prevention of type 2 diabetes in women with previous gestational diabetes. *Diabetes Care*. 2007;30 Suppl 2:S242-S245.

Rave, K., Heise, T., Heinemann, L., and Boss, A. H. Inhaled Technosphere insulin in comparison to subcutaneous regular human insulin: time action profile and variability in subjects with type 2 diabetes. *Journal of Diabetes Science & Technology*. 2008;2(2):205-212.

Rave, K., Heise, T., Pfutzner, A., and Boss, A. H. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. *Diabetes Care*. 2007;30(9):2307-2308.

Riche, D. M. and McClendon, K. S. Role of statins for the primary prevention of cardiovascular disease in patients with type 2 diabetes mellitus. *American Journal of Health-System Pharmacy*. 2007;64(15):1603-1610.

Riegersperger, M. and Sunder-Plassmann, G. How to prevent progression to end stage renal disease. *Journal of Renal Care*. 2007;33(3):105-107.

Ripsin, C. M., Kang, H., and Urban, R. J. Management of blood glucose in type 2 diabetes mellitus. *American Family Physician*. 2009;79(1):29-36.

Riserus, U., Willett, W. C., and Hu, F. B. Dietary fats and prevention of type 2 diabetes. *Progress in Lipid Research*. 2009;48(1):44-51.

Ritz, E. Total cardiovascular risk management. *American Journal of Cardiology*. 2007;100(3A):53J-60J.

Rivellese, A. A., Giacco, R., Annuzzi, G., De Natale, C., Patti, L., Di Marino, L., Minerva, V., Costabile, G., Santangelo, C., Masella, R., and Riccardi, G. Effects of monounsaturated vs. saturated fat on postprandial lipemia and adipose tissue lipases in type 2 diabetes. *Clinical Nutrition*. 2008;27(1):133-141.

Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., and Berneis, K. Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors. *Expert Opinion on Investigational Drugs*. 2009;18(10):1495-1503.

Robles-Orsorio, L., Aguilar-Salinas, C. A., Mehta, R., Gomez-Perez, F. J., and Rull, J. A. Analysis of fasting plasma glucose values for optimal detection of abnormal responses on the oral glucose tolerance test in at-risk study subjects. *Endocrine Practice*. 2007;13(6):583-589.

Roche, E., Reig, J. A., Campos, A., Paredes, B., Isaac, J. R., Lim, S., Calne, R. Y., and Soria, B. Insulin-secreting cells derived from stem cells: clinical perspectives, hypes and hopes. *Transplant Immunology*. 2005;15(2):113-129.

Roman, G. Early insulin treatment to prevent cardiovascular disease in prediabetes and overt diabetes. *Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme*. 2009;41(2):116-122.

Rosenstock, J. and Fitchet, M. Vildagliptin: clinical trials programme in monotherapy and combination therapy for type 2 diabetes. *International Journal of Clinical Practice*. 2008;Supplement.(159):15-23.

Rosenstock, J. and Zinman, B. Dipeptidyl peptidase-4 inhibitors and the management of type 2 diabetes mellitus. *Current Opinion in Endocrinology, Diabetes & Obesity*. 2007;14(2):98-107.

Rosenzweig, J. L., Ferrannini, E., Grundy, S. M., Haffner, S. M., Heine, R. J., Horton, E. S., Kawamori, R., and Endocrine, Society. Primary prevention of cardiovascular disease and type 2 diabetes in patients at metabolic risk: an endocrine society clinical practice guideline. *Journal of Clinical Endocrinology &*

Metabolism. 2008;93(10):3671-3689.

Rossi, M. C. and Nicolucci, A. Liraglutide in type 2 diabetes: from pharmacological development to clinical practice. *Acta Bio-Medica de l Ateneo Parmense*. 2009;80(2):93-101.

Ruilope, L. M. New ADVANCEs in guidelines. *Journal of Hypertension - Supplement*. 2008;26(2):S16-S18.

Ryan, G., Briscoe, T. A., and Jobe, L. Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. *Drug design, development & therapy*. 2009;2:203-214.

Sadikot, S. M. and Mogensen, C. E. Risk of coronary artery disease associated with initial sulphonylurea treatment of patients with type 2 diabetes: a matched case-control study. *Diabetes Research & Clinical Practice*. 2008;82(3):391-395.

Sahay, B. K. Role of yoga in diabetes. *Journal of the Association of Physicians of India*. 2007;55:121-126.

Salinari, S., Bertuzzi, A., Iaconelli, A., Manco, M., and Mingrone, G. Twenty-four hour insulin secretion and beta cell NEFA oxidation in type 2 diabetic, morbidly obese patients before and after bariatric surgery. *Diabetologia*. 2008;51(7):1276-1284.

Sandbaek, A., Griffin, S. J., Rutten, G., Davies, M., Stolk, R., Khunti, K., Borch-Johnsen, K., Wareham, N. J., and Lauritzen, T. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. *Diabetologia*. 2008;51(7):1127-1134.

Schafer, S., Kantartzis, K., Machann, J., Venter, C., Niess, A., Schick, F., Machicao, F., Haring, H. U., Fritsche, A., and Stefan, N. Lifestyle intervention in individuals with normal versus impaired glucose tolerance. *European Journal of Clinical Investigation*. 2007;37(7):535-543.

Schneiderhan, M. E., Batscha, C. L., and Rosen, C. Assessment of a point-of-care metabolic risk screening program in outpatients receiving antipsychotic agents. *Pharmacotherapy*. 2009;29(8):975-987.

Schwarz, P. E., Gruhl, U., Bornstein, S. R., Landgraf, R., Hall, M., and Tuomilehto, J. The European perspective on diabetes prevention: development and Implementation of A European Guideline and training standards for diabetes prevention (IMAGE). *Diabetes & Vascular Disease Research*. 2007;4(4):353-357.

Schwarz, P. E., Li, J., Lindstrom, J., Bergmann, A., Gruhl, U., Saaristo, T., and Tuomilehto, J. How should the clinician most effectively prevent type 2 diabetes in the obese person at high risk?. *Current Diabetes Reports*. 2007;7(5):353-362.

Schwarz, P. E., Lindstrom, J., Kissimova-Scarbeck, K., Szybinski, Z., Barengo, N. C., Peltonen, M., Tuomilehto, J., and project, De Plan. The European perspective of type 2 diabetes prevention: diabetes in Europe--prevention using lifestyle, physical activity and nutritional intervention (DE-PLAN) project. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116(3):167-172.

Seshiah, V., Balaji, V., and Balaji, M. S. Scope for prevention of diabetes--'focus intrauterine milieu interieur'. *Journal of the Association of Physicians of India*. 2008;56:109-113.

Sharma, S. K., Al-Mustafa, M., Oh, S. J., Azar, S. T., Shestakova, M., Guler, S., and Vaz, J. A. Biphasic insulin aspart 30 treatment in patients with type 2 diabetes poorly controlled on prior diabetes treatment: results from the PRESENT study. *Current Medical Research & Opinion*. 2008;24(3):645-652.

Singh, K. P., Periyandavar, I., Rajadhyaksha, G. C., Jayaram, S., Mishra, A. B., Kinagi, S., Sharma, A., and Baliga, V. P. Evaluation of the efficacy, safety and tolerability of miglitol in adult Indian patients

with uncomplicated type 2 diabetes mellitus. *Journal of the Indian Medical Association*. 105(6):344.

Sipkoff, M. Prediabetes: prevalent and preventable but underdiagnosed and undertreated. *Managed Care*. 17(12):33-34.

Spain, M. and Edlund, B. J. Pharmacological management of type 2 diabetes in newly diagnosed older adults. *Journal of Gerontological Nursing*. 2009;35(7):16-21.

Steiner, G. Lipid lowering in the patients with prediabetes/metabolic syndrome: what is the evidence?. *Current Opinion in Lipidology*. 2008;19(6):585-591.

Stuckey, H. L., Dellasega, C., Graber, N. J., Mauger, D. T., Lendel, I., and Gabbay, R. A. Diabetes nurse case management and motivational interviewing for change (DYNAMIC): study design and baseline characteristics in the Chronic Care Model for type 2 diabetes. *Contemporary Clinical Trials*. 2009;30(4):366-374.

Stumvoll, M., Haring, H. U., and Matthaei, S. Metformin. *Endocrine Research*. 2007;32(1-2):39-57.

Subramanian, U., Ackermann, R. T., Brizendine, E. J., Saha, C., Rosenman, M. B., Willis, D. R., and Marrero, D. G. Effect of advanced access scheduling on processes and intermediate outcomes of diabetes care and utilization. *Journal of General Internal Medicine*. 2009;24(3):327-333.

Sulistio, M. S., Zion, A., Thukral, N., and Chilton, R. PPARgamma agonists and coronary atherosclerosis. *Current Atherosclerosis Reports*. 2008;10(2):134-141.

Sun, P., Wang, R., and Jacober, S. The effectiveness of insulin initiation regimens in patients with type 2 diabetes mellitus: a large national medical records review study comparing a basal insulin analogue to premixed insulin. *Current Medical Research & Opinion*. 2007;23(12):3017-3023.

Szewieczek, J., Dulawa, J., Strzalkowska, D., Batko-Szwaczka, A., and Hornik, B. Normal insulin response to short-term intense exercise is abolished in Type 2 diabetic patients treated with gliclazide. *Journal of Diabetes & its Complications*. 2009;23(6):380-386.

Szewieczek, J., Dulawa, J., Strzalkowska, D., Hornik, B., and Kawecki, G. Impact of the short-term, intense exercise on postprandial glycemia in type 2 diabetic patients treated with gliclazide. *Journal of Diabetes & its Complications*. 2007;21(2):101-107.

Tahrani, A. A., Piya, M. K., and Barnett, A. H. Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus. *Advances in Therapy*. 2009;26(3):249-262.

Taton, J., Piatkiewicz, P., and Czech, A. Does cellular glucose transport respond to a controlled diet and sulfonylurea therapy in type 2 diabetes mellitus?. *Endokrynologia Polska*. 2010;61(1):75-81.

Tatti, P., Arrigoni, F., Longobardi, A., Costanza, F., Di Blasi, P., and Merante, D. Retrospective analysis of rosiglitazone and macular oedema in patients with type 2 diabetes mellitus. *Clinical Drug Investigation*. 2008;28(5):327-332.

Taylor, C. and Hobbs, F. D. Type 2 diabetes, thiazolidinediones, and cardiovascular risk. *British Journal of General Practice*. 2009;59(564):520-524.

Taylor, J. R. and Campbell, K. M. Diabetes drug update: how 4 new options stack up. *Journal of Family Practice*. 2007;56(3):207-215.

Tenenbaum, A., Fisman, E. Z., Motro, M., and Adler, Y. Optimal management of combined dyslipidemia: what have we behind statins monotherapy?. *Advances in Cardiology*. 2008;45:127-153.

Thakur, S. S. and Supiano, M. A. Screening for common clinical conditions in older women. *Clinical Obstetrics & Gynecology*. 2007;50(3):767-775.

Thomas, G. N. and Tomlinson, B. Prevention of macrovascular disease in type 2 diabetic patients:

blockade of the renin-angiotensin-aldosterone system. *Current Diabetes Reviews*. 2008;4(1):63-78.

Thongtang, N. and Sriwijitkamol, A. Incretins: the novel therapy of type 2 diabetes. *Journal of the Medical Association of Thailand*. 2008;91(6):943-954.

Tibaldi, J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. *American Journal of Medicine*. 2008;121(6 Suppl):S20-S29.

Tiwari, A. Linagliptin, a dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. *Current Opinion in Investigational Drugs*. 2009;10(10):1091-1104.

Toft, A. D. European Association for the Study of Diabetes--43rd Annual Meeting. Therapeutic approaches: Part 2. 18-21 September 2007, Amsterdam, the Netherlands. *Idrugs*. 2007;10(11):769-771.

Toledo, F. G., Menshikova, E. V., Ritov, V. B., Azuma, K., Radikova, Z., DeLany, J., and Kelley, D. E. Effects of physical activity and weight loss on skeletal muscle mitochondria and relationship with glucose control in type 2 diabetes. *Diabetes*. 2007;56(8):2142-2147.

Toth, P. P. The role of statins in managing diabetic dyslipidemia. *Journal of Family Practice*. 2010;59(5 Suppl):S23-S29.

Tudiver, F. Primary care providers' perceptions of home diabetes telemedicine care in the IDEATel project. *The Journal of rural health : official journal of the American Rural Health Association and the National Rural Health Care Association*. 2007;23(1):55-61.

Tuomilehto, J. Nonpharmacologic therapy and exercise in the prevention of type 2 diabetes. *Diabetes Care*. 2009;32 Suppl 2:S189-S193.

Tuttle, K. R. Protein kinase C-beta inhibition for diabetic kidney disease. *Diabetes Research & Clinical Practice*. 2008;82 Suppl 1:S70-S74.

Tyrberg, M., Melander, A., Lovestam-Adrian, M., and Lindblad, U. Retinopathy in subjects with impaired fasting glucose: the NANSY-Eye baseline report. *Diabetes, Obesity & Metabolism*. 2008;10(8):646-651.

Ulrich, H., Snyder, B., and Garg, S. K. Combining insulins for optimal blood glucose control in type I and 2 diabetes: focus on insulin glulisine. *Vascular Health & Risk Management*. 2007;3(3):245-254.

Unger, J. and Nadeau, D. A. Defining the role of incretin mimetic therapy in the management of type 2 diabetes. *Journal of Family Practice*. 2007;56(12 Suppl New):S4-S10.

Unger, J. Diagnosis and management of type 2 diabetes and prediabetes. *Primary Care; Clinics in Office Practice*. 34(4):731-759.

Usui, I., Fujisaka, S., Yamazaki, K., Takano, A., Murakami, S., Yamazaki, Y., Urakaze, M., Hachiya, H., Takata, M., Senda, S., Iwata, M., Satoh, A., Sasaoka, T., Ak, N. D., Temaru, R., and Kobayashi, M. Telmisartan reduced blood pressure and HOMA-IR with increasing plasma leptin level in hypertensive and type 2 diabetic patients. *Diabetes Research & Clinical Practice*. 2007;77(2):210-214.

Utzschneider, K. M., Prigeon, R. L., Tong, J., Gerchman, F., Carr, D. B., Zraika, S., Udayasankar, J., Montgomery, B., Mari, A., and Kahn, S. E. Within-subject variability of measures of beta cell function derived from a 2 h OGTT: implications for research studies. *Diabetologia*. 2007;50(12):2516-2525.

Utzschneider, K. M., Tong, J., Montgomery, B., Udayasankar, J., Gerchman, F., Marcovina, S. M., Watson, C. E., Ligueros-Saylan, M. A., Foley, J. E., Holst, J. J., Deacon, C. F., and Kahn, S. E. The dipeptidyl peptidase-4 inhibitor vildagliptin improves beta-cell function and insulin sensitivity in subjects with impaired fasting glucose. *Diabetes Care*. 2008;31(1):108-113.

Uusitupa, M. Ten-year mortality and cardiovascular morbidity in the Finnish Diabetes Prevention

Study--secondary analysis of the randomized trial. *PloS one*. 2009;4(5):e5656.

Van Gaal, L. F., Gutkin, S. W., and Nauck, M. A. Exploiting the antidiabetic properties of incretins to treat type 2 diabetes mellitus: glucagon-like peptide 1 receptor agonists or insulin for patients with inadequate glycemic control?. *European Journal of Endocrinology*. 2008;158(6):773-784.

VanDeKoppel, S., Choe, H. M., and Sweet, B. V. Managed care perspective on three new agents for type 2 diabetes. *Journal of Managed Care Pharmacy*. 2008;14(4):363-380.

Vasudevan, M. M. and Ballantyne, C. M. Advances in lipid testing and management in patients with diabetes mellitus. *Endocrine Practice*. 2009;15(6):641-652.

Viberti, G., Lachin, J., Holman, R., Zinman, B., Haffner, S., Kravitz, B., Heise, M. A., Jones, N. P., O'Neill, M. C., Freed, M. I., Kahn, S. E., Herman, W. H., and for the, Adopt Study Group. A Diabetes Outcome Progression Trial (ADOPT): baseline characteristics of Type 2 diabetic patients in North America and Europe. *Diabetic Medicine*. 2006;23(12):1289-1294.

Villacorta, L., Schopfer, F. J., Zhang, J., Freeman, B. A., and Chen, Y. E. PPARgamma and its ligands: therapeutic implications in cardiovascular disease. *Clinical Science*. 2009;116(3):205-218.

Vistisen, D., Colagiuri, S., Borch-Johnsen, K., and Collaboration, Detect. Bimodal distribution of glucose is not universally useful for diagnosing diabetes. *Diabetes Care*. 2009;32(3):397-403.

Vivian, E. M. The pharmacist's role in maintaining adherence to insulin therapy in type 2 diabetes mellitus. *Consultant Pharmacist*. 2007;22(4):320-332.

Vuksan, V., Rogovik, A. L., Jovanovski, E., and Jenkins, A. L. Fiber facts: benefits and recommendations for individuals with type 2 diabetes. *Current Diabetes Reports*. 2009;9(5):405-411.

Wajchenberg, B. L. beta-cell failure in diabetes and preservation by clinical treatment. *Endocrine Reviews*. 2007;28(2):187-218.

Wajchenberg, B. L. Clinical approaches to preserve beta-cell function in diabetes. *Advances in Experimental Medicine & Biology*. 2010;654:515-535.

Wan, Q., Harris, M. F., Davies, G. P., Jayasinghe, U. W., Flack, J., Georgiou, A., Burns, J. R., and Penn, D. L. Cardiovascular risk management and its impact in Australian general practice patients with type 2 diabetes in urban and rural areas. *International Journal of Clinical Practice*. 2008;62(1):53-58.

Wang, J. H. Effects of Tai Chi exercise on patients with type 2 diabetes. *Medicine & Sport Science*. 2008;52:230-238.

Wang, J., Bao, Y. Q., Hu, C., Zhang, R., Wang, C. R., Lu, J. X., Jia, W. P., and Xiang, K. S. Effects of ABCA1 variants on rosiglitazone monotherapy in newly diagnosed type 2 diabetes patients. *Acta Pharmacologica Sinica*. 2008;29(2):252-258.

Weir, M. R. Effects of renin-angiotensin system inhibition on end-organ protection: can we do better?. *Clinical Therapeutics*. 2007;29(9):1803-1824.

White, J. R., Jr. Do people with diabetes need statins?. *Diabetes Educator*. 2008;34(4):664-673.

White, R. D. The treat-to-target A1C approach to control type 2 diabetes and prevent complications. *Advances in Therapy*. 2007;24(3):545-559.

Whitson, B. A., Leslie, D. B., Kellogg, T. A., Maddaus, M. A., Buchwald, H., Billington, C. J., and Ikramuddin, S. Entero-endocrine changes after gastric bypass in diabetic and nondiabetic patients: a preliminary study. *Journal of Surgical Research*. 2007;141(1):31-39.

Wiedeman, P. E. DPPIV inhibition: promising therapy for the treatment of type 2 diabetes. *Progress in Medicinal Chemistry*. 2007;45:63-109.

Woo, V. C. Dapagliflozin: where does it fit in the treatment of type 2 diabetes?. *Expert Opinion on Pharmacotherapy*. 2009;10(15):2527-2535.

Wu, T. J., Ou, H. Y., Chou, C. W., Hsiao, S. H., Lin, C. Y., and Kao, P. C. Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate. *Annals of Clinical & Laboratory Science*. 2007;37(2):158-166.

Wyness, L. Understanding the role of diet in type 2 diabetes prevention. *British Journal of Community Nursing*. 2009;14(9):374-379.

Xanthos, T., Ekmektzoglou, K. A., and Papadimitriou, L. Reviewing myocardial silent ischemia: specific patient subgroups. *International Journal of Cardiology*. 2008;124(2):139-148.

Yamana, A., Arita, M., Furuta, M., Shimajiri, Y., and Sanke, T. The angiotensin II receptor blocker telmisartan improves insulin resistance and has beneficial effects in hypertensive patients with type 2 diabetes and poor glycemic control. *Diabetes Research & Clinical Practice*. 2008;82(1):127-131.

Yancy, W. S., Jr., Foy, M., Chalecki, A. M., Vernon, M. C., and Westman, E. C. A low-carbohydrate, ketogenic diet to treat type 2 diabetes. *Nutrition & Metabolism*. 2005;2:34.

Yang, W., Gao, Y., Liu, G., Chen, L., Fu, Z., Zou, D., Feng, P., and Zhao, Z. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. *Current Medical Research & Opinion*. 2010;26(1):101-107.

Yates, T., Davies, M., and Khunti, K. Preventing type 2 diabetes: can we make the evidence work?. *Postgraduate Medical Journal*. 2009;85(1007):475-480.

Yazbeck, R., Howarth, G. S., and Abbott, C. A. Dipeptidyl peptidase inhibitors, an emerging drug class for inflammatory disease?. *Trends in Pharmacological Sciences*. 2009;30(11):600-607.

Ye, S. D., Zheng, M., Zhao, L. L., Qian, Y., Yao, X. M., Ren, A., Li, S. M., and Jing, C. Y. Intensive insulin therapy decreases urinary MCP-1 and ICAM-1 excretions in incipient diabetic nephropathy. *European Journal of Clinical Investigation*. 2009;39(11):980-985.

Yurgin, N., Secnik, K., and Lage, M. J. Antidiabetic prescriptions and glycemic control in German patients with type 2 diabetes mellitus: a retrospective database study. *Clinical Therapeutics*. 2007;29(2):316-325.

Zanolla, L. and Vassanelli, C. Reducing diabetes incidence through the inhibition of the renin-angiotensin system: a strategy for reducing cardiovascular mortality and morbidity?. *Journal of Cardiovascular Medicine*. 2007;8(7):473-482.

Zanuso, S., Jimenez, A., Pugliese, G., Corigliano, G., and Balducci, S. Exercise for the management of type 2 diabetes: a review of the evidence. *Acta Diabetologica*. 2010;47(1):15-22.

Zarowitz, B. J. and Conner, C. The intersection of safety and adherence: new incretin-based therapies in patients with type 2 diabetes mellitus. *Pharmacotherapy*. 2009;29(12 Pt 2):55S-67S.

Zeqiri, S., Ylli, A., and Zeqiri, N. The effect of physical activity in glycemia in patients with diabetes mellitus. *Medicinski Arhiv*. 2007;61(3):146-149.

Zhang, W. L., Lopez-Garcia, E., Li, T. Y., Hu, F. B., and Van Dam, R. M. Coffee consumption and risk of cardiovascular events and all-cause mortality among women with type 2 diabetes. *Diabetologia*. 2009;52(5):810-817.

Zhou, J., Jia, W., Bao, Y., Ma, X., Lu, W., Li, H., Hu, C., and Xiang, K. Glycemic variability and its responses to intensive insulin treatment in newly diagnosed type 2 diabetes. *Medical Science Monitor*. 2008;14(11):CR552-CR558.

Zidek, W., Schrader, J., Luders, S., Matthaei, S., Hasslacher, C., Hoyer, J., Bramlage, P., Sturm, C. D., and Paar, W. D. First-line antihypertensive treatment in patients with pre-diabetes: rationale, design and baseline results of the ADaPT investigation. *Cardiovascular Diabetology*. 2008;7:22.

Ziyadeh, N., McAfee, A. T., Koro, C., Landon, J., and Arnold Chan, K. The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a US health insurance database. *Clinical Therapeutics*. 2009;31(11):2665-2677.

Diabetes Updated Database Excluded Studies List

Level 2, Diabetes Screening is not the Focus

Almeida, F. A., Shetterly, S., Smith-Ray, R. L., and Estabrooks, P. A. Reach and effectiveness of a weight loss intervention in patients with prediabetes in Colorado. *Preventing Chronic Disease*. 2010;7(5):A103.

Amini, M., Timori, A., and Aminorroaya, A. Quality of care for first-degree relatives of type 2 diabetes patients diagnosed with diabetes at a screening program one year after diagnosis. *The Review of Diabetic Studies*. 2008;5(1):52-58.

Arai, K., Matoba, K., Hirao, K., Matsuba, I., Takai, M., Takeda, H., Kanamori, A., Yamauchi, M., Mori, H., and Terauchi, Y. Present status of sulfonylurea treatment for type 2 diabetes in Japan: second report of a cross-sectional survey of 15,652 patients. *Endocrine Journal*. 2010;57(6):499-507.

Arnolds, S., Dellweg, S., Clair, J., Dain, M. P., Nauck, M. A., Rave, K., and Kapitza, C. Further improvement in postprandial glucose control with addition of exenatide or sitagliptin to combination therapy with insulin glargine and metformin: a proof-of-concept study. *Diabetes Care*. 2010;33(7):1509-1515.

Aujla, N., Skinner, T. C., Khunti, K., and Davies, M. J. The prevalence of depressive symptoms in a white European and South Asian population with impaired glucose regulation and screen-detected Type 2 diabetes mellitus: a comparison of two screening tools. *Diabetic Medicine*. 2010;27(8):896-905.

Bansal, S., Wackers, F. J., Inzucchi, S. E., Chyun, D. A., Davey, J. A., Staib, L. H., Young, L. H., and DIAD, Study, I. Five-year outcomes in high-risk participants in the Detection of Ischemia in Asymptomatic Diabetics (DIAD) study: a post hoc analysis. *Diabetes Care*. 2011;34(1):204-209.

Bao, Y. Q., Zhou, J., Zhou, M., Cheng, Y. J., Lu, W., Pan, X. P., Tang, J. L., Lu, H. J., and Jia, W. P. Glipizide controlled-release tablets, with or without acarbose, improve glycaemic variability in newly diagnosed Type 2 diabetes. *Clinical & Experimental Pharmacology & Physiology*. 2010;37(5-6):564-568.

Bartosch-Harlid, A. and Andersson, R. Diabetes mellitus in pancreatic cancer and the need for diagnosis of asymptomatic disease. [Review]. *Pancreatology*. 2010;10(4):423-428.

Ben, Khelifa S., Barboura, I., Dandana, A., Ferchichi, S., and Miled, A. [MODY type diabetes: overview and recent findings]. [Review] [French]. *Annales de Biologie Clinique*. 2011;69(5):531-540.

Bianchi, C., Miccoli, R., Bonadonna, R. C., Giorgino, F., Frontoni, S., Faloia, E., Marchesini, G., Dolci, M. A., Alviggi, L., Gnasso, A., Consoli, A., Cavalot, F., Cavallo, M. G., Leonetti, F., Giaccari, A., Del, Prato S., and GENFIEV, Investigators. Metabolic syndrome in subjects at high risk for type 2 diabetes: the genetic, physiopathology and evolution of type 2 diabetes (GENFIEV) study. *Nutrition Metabolism & Cardiovascular Diseases*. 2011;21(9):699-705.

Bilik, D., McEwen, L. N., Brown, M. B., Pomeroy, N. E., Kim, C., Asao, K., Crosson, J. C., Duru, O. K., Ferrara, A., Hsiao, V. C., Karter, A. J., Lee, P. G., Marrero, D. G., Selby, J. V., Subramanian, U., and Herman, W. H. Thiazolidinediones and fractures: evidence from translating research into action for diabetes. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(10):4560-4565.

Boltri, J. M., Davis-Smith, M., Okosun, I. S., Seale, J. P., and Foster, B. Translation of the National Institutes of Health Diabetes Prevention Program in African American churches. *Journal of the National Medical Association*. 2011;103(3):194-202.

Bonaldi, C., Vernay, M., Roudier, C., Salanave, B., Oleko, A., Malon, A., Castetbon, K., and Fagot-Campagna, A. A first national prevalence estimate of diagnosed and undiagnosed diabetes in France in 18- to 74-year-old individuals: the French Nutrition and Health Survey 2006/2007. *Diabetic Medicine*. 2011;28(5):583-589.

Brown, R. and National Diabetes Education Program. To catch a thief: recognizing diabetes. *NASN school nurse*. 2010;25(4):164-166.

Butler-Jones, D. Prediabetes, CANRISK and screening in Canada. *Chronic Diseases and Injuries in Canada*. 2011;32(1):1.

Cao, H., Ren, M., Guo, L., Shang, H., Zhang, J., Song, Y., Wang, H., Wang, B., Li, X., Hu, J., Wang, X., Wang, D., Chen, J., Li, S., and Chen, L. JinQi-Jiangtang tablet, a Chinese patent medicine, for pre-diabetes: a randomized controlled trial. *Trials*. 2010;Vol11, pp27, 2010:27.

Chang, A., Frank, J., Knaebel, J., Fullam, J., Pardo, S., and Simmons, D. A. Evaluation of an over-the-counter glycated hemoglobin (A1C) test kit. *Journal of Diabetes Science & Technology*. 2010;4(6):1495-1503.

Chawla, A., Saha, C., and Marrero, D. G. A novel application of the Problem Areas in Diabetes (PAID) instrument to improve glycemic control and patient satisfaction. *Diabetes Educator*. 2010;36(2):337-344.

Cheng, A. Y. and Leiter, L. A. Glucose lowering and cardiovascular disease: what do we know and what should we do?. [Review] [22 refs]. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2010;17:Suppl-31.

Chon, S., Oh, S., Kim, S. W., Kim, J. W., Kim, Y. S., and Woo, J. T. The effect of early insulin therapy on pancreatic β -cell function and long-term glycemic control in newly diagnosed type 2 diabetic patients. *Korean Journal of Internal Medicine*. 2010;25(3):273-281.

Dagogo-Jack, S. Pitfalls in the use of HbA1(c) as a diagnostic test: the ethnic conundrum. *Nature Reviews Endocrinology*. 2010;6(10):589-593.

de Koning L., Gerstein, H. C., Bosch, J., Diaz, R., Mohan, V., Dagenais, G., Yusuf, S., Anand, S. S., and EpiDREAM, Investigators. Anthropometric measures and glucose levels in a large multi-ethnic cohort of individuals at risk of developing type 2 diabetes. *Diabetologia*. 2010;53(7):1322-1330.

de Lusignan S., Khunti, K., Belsey, J., Hattersley, A., van, Vlymen J., Gallagher, H., Millett, C., Hague, N. J., Tomson, C., Harris, K., and Majeed, A. A method of identifying and correcting miscoding, misclassification and misdiagnosis in diabetes: a pilot and validation study of routinely collected data. [Review] [32 refs]. *Diabetic Medicine*. 2010;27(2):203-209.

Duran, A., Martin, P., Runkle, I., Perez, N., Abad, R., Fernandez, M., Del, Valle L., Sanz, M. F., and Calle-Pascual, A. L. Benefits of self-monitoring blood glucose in the management of new-onset Type 2 diabetes mellitus: the St Carlos Study, a prospective randomized clinic-based interventional study with parallel groups. *Journal Of Diabetes*. 2010;2(3):203-211.

Dyson, P. A., Beatty, S., and Matthews, D. R. An assessment of lifestyle video education for people newly diagnosed with type 2 diabetes. *Journal of Human Nutrition & Dietetics*. 2010;23(4):353-359.

Elley, C. R. and Kenealy, T. Intensive primary care treatment reduced cardiovascular risk factors in screen-detected type 2 diabetes. *Evidence Based Medicine*. 2009;14(4):108.

Elley, C. R. and Kenealy, T. ACP Journal Club. Intensive primary care treatment reduced cardiovascular risk factors at 1 year in screen-detected type 2 diabetes. *Annals of internal medicine*. 5-19-2009;150(10):JC5-JC9.

Fakhoury, W. K., Lereun, C., and Wright, D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. [Review]. *Pharmacology*. 2010;86(1):44-57.

Feller, S., Boeing, H., and Pischon, T. Body mass index, waist circumference, and the risk of type 2 diabetes mellitus: implications for routine clinical practice. *Deutsches Arzteblatt International*. 2010;107(26):470-476.

Ferrannini, E., Ramos, S. J., Salsali, A., Tang, W., and List, J. F. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. *Diabetes Care*. 2010;33(10):2217-2224.

Frank, H., Pscherer, S., Fliser, D., and Heemann, U. Effect of experimental hyperglycaemia on renal haemodynamics in prediabetic patients with and without AT1 receptor blockade. *European Journal of Clinical Investigation*. 2010;40(5):414-421.

Fukuoka, Y., Kamitani, E., Bonnet, K., and Lindgren, T. Real-time social support through a mobile virtual community to improve healthy behavior in overweight and sedentary adults: a focus group analysis. *Journal of Medical Internet Research*. 2011;13(3):e49.

Garg, S. and Hirsch, I. B. Self-monitoring of blood glucose. [Review]. *International Journal of Clinical Practice*. 2010;Supplement(166):1-10.

Gavin, J. R., III, Freeman, J. S., Shubrook, J. H., Jr., and Lavernia, F. Type 2 diabetes mellitus: practical approaches for primary care physicians. [Review]. *Journal of the American Osteopathic Association*. 2011;111(5:Suppl 4):Suppl-12.

Gillett, M., Dallosso, H. M., Dixon, S., Brennan, A., Carey, M. E., Campbell, M. J., Heller, S., Khunti, K., Skinner, T. C., and Davies, M. J. Delivering the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cost effectiveness analysis. *BMJ*. 2010;341:c4093.

Gilmer, T. P. and O'Connor, P. J. The growing importance of diabetes screening. *Diabetes Care*. 2010;33(7):1695-1697.

Girerd, X., Hansel, B., Villeneuve, F., and Dourmap, C. [Diabetes prevention in hypertensive patients]. *Archives des Maladies du Coeur et des Vaisseaux*. 2007;100(2):139-143.

Glasscock, R. J. Uremia (end-stage renal disease): how cost-effective are preventive strategies?. [Review]. *Journal of Renal Nutrition*. 2010;20(5:Suppl):Suppl-4.

Goldfine, A. B., Fonseca, V., Jablonski, K. A., Pyle, L., Staten, M. A., Shoelson, S. E., and TINSAL, T. The effects of salsalate on glycemic control in patients with type 2 diabetes: a randomized trial. *Annals of internal medicine*. 2010;152(6):346-357.

Golubnitschaja, O. Advanced Diabetes care: three levels of prediction, prevention & personalized treatment. [Review] [49 refs]. *Current Diabetes Reviews*. 2010;6(1):42-51.

Gornik, I., Vujaklija-Brajkovic, A., Renar, I. P., and Gasparovic, V. A prospective observational study of the relationship of critical illness associated hyperglycaemia in medical ICU patients and subsequent development of type 2 diabetes.[Erratum appears in *Crit Care*. 2010;14(5):444]. *Critical Care (London, England)*. 2010;14(4):R130.

Grzywa, M., Mazur, A., and Skrzypiec, J. Screening for the detection of impaired fasting glucose, impaired glucose tolerance and type 2 diabetes in welfare homes residents from south-eastern region of Poland. *International Journal of Clinical Practice*. 2011;65(7):818-819.

Haidinger, M., Werzowa, J., Voigt, H. C., Pleiner, J., Stemer, G., Hecking, M., Doller, D., Horl, W. H., Weichhart, T., and Saemann, M. D. A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. *Trials* [Electronic Resource]. 2010;11:91.

Hanefeld, M., Koehler, C., Hoffmann, C., Wilhelm, K., Kamke, W., and Gerstein, H. Effect of targeting normal fasting glucose levels with basal insulin glargine on glycaemic variability and risk of hypoglycaemia: a randomized, controlled study in patients with early Type 2 diabetes. *Diabetic medicine : a journal of the British Diabetic Association*. 2010;27(2):175-180.

Hansen, L. J., Olivarius, Nde F., and Siersma, V. 16-year excess all-cause mortality of newly diagnosed type 2 diabetic patients: a cohort study. *BMC Public Health*. 2009;9:400.

Heng, B. H., Sun, Y., Cheah, J. T., and Jong, M. The Singapore National Healthcare Group Diabetes Registry--descriptive epidemiology of type 2 diabetes mellitus. *Annals of the Academy of Medicine, Singapore*. 2010;39(5):348-352.

Herman, W. H. The economics of diabetes prevention. [Review]. *Medical Clinics of North America*. 2011;95(2):373-384.

Hernandez, C., Zapata, M. A., Losada, E., Villarroel, M., Garcia-Ramirez, M., Garcia-Arumi, J., and Simo, R. Effect of intensive insulin therapy on macular biometrics, plasma VEGF and its soluble receptor in newly diagnosed diabetic patients. *Diabetes/Metabolism Research Reviews*. 2010;26(5):386-392.

Hollander, P. A., Amod, A., Litwak, L. E., Chaudhari, U., and ARPEGGIO Study Group. Effect of rimonabant on glycemic control in insulin-treated type 2 diabetes: the ARPEGGIO trial. *Diabetes Care*. 2010;33(3):605-607.

Islam, M. S. Fasting blood glucose and diagnosis of type 2 diabetes. *Diabetes Research & Clinical Practice*. 2011;91(1):e26.

Jorgensen, M. E., Bjerregaard, P., Borch-Johnsen, K., and Witte, D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations?. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(11):E333-E336.

Kato, T., Inoue, T., and Node, K. Postprandial endothelial dysfunction in subjects with new-onset type 2 diabetes: an acarbose and nateglinide comparative study. *Cardiovascular Diabetology*. 2010;Vol9, pp12, 2010:12.

Khunti, K., Walker, N., Sattar, N., and Davies, M. Unanswered questions over NHS health checks. *BMJ*. 2011;342:c6312.

Klein Woolthuis, E. P., de Grauw, W. J., and van, Weel C. Opportunistic screening for type 2 diabetes in primary care. *Lancet*. 8-28-2010;376(9742):683-684.

Ko, G., So, W., Tong, P., Ma, R., Kong, A., Ozaki, R., Chow, C., Cockram, C., and Chan, J. A simple risk score to identify Southern Chinese at high risk for diabetes. *Diabetic Medicine*. 2010;27(6):644-649.

Koga, M., Murai, J., Saito, H., Kasayama, S., Imagawa, A., Hanafusa, T., Kobayashi, T., and Japan Diabetes Society's Committee on Research on Type. Serum glycated albumin to haemoglobin A(1C) ratio can distinguish fulminant type 1 diabetes mellitus from type 2 diabetes mellitus. *Annals of Clinical Biochemistry*. 2010;47(Pt:4):4-7.

Kutoh, E. Differential effects of pioglitazone on metabolic parameters in newly diagnosed, drug-naïve Japanese patients with type 2 diabetes with or without metabolic syndrome. *Endocrine Research*. 2010;35(3):118-127.

Li, R., Zhang, P., Barker, L. E., and Hoerger, T. J. Cost-effectiveness of aspirin use among persons with newly diagnosed type 2 diabetes. *Diabetes Care*. 2010;33(6):1193-1199.

Li, R., Zhang, P., Barker, L. E., Chowdhury, F. M., and Zhang, X. Cost-effectiveness of interventions to prevent and control diabetes mellitus: a systematic review. [Review]. *Diabetes Care*. 2010;33(8):1872-1894.

Li, Y., Xu, L., Shen, J., Ran, J., Zhang, Y., Wang, M., Yan, L., Cheng, H., and Fu, Z. Effects of short-term therapy with different insulin secretagogues on glucose metabolism, lipid parameters and oxidative stress in newly diagnosed Type 2 Diabetes Mellitus. *Diabetes research and clinical practice*. 2010;88(1):42-47.

Lindstrom, J., Absetz, P., Hemio, K., Peltomaki, P., and Peltonen, M. Reducing the risk of type 2 diabetes with nutrition and physical activity - efficacy and implementation of lifestyle interventions in Finland. *Public Health Nutrition*. 2010;13(6A):993-999.

Ludvigsson, J., Ludvigsson, M., and Sepa, A. Screening for prediabetes in the general child population: maternal attitude to participation. *Pediatric Diabetes*. 2001;2(4):170-174.

MacDonald, M. R., Eurich, D. T., Majumdar, S. R., Lewsey, J. D., Bhagra, S., Jhund, P. S., Petrie, M. C., McMurray, J. J., Petrie, J. R., and McAlister, F. A. Treatment of type 2 diabetes and outcomes in patients with heart failure: a nested case-control study from the U.K. General Practice Research Database. *Diabetes Care*. 2010;33(6):1213-1218.

Maclean, J. R., Chapman, R. H., Ferrufino, C. P., and Krishnarajah, G. Drug titration patterns and HbA 1c levels in type 2 diabetes. *International Journal of Clinical Practice*. 2009;63(7):1008-1016.

Malecki, M. T. The search for undiagnosed MODY patients: what is the next step?. *Diabetologia*. 2010;53(12):2465-2467.

Mantyselka, P., Korniloff, K., Saaristo, T., Koponen, H., Eriksson, J., Puolijoki, H., Timonen, M., Sundvall, J., Kautiainen, H., and Vanhala, M. Association of depressive symptoms with impaired glucose regulation, screen-detected, and previously known type 2 diabetes: findings from the Finnish D2D Survey. *Diabetes Care*. 2011;34(1):71-76.

Maple-Brown, L. J., Sinha, A. K., and Davis, E. A. Type 2 diabetes in indigenous Australian children and adolescents. [Review]. *Journal of Paediatrics & Child Health*. 2010;46(9):487-490.

Marteau, T. M., Mann, E., Prevost, A. T., Vasconcelos, J. C., Kellar, I., Sanderson, S., Parker, M., Griffin, S., Sutton, S., and Kinmonth, A. L. Impact of an informed choice invitation on uptake of screening for diabetes in primary care (DICISION): randomised trial. *BMJ (Clinical research ed)*. 2010;Vol340, ppc2138, 2010(Clinical research ed):c2138.

Mayurasakorn, K., Somthip, N., Caengow, S., Chulkarat, N., and Wanichsuwan, M. Glycemic control and microvascular complications among type 2 diabetes at primary care units. *Journal of the Medical Association of Thailand*. 2009;92(8):1094-1101.

Mellbin, L. G., Anselmino, M., and Ryden, L. Diabetes, prediabetes and cardiovascular risk. [Review] [41 refs]. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2010;17:Suppl-14.

Molfino, A., Cascino, A., Conte, C., Ramaccini, C., Rossi, Fanelli F., and Laviano, A. Caloric restriction and L-carnitine administration improves insulin sensitivity in patients with impaired glucose metabolism. *Jpen: Journal of Parenteral & Enteral Nutrition*. 2010;34(3):295-299.

Mousa, H. S., Yousef, S., Riccardo, F., Zeidan, W., and Sabatinelli, G. Hyperglycaemia, hypertension and their risk factors among Palestine refugees served by UNRWA. *Eastern Mediterranean Health Journal*. 2010;16(6):609-614.

Nafiu, O. O., Burke, C. C., Gupta, R., Christensen, R., Reynolds, P. I., and Malviya, S. Association of neck circumference with perioperative adverse respiratory events in children. *Pediatrics*. 2011;127(5):e1198-e1205.

Nakano, K., Hasegawa, G., Fukui, M., Yamasaki, M., Ishihara, K., Takashima, T., Kitagawa, Y., Fujinami, A., Ohta, M., Hara, H., Adachi, T., Ogata, M., Obayashi, H., and Nakamura, N. Effect of pioglitazone on various parameters of insulin resistance including lipoprotein subclass according to particle size by a gel-permeation high-performance liquid chromatography in newly diagnosed patients with type 2 diabetes. *Endocrine Journal*. 2010;57(5):423-430.

Nichols, G. A., Conner, C., and Brown, J. B. Initial nonadherence, primary failure and therapeutic success of metformin monotherapy in clinical practice. *Current Medical Research & Opinion*. 2010;26(9):2127-2135.

Nyenwe, E. A., Jerkins, T. W., Umpierrez, G. E., and Kitabchi, A. E. Management of type 2 diabetes: evolving strategies for the treatment of patients with type 2 diabetes. [Review]. *Metabolism: Clinical & Experimental*. 2011;60(1):1-23.

Oda, E. and Kawai, R. Comparison among body mass index (BMI), waist circumference (WC), and percent body fat (%BF) as anthropometric markers for the clustering of metabolic risk factors in Japanese. *Internal Medicine*. 2010;49(15):1477-1482.

Ozaki, R., Cheung, K. K., Wu, E., Kong, A., Yang, X., Lau, E., Brunswick, P., Calvet, J. H., Deslypere, J. P., and Chan, J. C. A new tool to detect kidney disease in Chinese type 2 diabetes patients: comparison of EZSCAN with standard screening methods. *Diabetes Technology & Therapeutics*. 2011;13(9):937-943.

Pajunen, P., Landgraf, R., Muylle, F., Neumann, A., Lindstrom, J., Schwarz, P. E., Peltonen, M., Acosta, T., Adler, M., AlKerwi, A., Barengo, N., Barengo, R., Boavida, J. M., Charlesworth, K., Christov, V., Claussen, B., Cos, X., Cosson, E., Deceukelier, S., Dimitrijevic-Sreckovic, V., Djordjevic, P., Evans, P., Felton, A. M., Fischer, M., Gabriel-Sanchez, R., Gilis-Januszewska, A., Goldfracht, M., Gomez, J. L., Greaves, C. J., Hall, M., Handke, U., Hauner, H., Herbst, J., Hermanns, N., Herrebrugh, L., Huber, C., Huhmer, U., Huttunen, J., Jotic, A., Kamenov, Z., Karadeniz, S., Katsilambros, N., Khalangot, M., Kissimova-Skarbek, K., Kohler, D., Kopp, V., Kronsbein, P., Kulzer, B., Kyne-Grzebalski, D., Lalic, K., Lalic, N., Landgraf, R., Lee-Barkey, Y. H., Liatis, S., Lindstrom, J., Makrilakis, K., McIntosh, C., McKee, M., Mesquita, A. C., Misina, D., Muylle, F., Neumann, A., Paiva, A. C., Pajunen, P., Paulweber, B., Peltonen, M., Perrenoud, L., Pfeiffer, A., Polonen, A., Puhl, S., Raposo, F., Reinehr, T., Rissanen, A., Robinson, C., Roden, M., Rothe, U., Saaristo, T., Scholl, J., Schwarz, P. E., Sheppard, K. E., Spiers, S., Stemper, T., Stratmann, B., Szendroedi, J., Szybinski, Z., Tankova, T., Telle-Hjellset, V., Terry, G., Tolks, D., Toti, F., Tuomilehto, J., Undeutsch, A., Valadas, C., Valensi, P., Velickiene, D., Vermunt, P., Weiss, R., Wens, J., and Yilmaz, T. Quality indicators for the prevention of type 2 diabetes in Europe--IMAGE. *Hormone & Metabolic Research*. 2010;42:Suppl-63.

Palmer, B. F. Screening tests for renal impairment in patients with type 2 diabetes: the what, when, and how. *Postgraduate Medicine*. 2011;123(1):7-14.

Papakonstantinou, E., Triantafyllidou, D., Panagiotakos, D. B., Koutsovasilis, A., Saliaris, M., Manolis, A., Melidonis, A., and Zampelas, A. A high-protein low-fat diet is more effective in improving blood pressure and triglycerides in calorie-restricted obese individuals with newly diagnosed type 2 diabetes. *European Journal of Clinical Nutrition*. 2010;64(6):595-602.

Paulweber, B., Valensi, P., Lindstrom, J., Lalic, N. M., Greaves, C. J., McKee, M., Kissimova-Skarbek, K., Liatis, S., Cosson, E., Szendroedi, J., Sheppard, K. E., Charlesworth, K., Felton, A. M., Hall, M., Rissanen, A., Tuomilehto, J., Schwarz, P. E., Roden, M., Paulweber, M., Stadlmayr, A., Kedenko, L., Katsilambros, N., Makrilakis, K., Kamenov, Z., Evans, P., Gilis-Januszewska, A., Lalic, K., Jotic, A., Djordjevic, P., Dimitrijevic-Sreckovic, V., Huhmer, U., Kulzer, B., Puhl, S., Lee-Barkey, Y. H., AlKerwi, A., Abraham, C., Hardeman, W., Acosta, T., Adler, M., AlKerwi, A., Barengo, N., Barengo, R., Boavida, J. M., Charlesworth, K., Christov, V., Claussen, B., Cos, X., Cosson, E., Deceukelier, S., Dimitrijevic-Sreckovic, V., Djordjevic, P., Evans, P., Felton, A. M., Fischer, M., Gabriel-Sanchez, R., Gilis-Januszewska, A., Goldfracht, M., Gomez, J. L., Greaves, C. J., Hall, M., Handke, U., Hauner, H., Herbst, J., Hermanns, N., Herrebrugh, L., Huber, C., Huhmer, U., Huttunen, J., Jotic, A., Kamenov, Z., Karadeniz, S., Katsilambros, N., Khalangot, M., Kissimova-Skarbek, K., Kohler, D., Kopp, V., Kronsbein, P., Kulzer, B., Kyne-Grzebalski, D., Lalic, K., Lalic, N., Landgraf, R., Lee-Barkey, Y. H., Liatis, S., Lindstrom, J., Makrilakis, K., McIntosh, C., McKee, M., Mesquita, A. C., Misina, D., Muylle, F., Neumann, A., Paiva, A. C., Pajunen, P., Paulweber, B., Peltonen, M., Perrenoud, L., Pfeiffer, A., Polonen, A., Puhl, S., Raposo, F., Reinehr, T., Rissanen, A., Robinson, C., Roden, M., Rothe, U., Saaristo, T., Scholl, J., Schwarz, P. E., Sheppard, K. E., Spiers, S., Stemper, T., Stratmann, B., Szendroedi, J., Szybinski, Z., Tankova, T., Telle-Hjellset, V., Terry, G., Tolks, D., Toti, F., Tuomilehto, J., Undeutsch, A., Valadas, C., Valensi, P., Velickiene, D., Vermunt, P., Weiss, R., Wens, J., and Yilmaz, T. A European evidence-based guideline for the prevention of type 2 diabetes. *Hormone & Metabolic Research*. 2010;42:Suppl-36.

Pimentel, G. D., Portero-McLellan, K. C., Oliveira, E. P., Spada, A. P., Oshiiwa, M., Zemdeg, J. C., and Barbalho, S. M. Long-term nutrition education reduces several risk factors for type 2 diabetes mellitus in

Brazilians with impaired glucose tolerance. *Nutrition research* (New York, NY). 1930;30(New York, NY):186-190.

Pines Corrales, P. J., Lopez Garrido, M. P., Louhibi, Rubio L., Aznar, Rodriguez S., Lopez Jimenez, L. M., Lamas, Oliveira C., Lozano Garcia, J. J., Alfaro Martinez, J. J., Hernandez, Lopez A., Requejo, Castillo R., Escribano, Martinez J., and Botella, Romero F. Importance of clinical variables in the diagnosis of MODY2 and MODY3. *Endocrinologia y Nutricion*. 2011;58(7):341-346.

Pluddemann, A., Heneghan, C., Price, C. P., Wolstenholme, J., and Thompson, M. Point-of-care blood test for ketones in patients with diabetes: primary care diagnostic technology update. [Review]. *British Journal of General Practice*. 2011;61(589):530-531.

Pluddemann, A., Price, C. P., Thompson, M., Wolstenholme, J., and Heneghan, C. Primary care diagnostic technology update: point-of-care testing for glycosylated haemoglobin. *British Journal of General Practice*. 2011;61(583):139-140.

Polonsky, W. H., Fisher, L., Guzman, S., Sieber, W. J., Philis-Tsimikas, A., and Edelman, S. V. Are patients' initial experiences at the diagnosis of type 2 diabetes associated with attitudes and self-management over time?. *Diabetes Educator*. 2010;36(5):828-834.

Porterfield, D. S., Hinnant, L., Stevens, D. M., Moy, E., and DPPI-IFA Case Study Group. The diabetes primary prevention initiative interventions focus area: a case study and recommendations. *American Journal of Preventive Medicine*. 2010;39(3):235-242.

Preiss, D. and Sattar, N. The case for diabetes screening: ADDITION-Europe. *Lancet*. 7-9-2011;378(9786):106-108.

Qiao, Q., Pang, Z., Gao, W., Wang, S., Dong, Y., Zhang, L., Nan, H., and Ren, J. A large-scale diabetes prevention program in real-life settings in Qingdao of China (2006-2012). *Primary care diabetes*. 2010;4(2):99-103.

Ramlawi, M. and Delemont, C. [Emergency department point of care testing: what are the benefits and for which patients?]. [French]. *Revue Medicale Suisse*. 8-24-2011;7(305):1584-1587.

Ray, J. G., Berger, H., Lipscombe, L. L., and Sermer, M. Gestational prediabetes: a new term for early prevention?. [Review]. *Indian Journal of Medical Research*. 2010;132:251-255.

Riche, D. M. and Travis, King S. Bone loss and fracture risk associated with thiazolidinedione therapy. [Review] [41 refs]. *Pharmacotherapy*. 2010;30(7):716-727.

Rizos, C. V., Milionis, H. J., Kostapanos, M. S., Florentin, M., Kostara, C. E., Elisaf, M. S., and Liberopoulos, E. N. Effects of rosuvastatin combined with olmesartan, irbesartan, or telmisartan on indices of glucose metabolism in Greek adults with impaired fasting glucose, hypertension, and mixed hyperlipidemia: a 24-week, randomized, open-label, prospective study. *Clinical Therapeutics*. 2010;32(3):492-505.

Roussel, R. [Three studies in type 2 diabetes: DREAM the wash-out results.]. *Annales d Endocrinologie*. 2007;68 Suppl 1:36-38.

Roussel, R. [Three studies in type 2 diabetes: SERENADE the rimonabant (a blocker of the CB 1 receptors) in monotherapy in type 2 diabetes.]. *Annales d Endocrinologie*. 2007;68 Suppl 1:33-35.

Roussel, R. [Three studies in type 2 diabetes: ADOPT Rosiglitazone monotherapy in type 2 diabetes: what indication?]. *Annales d Endocrinologie*. 2007;68 Suppl 1:28-32.

Rubak, S., Sandbaek, A., Lauritzen, T., Borch-Johnsen, K., and Christensen, B. Effect of "motivational interviewing" on quality of care measures in screen detected type 2 diabetes patients: a one-year follow-up of an RCT, ADDITION Denmark. *Scandinavian Journal of Primary Health Care*. 2011;29(2):92-98.

Ruiz, J. [The DREAM of diabetes prevention]. *Revue Medicale Suisse*. 3(94):132.

Ruiz, J., Egli, M., Gianinazzi, F., Izzo, F., Voefray Favre, A. C., Rossi, I., and Bodenman, P. [Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus]. [French]. *Revue Medicale Suisse*. 1180;6(252):1176-1178.

Sacks, D. B., Arnold, M., Bakris, G. L., Bruns, D. E., Horvath, A. R., Kirkman, M. S., Lernmark, A., Metzger, B. E., Nathan, D. M., National Academy of Clinical Biochemistry, and Evidence-Based Laboratory Medicine Committee of the American Association for Clinical Chemistry. Guidelines and recommendations for laboratory analysis in the diagnosis and management of diabetes mellitus. *Diabetes Care*. 2011;34(6):e61-e99.

Samoutis, G. A., Soteriades, E. S., Stoffers, H. E., Philalithis, A., Delicha, E. M., and Lionis, C. A pilot quality improvement intervention in patients with diabetes and hypertension in primary care settings of Cyprus. *Journal*. 2010;27(3):263-270.

Santoyo-Olsson, J., Cabrera, J., Freyre, R., Grossman, M., Alvarez, N., Mathur, D., Guerrero, M., Delgadillo, A. T., Kanaya, A. M., and Stewart, A. L. An innovative multiphased strategy to recruit underserved adults into a randomized trial of a community-based diabetes risk reduction program. *Gerontologist*. 2011;51:Suppl-93.

Scheen, A. J. [DREAM study: prevention of type 2 diabetes with ramipril and/or rosiglitazone in persons with dysglycaemia but no cardiovascular disease]. *Revue Medicale de Liege*. 2006;61(10):728-732.

Seino, Y., Rasmussen, M. F., Nishida, T., and Kaku, K. Efficacy and safety of the once-daily human GLP-1 analogue, liraglutide, vs glibenclamide monotherapy in Japanese patients with type 2 diabetes. *Current medical research and opinion*. 2010;26(5):1013-1022.

Serrano-Gil, M. and Jacob, S. Engaging and empowering patients to manage their type 2 diabetes, Part I: a knowledge, attitude, and practice gap?. [Review]. *Advances in Therapy*. 2010;27(6):321-333.

Shaw, J. Diagnosis of prediabetes. [Review]. *Medical Clinics of North America*. 2011;95(2):341-352.

Shubair, M. M. and Tobin, P. K. Type 2 diabetes in the First Nations population: a case example of clinical practice guidelines. [Review]. *Rural & Remote Health*. 2010;10(4):1505-1Dec.

Singh, S., Dhingra, S., Ramdath, D. D., Vasdev, S., Gill, V., and Singal, P. K. Risk factors preceding type 2 diabetes and cardiomyopathy. [Review]. *Journal of Cardiovascular Translational Research*. 2010;3(5):580-596.

Solomon, T. P., Haus, J. M., Kelly, K. R., Rocco, M., Kashyap, S. R., and Kirwan, J. P. Improved pancreatic beta-cell function in type 2 diabetic patients after lifestyle-induced weight loss is related to glucose-dependent insulinotropic polypeptide. *Diabetes Care*. 2010;33(7):1561-1566.

Stolar, M. W. Defining and achieving treatment success in patients with type 2 diabetes mellitus. [Review]. *Mayo Clinic Proceedings*. 2010;85(12:Suppl):Suppl-9.

Stolker, J. M., Sun, D., Conaway, D. G., Jones, P. G., Masoudi, F. A., Peterson, P. N., Krumholz, H. M., Kosiborod, M., and Spertus, J. A. Importance of measuring glycosylated hemoglobin in patients with myocardial infarction and known diabetes mellitus. *The American journal of cardiology*. 2010;105(8):1090-1094.

Stone, M. A., Camosso-Stefinovic, J., Wilkinson, J., de, Lusignan S., Hattersley, A. T., and Khunti, K. Incorrect and incomplete coding and classification of diabetes: a systematic review. [Review] [29 refs][Erratum appears in *Diabet Med*. 2010 Jun;27(6):732]. *Diabetic Medicine*. 2010;27(5):491-497.

Stronks, K. and van Valkengoed, I. G. How can we realise the potentially large public health benefit of screening for type 2 diabetes mellitus in south Asians?. *Diabetologia*. 2011;54(9):2214-2216.

Thanabalasingham, G. and Owen, K. R. Diagnosis and management of maturity onset diabetes of the young (MODY). [Review]. *BMJ*. 2011;343:d6044.

Thethy, I., Robertson, L., and Swaminathan, K. Diagnosis in diabetes: does it matter?. *Journal of the Royal College of Physicians of Edinburgh*. 2011;41(2):119-121.

Tomlinson, J., Millward, A., Stenhouse, E., and Pinkney, J. Type 2 diabetes and cardiovascular disease in polycystic ovary syndrome: what are the risks and can they be reduced?. [Review] [94 refs]. *Diabetic Medicine*. 2010;27(5):498-515.

Trento, M., Gamba, S., Gentile, L., Grassi, G., Miselli, V., Morone, G., Passera, P., Tonutti, L., Tomalino, M., Bondonio, P., Cavallo, F., Porta, M., and ROMEO, Investigators. Rethink Organization to iMprove Education and Outcomes (ROMEO): a multicenter randomized trial of lifestyle intervention by group care to manage type 2 diabetes. *Diabetes Care*. 2010;33(4):745-747.

Tsay, J., Pomeranz, C., Hassoun, A., Zandieh, S. O., Rutledge, J., Vogiatzi, M. G., Oberfield, S. E., and Motaghedi, R. Screening markers of impaired glucose tolerance in the obese pediatric population. *Hormone research in pdiatrics*. 2010;73(2):102-107.

van den Donk, M., Gorter, K. J., and Rutten, G. E. No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. *Quality of Life Research*. 2010;19(4):509-513.

Veeranna, V., Ramesh, K., Zalawadiya, S. K., Niraj, A., Pradhan, J., Jacob, S., and Afonso, L. Glycosylated hemoglobin and prevalent metabolic syndrome in nondiabetic multiethnic U.S. adults. *Metabolic Syndrome & Related Disorders*. 2011;9(5):361-367.

Vermunt, P. W., Milder, I. E., Wielaard, F., van Oers, J. A., and Westert, G. P. An active strategy to identify individuals eligible for type 2 diabetes prevention by lifestyle intervention in Dutch primary care: the APHRODITE study. *Family Practice*. 2010;27(3):312-319.

Viera, A. J. Predisease: when does it make sense?. [Review]. *Epidemiologic Reviews*. 2011;33(1):122-134.

Vieta, A., Badia, X., and Sacristan, J. A. A systematic review of patient-reported and economic outcomes: value to stakeholders in the decision-making process in patients with type 2 diabetes mellitus. *Clinical Therapeutics*. 2011;33(9):1225-1245.

Wan, Q., Wang, F., Wang, F., Guan, Q., Liu, Y., Wang, C., Feng, L., Gao, G., Gao, L., and Zhao, J. Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial. *Diabetic Medicine*. 2010;27(11):1312-1317.

Wareham, N. J. Epidemiology of type 2 diabetes. [Review] [17 refs]. *Endocrinologia y Nutricion*. 2009;56:Suppl-2.

Waugh, N., Cummins, E., Royle, P., Clar, C., Marien, M., Richter, B., and Philip, S. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation. [Review]. *Health Technology Assessment (Winchester, England)*. 2010;14(36):1-248.

White, K. M., Terry, D. J., Troup, C., Rempel, L. A., and Norman, P. Predicting the consumption of foods low in saturated fats among people diagnosed with Type 2 diabetes and cardiovascular disease. The role of planning in the theory of planned behaviour. *Appetite*. 2010;55(2):348-354.

White, R. O., DeWalt, D. A., Malone, R. M., Osborn, C. Y., Pignone, M. P., and Rothman, R. L. Leveling the field: addressing health disparities through diabetes disease management. *The American journal of managed care*. 2010;16(1):42-48.

Wojcik, K., Gjelsvik, A., and Goldman, D. Identifying populations at high risk for diabetes with the Behavioral Risk Factor Surveillance System, Rhode Island, 2003. *Preventing Chronic Disease*. 2010;7(4):A86.

Yu, W., Liu, T., Valdez, R., Gwinn, M., and Khoury, M. J. Application of support vector machine modeling for prediction of common diseases: the case of diabetes and pre-diabetes. *BMC Medical Informatics & Decision Making*. 2010;10:16.

Zhang, C. Y., Sun, A. J., Zhang, S. N., Wu, C. N., Fu, M. Q., Xia, G., Wang, K. Q., Zou, Y. Z., and Ge, J. B. Effects of intensive glucose control on incidence of cardiovascular events in patients with type 2 diabetes: a meta-analysis. *Annals of Medicine*. 5-6-2010;42(4):305-315.

Level 2: Comparison

Cederberg, H., Saukkonen, T., Laakso, M., Jokelainen, J., Harkonen, P., Timonen, M., Keinänen-Kiukaanniemi, S., and Rajala, U. Postchallenge glucose, A1C, and fasting glucose as predictors of type 2 diabetes and cardiovascular disease: a 10-year prospective cohort study. *Diabetes Care*. 2010;33(9):2077-2083.

Chatterjee, R., Narayan, K. M., Lipscomb, J., and Phillips, L. S. Screening adults for pre-diabetes and diabetes may be cost-saving. *Diabetes Care*. 2010;33(7):1484-1490.

Cohen, R. M., Haggerty, S., and Herman, W. H. HbA1c for the diagnosis of diabetes and prediabetes: is it time for a mid-course correction?. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(12):5203-5206.

Cosson, E., Hamo-Tchatchouang, E., Banu, I., Nguyen, M. T., Chiheb, S., Ba, H., and Valensi, P. A large proportion of prediabetes and diabetes goes undiagnosed when only fasting plasma glucose and/or HbA1c are measured in overweight or obese patients. *Diabetes & Metabolism*. 2010;36(4):312-318.

Fisher, B. G., Ang, Y. L., Goodhart, C., and Simmons, R. K. Record-based, stepwise screening for type 2 diabetes integrated into an annual cardiovascular care review system: Findings from a UK general practice. *Primary care diabetes*. 2011;5(4):265-269.

Gomez-Huelgas, R., Bernal-Lopez, M. R., Mancera, J., and Tinahones, F. J. HbA1c for diabetes diagnosis. Are we ready?. *Diabetic Medicine*. 2010;27(3):367-368.

Graffy, J., Grant, J., Williams, K., Cohn, S., Macbay, S., Griffin, S., and Kinmonth, A. L. More than measurement: practice team experiences of screening for type 2 diabetes. *Family Practice*. 2010;27(4):386-394.

Gray, L. J., Tringham, J. R., Davies, M. J., Webb, D. R., Jarvis, J., Skinner, T. C., Farooqi, A. M., and Khunti, K. Screening for type 2 diabetes in a multiethnic setting using known risk factors to identify those at high risk: a cross-sectional study. *Vascular Health & Risk Management*. 2010;6:837-842.

Hewat, N., McD, Taylor D., and Macdonald, E. Pilot study of random finger prick glucose testing as a screening tool for type 2 diabetes mellitus in the emergency department. *Emergency Medicine Journal*. 2009;26(10):732-733.

Howard, K., White, S., Salkeld, G., McDonald, S., Craig, J. C., Chadban, S., and Cass, A. Cost-effectiveness of screening and optimal management for diabetes, hypertension, and chronic kidney disease: a modeled analysis. *Value in Health*. 2010;13(2):196-208.

Howse, J. H., Jones, S., and Hungin, A. P. Screening for diabetes in unconventional locations: resource implications and economics of screening in optometry practices. *Health Policy*. 2011;102(2-3):193-199.

Hu, Y., Liu, W., Chen, Y., Zhang, M., Wang, L., Zhou, H., Wu, P., Teng, X., Dong, Y., Zhou, J., Xu, H., Zheng, J., Li, S., Tao, T., Hu, Y., and Jia, Y. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. *Acta Diabetologica*. 2010;47(3):231-236.

Jimenez-Navarro, M. F., Garcia-Pinilla, J. M., Garrido-Sanchez, L., Alonso-Briales, J. H., Perez-Cabeza, A., Ortiz-Garcia, C., Hernandez-Garcia, J. M., Tinahones, F., and de, Teresa E. Poor reproducibility of the oral glucose tolerance test in the diagnosis of diabetes during percutaneous coronary intervention. *International Journal of Cardiology*. 7-23-2010;142(3):245-249.

Lepercq, J. [Gestational diabetes mellitus]. *Revue du Praticien*. 2010;60(4):514-516.

Lorenzo, C., Wagenknecht, L. E., Hanley, A. J., Rewers, M. J., Karter, A. J., and Haffner, S. M. A1C between 5.7 and 6.4% as a marker for identifying pre-diabetes, insulin sensitivity and secretion, and cardiovascular risk factors: the Insulin Resistance Atherosclerosis Study (IRAS). *Diabetes Care*. 2010;33(9):2104-2109.

Olson, D. E., Rhee, M. K., Herrick, K., Ziemer, D. C., Twombly, J. G., and Phillips, L. S. Screening for diabetes and pre-diabetes with proposed A1C-based diagnostic criteria. *Diabetes Care*. 2010;33(10):2184-2189.

Oster, R. T. and Toth, E. L. Restoring Aboriginal culture through community-based type 2 diabetes screening. *International Journal of Circumpolar Health*. 2010;69(3):218-219.

Ramachandran, A., Moses, A., Shetty, S., Thirupurasundari, C. J., Seeli, A. C., Snehalatha, C., Singvi, S., and Deslypere, J. P. A new non-invasive technology to screen for dysglycaemia including diabetes. *Diabetes Research & Clinical Practice*. 2010;88(3):302-306.

Sargeant, L. A., Simmons, R. K., Barling, R. S., Butler, R., Williams, K. M., Prevost, A. T., Kinmonth, A. L., Wareham, N. J., and Griffin, S. J. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. *Diabetic Medicine*. 2010;27(9):995-1003.

Syed, I. A. Glycated haemoglobin; past, present, and future are we ready for the change. [Review]. *JPMMA - Journal of the Pakistan Medical Association*. 2011;61(4):383-388.

Waeber, G., Mooser, V., and Vollenweider, P. [Genetic and/or clinical scores to anticipate the onset of diabetes]. *Revue Medicale Suisse*. 2010;5(223):2136-2138.

Level 2: Outcome

Dalsgaard, E. M., Christensen, J. O., Skriver, M. V., Borch-Johnsen, K., Lauritzen, T., and Sandbaek, A. Comparison of different stepwise screening strategies for type 2 diabetes: Finding from Danish general practice, Addition-DK. *Primary care diabetes*. 2010;4(4):223-229.

Level 3: Population

Al-Baghli, N. A., Al-Ghamdi, A. J., Al-Turki, K. A., Al Elq, A. H., El-Zubaier, A. G., and Bahnassy, A. Prevalence of diabetes mellitus and impaired fasting glucose levels in the Eastern Province of Saudi Arabia: results of a screening campaign. *Singapore Medical Journal*. 2010;51(12):923-930.

Castro-Rios, A., Doubova, S. V., Martinez-Valverde, S., Coria-Soto, I., and Perez-Cuevas, R. Potential savings in Mexico from screening and prevention for early diabetes and hypertension. *Health Affairs*. 2010;29(12):2171-2179.

Collins, G. S., Mallett, S., Omar, O., and Yu, L. M. Developing risk prediction models for type 2 diabetes: a systematic review of methodology and reporting. [Review]. *BMC Medicine*. 2011;9:103.

de Burgos-Lunar, C., Salinero-Fort, M. A., Cardenas-Valladolid, J., Soto-Diaz, S., Fuentes-Rodriguez, C. Y., Abanades-Herranz, J. C., and del Cura-Gonzalez, I. Validation of diabetes mellitus and hypertension diagnosis in computerized medical records in primary health care. *BMC Medical Research Methodology*. 2011;11:146.

Flack, J. R., Payne, T. J., and Ross, G. P. Post-partum glucose tolerance assessment in women diagnosed with gestational diabetes: evidence supporting the need to undertake an oral glucose tolerance test. *Diabetic Medicine*. 2010;27(2):243-244.

Giugliano, D., Maiorino, M. I., Bellastella, G., Chiodini, P., and Esposito, K. Multiple HbA1c targets and insulin analogues in type 2 diabetes: a systematic review. [Review]. *Journal of Diabetes & its Complications*. 2011;25(4):275-281.

Harvey, I., Schulz, A., Israel, B., Sand, S., Myrie, D., Lockett, M., Weir, S., and Hill, Y. The Healthy Connections project: a community-based participatory research project involving women at risk for diabetes and hypertension. *Progress in Community Health Partnerships*. 2009;3(4):287-300.

Hische, M., Luis-Dominguez, O., Pfeiffer, A. F., Schwarz, P. E., Selbig, J., and Spranger, J. Decision trees as a simple-to-use and reliable tool to identify individuals with impaired glucose metabolism or type 2 diabetes mellitus. *European Journal of Endocrinology*. 2010;163(4):565-571.

Hunt, K. J., Logan, S. L., Conway, D. L., and Korte, J. E. Postpartum screening following GDM: how well are we doing?. [Review] [41 refs]. *Current Diabetes Reports*. 2010;10(3):235-241.

Jelinek, G. A., Weiland, T. J., Moore, G., Tan, G., Maslin, M., Bowman, K., Ward, G., and O'Dea, K. Screening for type 2 diabetes with random finger-prick glucose and bedside HbA1c in an Australian emergency department. *Emergency Medicine Australasia*. 2010;22(5):427-434.

Keely, E., Clark, H., Karovitch, A., and Graham, I. Screening for type 2 diabetes following gestational diabetes: family physician and patient perspectives. *Canadian Family Physician*. 2010;56(6):558-563.

Kenya, S., He, Q., Fullilove, R., and Kotler, D. P. Developing an objective evaluation method to estimate diabetes risk in community-based settings. *Diabetes Technology & Therapeutics*. 2011;13(5):557-561.

Kilmer, G., Hughes, E., Zhang, X., and Elam-Evans, L. Diabetes and prediabetes: screening and prevalence among adults with coronary heart disease. *American Journal of Preventive Medicine*. 2011;40(2):159-165.

Kumar, P. R., Bhansali, A., Ravikiran, M., Bhansali, S., Dutta, P., Thakur, J. S., Sachdeva, N., Bhadada, S. K., and Walia, R. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. *The Journal of clinical endocrinology and metabolism*. 2010;95(6):2832-2835.

McClean, S., Farrar, D., Kelly, C. A., Tuffnell, D. J., and Whitelaw, D. C. The importance of postpartum glucose tolerance testing after pregnancies complicated by gestational diabetes. *Diabetic Medicine*. 2010;27(6):650-654.

Meisinger, C., Strassburger, K., Heier, M., Thorand, B., Baumeister, S. E., Giani, G., and Rathmann, W. Prevalence of undiagnosed diabetes and impaired glucose regulation in 35-59-year-old individuals in Southern Germany: the KORA F4 Study. *Diabetic Medicine*. 2010;27(3):360-362.

Oster, R. T., Ralph-Campbell, K., Connor, T., Pick, M., and Toth, E. L. What happens after community-based screening for diabetes in rural and Indigenous individuals?. *Diabetes Research & Clinical Practice*. 2010;88(3):e28-e31.

Saadi, H., Nagelkerke, N., Al-Kaabi, J., Afandi, B., Al-Maskari, F., and Kazam, E. Screening strategy for type 2 diabetes in the United Arab Emirates. *Asia-Pacific Journal of Public Health*. 2010;22(3:Suppl):Suppl-59S.

Silverman, R. A., Thakker, U., Ellman, T., Wong, I., Smith, K., Ito, K., and Graff, K. Hemoglobin A1c as a screen for previously undiagnosed prediabetes and diabetes in an acute-care setting. *Diabetes Care*. 2011;34(9):1908-1912.

Stasenko, M., Cheng, Y. W., McLean, T., Jelin, A. C., Rand, L., and Caughey, A. B. Postpartum follow-up for women with gestational diabetes mellitus. *American Journal of Perinatology*. 2010;27(9):737-742.

van, Dieren S., Peelen, L. M., Nothlings, U., van der Schouw, Y. T., Rutten, G. E., Spijkerman, A. M., van der, A. DL, Sluik, D., Boeing, H., Moons, K. G., and Beulens, J. W. External validation of the UK Prospective Diabetes Study (UKPDS) risk engine in patients with type 2 diabetes. *Diabetologia*. 2011;54(2):264-270.

Velling, Magnussen L., Mumm, H., Andersen, M., and Glintborg, D. Hemoglobin A1c as a tool for the diagnosis of type 2 diabetes in 208 premenopausal women with polycystic ovary syndrome. *Fertility & Sterility*. 2011;96(5):1275-1280.

West, B., Parikh, P., Arniella, G., and Horowitz, C. R. Observations and recommendations for community-based diabetes screenings. *Diabetes Educator*. 2010;36(6):887-893.

Level 3: Not screening for Type II Diabetes

Bernal-Lopez, M. R., Santamaria-Fernandez, S., Lopez-Carmona, D., Tinahones, F. J., Mancera-Romero, J., Pena-Jimenez, D., Jansen-Chaparro, S., Baca-Orsorio, A. J., Cuesta-Munoz, A. L., Serrano-Rios, M., and Gomez-Huelgas, R. HbA(1c) in adults without known diabetes from southern Europe. Impact of the new diagnostic criteria in clinical practice. *Diabetic Medicine*. 2011;28(11):1319-1322.

Bonora, E., Kiechl, S., Mayr, A., Zoppini, G., Targher, G., Bonadonna, R. C., and Willeit, J. High-normal HbA1c is a strong predictor of type 2 diabetes in the general population. *Diabetes Care*. 2011;34(4):1038-1040.

Costa, B., Cabre, J. J., Sagarra, R., Sola-Morales, O., Barrio, F., Pinol, J. L., Cos, X., Bolibar, B., Castell, C., Kissimova-Skarbek, K., Tuomilehto, J., and DE-PLAN-CAT/PREDICE Research Group. Rationale and design of the PREDICE project: cost-effectiveness of type 2 diabetes prevention among high-risk Spanish individuals following lifestyle intervention in real-life primary care setting. *BMC Public Health*. 2011;11:623.

Gomez-Ambrosi, J., Silva, C., Galofre, J. C., Escalada, J., Santos, S., Gil, M. J., Valenti, V., Rotellar, F., Ramirez, B., Salvador, J., and Fruhbeck, G. Body adiposity and type 2 diabetes: increased risk with a high body fat percentage even having a normal BMI. *Obesity*. 2011;19(7):1439-1444.

Harris, D. E., Hamel, L., Aboueissa, A. M., and Johnson, D. A cardiovascular disease risk factor screening program designed to reach rural residents of Maine, USA. *Rural & Remote Health*. 2011;11(3):1-15.

Heianza, Y., Hara, S., Arase, Y., Saito, K., Fujiwara, K., Tsuji, H., Kodama, S., Hsieh, S. D., Mori, Y., Shimano, H., Yamada, N., Kosaka, K., and Sone, H. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. *Lancet*. 7-9-2011;378(9786):147-155.

Moore, S. M., Hardie, E. A., Hackworth, N. J., Critchley, C. R., Kyrios, M., Buzwell, S. A., and Crafti, N. A. Can the onset of type 2 diabetes be delayed by a group-based lifestyle intervention? A randomised control trial. *Psychology & Health*. 2011;26(4):485-499.

Mostafa, S. A., Davies, M. J., Webb, D., Gray, L. J., Srinivasan, B. T., Jarvis, J., and Khunti, K. The potential impact of using glycated haemoglobin as the preferred diagnostic tool for detecting Type 2 diabetes mellitus. *Diabetic Medicine*. 2010;27(7):762-769.

Pappas, Yannis, Wei, Igor, Car, Josip, Majeed, Azeem, Sheikh, and Aziz. Computer-assisted versus oral-and-written family history taking for identifying people with elevated risk of type 2 diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews* 2011;(8).

Pinelli, N. R., Jantz, A. S., Martin, E. T., and Jaber, L. A. Sensitivity and specificity of glycated hemoglobin as a diagnostic test for diabetes and prediabetes in arabs. *Journal of Clinical Endocrinology & Metabolism*. 2011;96(10):E1680-E1683.

Ritchie, G. E., Kengne, A. P., Joshi, R., Chow, C., Neal, B., Patel, A., and Zoungas, S. Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. *Diabetes Care*. 2011;34(1):44-49.

Sauvanet, J. P. [Diabetes and depression, from screening to intervention]. [French]. *Soins - Psychiatrie*. (268):11-Jun.

Wei, Igor, Pappas, Yannis, Car, Josip, Sheikh, Aziz, Majeed, and Azeem. Computer-assisted versus oral-and-written dietary history taking for diabetes mellitus [Systematic Review]. *Cochrane Database of Systematic Reviews* 2011;(8).

Level 3: Screening Comparator

Badings, E. A., Dyal, L., Schoterman, L., Lok, D. J., Stoel, I., Gerding, M. N., Gerstein, H. C., and Tijssen, J. G. Strategies to detect abnormal glucose metabolism in people at high risk of cardiovascular disease from the ORIGIN (Outcome Reduction with Initial Glargine Intervention) trial population. *Journal Of Diabetes*. 2011;3(3):232-237.

Hill, A. N. and Appel, S. J. Diagnosing diabetes with A1C: implications and considerations for measurement and surrogate markers. [Review]. *Nurse Practitioner*. 4-23-2010;35(10):16-23.

Kusumi, I., Ito, K., Uemura, K., Honda, M., Hayashishita, T., Miyamoto, K., Sawayama, H., Kako, Y., Tsuchida, S., Hashimoto, N., and Koyama, T. Screening for diabetes using monitoring guidance in schizophrenia patients treated with second-generation antipsychotics: a 1-year follow-up study. *Progress in Neuro-Psychopharmacology & Biological Psychiatry*. 2011;35(8):1922-1926.

Mostafa, S. A., Khunti, K., Srinivasan, B. T., Webb, D., Gray, L. J., and Davies, M. J. The potential impact and optimal cut-points of using glycated haemoglobin, HbA1c, to detect people with impaired glucose regulation in a UK multi-ethnic cohort. *Diabetes Research & Clinical Practice*. 2010;90(1):100-108.

Saaristo, T., Moilanen, L., Jokelainen, J., Korpi-Hyovalti, E., Vanhala, M., Saltevo, J., Niskanen, L., Peltonen, M., Oksa, H., Cederberg, H., Tuomilehto, J., Uusitupa, M., and Keinänen-Kiukaanniemi, S. Cardiometabolic profile of people screened for high risk of type 2 diabetes in a national diabetes prevention programme (FIN-D2D). *Primary care diabetes*. 2010;4(4):231-239.

Simmons, R. K., Echouffo-Tcheugui, J. B., and Griffin, S. J. Screening for type 2 diabetes: an update of the evidence. *Diabetes, Obesity & Metabolism*. 2010;12(10):838-844.

Skriver, M. V., Borch-Johnsen, K., Lauritzen, T., and Sandbaek, A. HbA1c as predictor of all-cause mortality in individuals at high risk of diabetes with normal glucose tolerance, identified by screening: a follow-up study of the Anglo-Danish-Dutch Study of Intensive Treatment in People with Screen-Detected Diabetes in Primary Care (ADDITION), Denmark. *Diabetologia*. 2010;53(11):2328-2333.

van den Donk, M., Sandbaek, A., Borch-Johnsen, K., Lauritzen, T., Simmons, R. K., Wareham, N. J., Griffin, S. J., Davies, M. J., Khunti, K., and Rutten, G. E. Screening for type 2 diabetes. Lessons from the ADDITION-Europe study. *Diabetic Medicine*. 2011;28(11):1416-1424.

Webb, D. R., Khunti, K., Srinivasan, B., Gray, L. J., Taub, N., Campbell, S., Barnett, J., Henson, J., Hiles, S., Farooqi, A., Griffin, S. J., Wareham, N. J., and Davies, M. J. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. *Trials*. 2010;Vol11, pp16, 2010:16.

Zhang, X., Gregg, E. W., Williamson, D. F., Barker, L. E., Thomas, W., Bullard, K. M., Imperatore, G., Williams, D. E., and Albright, A. L. A1C level and future risk of diabetes: a systematic review. [Review] [30 refs]. *Diabetes Care*. 2010;33(7):1665-1673.

Level 3: Outcomes

Bersoux, S., Cook, C. B., Wu, Q., Burritt, M. F., Hernandez, J. S., Verona, P. M., Larson, M. H., and LaRosa, C. S. Hemoglobin A1c testing alone does not sufficiently identify patients with prediabetes. *American Journal of Clinical Pathology*. 2011;135(5):674-677.

Costa, B., Barrio, F., Cabre, J. J., Pinol, J. L., Cos, F. X., Sole, C., Bolibar, B., Castell, C., Lindstrom, J., Barengo, N., Tuomilehto, J., and DE-PLAN-CAT Research Group. Shifting from glucose diagnostic criteria to the new HbA(1c) criteria would have a profound impact on prevalence of diabetes among a high-risk Spanish population. *Diabetic Medicine*. 2011;28(10):1234-1237.

Echouffo-Tcheugui, J. B., Ali, M. K., Griffin, S. J., and Narayan, K. M. Screening for type 2 diabetes and dysglycemia. [Review]. *Epidemiologic Reviews*. 2011;33(1):63-87.

Egli, M. and Ruiz, J. [Diabetes]. *Revue Medicale Suisse*. 6(232):100.

Fajans, S. S., Herman, W. H., and Oral, E. A. Insufficient sensitivity of hemoglobin A(1C) determination in diagnosis or screening of early diabetic states. *Metabolism: Clinical & Experimental*. 2011;60(1):86-91.

Kusumi, I., Ito, K., Honda, M., Hayashishita, T., Uemura, K., Hashimoto, N., Murasaki, M., Atsumi, Y., Kadowaki, T., and Koyama, T. Screening for diabetes using Japanese monitoring guidance in

schizophrenia patients treated with second-generation antipsychotics: a cross-sectional study using baseline data. *Psychiatry & Clinical Neurosciences*. 2011;65(4):349-355.

Rojas-Martinez, R., Aguilar-Salinas, C. A., and Jimenez-Corona, A. Optimal cutoff points for the detection of undiagnosed type 2 diabetes, hypertension and metabolic syndrome in Mexican adults. *Salud Publica de Mexico*. 2012;54(1):13-19.

Santos-Rey, K., Fernandez-Riejlos, P., Mateo, J., Sanchez-Margalet, V., and Goberna, R. Glycated hemoglobin vs. the oral glucose tolerance test for the exclusion of impaired glucose tolerance in high-risk individuals. *Clinical Chemistry & Laboratory Medicine*. 2010;48(12):1719-1722.

Sharma, K. M., Ranjani, H., Nguyen, H., Shetty, S., Datta, M., Narayan, K. M., and Mohan, V. Indian Diabetes Risk Score helps to distinguish type 2 from non-type 2 diabetes mellitus (GDRC-3). *Journal of Diabetes Science & Technology*. 2011;5(2):419-425.

Talbot, P. and Dunbar, M. J. Nova Scotia Prediabetes Project: upstream screening and community intervention for prediabetes and undiagnosed type 2 diabetes. *Chronic Diseases and Injuries in Canada*. 2011;32(1):2-11.

Verier-Mine, O. [Outcomes in women with history of gestational diabetes mellitus. Screening and prevention of type 2 diabetes mellitus. Literature review]. [French]. *Journal de Gynecologie, Obstetrique et Biologie de la Reproduction*. 2010;39(8:Suppl 2):Suppl-321.

Level 3: Study Design

Lipska, K. J., De, Rekeneire N., Van Ness, P. H., Johnson, K. C., Kanaya, A., Koster, A., Strotmeyer, E. S., Goodpaster, B. H., Harris, T., Gill, T. M., and Inzucchi, S. E. Identifying dysglycemic states in older adults: implications of the emerging use of hemoglobin A1c. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(12):5289-5295.

Sullivan, S. D., Garrison, L. P., Jr., Rinde, H., Kolberg, J., and Moler, E. J. Cost-effectiveness of risk stratification for preventing type 2 diabetes using a multi-marker diabetes risk score. *Journal of Medical Economics*. 2011;14(5):609-616.

Diabetes Preference and Values Excluded Studies List

Level 1: Preference and Values

Exenatide: new drug. Type 2 diabetes for some overweight patients. *Prescrire International*. 2007;16(92):228-231.

Yoga therapy helps relieve chronic lower back pain. *Harvard Women's Health Watch*. 2009;17(3):4.

Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Grant, R. W., Meigs, J. B., Soumerai, S. B., and Ross-Degnan, D. Medication adherence and racial differences in A1C control. *Diabetes Care*. 2008;31(5):916-921.

Adler, S., Lodermeier, S., Gaa, J., and Heemann, U. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. *Rheumatology*. 2008;47(10):1535-1538.

Adolfsson, E. T., Starrin, B., Smide, B., and Wikblad, K. Type 2 diabetic patients' experiences of two different educational approaches--a qualitative study. *International Journal of Nursing Studies*. 2008;45(7):986-994.

Adolfsson, E. T., Walker-Engstrom, M. L., Smide, B., and Wikblad, K. Patient education in type 2 diabetes: a randomized controlled 1-year follow-up study. *Diabetes Research & Clinical Practice*. 2007;76(3):341-350.

Alvarez, Guisasola F., Tofe, Povedano S., Krishnarajah, G., Lyu, R., Mavros, P., and Yin, D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal

in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. *Diabetes, Obesity & Metabolism*. 2008;10:Suppl-32.

Andersen, S. T., Jeppesen, T. D., Taivassalo, T., Sveen, M. L., Heinicke, K., Haller, R. G., and Vissing, J. Effect of changes in fat availability on exercise capacity in McArdle disease. *Archives of Neurology*. 2009;66(6):762-766.

Annunziato, R. A., Timko, C. A., Crerand, C. E., Didie, E. R., Bellace, D. L., Phelan, S., Kerzhnerman, I., and Lowe, M. R. A randomized trial examining differential meal replacement adherence in a weight loss maintenance program after one-year follow-up. *Eating Behaviors*. 2009;10(3):176-183.

Arevalo, J. F., Maia, M., Flynn, H. W., Jr., Saravia, M., Avery, R. L., Wu, L., Eid, Farah M., Pieramici, D. J., Berrocal, M. H., and Sanchez, J. G. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. *British Journal of Ophthalmology*. 2008;92(2):213-216.

Arrigo, I., Brunner-LaRocca, H., Lefkovits, M., Pfisterer, M., and Hoffmann, A. Comparative outcome one year after formal cardiac rehabilitation: the effects of a randomized intervention to improve exercise adherence. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2008;15(3):306-311.

Asakura, T. and Jensen, K. H. Comparison of intuitiveness, ease of use, and preference in two insulin pens. *Journal of Diabetes Science & Technology*. 2009;3(2):312-319.

Asakura, T., Seino, H., and Jensen, K. H. Patient acceptance and issues of education of two durable insulin pen devices. *Diabetes Technology & Therapeutics*. 2008;10(4):299-304.

Asche, C. V., McAdam-Marx, C., Shane-McWhorter, L., Sheng, X., and Plauschinat, C. A. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs & Aging*. 2008;25(7):611-622.

Aylwin, S. and Al Zaman, Y. Emerging concepts in the medical and surgical treatment of obesity. [Review] [101 refs]. *Frontiers of Hormone Research*. 2008;36:229-259.

Banez, C., Tully, S., Amaral, L., Kwan, D., Kung, A., Mak, K., Moghabghab, R., and Alibhai, S. M. Development, implementation, and evaluation of an Interprofessional Falls Prevention Program for older adults. *Journal of the American Geriatrics Society*. 2008;56(8):1549-1555.

Barnard, N. D., Gloede, L., Cohen, J., Jenkins, D. J., Turner-McGrievy, G., Green, A. A., and Ferdowsian, H. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. *Journal of the American Dietetic Association*. 2009;109(2):263-272.

Barnett, A. Dosing of insulin glargine in the treatment of type 2 diabetes. [Review] [47 refs]. *Clinical Therapeutics*. 2007;29(6):987-999.

Beddoe, A. E., Paul Yang, C. P., Kennedy, H. P., Weiss, S. J., and Lee, K. A. The effects of mindfulness-based yoga during pregnancy on maternal psychological and physical distress. *JOGNN - Journal of Obstetric, Gynecologic, & Neonatal Nursing*. 2009;38(3):310-319.

Ben Salah, Frih Z., Fendri, Y., Jellad, A., Boudoukhane, S., and Rejeb, N. Efficacy and treatment compliance of a home-based rehabilitation programme for chronic low back pain: a randomized, controlled study. *Annals of Physical & Rehabilitation Medicine*. 2009;52(6):485-496.

Bergental, R. M., Freemantle, N., Leyk, M., Cutler, G. B., Jr., Hayes, R. P., and Muchmore, D. B. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. *Diabetes Technology & Therapeutics*. 2009;11:Suppl-52.

Berhanu, P., Perez, A., and Yu, S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. *Diabetes, Obesity & Metabolism*. 2007;9(4):512-520.

Bersoux, S., Asbury, K. L., Cook, C. B., Verheijde, J. L., Larson, M. H., Aponte-Furlow, R. T., Flatten, S. S., Hooley, S. A., LaRosa, C. S., Seifert, K. M., Verona, P. M., Castro, J. C., and Jameson, K. A. An outpatient-based clinical program for type 2 diabetes prevention. *Endocrine Practice*. 2010;16(1):21-29.

Berthe, E., Lireux, B., Coffin, C., Goulet-Salmon, B., Houlbert, D., Boutreux, S., Fradin, S., and Reznik, Y. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. *Hormone & Metabolic Research*. 2007;39(3):224-229.

Best, J. H., Boye, K. S., Rubin, R. R., Cao, D., Kim, T. H., and Peyrot, M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. *Diabetic Medicine*. 2009;26(7):722-728.

Beverly, E. A., Miller, C. K., and Wray, L. A. Spousal support and food-related behavior change in middle-aged and older adults living with type 2 diabetes. *Health Education & Behavior*. 2008;35(5):707-720.

Biderman, A., Noff, E., Harris, S. B., Friedman, N., and Levy, A. Treatment satisfaction of diabetic patients: what are the contributing factors?. *Family Practice*. 2009;26(2):102-108.

Black, C., Cummins, E., Royle, P., Philip, S., and Waugh, N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. [Review] [179 refs]. *Health Technology Assessment (Winchester, England)*. 2007;11(33):1-126.

Blanson Henkemans, O. A., van der Boog, P. J., Lindenberg, J., van der Mast, C. A., Neerincx, M. A., and Zwetsloot-Schonk, B. J. An online lifestyle diary with a persuasive computer assistant providing feedback on self-management. *Technology & Health Care*. 2009;17(3):253-267.

Blevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J. H., and Aronoff, S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):118-128.

Boaz, M., Hellman, K., and Wainstein, J. An automated telemedicine system improves patient-reported well-being. *Diabetes Technology & Therapeutics*. 2009;11(3):181-186.

Bode, B. W. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. *Clinical Therapeutics*. 2007;29:Suppl-44.

Bond, D. S., Phelan, S., Wolfe, L. G., Evans, R. K., Meador, J. G., Kellum, J. M., Maher, J. W., and Wing, R. R. Becoming physically active after bariatric surgery is associated with improved weight loss and health-related quality of life. *Obesity*. 2009;17(1):78-83.

Bonutti, P. M., McGrath, M. S., Ulrich, S. D., McKenzie, S. A., Seyler, T. M., and Mont, M. A. Static progressive stretch for the treatment of knee stiffness. *Knee*. 2008;15(4):272-276.

Borges, W. J. and Ostwald, S. K. Improving foot self-care behaviors with Pies Sanos. *Western Journal of Nursing Research*. 342;30(3):325-341.

Bosak, K. A., Yates, B., and Pozehl, B. Effects of an Internet physical activity intervention in adults with metabolic syndrome. *Western Journal of Nursing Research*. 2010;32(1):5-22.

Boutati, E. I. and Raptis, S. A. Self-monitoring of blood glucose as part of the integral care of type 2 diabetes. [Review] [51 refs]. *Diabetes Care*. 2009;32:Suppl-10.

Bowman, A. M. Promoting safe exercise and foot care for clients with type 2 diabetes. *Canadian Nurse*. 2008;104(2):23-27.

Bradley, C., Plowright, R., Stewart, J., Valentine, J., and Witthaus, E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. *Health & Quality of Life Outcomes*. 2007;5:57.

Brandle, M., Goodall, G., Erny-Albrecht, K. M., Erdmann, E., and Valentine, W. J. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. *Swiss Medical Weekly*. 3-21-2009;139(11-12):173-184.

Brenner, M. A., Harkless, L. B., Mendicino, R. W., and Page, J. C. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. *Journal of the American Podiatric Medical Association*. 2007;97(3):195-202.

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., and Linn, T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.[Erratum appears in *Lancet*. 2008 Aug 30;372(9640):718]. *Lancet*. 3-29-2008;371(9618):1073-1084.

Brod, M., Cobden, D., Lammert, M., Bushnell, D., and Raskin, P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. *Health & Quality of Life Outcomes*. 2007;5:8.

Brown, S. E., Meltzer, D. O., Chin, M. H., and Huang, E. S. Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. *Journal of the American Geriatrics Society*. 2008;56(7):1183-1190.

Carels, R. A., Young, K. M., Wott, C. B., Harper, J., Gumble, A., Oehlof, M. W., and Clayton, A. M. Weight bias and weight loss treatment outcomes in treatment-seeking adults. *Annals of Behavioral Medicine*. 2009;37(3):350-355.

Cefalu, W. T., Mathieu, C., Davidson, J., Freemantle, N., Gough, S., Canovatchel, W., and OPTIMIZE, Coalition. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. *Diabetes Technology & Therapeutics*. 2008;10(1):25-38.

Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., and Marchant, N. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. *Pharmacoeconomics*. 2008;26(3):217-234.

Chaney, S. E. and Sheriff, S. Weight gain among women during smoking cessation: testing the effects of a multifaceted program. *AAOHN Journal*. 2008;56(3):99-105.

Chang, R. Y., Koo, M., Yu, Z. R., Kan, C. B., Chu, I. T., Hsu, C. T., and Chen, C. Y. The effect of t'ai chi exercise on autonomic nervous function of patients with coronary artery disease. *Journal of Alternative & Complementary Medicine*. 2008;14(9):1107-1113.

Chao, J., Nau, D. P., and Aikens, J. E. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. *Clinical Therapeutics*. 2007;29(1):177-180.

Chlup, R., Zapletalova, J., Seckar, P., Mala, E., Doubravova, B., Tancosova, S., Chlupova, L., Pukowietz, L., and Zatloukal, P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. *Diabetes Technology & Therapeutics*. 2007;9(3):223-231.

Cho, J. H., Lee, H. C., Lim, D. J., Kwon, H. S., and Yoon, K. H. Mobile communication using a mobile phone with a glucometer for glucose control in Type 2 patients with diabetes: as effective as an Internet-based glucose monitoring system. *Journal of Telemedicine & Telecare*. 2009;15(2):77-82.

Clancy, D. E., Huang, P., Okonofua, E., Yeager, D., and Magruder, K. M. Group visits: promoting adherence to diabetes guidelines. *Journal of General Internal Medicine*. 2007;22(5):620-624.

Clements, M. R., Tits, J., Kinsley, B. T., Rastam, J., Friberg, H. H., and Ligthelm, R. J. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(3):229-237.

Cleveringa, F. G., Welsing, P. M., van den, Donk M., Gorter, K. J., Niessen, L. W., Rutten, G. E., and Redekop, W. K. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision

support diabetes management intervention that reduces cardiovascular risk. *Diabetes Care*. 2010;33(2):258-263.

Coghill, N. and Cooper, A. R. Motivators and de-motivators for adherence to a program of sustained walking. *Preventive Medicine*. 2009;49(1):24-27.

Cohen, B. E., Chang, A. A., Grady, D., and Kanaya, A. M. Restorative yoga in adults with metabolic syndrome: a randomized, controlled pilot trial. *Metabolic Syndrome & Related Disorders*. 2008;6(3):223-229.

Cohen, B. E., Kanaya, A. M., Macer, J. L., Shen, H., Chang, A. A., and Grady, D. Feasibility and acceptability of restorative yoga for treatment of hot flushes: a pilot trial. *Maturitas*. 2-20-2007;56(2):198-204.

Colombi, A. M., Yu-Isenberg, K., and Priest, J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. *Journal of Occupational & Environmental Medicine*. 2008;50(5):535-541.

Cooper, S., Osborne, J., Harrison, T., and Tattersfield, A. Effect of mouth taping at night on asthma control--a randomised single-blind crossover study. *Respiratory Medicine*. 2009;103(6):813-819.

Coronado, G. D., Thompson, B., Tejeda, S., Godina, R., and Chen, L. Sociodemographic factors and self-management practices related to type 2 diabetes among Hispanics and non-Hispanic whites in a rural setting. *Journal of Rural Health*. 2007;23(1):49-54.

Cosson, E., Hamo-Tchatchouang, E., Dufaitre-Patouraux, L., Attali, J. R., Paries, J., and Schaepeelynck-Belicar, P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. *Diabetes & Metabolism*. 2009;35(4):312-318.

Costanza, M. C., Beer-Borst, S., and Morabia, A. Achieving energy balance at the population level through increases in physical activity. *American Journal of Public Health*. 2007;97(3):520-525.

Courneya, K. S., McKenzie, D. C., Reid, R. D., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Ladha, A. B., Proulx, C., Lane, K., Vallance, J. K., and Segal, R. J. Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. *Annals of Behavioral Medicine*. 2008;35(1):116-122.

Courneya, K. S., Segal, R. J., Gelmon, K., Reid, R. D., Mackey, J. R., Friedenreich, C. M., Proulx, C., Lane, K., Ladha, A. B., Vallance, J. K., and McKenzie, D. C. Predictors of supervised exercise adherence during breast cancer chemotherapy. *Medicine & Science in Sports & Exercise*. 2008;40(6):1180-1187.

Courneya, K. S., Sellar, C. M., Stevinson, C., McNeely, M. L., Peddle, C. J., Friedenreich, C. M., Tankel, K., Basi, S., Chua, N., Mazurek, A., and Reiman, T. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. *Journal of Clinical Oncology*. 9-20-2009;27(27):4605-4612.

Cuocolo, A., Concilio, C., Acampa, W., Ferro, A., Evangelista, L., Daniele, S., and Petretta, M. Cardiovascular risk stratification of diabetic patients. [Review] [89 refs]. *Minerva Endocrinologica*. 2009;34(3):205-221.

Curnow, D., Cobbin, D., Wyndham, J., and Boris Choy, S. T. Altered motor control, posture and the Pilates method of exercise prescription. *Journal of Bodywork & Movement Therapies*. 2009;13(1):104-111.

Cutler, T. W., Palmieri, J., Khalsa, M., and Stebbins, M. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group. *Journal of Managed Care Pharmacy*. 2007;13(7):578-588.

Cvetkovic, R. S. and Plosker, G. L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). [Review] [59 refs]. *Drugs*. 2007;67(6):935-954.

Dailey, G. Developing a pulmonary insulin delivery system for patients with diabetes. [Review] [57 refs]. *Clinical Therapeutics*. 2007;29(6:Pt 1):t-83.

Dale, J., Caramlau, I., Sturt, J., Friede, T., and Walker, R. Telephone peer-delivered intervention for diabetes motivation and support: the telecare exploratory RCT. *Patient Education & Counseling*. 2009;75(1):91-98.

Daley, A. J., Crank, H., Mutrie, N., Saxton, J. M., and Coleman, R. Determinants of adherence to exercise in women treated for breast cancer. *European Journal of Oncology Nursing*. 2007;11(5):392-399.

Darbyshire, J. L., Holman, R. R., and Price, H. C. Presenting the results of clinical trials to participants. *Clinical Medicine*. 2009;9(5):415-416.

Davis, A. H. Exercise adherence in patients with chronic obstructive pulmonary disease: an exploration of motivation and goals. *Rehabilitation Nursing*. 2007;32(3):104-110.

Davis, S. N. The role of inhaled insulin in the treatment of type 2 diabetes. [Review] [50 refs]. *Journal of Diabetes & its Complications*. 2008;22(6):420-429.

De Mattia, G., Laurenti, O., and Moretti, A. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. *Acta Diabetologica*. 2009;46(1):67-73.

Debacker, N., Nobels, F., Vandenberghe, H., Van Crombrugge, P., Scheen, A., and Van, Casteren, V. Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience. *Diabetic Medicine*. 2008;25(2):179-185.

Del Corral, P., Chandler-Laney, P. C., Casazza, K., Gower, B. A., and Hunter, G. R. Effect of dietary adherence with or without exercise on weight loss: a mechanistic approach to a global problem. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(5):1602-1607.

DePaula, A. L., Macedo, A. L., Rassi, N., Machado, C. A., Schraibman, V., Silva, L. Q., and Halpern, A. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. *Surgical Endoscopy*. 2008;22(3):706-716.

Derosa, G., D'Angelo, A., Franzetti, I. G., Ragonesi, P. D., Gadaleta, G., Scalise, F., Ciccarelli, L., Piccinni, M. N., and Cicero, A. F. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. *Journal of Clinical Pharmacy & Therapeutics*. 2009;34(3):267-276.

Dhillon, S. and Weber, J. Saxagliptin. *Drugs*. 2009;69(15):2103-2114.

Dijkstra, R., Braspenning, J., and Grol, R. Implementing diabetes passports to focus practice reorganization on improving diabetes care. *International Journal for Quality in Health Care*. 2008;20(1):72-77.

Donnelly, L. A., Morris, A. D., and Pearson, E. R. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. *Diabetes, Obesity & Metabolism*. 2009;11(4):338-342.

Donnelly, L. A., Morris, A. D., Evans, J. M., and collaboration, M. E. M. O. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. *Qjm*. 2007;100(6):345-350.

Downey, L. V. and Zun, L. S. The effects of deep breathing training on pain management in the emergency department. *Southern Medical Journal*. 2009;102(7):688-692.

Ebbeling, C. B., Leidig, M. M., Feldman, H. A., Lovesky, M. M., and Ludwig, D. S. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial.[Erratum appears in JAMA. 2007 Aug 8;298(6):627]. *JAMA*. 5-16-2007;297(19):2092-2102.

Edelman, S., Maier, H., and Wilhelm, K. Pramlintide in the treatment of diabetes mellitus. [Review] [72 refs]. *Biodrugs*. 2008;22(6):375-386.

El Mhandi, L., Millet, G. Y., Calmels, P., Richard, A., Oullion, R., Gautheron, V., and Feasson, L. Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease. *Muscle & Nerve*. 2008;37(5):601-610.

Elder, C., Ritenbaugh, C., Mist, S., Aickin, M., Schneider, J., Zwickey, H., and Elmer, P. Randomized trial of two mind-body interventions for weight-loss maintenance. *Journal of Alternative & Complementary Medicine*. 2007;13(1):67-78.

Ell, K., Katon, W., Cabassa, L. J., Xie, B., Lee, P. J., Kapetanovic, S., and Guterman, J. Depression and diabetes among low-income Hispanics: design elements of a socioculturally adapted collaborative care model randomized controlled trial. *International Journal of Psychiatry in Medicine*. 2009;39(2):113-132.

Ello-Martin, J. A., Roe, L. S., Ledikwe, J. H., Beach, A. M., and Rolls, B. J. Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. *American Journal of Clinical Nutrition*. 2007;85(6):1465-1477.

Farmer, A. J., Prevost, A. T., Hardeman, W., Craven, A., Sutton, S., Griffin, S. J., Kinmonth, A. L., and Support and Advice for Medication Trial Group. Protocol for SAMS (Support and Advice for Medication Study): a randomised controlled trial of an intervention to support patients with type 2 diabetes with adherence to medication. *BMC Family Practice*. 2008;9:20.

Fielding, R. A., Katula, J., Miller, M. E., Abbott-Pillola, K., Jordan, A., Glynn, N. W., Goodpaster, B., Walkup, M. P., King, A. C., Rejeski, W. J., and Life, Study, I. Activity adherence and physical function in older adults with functional limitations. *Medicine & Science in Sports & Exercise*. 2007;39(11):1997-2004.

Findorff, M. J., Wyman, J. F., and Gross, C. R. Predictors of long-term exercise adherence in a community-based sample of older women. *Journal of Women's Health*. 2009;18(11):1769-1776.

Finne, E., Reinehr, T., Schaefer, A., Winkel, K., and Kolip, P. Overweight children and adolescents--is there a subjective need for treatment?. *International Journal of Public Health*. 2009;54(2):112-116.

Finnell, D. and Ditz, K. A. Health diaries for self-monitoring and self-regulation: applications to individuals with serious mental illness. [Review] [31 refs]. *Issues in Mental Health Nursing*. 2007;28(12):1293-1307.

Fish, A. F., Frid, D. J., Mitchell, G. L., Fish, J. L., Christman, S. K., and Astroth, K. S. Readiness to exercise: a comparison of 3 instruments and an interview. *Progress in Cardiovascular Nursing*. 2007;22(4):201-206.

Flapper, B. C., Duiverman, E. J., Gerritsen, J., Postema, K., and van der Schans, C. P. Happiness to be gained in paediatric asthma care. *European Respiratory Journal*. 2008;32(6):1555-1562.

Flegal, K. E., Kishiyama, S., Zajdel, D., Haas, M., and Oken, B. S. Adherence to yoga and exercise interventions in a 6-month clinical trial. *BMC Complementary & Alternative Medicine*. 2007;7:37.

Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., and Mahaffey, K. W. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):16-27.

Furse, J., Clarke, M., Jones, R., Khemka, S., and Findlay, G. Early experience in using telemonitoring for the management of chronic disease in primary care. *Journal of Telemedicine & Telecare*. 2008;14(3):122-124.

Gagliardino, J. J., Lapertosa, S., Villagra, M., Caporale, J. E., Oliver, P., Gonzalez, C., Siri, F., Clark, Ch, Jr., and PRODIACOR. PRODIACOR: a patient-centered treatment program for type 2 diabetes and associated cardiovascular risk factors in the city of Corrientes, Argentina: study design and baseline data. *Contemporary Clinical Trials*. 2007;28(4):548-556.

Garfield, S., Smith, F., Francis, S. A., and Chalmers, C. Can patients' preferences for involvement in decision-making regarding the use of medicines be predicted?. *Patient Education & Counseling*. 2007;66(3):361-367.

Geloneze, B., Geloneze, S. R., Fiori, C., Stabe, C., Tambascia, M. A., Chaim, E. A., Astiarraga, B. D., and Pareja, J. C. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. *Obesity Surgery*. 2009;19(8):1077-1083.

Gerber, J. B., Bloom, P. A., and Ross, J. S. The physical activity contract--tailored to promote physical activity in a geriatric outpatient setting: a pilot study. *Journal of the American Geriatrics Society*. 2010;58(3):604-606.

Ghosh, S. and Collier, A. Inhaled insulins. [Review] [51 refs]. *Postgraduate Medical Journal*. 2007;83(977):178-181.

Gillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., and Khunti, K. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. *BMJ*. 5-24-2008;336(7654):1180-1185.

Gold, S. M., Schulz, H., Stein, H., Solf, K., Schulz, K. H., and Heesen, C. Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings. *Journal of the Neurological Sciences*. 3-15-2010;290(1-2):102-106.

Gonzalez, J. S., Peyrot, M., McCarl, L. A., Collins, E. M., Serpa, L., Mimiaga, M. J., and Safren, S. A. Depression and diabetes treatment nonadherence: a meta-analysis. [Review] [40 refs]. *Diabetes Care*. 2008;31(12):2398-2403.

Gonzalez, J. S., Safren, S. A., Delahanty, L. M., Cagliero, E., Wexler, D. J., Meigs, J. B., and Grant, R. W. Symptoms of depression prospectively predict poorer self-care in patients with Type 2 diabetes. *Diabetic Medicine*. 2008;25(9):1102-1107.

Grant, R. W., Wald, J. S., Schnipper, J. L., Gandhi, T. K., Poon, E. G., Orav, E. J., Williams, D. H., Volk, L. A., and Middleton, B. Practice-linked online personal health records for type 2 diabetes mellitus: a randomized controlled trial. *Archives of Internal Medicine*. 9-8-2008;168(16):1776-1782.

Graziano, J. A. and Gross, C. R. A randomized controlled trial of an automated telephone intervention to improve glycemic control in type 2 diabetes. *Advances in Nursing Science*. 2009;32(3):E42-E57.

Gredal, C., Rosenfalck, A., Dejgaard, A., and Hilsted, J. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;80(2):293-298.

Greenberg, I., Stampfer, M. J., Schwarzfuchs, D., Shai, I., and DIRECT Group. Adherence and success in long-term weight loss diets: the dietary intervention randomized controlled trial (DIRECT). *Journal of the American College of Nutrition*. 2009;28(2):159-168.

Gross, C. C., Scain, S. F., Scheffel, R., Gross, J. L., and Hutz, C. S. Brazilian version of the Problem Areas in Diabetes Scale (B-PAID): validation and identification of individuals at high risk for emotional distress. *Diabetes Research & Clinical Practice*. 2007;76(3):455-459.

Gucciardi, E., DeMelo, M., Booth, G., Tomlinson, G., and Stewart, D. E. Individual and contextual factors associated with follow-up use of diabetes self-management education programmes: a multisite prospective analysis. *Diabetic Medicine*. 2009;26(5):510-517.

Gulmez, O., Yildirim, A., Bal, U., Konas, N. D., Aydin, A., Demir, O., Atar, I., Ertan, C., Ozin, B., and Muderrisoglu, H. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. *Blood Coagulation & Fibrinolysis*. 2007;18(1):9-13.

Gunther, A. L., Liese, A. D., Bell, R. A., Dabelea, D., Lawrence, J. M., Rodriguez, B. L., Standiford, D. A., and Mayer-Davis, E. J. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. *Hypertension*. 2009;53(1):6-12.

Guo, X., Zhou, B., Nishimura, T., Teramukai, S., and Fukushima, M. Clinical effect of qigong practice on essential hypertension: a meta-analysis of randomized controlled trials. [Review] [37 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(1):27-37.

Hall, A. M., Maher, C. G., Latimer, J., Ferreira, M. L., and Lam, P. A randomized controlled trial of tai chi for long-term low back pain (TAI CHI): study rationale, design, and methods. *BMC Musculoskeletal Disorders*. 2009;10:55.

Halm, J. and Amoako, E. Physical activity recommendation for hypertension management: does healthcare provider advice make a difference?.[Summary for patients in *Ethn Dis*. 2008 Summer;18(3):389; PMID: 18788117]. *Ethnicity & Disease*. 2008;18(3):278-282.

Hanssen, T. A., Nordrehaug, J. E., Eide, G. E., and Hanestad, B. R. Improving outcomes after myocardial infarction: a randomized controlled trial evaluating effects of a telephone follow-up intervention. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2007;14(3):429-437.

Harris, M. A., Freeman, K. A., and Beers, M. Family therapy for adolescents with poorly controlled diabetes: initial test of clinical significance. *Journal of Pediatric Psychology*. 2009;34(10):1097-1107.

Harris, S., Yale, J. F., Dempsey, E., and Gerstein, H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. *Canadian Family Physician*. 2008;54(4):550-558.

Harris, T. J., Victor, C. R., Carey, I. M., Adams, R., and Cook, D. G. Less healthy, but more active: opposing selection biases when recruiting older people to a physical activity study through primary care. *BMC Public Health*. 2008;8:182.

Hattori, Y., Hashizume, K., Nakajima, K., Nishimura, Y., Naka, M., and Miyanaga, K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. *Current Medical Research & Opinion*. 2007;23(8):1913-1917.

Hatzichristou, D., Gambla, M., Rubio-Aurioles, E., Buvat, J., Brock, G. B., Spera, G., Rose, L., Lording, D., and Liang, S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. *Diabetic Medicine*. 2008;25(2):138-146.

Hawkes, A. L., Gollschewski, S., Lynch, B. M., and Chambers, S. A telephone-delivered lifestyle intervention for colorectal cancer survivors 'CanChange': a pilot study. *Psycho-Oncology*. 2009;18(4):449-455.

Hayes, R. P. and Fitzgerald, J. T. Perceptions and attitudes are primary contributors to insulin delivery system satisfaction in people with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2009;11(7):419-426.

Hayes, R. P., Nakano, M., Muchmore, D., and Schmitke, J. Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system. *Diabetes Technology & Therapeutics*. 2007;9(1):89-98.

Hollis, J. F., Gullion, C. M., Stevens, V. J., Brantley, P. J., Appel, L. J., Ard, J. D., Champagne, C. M., Dalcin, A., Erlinger, T. P., Funk, K., Laferriere, D., Lin, P. H., Loria, C. M., Samuel-Hodge, C., Vollmer, W. M., Svetkey, L. P., and Weight Loss Maintenance Trial Research Group. Weight loss during the intensive intervention phase of the weight-loss maintenance trial. *American Journal of Preventive Medicine*. 2008;35(2):118-126.

Hornsten, A., Stenlund, H., Lundman, B., and Sandstrom, H. Improvements in HbA1c remain after 5 years--a follow up of an educational intervention focusing on patients' personal understandings of type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;81(1):50-55.

Houlden, R., Ross, S., Harris, S., Yale, J. F., Sauriol, L., and Gerstein, H. C. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. *Diabetes Research & Clinical Practice*. 2007;78(2):254-258.

Houweling, S. T., Kleefstra, N., van Hateren, K. J., Kooy, A., Groenier, K. H., Ten Vergert, E., Meyboom-de Jong, B., Bilo, H. J., and Langerhans Medical Research Group. Diabetes specialist nurse as main care provider for patients with type 2 diabetes. *Netherlands Journal of Medicine*. 2009;67(7):279-284.

Huberty, J. L., Vener, J., Waltman, N., Ott, C., Twiss, J., Gross, G., McGuire, R., and Dwyer, A. Development of an instrument to measure adherence to strength training in postmenopausal breast cancer survivors. *Oncology Nursing Forum*. 2009;36(5):E266-E273.

Huffman, F. G., Vaccaro, J. A., Nath, S., and Zarini, G. G. Diabetes self management: are Cuban Americans receiving quality health care?. *Journal of Health & Human Services Administration*. 2009;32(3):278-304.

Ingrid, B. and Marsella, A. Factors influencing exercise participation by clients in long-term care. *Perspectives*. 2008;32(4):5-11.

Inskip, H. M., Crozier, S. R., Godfrey, K. M., Borland, S. E., Cooper, C., Robinson, S. M., and Southampton Women's Survey Study Group. Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. *BMJ*. 2009;338:b481.

Irwin, M. R., Olmstead, R., and Motivala, S. J. Improving sleep quality in older adults with moderate sleep complaints: A randomized controlled trial of Tai Chi Chih. *Sleep*. 7-1-2008;31(7):1001-1008.

Jacobsen, P. B., Donovan, K. A., Vadaparampil, S. T., and Small, B. J. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. [Review] [70 refs][Erratum appears in *Health Psychol*. 2008 Jan;27(1):42]. *Health Psychology*. 2007;26(6):660-667.

Jang, H. C., Guler, S., Shestakova, M., and PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. *International Journal of Clinical Practice*. 2008;62(7):1013-1018.

Jang, H. C., Lee, S. R., and Vaz, J. A. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy. *Diabetes, Obesity & Metabolism*. 2009;11(1):20-26.

Johnson, C. L., Nicholas, A., Divine, H., Perrier, D. G., Blumenschein, K., and Steinke, D. T. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. *Journal of the American Pharmacists Association: JAPhA*. 2008;48(6):722-730.

Johnson, R. E., Jones, G. T., Wiles, N. J., Chaddock, C., Potter, R. G., Roberts, C., Symmons, D. P., Watson, P. J., Torgerson, D. J., and Macfarlane, G. J. Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. *Spine*. 7-1-2007;32(15):1578-1585.

Jones, M. I., Greenfield, S., Jolly, K., and BRUM Trial Steering Committee. Patients' experience of home and hospital based cardiac rehabilitation: a focus group study. *European Journal of Cardiovascular Nursing*. 2009;8(1):9-17.

Joshy, G., Colonne, C. K., Dunn, P., Simmons, D., and Lawrenson, R. Ethnic disparities in causes of death among diabetes patients in the Waikato region of New Zealand. *New Zealand Medical Journal*. 2010;123(1310):19-29.

Joy, S. V. Clinical pearls and strategies to optimize patient outcomes. *Diabetes Educator*. 2008;34:Suppl-59S.

Kadoglou, N. P., Tsanikidis, H., Kapelouzou, A., Vrabas, I., Vitta, I., Karayannacos, P. E., Liapis, C. D., and Sailer, N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(3):373-379.

- Kalsekar, I., Sheehan, C., and Peak, A. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent). *Research In Social & Administrative Pharmacy*. 2007;3(4):378-391.
- Karl, D., Philis-Tsimikas, A., Darsow, T., Lorenzi, G., Kellmeyer, T., Lutz, K., Wang, Y., and Frias, J. P. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. *Diabetes Technology & Therapeutics*. 2007;9(2):191-199.
- Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., and Martin, B. C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. *Medical Care*. 2008;46(11):1125-1133.
- Kelley, K. and Dempsey, C. An evaluation of an insulin transfer programme delivered in a group setting. *Journal of Clinical Nursing*. 2007;16(7B):152-158.
- Kerssen, A., Goudswaard, A. N., Quartel, M., Zuithoff, N. P., and Rutten, G. E. The feasibility of a self-management education program for patients with type 2 diabetes mellitus: Do the perceptions of patients and educators match?. *Primary care diabetes*. 2009;3(2):79-83.
- Kindmalm, L., Melander, A., and Nilsson, J. L. Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes. *Acta Diabetologica*. 2007;44(4):209-213.
- King, D. E., Mainous, A. G., III, Carnemolla, M., and Everett, C. J. Adherence to healthy lifestyle habits in US adults, 1988-2006. *American Journal of Medicine*. 2009;122(6):528-534.
- Kipnes, M. S., Joseph, H., Morris, H., Manko, J., and Bell, D. E. Clinical performance of the TRUE2go blood glucose system--a novel integrated system for meter and strips. *Diabetes Technology & Therapeutics*. 2009;11(10):649-655.
- Kloos, C., Samann, A., Lehmann, T., Braun, A., Heckmann, B., and Muller, U. A. Flexible intensive versus conventional insulin therapy in insulin-naïve adults with type 2 diabetes: an open-label, randomized, controlled, crossover clinical trial of metabolic control and patient preference. *Diabetes Care*. 2007;30(12):3031-3032.
- Knobloch, K., Schreibmueller, L., Longo, U. G., and Vogt, P. M. Eccentric exercises for the management of tendinopathy of the main body of the Achilles tendon with or without an AirHeel Brace. A randomized controlled trial. B: Effects of compliance. *Disability & Rehabilitation*. 2008;30(20-22):1692-1696.
- Koc, Z., Ozcikir, S., Sivrioglu, K., Gurbet, A., and Kucukoglu, S. Effectiveness of physical therapy and epidural steroid injections in lumbar spinal stenosis. *Spine*. 5-1-2009;34(10):985-989.
- Kontos, P. C., Miller, K. L., Brooks, D., Jassal, S. V., Spanjevic, L., Devins, G. M., De Souza, M. J., Heck, C., Laprade, J., and Naglie, G. Factors influencing exercise participation by older adults requiring chronic hemodialysis: a qualitative study. *International Urology & Nephrology*. 2007;39(4):1303-1311.
- Krousel-Wood, M. A., Berger, L., Jiang, X., Blonde, L., Myers, L., and Webber, L. Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial. *Diabetes Research & Clinical Practice*. 2008;79(2):230-236.
- Latifpour, D. H., Grenner, J., and Sjodahl, C. The effect of a new treatment based on somatosensory stimulation in a group of patients with somatically related tinnitus. *International Tinnitus Journal*. 2009;15(1):94-99.
- Latka, R. N., Alvarez-Reeves, M., Cadmus, L., and Irwin, M. L. Adherence to a randomized controlled trial of aerobic exercise in breast cancer survivors: the Yale exercise and survivorship study. *Journal of Cancer Survivorship*. 2009;3(3):148-157.
- Lawton, J., Peel, E., Parry, O., and Douglas, M. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. *Diabetic Medicine*. 2008;25(4):491-495.

Lee, I. T., Liao, Y. J., Lee, W. J., Huang, C. N., and Sheu, W. H. Continuous subcutaneous insulin infusion providing better glycemic control and quality of life in Type 2 diabetic subjects hospitalized for marked hyperglycemia. *Journal of Evaluation in Clinical Practice*. 2010;16(1):202-205.

Lee, S. H. and Lee, B. C. Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. *Urology*. 2009;73(5):1036-1041.

Lee, S. J., Choi, E. J., and Kwon, J. S. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry*. 2008;69(4):555-562.

Lee, T. I., Yeh, Y. T., Liu, C. T., and Chen, P. L. Development and evaluation of a patient-oriented education system for diabetes management. *International Journal of Medical Informatics*. 2007;76(9):655-663.

Lemmetty, R. and Makela, K. Mobile digital fundus screening of type 2 diabetes patients in the Finnish county of South-Ostrobothnia. *Journal of Telemedicine & Telecare*. 2009;15(2):68-72.

Lenfant, C. Can prevention of hypertension work?. *American Journal of Therapeutics*. 2008;15(4):334-339.

Leonhardt, C., Keller, S., Chenot, J. F., Luckmann, J., Basler, H. D., Wegscheider, K., Baum, E., Donner-Banzhoff, N., Pflingsten, M., Hildebrandt, J., Kochen, M. M., and Becker, A. TTM-based motivational counselling does not increase physical activity of low back pain patients in a primary care setting--A cluster-randomized controlled trial. *Patient Education & Counseling*. 2008;70(1):50-60.

Lera, S., Gelman, S. M., Lopez, M. J., Abenoza, M., Zorrilla, J. G., Castro-Fornieles, J., and Salamero, M. Multidisciplinary treatment of fibromyalgia: does cognitive behavior therapy increase the response to treatment?. *Journal of Psychosomatic Research*. 2009;67(5):433-441.

Leung, Y. W., Grewal, K., Stewart, D. E., and Grace, S. L. Gender differences in motivations and perceived effects of Mind-Body Therapy (MBT) practice and views on integrative cardiac rehabilitation among acute coronary syndrome patients: why do women use MBT?. *Complementary Therapies in Medicine*. 2008;16(6):311-317.

Liebl, A. Insulin intensification--the rationale and the target. [Review] [27 refs]. *International Journal of Clinical Practice*. 2009;Supplement.(164):1-5.

Liese, A. D., Liu, L., Davis, C., Standiford, D., Waitzfelder, B., Dabelea, D., Bell, R., Williams, D., Imperatore, G., and Lawrence, J. M. Participation in pediatric epidemiologic research: the SEARCH for Diabetes in Youth Study experience. *Contemporary Clinical Trials*. 2008;29(6):829-836.

Liese, A. D., Nichols, M., Sun, X., D'Agostino, R. B., Jr., and Haffner, S. M. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes Care*. 2009;32(8):1434-1436.

Lim, S. S., Norman, R. J., Clifton, P. M., and Noakes, M. Psychological effects of prescriptive vs general lifestyle advice for weight loss in young women. *Journal of the American Dietetic Association*. 2009;109(11):1917-1921.

Lingvay, I., Kaloyanova, P. F., Adams-Huet, B., Salinas, K., and Raskin, P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. *Journal of Investigative Medicine*. 2007;55(2):62-68.

Lucia, A., Smith, L., Naidoo, M., Gonzalez-Freire, M., Perez, M., Rubio, J. C., Martin, M. A., Andreu, A. L., and Arenas, J. McArdle disease: another systemic low-inflammation disorder?. *Neuroscience Letters*. 1-31-2008;431(2):106-111.

Lund, S. S., Tarnow, L., Stehouwer, C. D., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., and Vaag, A. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes, Obesity & Metabolism*. 2007;9(3):394-407.

Lundgren, T., Dahl, J., Yardi, N., and Melin, L. Acceptance and Commitment Therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. *Epilepsy & Behavior*. 2008;13(1):102-108.

Maddocks, M., Mockett, S., and Wilcock, A. Is exercise an acceptable and practical therapy for people with or cured of cancer? A systematic review. [Review] [73 refs]. *Cancer Treatment Reviews*. 2009;35(4):383-390.

Malanda, U. L., Bot, S. D., Kostense, P. J., Snoek, F. J., Dekker, J. M., and Nijpels, G. Effects of self-monitoring of glucose in non-insulin treated patients with type 2 diabetes: design of the IN CONTROL-trial. *BMC Family Practice*. 2009;10:26.

Malpass, A., Andrews, R., and Turner, K. M. Patients with Type 2 Diabetes experiences of making multiple lifestyle changes: a qualitative study. *Patient Education & Counseling*. 2009;74(2):258-263.

Marrero, D. G. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. [Review] [28 refs]. *Clinical Cornerstone*. 1941;8(2):33-40.

Marshall, J. G., Cowell, J. M., Campbell, E. S., and McNaughton, D. B. Regional variations in cancer screening rates found in women with diabetes. *Nursing Research*. 2010;59(1):34-41.

Martin, S., Kolb, H., Schneider, B., Heinemann, L., Weber, C., Kocher, S., Tshiananga, J. K., Scherbaum, W. A., and Lodwig, V. Myocardial infarction and stroke in early years after diagnosis of type 2 diabetes: risk factors and relation to self-monitoring of blood glucose. *Diabetes Technology & Therapeutics*. 2009;11(4):234-241.

Martinez, L., Consoli, S. M., Monnier, L., Simon, D., Wong, O., Yomtov, B., Gueron, B., Benmedjahed, K., Guillemin, I., and Arnould, B. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. *Health & Quality of Life Outcomes*. 2007;5:53.

Martinez, Y. V., Prado-Aguilar, C. A., Rascon-Pacheco, R. A., and Valdivia-Martinez, J. J. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. *BMC Health Services Research*. 2008;8:164.

Martinez-Gonzalez, M. A., Fuente-Arrillaga, C., Nunez-Cordoba, J. M., Basterra-Gortari, F. J., Beunza, J. J., Vazquez, Z., Benito, S., Tortosa, A., and Bes-Rastrollo, M. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ*. 6-14-2008;336(7657):1348-1351.

May, A. M., Duivenvoorden, H. J., Korstjens, I., van Weert, E., Hoekstra-Weebers, J. E., van den Borne, B., Mesters, I., van der Schans, C. P., and Ros, W. J. The effect of group cohesion on rehabilitation outcome in cancer survivors. *Psycho-Oncology*. 2008;17(9):917-925.

McConnon, A., Kirk, S. F., and Ransley, J. K. Process evaluation of an internet-based resource for weight control: use and views of an obese sample. *Journal of Nutrition Education & Behavior*. 2009;41(4):261-267.

McDowell, J. R., McPhail, K., Halyburton, G., Brown, M., and Lindsay, G. Perceptions of a service redesign by adults living with type 2 diabetes. *Journal of Advanced Nursing*. 2009;65(7):1432-1441.

McLachlan, K., Jenkins, A., and O'Neal, D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2007;47(3):186-190.

Menard, J., Payette, H., Dubuc, N., Baillargeon, J. P., Maheux, P., and Ardilouze, J. L. Quality of life in type 2 diabetes patients under intensive multitherapy. *Diabetes & Metabolism*. 2007;33(1):54-60.

Mishali, M., Sominsky, L., and Heymann, A. D. Reducing resistance to diabetes treatment using short narrative interventions. *Family Practice*. 2010;27(2):192-197.

Monahan, P. O., Lane, K. A., Hayes, R. P., McHorney, C. A., and Marrero, D. G. Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D. *Quality of Life Research*. 2009;18(7):941-952.

Moreira, E. D., Jr., Neves, R. C., Nunes, Z. O., de Almeida, M. C., Mendes, A. B., Fittipaldi, J. A., Ablan, F., and Venezuelan Diabetes Investigators' Group. Glycemic control and its correlates in patients with diabetes in Venezuela: results from a nationwide survey. *Diabetes Research & Clinical Practice*. 2010;87(3):407-414.

Moro, J. A., Almenar, L., Martnez-Dolz, L., Agüero, J., Sanchez-Lazaro, I., Iglesias, P., Igual, V., and Salvador, A. Support program for heart transplant patients: initial experience. *Transplantation Proceedings*. 2008;40(9):3039-3040.

Mukherjee, A. K., Reddy, V. S., Shah, S., Jhingan, A. K., Ramakrishnan, P., Prusty, V., and Singh, N. S. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. *Journal of the Indian Medical Association*. 2009;107(7):464-470.

Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebe, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., and Smith, S. A. The diabetes mellitus medication choice decision aid: a randomized trial. *Archives of Internal Medicine*. 2009;169(17):1560-1568.

Nansel, T. R., Anderson, B. J., Laffel, L. M., Simons-Morton, B. G., Weissberg-Benchell, J., Wysocki, T., Iannotti, R. J., Holmbeck, G. N., Hood, K. K., and Lochrie, A. S. A multisite trial of a clinic-integrated intervention for promoting family management of pediatric type 1 diabetes: feasibility and design. *Pediatric Diabetes*. 2009;10(2):105-115.

Nantel, J., Termoz, N., Vendittoli, P. A., Lavigne, M., and Prince, F. Gait patterns after total hip arthroplasty and surface replacement arthroplasty. *Archives of Physical Medicine & Rehabilitation*. 2009;90(3):463-469.

Neutel, J. M., Kereiakes, D. J., Waverczak, W. F., Stoakes, K. A., Xu, J., and Shojaaee, A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. *Current Medical Research & Opinion*. 2010;26(3):721-728.

Nikkanen, T., Timonen, M., Ylitalo, K., Timonen, O., Keinänen-Kiukaanniemi, S., and Rajala, U. Quality of diabetes care among patients managed by teleconsultation. *Journal of Telemedicine & Telecare*. 2008;14(6):295-299.

Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Mogensen, C. E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancina, G., Woodward, M., Macmahon, S., Chalmers, J., and ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *Journal of the American Society of Nephrology*. 2009;20(8):1813-1821.

O'Shea, S. D., Taylor, N. F., and Paratz, J. D. .. But watch out for the weather: factors affecting adherence to progressive resistance exercise for persons with COPD. *Journal of Cardiopulmonary Rehabilitation & Prevention*. 175;27(3):166-174.

O'Sullivan, T. L., Fortier, M. S., Faubert, C., Culver, D., Blanchard, C., Reid, R., and Hogg, W. E. Interdisciplinary physical activity counseling in primary care: a qualitative inquiry of the patient experience. *Journal of Health Psychology*. 2010;15(3):362-372.

Odegard, P. S. and Gray, S. L. Barriers to medication adherence in poorly controlled diabetes mellitus. *Diabetes Educator*. 2008;34(4):692-697.

Olivarius, Nde F., Siersma, V., Hansen, L. J., Drivsholm, T., and Horder, M. Changes in levels of haemoglobin A1c during the first 6 years after diagnosis of clinical type 2 diabetes. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2009;69(8):851-857.

Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., and Rodby, R. A. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. *Nephrology Dialysis Transplantation*. 2008;23(4):1216-1223.

Palmer, J. L., Gibbs, M., Scheijbeler, H. W., Kotchie, R. W., Nielsen, S., White, J., and Valentine, W. J. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. *Advances in Therapy*. 2008;25(8):752-774.

Paltiel, H., Solvoll, E., Loge, J. H., Kaasa, S., and Oldervoll, L. "The healthy me appears": palliative cancer patients' experiences of participation in a physical group exercise program. *Palliative & Supportive Care*. 2009;7(4):459-467.

Pan, C. Y. and Landen, H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. *Clinical Drug Investigation*. 2007;27(6):397-405.

Panton, L. B., Figueroa, A., Kingsley, J. D., Hornbuckle, L., Wilson, J., St John, N., Abood, D., Mathis, R., VanTassel, J., and McMillan, V. Effects of resistance training and chiropractic treatment in women with fibromyalgia. *Journal of Alternative & Complementary Medicine*. 2009;15(3):321-328.

Parkner, T., Moller, M. K., Chen, J. W., Laursen, T., Jorgensen, C., Smedegaard, J. S., Lauritzen, T., and Christiansen, J. S. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(7):556-563.

Pearce, K. A., Love, M. M., Shelton, B. J., Schoenberg, N. E., Williamson, M. A., Barron, M. A., Houlihan, J. M., and Kentucky, Ambulatory Network. Cardiovascular risk education and social support (CaRESS): report of a randomized controlled trial from the Kentucky Ambulatory Network (KAN). *Journal of the American Board of Family Medicine: JABFM*. 2008;21(4):269-281.

Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia-Unzueta, M. T., Ramirez-Bonilla, M. L., Gonzalez-Blanch, C., Martinez-Garcia, O., and Vazquez-Barquero, J. L. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. *Journal of Clinical Psychiatry*. 2007;68(11):1733-1740.

Petrak, F., Stridde, E., Leverkus, F., Crispin, A. A., Forst, T., and Pfitzner, A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. *Diabetes Care*. 2007;30(9):2199-2204.

Peyrot, M. and Rubin, R. R. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. *Diabetes Technology & Therapeutics*. 2010;12(1):49-55.

Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J., McMurray, J. J., Parfrey, P., Parving, H. H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., Uno, H., and TREAT, Investigators. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *American Journal of Kidney Diseases*. 2009;54(1):59-69.

Piaggese, A., Macchiarini, S., Rizzo, L., Palumbo, F., Tedeschi, A., Nobili, L. A., Leporati, E., Scire, V., Teobaldi, I., and Del Prato, S. An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast. *Diabetes Care*. 2007;30(3):586-590.

Pinto, B. M., Rabin, C., and Dunsiger, S. Home-based exercise among cancer survivors: adherence and its predictors. *Psycho-Oncology*. 2009;18(4):369-376.

Pollack, M. F., Purayidathil, F. W., Bolge, S. C., and Williams, S. A. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. *Diabetes Research & Clinical Practice*. 2010;87(2):204-210.

Prado-Aguilar, C. A., Martinez, Y. V., Segovia-Bernal, Y., Reyes-Martinez, R., and Arias-Ulloa, R. Performance of two questionnaires to measure treatment adherence in patients with Type-2 diabetes. *BMC Public Health*. 2009;9:38.

- Priebe, M. G., van Binsbergen, J. J., de Vos, R., and Vonk, R. J. Whole grain foods for the prevention of type 2 diabetes mellitus. [Review] [62 refs]. *Cochrane Database of Systematic Reviews*. 2008;(1):CD006061.
- Quinn, C. C., Clough, S. S., Minor, J. M., Lender, D., Okafor, M. C., and Gruber-Baldini, A. WellDoc mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction. *Diabetes Technology & Therapeutics*. 2008;10(3):160-168.
- Rana, A. K., Lundborg, C. S., Wahlin, A., Ahmed, S. M., and Kabir, Z. N. The impact of health education in managing self-reported arthritis-related illness among elderly persons in rural Bangladesh. *Health Education Research*. 2008;23(1):94-105.
- Rattanachaiyanont, M. and Kuptniratsaikul, V. No additional benefit of shortwave diathermy over exercise program for knee osteoarthritis in peri-/post-menopausal women: an equivalence trial. *Osteoarthritis & Cartilage*. 2008;16(7):823-828.
- Reimer, T., Hohberg, C., Pfitzner, A. H., Jorgensen, C., Jensen, K. H., and Pfitzner, A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. *Clinical Therapeutics*. 2008;30(12):2252-2262.
- Reinehr, T., Schober, E., Roth, C. L., Wiegand, S., Holl, R., and DPV-Wiss Study Group. Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. *Hormone Research*. 2008;69(2):107-113.
- Rhodes, R. E., Warburton, D. E., and Bredin, S. S. Predicting the effect of interactive video bikes on exercise adherence: An efficacy trial. *Psychology Health & Medicine*. 2009;14(6):631-640.
- Rivellese, A. A., Boemi, M., Cavalot, F., Costagliola, L., De Feo, P., Miccoli, R., Patti, L., Trovati, M., Vaccaro, O., Zavaroni, I., and Mind.it Study Group. Dietary habits in type II diabetes mellitus: how is adherence to dietary recommendations?. *European Journal of Clinical Nutrition*. 2008;62(5):660-664.
- Roek, M. G., Welschen, L. M., Kostense, P. J., Dekker, J. M., Snoek, F. J., and Nijpels, G. Web-based guided insulin self-titration in patients with type 2 diabetes: the Di@log study. Design of a cluster randomised controlled trial [TC1316]. *BMC Family Practice*. 2009;10:40.
- Roijzon, U., Bjorklund, M., Bergenheim, M., and Djupsjobacka, M. A novel method for neck coordination exercise--a pilot study on persons with chronic non-specific neck pain. *Journal of Neuroengineering & Rehabilitation*. 2008;5:36.
- Rome, A., Persson, U., Ekdahl, C., and Gard, G. Willingness to pay for health improvements of physical activity on prescription. *Scandinavian Journal of Public Health*. 2010;38(2):151-159.
- Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., and Schweizer, A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.[Erratum appears in *Diabetes Care*. 2007 May;30(5):1330]. *Diabetes Care*. 2007;30(2):217-223.
- Rosenstock, J., Cefalu, W. T., Hollander, P. A., Klioze, S. S., Reis, J., and Duggan, W. T. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. *Diabetes Technology & Therapeutics*. 2009;11(11):697-705.
- Royle, P., Waugh, N., Deakin, M., and Philip, S. WITHDRAWN: Inhaled insulin in diabetes mellitus. [Review] [52 refs][Update of *Cochrane Database Syst Rev*. 2004;(3):CD003890; PMID: 15266506]. *Cochrane Database of Systematic Reviews*. 2009;(1):CD003890.
- Rubin, R. R. and Peyrot, M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. *Current Medical Research & Opinion*. 2007;23(8):1919-1929.
- Ruiz, M. A., Pardo, A., Rejas, J., Soto, J., Villasante, F., and Aranguren, J. L. Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). *Value in Health*. 2008;11(5):913-926.

Russell, K. L. and Bray, S. R. Self-determined motivation predicts independent, home-based exercise following cardiac rehabilitation. *Rehabilitation Psychology*. 2009;54(2):150-156.

Sacco, W. P., Wells, K. J., Friedman, A., Matthew, R., Perez, S., and Vaughan, C. A. Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy. *Health Psychology*. 2007;26(6):693-700.

Sakraida, T. J. and Robinson, M. V. Health literacy self-management by patients with type 2 diabetes and stage 3 chronic kidney disease. *Western Journal of Nursing Research*. 2009;31(5):627-647.

Salvetti, X. M., Oliveira, J. A., Servantes, D. M., and Vincenzo de Paola, A. A. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. *Clinical Rehabilitation*. 2008;22(10-11):987-996.

Samoutis, G. A., Soteriades, E. S., Stoffers, H. E., Zachariadou, T., Philalithis, A., and Lionis, C. Designing a multifaceted quality improvement intervention in primary care in a country where general practice is seeking recognition: the case of Cyprus. *BMC Health Services Research*. 2008;8:181.

Sanigorski, A. M., Bell, A. C., Kremer, P. J., Cuttler, R., and Swinburn, B. A. Reducing unhealthy weight gain in children through community capacity-building: results of a quasi-experimental intervention program, Be Active Eat Well. *International Journal of Obesity*. 2008;32(7):1060-1067.

Saper, R. B., Sherman, K. J., Cullum-Dugan, D., Davis, R. B., Phillips, R. S., and Culpepper, L. Yoga for chronic low back pain in a predominantly minority population: a pilot randomized controlled trial. *Alternative Therapies in Health & Medicine*. 2009;15(6):18-27.

Scheen, A. J. and Van Gaal, L. F. [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. [French]. *Revue Medicale de Liege*. 2010;65(3):127-132.

Schiel, R. and Muller, U. A. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116(1):58-64.

Schillinger, D., Handley, M., Wang, F., and Hammer, H. Effects of self-management support on structure, process, and outcomes among vulnerable patients with diabetes: a three-arm practical clinical trial. *Diabetes Care*. 2009;32(4):559-566.

Schmittiel, J. A., Traylor, A., Uratsu, C. S., Mangione, C. M., Ferrara, A., and Subramanian, U. The association of patient-physician gender concordance with cardiovascular disease risk factor control and treatment in diabetes. *Journal of Women's Health*. 2009;18(12):2065-2070.

Schulz, P. J., Rubinell, S., and Hartung, U. An internet-based approach to enhance self-management of chronic low back pain in the italian-speaking population of Switzerland: results from a pilot study. *International Journal of Public Health*. 2007;52(5):286-294.

Schwartz, S. M., Bansal, V. P., Hale, C., Rossi, M., and Engle, J. P. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. *Obesity*. 2008;16(3):623-629.

Schwarz, S. L., Gerich, J. E., Marcellari, A., Jean-Louis, L., Purkayastha, D., and Baron, M. A. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(8):652-660.

Serour, M., Alqhenaei, H., Al Saqabi, S., Mustafa, A. R., and Ben Nakhi, A. Cultural factors and patients' adherence to lifestyle measures. *British Journal of General Practice*. 2007;57(537):291-295.

Shah, S., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shestakova, M., Wenying, Y., Valensi, P., and IMPROVE Study Group. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE observational study. *International Journal of Clinical Practice*. 2009;63(4):574-582.

- Shah, S., Das, A. K., Kumar, A., Unnikrishnan, A. G., Kalra, S., Baruah, M. P., Ganapathi, B., and Sahay, R. K. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. *Advances in Therapy*. 2009;26(3):325-335.
- Sharp, L. K., Fitzgibbon, M. L., and Schiffer, L. Recruitment of obese black women into a physical activity and nutrition intervention trial. *Journal of Physical Activity & Health*. 2008;5(6):870-881.
- Sharpe, P. A., Blanck, H. M., Williams, J. E., Ainsworth, B. E., and Conway, J. M. Use of complementary and alternative medicine for weight control in the United States. *Journal of Alternative & Complementary Medicine*. 2007;13(2):217-222.
- Shay, L. E., Seibert, D., Watts, D., Sbrocco, T., and Pagliara, C. Adherence and weight loss outcomes associated with food-exercise diary preference in a military weight management program. *Eating Behaviors*. 2009;10(4):220-227.
- Shepich, J., Slowiak, J. M., and Keniston, A. Do subsidization and monitoring enhance adherence to prescribed exercise?. *American Journal of Health Promotion*. 2007;22(1):2-5.
- Shih, H. C., Chou, P., Chen, S. J., Liu, J. H., Lee, F. L., Liu, C. M., and Tung, T. H. A community-based study of the willingness to pay associated with screening for diabetic retinopathy among type 2 diabetes in Kinmen, Taiwan. *Journal of Epidemiology*. 2007;17(6):186-193.
- Siegmund, T., Blankenfeld, H., and Schumm-Draeger, P. M. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. *Diabetes Technology & Therapeutics*. 2009;11(8):523-528.
- Sirard, J. R. and Slater, M. E. Compliance with wearing physical activity accelerometers in high school students. *Journal of Physical Activity & Health*. 2009;6:Suppl-55.
- Sjosten, N. M., Salonoja, M., Piirtola, M., Vahlberg, T. J., Isoaho, R., Hyttinen, H. K., Aarnio, P. T., and Kivela, S. L. A multifactorial fall prevention programme in the community-dwelling aged: predictors of adherence. *European Journal of Public Health*. 2007;17(5):464-470.
- Slack, S. Near patient testing for glycated haemoglobin in people with type 2 diabetes mellitus managed in primary care: acceptability and satisfaction; Impact of self-monitoring of blood glucose in the management of patients with non-insulin-treated diabetes: open parallel group randomized trial. *Annals of Clinical Biochemistry*. 2008;45(Pt:1):1-5.
- Slade, S. C. and Keating, J. L. Effects of preferred-exercise prescription compared to usual exercise prescription on outcomes for people with non-specific low back pain: a randomized controlled trial [ACTRN12608000524392]. *BMC Musculoskeletal Disorders*. 2009;10:14.
- Smits, J. A., Tart, C. D., Presnell, K., Rosenfield, D., and Otto, M. W. Identifying potential barriers to physical activity adherence: anxiety sensitivity and body mass as predictors of fear during exercise. *Cognitive Behaviour Therapy*. 2010;39(1):28-36.
- Song, M. S. and Kim, H. S. Intensive management program to improve glycosylated hemoglobin levels and adherence to diet in patients with type 2 diabetes. *Applied Nursing Research*. 2009;22(1):42-47.
- Song, R., Roberts, B. L., Lee, E. O., Lam, P., and Bae, S. C. A randomized study of the effects of t'ai chi on muscle strength, bone mineral density, and fear of falling in women with osteoarthritis. *Journal of Alternative & Complementary Medicine*. 2010;16(3):227-233.
- Sopkova, Z., Dorkova, Z., and Tkacova, R. Predictors of compliance with continuous positive airway pressure treatment in patients with obstructive sleep apnea and metabolic syndrome. *Wiener Klinische Wochenschrift*. 2009;121(11-12):398-404.
- Sowattanagoon, N., Kochabhakdi, N., and Petrie, K. J. Buddhist values are associated with better diabetes control in Thai patients. *International Journal of Psychiatry in Medicine*. 2008;38(4):481-491.

Sowden, S. L., Breeze, E., Barber, J., and Raine, R. Do general practices provide equitable access to physical activity interventions?. *British Journal of General Practice*. 2008;58(555):e1-e8.

Speroni, K. G., Tea, C., Earley, C., Niehoff, V., and Atherton, M. Evaluation of a pilot hospital-based community program implementing fitness and nutrition education for overweight children. *Journal for Specialists in Pediatric Nursing: JSPN*. 2008;13(3):144-153.

Spinks, A. B., Macpherson, A. K., Bain, C., and McClure, R. J. Compliance with the Australian national physical activity guidelines for children: relationship to overweight status. *Journal of Science & Medicine in Sport*. 2007;10(3):156-163.

Stargardt, T., Yin, D. D., and Alexander, C. M. Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2009;11(5):491-497.

Staud, R. Pharmacological treatment of fibromyalgia syndrome: new developments. *Drugs*. 2010;70(1):1-14.

Steele, B. G., Belza, B., Cain, K. C., Coppersmith, J., Lakshminarayan, S., Howard, J., and Haselkorn, J. K. A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease. *Archives of Physical Medicine & Rehabilitation*. 2008;89(3):404-412.

Steele, R., Mummery, K. W., and Dwyer, T. Development and process evaluation of an internet-based physical activity behaviour change program. *Patient Education & Counseling*. 2007;67(1-2):127-136.

Stuckey, H. L., Dellasega, C., Graber, N. J., Mauger, D. T., Lendel, I., and Gabbay, R. A. Diabetes nurse case management and motivational interviewing for change (DYNAMIC): study design and baseline characteristics in the Chronic Care Model for type 2 diabetes. *Contemporary Clinical Trials*. 2009;30(4):366-374.

Sturt, J. A., Whitlock, S., Fox, C., Hearnshaw, H., Farmer, A. J., Wakelin, M., Eldridge, S., Griffiths, F., and Dale, J. Effects of the Diabetes Manual 1:1 structured education in primary care. *Diabetic Medicine*. 2008;25(6):722-731.

Subramanian, U., Ackermann, R. T., Brizendine, E. J., Saha, C., Rosenman, M. B., Willis, D. R., and Marrero, D. G. Effect of advanced access scheduling on processes and intermediate outcomes of diabetes care and utilization. *Journal of General Internal Medicine*. 2009;24(3):327-333.

Szecsényi, J., Rosemann, T., Joos, S., Peters-Klimm, F., and Miksch, A. German diabetes disease management programs are appropriate for restructuring care according to the chronic care model: an evaluation with the patient assessment of chronic illness care instrument. *Diabetes Care*. 2008;31(6):1150-1154.

Tajima, T., Tsubaki, J., Ishizu, K., Jo, W., Ishi, N., and Fujieda, K. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. *Endocrine Journal*. 2008;55(3):595-599.

Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A., Pirraglia, P. A., and Wu, W. C. Pharmacist-led group medical appointment model in type 2 diabetes. *Diabetes Educator*. 2010;36(1):109-117.

Thamer, C., Machann, J., Stefan, N., Haap, M., Schafer, S., Brenner, S., Kantartzis, K., Claussen, C., Schick, F., Haring, H., and Fritsche, A. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. *Obesity*. 2007;15(2):531-538.

Thomsen, N. O., Cederlund, R., Rosen, I., Bjork, J., and Dahlin, L. B. Clinical outcomes of surgical release among diabetic patients with carpal tunnel syndrome: prospective follow-up with matched controls. *Journal of Hand Surgery - American Volume*. 2009;34(7):1177-1187.

Tibaldi, J. T. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice. *Advances in Therapy*. 2007;24(6):1348-1356.

- Toft, U. N., Kristoffersen, L. H., Aadahl, M., von Huth, Smith L., Pisinger, C., and Jorgensen, T. Diet and exercise intervention in a general population--mediators of participation and adherence: the Inter99 study. *European Journal of Public Health*. 2007;17(5):455-463.
- Tudiver, F., Wolff, L. T., Morin, P. C., Teresi, J., Palmas, W., Starren, J., Shea, S., and Weinstock, R. S. Primary care providers' perceptions of home diabetes telemedicine care in the IDEATel project. *Journal of Rural Health*. 2007;23(1):55-61.
- Utsugi-Ozaki, M., Bito, S., Matsumura, S., Hayashino, Y., Fukuhara, S., and MEMO, J. Physician job satisfaction and quality of care among hospital employed physicians in Japan. *Journal of General Internal Medicine*. 2009;24(3):387-392.
- Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Wenying, Y., and IMPROVE Study Group. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. *International Journal of Clinical Practice*. 2009;63(3):522-531.
- Valentine, W. J., Bottomley, J. M., Palmer, A. J., Brandle, M., Foos, V., Williams, R., Dormandy, J. A., Yates, J., Tan, M. H., Massi-Benedetti, M., and PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. *Diabetic Medicine*. 2007;24(9):982-1002.
- van den Berg, M. H., Ronday, H. K., Peeters, A. J., Voogt-van der Harst EM, Munneke, M., Breedveld, F. C., and Vliet Vlieland, T. P. Engagement and satisfaction with an Internet-based physical activity intervention in patients with rheumatoid arthritis. *Rheumatology*. 2007;46(3):545-552.
- van den Berg, M. H., van der Giesen, F. J., van Zeven, D., van Groenendaal, J. H., Seys, P. E., and Vliet Vlieland, T. P. Implementation of a physical activity intervention for people with rheumatoid arthritis: a case study. *Musculoskeletal Care*. 2008;6(2):69-85.
- van Kuijk, J. P., Dunkelgrun, M., Schreiner, F., Flu, W. J., Galal, W., van Domburg, R. T., Hoeks, S. E., van Gestel, Y. R., Bax, J. J., and Poldermans, D. Preoperative oral glucose tolerance testing in vascular surgery patients: long-term cardiovascular outcome. *American Heart Journal*. 2009;157(5):919-925.
- Vandelandotte, C., De, Bourdeaudhuij, I, and Brug, J. Two-year follow-up of sequential and simultaneous interactive computer-tailored interventions for increasing physical activity and decreasing fat intake. *Annals of Behavioral Medicine*. 2007;33(2):213-219.
- Vashdi, E., Hutzler, Y., and Roth, D. Compliance of children with moderate to severe intellectual disability to treadmill walking: a pilot study. *Journal of Intellectual Disability Research*. 2008;52(Pt:5):5-9.
- Velazquez, Lopez L., Sil Acosta, M. J., Goycochea Robles, M. V., Torres, Tamayo M., and Castaneda, Limones R. Effect of protein restriction diet on renal function and metabolic control in patients with type 2 diabetes: a randomized clinical trial. *Nutricion Hospitalaria*. 2008;23(2):141-147.
- Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., and Yin, D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. *Diabetes, Obesity & Metabolism*. 2008;10:Suppl-24.
- Vonk, F., Verhagen, A. P., Twisk, J. W., Koke, A. J., Luiten, M. W., and Koes, B. W. Effectiveness of a behaviour graded activity program versus conventional exercise for chronic neck pain patients. *European Journal of Pain: Ejp*. 2009;13(5):533-541.
- Wallston, K. A., Rothman, R. L., and Cherrington, A. Psychometric properties of the Perceived Diabetes Self-Management Scale (PDSMS). *Journal of Behavioral Medicine*. 2007;30(5):395-401.
- Walsh, J. S. and Plonczynski, D. J. Evaluation of a protocol for prevention of facility-acquired heel pressure ulcers. *Journal of Wound, Ostomy, & Continence Nursing*. 2007;34(2):178-183.
- Wang, W. Q., Zhang, Y. F., Zhou, D. J., Liu, Z. M., Hong, X., Qiu, M. C., Shi, Y. Q., Xia, P. J., Lu, J., Xu, M. J., An, L., Feng, W., Zhang, P., Schwamman, J., and Ning, G. Open-label, randomized, multiple-

center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus. *Endocrine*. 2008;33(1):45-52.

Wassink, A. M., van der Graaf Y., Olijhoek, J. K., Visseren, F. L., and SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *European Heart Journal*. 2008;29(2):213-223.

Watson, A. J., Kvedar, J. C., Rahman, B., Pelletier, A. C., Salber, G., and Grant, R. W. Diabetes connected health: a pilot study of a patient- and provider-shared glucose monitoring web application. *Journal of Diabetes Science & Technology*. 2009;3(2):345-352.

Wayne, P. M. and Kaptchuk, T. J. Challenges inherent to t'ai chi research: part I--t'ai chi as a complex multicomponent intervention. [Review] [101 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(1):95-102.

Wayne, P. M. and Kaptchuk, T. J. Challenges inherent to t'ai chi research: part II-defining the intervention and optimal study design. [Review] [49 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(2):191-197.

Weck, M., Rietzsch, H., Lawall, H., Pichlmeier, U., Bramlage, P., and Schellong, S. Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. *Thrombosis & Haemostasis*. 2008;100(3):475-482.

Wellman, N. S., Kamp, B., Kirk-Sanchez, N. J., and Johnson, P. M. Eat better & move more: a community-based program designed to improve diets and increase physical activity among older Americans. *American Journal of Public Health*. 2007;97(4):710-717.

Welschen, L. M., van Oppen, P., Dekker, J. M., Bouter, L. M., Stalman, W. A., and Nijpels, G. The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. *BMC Public Health*. 2007;7:74.

Wenying, Y., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Ligthelm, R., Valensi, P., and IMPROVE Study Group. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. *Current Medical Research & Opinion*. 2009;25(11):2643-2654.

Whittemore, R., Melkus, G., Wagner, J., Dziura, J., Northrup, V., and Grey, M. Translating the diabetes prevention program to primary care: a pilot study. *Nursing Research*. 2009;58(1):2-12.

Williams, D. M., Lewis, B. A., Dunsiger, S., Whiteley, J. A., Papandonatos, G. D., Napolitano, M. A., Bock, B. C., Ciccolo, J. T., and Marcus, B. H. Comparing psychosocial predictors of physical activity adoption and maintenance. *Annals of Behavioral Medicine*. 2008;36(2):186-194.

Williams, G. C., Lynch, M., and Glasgow, R. E. Computer-assisted intervention improves patient-centered diabetes care by increasing autonomy support. *Health Psychology*. 2007;26(6):728-734.

Williams, N. H., Hendry, M., France, B., Lewis, R., and Wilkinson, C. Effectiveness of exercise-referral schemes to promote physical activity in adults: systematic review. [Review] [41 refs]. *British Journal of General Practice*. 2007;57(545):979-986.

Wittlin, S. D., Marcus, A. O., Weng, C. S., Howard, C. P., Schorr, A. B., and CONTROL Study Group. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. *Diabetes Technology & Therapeutics*. 2008;10(1):1-10.

Yackobovitch-Gavan, M., Nagelberg, N., Phillip, M., Ashkenazi-Hoffnung, L., HersHKovitz, E., and Shalitin, S. The influence of diet and/or exercise and parental compliance on health-related quality of life in obese children. *Nutrition Research*. 2009;29(6):397-404.

Yamakawa, M. and Makimoto, K. Positive experiences of type 2 diabetes in Japanese patients: an exploratory qualitative study. *International Journal of Nursing Studies*. 2008;45(7):1032-1041.

Yang, W., Gao, Y., Liu, G., Chen, L., Fu, Z., Zou, D., Feng, P., and Zhao, Z. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. *Current Medical Research & Opinion*. 2010;26(1):101-107.

Yeo, S. Adherence to walking or stretching, and risk of preeclampsia in sedentary pregnant women. *Research in Nursing & Health*. 2009;32(4):379-390.

Yin, J., Xing, H., and Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(5):712-717.

Zazpe, I., Estruch, R., Toledo, E., Sanchez-Tainta, A., Corella, D., Bullo, M., Fiol, M., Iglesias, P., Gomez-Gracia, E., Aros, F., Ros, E., Schroder, H., Serra-Majem, L., Pinto, X., Lamuela-Raventos, R., Ruiz-Gutierrez, V., and Martinez-Gonzalez, M. A. Predictors of adherence to a Mediterranean-type diet in the PREDIMED trial. *European Journal of Nutrition*. 2010;49(2):91-99.

Zhao, G., Ford, E. S., Li, C., and Mokdad, A. H. Compliance with physical activity recommendations in US adults with diabetes. *Diabetic Medicine*. 2008;25(2):221-227.

Zick, R., Petersen, B., Richter, M., Haug, C., and SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. *Diabetes Technology & Therapeutics*. 2007;9(6):483-492.

Zinman, B., Hoogwerf, B. J., Duran, Garcia S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., and Brodows, R. G. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.[Erratum appears in *Ann Intern Med*. 2007 Jun 19;146(12):896]. [Summary for patients in *Ann Intern Med*. 2007 Apr 3;146(7):I18; PMID: 17404346]. *Annals of Internal Medicine*. 4-3-2007;146(7):477-485.

Diabetes Risk Assessment and Diagnostic Test Excluded Studies List

Level 3: Population

Adhikari, P., Pathak, R., and Kotian, S. Validation of the MDRF-Indian Diabetes Risk Score (IDRS) in another south Indian population through the Boloor Diabetes Study (BDS). *Journal of the Association of Physicians of India*. 2010;58:434-436.

Aekplakorn, W., Bunnag, P., Woodward, M., Sritara, P., Cheepudomwit, S., Yamwong, S., Yipintsoi, T., and Rajatanavin, R. A risk score for predicting incident diabetes in the Thai population. *Diabetes Care*. 2006;29(8):1872-1877.

Al Khalaf, M. M., Eid, M. M., Najjar, H. A., Alhajry, K. M., Doi, S. A., and Thalib, L. Screening for diabetes in Kuwait and evaluation of risk scores. *Eastern Mediterranean Health Journal*. 2010;16(7):725-731.

Al-Lawati, J. A. and Tuomilehto, J. Diabetes risk score in Oman: a tool to identify prevalent type 2 diabetes among Arabs of the Middle East. *Diabetes Research & Clinical Practice*. 2007;77(3):438-444.

Almajwal, A. M., Al-Baghli, N. A., Batterham, M. J., Williams, P. G., Al-Turki, K. A., and Al-Ghamdi, A. J. Performance of body mass index in predicting diabetes and hypertension in the Eastern Province of Saudi Arabia. *Annals of Saudi Medicine*. 2009;29(6):437-445.

Araneta, M. R., Grandinetti, A., and Chang, H. K. A1C and diabetes diagnosis among Filipino Americans, Japanese Americans, and Native Hawaiians. *Diabetes Care*. 2010;33(12):2626-2628.

Bando, Y., Kanehara, H., Aoki, K., Katoh, K., Toya, D., and Tanaka, N. Characteristics of undiagnosed diabetes mellitus in a population undergoing health screening in Japan: target populations for efficient screening. *Diabetes Research & Clinical Practice*. 2009;83(3):341-346.

Bao, Y., Ma, X., Li, H., Zhou, M., Hu, C., Wu, H., Tang, J., Hou, X., Xiang, K., and Jia, W. Glycated

haemoglobin A1c for diagnosing diabetes in Chinese population: cross sectional epidemiological survey. *BMJ*. 2010;340:c2249.

Bindraban, N. R., van Valkengoed, I. G., Mairuhu, G., Holleman, F., Hoekstra, J. B., Michels, B. P., Koopmans, R. P., and Stronks, K. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross-sectional population-based study. *BMC Public Health*. 2008;8:271.

Cabrera de, Leon A., Coello, S. D., Rodriguez Perez, Mdel C., Medina, M. B., Almeida, Gonzalez D., Diaz, B. B., de Fuentes, M. M., and Aguirre-Jaime, A. A simple clinical score for type 2 diabetes mellitus screening in the Canary Islands. *Diabetes Research & Clinical Practice*. 2008;80(1):128-133.

Can, A. S., Yildiz, E. A., Samur, G., Rakicioglu, N., Pekcan, G., Ozbayrakci, S., Palaoglu, K. E., Gonen, M., and Bersot, T. P. Optimal waist:height ratio cut-off point for cardiometabolic risk factors in Turkish adults. *Public Health Nutrition*. 2010;13(4):488-495.

Cavagnoli, G., Comerlato, J., Comerlato, C., Renz, P. B., Gross, J. L., and Camargo, J. L. HbA(1c) measurement for the diagnosis of diabetes: is it enough?. *Diabetic Medicine*. 2011;28(1):31-35.

Chen, G., Zou, X., Yao, J., Jiang, Q., Zhang, Y., Tu, M., Yang, S., Xu, S., Lin, W., Huang, H., Liang, J., Li, L., and Lin, L. The correlation between the oral glucose tolerance test 30-minutes plasma glucose and risk factors for diabetes and cardiovascular diseases: a cross-sectional epidemiological study of diabetes in Fujian Province in the South-East of China. *Journal of Endocrinological Investigation*. 2011;34(5):e115-e120.

Chien, K. L., Lin, H. J., Lee, B. C., Hsu, H. C., and Chen, M. F. Prediction model for high glycated hemoglobin concentration among ethnic Chinese in Taiwan. *Cardiovascular Diabetology*. 2010;9:59.

Chihaoui, M., Kanoun, F., Ben, Rehaïem B., Ben, Brahim S., Ftouhi, B., Mekaouar, A., Fekih, M., Mbazad, A., Zouari, B., and Ben, Khalifa F. Predictive risk factors for deterioration from normoglycemic state to type 2 diabetes mellitus or impaired glucose tolerance in a Tunisian urban population. *Diabetes & Metabolism*. 2001;27(4:Pt 1):t-95.

Choi, S. H., Kim, T. H., Lim, S., Park, K. S., Jang, H. C., and Cho, N. H. Hemoglobin A1c as a diagnostic tool for diabetes screening and new-onset diabetes prediction: a 6-year community-based prospective study. *Diabetes Care*. 2011;34(4):944-949.

Choi, S. J., Keam, B., Park, S. H., and Park, H. Y. Appropriate waist circumference cut-offs to predict diabetes in the Korean population - the Korean Genome and Epidemiology Study . *Circulation Journal*. 2010;74(7):1357-1363.

Cubeddu, L. X. and Hoffmann, I. S. One-hour postload plasma glucose levels, a predictor of additional risk for diabetes: prevalence, mechanisms, and associated cardiovascular and metabolic risk factors in Hispanics. *Metabolic Syndrome & Related Disorders*. 2010;8(5):395-402.

Doi, Y., Kubo, M., Yonemoto, K., Ninomiya, T., Iwase, M., Arima, H., Hata, J., Tanizaki, Y., Iida, M., and Kiyohara, Y. Fasting plasma glucose cutoff for diagnosis of diabetes in a Japanese population. *Journal of Clinical Endocrinology & Metabolism*. 2008;93(9):3425-3429.

Dong, X. L., Liu, Y., Sun, Y., Sun, C., Fu, F. M., Wang, S. L., and Chen, L. Comparison of HbA1c and OGTT criteria to diagnose diabetes among Chinese. *Experimental & Clinical Endocrinology & Diabetes*. 2011;119(6):366-369.

Gao, W. G., Dong, Y. H., Pang, Z. C., Nan, H. R., Wang, S. J., Ren, J., Zhang, L., Tuomilehto, J., and Qiao, Q. A simple Chinese risk score for undiagnosed diabetes. *Diabetic Medicine*. 2010;27(3):274-281.

Gao, W. G., Qiao, Q., Pitkaniemi, J., Wild, S., Magliano, D., Shaw, J., Soderberg, S., Zimmet, P.,

Chitson, P., Knowlessur, S., Alberti, G., and Tuomilehto, J. Risk prediction models for the development of diabetes in Mauritian Indians. *Diabetic Medicine*. 2009;26(10):996-1002.

Gu, J. J., Rafalson, L., Zhao, G. M., Wu, H. Y., Zhou, Y., Jiang, Q. W., Bai, Y., Zhu, Q. L., Fu, X. J., Zhang, H., Qiu, H., Yang, L. M., Ruan, X. N., and Xu, W. H. Anthropometric measurements for prediction of metabolic risk among Chinese adults in Pudong new area of Shanghai. *Experimental & Clinical Endocrinology & Diabetes*. 2011;119(7):387-394.

Hadaegh, F., Hatami, M., Tohidi, M., Sarbakhsh, P., Saadat, N., and Azizi, F. Lipid ratios and appropriate cut off values for prediction of diabetes: a cohort of Iranian men and women. *Lipids in Health & Disease*. 2010;9:85.

Harati, H., Hadaegh, F., Tohidi, M., and Azizi, F. Impaired fasting glucose cutoff value of 5.6 mmol/l combined with other cardiovascular risk markers is a better predictor for incident Type 2 diabetes than the 6.1 mmol/l value: Tehran lipid and glucose study. *Diabetes Research & Clinical Practice*. 2009;85(1):90-95.

Heianza, Y., Hara, S., Arase, Y., Saito, K., Fujiwara, K., Tsuji, H., Kodama, S., Hsieh, S. D., Mori, Y., Shimano, H., Yamada, N., Kosaka, K., and Sone, H. HbA1c 5.7-6.4% and impaired fasting plasma glucose for diagnosis of prediabetes and risk of progression to diabetes in Japan (TOPICS 3): a longitudinal cohort study. *Lancet*. 7-9-2011;378(9786):147-155.

Hu, Y., Liu, W., Chen, Y., Zhang, M., Wang, L., Zhou, H., Wu, P., Teng, X., Dong, Y., Zhou, J., Xu, H., Zheng, J., Li, S., Tao, T., Hu, Y., and Jia, Y. Combined use of fasting plasma glucose and glycated hemoglobin A1c in the screening of diabetes and impaired glucose tolerance. *Acta Diabetologica*. 2010;47(3):231-236.

Hwang, L. C., Chen, C. J., and Lin, B. J. Obesity and changes in body weight related to 10-year diabetes incidence in women in Taiwan. *Asia Pacific Journal of Clinical Nutrition*. 2007;16(4):677-682.

Ihsan, A. B., Charles, B., Raid, B., and Ali, A. Y. Diagnostic accuracy of the American Diabetes Association criteria in the diagnosis of glucose intolerance among high-risk Omani subjects. *Annals of Saudi Medicine*. 2004;24(3):183-185.

Inoue, K., Matsumoto, M., and Akimoto, K. Fasting plasma glucose and HbA1c as risk factors for Type 2 diabetes. *Diabetic Medicine*. 2008;25(10):1157-1163.

Inoue, K., Matsumoto, M., and Akimoto, K. The threshold for definition of impaired fasting glucose in a Japanese population. *Diabetic Medicine*. 2009;26(11):1175-1178.

Inoue, K., Matsumoto, M., and Kobayashi, Y. The combination of fasting plasma glucose and glycosylated hemoglobin predicts type 2 diabetes in Japanese workers. *Diabetes Research & Clinical Practice*. 2007;77(3):451-458.

Jahanlou, A. S., Ghofranipour, F., Kimmiagar, M., Vafaei, M., Heydarnia, A., and Sobhani, A. Can quality of life questionnaires be used in diabetics to assess the relation between HbA1c and patients' domain aspects?. *Acta Medica Iranica*. 2011;49(4):246-251.

Jorgensen, M. E., Bjerregaard, P., Borch-Johnsen, K., and Witte, D. New diagnostic criteria for diabetes: is the change from glucose to HbA1c possible in all populations?. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(11):E333-E336.

Keesukphan, P., Chanprasertyothin, S., Ongphiphadhanakul, B., and Puavilai, G. The development and validation of a diabetes risk score for high-risk Thai adults. *Journal of the Medical Association of Thailand*. 2007;90(1):149-154.

Kim, C. H., Kim, H. K., Bae, S. J., Park, J. Y., and Lee, K. U. Discordance between fasting glucose-based and hemoglobin A1c-based diagnosis of diabetes mellitus in Koreans. *Diabetes Research &*

Clinical Practice. 2011;91(1):e8-e10.

Kim, D. J., Cho, N. H., Noh, J. H., Kim, H. J., Choi, Y. H., Jung, J. H., Min, Y. K., Lee, M. S., Lee, M. K., and Kim, K. W. Fasting plasma glucose cutoff value for the prediction of future diabetes development: a study of middle-aged Koreans in a health promotion center. *Journal of Korean Medical Science*. 2005;20(4):562-565.

Ko, G., So, W., Tong, P., Ma, R., Kong, A., Ozaki, R., Chow, C., Cockram, C., and Chan, J. A simple risk score to identify Southern Chinese at high risk for diabetes. *Diabetic Medicine*. 2010;27(6):644-649.

Kumar, P. R., Bhansali, A., Ravikiran, M., Bhansali, S., Dutta, P., Thakur, J. S., Sachdeva, N., Bhadada, S. K., and Walia, R. Utility of glycated hemoglobin in diagnosing type 2 diabetes mellitus: a community-based study. *Journal of Clinical Endocrinology & Metabolism*. 2010;95(6):2832-2835.

Law, L. S., Tso, A. W., Tam, S., Wat, N. M., Cheung, B. M., and Lam, K. S. Haemoglobin A1c is superior to fasting glucose in predicting the incidence of diabetes over 8 years among Chinese. *Diabetes Research & Clinical Practice*. 2011;91(2):e53-e56.

Li, H. Y., Lin, M. S., Shih, S. R., Hua, C. H., Liu, Y. L., Chuang, L. M., Sung, F. C., Chen, M. F., Lee, J. C., Chiao, C. H., and Wei, J. N. The performance of risk scores and hemoglobin A1c to find undiagnosed diabetes with isolated postload hyperglycemia. *Endocrine Journal*. 2011;58(6):441-448.

Liu, M., Pan, C., and Jin, M. A Chinese diabetes risk score for screening of undiagnosed diabetes and abnormal glucose tolerance. *Diabetes Technology & Therapeutics*. 2011;13(5):501-507.

Ma, X. J., Pan, J. M., Bao, Y. Q., Zhou, J., Tang, J. L., Li, Q., Xiang, K. S., and Jia, W. P. Combined assessment of glycated albumin and fasting plasma glucose improves the detection of diabetes in Chinese subjects. *Clinical & Experimental Pharmacology & Physiology*. 2010;37(10):974-979.

Makulo, J. R., Nseka, N. M., Lepira, F. B., Bieleli, E., and Nge, O. A. [Correlation between capillary fasting glucose and HbA1c: study on 181 type 2 diabetics patients in Democratic Republic of the Congo]. [French]. *Medecine Tropicale*. 2010;70(5-6):513-516.

Martin, D. D., Shephard, M. D., Freeman, H., Bulsara, M. K., Jones, T. W., Davis, E. A., and Maguire, G. P. Point-of-care testing of HbA1c and blood glucose in a remote Aboriginal Australian community. [Erratum appears in *Med J Aust*. 2005 Jun 20;182(12):656 Note: Bulsara, Max K [added]]. *Medical Journal of Australia*. 5-16-2005;182(10):524-527.

Milton, E. C., Herman, W. H., Aiello, A. E., Danielson, K. R., Mendoza-Avelarez, M. O., and Piette, J. D. Validation of a type 2 diabetes screening tool in rural Honduras. *Diabetes Care*. 2010;33(2):275-277.

Miranda, J. J., Bernabe-Ortiz, A., Stanojevic, S., Malaga, G., Gilman, R. H., and Smeeth, L. A1C as a diagnostic criteria for diabetes in low- and middle-income settings: evidence from Peru. *PLoS ONE* [Electronic Resource]. 2011;6(3):e18069.

Miyake, K., Yang, W., Hara, K., Yasuda, K., Horikawa, Y., Osawa, H., Furuta, H., Ng, M. C., Hirota, Y., Mori, H., Ido, K., Yamagata, K., Hinokio, Y., Oka, Y., Iwasaki, N., Iwamoto, Y., Yamada, Y., Seino, Y., Maegawa, H., Kashiwagi, A., Wang, H. Y., Tanahashi, T., Nakamura, N., Takeda, J., Maeda, E., Yamamoto, K., Tokunaga, K., Ma, R. C., So, W. Y., Chan, J. C., Kamatani, N., Makino, H., Nanjo, K., Kadowaki, T., and Kasuga, M. Construction of a prediction model for type 2 diabetes mellitus in the Japanese population based on 11 genes with strong evidence of the association. *Journal of Human Genetics*. 2009;54(4):236-241.

Mohan, V., Deepa, R., Deepa, M., Somannavar, S., and Datta, M. A simplified Indian Diabetes Risk Score for screening for undiagnosed diabetic subjects. *Journal of the Association of Physicians of India*. 2005;53:759-763.

- Mohan, V., Goldhaber-Fiebert, J. D., Radha, V., and Gokulakrishnan, K. Screening with OGTT alone or in combination with the Indian diabetes risk score or genotyping of TCF7L2 to detect undiagnosed type 2 diabetes in Asian Indians. *Indian Journal of Medical Research*. 2011;133(3):294-299.
- Nair, M., Prabhakaran, D., Narayan, K. M., Sinha, R., Lakshmy, R., Devasenapathy, N., Daniel, C. R., Gupta, R., George, P. S., Mathew, A., Tandon, N., and Reddy, K. S. HbA(1c) values for defining diabetes and impaired fasting glucose in Asian Indians. *Primary care diabetes*. 2011;5(2):95-102.
- Nakagami, T., Tajima, N., Oizumi, T., Karasawa, S., Wada, K., Kameda, W., Susa, S., Kato, T., and Daimon, M. Hemoglobin A1c in predicting progression to diabetes. *Diabetes Research & Clinical Practice*. 2010;87(1):126-131.
- Nakagami, T., Tominaga, M., Nishimura, R., Daimon, M., Oizumi, T., Yoshiike, N., and Tajima, N. Combined use of fasting plasma glucose and glycated hemoglobin A1c in a stepwise fashion to detect undiagnosed diabetes mellitus. *Tohoku Journal of Experimental Medicine*. 2007;213(1):25-32.
- Nakagami, T., Tominaga, M., Nishimura, R., Yoshiike, N., Daimon, M., Oizumi, T., and Tajima, N. Is the measurement of glycated hemoglobin A1c alone an efficient screening test for undiagnosed diabetes? Japan National Diabetes Survey. *Diabetes Research & Clinical Practice*. 2007;76(2):251-256.
- Noda, M., Kato, M., Takahashi, Y., Matsushita, Y., Mizoue, T., Inoue, M., Tsugane, S., and Kadowaki, T. Fasting plasma glucose and 5-year incidence of diabetes in the JPHC diabetes study - suggestion for the threshold for impaired fasting glucose among Japanese. *Endocrine Journal*. 7-30-2010;57(7):629-637.
- Piette, J. D., Milton, E. C., Aiello, A. E., Mendoza-Avelares, M. O., and Herman, W. H. Comparison of three methods for diabetes screening in a rural clinic in Honduras. *Pan American Journal of Public Health*. 2010;28(1):49-57.
- Pires de Sousa, A. G., Pereira, A. C., Marquezine, G. F., Marques, do Nascimento-Neto, Freitas, S. N., de, C. Nicolato RL, Machado-Coelho, G. L., Rodrigues, S. L., Mill, J. G., and Krieger, J. E. Derivation and external validation of a simple prediction model for the diagnosis of type 2 diabetes mellitus in the Brazilian urban population. *European Journal of Epidemiology*. 2009;24(2):101-109.
- Ramachandran, A., Snehalatha, C., Vijay, V., Wareham, N. J., and Colagiuri, S. Derivation and validation of diabetes risk score for urban Asian Indians. *Diabetes Research & Clinical Practice*. 2005;70(1):63-70.
- Ravikumar, P., Bhansali, A., Walia, R., Shanmugasundar, G., and Ravikiran, M. Alterations in HbA(1c) with advancing age in subjects with normal glucose tolerance: Chandigarh Urban Diabetes Study (CUDS). *Diabetic Medicine*. 2011;28(5):590-594.
- Ritchie, G. E., Kengne, A. P., Joshi, R., Chow, C., Neal, B., Patel, A., and Zoungas, S. Comparison of near-patient capillary glucose measurement and a risk assessment questionnaire in screening for type 2 diabetes in a high-risk population in rural India. *Diabetes Care*. 2011;34(1):44-49.
- Rostambeigi, N., Shaw, J. E., Atkins, R. C., Ghanbarian, A., Cameron, A. J., Forbes, A., Momenan, A., Hadaegh, F., Mirmiran, P., Zimmet, P. Z., Azizi, F., and Tonkin, A. M. Waist circumference has heterogeneous impact on development of diabetes in different populations: longitudinal comparative study between Australia and Iran. *Diabetes Research & Clinical Practice*. 2010;88(1):117-124.
- Saadi, H., Nagelkerke, N., Al-Kaabi, J., Afandi, B., Al-Maskari, F., and Kazam, E. Screening strategy for type 2 diabetes in the United Arab Emirates. *Asia-Pacific Journal of Public Health*. 2010;22(3:Suppl):Suppl-59S.
- Sato, K. K., Hayashi, T., Harita, N., Yoneda, T., Nakamura, Y., Endo, G., and Kambe, H. Combined measurement of fasting plasma glucose and A1C is effective for the prediction of type 2 diabetes: the

Kansai Healthcare Study. *Diabetes Care*. 2009;32(4):644-646.

Shah, A., Bhandary, S., Malik, S. L., Risal, P., and Koju, R. Waist circumference and waist-hip ratio as predictors of type 2 diabetes mellitus in the Nepalese population of Kavre District. *Nepal Medical College Journal: NMCJ*. 2009;11(4):261-267.

Shibata, K., Suzuki, S., Sato, J., Ohsawa, I., Goto, S., Iritani, I., and Tokudome, S. Diagnostic accuracy of glycohemoglobin A1c (HbA1c) for postprandial hyperglycemia was equivalent to that of fasting blood glucose. *Journal of Clinical Epidemiology*. 2005;58(10):1052-1057.

Srichang, N., Jiamjarasrangsri, W., Aekplakorn, W., and Supakankunti, S. Cost and effectiveness of screening methods for abnormal fasting plasma glucose among Thai adults participating in the annual health check-up at King Chulalongkorn Memorial Hospital. *Journal of the Medical Association of Thailand*. 2011;94(7):833-841.

Sun, F., Tao, Q., and Zhan, S. An accurate risk score for estimation 5-year risk of type 2 diabetes based on a health screening population in Taiwan. *Diabetes Research & Clinical Practice*. 2009;85(2):228-234.

Takahashi, O., Farmer, A. J., Shimbo, T., Fukui, T., and Glasziou, P. P. A1C to detect diabetes in healthy adults: when should we recheck?. *Diabetes Care*. 2010;33(9):2016-2017.

Tay, T. L., Foo, J. P., Tan, E., Chen, R., Khoo, J., Soh, S. B., Au, V., and Cho, L. W. HbA1c may not be a sensitive determinant of diabetic status in the elderly. *Diabetes Research & Clinical Practice*. 2011;92(2):e31-e33.

Wang, J. J., Yuan, S. Y., Zhu, L. X., Fu, H. J., Li, H. B., Hu, G., and Tuomilehto, J. Effects of impaired fasting glucose and impaired glucose tolerance on predicting incident type 2 diabetes in a Chinese population with high post-prandial glucose. *Diabetes Research & Clinical Practice*. 2004;66(2):183-191.

Xin, Z., Yuan, J., Hua, L., Ma, Y. H., Zhao, L., Lu, Y., and Yang, J. K. A simple tool detected diabetes and prediabetes in rural Chinese. *Journal of Clinical Epidemiology*. 2010;63(9):1030-1035.

Yu, D., Huang, J., Hu, D., Chen, J., Cao, J., and Li, J. Is an appropriate cutoff of hypertriglyceridemic waist designated for type 2 diabetes among Chinese adults?. *Clinical Nutrition*. 2010;29(2):192-198.

Zhang, Y. Q., Zhang, Y. N., Cui, C., Fan, Y., Chang, M. L., Yu, W. G., Liu, F. C., Tan, N., and Zhang, J. C. The role of oral glucose tolerance test in screening for diabetes mellitus in the elderly of Harbin, China. *Chinese Medical Journal*. 3-5-2005;118(5):418-420.

Zhou, H., Guo, Z. R., Yu, L. G., Hu, X. S., Xu, B. H., Liu, H. B., Wu, M., and Zhou, Z. Y. Evidence on the applicability of the ATPIII, IDF and CDS metabolic syndrome diagnostic criteria to identify CVD and T2DM in the Chinese population from a 6.3-year cohort study in mid-eastern China. *Diabetes Research & Clinical Practice*. 2010;90(3):319-325.

Zhou, X. H., Ji, L. N., Luo, Y. Y., Zhang, X. Y., Han, X. Y., and Qiao, Q. Performance of HbA(1c) for detecting newly diagnosed diabetes and pre-diabetes in Chinese communities living in Beijing. *Diabetic Medicine*. 2009;26(12):1262-1268.

Zhou, X., Pang, Z., Gao, W., Wang, S., Zhang, L., Ning, F., and Qiao, Q. Performance of an A1C and fasting capillary blood glucose test for screening newly diagnosed diabetes and pre-diabetes defined by an oral glucose tolerance test in Qingdao, China. *Diabetes Care*. 2010;33(3):545-550.

Level 3: Risk Assessment or Diagnostic Tool

Bozkaya, G., Ozgu, E., and Karaca, B. The association between estimated average glucose levels and

fasting plasma glucose levels. *Clinics (Sao Paulo, Brazil)*. 2010;65(11):1077-1080.

Chang, A., Frank, J., Knaebel, J., Fullam, J., Pardo, S., and Simmons, D. A. Evaluation of an over-the-counter glycated hemoglobin (A1C) test kit. *Journal of Diabetes Science & Technology*. 2010;4(6):1495-1503.

Fukudome, M., Nakazaki, M., Fukushige, E., Koriyama, N., Ikeda, Y., Kato, K., Kimura, T., and Tei, C. Interindividual divergence in the relationship between the values of plasma glucose and hemoglobin A1c in type 2 diabetes. *Internal Medicine*. 2009;48(5):273-279.

Gianotti, N., Visco, F., Galli, L., Barda, B., Piatti, P., Salpietro, S., Bigoloni, A., Vinci, C., Nozza, S., Gallotta, G., Lazzarin, A., and Castagna, A. Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. *HIV Medicine*. 2011;12(2):109-117.

Jazet, I. M. and Meinders, A. E. Glucoregulation in type 2 diabetes: the lower the better? Glycosylated HbA1c of 6.5% seems to be the limit. [Review] [25 refs]. *European Journal of Internal Medicine*. 2009;20(3):232-235.

Klein Woolthuis, E. P., de Grauw, W. J., van Gerwen, W. H., van den Hoogen, H. J., van de Lisdonk, E. H., Metsemakers, J. F., and van, Weel C. Identifying people at risk for undiagnosed type 2 diabetes using the GP's electronic medical record. *Family Practice*. 2007;24(3):230-236.

Liberopoulos, E. N., Florentin, M., Kei, A., Mountzouri, E., Agouridis, A., and Elisaf, M. S. Comparison of hemoglobin A1c and fasting glucose criteria to diagnose diabetes among people with metabolic syndrome and fasting glucose above 100 mg/dL (5.5 mmol/L). *Journal of Clinical Hypertension*. 7-1-2010;12(7):543-548.

Moran, L. J., Strauss, B. J., and Teede, H. J. Diabetes risk score in the diagnostic categories of polycystic ovary syndrome. *Fertility & Sterility*. 2011;95(5):1742-1748.

Skeie, S., Perich, C., Ricos, C., Araczk, A., Horvath, A. R., Oosterhuis, W. P., Bubner, T., Nordin, G., Delport, R., Thue, G., and Sandberg, S. Postanalytical external quality assessment of blood glucose and hemoglobin A1c: an international survey. *Clinical Chemistry*. 2005;51(7):1145-1153.

Tuomilehto, J., Lindstrom, J., Hellmich, M., Lehmacher, W., Westermeier, T., Evers, T., Bruckner, A., Peltonen, M., Qiao, Q., and Chiasson, J. L. Development and validation of a risk-score model for subjects with impaired glucose tolerance for the assessment of the risk of type 2 diabetes mellitus-The STOP-NIDDM risk-score. *Diabetes Research & Clinical Practice*. 2010;87(2):267-274.

Valderhaug, T. G., Jenssen, T., Hartmann, A., Midtvedt, K., Holdaas, H., Reisaeter, A. V., and Hjeltnes, J. Fasting plasma glucose and glycosylated hemoglobin in the screening for diabetes mellitus after renal transplantation. *Transplantation*. 8-15-2009;88(3):429-434.

Level 3: Comparison

A new tool to predict your risk of diabetes. Assess your probability with the Diabetes Risk Calculator. *Duke Medicine Health News*. 2008;14(8):1.

Ginde, A. A., Cagliero, E., Nathan, D. M., and Camargo, C. A., Jr. Point-of-care glucose and hemoglobin A1c in emergency department patients without known diabetes: implications for opportunistic screening. *Academic Emergency Medicine*. 2008;15(12):1241-1247.

Greiver, M., Aliarzadeh, B., Moineddin, R., Meaney, C., and Ivers, N. Diabetes screening with hemoglobin A1c prior to a change in guideline recommendations: prevalence and patient characteristics. *BMC Family Practice*. 2011;12:91.

Gupta, A. K., Prieto-Merino, D., Dahlof, B., Sever, P. S., Poulter, N. R., and ASCOT, Investigators. Metabolic syndrome, impaired fasting glucose and obesity, as predictors of incident diabetes in 14 120 hypertensive patients of ASCOT-BPLA: comparison of their relative predictability using a novel approach. *Diabetic Medicine*. 2011;28(8):941-947.

Level 3: Accuracy

Abdul-Ghani, M. A., Stern, M. P., Lyssenko, V., Tuomi, T., Groop, L., and DeFronzo, R. A. Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose. *Diabetes Care*. 2010;33(3):557-561.

Klein Woolthuis, E. P., de Grauw, W. J., van Gerwen, W. H., van den Hoogen, H. J., van de Lisdonk, E. H., Metsemakers, J. F., and van, Weel C. Yield of opportunistic targeted screening for type 2 diabetes in primary care: the diabscreen study. *Annals of Family Medicine*. 2009;7(5):422-430.

Phillips, L. S., Ziemer, D. C., Kolm, P., Weintraub, W. S., Vaccarino, V., Rhee, M. K., Chatterjee, R., Narayan, K. M., and Koch, D. D. Glucose challenge test screening for prediabetes and undiagnosed diabetes. *Diabetologia*. 2009;52(9):1798-1807.

Rush, E., Crook, N., and Simmons, D. Point-of-care testing as a tool for screening for diabetes and pre-diabetes. *Diabetic Medicine*. 2008;25(9):1070-1075.

Triolo, T. M., Chase, H. P., Barker, J. M., and Study Group. Diabetic subjects diagnosed through the Diabetes Prevention Trial-Type 1 (DPT-1) are often asymptomatic with normal A1C at diabetes onset. *Diabetes Care*. 2009;32(5):769-773.

Utzschneider, K. M., Prigeon, R. L., Faulenbach, M. V., Tong, J., Carr, D. B., Boyko, E. J., Leonetti, D. L., McNeely, M. J., Fujimoto, W. Y., and Kahn, S. E. Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels.[Erratum appears in *Diabetes Care*. 2009 Jul;32(7):1355]. *Diabetes Care*. 2009;32(2):335-341.

Level 3: Study Design

Bartoli, E., Fra, G. P., and Carnevale Schianca, G. P. The oral glucose tolerance test (OGTT) revisited. [Review]. *European Journal of Internal Medicine*. 2011;22(1):8-12.

Christensen, D. L., Witte, D. R., Kaduka, L., Jorgensen, M. E., Borch-Johnsen, K., Mohan, V., Shaw, J. E., Tabak, A. G., and Vistisen, D. Moving to an A1C-based diagnosis of diabetes has a different impact on prevalence in different ethnic groups. *Diabetes Care*. 2010;33(3):580-582.

Klein, S., Allison, D. B., Heymsfield, S. B., Kelley, D. E., Leibel, R. L., Nonas, C., and Kahn, R. Waist Circumference and Cardiometabolic Risk: a Consensus Statement from Shaping America's Health: Association for Weight Management and Obesity Prevention; NAASO, the Obesity Society; the American Society for Nutrition; and the American Diabetes Association. [Review] [38 refs]. *Obesity*. 2007;15(5):1061-1067.

Malkani, S. and Mordes, J. P. Implications of using hemoglobin A1C for diagnosing diabetes mellitus. [Review]. *American Journal of Medicine*. 2011;124(5):395-401.

Mostafa, S. A., Davies, M. J., Srinivasan, B. T., Carey, M. E., Webb, D., and Khunti, K. Should glycated haemoglobin (HbA1c) be used to detect people with type 2 diabetes mellitus and impaired glucose regulation?. [Review]. *Postgraduate Medical Journal*. 2010;86(1021):656-662.

Saudek, C. D., Herman, W. H., Sacks, D. B., Bergenstal, R. M., Edelman, D., and Davidson, M. B. A new look at screening and diagnosing diabetes mellitus. [Review] [70 refs]. *Journal of Clinical*

Endocrinology & Metabolism. 2008;93(7):2447-2453.

Level 4: Risk Assessment

Balkau, B., Lange, C., Fezeu, L., Tichet, J., de Lauzon-Guillain, B., Czernichow, S., Fumeron, F., Froguel, P., Vaxillaire, M., Cauchi, S., Ducimetiere, P., and Eschwege, E. Predicting diabetes: clinical, biological, and genetic approaches: data from the Epidemiological Study on the Insulin Resistance Syndrome (DESIR). *Diabetes Care*. 2008;31(10):2056-2061.

Cameron, A. J., Magliano, D. J., Zimmet, P. Z., Welborn, T. A., Colagiuri, S., Tonkin, A. M., and Shaw, J. E. The metabolic syndrome as a tool for predicting future diabetes: the AusDiab study. *Journal of Internal Medicine*. 2008;264(2):177-186.

Chen, L., Magliano, D. J., Balkau, B., Colagiuri, S., Zimmet, P. Z., Tonkin, A. M., Mitchell, P., Phillips, P. J., and Shaw, J. E. AUSDRISK: an Australian Type 2 Diabetes Risk Assessment Tool based on demographic, lifestyle and simple anthropometric measures.[Erratum appears in *Med J Aust*. 2010 Mar 1;192(5):274]. *Medical Journal of Australia*. 2-15-2010;192(4):197-202.

Collins, G. S. and Altman, D. G. External validation of QDScore([REGISTERED]) for predicting the 10-year risk of developing Type 2 diabetes. *Diabetic Medicine*. 2011;28(5):599-607.

Hippisley-Cox, J., Coupland, C., Robson, J., Sheikh, A., and Brindle, P. Predicting risk of type 2 diabetes in England and Wales: prospective derivation and validation of QDScore. *BMJ*. 2009;338:b880.

Kahn, H. S., Cheng, Y. J., Thompson, T. J., Imperatore, G., and Gregg, E. W. Two risk-scoring systems for predicting incident diabetes mellitus in U.S. adults age 45 to 64 years. *Annals of Internal Medicine*. 6-2-2009;150(11):741-751.

Klotsche, J., Ferger, D., Pieper, L., Rehm, J., and Wittchen, H. U. A novel nonparametric approach for estimating cut-offs in continuous risk indicators with application to diabetes epidemiology. *BMC Medical Research Methodology*. 2009;9:63.

Lindstrom, J. and Tuomilehto, J. The diabetes risk score: a practical tool to predict type 2 diabetes risk. *Diabetes Care*. 2003;26(3):725-731.

Mann, D. M., Bertoni, A. G., Shimbo, D., Carnethon, M. R., Chen, H., Jenny, N. S., and Muntner, P. Comparative validity of 3 diabetes mellitus risk prediction scoring models in a multiethnic US cohort: the Multi-Ethnic Study of Atherosclerosis. *American Journal of Epidemiology*. 5-1-2010;171(9):980-988.

Rahman, M., Simmons, R. K., Harding, A. H., Wareham, N. J., and Griffin, S. J. A simple risk score identifies individuals at high risk of developing Type 2 diabetes: a prospective cohort study. *Family Practice*. 2008;25(3):191-196.

Rosella, L. C., Manuel, D. G., Burchill, C., Stukel, T. A., and PHIAT-DM team. A population-based risk algorithm for the development of diabetes: development and validation of the Diabetes Population Risk Tool (DPoRT). *Journal of Epidemiology & Community Health*. 2011;65(7):613-620.

Schulze, M. B., Hoffmann, K., Boeing, H., Linseisen, J., Rohrmann, S., Mohlig, M., Pfeiffer, A. F., Spranger, J., Thamer, C., Haring, H. U., Fritsche, A., and Joost, H. G. An accurate risk score based on anthropometric, dietary, and lifestyle factors to predict the development of type 2 diabetes. *Diabetes Care*. 2007;30(3):510-515.

Simmons, R. K., Harding, A. H., Wareham, N. J., Griffin, S. J., and EPIC-Norfolk Project Team. Do simple questions about diet and physical activity help to identify those at risk of Type 2 diabetes?. *Diabetic Medicine*. 2007;24(8):830-835.

Urdea, M., Kolberg, J., Wilber, J., Gerwien, R., Moler, E., Rowe, M., Jorgensen, P., Hansen, T., Pedersen, O., Jorgensen, T., and Borch-Johnsen, K. Validation of a multimarker model for assessing risk of type 2 diabetes from a five-year prospective study of 6784 Danish people (Inter99). *Journal of Diabetes Science & Technology*. 2009;3(4):748-755.

Wannamethee, S. G., Papacosta, O., Whincup, P. H., Thomas, M. C., Carson, C., Lawlor, D. A., Ebrahim, S., and Sattar, N. The potential for a two-stage diabetes risk algorithm combining non-laboratory-based scores with subsequent routine non-fasting blood tests: results from prospective studies in older men and women. *Diabetic Medicine*. 2011;28(1):23-30.

Wannamethee, S. G., Shaper, A. G., Lennon, L., and Morris, R. W. Metabolic syndrome vs Framingham Risk Score for prediction of coronary heart disease, stroke, and type 2 diabetes mellitus. *Archives of Internal Medicine*. 12-12-2005;165(22):2644-2650.

MERSC Diabetes Intervals Excluded Studies List

Level 2: Screening

Gray, L. J., Taub, N. A., Khunti, K., Gardiner, E., Hiles, S., Webb, D. R., Srinivasan, B. T., and Davies, M. J. The Leicester Risk Assessment score for detecting undiagnosed Type 2 diabetes and impaired glucose regulation for use in a multiethnic UK setting. *Diabetic Medicine*. 2010;27(8):887-895.

Kilmer, G., Hughes, E., Zhang, X., and Elam-Evans, L. Diabetes and prediabetes: screening and prevalence among adults with coronary heart disease. *American Journal of Preventive Medicine*. 2011;40(2):159-165.

Mantyselka, P., Korniloff, K., Saaristo, T., Koponen, H., Eriksson, J., Puolijoki, H., Timonen, M., Sundvall, J., Kautiainen, H., and Vanhala, M. Association of depressive symptoms with impaired glucose regulation, screen-detected, and previously known type 2 diabetes: findings from the Finnish D2D Survey. *Diabetes Care*. 2011;34(1):71-76.

Misra, A., Bachmann, M. O., Greenwood, R. H., Jenkins, C., Shaw, A., Barakat, O., Flatman, M., and Jones, C. D. Trends in yield and effects of screening intervals during 17 years of a large UK community-based diabetic retinopathy screening programme. *Diabetic Medicine*. 2009;26(10):1040-1047.

Level 2: Comparison

Beljic, Zivkovic T., Marjanovic, M., Prgomelja, S., Soldatovic, I., Koprivica, B., Ackovic, D., and Zivkovic, R. Screening for diabetes among Roma people living in Serbia. *Croatian Medical Journal*. 4-15-2010;51(2):144-150.

Bindraban, N. R., van Valkengoed, I. G., Mairuhu, G., Holleman, F., Hoekstra, J. B., Michels, B. P., Koopmans, R. P., and Stronks, K. Prevalence of diabetes mellitus and the performance of a risk score among Hindustani Surinamese, African Surinamese and ethnic Dutch: a cross-sectional population-based study. *BMC Public Health*. 2008;8:271.

Cai, X. L., Han, X. Y., and Ji, L. N. Association between serum uric acid and different states of glucose metabolism and glomerular filtration rate. *Chinese Medical Journal*. 2010;123(21):3118-3122.

Grassi, A., Gaetano, L., Pacini, G., Kautzky-Willer, A., and Tura, A. A Markov chain probability model of glucose tolerance in post gestational diabetes follow up study. *Studies in Health Technology & Informatics*. 2010;160(Pt:2):2-9.

Hanif, M. W., Valsamakis, G., Dixon, A., Boutsiadis, A., Jones, A. F., Barnett, A. H., and Kumar, S. Detection of impaired glucose tolerance and undiagnosed type 2 diabetes in UK South Asians: an effective screening strategy. *Diabetes, Obesity & Metabolism*. 2008;10(9):755-762.

Ishizaka, N., Ishizaka, Y., Yamakado, M., Toda, E., Koike, K., and Nagai, R. Association between metabolic syndrome and carotid atherosclerosis in individuals without diabetes based on the oral glucose tolerance test. *Atherosclerosis*. 2009;204(2):619-623.

Koopman, R. J., Mainous, A. G., III, Everett, C. J., and Carter, R. E. Tool to assess likelihood of fasting glucose impairment (TAG-IT). *Annals of Family Medicine*. 2008;6(6):555-561.

Li, J., Bergmann, A., Reimann, M., Bornstein, S. R., and Schwarz, P. E. A more simplified Finnish diabetes risk score for opportunistic screening of undiagnosed type 2 diabetes in a German population with a family history of the metabolic syndrome. *Hormone & Metabolic Research*. 2009;41(2):98-103.

Mihardja, L., Delima, Manz, H. S., Ghani, L., and Soegondo, S. Prevalence and determinants of diabetes mellitus and impaired glucose tolerance in Indonesia (a part of basic health research/Riskesdas). *Acta Medica Indonesiana*. 2009;41(4):169-174.

Mousa, H. S., Yousef, S., Riccardo, F., Zeidan, W., and Sabatinelli, G. Hyperglycaemia, hypertension and their risk factors among Palestine refugees served by UNRWA. *Eastern Mediterranean Health Journal*. 2010;16(6):609-614.

Norberg, M., Eriksson, J. W., Lindahl, B., Andersson, C., Rolandsson, O., Stenlund, H., and Weinehall, L. A combination of HbA1c, fasting glucose and BMI is effective in screening for individuals at risk of future type 2 diabetes: OGTT is not needed.[Erratum appears in *J Intern Med*. 2006 Nov;260(5):491]. *Journal of Internal Medicine*. 2006;260(3):263-271.

Thomas, C., Hypponen, E., and Power, C. Type 2 diabetes mellitus in midlife estimated from the Cambridge Risk Score and body mass index. *Archives of Internal Medicine*. 3-27-2006;166(6):682-688.

Tsui, C. W., Caudle, J. M., Ziemer, D. C., and Phillips, L. S. An informatics model for clinical research--screening for impaired glucose tolerance study. *AMIA*. 2006;Annual:Symposium.

Level 2: Intervals of Screening

Bennett, C. M., Guo, M., and Dharmage, S. C. HbA(1c) as a screening tool for detection of Type 2 diabetes: a systematic review. [Review] [42 refs][Erratum appears in *Diabet Med*. 2007 Sep;24(9):1054]. *Diabetic Medicine*. 2007;24(4):333-343.

Simmons, R. K., Rahman, M., Jakes, R. W., Yuyun, M. F., Niggebrugge, A. R., Hennings, S. H., Williams, D. R., Wareham, N. J., and Griffin, S. J. Effect of population screening for type 2 diabetes on mortality: long-term follow-up of the Ely cohort. *Diabetologia*. 2011;54(2):312-319.

Diabetes Preference and Values Excluded Studies List

Level 1: Preference and Values

Exenatide: new drug. Type 2 diabetes for some overweight patients. *Prescrire International*. 2007;16(92):228-231.

Yoga therapy helps relieve chronic lower back pain. *Harvard Women's Health Watch*. 2009;17(3):4.

Adams, A. S., Trinacty, C. M., Zhang, F., Kleinman, K., Grant, R. W., Meigs, J. B., Soumerai, S. B., and Ross-Degnan, D. Medication adherence and racial differences in A1C control. *Diabetes Care*. 2008;31(5):916-921.

Adler, S., Lodermeier, S., Gaa, J., and Heemann, U. Successful mycophenolate mofetil therapy in nine patients with idiopathic retroperitoneal fibrosis. *Rheumatology*. 2008;47(10):1535-1538.

Adolfsson, E. T., Starrin, B., Smide, B., and Wikblad, K. Type 2 diabetic patients' experiences of two different educational approaches--a qualitative study. *International Journal of Nursing Studies*. 2008;45(7):986-994.

Adolfsson, E. T., Walker-Engstrom, M. L., Smide, B., and Wikblad, K. Patient education in type 2 diabetes: a randomized controlled 1-year follow-up study. *Diabetes Research & Clinical Practice*. 2007;76(3):341-350.

Alvarez, Guisasola F., Tofe, Povedano S., Krishnarajah, G., Lyu, R., Mavros, P., and Yin, D. Hypoglycaemic symptoms, treatment satisfaction, adherence and their associations with glycaemic goal in patients with type 2 diabetes mellitus: findings from the Real-Life Effectiveness and Care Patterns of Diabetes Management (RECAP-DM) Study. *Diabetes, Obesity & Metabolism*. 2008;10:Suppl-32.

Andersen, S. T., Jeppesen, T. D., Taivassalo, T., Sveen, M. L., Heinicke, K., Haller, R. G., and Vissing, J. Effect of changes in fat availability on exercise capacity in McArdle disease. *Archives of Neurology*. 2009;66(6):762-766.

Annunziato, R. A., Timko, C. A., Crerand, C. E., Didie, E. R., Bellace, D. L., Phelan, S., Kerzhnerman, I., and Lowe, M. R. A randomized trial examining differential meal replacement adherence in a weight loss maintenance program after one-year follow-up. *Eating Behaviors*. 2009;10(3):176-183.

Arevalo, J. F., Maia, M., Flynn, H. W., Jr., Saravia, M., Avery, R. L., Wu, L., Eid, Farah M., Pieramici, D. J., Berrocal, M. H., and Sanchez, J. G. Tractional retinal detachment following intravitreal bevacizumab (Avastin) in patients with severe proliferative diabetic retinopathy. *British Journal of Ophthalmology*. 2008;92(2):213-216.

Arrigo, I., Brunner-LaRocca, H., Lefkovits, M., Pfisterer, M., and Hoffmann, A. Comparative outcome one year after formal cardiac rehabilitation: the effects of a randomized intervention to improve exercise adherence. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2008;15(3):306-311.

Asakura, T. and Jensen, K. H. Comparison of intuitiveness, ease of use, and preference in two insulin pens. *Journal of Diabetes Science & Technology*. 2009;3(2):312-319.

Asakura, T., Seino, H., and Jensen, K. H. Patient acceptance and issues of education of two durable insulin pen devices. *Diabetes Technology & Therapeutics*. 2008;10(4):299-304.

Asche, C. V., McAdam-Marx, C., Shane-McWhorter, L., Sheng, X., and Plauschinat, C. A. Evaluation of adverse events of oral antihyperglycemic monotherapy experienced by a geriatric population in a real-world setting: a retrospective cohort analysis. *Drugs & Aging*. 2008;25(7):611-622.

Aylwin, S. and Al Zaman, Y. Emerging concepts in the medical and surgical treatment of obesity. [Review] [101 refs]. *Frontiers of Hormone Research*. 2008;36:229-259.

Banez, C., Tully, S., Amaral, L., Kwan, D., Kung, A., Mak, K., Moghabghab, R., and Alibhai, S. M. Development, implementation, and evaluation of an Interprofessional Falls Prevention Program for older adults. *Journal of the American Geriatrics Society*. 2008;56(8):1549-1555.

Barnard, N. D., Gloede, L., Cohen, J., Jenkins, D. J., Turner-McGrievy, G., Green, A. A., and Ferdowsian, H. A low-fat vegan diet elicits greater macronutrient changes, but is comparable in adherence and acceptability, compared with a more conventional diabetes diet among individuals with type 2 diabetes. *Journal of the American Dietetic Association*. 2009;109(2):263-272.

Barnett, A. Dosing of insulin glargine in the treatment of type 2 diabetes. [Review] [47 refs]. *Clinical Therapeutics*. 2007;29(6):987-999.

Beddoe, A. E., Paul Yang, C. P., Kennedy, H. P., Weiss, S. J., and Lee, K. A. The effects of mindfulness-based yoga during pregnancy on maternal psychological and physical distress. *JOGNN - Journal of Obstetric, Gynecologic, & Neonatal Nursing*. 2009;38(3):310-319.

Ben Salah, Farih Z., Fendri, Y., Jellad, A., Boudoukhane, S., and Rejeb, N. Efficacy and treatment compliance of a home-based rehabilitation programme for chronic low back pain: a randomized, controlled study. *Annals of Physical & Rehabilitation Medicine*. 2009;52(6):485-496.

Bergental, R. M., Freemantle, N., Leyk, M., Cutler, G. B., Jr., Hayes, R. P., and Muchmore, D. B. Does availability of AIR insulin increase insulin use and improve glycemic control in patients with type 2 diabetes?. *Diabetes Technology & Therapeutics*. 2009;11:Suppl-52.

Berhanu, P., Perez, A., and Yu, S. Effect of pioglitazone in combination with insulin therapy on glycaemic control, insulin dose requirement and lipid profile in patients with type 2 diabetes previously poorly controlled with combination therapy. *Diabetes, Obesity & Metabolism*. 2007;9(4):512-520.

Bersoux, S., Asbury, K. L., Cook, C. B., Verheijde, J. L., Larson, M. H., Aponte-Furlow, R. T., Flatten, S. S., Hooley, S. A., LaRosa, C. S., Seifert, K. M., Verona, P. M., Castro, J. C., and Jameson, K. A. An outpatient-based clinical program for type 2 diabetes prevention. *Endocrine Practice*. 2010;16(1):21-29.

Berthe, E., Lireux, B., Coffin, C., Goulet-Salmon, B., Houlbert, D., Boutreux, S., Fradin, S., and Reznik, Y. Effectiveness of intensive insulin therapy by multiple daily injections and continuous subcutaneous infusion: a comparison study in type 2 diabetes with conventional insulin regimen failure. *Hormone & Metabolic Research*. 2007;39(3):224-229.

Best, J. H., Boye, K. S., Rubin, R. R., Cao, D., Kim, T. H., and Peyrot, M. Improved treatment satisfaction and weight-related quality of life with exenatide once weekly or twice daily. *Diabetic Medicine*. 2009;26(7):722-728.

Beverly, E. A., Miller, C. K., and Wray, L. A. Spousal support and food-related behavior change in middle-aged and older adults living with type 2 diabetes. *Health Education & Behavior*. 2008;35(5):707-720.

Biderman, A., Noff, E., Harris, S. B., Friedman, N., and Levy, A. Treatment satisfaction of diabetic patients: what are the contributing factors?. *Family Practice*. 2009;26(2):102-108.

Black, C., Cummins, E., Royle, P., Philip, S., and Waugh, N. The clinical effectiveness and cost-effectiveness of inhaled insulin in diabetes mellitus: a systematic review and economic evaluation. [Review] [179 refs]. *Health Technology Assessment (Winchester, England)*. 2007;11(33):1-126.

Blanson Henkemans, O. A., van der Boog, P. J., Lindenberg, J., van der Mast, C. A., Neerincx, M. A., and Zwetsloot-Schonk, B. J. An online lifestyle diary with a persuasive computer assistant providing feedback on self-management. *Technology & Health Care*. 2009;17(3):253-267.

Blevins, T., Han, J., Nicewarner, D., Chen, S., Oliveira, J. H., and Aronoff, S. Exenatide is non-inferior to insulin in reducing HbA1c: an integrated analysis of 1423 patients with type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):118-128.

Boaz, M., Hellman, K., and Wainstein, J. An automated telemedicine system improves patient-reported well-being. *Diabetes Technology & Therapeutics*. 2009;11(3):181-186.

Bode, B. W. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections. *Clinical Therapeutics*. 2007;29:Suppl-44.

Bond, D. S., Phelan, S., Wolfe, L. G., Evans, R. K., Meador, J. G., Kellum, J. M., Maher, J. W., and Wing, R. R. Becoming physically active after bariatric surgery is associated with improved weight loss and health-related quality of life. *Obesity*. 2009;17(1):78-83.

Bonutti, P. M., McGrath, M. S., Ulrich, S. D., McKenzie, S. A., Seyler, T. M., and Mont, M. A. Static progressive stretch for the treatment of knee stiffness. *Knee*. 2008;15(4):272-276.

Borges, W. J. and Ostwald, S. K. Improving foot self-care behaviors with Pies Sanos. *Western Journal of Nursing Research*. 342;30(3):325-341.

Bosak, K. A., Yates, B., and Pozehl, B. Effects of an Internet physical activity intervention in adults with metabolic syndrome. *Western Journal of Nursing Research*. 2010;32(1):5-22.

Boutati, E. I. and Raptis, S. A. Self-monitoring of blood glucose as part of the integral care of type 2 diabetes. [Review] [51 refs]. *Diabetes Care*. 2009;32:Suppl-10.

Bowman, A. M. Promoting safe exercise and foot care for clients with type 2 diabetes. *Canadian Nurse*. 2008;104(2):23-27.

Bradley, C., Plowright, R., Stewart, J., Valentine, J., and Witthaus, E. The Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) evaluated in insulin glargine trials shows greater responsiveness to improvements than the original DTSQ. *Health & Quality of Life Outcomes*. 2007;5:57.

Brandle, M., Goodall, G., Erny-Albrecht, K. M., Erdmann, E., and Valentine, W. J. Cost-effectiveness of pioglitazone in patients with type 2 diabetes and a history of macrovascular disease in a Swiss setting. *Swiss Medical Weekly*. 3-21-2009;139(11-12):173-184.

Brenner, M. A., Harkless, L. B., Mendicino, R. W., and Page, J. C. Ciclopirox 8% nail lacquer topical solution for the treatment of onychomycosis in patients with diabetes: a multicenter, open-label study. *Journal of the American Podiatric Medical Association*. 2007;97(3):195-202.

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., and Linn, T. Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial.[Erratum appears in *Lancet*. 2008 Aug 30;372(9640):718]. *Lancet*. 3-29-2008;371(9618):1073-1084.

Brod, M., Cobden, D., Lammert, M., Bushnell, D., and Raskin, P. Examining correlates of treatment satisfaction for injectable insulin in type 2 diabetes: lessons learned from a clinical trial comparing biphasic and basal analogues. *Health & Quality of Life Outcomes*. 2007;5:8.

Brown, S. E., Meltzer, D. O., Chin, M. H., and Huang, E. S. Perceptions of quality-of-life effects of treatments for diabetes mellitus in vulnerable and nonvulnerable older patients. *Journal of the American Geriatrics Society*. 2008;56(7):1183-1190.

Carels, R. A., Young, K. M., Wott, C. B., Harper, J., Gumble, A., Oehlof, M. W., and Clayton, A. M. Weight bias and weight loss treatment outcomes in treatment-seeking adults. *Annals of Behavioral Medicine*. 2009;37(3):350-355.

Cefalu, W. T., Mathieu, C., Davidson, J., Freemantle, N., Gough, S., Canovatchel, W., and OPTIMIZE, Coalition. Patients' perceptions of subcutaneous insulin in the OPTIMIZE study: a multicenter follow-up study. *Diabetes Technology & Therapeutics*. 2008;10(1):25-38.

Chancellor, J., Aballea, S., Lawrence, A., Sheldon, R., Cure, S., Plun-Favreau, J., and Marchant, N. Preferences of patients with diabetes mellitus for inhaled versus injectable insulin regimens. *Pharmacoeconomics*. 2008;26(3):217-234.

Chaney, S. E. and Sheriff, S. Weight gain among women during smoking cessation: testing the effects of a multifaceted program. *AAOHN Journal*. 2008;56(3):99-105.

Chang, R. Y., Koo, M., Yu, Z. R., Kan, C. B., Chu, I. T., Hsu, C. T., and Chen, C. Y. The effect of t'ai chi exercise on autonomic nervous function of patients with coronary artery disease. *Journal of Alternative & Complementary Medicine*. 2008;14(9):1107-1113.

Chao, J., Nau, D. P., and Aikens, J. E. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. *Clinical Therapeutics*. 2007;29(1):177-180.

Chlup, R., Zapletalova, J., Seckar, P., Mala, E., Doubravova, B., Tancosova, S., Chlupova, L., Pukowietz, L., and Zatloukal, P. Benefits of complementary therapy with insulin aspart versus human regular insulin in persons with type 2 diabetes mellitus. *Diabetes Technology & Therapeutics*. 2007;9(3):223-231.

Cho, J. H., Lee, H. C., Lim, D. J., Kwon, H. S., and Yoon, K. H. Mobile communication using a mobile phone with a glucometer for glucose control in Type 2 patients with diabetes: as effective as an Internet-based glucose monitoring system. *Journal of Telemedicine & Telecare*. 2009;15(2):77-82.

Clancy, D. E., Huang, P., Okonofua, E., Yeager, D., and Magruder, K. M. Group visits: promoting adherence to diabetes guidelines. *Journal of General Internal Medicine*. 2007;22(5):620-624.

Clements, M. R., Tits, J., Kinsley, B. T., Rastam, J., Friberg, H. H., and Ligthelm, R. J. Improved glycaemic control of thrice-daily biphasic insulin aspart compared with twice-daily biphasic human

insulin; a randomized, open-label trial in patients with type 1 or type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(3):229-237.

Cleveringa, F. G., Welsing, P. M., van den, Donk M., Gorter, K. J., Niessen, L. W., Rutten, G. E., and Redekop, W. K. Cost-effectiveness of the diabetes care protocol, a multifaceted computerized decision support diabetes management intervention that reduces cardiovascular risk. *Diabetes Care*. 2010;33(2):258-263.

Coghill, N. and Cooper, A. R. Motivators and de-motivators for adherence to a program of sustained walking. *Preventive Medicine*. 2009;49(1):24-27.

Cohen, B. E., Chang, A. A., Grady, D., and Kanaya, A. M. Restorative yoga in adults with metabolic syndrome: a randomized, controlled pilot trial. *Metabolic Syndrome & Related Disorders*. 2008;6(3):223-229.

Cohen, B. E., Kanaya, A. M., Macer, J. L., Shen, H., Chang, A. A., and Grady, D. Feasibility and acceptability of restorative yoga for treatment of hot flushes: a pilot trial. *Maturitas*. 2-20-2007;56(2):198-204.

Colombi, A. M., Yu-Isenberg, K., and Priest, J. The effects of health plan copayments on adherence to oral diabetes medication and health resource utilization. *Journal of Occupational & Environmental Medicine*. 2008;50(5):535-541.

Cooper, S., Osborne, J., Harrison, T., and Tattersfield, A. Effect of mouth taping at night on asthma control--a randomised single-blind crossover study. *Respiratory Medicine*. 2009;103(6):813-819.

Coronado, G. D., Thompson, B., Tejeda, S., Godina, R., and Chen, L. Sociodemographic factors and self-management practices related to type 2 diabetes among Hispanics and non-Hispanic whites in a rural setting. *Journal of Rural Health*. 2007;23(1):49-54.

Cosson, E., Hamo-Tchatchouang, E., Dufaitre-Patouraux, L., Attali, J. R., Paries, J., and Schaepelynck-Belicar, P. Multicentre, randomised, controlled study of the impact of continuous sub-cutaneous glucose monitoring (GlucoDay) on glycaemic control in type 1 and type 2 diabetes patients. *Diabetes & Metabolism*. 2009;35(4):312-318.

Costanza, M. C., Beer-Borst, S., and Morabia, A. Achieving energy balance at the population level through increases in physical activity. *American Journal of Public Health*. 2007;97(3):520-525.

Courneya, K. S., McKenzie, D. C., Reid, R. D., Mackey, J. R., Gelmon, K., Friedenreich, C. M., Ladha, A. B., Proulx, C., Lane, K., Vallance, J. K., and Segal, R. J. Barriers to supervised exercise training in a randomized controlled trial of breast cancer patients receiving chemotherapy. *Annals of Behavioral Medicine*. 2008;35(1):116-122.

Courneya, K. S., Segal, R. J., Gelmon, K., Reid, R. D., Mackey, J. R., Friedenreich, C. M., Proulx, C., Lane, K., Ladha, A. B., Vallance, J. K., and McKenzie, D. C. Predictors of supervised exercise adherence during breast cancer chemotherapy. *Medicine & Science in Sports & Exercise*. 2008;40(6):1180-1187.

Courneya, K. S., Sellar, C. M., Stevinson, C., McNeely, M. L., Peddle, C. J., Friedenreich, C. M., Tankel, K., Basi, S., Chua, N., Mazurek, A., and Reiman, T. Randomized controlled trial of the effects of aerobic exercise on physical functioning and quality of life in lymphoma patients. *Journal of Clinical Oncology*. 9-20-2009;27(27):4605-4612.

Cuocolo, A., Concilio, C., Acampa, W., Ferro, A., Evangelista, L., Daniele, S., and Petretta, M. Cardiovascular risk stratification of diabetic patients. [Review] [89 refs]. *Minerva Endocrinologica*. 2009;34(3):205-221.

Curnow, D., Cobbin, D., Wyndham, J., and Boris Choy, S. T. Altered motor control, posture and the Pilates method of exercise prescription. *Journal of Bodywork & Movement Therapies*. 2009;13(1):104-111.

Cutler, T. W., Palmieri, J., Khalsa, M., and Stebbins, M. Evaluation of the relationship between a chronic disease care management program and california pay-for-performance diabetes care cholesterol measures in one medical group. *Journal of Managed Care Pharmacy*. 2007;13(7):578-588.

Cvetkovic, R. S. and Plosker, G. L. Exenatide: a review of its use in patients with type 2 diabetes mellitus (as an adjunct to metformin and/or a sulfonylurea). [Review] [59 refs]. *Drugs*. 2007;67(6):935-954.

Dailey, G. Developing a pulmonary insulin delivery system for patients with diabetes. [Review] [57 refs]. *Clinical Therapeutics*. 2007;29(6:Pt 1):t-83.

Dale, J., Caramlau, I., Sturt, J., Friede, T., and Walker, R. Telephone peer-delivered intervention for diabetes motivation and support: the telecare exploratory RCT. *Patient Education & Counseling*. 2009;75(1):91-98.

Daley, A. J., Crank, H., Mutrie, N., Saxton, J. M., and Coleman, R. Determinants of adherence to exercise in women treated for breast cancer. *European Journal of Oncology Nursing*. 2007;11(5):392-399.

Darbyshire, J. L., Holman, R. R., and Price, H. C. Presenting the results of clinical trials to participants. *Clinical Medicine*. 2009;9(5):415-416.

Davis, A. H. Exercise adherence in patients with chronic obstructive pulmonary disease: an exploration of motivation and goals. *Rehabilitation Nursing*. 2007;32(3):104-110.

Davis, S. N. The role of inhaled insulin in the treatment of type 2 diabetes. [Review] [50 refs]. *Journal of Diabetes & its Complications*. 2008;22(6):420-429.

De Mattia, G., Laurenti, O., and Moretti, A. Comparison of glycaemic control in patients with Type 2 diabetes on basal insulin and fixed combination oral antidiabetic treatment: results of a pilot study. *Acta Diabetologica*. 2009;46(1):67-73.

Debacker, N., Nobels, F., Vandenberghe, H., Van Crombrugge, P., Scheen, A., and Van, Casteren, V. Organization of a quality-assurance project in all Belgian multidisciplinary diabetes centres treating insulin-treated diabetes patients: 5 years' experience. *Diabetic Medicine*. 2008;25(2):179-185.

Del Corral, P., Chandler-Laney, P. C., Casazza, K., Gower, B. A., and Hunter, G. R. Effect of dietary adherence with or without exercise on weight loss: a mechanistic approach to a global problem. *Journal of Clinical Endocrinology & Metabolism*. 2009;94(5):1602-1607.

DePaula, A. L., Macedo, A. L., Rassi, N., Machado, C. A., Schraibman, V., Silva, L. Q., and Halpern, A. Laparoscopic treatment of type 2 diabetes mellitus for patients with a body mass index less than 35. *Surgical Endoscopy*. 2008;22(3):706-716.

Derosa, G., D'Angelo, A., Franzetti, I. G., Ragonesi, P. D., Gadaleta, G., Scalise, F., Ciccarelli, L., Piccinni, M. N., and Cicero, A. F. Efficacy and safety of ezetimibe/simvastatin association on non-diabetic and diabetic patients with polygenic hypercholesterolemia or combined hyperlipidemia and previously intolerant to standard statin treatment. *Journal of Clinical Pharmacy & Therapeutics*. 2009;34(3):267-276.

Dhillon, S. and Weber, J. Saxagliptin. *Drugs*. 2009;69(15):2103-2114.

Dijkstra, R., Braspenning, J., and Grol, R. Implementing diabetes passports to focus practice reorganization on improving diabetes care. *International Journal for Quality in Health Care*. 2008;20(1):72-77.

Donnelly, L. A., Morris, A. D., and Pearson, E. R. Adherence in patients transferred from immediate release metformin to a sustained release formulation: a population-based study. *Diabetes, Obesity & Metabolism*. 2009;11(4):338-342.

Donnelly, L. A., Morris, A. D., Evans, J. M., and collaboration, M. E. M. O. Adherence to insulin and its association with glycaemic control in patients with type 2 diabetes. *Qjm*. 2007;100(6):345-350.

Downey, L. V. and Zun, L. S. The effects of deep breathing training on pain management in the emergency department. *Southern Medical Journal*. 2009;102(7):688-692.

Ebbeling, C. B., Leidig, M. M., Feldman, H. A., Lovesky, M. M., and Ludwig, D. S. Effects of a low-glycemic load vs low-fat diet in obese young adults: a randomized trial.[Erratum appears in JAMA. 2007 Aug 8;298(6):627]. JAMA. 5-16-2007;297(19):2092-2102.

Edelman, S., Maier, H., and Wilhelm, K. Pramlintide in the treatment of diabetes mellitus. [Review] [72 refs]. *Biodrugs*. 2008;22(6):375-386.

El Mhandi, L., Millet, G. Y., Calmels, P., Richard, A., Oullion, R., Gautheron, V., and Feasson, L. Benefits of interval-training on fatigue and functional capacities in Charcot-Marie-Tooth disease. *Muscle & Nerve*. 2008;37(5):601-610.

Elder, C., Ritenbaugh, C., Mist, S., Aickin, M., Schneider, J., Zwickey, H., and Elmer, P. Randomized trial of two mind-body interventions for weight-loss maintenance. *Journal of Alternative & Complementary Medicine*. 2007;13(1):67-78.

Ell, K., Katon, W., Cabassa, L. J., Xie, B., Lee, P. J., Kapetanovic, S., and Guterman, J. Depression and diabetes among low-income Hispanics: design elements of a socioculturally adapted collaborative care model randomized controlled trial. *International Journal of Psychiatry in Medicine*. 2009;39(2):113-132.

Ello-Martin, J. A., Roe, L. S., Ledikwe, J. H., Beach, A. M., and Rolls, B. J. Dietary energy density in the treatment of obesity: a year-long trial comparing 2 weight-loss diets. *American Journal of Clinical Nutrition*. 2007;85(6):1465-1477.

Farmer, A. J., Prevost, A. T., Hardeman, W., Craven, A., Sutton, S., Griffin, S. J., Kinmonth, A. L., and Support and Advice for Medication Trial Group. Protocol for SAMS (Support and Advice for Medication Study): a randomised controlled trial of an intervention to support patients with type 2 diabetes with adherence to medication. *BMC Family Practice*. 2008;9:20.

Fielding, R. A., Katula, J., Miller, M. E., Abbott-Pillola, K., Jordan, A., Glynn, N. W., Goodpaster, B., Walkup, M. P., King, A. C., Rejeski, W. J., and Life, Study, I. Activity adherence and physical function in older adults with functional limitations. *Medicine & Science in Sports & Exercise*. 2007;39(11):1997-2004.

Findorff, M. J., Wyman, J. F., and Gross, C. R. Predictors of long-term exercise adherence in a community-based sample of older women. *Journal of Women's Health*. 2009;18(11):1769-1776.

Finne, E., Reinehr, T., Schaefer, A., Winkel, K., and Kolip, P. Overweight children and adolescents--is there a subjective need for treatment?. *International Journal of Public Health*. 2009;54(2):112-116.

Finnell, D. and Ditz, K. A. Health diaries for self-monitoring and self-regulation: applications to individuals with serious mental illness. [Review] [31 refs]. *Issues in Mental Health Nursing*. 2007;28(12):1293-1307.

Fish, A. F., Frid, D. J., Mitchell, G. L., Fish, J. L., Christman, S. K., and Astroth, K. S. Readiness to exercise: a comparison of 3 instruments and an interview. *Progress in Cardiovascular Nursing*. 2007;22(4):201-206.

Flapper, B. C., Duiverman, E. J., Gerritsen, J., Postema, K., and van der Schans, C. P. Happiness to be gained in paediatric asthma care. *European Respiratory Journal*. 2008;32(6):1555-1562.

Flegal, K. E., Kishiyama, S., Zajdel, D., Haas, M., and Oken, B. S. Adherence to yoga and exercise interventions in a 6-month clinical trial. *BMC Complementary & Alternative Medicine*. 2007;7:37.

Frederich, R., Alexander, J. H., Fiedorek, F. T., Donovan, M., Berglind, N., Harris, S., Chen, R., Wolf, R., and Mahaffey, K. W. A systematic assessment of cardiovascular outcomes in the saxagliptin drug development program for type 2 diabetes. *Postgraduate Medicine*. 2010;122(3):16-27.

Furse, J., Clarke, M., Jones, R., Khemka, S., and Findlay, G. Early experience in using telemonitoring for the management of chronic disease in primary care. *Journal of Telemedicine & Telecare*. 2008;14(3):122-124.

Gagliardino, J. J., Lapertosa, S., Villagra, M., Caporale, J. E., Oliver, P., Gonzalez, C., Siri, F., Clark, Ch, Jr., and PRODIACOR. PRODIACOR: a patient-centered treatment program for type 2 diabetes and

associated cardiovascular risk factors in the city of Corrientes, Argentina: study design and baseline data. *Contemporary Clinical Trials*. 2007;28(4):548-556.

Garfield, S., Smith, F., Francis, S. A., and Chalmers, C. Can patients' preferences for involvement in decision-making regarding the use of medicines be predicted?. *Patient Education & Counseling*. 2007;66(3):361-367.

Geloneze, B., Geloneze, S. R., Fiori, C., Stabe, C., Tambascia, M. A., Chaim, E. A., Astiarraga, B. D., and Pareja, J. C. Surgery for nonobese type 2 diabetic patients: an interventional study with duodenal-jejunal exclusion. *Obesity Surgery*. 2009;19(8):1077-1083.

Gerber, J. B., Bloom, P. A., and Ross, J. S. The physical activity contract--tailored to promote physical activity in a geriatric outpatient setting: a pilot study. *Journal of the American Geriatrics Society*. 2010;58(3):604-606.

Ghosh, S. and Collier, A. Inhaled insulins. [Review] [51 refs]. *Postgraduate Medical Journal*. 2007;83(977):178-181.

Gillies, C. L., Lambert, P. C., Abrams, K. R., Sutton, A. J., Cooper, N. J., Hsu, R. T., Davies, M. J., and Khunti, K. Different strategies for screening and prevention of type 2 diabetes in adults: cost effectiveness analysis. *BMJ*. 5-24-2008;336(7654):1180-1185.

Gold, S. M., Schulz, H., Stein, H., Solf, K., Schulz, K. H., and Heesen, C. Responsiveness of patient-based and external rating scales in multiple sclerosis: head-to-head comparison in three clinical settings. *Journal of the Neurological Sciences*. 3-15-2010;290(1-2):102-106.

Gonzalez, J. S., Peyrot, M., McCarl, L. A., Collins, E. M., Serpa, L., Mimiaga, M. J., and Safren, S. A. Depression and diabetes treatment nonadherence: a meta-analysis. [Review] [40 refs]. *Diabetes Care*. 2008;31(12):2398-2403.

Gonzalez, J. S., Safren, S. A., Delahanty, L. M., Cagliero, E., Wexler, D. J., Meigs, J. B., and Grant, R. W. Symptoms of depression prospectively predict poorer self-care in patients with Type 2 diabetes. *Diabetic Medicine*. 2008;25(9):1102-1107.

Grant, R. W., Wald, J. S., Schnipper, J. L., Gandhi, T. K., Poon, E. G., Orav, E. J., Williams, D. H., Volk, L. A., and Middleton, B. Practice-linked online personal health records for type 2 diabetes mellitus: a randomized controlled trial. *Archives of Internal Medicine*. 9-8-2008;168(16):1776-1782.

Graziano, J. A. and Gross, C. R. A randomized controlled trial of an automated telephone intervention to improve glycemic control in type 2 diabetes. *Advances in Nursing Science*. 2009;32(3):E42-E57.

Gredal, C., Rosenfalck, A., Dejgaard, A., and Hilsted, J. Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;80(2):293-298.

Greenberg, I., Stampfer, M. J., Schwarzfuchs, D., Shai, I., and DIRECT Group. Adherence and success in long-term weight loss diets: the dietary intervention randomized controlled trial (DIRECT). *Journal of the American College of Nutrition*. 2009;28(2):159-168.

Gross, C. C., Scain, S. F., Scheffel, R., Gross, J. L., and Hutz, C. S. Brazilian version of the Problem Areas in Diabetes Scale (B-PAID): validation and identification of individuals at high risk for emotional distress. *Diabetes Research & Clinical Practice*. 2007;76(3):455-459.

Gucciardi, E., DeMelo, M., Booth, G., Tomlinson, G., and Stewart, D. E. Individual and contextual factors associated with follow-up use of diabetes self-management education programmes: a multisite prospective analysis. *Diabetic Medicine*. 2009;26(5):510-517.

Gulmez, O., Yildirim, A., Bal, U., Konas, N. D., Aydin, A., Demir, O., Atar, I., Ertan, C., Ozin, B., and Muderrisoglu, H. Assessment of biochemical aspirin resistance at rest and immediately after exercise testing. *Blood Coagulation & Fibrinolysis*. 2007;18(1):9-13.

Gunther, A. L., Liese, A. D., Bell, R. A., Dabelea, D., Lawrence, J. M., Rodriguez, B. L., Standiford, D. A., and Mayer-Davis, E. J. Association between the dietary approaches to hypertension diet and hypertension in youth with diabetes mellitus. *Hypertension*. 2009;53(1):6-12.

Guo, X., Zhou, B., Nishimura, T., Teramukai, S., and Fukushima, M. Clinical effect of qigong practice on essential hypertension: a meta-analysis of randomized controlled trials. [Review] [37 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(1):27-37.

Hall, A. M., Maher, C. G., Latimer, J., Ferreira, M. L., and Lam, P. A randomized controlled trial of tai chi for long-term low back pain (TAI CHI): study rationale, design, and methods. *BMC Musculoskeletal Disorders*. 2009;10:55.

Halm, J. and Amoako, E. Physical activity recommendation for hypertension management: does healthcare provider advice make a difference?.[Summary for patients in *Ethn Dis*. 2008 Summer;18(3):389; PMID: 18788117]. *Ethnicity & Disease*. 2008;18(3):278-282.

Hanssen, T. A., Nordrehaug, J. E., Eide, G. E., and Hanestad, B. R. Improving outcomes after myocardial infarction: a randomized controlled trial evaluating effects of a telephone follow-up intervention. *European Journal of Cardiovascular Prevention & Rehabilitation*. 2007;14(3):429-437.

Harris, M. A., Freeman, K. A., and Beers, M. Family therapy for adolescents with poorly controlled diabetes: initial test of clinical significance. *Journal of Pediatric Psychology*. 2009;34(10):1097-1107.

Harris, S., Yale, J. F., Dempsey, E., and Gerstein, H. Can family physicians help patients initiate basal insulin therapy successfully?: randomized trial of patient-titrated insulin glargine compared with standard oral therapy: lessons for family practice from the Canadian INSIGHT trial. *Canadian Family Physician*. 2008;54(4):550-558.

Harris, T. J., Victor, C. R., Carey, I. M., Adams, R., and Cook, D. G. Less healthy, but more active: opposing selection biases when recruiting older people to a physical activity study through primary care. *BMC Public Health*. 2008;8:182.

Hattori, Y., Hashizume, K., Nakajima, K., Nishimura, Y., Naka, M., and Miyanaga, K. The effect of long-term treatment with sulindac on the progression of diabetic retinopathy. *Current Medical Research & Opinion*. 2007;23(8):1913-1917.

Hatzichristou, D., Gambla, M., Rubio-Aurioles, E., Buvat, J., Brock, G. B., Spera, G., Rose, L., Lording, D., and Liang, S. Efficacy of tadalafil once daily in men with diabetes mellitus and erectile dysfunction. *Diabetic Medicine*. 2008;25(2):138-146.

Hawkes, A. L., Gollschewski, S., Lynch, B. M., and Chambers, S. A telephone-delivered lifestyle intervention for colorectal cancer survivors 'CanChange': a pilot study. *Psycho-Oncology*. 2009;18(4):449-455.

Hayes, R. P. and Fitzgerald, J. T. Perceptions and attitudes are primary contributors to insulin delivery system satisfaction in people with type 2 diabetes. *Diabetes Technology & Therapeutics*. 2009;11(7):419-426.

Hayes, R. P., Nakano, M., Muchmore, D., and Schmitke, J. Effect of standard (self-directed) training versus intensive training for Lilly/Alkermes human insulin inhalation powder delivery system on patient-reported outcomes and patient evaluation of the system. *Diabetes Technology & Therapeutics*. 2007;9(1):89-98.

Hollis, J. F., Gullion, C. M., Stevens, V. J., Brantley, P. J., Appel, L. J., Ard, J. D., Champagne, C. M., Dalcin, A., Erlinger, T. P., Funk, K., Laferriere, D., Lin, P. H., Loria, C. M., Samuel-Hodge, C., Vollmer, W. M., Svetkey, L. P., and Weight Loss Maintenance Trial Research Group. Weight loss during the intensive intervention phase of the weight-loss maintenance trial. *American Journal of Preventive Medicine*. 2008;35(2):118-126.

Hornsten, A., Stenlund, H., Lundman, B., and Sandstrom, H. Improvements in HbA1c remain after 5 years--a follow up of an educational intervention focusing on patients' personal understandings of type 2 diabetes. *Diabetes Research & Clinical Practice*. 2008;81(1):50-55.

Houlden, R., Ross, S., Harris, S., Yale, J. F., Sauriol, L., and Gerstein, H. C. Treatment satisfaction and quality of life using an early insulinization strategy with insulin glargine compared to an adjusted oral therapy in the management of Type 2 diabetes: the Canadian INSIGHT Study. *Diabetes Research & Clinical Practice*. 2007;78(2):254-258.

Houweling, S. T., Kleefstra, N., van Hateren, K. J., Kooy, A., Groenier, K. H., Ten Vergert, E., Meyboom-de Jong, B., Bilo, H. J., and Langerhans Medical Research Group. Diabetes specialist nurse as main care provider for patients with type 2 diabetes. *Netherlands Journal of Medicine*. 2009;67(7):279-284.

Huberty, J. L., Vener, J., Waltman, N., Ott, C., Twiss, J., Gross, G., McGuire, R., and Dwyer, A. Development of an instrument to measure adherence to strength training in postmenopausal breast cancer survivors. *Oncology Nursing Forum*. 2009;36(5):E266-E273.

Huffman, F. G., Vaccaro, J. A., Nath, S., and Zarini, G. G. Diabetes self management: are Cuban Americans receiving quality health care?. *Journal of Health & Human Services Administration*. 2009;32(3):278-304.

Ingrid, B. and Marsella, A. Factors influencing exercise participation by clients in long-term care. *Perspectives*. 2008;32(4):5-11.

Inskip, H. M., Crozier, S. R., Godfrey, K. M., Borland, S. E., Cooper, C., Robinson, S. M., and Southampton Women's Survey Study Group. Women's compliance with nutrition and lifestyle recommendations before pregnancy: general population cohort study. *BMJ*. 2009;338:b481.

Irwin, M. R., Olmstead, R., and Motivala, S. J. Improving sleep quality in older adults with moderate sleep complaints: A randomized controlled trial of Tai Chi Chih. *Sleep*. 7-1-2008;31(7):1001-1008.

Jacobsen, P. B., Donovan, K. A., Vadaparampil, S. T., and Small, B. J. Systematic review and meta-analysis of psychological and activity-based interventions for cancer-related fatigue. [Review] [70 refs][Erratum appears in *Health Psychol*. 2008 Jan;27(1):42]. *Health Psychology*. 2007;26(6):660-667.

Jang, H. C., Guler, S., Shestakova, M., and PRESENT Study Group. When glycaemic targets can no longer be achieved with basal insulin in type 2 diabetes, can simple intensification with a modern premixed insulin help? Results from a subanalysis of the PRESENT study. *International Journal of Clinical Practice*. 2008;62(7):1013-1018.

Jang, H. C., Lee, S. R., and Vaz, J. A. Biphasic insulin aspart 30 in the treatment of elderly patients with type 2 diabetes: a subgroup analysis of the PRESENT Korea NovoMixstudy. *Diabetes, Obesity & Metabolism*. 2009;11(1):20-26.

Johnson, C. L., Nicholas, A., Divine, H., Perrier, D. G., Blumenschein, K., and Steinke, D. T. Outcomes from DiabetesCARE: a pharmacist-provided diabetes management service. *Journal of the American Pharmacists Association: JAPhA*. 2008;48(6):722-730.

Johnson, R. E., Jones, G. T., Wiles, N. J., Chaddock, C., Potter, R. G., Roberts, C., Symmons, D. P., Watson, P. J., Torgerson, D. J., and Macfarlane, G. J. Active exercise, education, and cognitive behavioral therapy for persistent disabling low back pain: a randomized controlled trial. *Spine*. 7-1-2007;32(15):1578-1585.

Jones, M. I., Greenfield, S., Jolly, K., and BRUM Trial Steering Committee. Patients' experience of home and hospital based cardiac rehabilitation: a focus group study. *European Journal of Cardiovascular Nursing*. 2009;8(1):9-17.

Joshy, G., Colonne, C. K., Dunn, P., Simmons, D., and Lawrenson, R. Ethnic disparities in causes of death among diabetes patients in the Waikato region of New Zealand. *New Zealand Medical Journal*. 2010;123(1310):19-29.

Joy, S. V. Clinical pearls and strategies to optimize patient outcomes. *Diabetes Educator*. 2008;34:Suppl-59S.

Kadoglou, N. P., Tsanikidis, H., Kapelouzou, A., Vrabas, I., Vitta, I., Karayannacos, P. E., Liapis, C. D., and Sailer, N. Effects of rosiglitazone and metformin treatment on apelin, visfatin, and ghrelin levels in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2010;59(3):373-379.

Kalsekar, I., Sheehan, C., and Peak, A. Utilization patterns and medication adherence in patients with type 2 diabetes: variations based on type of pharmacy (chain vs independent). *Research In Social & Administrative Pharmacy*. 2007;3(4):378-391.

Karl, D., Philis-Tsimikas, A., Darsow, T., Lorenzi, G., Kellmeyer, T., Lutz, K., Wang, Y., and Frias, J. P. Pramlintide as an adjunct to insulin in patients with type 2 diabetes in a clinical practice setting reduced A1C, postprandial glucose excursions, and weight. *Diabetes Technology & Therapeutics*. 2007;9(2):191-199.

Karve, S., Cleves, M. A., Helm, M., Hudson, T. J., West, D. S., and Martin, B. C. An empirical basis for standardizing adherence measures derived from administrative claims data among diabetic patients. *Medical Care*. 2008;46(11):1125-1133.

Kelley, K. and Dempsey, C. An evaluation of an insulin transfer programme delivered in a group setting. *Journal of Clinical Nursing*. 2007;16(7B):152-158.

Kerssen, A., Goudswaard, A. N., Quartel, M., Zuithoff, N. P., and Rutten, G. E. The feasibility of a self-management education program for patients with type 2 diabetes mellitus: Do the perceptions of patients and educators match?. *Primary care diabetes*. 2009;3(2):79-83.

Kindmalm, L., Melander, A., and Nilsson, J. L. Refill adherence of antihyperglycaemic drugs related to glucose control (HbA1c) in patients with type 2 diabetes. *Acta Diabetologica*. 2007;44(4):209-213.

King, D. E., Mainous, A. G., III, Carnemolla, M., and Everett, C. J. Adherence to healthy lifestyle habits in US adults, 1988-2006. *American Journal of Medicine*. 2009;122(6):528-534.

Kipnes, M. S., Joseph, H., Morris, H., Manko, J., and Bell, D. E. Clinical performance of the TRUE2go blood glucose system--a novel integrated system for meter and strips. *Diabetes Technology & Therapeutics*. 2009;11(10):649-655.

Kloos, C., Samann, A., Lehmann, T., Braun, A., Heckmann, B., and Muller, U. A. Flexible intensive versus conventional insulin therapy in insulin-naïve adults with type 2 diabetes: an open-label, randomized, controlled, crossover clinical trial of metabolic control and patient preference. *Diabetes Care*. 2007;30(12):3031-3032.

Knobloch, K., Schreibueller, L., Longo, U. G., and Vogt, P. M. Eccentric exercises for the management of tendinopathy of the main body of the Achilles tendon with or without an AirHeel Brace. A randomized controlled trial. B: Effects of compliance. *Disability & Rehabilitation*. 2008;30(20-22):1692-1696.

Koc, Z., Ozcakil, S., Sivrioglu, K., Gurbet, A., and Kucukoglu, S. Effectiveness of physical therapy and epidural steroid injections in lumbar spinal stenosis. *Spine*. 5-1-2009;34(10):985-989.

Kontos, P. C., Miller, K. L., Brooks, D., Jassal, S. V., Spanjevic, L., Devins, G. M., De Souza, M. J., Heck, C., Laprade, J., and Naglie, G. Factors influencing exercise participation by older adults requiring chronic hemodialysis: a qualitative study. *International Urology & Nephrology*. 2007;39(4):1303-1311.

Krousel-Wood, M. A., Berger, L., Jiang, X., Blonde, L., Myers, L., and Webber, L. Does home-based exercise improve body mass index in patients with type 2 diabetes? Results of a feasibility trial. *Diabetes Research & Clinical Practice*. 2008;79(2):230-236.

Latifpour, D. H., Grenner, J., and Sjodahl, C. The effect of a new treatment based on somatosensory stimulation in a group of patients with somatically related tinnitus. *International Tinnitus Journal*. 2009;15(1):94-99.

Latka, R. N., Alvarez-Reeves, M., Cadmus, L., and Irwin, M. L. Adherence to a randomized controlled trial of aerobic exercise in breast cancer survivors: the Yale exercise and survivorship study. *Journal of Cancer Survivorship*. 2009;3(3):148-157.

Lawton, J., Peel, E., Parry, O., and Douglas, M. Patients' perceptions and experiences of taking oral glucose-lowering agents: a longitudinal qualitative study. *Diabetic Medicine*. 2008;25(4):491-495.

Lee, I. T., Liao, Y. J., Lee, W. J., Huang, C. N., and Sheu, W. H. Continuous subcutaneous insulin infusion providing better glycemic control and quality of life in Type 2 diabetic subjects hospitalized for marked hyperglycemia. *Journal of Evaluation in Clinical Practice*. 2010;16(1):202-205.

Lee, S. H. and Lee, B. C. Electroacupuncture relieves pain in men with chronic prostatitis/chronic pelvic pain syndrome: three-arm randomized trial. *Urology*. 2009;73(5):1036-1041.

Lee, S. J., Choi, E. J., and Kwon, J. S. A naturalistic multicenter trial of a 12-week weight management program for overweight and obese patients with schizophrenia or schizoaffective disorder. *Journal of Clinical Psychiatry*. 2008;69(4):555-562.

Lee, T. I., Yeh, Y. T., Liu, C. T., and Chen, P. L. Development and evaluation of a patient-oriented education system for diabetes management. *International Journal of Medical Informatics*. 2007;76(9):655-663.

Lemmetty, R. and Makela, K. Mobile digital fundus screening of type 2 diabetes patients in the Finnish county of South-Ostrobothnia. *Journal of Telemedicine & Telecare*. 2009;15(2):68-72.

Lenfant, C. Can prevention of hypertension work?. *American Journal of Therapeutics*. 2008;15(4):334-339.

Leonhardt, C., Keller, S., Chenot, J. F., Luckmann, J., Basler, H. D., Wegscheider, K., Baum, E., Donner-Banzhoff, N., Pflingsten, M., Hildebrandt, J., Kochen, M. M., and Becker, A. TTM-based motivational counselling does not increase physical activity of low back pain patients in a primary care setting--A cluster-randomized controlled trial. *Patient Education & Counseling*. 2008;70(1):50-60.

Lera, S., Gelman, S. M., Lopez, M. J., Abenoza, M., Zorrilla, J. G., Castro-Fornieles, J., and Salamero, M. Multidisciplinary treatment of fibromyalgia: does cognitive behavior therapy increase the response to treatment?. *Journal of Psychosomatic Research*. 2009;67(5):433-441.

Leung, Y. W., Grewal, K., Stewart, D. E., and Grace, S. L. Gender differences in motivations and perceived effects of Mind-Body Therapy (MBT) practice and views on integrative cardiac rehabilitation among acute coronary syndrome patients: why do women use MBT?. *Complementary Therapies in Medicine*. 2008;16(6):311-317.

Liebl, A. Insulin intensification--the rationale and the target. [Review] [27 refs]. *International Journal of Clinical Practice*. 2009;Supplement.(164):1-5.

Liese, A. D., Liu, L., Davis, C., Standiford, D., Waitzfelder, B., Dabelea, D., Bell, R., Williams, D., Imperatore, G., and Lawrence, J. M. Participation in pediatric epidemiologic research: the SEARCH for Diabetes in Youth Study experience. *Contemporary Clinical Trials*. 2008;29(6):829-836.

Liese, A. D., Nichols, M., Sun, X., D'Agostino, R. B., Jr., and Haffner, S. M. Adherence to the DASH Diet is inversely associated with incidence of type 2 diabetes: the insulin resistance atherosclerosis study. *Diabetes Care*. 2009;32(8):1434-1436.

Lim, S. S., Norman, R. J., Clifton, P. M., and Noakes, M. Psychological effects of prescriptive vs general lifestyle advice for weight loss in young women. *Journal of the American Dietetic Association*. 2009;109(11):1917-1921.

Lingvay, I., Kaloyanova, P. F., Adams-Huet, B., Salinas, K., and Raskin, P. Insulin as initial therapy in type 2 diabetes: effective, safe, and well accepted. *Journal of Investigative Medicine*. 2007;55(2):62-68.

Lucia, A., Smith, L., Naidoo, M., Gonzalez-Freire, M., Perez, M., Rubio, J. C., Martin, M. A., Andreu, A. L., and Arenas, J. McArdle disease: another systemic low-inflammation disorder?. *Neuroscience Letters*. 1-31-2008;431(2):106-111.

Lund, S. S., Tarnow, L., Stehouwer, C. D., Schalkwijk, C. G., Frandsen, M., Smidt, U. M., Pedersen, O., Parving, H. H., and Vaag, A. Targeting hyperglycaemia with either metformin or repaglinide in non-obese patients with type 2 diabetes: results from a randomized crossover trial. *Diabetes, Obesity & Metabolism*. 2007;9(3):394-407.

Lundgren, T., Dahl, J., Yardi, N., and Melin, L. Acceptance and Commitment Therapy and yoga for drug-refractory epilepsy: a randomized controlled trial. *Epilepsy & Behavior*. 2008;13(1):102-108.

Maddocks, M., Mockett, S., and Wilcock, A. Is exercise an acceptable and practical therapy for people with or cured of cancer? A systematic review. [Review] [73 refs]. *Cancer Treatment Reviews*. 2009;35(4):383-390.

Malanda, U. L., Bot, S. D., Kostense, P. J., Snoek, F. J., Dekker, J. M., and Nijpels, G. Effects of self-monitoring of glucose in non-insulin treated patients with type 2 diabetes: design of the IN CONTROL-trial. *BMC Family Practice*. 2009;10:26.

Malpass, A., Andrews, R., and Turner, K. M. Patients with Type 2 Diabetes experiences of making multiple lifestyle changes: a qualitative study. *Patient Education & Counseling*. 2009;74(2):258-263.

Marrero, D. G. Overcoming patient barriers to initiating insulin therapy in type 2 diabetes mellitus. [Review] [28 refs]. *Clinical Cornerstone*. 1941;8(2):33-40.

Marshall, J. G., Cowell, J. M., Campbell, E. S., and McNaughton, D. B. Regional variations in cancer screening rates found in women with diabetes. *Nursing Research*. 2010;59(1):34-41.

Martin, S., Kolb, H., Schneider, B., Heinemann, L., Weber, C., Kocher, S., Tshiananga, J. K., Scherbaum, W. A., and Lodwig, V. Myocardial infarction and stroke in early years after diagnosis of type 2 diabetes: risk factors and relation to self-monitoring of blood glucose. *Diabetes Technology & Therapeutics*. 2009;11(4):234-241.

Martinez, L., Consoli, S. M., Monnier, L., Simon, D., Wong, O., Yomtov, B., Gueron, B., Benmedjahed, K., Guillemin, I., and Arnould, B. Studying the Hurdles of Insulin Prescription (SHIP): development, scoring and initial validation of a new self-administered questionnaire. *Health & Quality of Life Outcomes*. 2007;5:53.

Martinez, Y. V., Prado-Aguilar, C. A., Rascon-Pacheco, R. A., and Valdivia-Martinez, J. J. Quality of life associated with treatment adherence in patients with type 2 diabetes: a cross-sectional study. *BMC Health Services Research*. 2008;8:164.

Martinez-Gonzalez, M. A., Fuente-Arrillaga, C., Nunez-Cordoba, J. M., Basterra-Gortari, F. J., Beunza, J. J., Vazquez, Z., Benito, S., Tortosa, A., and Bes-Rastrollo, M. Adherence to Mediterranean diet and risk of developing diabetes: prospective cohort study. *BMJ*. 6-14-2008;336(7657):1348-1351.

May, A. M., Duivenvoorden, H. J., Korstjens, I., van Weert, E., Hoekstra-Weebers, J. E., van den Borne, B., Mesters, I., van der Schans, C. P., and Ros, W. J. The effect of group cohesion on rehabilitation outcome in cancer survivors. *Psycho-Oncology*. 2008;17(9):917-925.

McConnon, A., Kirk, S. F., and Ransley, J. K. Process evaluation of an internet-based resource for weight control: use and views of an obese sample. *Journal of Nutrition Education & Behavior*. 2009;41(4):261-267.

McDowell, J. R., McPhail, K., Halyburton, G., Brown, M., and Lindsay, G. Perceptions of a service redesign by adults living with type 2 diabetes. *Journal of Advanced Nursing*. 2009;65(7):1432-1441.

McLachlan, K., Jenkins, A., and O'Neal, D. The role of continuous glucose monitoring in clinical decision-making in diabetes in pregnancy. *Australian & New Zealand Journal of Obstetrics & Gynaecology*. 2007;47(3):186-190.

Menard, J., Payette, H., Dubuc, N., Baillargeon, J. P., Maheux, P., and Ardilouze, J. L. Quality of life in type 2 diabetes patients under intensive multitherapy. *Diabetes & Metabolism*. 2007;33(1):54-60.

Mishali, M., Sominsky, L., and Heymann, A. D. Reducing resistance to diabetes treatment using short narrative interventions. *Family Practice*. 2010;27(2):192-197.

- Monahan, P. O., Lane, K. A., Hayes, R. P., McHorney, C. A., and Marrero, D. G. Reliability and validity of an instrument for assessing patients' perceptions about medications for diabetes: the PAM-D. *Quality of Life Research*. 2009;18(7):941-952.
- Moreira, E. D., Jr., Neves, R. C., Nunes, Z. O., de Almeida, M. C., Mendes, A. B., Fittipaldi, J. A., Ablan, F., and Venezuelan Diabetes Investigators' Group. Glycemic control and its correlates in patients with diabetes in Venezuela: results from a nationwide survey. *Diabetes Research & Clinical Practice*. 2010;87(3):407-414.
- Moro, J. A., Almenar, L., Martnez-Dolz, L., Agüero, J., Sanchez-Lazaro, I., Iglesias, P., Igual, V., and Salvador, A. Support program for heart transplant patients: initial experience. *Transplantation Proceedings*. 2008;40(9):3039-3040.
- Mukherjee, A. K., Reddy, V. S., Shah, S., Jhingan, A. K., Ramakrishnan, P., Prusty, V., and Singh, N. S. Quality of life as a key indicator of patient satisfaction and treatment compliance in people with type 2 diabetes mellitus in the IMPROVE study: a multicentre, open label, non-randomised, observational trial. *Journal of the Indian Medical Association*. 2009;107(7):464-470.
- Mullan, R. J., Montori, V. M., Shah, N. D., Christianson, T. J., Bryant, S. C., Guyatt, G. H., Perestelo-Perez, L. I., Stroebe, R. J., Yawn, B. P., Yapuncich, V., Breslin, M. A., Pencille, L., and Smith, S. A. The diabetes mellitus medication choice decision aid: a randomized trial. *Archives of Internal Medicine*. 2009;169(17):1560-1568.
- Nansel, T. R., Anderson, B. J., Laffel, L. M., Simons-Morton, B. G., Weissberg-Benchell, J., Wysocki, T., Iannotti, R. J., Holmbeck, G. N., Hood, K. K., and Lochrie, A. S. A multisite trial of a clinic-integrated intervention for promoting family management of pediatric type 1 diabetes: feasibility and design. *Pediatric Diabetes*. 2009;10(2):105-115.
- Nantel, J., Termoz, N., Vendittoli, P. A., Lavigne, M., and Prince, F. Gait patterns after total hip arthroplasty and surface replacement arthroplasty. *Archives of Physical Medicine & Rehabilitation*. 2009;90(3):463-469.
- Neutel, J. M., Kereiakes, D. J., Waverczak, W. F., Stoakes, K. A., Xu, J., and Shojaee, A. Effects of an olmesartan medoxomil based treatment algorithm on 24-hour blood pressure control in patients with hypertension and type 2 diabetes. *Current Medical Research & Opinion*. 2010;26(3):721-728.
- Nikkanen, T., Timonen, M., Ylitalo, K., Timonen, O., Keinänen-Kiukaanniemi, S., and Rajala, U. Quality of diabetes care among patients managed by teleconsultation. *Journal of Telemedicine & Telecare*. 2008;14(6):295-299.
- Ninomiya, T., Perkovic, V., de Galan, B. E., Zoungas, S., Pillai, A., Jardine, M., Patel, A., Cass, A., Neal, B., Poulter, N., Mogensen, C. E., Cooper, M., Marre, M., Williams, B., Hamet, P., Mancina, G., Woodward, M., Macmahon, S., Chalmers, J., and ADVANCE Collaborative Group. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. *Journal of the American Society of Nephrology*. 2009;20(8):1813-1821.
- O'Shea, S. D., Taylor, N. F., and Paratz, J. D. .. But watch out for the weather: factors affecting adherence to progressive resistance exercise for persons with COPD. *Journal of Cardiopulmonary Rehabilitation & Prevention*. 2007;27(3):166-174.
- O'Sullivan, T. L., Fortier, M. S., Faubert, C., Culver, D., Blanchard, C., Reid, R., and Hogg, W. E. Interdisciplinary physical activity counseling in primary care: a qualitative inquiry of the patient experience. *Journal of Health Psychology*. 2010;15(3):362-372.
- Odegard, P. S. and Gray, S. L. Barriers to medication adherence in poorly controlled diabetes mellitus. *Diabetes Educator*. 2008;34(4):692-697.
- Olivarius, N. F., Siersma, V., Hansen, L. J., Drivsholm, T., and Horder, M. Changes in levels of haemoglobin A1c during the first 6 years after diagnosis of clinical type 2 diabetes. *Scandinavian Journal of Clinical & Laboratory Investigation*. 2009;69(8):851-857.

Palmer, A. J., Valentine, W. J., Chen, R., Mehin, N., Gabriel, S., Bregman, B., and Rodby, R. A. A health economic analysis of screening and optimal treatment of nephropathy in patients with type 2 diabetes and hypertension in the USA. *Nephrology Dialysis Transplantation*. 2008;23(4):1216-1223.

Palmer, J. L., Gibbs, M., Scheijbeler, H. W., Kotchie, R. W., Nielsen, S., White, J., and Valentine, W. J. Cost-effectiveness of switching to biphasic insulin aspart in poorly-controlled type 2 diabetes patients in China. *Advances in Therapy*. 2008;25(8):752-774.

Paltiel, H., Solvoll, E., Loge, J. H., Kaasa, S., and Oldervoll, L. "The healthy me appears": palliative cancer patients' experiences of participation in a physical group exercise program. *Palliative & Supportive Care*. 2009;7(4):459-467.

Pan, C. Y. and Landen, H. Post-marketing surveillance of acarbose treatment in patients with type 2 diabetes mellitus and subjects with impaired glucose tolerance in China. *Clinical Drug Investigation*. 2007;27(6):397-405.

Panton, L. B., Figueroa, A., Kingsley, J. D., Hornbuckle, L., Wilson, J., St John, N., Abood, D., Mathis, R., VanTassel, J., and McMillan, V. Effects of resistance training and chiropractic treatment in women with fibromyalgia. *Journal of Alternative & Complementary Medicine*. 2009;15(3):321-328.

Parkner, T., Moller, M. K., Chen, J. W., Laursen, T., Jorgensen, C., Smedegaard, J. S., Lauritzen, T., and Christiansen, J. S. Overnight CSII as supplement to oral antidiabetic drugs in type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(7):556-563.

Pearce, K. A., Love, M. M., Shelton, B. J., Schoenberg, N. E., Williamson, M. A., Barron, M. A., Houlihan, J. M., and Kentucky, Ambulatory Network. Cardiovascular risk education and social support (CaRESS): report of a randomized controlled trial from the Kentucky Ambulatory Network (KAN). *Journal of the American Board of Family Medicine: JABFM*. 2008;21(4):269-281.

Perez-Iglesias, R., Crespo-Facorro, B., Amado, J. A., Garcia-Unzueta, M. T., Ramirez-Bonilla, M. L., Gonzalez-Blanch, C., Martinez-Garcia, O., and Vazquez-Barquero, J. L. A 12-week randomized clinical trial to evaluate metabolic changes in drug-naïve, first-episode psychosis patients treated with haloperidol, olanzapine, or risperidone. *Journal of Clinical Psychiatry*. 2007;68(11):1733-1740.

Petrak, F., Stridde, E., Leverkus, F., Crispin, A. A., Forst, T., and Pflutzner, A. Development and validation of a new measure to evaluate psychological resistance to insulin treatment. *Diabetes Care*. 2007;30(9):2199-2204.

Peyrot, M. and Rubin, R. R. Effect of technosphere inhaled insulin on quality of life and treatment satisfaction. *Diabetes Technology & Therapeutics*. 2010;12(1):49-55.

Pfeffer, M. A., Burdmann, E. A., Chen, C. Y., Cooper, M. E., de Zeeuw, D., Eckardt, K. U., Ivanovich, P., Kewalramani, R., Levey, A. S., Lewis, E. F., McGill, J., McMurray, J. J., Parfrey, P., Parving, H. H., Remuzzi, G., Singh, A. K., Solomon, S. D., Toto, R., Uno, H., and TREAT, Investigators. Baseline characteristics in the Trial to Reduce Cardiovascular Events With Aranesp Therapy (TREAT). *American Journal of Kidney Diseases*. 2009;54(1):59-69.

Piaggese, A., Macchiarini, S., Rizzo, L., Palumbo, F., Tedeschi, A., Nobili, L. A., Leporati, E., Scire, V., Teobaldi, I., and Del Prato, S. An off-the-shelf instant contact casting device for the management of diabetic foot ulcers: a randomized prospective trial versus traditional fiberglass cast. *Diabetes Care*. 2007;30(3):586-590.

Pinto, B. M., Rabin, C., and Dunsiger, S. Home-based exercise among cancer survivors: adherence and its predictors. *Psycho-Oncology*. 2009;18(4):369-376.

Pollack, M. F., Purayidathil, F. W., Bolge, S. C., and Williams, S. A. Patient-reported tolerability issues with oral antidiabetic agents: Associations with adherence; treatment satisfaction and health-related quality of life. *Diabetes Research & Clinical Practice*. 2010;87(2):204-210.

Prado-Aguilar, C. A., Martinez, Y. V., Segovia-Bernal, Y., Reyes-Martinez, R., and Arias-Ulloa, R. Performance of two questionnaires to measure treatment adherence in patients with Type-2 diabetes. *BMC Public Health*. 2009;9:38.

Priebe, M. G., van Binsbergen, J. J., de Vos, R., and Vonk, R. J. Whole grain foods for the prevention of type 2 diabetes mellitus. [Review] [62 refs]. *Cochrane Database of Systematic Reviews*. 2008;(1):CD006061.

Quinn, C. C., Clough, S. S., Minor, J. M., Lender, D., Okafor, M. C., and Gruber-Baldini, A. WellDoc mobile diabetes management randomized controlled trial: change in clinical and behavioral outcomes and patient and physician satisfaction. *Diabetes Technology & Therapeutics*. 2008;10(3):160-168.

Rana, A. K., Lundborg, C. S., Wahlin, A., Ahmed, S. M., and Kabir, Z. N. The impact of health education in managing self-reported arthritis-related illness among elderly persons in rural Bangladesh. *Health Education Research*. 2008;23(1):94-105.

Rattanachaiyanont, M. and Kuptniratsaikul, V. No additional benefit of shortwave diathermy over exercise program for knee osteoarthritis in peri-/post-menopausal women: an equivalence trial. *Osteoarthritis & Cartilage*. 2008;16(7):823-828.

Reimer, T., Hohberg, C., Pfitzner, A. H., Jorgensen, C., Jensen, K. H., and Pfitzner, A. Intuitiveness, instruction time, and patient acceptance of a prefilled insulin delivery device and a reusable insulin delivery device in a randomized, open-label, crossover handling study in patients with type 2 diabetes. *Clinical Therapeutics*. 2008;30(12):2252-2262.

Reinehr, T., Schober, E., Roth, C. L., Wiegand, S., Holl, R., and DPV-Wiss Study Group. Type 2 diabetes in children and adolescents in a 2-year follow-up: insufficient adherence to diabetes centers. *Hormone Research*. 2008;69(2):107-113.

Rhodes, R. E., Warburton, D. E., and Bredin, S. S. Predicting the effect of interactive video bikes on exercise adherence: An efficacy trial. *Psychology Health & Medicine*. 2009;14(6):631-640.

Rivellese, A. A., Boemi, M., Cavalot, F., Costagliola, L., De Feo, P., Miccoli, R., Patti, L., Trovati, M., Vaccaro, O., Zavaroni, I., and Mind.it Study Group. Dietary habits in type II diabetes mellitus: how is adherence to dietary recommendations?. *European Journal of Clinical Nutrition*. 2008;62(5):660-664.

Roek, M. G., Welschen, L. M., Kostense, P. J., Dekker, J. M., Snoek, F. J., and Nijpels, G. Web-based guided insulin self-titration in patients with type 2 diabetes: the Di@log study. Design of a cluster randomised controlled trial [TC1316]. *BMC Family Practice*. 2009;10:40.

Roijezon, U., Bjorklund, M., Bergenheim, M., and Djupsjobacka, M. A novel method for neck coordination exercise--a pilot study on persons with chronic non-specific neck pain. *Journal of Neuroengineering & Rehabilitation*. 2008;5:36.

Rome, A., Persson, U., Ekdahl, C., and Gard, G. Willingness to pay for health improvements of physical activity on prescription. *Scandinavian Journal of Public Health*. 2010;38(2):151-159.

Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., and Schweizer, A. Comparison of vildagliptin and rosiglitazone monotherapy in patients with type 2 diabetes: a 24-week, double-blind, randomized trial.[Erratum appears in *Diabetes Care*. 2007 May;30(5):1330]. *Diabetes Care*. 2007;30(2):217-223.

Rosenstock, J., Cefalu, W. T., Hollander, P. A., Klioze, S. S., Reis, J., and Duggan, W. T. Safety and efficacy of inhaled human insulin (exubera) during discontinuation and readministration of therapy in adults with type 2 diabetes: a 3-year randomized controlled trial. *Diabetes Technology & Therapeutics*. 2009;11(11):697-705.

Royle, P., Waugh, N., Deakin, M., and Philip, S. WITHDRAWN: Inhaled insulin in diabetes mellitus. [Review] [52 refs][Update of *Cochrane Database Syst Rev*. 2004;(3):CD003890; PMID: 15266506]. *Cochrane Database of Systematic Reviews*. 2009;(1):CD003890.

Rubin, R. R. and Peyrot, M. Assessing treatment satisfaction in patients treated with pramlintide as an adjunct to insulin therapy. *Current Medical Research & Opinion*. 2007;23(8):1919-1929.

Ruiz, M. A., Pardo, A., Rejas, J., Soto, J., Villasante, F., and Aranguren, J. L. Development and validation of the "Treatment Satisfaction with Medicines Questionnaire" (SATMED-Q). *Value in Health*. 2008;11(5):913-926.

Russell, K. L. and Bray, S. R. Self-determined motivation predicts independent, home-based exercise following cardiac rehabilitation. *Rehabilitation Psychology*. 2009;54(2):150-156.

Sacco, W. P., Wells, K. J., Friedman, A., Matthew, R., Perez, S., and Vaughan, C. A. Adherence, body mass index, and depression in adults with type 2 diabetes: the mediational role of diabetes symptoms and self-efficacy. *Health Psychology*. 2007;26(6):693-700.

Sakraida, T. J. and Robinson, M. V. Health literacy self-management by patients with type 2 diabetes and stage 3 chronic kidney disease. *Western Journal of Nursing Research*. 2009;31(5):627-647.

Salvetti, X. M., Oliveira, J. A., Servantes, D. M., and Vincenzo de Paola, A. A. How much do the benefits cost? Effects of a home-based training programme on cardiovascular fitness, quality of life, programme cost and adherence for patients with coronary disease. *Clinical Rehabilitation*. 2008;22(10-11):987-996.

Samoutis, G. A., Soteriades, E. S., Stoffers, H. E., Zachariadou, T., Philalithis, A., and Lionis, C. Designing a multifaceted quality improvement intervention in primary care in a country where general practice is seeking recognition: the case of Cyprus. *BMC Health Services Research*. 2008;8:181.

Sanigorski, A. M., Bell, A. C., Kremer, P. J., Cuttler, R., and Swinburn, B. A. Reducing unhealthy weight gain in children through community capacity-building: results of a quasi-experimental intervention program, Be Active Eat Well. *International Journal of Obesity*. 2008;32(7):1060-1067.

Saper, R. B., Sherman, K. J., Cullum-Dugan, D., Davis, R. B., Phillips, R. S., and Culpepper, L. Yoga for chronic low back pain in a predominantly minority population: a pilot randomized controlled trial. *Alternative Therapies in Health & Medicine*. 2009;15(6):18-27.

Scheen, A. J. and Van Gaal, L. F. [Sugar: results of a Belgian observational study on the use of sitagliptin in patients with type 2 diabetes]. [French]. *Revue Medicale de Liege*. 2010;65(3):127-132.

Schiel, R. and Muller, U. A. Efficacy and treatment satisfaction of once-daily insulin glargine plus one or two oral antidiabetic agents versus continuing premixed human insulin in patients with Type 2 diabetes previously on long-term conventional insulin therapy: the SWITCH Pilot Study. *Experimental & Clinical Endocrinology & Diabetes*. 2008;116(1):58-64.

Schillinger, D., Handley, M., Wang, F., and Hammer, H. Effects of self-management support on structure, process, and outcomes among vulnerable patients with diabetes: a three-arm practical clinical trial. *Diabetes Care*. 2009;32(4):559-566.

Schmittiel, J. A., Traylor, A., Uratsu, C. S., Mangione, C. M., Ferrara, A., and Subramanian, U. The association of patient-physician gender concordance with cardiovascular disease risk factor control and treatment in diabetes. *Journal of Women's Health*. 2009;18(12):2065-2070.

Schulz, P. J., Rubinell, S., and Hartung, U. An internet-based approach to enhance self-management of chronic low back pain in the italian-speaking population of Switzerland: results from a pilot study. *International Journal of Public Health*. 2007;52(5):286-294.

Schwartz, S. M., Bansal, V. P., Hale, C., Rossi, M., and Engle, J. P. Compliance, behavior change, and weight loss with orlistat in an over-the-counter setting. *Obesity*. 2008;16(3):623-629.

Schwarz, S. L., Gerich, J. E., Marcellari, A., Jean-Louis, L., Purkayastha, D., and Baron, M. A. Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment-naïve elderly patients with type 2 diabetes. *Diabetes, Obesity & Metabolism*. 2008;10(8):652-660.

Serour, M., Alqhenaei, H., Al Saqabi, S., Mustafa, A. R., and Ben Nakhi, A. Cultural factors and patients' adherence to lifestyle measures. *British Journal of General Practice*. 2007;57(537):291-295.

Shah, S., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shestakova, M., Wenying, Y., Valensi, P., and IMPROVE Study Group. Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup

analysis from the 6-month IMPROVE observational study. *International Journal of Clinical Practice*. 2009;63(4):574-582.

Shah, S., Das, A. K., Kumar, A., Unnikrishnan, A. G., Kalra, S., Baruah, M. P., Ganapathi, B., and Sahay, R. K. Baseline characteristics of the Indian cohort from the IMPROVE study: a multinational, observational study of biphasic insulin aspart 30 treatment for type 2 diabetes. *Advances in Therapy*. 2009;26(3):325-335.

Sharp, L. K., Fitzgibbon, M. L., and Schiffer, L. Recruitment of obese black women into a physical activity and nutrition intervention trial. *Journal of Physical Activity & Health*. 2008;5(6):870-881.

Sharpe, P. A., Blanck, H. M., Williams, J. E., Ainsworth, B. E., and Conway, J. M. Use of complementary and alternative medicine for weight control in the United States. *Journal of Alternative & Complementary Medicine*. 2007;13(2):217-222.

Shay, L. E., Seibert, D., Watts, D., Sbrocco, T., and Pagliara, C. Adherence and weight loss outcomes associated with food-exercise diary preference in a military weight management program. *Eating Behaviors*. 2009;10(4):220-227.

Shepich, J., Slowiak, J. M., and Keniston, A. Do subsidization and monitoring enhance adherence to prescribed exercise?. *American Journal of Health Promotion*. 2007;22(1):2-5.

Shih, H. C., Chou, P., Chen, S. J., Liu, J. H., Lee, F. L., Liu, C. M., and Tung, T. H. A community-based study of the willingness to pay associated with screening for diabetic retinopathy among type 2 diabetes in Kinmen, Taiwan. *Journal of Epidemiology*. 2007;17(6):186-193.

Siegmund, T., Blankenfeld, H., and Schumm-Draeger, P. M. Comparison of usability and patient preference for insulin pen needles produced with different production techniques: "thin-wall" needles compared to "regular-wall" needles: an open-label study. *Diabetes Technology & Therapeutics*. 2009;11(8):523-528.

Sirard, J. R. and Slater, M. E. Compliance with wearing physical activity accelerometers in high school students. *Journal of Physical Activity & Health*. 2009;6:Suppl-55.

Sjosten, N. M., Salonoja, M., Piirtola, M., Vahlberg, T. J., Isoaho, R., Hyttinen, H. K., Aarnio, P. T., and Kivela, S. L. A multifactorial fall prevention programme in the community-dwelling aged: predictors of adherence. *European Journal of Public Health*. 2007;17(5):464-470.

Slack, S. Near patient testing for glycated haemoglobin in people with type 2 diabetes mellitus managed in primary care: acceptability and satisfaction; Impact of self-monitoring of blood glucose in the management of patients with non-insulin-treated diabetes: open parallel group randomized trial. *Annals of Clinical Biochemistry*. 2008;45(Pt:1):1-5.

Slade, S. C. and Keating, J. L. Effects of preferred-exercise prescription compared to usual exercise prescription on outcomes for people with non-specific low back pain: a randomized controlled trial [ACTRN12608000524392]. *BMC Musculoskeletal Disorders*. 2009;10:14.

Smits, J. A., Tart, C. D., Presnell, K., Rosenfield, D., and Otto, M. W. Identifying potential barriers to physical activity adherence: anxiety sensitivity and body mass as predictors of fear during exercise. *Cognitive Behaviour Therapy*. 2010;39(1):28-36.

Song, M. S. and Kim, H. S. Intensive management program to improve glycosylated hemoglobin levels and adherence to diet in patients with type 2 diabetes. *Applied Nursing Research*. 2009;22(1):42-47.

Song, R., Roberts, B. L., Lee, E. O., Lam, P., and Bae, S. C. A randomized study of the effects of t'ai chi on muscle strength, bone mineral density, and fear of falling in women with osteoarthritis. *Journal of Alternative & Complementary Medicine*. 2010;16(3):227-233.

Sopkova, Z., Dorkova, Z., and Tkacova, R. Predictors of compliance with continuous positive airway pressure treatment in patients with obstructive sleep apnea and metabolic syndrome. *Wiener Klinische Wochenschrift*. 2009;121(11-12):398-404.

Sowattanangoon, N., Kochabhakdi, N., and Petrie, K. J. Buddhist values are associated with better diabetes control in Thai patients. *International Journal of Psychiatry in Medicine*. 2008;38(4):481-491.

Sowden, S. L., Breeze, E., Barber, J., and Raine, R. Do general practices provide equitable access to physical activity interventions?. *British Journal of General Practice*. 2008;58(555):e1-e8.

Speroni, K. G., Tea, C., Earley, C., Niehoff, V., and Atherton, M. Evaluation of a pilot hospital-based community program implementing fitness and nutrition education for overweight children. *Journal for Specialists in Pediatric Nursing: JSPN*. 2008;13(3):144-153.

Spinks, A. B., Macpherson, A. K., Bain, C., and McClure, R. J. Compliance with the Australian national physical activity guidelines for children: relationship to overweight status. *Journal of Science & Medicine in Sport*. 2007;10(3):156-163.

Stargardt, T., Yin, D. D., and Alexander, C. M. Treatment choice and effectiveness of adding sulphonylurea or glitazones to metformin for the treatment of type 2 diabetes mellitus. *Diabetes, Obesity & Metabolism*. 2009;11(5):491-497.

Staud, R. Pharmacological treatment of fibromyalgia syndrome: new developments. *Drugs*. 2010;70(1):1-14.

Steele, B. G., Belza, B., Cain, K. C., Coppersmith, J., Lakshminarayan, S., Howard, J., and Haselkorn, J. K. A randomized clinical trial of an activity and exercise adherence intervention in chronic pulmonary disease. *Archives of Physical Medicine & Rehabilitation*. 2008;89(3):404-412.

Steele, R., Mummery, K. W., and Dwyer, T. Development and process evaluation of an internet-based physical activity behaviour change program. *Patient Education & Counseling*. 2007;67(1-2):127-136.

Stuckey, H. L., Dellasega, C., Graber, N. J., Mauger, D. T., Lendel, I., and Gabbay, R. A. Diabetes nurse case management and motivational interviewing for change (DYNAMIC): study design and baseline characteristics in the Chronic Care Model for type 2 diabetes. *Contemporary Clinical Trials*. 2009;30(4):366-374.

Sturt, J. A., Whitlock, S., Fox, C., Hearnshaw, H., Farmer, A. J., Wakelin, M., Eldridge, S., Griffiths, F., and Dale, J. Effects of the Diabetes Manual 1:1 structured education in primary care. *Diabetic Medicine*. 2008;25(6):722-731.

Subramanian, U., Ackermann, R. T., Brizendine, E. J., Saha, C., Rosenman, M. B., Willis, D. R., and Marrero, D. G. Effect of advanced access scheduling on processes and intermediate outcomes of diabetes care and utilization. *Journal of General Internal Medicine*. 2009;24(3):327-333.

Szecsényi, J., Rosemann, T., Joos, S., Peters-Klimm, F., and Miksch, A. German diabetes disease management programs are appropriate for restructuring care according to the chronic care model: an evaluation with the patient assessment of chronic illness care instrument. *Diabetes Care*. 2008;31(6):1150-1154.

Tajima, T., Tsubaki, J., Ishizu, K., Jo, W., Ishi, N., and Fujieda, K. Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. *Endocrine Journal*. 2008;55(3):595-599.

Taveira, T. H., Friedmann, P. D., Cohen, L. B., Dooley, A. G., Khatana, S. A., Pirraglia, P. A., and Wu, W. C. Pharmacist-led group medical appointment model in type 2 diabetes. *Diabetes Educator*. 2010;36(1):109-117.

Thamer, C., Machann, J., Stefan, N., Haap, M., Schafer, S., Brenner, S., Kantartzis, K., Claussen, C., Schick, F., Haring, H., and Fritsche, A. High visceral fat mass and high liver fat are associated with resistance to lifestyle intervention. *Obesity*. 2007;15(2):531-538.

Thomsen, N. O., Cederlund, R., Rosen, I., Bjork, J., and Dahlin, L. B. Clinical outcomes of surgical release among diabetic patients with carpal tunnel syndrome: prospective follow-up with matched controls. *Journal of Hand Surgery - American Volume*. 2009;34(7):1177-1187.

- Tibaldi, J. T. Biphasic insulin aspart 70/30 three times a day in older patients with type 2 diabetes not achieving optimal glycemic control on a twice-daily regimen: a retrospective case series analysis from clinical practice. *Advances in Therapy*. 2007;24(6):1348-1356.
- Toft, U. N., Kristoffersen, L. H., Aadahl, M., von Huth, Smith L., Pisinger, C., and Jorgensen, T. Diet and exercise intervention in a general population--mediators of participation and adherence: the Inter99 study. *European Journal of Public Health*. 2007;17(5):455-463.
- Tudiver, F., Wolff, L. T., Morin, P. C., Teresi, J., Palmas, W., Starren, J., Shea, S., and Weinstock, R. S. Primary care providers' perceptions of home diabetes telemedicine care in the IDEATel project. *Journal of Rural Health*. 2007;23(1):55-61.
- Utsugi-Ozaki, M., Bito, S., Matsumura, S., Hayashino, Y., Fukuhara, S., and MEMO, J. Physician job satisfaction and quality of care among hospital employed physicians in Japan. *Journal of General Internal Medicine*. 2009;24(3):387-392.
- Valensi, P., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Wenying, Y., and IMPROVE Study Group. Initiating insulin therapy with, or switching existing insulin therapy to, biphasic insulin aspart 30/70 (NovoMix 30) in routine care: safety and effectiveness in patients with type 2 diabetes in the IMPROVE observational study. *International Journal of Clinical Practice*. 2009;63(3):522-531.
- Valentine, W. J., Bottomley, J. M., Palmer, A. J., Brandle, M., Foos, V., Williams, R., Dormandy, J. A., Yates, J., Tan, M. H., Massi-Benedetti, M., and PROactive Study Group. PROactive 06: cost-effectiveness of pioglitazone in Type 2 diabetes in the UK. *Diabetic Medicine*. 2007;24(9):982-1002.
- van den Berg, M. H., Ronday, H. K., Peeters, A. J., Voogt-van der Harst EM, Munneke, M., Breedveld, F. C., and Vliet Vlieland, T. P. Engagement and satisfaction with an Internet-based physical activity intervention in patients with rheumatoid arthritis. *Rheumatology*. 2007;46(3):545-552.
- van den Berg, M. H., van der Giesen, F. J., van Zeven, D., van Groenendaal, J. H., Seys, P. E., and Vliet Vlieland, T. P. Implementation of a physical activity intervention for people with rheumatoid arthritis: a case study. *Musculoskeletal Care*. 2008;6(2):69-85.
- van Kuijk, J. P., Dunkelgrun, M., Schreiner, F., Flu, W. J., Galal, W., van Domburg, R. T., Hoeks, S. E., van Gestel, Y. R., Bax, J. J., and Poldermans, D. Preoperative oral glucose tolerance testing in vascular surgery patients: long-term cardiovascular outcome. *American Heart Journal*. 2009;157(5):919-925.
- Vandelanotte, C., De, Bourdeaudhuij, I., and Brug, J. Two-year follow-up of sequential and simultaneous interactive computer-tailored interventions for increasing physical activity and decreasing fat intake. *Annals of Behavioral Medicine*. 2007;33(2):213-219.
- Vashdi, E., Hutzler, Y., and Roth, D. Compliance of children with moderate to severe intellectual disability to treadmill walking: a pilot study. *Journal of Intellectual Disability Research*. 2008;52(Pt:5):5-9.
- Velazquez, Lopez L., Sil Acosta, M. J., Goycochea Robles, M. V., Torres, Tamayo M., and Castaneda, Limones R. Effect of protein restriction diet on renal function and metabolic control in patients with type 2 diabetes: a randomized clinical trial. *Nutricion Hospitalaria*. 2008;23(2):141-147.
- Vexiau, P., Mavros, P., Krishnarajah, G., Lyu, R., and Yin, D. Hypoglycaemia in patients with type 2 diabetes treated with a combination of metformin and sulphonylurea therapy in France. *Diabetes, Obesity & Metabolism*. 2008;10:Suppl-24.
- Vonk, F., Verhagen, A. P., Twisk, J. W., Koke, A. J., Luiten, M. W., and Koes, B. W. Effectiveness of a behaviour graded activity program versus conventional exercise for chronic neck pain patients. *European Journal of Pain: Ejp*. 2009;13(5):533-541.
- Wallston, K. A., Rothman, R. L., and Cherrington, A. Psychometric properties of the Perceived Diabetes Self-Management Scale (PDSMS). *Journal of Behavioral Medicine*. 2007;30(5):395-401.

Walsh, J. S. and Plonczynski, D. J. Evaluation of a protocol for prevention of facility-acquired heel pressure ulcers. *Journal of Wound, Ostomy, & Continence Nursing*. 2007;34(2):178-183.

Wang, W. Q., Zhang, Y. F., Zhou, D. J., Liu, Z. M., Hong, X., Qiu, M. C., Shi, Y. Q., Xia, P. J., Lu, J., Xu, M. J., An, L., Feng, W., Zhang, P., Schwamman, J., and Ning, G. Open-label, randomized, multiple-center, parallel study comparing glycemic responses and safety profiles of Glucerna versus Fresubin in subjects of type 2 diabetes mellitus. *Endocrine*. 2008;33(1):45-52.

Wassink, A. M., van der Graaf Y., Olijhoek, J. K., Visseren, F. L., and SMART Study Group. Metabolic syndrome and the risk of new vascular events and all-cause mortality in patients with coronary artery disease, cerebrovascular disease, peripheral arterial disease or abdominal aortic aneurysm. *European Heart Journal*. 2008;29(2):213-223.

Watson, A. J., Kvedar, J. C., Rahman, B., Pelletier, A. C., Salber, G., and Grant, R. W. Diabetes connected health: a pilot study of a patient- and provider-shared glucose monitoring web application. *Journal of Diabetes Science & Technology*. 2009;3(2):345-352.

Wayne, P. M. and Kaptchuk, T. J. Challenges inherent to t'ai chi research: part I--t'ai chi as a complex multicomponent intervention. [Review] [101 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(1):95-102.

Wayne, P. M. and Kaptchuk, T. J. Challenges inherent to t'ai chi research: part II-defining the intervention and optimal study design. [Review] [49 refs]. *Journal of Alternative & Complementary Medicine*. 2008;14(2):191-197.

Weck, M., Rietzsch, H., Lawall, H., Pichlmeier, U., Bramlage, P., and Schellong, S. Intermittent intravenous urokinase for critical limb ischemia in diabetic foot ulceration. *Thrombosis & Haemostasis*. 2008;100(3):475-482.

Wellman, N. S., Kamp, B., Kirk-Sanchez, N. J., and Johnson, P. M. Eat better & move more: a community-based program designed to improve diets and increase physical activity among older Americans. *American Journal of Public Health*. 2007;97(4):710-717.

Welschen, L. M., van Oppen, P., Dekker, J. M., Bouter, L. M., Stalman, W. A., and Nijpels, G. The effectiveness of adding cognitive behavioural therapy aimed at changing lifestyle to managed diabetes care for patients with type 2 diabetes: design of a randomised controlled trial. *BMC Public Health*. 2007;7:74.

Wenying, Y., Benroubi, M., Borzi, V., Gumprecht, J., Kawamori, R., Shaban, J., Shah, S., Shestakova, M., Ligthelm, R., Valensi, P., and IMPROVE Study Group. Improved glycaemic control with BIAsp 30 in insulin-naïve type 2 diabetes patients inadequately controlled on oral antidiabetics: subgroup analysis from the IMPROVE study. *Current Medical Research & Opinion*. 2009;25(11):2643-2654.

Whittemore, R., Melkus, G., Wagner, J., Dziura, J., Northrup, V., and Grey, M. Translating the diabetes prevention program to primary care: a pilot study. *Nursing Research*. 2009;58(1):2-12.

Williams, D. M., Lewis, B. A., Dunsiger, S., Whiteley, J. A., Papandonatos, G. D., Napolitano, M. A., Bock, B. C., Ciccolo, J. T., and Marcus, B. H. Comparing psychosocial predictors of physical activity adoption and maintenance. *Annals of Behavioral Medicine*. 2008;36(2):186-194.

Williams, G. C., Lynch, M., and Glasgow, R. E. Computer-assisted intervention improves patient-centered diabetes care by increasing autonomy support. *Health Psychology*. 2007;26(6):728-734.

Williams, N. H., Hendry, M., France, B., Lewis, R., and Wilkinson, C. Effectiveness of exercise-referral schemes to promote physical activity in adults: systematic review. [Review] [41 refs]. *British Journal of General Practice*. 2007;57(545):979-986.

Wittlin, S. D., Marcus, A. O., Weng, C. S., Howard, C. P., Schorr, A. B., and CONTROL Study Group. Evaluation of treatment satisfaction associated with the use of insulin aspart in continuous subcutaneous insulin infusion. *Diabetes Technology & Therapeutics*. 2008;10(1):1-10.

Yackobovitch-Gavan, M., Nagelberg, N., Phillip, M., Ashkenazi-Hoffnung, L., HersHKovitz, E., and Shalitin, S. The influence of diet and/or exercise and parental compliance on health-related quality of life in obese children. *Nutrition Research*. 2009;29(6):397-404.

Yamakawa, M. and Makimoto, K. Positive experiences of type 2 diabetes in Japanese patients: an exploratory qualitative study. *International Journal of Nursing Studies*. 2008;45(7):1032-1041.

Yang, W., Gao, Y., Liu, G., Chen, L., Fu, Z., Zou, D., Feng, P., and Zhao, Z. Biphasic insulin aspart 30 as insulin initiation or replacement therapy: the China cohort of the IMPROVE study. *Current Medical Research & Opinion*. 2010;26(1):101-107.

Yeo, S. Adherence to walking or stretching, and risk of preeclampsia in sedentary pregnant women. *Research in Nursing & Health*. 2009;32(4):379-390.

Yin, J., Xing, H., and Ye, J. Efficacy of berberine in patients with type 2 diabetes mellitus. *Metabolism: Clinical & Experimental*. 2008;57(5):712-717.

Zazpe, I., Estruch, R., Toledo, E., Sanchez-Tainta, A., Corella, D., Bullo, M., Fiol, M., Iglesias, P., Gomez-Gracia, E., Aros, F., Ros, E., Schroder, H., Serra-Majem, L., Pinto, X., Lamuela-Raventos, R., Ruiz-Gutierrez, V., and Martinez-Gonzalez, M. A. Predictors of adherence to a Mediterranean-type diet in the PREDIMED trial. *European Journal of Nutrition*. 2010;49(2):91-99.

Zhao, G., Ford, E. S., Li, C., and Mokdad, A. H. Compliance with physical activity recommendations in US adults with diabetes. *Diabetic Medicine*. 2008;25(2):221-227.

Zick, R., Petersen, B., Richter, M., Haug, C., and SAFIR Study Group. Comparison of continuous blood glucose measurement with conventional documentation of hypoglycemia in patients with Type 2 diabetes on multiple daily insulin injection therapy. *Diabetes Technology & Therapeutics*. 2007;9(6):483-492.

Zinman, B., Hoogwerf, B. J., Duran, Garcia S., Milton, D. R., Giaconia, J. M., Kim, D. D., Trautmann, M. E., and Brodows, R. G. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.[Erratum appears in *Ann Intern Med*. 2007 Jun 19;146(12):896]. [Summary for patients in *Ann Intern Med*. 2007 Apr 3;146(7):I18; PMID: 17404346]. *Annals of Internal Medicine*. 4-3-2007;146(7):477-485.